Scientific Report

ibima
Plataforma BIONAND

IBIMA 2025

IBIMA

CONTENTS

LETTER FROM THE SCIENTIFIC MANAGEMENT 5

1. INTRODUCTION 9

2. GOVERNING AND ADVISORY BODIES 13

3. ORGANIZATIONAL STRUCTURE 17

3.1. SCIENTIFIC AREAS & RESEARCH UNITS 19
3.2. HUMAN RESOURCES 28

4. SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA 33

4.1. SCIENTIFIC PRODUCTION. BIBLIOMETRIC INDICATORS 34
4.2. CLINICAL PRACTICE GUIDELINES 40
4.3. RESEARCH PROJECTS 43
4.4. HUMAN RESOURCES 48
4.5. RICORS, RETICS, INTERNATIONAL NETWORKS, AND ISCIII AND CIBER PLATFORMS 53
4.6. CLINICAL TRIALS 58
4.7. INNOVATION AND TRANSFER 62
4.8. CLINICAL PRACTICE GUIDELINES IMPLEMENTED IN HEALTHCARE CENTERS 69

5. RESEARCH AREAS AND GROUPS 73

5.1. PRIORITY SCIENTIFIC AREAS 74
5.2. RESEARCH GROUPS 91

6. FUNDING 237

7. EDUCATION 245

8. COMMUNICATIONS 257

9. COMMON RESEARCH SUPPORT SERVICES (ECAI) 267

ANNEXES 305

PUBLICATIONS 306

ACTIVE COMPETITIVE RESEARCH GRANTS IN 2025 446

ACTIVE CLINICAL STUDIES IN 2025 522

LETTER FROM THE SCIENTIFIC MANAGEMENT

LETTER FROM THE SCIENTIFIC MANAGEMENT



I am pleased to present the 2025 IBIMA Plataforma BIONAND Annual Report. This year has been marked by institutional consolidation, scientific growth, and the strengthening of our research capacity.

One of the most significant milestones of this fiscal year has been the incorporation of the Costa del Sol University Hospital into our research institute. This integration represents a significant advance in our multidisciplinary and collaborative model, expanding our scientific capabilities and reinforcing our commitment to translational research aimed at improving individuals' health.

In addition, this year we received approval for the renewal of IBIMA Plataforma BIONAND's accreditation as a Health Research Institute for the next five years. This recognition is a testament to the strength of our scientific project, the quality of our research activities, and the sustained commitment of our professionals to excellence and innovation in health.

IBIMA Plataforma BIONAND's plan, which is in its sixth edition in 2025, has become one of the most highly valued initiatives by the institute's professionals. This program reflects our firm commitment to promoting scientific quality, the transfer of results, and the visibility of the work carried out by our research groups.

In the scientific sphere, and due to the change introduced this year in the bibliometric monitoring criteria of the Carlos III Health Institute, the officially recorded scientific output amounts to 584 publications with direct institutional affiliation. However, the institute's research staff has contributed to 951 articles published in journals indexed in the Journal Citation Reports (JCR), reflecting intense collaborative scientific activity. Consequently, this report includes only the bibliometric indicators corresponding to publications that explicitly include IBIMA Plataforma BIONAND in the author's institutional affiliation in the author byline.

The institute's competitive capacity has also been strengthened during this fiscal year. In 2025, we secured more than €37 million for health research projects, an increase of €5 million compared to the previous year. Currently, 388 projects funded through competitive regional, national, and international calls for proposals are being conducted and funding has been obtained for 61 new projects.

Our international activity has been particularly noteworthy, with the securing of €3.5 million in European calls for proposals, funding for ten new projects, and receipt of the institute's second ERC Starting Grant for human resources, thus strengthening our strategy to attract and consolidate research talent. In addition, we continue to actively participate in leading collaborative networks and structures, including ten RICORS networks, 34 COST actions, seven CIBERs, and four platforms of the Carlos III Health Institute.

Another strategic area that continues to experience significant growth is clinical trials. In 2025, we had 1,550 active studies, a 20% increase over the previous year, and the associated revenue exceeded €14 million, a 13% increase This growth has been accompanied by new infrastructure for clinical research, such as the opening of Phase I, II, and III Clinical Trial Units at the Regional University Hospital of Málaga and the call for bids to expand the Pharmacy and Clinical Trials departments at the Mother and Child Hospital - Regional University Hospital of Málaga.

The year 2025 was also marked by numerous scientific, institutional, and social initiatives that reflect our commitment to society and to biomedical progress. Notable among them are the Farmaindustria Conference "Bringing Science to Schools," the Third Conference on Care Research, the Novartis Conference on Advanced Therapies, the recognition received through the Fundación Unicaja Award for Innovation in Biomedicine and Health, and the Third Regional University Hospital of Málaga/ IBIMA Plataforma BIONAND 7-a-side Soccer Tournament. Together with the "Málaga United Against Cancer" crowdfunding campaign and other charitable initiatives, these efforts have raised more than €365,000 to promote new research projects.

Our commitment to outreach and citizen engagement has also continued to grow through open houses and visits by school groups, patient associations, professionals, and biotechnology companies, bringing science closer to society and demonstrating the real impact of the work carried out in our laboratories and scientific platforms.

In conclusion, 2025 has been a year of growth, consolidation, and new challenges for IBIMA Plataforma BIONAND. All these achievements have been possible thanks to the effort, dedication, and commitment of our professionals, collaborating entities, and research teams. We continue advancing with our sights set on the future, working to establish ourselves as a leading, innovative, and competitive health research institute committed to improving the health and well-being of the public.

Francisco J. Tinahones Madueño
Scientific Director of IBIMA Platform BIONAND

INTRODUCTION

1

The following report summarizes the scientific activity conducted by the Biomedical Research Institute of Málaga and Nanomedicine Platform, IBIMA Plataforma BIONAND, in 2025.

The institute's **mission** is to **develop and promote a multidisciplinary scientific space** for R&D&i of excellence in the field of biomedicine and nanomedicine aimed at industrial transfer and the translation into clinical practice in Málaga. The institute is centered around the Regional and Virgen de la Victoria University Hospitals in Málaga together with primary care centers and University of Málaga biotechnology groups.

It is the institute's intention to **integrate** the talent, structures, and centers dedicated to biomedical research in order to promote scientific and technological **innovation** and to **inspire** the research callings of new professionals, attracting talent, and training.

The **vision** of IBIMA Plataforma BIONAND as a biomedical research institute is **to be a proactive and innovative organization, a national and European point of reference that aims to offer the best possible research at all times**. This vision means the institute is:

- Focused on the organization and structuring of the research system, with knowledge applied to health being the center of the system.
- Attentive to the reality that surrounds the institute in order to take advantage of the possibility for development arising from opportunities that surround it and to successfully face threats by joining European knowledge and development networks.
- Actively involved in achieving the sustainability of the system, characterized by quality, efficiency, and effectiveness.
- Willing to continuously incorporate innovation (social, organizational, and technological) as an element of efficiency and for good results the Institute.
- Integrated among all the agents involved in the health and research systems with its own identity that is in consonance with the rest of the agents.

The IBIMA Plataforma BIONAND is accredited as a Health Research Institute by the Carlos III Institute of Health since January 15, 2015 and was reaccredited on January 15, 2025 according to Royal Decree 279/2016, of June 24. The legal ownership of the institute belongs to the Foundation for Health and Biomedicine Research in Málaga (FIMABIS).

GOVERNING AND ADVISORY BODIES

2

The governing bodies of the IBIMA Plataforma BIONAND institute are the Board of Directors and the Delegated Commission, as collegiate bodies, and the Scientific Directorate, Vice-Scientific Directorate, and Management as individual bodies. The advisory bodies of the institute are the External Scientific Committee, the Internal Scientific Committee, and the Senate.

In addition, various committees have been organized to ensure compliance with the plans and policies approved by the Board of Directors: **Training and Postgraduate Commission, Innovation Commission, Quality Commission, Infrastructure Commission, Biosafety Committee, and Equality Commission.**

The IBIMA Plataforma BIONAND **Board of Directors** is the institute's highest governing body. Its nature and role are defined by the Collaboration Agreement between the Regional Ministry of Health and Consumer Affairs; the Regional Ministry of Economic Transformation, Industry, Knowledge, and Universities; the University of Málaga; the Andalusian Health Service; and the Andalusian Public Foundation FIMABIS for the conduct of biomedical research in Málaga, signed on December 30, 2021. The Governing Council comprises the following members:

- Two representatives from the Regional Ministry of Health and Consumer Affairs of the Autonomous Government of Andalusia.
- Two representatives from the Regional Ministry of Economic Transformation, Industry, Knowledge, and Universities of the Regional Government of Andalusia, one of which belonging to the Andalusian Health Service.
- Two representatives from the University of Málaga.

The Scientific Directorate, the Vice-Scientific Directorate, and the Management of the IBIMA Plataforma BIONAND as well as a representative of the Andalusian Public Foundation for Progress and Health, as the central research support and management entity of the Regional Ministry of Health and Consumer Affairs will be non-voting members in order to coordinate with the general and sectoral strategies for research, development, and innovation.

The **Delegated Commission** is an entity aimed at providing the institute with greater agility in decision-making in the periods between Board of Directors meetings. It was created by virtue of a resolution of the Board of Directors dated 11/24/2014. It comprises the following members:

- A representative of the Regional Ministry of Health and Consumer Affairs of the Autonomous Government of Andalusia or, as the case may be, the regional ministry with authority in health matters, designed by the person in charge of the regional ministry.
- A representative of the Regional Ministry of Universities, Research, and Innovation of the Autonomous Government of Andalusia or, as the case may be, the regional ministry with authority in research matters, designed by the person in charge of the regional ministry.
- A representative of the University of Málaga appointed by the Dean of the University of Málaga.

The Scientific Directorate, the Vice-Scientific Directorate, and the Management of the IBIMA Plataforma BIONAND as well as a representative of the Andalusian Public Foundation for Progress and Health will be non-voting members.

The **External Scientific Committee** is an advisory body for the institute that oversees its scientific quality and advises the Scientific Directorate and the Board of Directors, with independent judgment and autonomy for decision-making. It is formed of highly qualified professionals with recognized experience in the field of research.

The External Scientific Committee was proposed and approved at the institute's first Board of Directors meeting in July 2012 and was updated in 2024. Current members include:

- **Carlos Diéguez González**. Full Professor of Physiology. University of Santiago de Compostela. Chair.
- **Mariano Esteban Rodríguez**. Department of Molecular and Cellular Biology National Center for Biotechnology (CSIC).
- **Rafael Bañares Cañizares.** Chief of the Gastrointestinal Medicine Department. Gregorio Marañón University General Hospital. Madrid. Former Scientific Director of Gregorio Marañón Health Research Institute (2011-2015)
- **Pablo Lapunzina Badía.** Coordinator of the Institute of Medical and Molecular Genetics (INGEMM) of the La Paz University Hospital Research Institute (IdiPaz) and Scientific Director of CIBER-ER.
- **Eva Carmona Porquera.** Researcher at the Mayo Clinic. Rochester, Minnesota, USA.
- **María Vallet Regí.** Full Professor of Inorganic Chemistry and Director of the Department of Inorganic and Bioinorganic Chemistry, School of Pharmacy, Complutense University of Madrid.
- **Pilar Marco Colás**, Institute for Advanced Chemistry of Catalonia (IQAC, CSIC, Barcelona).
- **Jesús Jiménez Barbero**, Institute of Organic Chemistry of the CSIC and Scientific Director of the Center for Cooperative Research in Biosciences (CIC bioGUNE, Bilbao, Spain).
- **Laura Lechuga Gómez**, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, and CIBER-BBN.
- **Lina Badimon**, Cardiovascular Research Center CSIC-ICCC, Santa Creu i Sant Pau Hospital, (CIC, Barcelona).
- **Luis García Ortiz**, Scientific Director of the Biomedical Research Institute of Salamanca (IBSAL), Primary Care Research Unit of Salamanca (APISAL).

The **Internal Scientific Committee** is an advisory body to the Scientific Directorate on all scientific and organizational matters at the institute. Its decisions are non-binding. It is constituted at the proposal of the Scientific Directorate and is ratified by the Board of Directors. It includes the following members:

- Scientific Directorate of IBIMA Plataforma BIONAND.
- Scientific Vice-Directorate of IBIMA Plataforma BIONAND.
- IBIMA Plataforma BIONAND Management.
- A representative of the Virgen de la Victoria University Hospital management, a representative of the Regional University Hospital of Málaga management, and a representative of the Costa del Sol University Hospital management.
- A representative of the University of Málaga.
- A representative from Primary Care.
- The coordinators of the IBIMA Plataforma BIONAND scientific areas.
- A representative of the Training and Postgraduate Commission.
- A representative of the Quality Commission.
- A representative of the Innovation Commission.
- A representative of the postdoctoral researchers and a representative of the predoctoral researchers.
- A representative of the technical staff of the research support units.
- A representative of the Spanish Association Against Cancer.

ORGANIZATIONAL STRUCTURE

3

The IBIMA Plataforma BIONAND institute is divided into 2 research programs; 7 scientific areas, 2 of which are multidisciplinary; and one research unit. The organization chart is as follows:



3.1 SCIENTIFIC AREAS & RESEARCH UNITS

Preclinical and Clinical Research Program:

- Area 1. **Cardiovascular diseases, obesity, and diabetes. Environmental Determinants and Lifestyle.**
  Coordinator. Ricardo Gómez Huelgas
  Deputy Coordinator. M. Rosa Bernal López
- CIMO Onco-Hematology Unit
  Coordinator. Melissa García Caballero
  Deputy Coordinator. Elisa Matas Rico / Julia Alcaide García
- Area 3. **Neurosciences, Chronicity, Aging, and Health in Vulnerable Populations.**
  Coordinator. Antonia Serrano Criado
  Deputy Coordinator. Patricia Moreno Peral
- Area 4. **Autoimmune diseases, infectious diseases, inflammation, and allergies.**
  Coordinator. Lina Mayorga Mayorga
  Deputy Coordinator. Mercedes Robles Díaz

Nanomedicine Research Program:

- Area 7. **Nanodiagnostics.**
  Coordinator. María Luisa García Martín
- Area 8. **Nanosystems and Advanced Therapies.**
  Coordinator. Elena González Muñoz

and two multidisciplinary areas:

- Area 5. **Rare: Rare diseases.**
  Coordinator. Raquel Yahyaoui Macias
  Deputy Coordinator. Juan Antonio García Ranea
- Area 6. **Tech: Health Technology and Innovation Area.**
  Coordinator. Antonio I. Cuesta Vargas
  Deputy Coordinator. Francisco Ángel Moreno Dueñas

These areas comprise the 91 research groups that formed the Institute in 2025: 54 consolidated, 24 emerging, and 11 associated research groups from the different institutions that make up the IBIMA Plataforma BIONAND. In addition, 3 associated external groups participate.

The distribution of the groups by areas and categories is as follows:



Figure 1: Consolidated, emerging, and associated groups by scientific areas

The list of each research area and group with their Lead Researchers (LR) and Co-Lead Researchers (Co-LR) are as follows:

Area 1. Cardiovascular diseases, obesity, and diabetes. Environmental Determinants and Lifestyle.

Consolidated groups:

Code	LR/Co-LR	Group Name
A-01	LR Gabriel Olveira Fuster Gabriel. Co-LR Javier Bermúdez Silva	ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY
A-02	LR Francisco Tinahones Madueño. Co-LR Manuel Macias González. Co-LR Isabel Moreno Indias	OBESITY, DIABETES, AND THEIR COMORBIDITIES: PREVENTION AND TREATMENT.
A-03	LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas, Co-LR Francisco Javier Pavón Morón	CARDIOVASCULAR RESEARCH FOR HEALTH
A-06	LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal	DIABETES, OBESITY, AND OTHER VASCULAR RISK FACTORS. SYSTEMIC AUTOIMMUNE DISEASES.
A-07	LR José Antonio González Correa. Co-LR José Pedro de la Cruz Cortés	TRANSLATIONAL RESEARCH IN CARDIOVASCULAR DISEASE
A-09	LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares.	RESEARCH IN ARTERIOSCLEROSIS, CARDIOVASCULAR PREVENTION, METABOLISM, AND NEUROLOGICAL DISEASES.
A-10	LR Julia Warnberg. Co-LR Napoleón Pérez Farinós	EPIDEMIOLOGY, PHYSICAL ACTIVITY, ACCELEROMETRY, and NUTRITION (EpiPHAAN).
A-11	LR. Verónica López Jiménez. Co-LR Juana Alonso Titos.	NEPHROLOGY AND RENAL TRANSPLANTATION
A-17	LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero	ANIMAL MODELS IN CARDIOVASCULAR RESEARCH.
A-19	LR Isabel Leiva Gea, Co-LR David Moreno Pérez	MULTIDISCIPLINARY PEDIATRIC RESEARCH GROUP
A-21	LR José Luis Guerrero Orriach. Co-LR José Cruz Mañas	RESEARCH ON ORGAN PROTECTION IN THE PERIOPERATIVE PERIOD OF HEART SURGERY
A-23	LR. Mario Gutiérrez Bedmar. Co-LR Rosa López Gigosos	PREVENTIVE MEDICINE AND PUBLIC HEALTH

Emerging groups:

Code	LR/Co-LR	Group Name
AE-25	LR Néstor Oliva - Damaso	NEFROCONSULTOR

Associated groups:

Code	LR/Co-LR	Group Name
AA-04	LR María Antonia Estecha Foncea	INTENSIVE CARE MEDICINE
AA-15	LR Cristobal Urbano Carrillo	HEART AND VASCULAR DISEASE
AA-20	LR Cipriano Viñas. Co-LR Antonio Jesús Núñez Montenegro	RESEARCH GROUP ON CARE IN MÁLAGA (INVESCUIDA)
AA-22	LR Eduardo Sánchez Guerrero	BIOPSYCHOSOCIAL INTERVENTION IN COMPLEX HEALTH SYSTEM PROCESSES
AA-26	LR Manuel Salido Mota, Co-LR Eva Fragero Blesa	REM-ERIT (Regional of Málaga - Emergency Research and Innovation Team)

External associated groups:

Code	LR/Co-LR	Group Name
AA-24	LR Miguel Ángel García Ordóñez. Co-LR: Jesus Olmedo Llanes	VASCULAR RISK AND CHRONIC DISEASES

CIMO Onco-Hematology Unit

Consolidated groups:

Code	LR/Co-LR	Group Name
B-01	LR Emilio Alba Conejo. Co-LR Iñaki Comino Méndez	CLINICAL AND TRANSLATIONAL RESEARCH IN CANCER
B-04	LR Miguel Ángel Medina Torres	MOLECULAR BASIS OF BIOLOGICAL SYSTEMS (SIBIUMA)
B-05	LR Antonio Rueda Domínguez. Co-LR. Isabel Barragan Mallofret	TRANSLATIONAL RESEARCH IN CANCER IMMUNOTHERAPY AND EPIGENETICS
B-07	LR Javier Márquez Gómez. Co-LR José Manuel Matés Sánchez.	CANCEROMICS
B-10	LR María Victoria de Gálvez Aranda. Co-LR Enrique Herrera Acosta	SKIN CANCER
B-11	LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico	TRANSLATIONAL RESEARCH GROUP IN GENITOURINARY TUMORS
B-12	LR José Manuel Jerez Aragonés	COMPUTATIONAL INTELLIGENCE IN BIOMEDICINE
B-14	LR Maximino Redondo Bautista. Co-LR Marilina García Aranda	TRANSLATIONAL RESEARCH IN CANCER AND OTHER PREVALENT CHRONIC DISEASES
B-22	LR Manuel Cobo Dols. Co-LR Inmaculada Ales Diaz	EMERGING ANTITUMOR ADAPTATION THERAPIES

Emerging groups:

Code	LR/Co-LR	Group Name
BE-03	LR Francisco José López Jaime	HEMATOLOGY AND HEMATOTHERAPY
BE-15	LR Isabel Hierro. Co-LR Rafael E. Carvia Ponsaillé	PATHOLOGICAL ANATOMY
BE-17	LR Jaime Gómez-Millán Barrachina. Co-LR María Jesús García Anaya	CLINICAL, MOLECULAR, AND TECHNOLOGICAL RESEARCH IN RADIATION ONCOLOGY
BE-18	LR Melissa García Caballero	VASCULAR BIOLOGY, TUMOR MICROENVIRONMENT & TARGET DISCOVERY
BE-19	LR Miguel José Ruiz Gómez	RADIOBIOLOGY
BE-21	LR Regina García Delgado. Co-LR Alejandro Escamilla Sánchez	HEMATOLOGY AND IMMUNOLOGY
BE-23	LR Miguel Ángel Berciano Guerrero. Co-LR Julia Alcaide García.	NEW HORIZONS FOR ONCOLOGY PATIENTS

Associated groups:

Code	LR/Co-LR	Group Name
BA-16	LR Adolfo Romero Ruiz	QUALITY AND SAFETY IN LABORATORY AND HEMATOLOGY CARE
BA-20	LR Jorge Contreras Martínez	ONCOLOGY AND BENIGN PATHOLOGY

Area 3. Neurosciences, Chronicity, Aging, and Health in vulnerable populations

Consolidated groups:

Code	LR/Co-LR	Group Name
C-01	LR Pedro Serrano Castro, Co-LR Guillermo Estivill, Co-LR Laura Leyva	NEUROIMMUNOLOGY AND NEUROINFLAMMATION
C-02	LR Juan Ángel Bellón Saameño. Co-LR Patricia Moreno Peral	MENTAL HEALTH, SERVICES, AND PRIMARY CARE (SAMSERAP).
C-03	LR Jose Guzmán Parra, Co-LR Jessica Goodman Casanova, Co-LR Jesús Herrera Imbroda	BASIC, CLINICAL, AND EPIDEMIOLOGICAL RESEARCH ON MENTAL HEALTH GROUP
C-05	LR Antonio J. Jiménez Lara	DEGENERATION AND REGENERATION OF THE CENTRAL NERVOUS SYSTEM
C-06	LR Fernando Rodríguez de Fonseca. Co-LR: Antonia María Serrano Criado. Co-LR: Juan Suárez Pérez	NEUROPSYCHOPHARMACOLOGY
C-07	LR Zaida Diaz Cabiale, Co-LR José Pablo Lara Muñoz. Co-LR María Inmaculada García Fernández	BASIC AND APPLIED ASPECTS OF NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES
C-08	LR Francisca Leiva Fernández. Co-LR: Antonio García Ruiz	MAEPAP. MULTIMORBIDITY, ADHERENCE, ECONOMIC EVALUATION, AND PALLIATIVE CARE IN PRIMARY CARE
C-09	LR Antonia Gutiérrez Pérez	NEUROPATHOLOGY OF ALZHEIMER'S DISEASE (NEUROAD)
C-11	LR María Carmen Ramírez Maestre	VULNERABILITY AND RESILIENCE TO CHRONIC PAIN: IMPLICATIONS FOR PSYCHOLOGICAL INTERVENTION
C-12	LR Guadalupe Dávila Arias	COGNITIVE NEUROSCIENCE: APHASIA AND RELATED DISORDERS (UNCA)
C-13	LR José Miguel Morales Asencio	CHRONICITY, DEPENDENCY, CARE, AND HEALTH SERVICES
C-14	LR Maria Dolores Martín Escalante. Co-LR Julian Olalla Sierra	CHRONIC DISEASES AND AGING
C-16	LR Ernesto González Mesa. Co-LR Jesús Salvador Jiménez López	MATERNAL-FETAL MEDICINE, EPIGENETICS, WOMEN'S HEALTH CONDITIONS, AND REPRODUCTIVE HEALTH RESEARCH GROUP
C-18	LR. Stella Martín de las Heras. Co-LR Leticia Rubio Lamia	FORENSIC MEDICINE, TOXICOLOGY, AND FORENSIC ODONTOLOGY
C-22	LR Dasiel Óscar Borroto Escuela /Co-LR Manuel Narváez Peláez	RECEPTOMICS AND SIGNALING NETWORKS IN BRAIN DISEASES

Emerging groups:

Code	LR/Co-LR	Group Name
CE-17	LR. Carmen Ortiz García. Co-LR Ángela García de la Torre. Co-LR Begoña Mora Ordoñez	TECHNOLOGY AND INNOVATION IN EMERGENCY DEPARTMENTS AND HOSPITALIZATION
CE-20	LR Carlos Rocha de Lossada	OPHTHALMOLOGY
CE-21	LR: Marina García Gámez	FRAILTY, AGING, COMPLEX CHRONICITY, AND TEACHING.
CE-23	LR Ana Belén Ortega Ávila	Podology, Inclusive health, and Equality (PODOSALUD_IG)
CE-24	LR Shakira Kaknani Uttumchandani, Co-LR Eloísa Fernández Ordóñez	Comprehensive Women's Health with a Gender Perspective (SIMGE).

Associated groups:

Code	LR/Co-LR	Group Name
CA-10.	LR David Luque Ruiz. Co-LR Pedro Luis Cobos Cano.	CAUSAL COGNITION GROUP

External associated groups:

Code	LR/Co-LR	Group Name
CA-15.	LR Pilar Barnestein Fonseca	PALLIATIVE CARE
CA-19.	LR Carmen Aránzazu Bermúdez Martín	DigCompSalud. Digital competence for lifelong learning

Area 4. Autoimmune diseases, infectious diseases, inflammation, and allergies.

Consolidated groups:

Code	LR/Co-LR	Group Name
D-01.	LR Jesús Santos González. Co-LR Rosario Palacios Muñoz	CLINICAL RESEARCH GROUP ON HIV INFECTION, ENDOVASCULAR INFECTION, AND BACTEREMIA
D-03.	LR Antonio Fernández Nebro. Co-LR Natalia Mena Vázquez	INFLAMMATORY AND AUTOIMMUNE DISEASES
D-04	LR Mª José Torres Jaén, Co-LR: Lina Mayorga Mayorga	ALLERGIC DISEASES TO DRUGS AND ALLERGENS
D-05	LR Raúl J. Andrade Bellido, Co-LR Eduardo Garcia Fuentes, Co-LR Mercedes Robles Díaz	HEPATOGASTROENTEROLOGY, PHARMACOLOG, AND TRANSLATIONAL CLINICAL THERAPEUTICS

Emerging groups:

Code	LR/Co-LR	Group Name
DE-02	LR José María Reguera	GROUP FOR THE STUDY OF INFECTIOUS DISEASES
DE-07	LR Manuel Enrique Herrera Gutierrez. Co-LR Emilio Curiel Balsera	INFLAMMATION IN CRITICALLY ILL PATIENTS
DE-08	LR Miguel Jiménez Pérez. Co-LR Julio Santoyo Santoyo	HEPATOGASTROENTEROLOGY, ENDOSCOPY, AND GASTROINTESTINAL SURGERY
DE-09	LR Juan José Borrego García. Co-LR José Manuel Jiménez Guardeño. Co-LR Ana María Ortega Prieto	IMMUNE RESPONSE TO VIRAL INFECTIONS.
DE-10	LR Rafael Luque Aranda. Co-LR Carmen Alba Linero	OPHTHALMOLOGY
DE-11	LR Jose Luis Velasco Garrido	PULMONOLOGY

Associated groups:

Code	LR/Co-LR	Group Name
DA-06	LR Rosa García Portales. Co-LR María del Carmen Ordóñez Cañizares	IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMID)

Area 5. IBIMA RARE. Multidisciplinary

Code	LR/Co-LR	Group Name
A-01	LR Gabriel Olveira Fuster Gabriel. Co-LR Javier Bermúdez Silva	ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY
A-03	LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas, Co-LR Francisco Javier Pavón Morón	CARDIOVASCULAR RESEARCH FOR HEALTH
A-06	LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal	DIABETES, OBESITY, AND OTHER VASCULAR RISK FACTORS. SYSTEMIC AUTOIMMUNE DISEASES.
A-09	LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares.	RESEARCH IN ARTERIOSCLEROSIS, CARDIOVASCULAR PREVENTION, METABOLISM, AND NEUROLOGICAL DISEASES.
A-17	LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero	ANIMAL MODELS IN CARDIOVASCULAR RESEARCH.
A-19	LR Isabel Leiva Gea, Co-LR David Moreno Pérez	MULTIDISCIPLINARY PEDIATRIC RESEARCH GROUP
AA-22	LR Eduardo Sánchez Guerrero	BIOPSYCHOSOCIAL INTERVENTION IN COMPLEX HEALTH SYSTEM PROCESSES
B-04	LR Miguel Ángel Medina Torres	MOLECULAR BASIS OF BIOLOGICAL SYSTEMS (SIBIUMA)

Code	LR/Co-LR	Group Name
B-11	LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico	TRANSLATIONAL RESEARCH GROUP IN GENITOURINARY TUMORS
BE-21	LR Regina García Delgado. Co-LR Alejandro Escamilla Sánchez	HEMATOLOGY AND IMMUNOLOGY
C-01	LR Pedro Serrano Castro, Co-LR Guillermo Estivill, Co-LR Laura Leyva	NEUROIMMUNOLOGY AND NEUROINFLAMMATION
C-03	LR Jose Guzmán Parra, Co-LR Jessica Goodman Casanova, Co-LR Jesús Herrera Imbroda	BASIC, CLINICAL, AND EPIDEMIOLOGICAL RESEARCH ON MENTAL HEALTH GROUP
C-06	LR Fernando Rodríguez de Fonseca. Co-LR: Antonia María Serrano Criado. Co-LR: Juan Suárez Pérez	NEUROPSYCHOPHARMACOLOGY
C-07	LR Zaida Diaz Cabiale, Co-LR José Pablo Lara Muñoz. Co-LR María Inmaculada García Fernández	BASIC AND APPLIED ASPECTS OF NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES
FA-07	LR Antonio Leiva Gea	RESEARCH IN ORTHOPEDIC SURGERY AND TRAUMATOLOGY
H-02	LR Iván Durán Jiménez. Co-LR Fabiana Csukasi	Laboratory of Skeletal Biomedicine

Area 6. IBIMA Tech: Health Technology and Innovation Area

Consolidated groups:

Code	LR/Co-LR	Group Name
F-02	LR Ezequiel López Rubio	COMPUTATIONAL INTELLIGENCE AND IMAGE ANALYSIS
F-03	LR Iñigo Molina Fernández	COMMUNICATIONS ENGINEERING
F-04	LR Javier González Jiménez. Co-LR Francisco Ángel Moreno Dueñas	MAPIR (MACHINE PERCEPTION AND INTELLIGENT ROBOTICS GROUP)
F-05	LR. Víctor Fernando Muñoz Martínez	MEDICAL ROBOTICS
F-09	LR Fernando Vidal Verdú.	ELECTRONICS FOR INSTRUMENTATION AND SYSTEMS.
F-10	LR Ezequiel Pérez Inestrosa. Co-LR Francisco Nájera Albendín	BIOMIMETIC DENDRIMERS AND PHOTONIC LABORATORY
F-14	LR Antonio Ignacio Cuesta Vargas	CLINIMETRICS IN PHYSICAL THERAPY
F-15	LR José F. Aldana Montes. Co-LR Ismael Navas Delgado	DATA AND KNOWLEDGE MANAGEMENT, INTEGRATION, AND ANALYSIS (KHAOS)
F-16	LR Enrique Guerado Parra	INNOVATIVE THERAPIES AND NEW TECHNOLOGIES IN THE MUSCULOSKELETAL SYSTEM
F-19	LR José Ignacio Peláez Sánchez. Co-LR José Antonio Gómez Ruiz	ARTIFICIAL INTELLIGENCE AND SOCIAL RESEARCH

Emerging groups:

Code	LR/Co-LR	Group Name
FE-17	LR Raquel Cantero Téllez. Co-LR Javier García Orza	HandResearchTeam
FE-18	LR Lorena Aguilar Cano. Co-LR: Francisco Luna Cabrera	REHABILITATION, INNOVATION, AND QUALITY OF LIFE
FE-20	LR Francisco Sendra Portero	ARTIFICIAL INTELLIGENCE IN MEDICAL IMAGING
FE-22	LR Alfonso Castillo Rodríguez.	EDUCATION, SPORTS, INNOVATION, AND HEALTH.

Associated groups:

Code	LR/Co-LR	Group Name
FA-07	LR Antonio Leiva Gea	RESEARCH IN ORTHOPEDIC SURGERY AND TRAUMATOLOGY
FA-08	LR Alfonso Gago Calderón	OTOTECH

Area 7. Nanodiagnostics

Consolidated groups:

Code	LR/Co-LR	Group Name
G-01.	LR María Luisa García Martín	BIOMEDICAL MAGNETIC RESONANCE LABORATORY (BMRL)

Area 8. Nanosystems and advanced therapies

Consolidated groups:

Code	LR/Co-LR	Group Name
H-02	LR Iván Durán Jiménez. Co-LR Fabiana Csukasi	LABORATORY OF SKELETAL BIOMEDICINE/ LABORATORIO DE BIOMEDICINA DEL SKELETO
H-03	LR Jose María Pérez Pomares	DEVELOPMENT AND CARDIOVASCULAR DISEASE

Emerging groups:

Code	LR/Co-LR	Group Name
HE-01	LR Elena González Muñoz	CELL REPROGRAMMING (iPSCs) AND DISEASE CELL MODELS FOR BIOMEDICAL APPLICATIONS

The **objectives of the scientific areas** and their research groups are explained in the 2023-2027 strategic plan and in the cooperative scientific plan with the general objective of fostering synergies between the institute's research groups by promoting inter-institutional, inter-area, and intra-area collaboration.
The IBIMA Plataforma BIONAND areas have proposed the following specific objectives:

- Increase scientific production and the conduct of projects resulting from collaboration among the Institute's groups.
- Promote collaborative translational research with results close to the market.
- Comply with new strategies and policies on Open Science.

The extent to which the annual objectives have been met is measured every six months and submitted to the Board of Directors. The following sections of this report describe the results achieved for the year 2025.

3.2. HUMAN RESOURCES

In 2025, the IBIMA staff consisted of a total of 1,602 professionals, including researchers (1,383), support technicians (178), and managers (41).



Figure 2: Number of professionals by category and gender in 2025



Figure 3: Percentage of professionals by category in 2025

In 2025, IBIMA Plataforma BIONAND has implemented the actions planned according to its Human Resources Strategy for Researchers (HRS4R). The strategy was launched 2017 after obtaining the "HR Excellence in Research" recognition awarded by the European Commission.
IBIMA's HRS4R action plan is aligned with the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers with the aim of improving the working and employment conditions of researchers with open, transparent, and merit-based recruitment and hiring practices.
The distribution of IBIMA Plataforma BIONAND personnel by gender and category and according to the European classification of research profiles R1 – R4 (https://euraxess.ec.europa.eu/europe/career-development/training-researchers/research-profiles-descriptors) is as follows:



Figure 4: IBIMA Plataforma BIONAND personnel in 2025 by category (Euraxess) and gender

Of the 1,383 researchers who formed part of the Institute in 20245, 262 were R1 researchers, 175 were R2 researchers, 794 were R3 researcher, and 152 were R4 researchers, according to the European classification of research profiles. In addition, 45% (619) were men and 55% (764) were women.



Figure 5: IBIMA Plataforma BIONAND researchers according to the European classification of researchers



Figure 6: IBIMA Plataforma BIONAND Researchers according to European classification of researchers and gender

Research group leaders (LR and/or Co-LR by gender):



Figure 7: Research group leaders (LR/Co-LR) by gender

In addition, 61% of researchers have clinical practice activity (figure 8).



Figure 8: Distribution of researchers according to clinical practice activity

The institute's management personnel are organized into **Research Support Units (RSU),** whose functions include supporting the institute's scientific objectives through its managing entity FIMABIS:

- Advisory service for fundraising and establishing collaborations.
- Fund management service for R&I activities.
- International project advisory service.
- Clinical trials management service.
- Methodological and statistical support service.
- Advisory and management service for the protection, transfer, and dissemination of results.
- Communication to society and event coordination.
- Management of health research centers and institutes linked to the Andalusian Public Healthcare System.

SCIENTIFIC ACTIVITY AND PRODUCTION.
OVERALL DATA

4

4.1. SCIENTIFIC PRODUCTION. BIBLIOMETRIC INDICATORS

To calculate the bibliometric indicators presented in this report, only original articles and reviews published in scientific journals indexed in the 2024 edition of the Journal Citation Reports (JCR) — the most recent edition available at the time of this report's writing — were considered, provided they explicitly included the institute's affiliation in the institutional byline.

Other document types, such as editorials, letters, meeting abstracts, errata, and preprints (in press, online ahead of print, or early access), were excluded from the analysis.

The evolution of IBIMA Plataforma BIONAND's overall scientific output over the past five years is illustrated in the following graph, which shows the number of publications broken down by document type. A sustained upward trend is observed, reaching a total of 951 scientific publications in 2025. Of these, 584 properly include the IBIMA Plataforma BIONAND institutional affiliation, which highlights both the growth in research activity and the importance of ensuring proper institutional affiliation in scientific publications.



Figure 9: Changes in the number of publications by document type in the last five years

The percentage corresponding to each document type in 2025 is shown in the following figure. Original articles are the institute's principal format for scientific publication, accounting for 88% of its total output, while the remaining percentage consists of review articles. These data reflect a strong orientation toward the generation of original knowledge and results of primary research.



Figure 10: Percentage of publications by document type

On the other hand, regarding the position of the publications in the JCR subject category in which they are indexed, following figure shows the percentage of publications in first quartile (Q1) and first decile (D1) scientific journals in the last five years. The data show an upward trend, especially in the percentage of publications in D1 journals, even when considering only publications which explicitly include IBIMA Plataforma BIONAND affiliation. These results reflect a progressive increase in the visibility and scientific impact of the institute's production in journals of the greatest international prestige.



Figure 11: Change in the percentage of first quartile (Q1) and first decile (D1) publications

The distribution of the number of publications by quartile is shown below. Of them, 88% were published in first quartile (Q1) and second quartile (Q2) journals.



Figure 12: Publications by quartiles

The percentage of Open Access publications in 2024, considering the gold, green, hybrid and bronze pathways, was 80%.

Leadership

Scientific output led by researchers from IBIMA's BIONAND Platform—defined as publications in which they serve as first author, last author, or corresponding author—accounts for 55% of the total, as shown in the following graph. This result reflects a high level of scientific leadership, as well as the institute's excellent standing and remarkable research autonomy in the field of biomedical research.



Figure 13: Change in the percentage of publications led by IBIMA researchers in the last five years.

Impact Factor

When calculating the Impact Factor (IF), only **original research articles and review articles** were considered. Collaborative publications among different groups and/or areas of the institute were only counted once for the overall calculation.

The institute's cumulative impact factor in 2025 was 3322 points. The trend over the past five years is shown in the following graph, where we once again emphasize that only publications explicitly affiliated with the institute have been included:



Figure 14: Changes in cumulative impact factor.

Collaborations

The following figure shows the percentage of publications by IBIMA Plataforma BIONAND researchers published in collaboration with other researchers from national institutions outside of Andalusia (national collaborations) and institutions of other nationalities (international).



Figure 15: Change in the percentage of scientific production according to national and international collaboration.

On the other hand, the percentage of publications from intra-institute collaborations among different research groups and institutions that make up the IBIMA Plataforma BIONAND is shown in the following figure:



Figure 16: Percentage of publications produced in collaboration among groups and among institutions that make up the IBIMA Plataforma BIONAND.

Journals with IF >20 in which works were published in 2025

No. of Publications by GRUPO	Source Title	IF
B-11 (1) / BE-23(2)	ANNALS OF ONCOLOGY	65.4
C-03	NATURE	48.5
B-05 (1) / B-22(1)	JOURNAL OF CLINICAL ONCOLOGY	43.4
B-22	JOURNAL OF CLINICAL ONCOLOGY	43.4
B-01 (1) / B-11(1)	LANCET ONCOLOGY	35.9
A-03 (3) / A-02(1)	EUROPEAN HEART JOURNAL	35.7
A-02/B-04/G-01	GUT	26.2
A-03	LANCET DIGITAL HEALTH	24.1
D-01	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	22.3
B-05 (1) / B-22(3)	JOURNAL OF THORACIC ONCOLOGY	20.8
A-02	NATURE METABOLISM	20.8
C-03	NATURE NEUROSCIENCE	20

4.2. CLINICAL PRACTICE GUIDELINES

In 2025, 18 clinical practice guidelines and/or consensus documents with the participation of researchers from the institute were published in JCR-indexed journals:

Group	Authors	Article Title	Source Title	Year
A-03	Paradies, V; Masiero, G; Rubboli, A; Van Beusekom, HMM; Costa, F; Capranzano, P; Degrauwe, S; Gorog, DA; Jorge, CM; Buchanan, GL; Alasnag, M; Trabattoni, D; Fraccaro, C; Sibbing, D; Dudek, D; Vilahur, G; Chieffo, A; Mehran, R; Capodanno, D; Barbato, E; Siller-Matula, JM	Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.	EUROPEAN HEART JOURNAL	2025
A-03	Paradies, V; Masiero, G; Rubboli, A; Van Beusekom, HMM; Costa, F; Capranzano, P; Degrauwe, S; Gorog, DA; Jorge, CM; Buchanan, GL; Alasnag, M; Trabattoni, D; Fraccaro, C; Sibbing, D; Dudek, D; Vilahur, G; Chieffo, A; Mehran, R; Capodanno, D; Barbato, E; Siller-Matula, JM	Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis	EUROINTERVEN-TION	2025
A-19/ A-09	Hermida-Ameijeiras, A; Blasco-Alonso, J; Carrillo-Linares, JL; González-Dieguez, ML; Pastor-Rosado, J; Morales-Conejo, M; Bellusci, M; Mercadal-Hally, M	Childhood to adult transition in youth patients with lysosomal acid lipase deficiency: 43 recommendations from experts	ORPHANET JOURNAL OF RARE DISEASES	2025
C-01	Mascaro, RS; Sobrino, TG; Hernandez, AH; Negro, ALP; Jimenez, AA; Pose, AA; Gallego, MDC; Casasnovas, C; Fernandez, CAC; Perez, JE; Cortes, MF; Carrera, MF; Petit, MPG; Munoz, AG; Gutierrez, GG; Martinez, AG; Morales, RJ; Ciano-Petersen, NL; Ulloa, PLM; Hengstl, SM; Sancho, EM; Barrero, FJN; Faubel, FEN; Fernandez, JP; Pascual, SIP; Lucas, JP; Minguez, JP; Perez, MR; Gonzalez, MS; Sotoca, J; Santiago, BR; Garcia, RR; Turon-Sans, J; Carsiy, VV; Mantecona, TS	Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease in Spain	NEUROLOGIA	2025
A-19	Martinez-Brocca, MA; Bellido, V; Cardona-Hernandez, R; Castaño, L; Conget, I; Fernández, A; Gila, ALG; Leiva-Gea, I; Mauricio, D	Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP	ENDOCRINOLOGIA DIABETES Y NUTRICION	2025
A-19	Martinez-Brocca, Maria Asuncion; Bellido, Virginia; Cardona-Hernandez, Roque; Castano, Luis; Conget, Ignacio; Fernandez, Alberto; Gomez Gila, Ana Lucia; Leiva-Gea, Isabel; Mauricio, Didac	Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: consensus of the scientific societies SED, SEEN and SEEP.	ANALES DE PEDI-ATRIA	2025
D-04	Price, OJ; Papadopoulos, NG; Amerigo, DA; Backer, V; Bougault, V; Del Giacco, S; Gawlik, R; Eguiluz-Gracia, I; Heffler, E; Janson, C; Mcdonald, VM; Moreira, A; Simpson, A; Bonini, M	Exercise Recommendations and Practical Considerations for Asthma Management-An EAACI Position Paper	ALLERGY	2025
D-01	Retamar-Gentil, P; Alegre-Albendea, M; De Santis, LV; Caston-Osorio, JJ; Márquez-Gomez, I; Corzo-Delgado, JE; Praena-Segovia, J; Herrero-Rodríguez, C; Esteban-Moreno, MA; Martín-Aspas, A; Jiménez-Aguilar, P; Martínez-Marcos, FJ; Lopez-Cárdenas, S; Ojeda-Burgos, G; Sadyrbaeva-Dolgova, S; Anguita-Santos, F; Baño, JR; Palacios-Baena, ZR	How to use novel antimicrobials beyond official indications: an expert consensus	JAC-ANTIMICROBIAL RESISTANCE	2025
D-05	Steplewski, K; Walker, L; Coffee, N; Fallon, M; Yonemochi, R; Alpers, D; Rockey, D; Lewis, J; Cohen, E; Caminis, J; Hey-Hadavi, J; Andrade, RJ; Palmer, M	IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials	DRUG SAFETY	2025
A-11	Garcia-Cosio Carmena, Maria Dolores; Farrero, Marta; Blasco Peiro, Maria Teresa; Crespo, Marta; Delgado Jimenez, Juan; Diaz Molina, Beatriz; Fernandez Rivera, Constantino; Garrido Bravo, Iris Paula; Lopez Jimenez, Veronica; Melilli, Edoardo; Mirabet Perez, Sonia; Perez Tamajon, Maria Lourdes; Rangel Sousa, Diego; Rodrigo, Emilio; Cruzado, Josep Maria; Hernandez Marrero, Domingo	Management of Kidney Disease in Heart Transplant Patients: A National Delphi Survey-based Consensus Expert Paper.	Transplantation	2025

Group	Authors	Article Title	Source Title	Year
A-06/ A-02	Romero-Gómez, M; Escalada, J; Noguerol, M; Pérez, A; Carretero, J; Crespo, J; Mascort, JJ; Aguilar, I; Tinahones, F; Canones, P; Gómez-Huelgas, R; de Luis, D; Trullos, IG; Aller, R; Rubio, MA	Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis	GASTROENTEROLOGIA Y HEPATOLOGIA	2025
C-02	Uriko, K; Christoforou, A; Motrico, E; Moreno-Peral, P; Akik, BK; Zutic, M; van den Berg, MPL	Paternal peripartum depression: emerging issues and questions on prevention, diagnosis and treatment. A consensus report from the cost action Riseup-PPD	JOURNAL OF REPRODUCTIVE AND INFANT PSYCHOLOGY	2025
D-04	Venter, C; Alonso-Coello, P; Beltran, J; Bracchiglione, J; Fernandez-Saenz, K; Riera, P; Solà, I; Arasi, S; Canani, RB; Fleischer, D; Eguiluz-Gracia, I; Meyer, R; Roberts, G; Roth-Walter, F; Santos, AF; Skypala, I; Smith, PK; Sokolowska, M; Torres, MJ; Vassilopoulou, E; Walter, J; O'Mahony, L	Protocol: Scoping review of the association between complementary feeding, growth, and immune health in infants and toddlers-An EAACI guideline paper	PEDIATRIC ALLERGY AND IMMUNOLOGY	2025
C-08	Rivero-de-Aguilar, A; Mascareñas-García, M; Pérez-Rios, M; Llaneza-Gonzalez, MA; Mulero, P; Mendibe, M; Rovira, A; Meca-Lallana, V; García-Ruiz, AJ; Landete, L; Hermida, JRV; Rueda, PC; Ruano-Raviña, A; Puente-Hernandez, M; Varela-Lema, L	Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis	NEUROLOGIA	2025
D-03	Morales, E; Rúa-Figueroa, I; Rubio, JLC; Bernabéu, AA; Alonso, RB; Xutgla, MCC; Juárez, GF; Mena-Vázquez, N; Blanco, JJR; Escola, JM; García, FJN; Sopeña, B; Porras, LFQ; Romero-Yusten, S; Laqué, RS	Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis	NEFROLOGIA	2025
B-05	Gumà, J; Palazón-Carrión, N; Rueda-Domínguez, A; Sequero, S; Calvo, V; García-Arroyo, R; Gómez-Codina, J; Llanos, M; Martínez-Banaclocha, N; Provencio, M	SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025)	CLINICAL & TRANSLATIONAL ONCOLOGY	2025
A-06	Uyaroglu, OA; Ruza, I; Skrha, J; Patoulias, D; Bevc, S; Bojadjiev, BI; Gómez-Huelgas, R; Bojunga, J; Lesniak, W; Carretero-Gómez, J; Wacker, J; Pérez-Belmonte, LM; Dicker, D; Petreski, T; Marín-León, I	Treatment of hospitalized patient with hyperglycemia: An EFIM critically appraised and adapted guideline	EUROPEAN JOURNAL OF INTERNAL MEDICINE	2025
C-03	Mora, F; Ramos-Quiroga, JA; Baca-García, E; Crespo, JM; Gutiérrez-Rojas, L; Madrazo, A; Costillas, LP; Saiz, PA; Tordera, V; Vieta, E	Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects	FRONTIERS IN PSYCHIATRY	2025

4.3. RESEARCH PROJECTS

In 2025, 388 research projects funded in regional, national, and international competitive calls were conducted at IBIMA Plataforma BIONAND. Of these, 248 were projects managed directly by FIMABIS as the Institute's managing entity.



Figure 17: Active competitive research projects in 2025



Figure 18: Changes in active competitive research projects at IBIMA 2021–2025

Sixty-one new competitive projects were awarded to IBIMA Plataforma BIONAND research groups, with a success rate of 22% (61 granted/278 requested).



Figure 19: Competitive research projects applied for and funded in 2025

The following table shows the success rates in the main national and regional competitive calls for research projects:

	Applied for	Awarded
COMPETITIVE RESEARCH PROJECTS:	**275**	**47**
NATIONAL	**136**	**38**
Public	**103**	**28**
STATE RESEARCH AGENCY	**27**	**4**
GRANTS FOR PUBLIC-PRIVATE PARTNERSHIP PROJECTS 2024	5	2
GRANTS FOR R%D%I PROJECTS TO CONDUCT PROOF OF CONCEPT TESTING 2025	1	1
PROJECTS FOR KNOWLEDGE GENERATION AND ASSOCIATED PREDOCTORAL GRANTS 2024	9	1
PROJECTS FOR KNOWLEDGE GENERATION AND ASSOCIATED PREDOCTORAL GRANTS 2025	10	
PROJECTS IN THE FIELD OF ARTIFICIAL INTELLIGENCE 2025	2	
FECYT - SPANISH FOUNDATION FOR SCIENCE AND TECHNOLOGY	**2**	
COMPETITIVE RESEARCH PROJECTS:	**275**	**47**
GRANTS FOR THE PROMOTION OF SCIENTIFIC CULTURE, TECHNOLOGY, AND INNOVATION 2025	**1**	
GRANTS TO PROMOTE A CULTURE OF PUBLIC INNOVATION 2025	1	
CARLOS III INSTITUTE OF HEALTH	**65**	**23**
STRATEGIC HEALTH ACTION - CALL FOR INDEPENDENT CLINICAL RESEARCH PROJECTS 2025	2	1
STRATEGIC HEALTH ACTION - HEALTH TECHNOLOGY DEVELOPMENT PROJECTS 2025	2	2
STRATEGIC HEALTH ACTION - HEALTH R&D&I PROJECTS 2025	61	20
MINISTRY OF DEFENSE	**2**	
PROGRAM FOR COOPERATION IN SCIENTIFIC RESEARCH AND DEVELOPMENT IN STRATEGIC TECHNOLOGIES (COINCIDENTE PROGRAM) 2025	2	
MINISTRY OF HEALTH	**5**	**1**
GRANTS FOR ADDICTION RESEARCH PROJECTS 2025	5	1
MINISTRY OF DIGITAL TRANSFORMATION AND PUBLIC SERVICE	**1**	
GRANTS FOR DIGITALIZATION TO SUPPORT THE DIGITAL TRANSFORMATION OF STRATEGIC PRODUCTIVE SECTORS - DATA SPACE 2025	1	
Private	**33**	**10**
SPANISH ASSOCIATION FOR CANCER RESEARCH	**1**	
GRANT FOR ONCOLOGY RESEARCH ASEICA + QUEUNTRAIL ALCOI 2025	1	
PURPLE WARRIORS ASSOCIATION	**1**	
I CALL FOR APPLICATIONS FOR THE 2025 PURPLE WARRIORS RESEARCH GRANTS	1	
ASTRAZENECA FARMACEUTICA ESPAÑA S.A.	**2**	
CALL FOR YOUNG RESEARCHER AWARDS 2025	2	
BAYER HISPANIA S.L.	**1**	**1**
FELLOWSHIPS IN CARE QUALITY FOR NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC HORMONE-SENSITIVE PROSTATE CANCER 2025	1	1
SPANISH FEDERATION OF FAMILY THERAPY ASSOCIATIONS	**1**	**1**
SUPPORT FOR RESEARCH ON THE EFFECTIVENESS OF FAMILY THERAPY 2025	1	1
BBVA FOUNDATION	**2**	
LEONARDO GRANTS TO RESEARCHERS AND CULTURAL CREATORS 2025	1	
FUNDAMENTOS RESEARCH PROGRAM 2025	1	
SPANISH SURGERY FOUNDATION	**1**	**1**

	Applied for	Awarded
COMPETITIVE RESEARCH PROJECTS:	**275**	**47**
2025 SCHOLARSHIPS FOR STUDIES AND RESEARCH IN MULTICENTER REGISTRIES	1	1
FERO CANCER RESEARCH FOUNDATION	**1**	
FERO SCHOLARSHIP FOR YOUNG RESEARCHERS 2025	1	
FUNDACIÓN DE LA SOCIEDAD ESPAÑOLA ENDOCRINOLOGÍA Y NUTRICIÓN	**1**	**1**
SEEN FOUNDATION DIABETES SCHOLARSHIP 2025	1	1
SPANISH SOCIETY FOR ATHEROSCLEROSIS	**1**	**1**
RESEARCH GRANTS 2025	1	1
SPANISH QUALITY OF CARE SCHOLARSHIP	**1**	
FECA RESEARCH SCHOLARSHIPS CALL FOR APPLICATIONS 2025	1	
EUGENIO RODRIGUEZ PASCUAL FOUNDATION	**1**	
BIOMEDICAL RESEARCH GRANTS 2025	1	
ISABEL GEMIO FOUNDATION	**1**	
RESEARCH PROJECTS ON RARE DISEASES 2025	1	
LA CAIXA FOUNDATION	**4**	**2**
GRANTS FOR SOCIAL PROJECTS IN ANDALUSIA 2025	1	1
CAIXAIMPULSE HEALTH INNOVATION 2025 CALL FOR PROPOSALS	2	1
HEALTH RESEARCH CALL FOR PROPOSALS 2026	1	
LUZÓN FOUNDATION	**1**	
UNZUÉ-LUZÓN GRANTS 2025	1	
MUTUA MADRILEÑA FOUNDATION	**3**	
GRANTS FOR HEALTH RESEARCH PROJECTS 2025	3	
SAN RAFAEL FOUNDATION	**1**	
GRANTS FOR RESEARCH PROJECTS 2025	1	
SPANISH DIABETES SOCIETY FOUNDATION	**1**	
SED GRANTS FOR RESEARCH PROJECTS LED BY YOUNG RESEARCHERS 2025	1	
SPANISH SOCIETY OF MEDICAL ONCOLOGY FOUNDATION	1	
SEOM-SEOR 2025 RESEARCH PROJECT GRANT	1	
GILEAD SCIENCES, S.L.U.	**2**	**1**
GILEAD BIOMEDICAL RESEARCH GRANTS 2025	2	1
MUTUAL MÉDICA, MUTUALIDAD DE PREVISION SOCIAL A PRIMA UNICA	**1**	
MUTUAL MÉDICA GRANT 2025	1	

	Applied for	Awarded
COMPETITIVE RESEARCH PROJECTS:	**275**	**47**
SPANISH SOCIETY OF ORTHOPEDIC SURGERY AND TRAUMATOLOGY	**2**	**2**
GRANTS FOR RESEARCH AND START-UP PROJECTS IN ORTHOPEDIC SURGERY AND TRAUMATOLOGY 2025	2	2
SPANISH SOCIETY OF EMERGENCY AND URGENT CARE MEDICINE	**1**	
FEMUE JUAN G. ARMENGOL RESEARCH GRANTS 2025	1	
SPANISH SOCIETY OF RADIOTHERAPY ONCOLOGY	**1**	
IRAD-FEOR 2025 RADIOTHERAPY ONCOLOGY RESEARCH PROJECT	1	
REGIONAL	**139**	**9**
Public	**136**	**7**
REGIONAL MINISTRY OF HEALTH, PRESIDENCY, AND EMERGENCIES	136	7
PUBLIC-PRIVATE COLLABORATION RESEARCH AND INNOVATION PROJECTS 2025	3	1
RESEARCH PROJECTS IN PRIMARY CARE, REGIONAL HOSPITALS, AND CHARES 2025	8	2
GENERAL HEALTH RESEARCH PROJECTS 2025	65	4
STRATEGIC HEALTH INNOVATION PROJECTS 2025	6	
STRATEGIC RESEARCH PROJECTS FOR EMERGING GROUPS 2025	9	
STRATEGIC RESEARCH PROJECTS ON CHRONIC DISEASES AND PATIENTS WITH MULTIPLE CONDITIONS 2025	7	
STRATEGIC RESEARCH PROJECTS ON RARE DISEASES 2025	6	
STRATEGIC RESEARCH PROJECTS IN PERSONALIZED MEDICINE AND ADVANCED THERAPIES 2025	23	
STRATEGIC RESEARCH PROJECTS IN DIGITAL HEALTH AND ARTIFICIAL INTELLIGENCE (AI) AND REAL-WORLD EVIDENCE – IRWD 2025	8	
STRATEGIC RESEARCH PROJECTS IN PUBLIC HEALTH AND ONE HEALTH 2025	1	
Private	**3**	**2**
ANDALUSIAN ASSOCIATION OF HEMATOLOGY AND HEMOTHERAPY	**2**	**1**
AAHH/FAETH 2025 RESEARCH GRANT APPLICATION	2	1
ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	**1**	**1**
SPAO GRANTS FOR RESEARCH IN PEDIATRICS 2025	1	1

4.4. HUMAN RESOURCES

In 2025, IBIMA Plataforma BIONAND had 187 active human resources grants funded in competitive calls.



Figure 20: Human resources grants active in 2025

The research personnel funded entirely or in part through competitive calls and research networks are as follows:

ENTITY	CALL/NETWORK	No. OF PERSONNEL FINANCED
ISCIII	i-PFIS	2
	JR	7
	MSI	7
	MSII	1
	PFIS	15
	RH	15
	SB	12
	MANAGEMENT TECH.	1
Total ISCIII		58
AECC	AECC PREDOCTORAL GRANTS 2023	3
	JUNIOR CLINICIAN 2023	3
	SENIOR CLINICIAN 2025	1
Total AECC		7
STATE RESEARCH AGENCY	PREDOCTORAL CONTRACTS FOR THE TRAINING OF DOCTORS 2021-2022	3
	RAMÓN Y CAJAL CONTRACTS	3
	GRANTS TO PROMOTE RESEARCH CONSOLIDATION 2023	3
Total STATE RESEARCH AGENCY		9
MINISTRY OF UNIVERSITIES	PREDOCTORAL CONTRACTS FOR UNIVERSITY PROFESSOR TRAINING (FPU)	1
Total MINISTRY OF UNIVERSITIES		1
EUROPEAN COMMISSION	MARIE SKLODOWSKA-CURIE	4
Total EUROPEAN COMMISSION		4
Regional Ministry of Health and Consumer Affairs	Incorporation of Postdoctoral Researchers to Groups in the Health and Research Centers of the Andalusian Public Health System	6
Total Health and Consumer Affairs		6
REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	HIRING OF PREDOCTORAL RESEARCH PERSONNEL IN TRAINING BY THE AGENTS OF THE ANDALUSIAN KNOWLEDGE SYSTEM 2021	3
Total REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION		3
REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT	RESEARCH PROGRAM 2022	26
Total REGIONAL MINISTRY OF EMPLOYMENT, COMPANIES, AND SELF-EMPLOYMENT		26
SAS	Action B. Clinical Researcher	6
	Renewal Action B Long-term reinforcement	8
	Action C. Nicolás Monardes	8
	Renewal of Action C (Nicolás Monardes program)	12
	INVESTIGA C Program	2
Total SAS		36
RD21/0002/0037	Chronic Disease and Transplant Network	2
RD21/0005/0012	Inflammatory Diseases Network	1
RD21/0016/0012	Research Network on Chronicity, Primary Care, and Health Promotion	1
PT23/00082	Innovation Platform	4

ENTITY	CALL/NETWORK	No. OF PERSONNEL FINANCED
RD21-0016-0015	Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS). LR: Maximino Redondo Bautista	1
PT23/00049	Biobank and Biomodel Platform	5
PT23/00137	CT Platform	2
CERT22/00034	Networked State Consortium for the Development of Medicines for Advanced Therapies (CERTERA)	2
RD24/0005/0011	Research Network on Chronicity, Primary Care and Prevention, and Health Promotion (RICAPPS)	4
RD24/0005/0016	Research Network on Chronicity, Primary Care and Prevention, and Health Promotion (RICAPPS)	2
RD24/0003/0012	Primary Care Addiction Research Network (RIAPAd)	3
RD24/0007/0024	Inflammatory Diseases Network (REI)	1
RD24/0007/0036	RICORS2040-Renal	1
RD24/0004/0026	Inflammatory Diseases Network (REI)	1

What's more, IBIMA Plataforma BIONAND has been granted 83 new resources out of a total of 151 applied for, which represents a success rate of 55%.



Figure 21: Human resources grants applied for and funded in 2025

The following table reflects the competitive HR grants awarded in national and regional calls in 2025 according to funding entity and grant type:

	Applied for	Awarded
COMPETITIVE HR GRANTS	**168**	**87**
NATIONAL	**97**	**43**
Public	**88**	**43**
STATE RESEARCH AGENCY	**24**	**4**
JUAN DE LA CIERVA GRANTS 2024	9	4
JUAN DE LA CIERVA GRANTS 2025	10	
GRANTS FOR TECHNICAL SUPPORT PERSONNEL (PTA) 2025	5	
CARLOS III INSTITUTE OF HEALTH	**62**	**38**
STRATEGIC HEALTH ACTION — MANAGEMENT CONTRACTS FOR HEALTH RESEARCH AT ACCREDITED HEALTH RESEARCH INSTITUTES 2025	2	1
STRATEGIC HEALTH ACTION - CONTRACTS FOR BIOINFORMATICS TECHNICIANS TO SUPPORT RESEARCH AT HEALTH RESEARCH INSTITUTES (IIS) 2025	2	1
STRATEGIC HEALTH ACTION - i-PFIS CONTRACTS: DOCTORATES HEALTH RESEARCH INSTITUTES (IIS)-BUSINESSES IN HEALTH SCIENCES AND TECHNOLOGY 2025	3	2
STRATEGIC HEALTH ACTION - JUAN RODÉS CONTRACTS 2025	4	3
STRATEGIC HEALTH ACTION - MIGUEL SERVET CONTRACTS 2025	8	6
STRATEGIC HEALTH ACTION - CONTRACTS FOR THE INTENSIFICATION OF RESEARCH ACTIVITY IN THE NATIONAL HEALTH SYSTEM (SNS) 2025	4	4
STRATEGIC HEALTH ACTION - PFIS CONTRACTS: PREDOCTORAL CONTRACTS FOR HEALTH RESEARCH TRAINING 2025	4	3
STRATEGIC HEALTH ACTION - PFIS CONTRACTS: PREDOCTORAL CONTRACTS FOR HEALTH RESEARCH TRAINING 2025 (WITH SS)	4	2
STRATEGIC HEALTH ACTION - RÍO HORTEGA CONTRACTS 2025	14	8
STRATEGIC HEALTH ACTION - SARA BORRELL CONTRACTS 2025	10	6
STRATEGIC HEALTH ACTION - MOBILITY OF RESEARCH STAFF HIRED UNDER THE AES (M-AES) 2025	7	2
MINISTRY OF SCIENCE, INNOVATION, AND UNIVERSITIES	**1**	**1**
GRANTS FOR MOBILITY STAYS FOR TEACHING AND RESEARCH STAFF 2024	1	1
MINISTRY OF LABOR AND SOCIAL ECONOMY	**1**	
HIRING OF UNEMPLOYED YOUTH: RESEARCH PROJECTS 2025	1	
Private	**9**	
SCIENTIFIC FOUNDATION OF THE SPANISH ASSOCIATION AGAINST CANCER	**9**	
AECC POSTDOCTORAL GRANTS 2026	2	
AECC PREDOCTORAL GRANTS 2026	3	
JUNIOR CLINICIAN IN THE AECC FIELD 2026	2	
AECC RESEARCHER 2026	2	

	Applied for	Awarded
COMPETITIVE HR GRANTS	**168**	**87**
REGIONAL	**71**	**44**
Public	**66**	**44**
REGIONAL MINISTRY OF HEALTH, PRESIDENCY, AND EMERGENCIES	**22**	**2**
CALL FOR THE INCORPORATION OF POSTDOCTORAL RESEARCHERS TO GROUPS IN THE HEALTH AND RESEARCH CENTERS OF THE ANDALUSIAN PUBLIC HEALTH SYSTEM 2025	22	2
ANDALUSIAN HEALTH SERVICE	**44**	**42**
ACTION A. ANNUAL REINFORCEMENT OF RESEARCH ACTIVITY IN THE CLINICAL UNITS OF THE ANDALUSIAN HEALTH SERVICE 2025	28	19
ACTION B. INCORPORATION OF CLINICAL-RESEARCH PROFESSIONALS INTO ANDALUSIAN HEALTH SERVICE CLINICAL UNITS 2025	4	3
ACTION C. PROMOTION OF TRANSLATIONAL RESEARCH IN THE CUs (NICOLÁS MONARDES PROGRAM) 2025	5	5
MARÍA CASTELLANO ARROYO TRAINING AND RESEARCH PROGRAM - UMA 2025	2	2
ACTION C RENEWAL (NICOLÁS MONARDES PROGRAM) 2025 - PHASE 1	3	3
ACTION C RENEWAL (NICOLÁS MONARDES PROGRAM) 2025 - PHASE 2	2	2
Private	**5**	
CRIS FOUNDATION FOR RESEARCH TO BEAT CANCER	**1**	
CRIS PROGRAM OF EXCELLENCE 2025	1	
LA CAIXA FOUNDATION	**2**	
POSTDOCTORAL JUNIOR LEADER-INCOMING 2025	2	
RAMÓN ARECES FOUNDATION	**2**	
GRANTS FOR THE COMPLETION OF DOCTORAL THESES IN LIFE AND MATERIALS SCIENCES 2025	2	

4.5. RICORS, RETICS, INTERNATIONAL NETWORKS, AND ISCIII AND CIBER PLATFORMS

RICORS:

AREA	NETWORK NAME	IBIMA PARTICIPATION	IBIMA LR	GROUP(S)
PRIMARY CARE, CHRONICITY, AND HEALTH PROMOTION	RESEARCH NETWORK ON CHRONIC DISEASES, PRIMARY CARE, AND HEALTH PROMOTION (RICAPPS) RD24-0005-0016	RESEARCH GROUP	Maximino Redondo	B-14
	RESEARCH NETWORK ON CHRONIC DISEASES, PRIMARY CARE, AND HEALTH PROMOTION (RICAPPS) RD21/ 0016/ 0012	RESEARCH GROUP	Juan Ángel Bellón Saameño	C-02
	RESEARCH NETWORK ON PRIMARY CARE FOR ADDICTIONS (RIAPAd) RD24/0003/012	RESEARCH GROUP	Fernando Rodríguez de Fonseca	C-06
INFLAMMATION AND IMMUNOPATHOLOGY OF ORGANS AND SYSTEMS	INFLAMMATORY DISEASES RICORS-REI RD24-0007-0036	RESEARCH GROUP	Antonio Fernández Nebro	D-03
	INFLAMMATORY DISEASES RICORS-REI RD24/0007/0024	RESEARCH GROUP	María José Torres Jaén	D-04
	INFLAMMATORY DISEASES RICORS-REI	ASSOCIATED CLINICAL GROUP	Carlos Rodríguez Escalera	DA-06
	INFLAMMATORY DISEASES RICORS-REI	ASSOCIATED CLINICAL GROUP	Carmen Alba Linero	DE-10
	RICORS2040 (KIDNEY DISEASE RD21-0005-0012	RESEARCH GROUP	Verónica López Jiménez	A-11
CEREBRAL VASCULAR DISEASES	RICORS-ICTUS	ASSOCIATED CLINICAL GROUP	Carlos de la Cruz Cosme	A-09
ADVANCED THERAPIES	RICORS TERAV	COLLABORATING RESEARCHER	Antonio Rodriguez Acosta	ECAI-06

INTERNATIONAL NETWORKS

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
A-02	CA23151 (Medi-CaSE) - Mediterranean Cancer Screening and Early Diagnosis Network	NETWORK	EUROPEAN COMMISSION	MANUEL MACIAS GONZÁLEZ
A-02	CA20110 (exRNA-PATH) - RNA communication across kingdoms: new mechanisms and strategies in pathogen control	NETWORK	EUROPEAN COMMISSION	MARIA MERCEDES CLEMENTE POSTIGO
A-02	CA20117 (Mye-InfoBank) - Conversion of myeloid cell molecular profiles into inflammation and cancer biomarkers	NETWORK	EUROPEAN COMMISSION	ALMUDENA ORTEGA GOMEZ
A-02	CA23110 (INFOGUT) - International networking on in vitro colon models simulating gut microbiota mediated interactions	NETWORK	EUROPEAN COMMISSION	PATRICIA RUIZ LIMON/ LOURDES GARRIDO SÁNCHEZ/ DANIEL HINOJOSA NOGUEIRA/ CAROLINA GUTIÉRREZ REPISO
A-02/ B-04	CA23146(EURO-VALDI-NET) - European vascular liver diseases network	NETWORK	EUROPEAN COMMISSION	LOURDES GARRIDO SÁNCHEZ/ BEATRIZ MARTÍNEZ POVEDA
A-02/ D-01	CA20128 (PIMENTO): Promoting Innovation of fermented foods	NETWORK	EUROPEAN COMMISSION	ISABEL MORENO INDIAS/ PATRICIA RUIZ LIMON/ CAROLINA GUTIÉRREZ REPISO/ CARMEN MARÍA GONZÁLEZ DOMENECH
A-02/ C-06/ C-16	CA22114 (TREARURE) - Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	NETWORK	EUROPEAN COMMISSION	Mª SONSOLES MORCILLO ESPINA/ ADRIANA CASTRO ZAVALA/ ERNESTO GONZÁLEZ MESA/ MARÍA FERNANDA LARA CABANÁS
A-02/ B-14/ BE-18/ BE-21	CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer	NETWORK	EUROPEAN COMMISSION	MANUEL MACÍAS GONZÁLEZ/ DESIRÉE MARTÍN GARCÍA/ MARILINA GARCIA ARANDA/ MELISSA GARCÍA CABALLERO/ ALEJANDRO ESCAMILLA SANCHEZ
A-03	CA24112 Implementation of Tear Fluid Biomarkers in Precision Medicine (TEAR-Precision)	NETWORK	EUROPEAN COMMISSION	MANUEL FRANCISCO JIMÉNEZ NAVARRO
A-03	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-03	CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-03	CA20137 (VOICES) - Making Young Researchers' Voices Heard for Gender Equality	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-03/ C-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	NETWORK	EUROPEAN COMMISSION	JORGE RODRIGUEZ CAPITAN/ ANA BELÉN PABA DOTES
A-03/ C-01	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO/ BEATRIZ GARCIA DIAZ
A-06	CA21147 (ENOTTA) - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases	NETWORK	EUROPEAN COMMISSION	MARIA DEL MAR AYALA GUTIÉRREZ
A-19/ D-01	CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	NETWORK	EUROPEAN COMMISSION	PILAR SÁNCHEZ YAÑEZ/ CARMEN MARÍA GONZÁLEZ DOMENECH
A-19/ C-13	CA21168 (JIR-CliPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	NETWORK	EUROPEAN COMMISSION	ROCIO GALINDO ZAVALA/ EVA TIMONET ANDREU
A-21/ B-14/ F-14	CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care	NETWORK	EUROPEAN COMMISSION	AIDA RAIGÓN PONFERRADA/ MARÍA PADILLA RUIZ/ CRISTINA ROLDÁN JIMÉNEZ
B-14	CA21139 (IMPROVE) - 3Rs concepts to improve the quality of biomedical science	NETWORK	EUROPEAN COMMISSION	MARILINA GARCIA ARANDA
B-14	CA23119 (SENESCENCE2030) - Targeting Cell Senescence to Prevent Age-Related Diseases	NETWORK	EUROPEAN COMMISSION	MARILINA GARCIA ARANDA
BE-18	CA21154 (TRANSLACORE) - Translational control in Cancer European Network	NETWORK	EUROPEAN COMMISSION	MELISSA GARCÍA CABALLERO
C-02/ C-03	CA23153 (YouthDMH) - Digital Mental Health for Young People	NETWORK	EUROPEAN COMMISSION	MARIA RODRIGUEZ GARCIA/ SONIA CONEJO CERÓN/ JOSÉ GUZMAN PARRA/ JESSICA MARIAN GOODMAN CASANOVA
C-03	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	NETWORK	EUROPEAN COMMISSION	GLORIA MARGARITA GUERRERO PERTÍÑEZ

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
C-06	CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development	NETWORK	EUROPEAN COMMISSION	ANTONIA SERRANO CRIADO
C-06	CA24130 (PSY-NET): Psychedelic renaissance: turn on, tune in and drop in	NETWORK	EUROPEAN COMMISSION	JUAN SUÁREZ PÉREZ
C-13	CA24107 (SAFE-ICU) - Patient SAFety Related Outcome Measures in European ICUs	NETWORK	EUROPEAN COMMISSION	ÁNGELA ORTEGA LOPEZ
C-13/ FE-17	CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research	NETWORK	EUROPEAN COMMISSION	EVA TIMONET ANDREU/ GABRIEL ANTONIO GIJON NOGUERON/ ANA BELEN ORTEGA AVILA / RAQUEL CANTERO TELLEZ
C-16	CA21108 (NETSKINMODELS) - European Network for Skin Engineering and Modeling	NETWORK	EUROPEAN COMMISSION	MARÍA FERNANDA LARA CABANÁS
C-18	CA22106 (MDVI): Migrant Disaster Victim Identification	NETWORK	EUROPEAN COMMISSION	STELLA MARTIN DE LAS HERAS/ LETICIA OLGA RUBIO LAMIA
C-18	CA24147 (AID-AgE) Artificial Intelligence Driven Dental AgEstimation Network	NETWORK	EUROPEAN COMMISSION	LETICIA OLGA RUBIO LAMIA
D-01	CA21164 (ADVANCE-TB) - Towards an improvement in diagnostics and treatment strategies for TB control	NETWORK	EUROPEAN COMMISSION	ISABEL ASCENSION PEREZ HERNANDEZ
H-02	CA22170 (TENET) - TEndon Regeneration NETwork	NETWORK	EUROPEAN COMMISSION	IVAN DURAN JIMENEZ
HE-01	CA21151 (HAPLO-iPS) - GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELLS FROM HAPLO-SELECTED CORD BLOOD SAMPLES	NETWORK	EUROPEAN COMMISSION	MARIA ELENA GONZALEZ MUÑOZ
HE-01	CA20140 (CorEuStem) - The European Network for Stem Cell Core Facilities	NETWORK	EUROPEAN COMMISSION	MARIA ELENA GONZALEZ MUÑOZ

PARTICIPATION IN ISCIII PLATFORMS

Title	Subtype	Name of the Funding Entity	LR Name
PT23/00082 IBIMA BIONAND Platform Innovation Unit. Promotion of technological valorization, knowledge transfer, and consolidation of the industrial network.	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FERNANDO RODRÍGUEZ DE FONSECA
PT23/00049 Biobank and Biomodels Platform, cornerstone of Precision Medicine: expansion, virtualization, and internationalization of the service. Generation of organoids	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FRANCISCO JOSÉ TINAHONES
PT23/00137 Clinical Research and Clinical Trials Unit, UICEC IBIMA Plataforma BIONAND. ISCIII Clinical Research Platform: Consolidation of its international projection, comprehensive management, collaboration, and transfer.	PLATFORM	CARLOS III INSTITUTE OF HEALTH	MARIA ISABEL LUCENA GONZÁLEZ
CERT22-00034. Networked State Consortium for the Development of Medicines for Advanced Therapies (CERTERA)	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FRANCISCO JOSÉ TINAHONES

PARTICIPATION OF GROUPS IN CIBER

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
A-01	CIBERDEM CB07/08/0019 Diabetes and Associated Metabolic Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	GEMMA ROJO MARTÍNEZ
A-02	CIBEROBN CB06/03/0018 Physiopathology of Obesity and Nutrition	CIBER	CARLOS III INSTITUTE OF HEALTH	FRANCISCO TINAHONES
A-03	CIBERCV CB16/11/00360 Cardiovascular Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	MANUEL FRANCISCO JIMÉNEZ NAVARRO
B-01	CIBERONC CB16/12/00481 Cancer	CIBER	CARLOS III INSTITUTE OF HEALTH	EMILIO ALBA CONEJO
B-04	CIBERER CB06/07/0046 Rare Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	JUAN ANTONIO GARCÍA RANEA
C-09	CIBERNED Neurodegenerative Diseases CB06/05/1116	CIBER	CARLOS III INSTITUTE OF HEALTH	ANTONIA GUTIÉRREZ PÉREZ
D-05	CIBEREHD CB07/04/2008 Liver and Gastrointestinal Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	RAÚL ANDRADE

4.6. CLINICAL TRIALS

In 2025, 1550 clinical studies were conducted at IBIMA and 273 new studies were signed:



Figure 22: Active Clinical Studies (Clinical Trials and Observational Studies) in 2025



Figure 23: New Clinical Studies (Clinical Trials and Observational Studies) signed in 2025

Of the 1550 clinical studies conducted in 2025, 1120 were clinical trials. Of the 273 new studies signed, 223 were new trials. The following graphs show these active and new clinical trials according to their phase:



Figure 24: Active clinical trials in 2025



Figure 25: New clinical trials signed in 2025

Changes in the clinical trials and studies conducted at the institute during the last five years is as follows:



Figure 26: Changes in Active Clinical Trials and Observational Studies from 2021–2025

Changes in early phase (phases I and II) clinical trials conducted at the Institute in the last five years is shown below:



Figure 27: Changes in active early-phase clinical trials 2021–2025

The following figure shows changes in revenue for clinical trials conducted in the last five years:



Figure 28: Changes in clinical trial revenue 2021–2025

4.7. INNOVATION AND TRANSFER

Protection

This section summarizes the results of national and international patents and utility models applied for from 2021 to 2025 by researchers at the institute as well as the list of patents applied for in 2025 and granted from 2021 to 2025.

INDICATOR	2021	2022	2023	2024	2025
National patents and utility models	12	16	15	9	9
PCT, international extensions1	20	14	9	28	20

PCT: Requests for international extension through the Patent Cooperation Treaty procedure. International extensions of patent applications.

APPLICATIONS FOR PRIORITY PATENTS/UTILITY MODELS, INDUSTRIAL DESIGNS, AND INTELLECTUAL PROPERTY REGISTRATIONS IN 2025

TITLE	REFERENCE	APPLICATION DATE	IBIMA GROUP
APP for nutritional guidance	RPISC2511173717445	11/17/2025	A-02 Bioinformatics ECAI
A holding device for supporting a radiopharmaceutical syringe.	U202530300	02/24/2025	B-05
A method for predicting response and prognosis to immunotherapy treatment for cancer.	P202530760	08/11/2025	B-05
Composition and Use as a Photoprotectant and Photostabilizer	P202530732	08/01/2025	B-10
Biomarkers for Predicting Metastasis to the Central Nervous System in Patients with Breast Cancer	P202531230	12/22/2025	B-14
An in vitro method for the diagnosis and assessment of the clinical status of multiple sclerosis.	P202530753	08/08/2025	C-01
Biomarkers associated with multiple sclerosis.	P202530754	08/08/2025	C-01
Protein for treating growth problems and improving bone quality.	P202531227	12/22/2025	C-01 C-06 C-18
GAL (1-15) and nonselective mu-opioid receptor antagonists for use in the treatment of Alcohol Use Disorder (AUD)	P202530268	04/01/2025	C-07
Dual-functional fluorinated nanoparticles for brain targeting and transport of drugs into the brain	PT120693	10/23/2025	C-09
PROSAKI: Software and Database Design.	RPI 2506302334334	06/30/2025	Bioinformatics ECAI

INTERNATIONAL PATENT APPLICATIONS (PCT) IN 2025

TITLE	REFERENCE	APPLICATION DATE	IBIMA GROUP
A method for diagnosing patients with rheumatoid arthritis.	PCT/ ES2025/070241	05/02/2025	A-02 D-03
Epitranscriptomic biomarkers for the early detection of colorectal cancer.	PCT/ IB2025/056877	07/08/2025	A-02
Platform for a premature infant.	PCT/ ES2025/000011	03/21/2025	A-19
Method for predicting the phenotypic effects of molecular agents with therapeutic potential	PCT/ ES2025/070810	12/23/2025	B-04
Sulfamide derivatives for alcohol use disorder.	PCT/ ES2025/070620	10/15/2025	C-06
Orthopedic device for the lower limb	PCT/ ES2025/000010	03/21/2025	FE-17
Preparation of cationic carbon nanoparticles and associated gene delivery methods and systems	PCT/ ES2025/070103	02/27/2025	HE-01

NTERNATIONAL EXTENSIONS IN 2025

TITLE	APPLICATION No.	APPLICATION DATE	IBIMA
Lighting device with directional LEDs.	US19/196.615	05/01/2025	B-10
Composition for preventing and treating tauopathies.	EP25184 120	06/20/2025	C-06
Composition for preventing and treating tauopathies.	CN2025111121807	08/08/2025	C-06
Composition for preventing and treating tauopathies.	JP2025-135132	08/14/2025	C-06
Composition for preventing and treating tauopathies.	EP4045022CH EP4045022ES EP4045022GB EP4045022IE EP4045022PL	06/20/2025	C-06
Composition for preventing and treating tauopathies.	EP4045022EU	06/20/2025	C-06
Mesoporous silica nanoparticles and their use in immunoglobulin uptake.	EP23845756	02/28/2025	D-04
Device, system and activation method for intraoperatively disinfecting bone prostheses using bioelectric effect.	US18/996.553	01/17/2025	F-16

NTERNATIONAL EXTENSIONS IN 2025			
TITLE	**APPLICATION No.**	**APPLICATION DATE**	**IBIMA**
Integrated mode converter and multiplexer	EP18773768ES EP18773768BE EP18773768FR EP18773768DE EP18773768IE EP18773768GB EP18773768NL	03/11/2025	F-03
Integrated photonic biosensor with layer discrimination ability and coherent reading system, and device, assembly and methods associated with same	US19130347	05/15/2025	F-03
Waveguide, method for manufacturing a waveguide, and polarization splitter using said waveguide	EP19759632ES EP19759632GB EP19759632NL EP19759632IE EP19759632FR EP19759632BE EP19759632DE	05/14/2025	F-03
Integrated photonic biosensor with layer discrimination ability and coherent reading system, and device, assembly and methods associated with same	EP23890942	09/05/2025	F-03
Murine extracellular matrix and use thereof in cell culture	EP24763310	09/24/2025	H-03

PATENT APPLICATIONS GRANTED 2021–2025		
TITLE	APPLICATION No.	IBIMA GROUP
PARKINSON'S DISEASE AND RELATED NEURODEGENERATIVE AND/OR MOTOR DISORDERS.	P202130377	A-01 C-01 C-07
GENE EXPRESSION SIGNATURE AS A PROGNOSTIC MARKER OF RELAPSE IN PATIENTS WITH STAGE I NONSEMINOMATOUS TESTICULAR GERM CELL TUMORS	P202030506	B-01
MICRORNA SIGNATURE AS AN INDICATOR OF RISK OF EARLY RECURRENCE IN PATIENTS WITH BREAST CANCER	US 15/125.714	B-01
METHOD FOR PREDICTING OR PROGNOSTICATE RESPONSE TO TREATMENT OF MULTIPLE SCLEROSIS WITH INTERFERON BETA	EP19869444	C-01
GAL (1-15) AND ANALOGUES THEREOF FOR USE IN THE PREVENTION AND/OR TREATMENT OF ALCOHOL-RELATED EFFECTS AND DISORDERS	US16757706	C-01 C-07
RECOMBINANT PROTEIN AND USES IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS	EP 13856322.6	C-01 / D-04
FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS	US 15/529.433	C-06

PATENT APPLICATIONS GRANTED 2021–2025		
TITLE	APPLICATION No.	IBIMA GROUP
COMPOSITION FOR PREVENTING AND TREATING TAUOPATHIES	EP3789018	C-06 A-03
COMPOSITION FOR PREVENTING AND TREATING TAUOPATHIES	EP20780933	C-06 A-03
WAVEGUIDE, WAVEGUIDE PRODUCTION METHOD AND POLARISATION SPLITTER USING SAID WAVEGUIDE	SG11202013094U	F-03
INTEGRATED PHOTONIC BIOSENSOR WITH LAYER DISCRIMINATION CAPABILITY AND COHERENT READOUT SYSTEM: DEVICE, ASSEMBLY, AND METHODS ASSOCIATED WITH IT	P202230993	F-03
INTEGRATED MODE CONVERTER AND MULTIPLEXER	SG11202002241S	F-03
SUB-WAVELENGTH PERIODIC WAVEGUIDE GRATING, MODAL ADAPTER, POWER DIVIDER, AND POLARIZATION DIVIDER THAT MAKE USE OF SAID WAVEGUIDE	P202030367	F-03
SINGLE-BEAM SIDE DEFLECTOR, MULTIPLEXER/DEMULTIPLEXER, AND OPTICAL ANTENNA FEEDING DEVICE THAT INCORPORATE THE DEFLECTOR, AND METHODS THAT USE THEM	P202031204	F-03
DEVICE FOR THE INSTILLATION OF GASES INTO A BODY CAVITY	U202031502	F-05
CLAY FILTERING AND RECOVERY SYSTEM	U202331751	F-05
AORTIC OPENING GUIDE DEVICE FOR SUTURELESS PROSTHESIS IMPLANTATION	U202031652	F-05
WALKING AID HANDLE EQUIPPED WITH GALVANIC SKIN RESPONSE (GSR) AND TEMPERATURE SENSORS	U202032693	F-09
WALKING AID HANDLE EQUIPPED WITH PULSE OXIMETER	U202032695	F-09
DEVICE, SYSTEM, AND ACTIVATION PROCEDURE FOR INTRAOPERATIVE DISINFECTION OF BONE PROSTHESES THROUGH THE BIOELECTRIC EFFECT	P202230480	F-16

Collaboration with industry

Below is a summary of the indicators of collaboration between the IBIMA Plataforma BIONAND and industry. This includes active licenses, collaborations managed by FIMABIS, and technology companies founded based on a technology developed at IBIMA Plataforma BIONAND from 2021–2025.

INDICATOR	2021	2022	2023	2024	2025
Active Licenses[1]	11	13	17	18	19
Collaborations[2]	16	17	19	17	24
SPIN-OFFS/START-UPS CREATED AND ACTIVE	2	3	3	3	3

(1) The number of license agreements, not the number of licensed patent families is counted; a single license may contain several families.
(2) Contracts/agreements for conducting collaborative R&D&I projects

LICENSED/TRANSFERRED PATENT FAMILIES		
TITLE	**APPLICATION No.**	**GROUP**
LIGHTING DEVICE WITH DIRECTED LEDs	P202130442 PCT/ES2022/070297	B-10
RECOMBINANT PROTEIN AND ITS USES IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS	ES2470816-US10393758-EP2930183	C-01
METHOD FOR PREDICTING OR FORECASTING THE RESPONSE TO THE TREATMENT OF MULTIPLE SCLEROSIS WITH BETA INTERFERON	PCT/ES2019/070660-P201830953-US17281520-EP19869444.0	C-01
IN VITRO METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF MULTIPLE SCLEROSIS	EP21383087.0 PCT/EP2022/084300 MX/a/2024/006686 CL202401630 BR112024010997-6 IR140350140003001647 US18715308 NZ811638 AU2022400255 EP22830191.7 RU2024117832 CA3242713 AP202216549	C-01
USE OF ANTIOXIDANTS FOR THE TREATMENT OF COGNITIVE AND BEHAVIOURAL DISORDERS IN INDIVIDUALS WITH FRAGILE X SYNDROME	PCT/ES2011/070875-US 14/977,413-EP11848650.5	C-03
COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ALCOHOL USE DISORDERS	P201630447-PCT/ES2017/070225-EP160933084	C-06
PPAR-ALPHA AGONISTS, DUAL AGONISTS, AND COMBINATIONS FOR THE TREATMENT OF ALCOHOL USE DISORDER	PCT/ES2019/070565-P201830824-P201830825	C-06
1,2,4-OXADIAZOLE DERIVATIVES	P201030093-PCTES2011/070042	C-06
FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS	PCT/ES2015/070848	C-06
CLAVULANIC ACID COMPOSITION AND ITS DIAGNOSTIC USE IN ALLERGOLOGY	P200930781	D-04
INTEGRATED MODE CONVERTER AND MULTIPLEXER	PCT/EP2018/075753 US17837774	F-03
INTEGRATED POLARIZATION DIVIDER	P201830129 PCT/ES2019/070031	F-03
WAVEGUIDE, METHOD OF MANUFACTURING SAID WAVEGUIDE, AND POLARIZATION SPLITTER THAT MAKES USE OF SAID WAVEGUIDE	P201830653 PCT/ES2019/070452 EP19759632.3	F-03
BRICKED SUB-WAVELENGTH PERIODIC WAVEGUIDE, MODAL ADAPTER, POWER DIVIDER AND POLARISATION SPLITTER THAT USE SAID WAVEGUIDE	PCT/ES2021/070279 US17922350	F-03

LICENSED/TRANSFERRED PATENT FAMILIES		
TITLE	**APPLICATION No.**	**GROUP**
MULTIMODE INTERFERENCE COUPLER AND METHOD FOR THE STRUCTURAL CONFIGURATION THEREOF	PCT/EP2009/061149 EP09782346.2 US13060341	F-03
Integrated mode converter and multiplexer	PCT/EP2018/075753	F-03
INTEGRATED MODE CONVERTER AND MULTIPLEXER	P201731166, PCT/EP2018/075753	F-03
INTEGRATED PHOTONIC BIOSENSOR WITH LAYER DISCRIMINATION CAPABILITY AND COHERENT READOUT SYSTEM: DEVICE, ASSEMBLY, AND METHODS ASSOCIATED WITH IT	P202230993 PCT/ES2023/070688	F-03
SURFACE GRATING COUPLER SUITABLE FOR PHOTONIC DEVICES, ASSOCIATED METHOD, AND ASSEMBLY WITH SURFACE GRATING COUPLER	P202330970 PCT/ES2024/070735	F-03
MULTIVALENT HAPTEN CARRIER COMPLEXES WITH DENDRIMERS AS CARRIER PROTEIN EMULATORS	P200302737	F-10
EXTERNAL FIXATOR FOR PELVIC FRACTURES AND TENSIONER FOR OPENING THE FIXATOR	PCT/ES2013/000051-EP 13755839.1	FA-07

SPIN-OFFS/START-UPS CREATED AND ACTIVE		GROUP
GALEA Therapeutics	Research and development of drugs for the treatment of fatty liver disease and related diseases. Focusing on the disease's origin related to obesity and/or alcohol intake.	C-06
ALA Diagnostics	Development and marketing of In Vitro Diagnostic Kits for highly prevalent diseases and/or unresolved medical needs.	C-01
Bioherent	Diagnosis of drug allergies through a system based on a photonic biosensor.	D-04 F-03 F-10

INNOVATIONS GENERATED IN 2025

EXPANDED NEONATAL SCREENING

IBIMA Plataforma BIONAND Group: **ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY (A-01)**
This involves expanding the "heel prick test" to include early detection of conditions such as spinal muscular atrophy (SMA) and severe combined immunodeficiency (bubble children). The system makes it possible to identify these new conditions before they cause irreversible damage, ensuring immediate treatment that changes the baby's vital prognosis.

TCA-DIGITAL DETECTION

IBIMA Plataforma BIONAND Group: **HEMATOLOGY AND IMMUNOLOGY (BE-21)**
This methodology is a clinical assessment protocol designed for the hospital setting, optimized to analyze the correlation between problematic internet use and the development of eating disorders (EDs). Its goal is to enable the early detection by physicians of risk profiles in young patients by identifying how digital habits and social media addiction influence the severity of conditions such as anorexia and bulimia, thus facilitating personalized preventive intervention.

iDILInet: IDIOSYNCRATIC & INTEGRATED DILI NETWORK.

IBIMA Plataforma BIONAND Group: **HEPATOGASTROENTEROLOGY, PHARMACOLOGY, AND TRANSLATIONAL CLINICAL THERAPY (D-05)**
An interactive website that allows users to search for risk and protective alleles associated with DILI, linked to drugs responsible for DILI, and their relationship to candidate genes and orthologs in zebrafish, enabling users to view the interaction networks among all of them.
The website can be accessed at: http://konulabapps.bilkent.edu.tr:3838/iDILInet

ACTIVE IDEAS

The Innovation and Technology Transfer Unit of IBIMA Plataforma BIONAND had 112 active ideas and 5 lines of work based on research areas of the groups with high technology transfer potential.

These ideas are in different stages of technological maturity and represent the collective effort of the institute's research groups to generate knowledge with a potential impact on health and society.

Some 34% of the ideas are already on the market. They have been implemented in the healthcare system, licensed to third parties, or made available to the community through open resources such as bioinformatics or patient support tools.

On the other hand, 29% of the ideas are in the transfer phase. This implies that they have a result with the potential to be implemented in clinical practice, either directly or through agreements with external agents that continue their development.

In about 16% of cases, the ideas are in the development phase, with an active innovation or technology project underway. Many of these continue to progress, although they are already in the process of being transferred, which highlights the need to advance in parallel along both lines.

Only 6% of the initiatives are under analysis, either studying their technical feasibility, patentability, or seeking funding to take the next step.

Lastly, 15% of the ideas are still in the data collection phase: the information needed to evaluate them and define their potential is still being gathered.
This mind map reflects IBIMA Plataforma BIONAND's commitment to the valuation of the knowledge generated with a focus on concrete results that improve people's health and strengthen collaboration with the business environment.



Figure 29: Active ideas

4.8. CLINICAL PRACTICE GUIDELINES IMPLEMENTED IN HEALTHCARE CENTERS

- **"Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis",** GASTROENTEROLOGIA Y HEPATOLOGIA. Romero-Gomez, Manuel; Escalada, Javier; Noguerol, Mar; Perez, Antonio; Carretero, Juana; Crespo, Javier; Mascort, Juan J.; Aguilar, Ignacio; Tinahones, Francisco; Canones, Pedro; Gomez-Huelgas, Ricardo; de Luis, Daniel; Trullos, Idoia Genua; Aller, Rocio; Rubio, Miguel A.
- **"Treatment of hospitalized patient with hyperglycemia: An EFIM critically appraised and adapted guideline",** EUROPEAN JOURNAL OF INTERNAL MEDICINE. Uyaroglu, Oguz Abdullah; Ruza, Ieva; Skrha, Jan; Patoulias, Dimitrios; Bevc, Sebastjan; Bojadjiev, Biljana Ivanovska; Gomez-Huelgas, Ricardo; Bojunga, Joerg; Lesniak, Wiktoria; Carretero-Gomez, Juana; Wacker, Julio; Perez-Belmonte, Luis M.; Dicker, Dror; Petreski, Tadej; Marin-Leon, Ignacio.
- **"Management of Kidney Disease in Heart Transplant Patients: A National Delphi Survey-based Consensus Expert Paper",** TRANSPLANTATION. Garcia-Cosio Carmena, Maria Dolores; Farrero, Marta; Blasco Peiro, Maria Teresa; Crespo, Marta; Delgado Jimenez, Juan; Diaz Molina, Beatriz; Fernandez Rivera, Constantino; Garrido Bravo, Iris Paula; Lopez Jimenez, Veronica; Melilli, Edoardo; Mirabet Perez, Sonia;

Perez Tamajon, Maria Lourdes; Rangel Sousa, Diego; Rodrigo, Emilio; Cruzado, Josep Maria; Hernandez Marrero, Domingo.

- **"Childhood to adult transition in youth patients with lysosomal acid lipase deficiency: 43 recommendations from experts",** ORPHANET JOURNAL OF RARE DISEASES. Childhood to adult transition in youth patients with lysosomal acid lipase deficiency: 43 recommendations from experts.
- **"Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP",** ENDOCRINOLOGIA DIABETES Y NUTRICION. Martinez-Brocca, Maria Asuncion; Bellido, Virginia; Cardona-Hernandez, Roque; Castano, Luis; Conget, Ignacio; Fernandez, Alberto; Gila, Ana Lucia Gomez; Leiva-Gea, Isabel; Mauricio, Didac.
- **"Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP",** ANALES DE PEDIATRIA. Martinez-Brocca, Maria Asuncion; Bellido, Virginia; Cardona-Hernandez, Roque; Castano, Luis; Conget, Ignacio; Fernandez, Alberto; Gila, Ana Lucia Gomez; Leiva-Gea, Isabel; Mauricio, Didac.
- **"Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease in Spain",** NEUROLOGIA. Mascaro, R. Sivera; Sobrino, T. Garcia; Hernandez, A. Horga; Negro, A. L. Pelayo; Jimenez, A. Alonso; Pose, A. Antelo; Gallego, M. D. Calabria; Casasnovas, C.; Fernandez, C. A. Cemillan; Perez, J. Esteban; Cortes, M. Fenollar; Carrera, M. Frasquet; Petit, M. P. Gallano; Munoz, A. Gimenez; Gutierrez, G. Gutierrez; Martinez, A. Gutierrez; Morales, R. Juntas; Ciano-Petersen, N. L.; Ulloa, P. L. Martinez; Hengstl, S. Mederer; Sancho, E. Millet; Barrero, F. J. Navacerrada; Faubel, F. E. Navarrete; Fernandez, J. Pardo; Pascual, S. I. Pascual; Lucas, J. Perez; Minguez, J. Pino; Perez, M. Rabasa; Gonzalez, M. Sanchez; Sotoca, J.; Santiago, B. Rodriguez; Garcia, R. Rojas; Turon-Sans, J.; Carsiy, V. Vicent; Mantecona, T. Sevilla.
- **"Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects",** FRONTIERS IN PSYCHIATRY. Mora, Fernando; Ramos-Quiroga, Jose Antoni; Baca-Garcia, Enrique; Crespo, Jose Manuel; Gutierrez-Rojas, Luis; Madrazo, Aranzazu; Perez Costillas, Lucia; Saiz, Pilar A.; Tordera, Vicente; Vieta, Eduard.
- **"Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis",** NEFROLOGIA. Morales, Enrique; Rua-Figueroa, Inigo; Rubio, Jose Luis Callejas; Bernabeu, Ana avila; Alonso, Ricardo Blanco; Xutgla, Maria C. Cid; Juarez, Gema Fernandez; Mena-Vazquez, Natalia; Blanco, Juan Jose Rios; Escola, Joaquin Manrique; Garcia, F. Javier Narvaez; Sopena, Bernardo; Porras, Luis F. Quintana; Romero-Yusten, Susana; Laque, Roser Solans.
- **"Exercise Recommendations and Practical Considerations for Asthma Management-An EAACI Position Paper",** ALLERGY. Price, Oliver J.; Papadopoulos, Nikolaos G.; Amerigo, Dario Antolin; Backer, Vibeke; Bougault, Valerie; Del Giacco, Stefano; Gawlik, Radoslaw; Eguiluz-Gracia, Ibon; Heffler, Enrico; Janson, Christer; Mcdonald, Vanessa M.; Moreira, Andre; Simpson, Andrew; Bonini, Matteo.
- **"Protocol: Scoping review of the association between complementary feeding, growth, and immune health in infants and toddlers-An EAACI guideline paper",** PEDIATRIC ALLERGY AND IMMUNOLOGY. Venter, Carina; Alonso-Coello, Pablo; Beltran, Jessica; Bracchiglione, Javier; Fernandez-Saenz, Karina; Riera, Pau; Sola, Ivan; Arasi, Stefania; Berni Canani, Roberto; Fleischer, David; Eguiluz-Gracia, Ibon; Meyer, Rosan; Roberts, Graham; Roth-Walter, Franziska; Santos, Alexandra F.; Skypala, Isabel; Smith, Peter K.; Sokolowska, Milena; Torres, Maria J.; Vassilopoulou, Emilia; Walter, Jens; O'Mahony, Liam.
- **"Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis",** GASTROENTEROLOGIA Y HEPATOLOGIA. Romero-Gomez, Manuel; Escalada, Javier; Noguerol, Mar; Perez, Antonio; Carretero, Juana; Crespo, Javier; Mascort, Juan J.; Aguilar, Ignacio; Tinahones, Francisco; Canones, Pedro; Gomez-Huelgas, Ricardo; de Luis, Daniel; Trullos, Idoia Genua; Aller, Rocio; Rubio, Miguel A.

- **"Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis",** EUROINTERVENTION / EUROPEAN HEART JOURNAL. Paradies, V; Masiero, G; Rubboli, A; Van Beusekom, HMM; Costa, F; Capranzano, P; Degrauwe, S; Gorog, DA; Jorge, CM; Buchanan, GL; Alasnag, M; Trabattoni, D; Fraccaro, C; Sibbing, D; Dudek, D; Vilahur, G; Chieffo, A; Mehran, R; Capodanno, D; Barbato, E; Siller-Matula, JM.
- **"SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025)",** CLINICAL & TRANSLATIONAL ONCOLOGY. Guma, Josep; Palazon-Carrion, Natalia; Rueda-Dominguez, Antonio; Sequero, Silvia; Calvo, Virginia; Garcia-Arroyo, Ramon; Gomez-Codina, Jose; Llanos, Marta; Martinez-Banaclocha, Natividad; Provencio, Mariano.
- **"How to use novel antimicrobials beyond official indications: an expert consensus",** JAC-ANTIMICROBIAL RESISTANCE. Retamar-Gentil, Pilar; Alegre-Albendea, Maria; Valiente De Santis, Lucia; Caston-Osorio, Juan Jose; Marquez-Gomez, Ignacio; Corzo-Delgado, Juan Enrique; Praena-Segovia, Julia; Herrero-Rodriguez, Carmen; Esteban-Moreno, M. Angeles; Martin-Aspas, Andres; Jimenez-Aguilar, Patricia; Martinez-Marcos, Francisco Javier; Lopez-Cardenas, Salvador; Ojeda-Burgos, Guillermo; Sadyrbaeva-Dolgova, Svetlana; Anguita-Santos, Francisco; Rodriguez Bano, Jesus; Palacios-Baena, Zaira R.
- **"IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials"**, DRUG SAFETY. Steplewski, Klaudia; Walker, Lucy; Coffee, Nefeteria; Fallon, Maura; Yonemochi, Rie; Alpers, David; Rockey, Don; Lewis, James; Cohen, Eric; Caminis, John; Hey-Hadavi, Judith; Andrade, Raul Jesus; Palmer, Melissa.

RESEARCH AREAS AND GROUPS

5

5.1. PRIORITY SCIENTIFIC AREAS

SCIENTIFIC PRODUCTION

This section presents a breakdown of the scientific output data corresponding to IBIMA Plataforma BIONAND's priority research areas. To avoid duplication, publications resulting from collaborations between different groups within the area field have been counted only once. Similarly, Area 5 (IBIMA-Rare), which is multidisciplinary in nature, is not included independently in the analysis, since its publications are already accounted for in the other relevant research areas.



Figure 30: Cumulative and average impact factor by research areas



Figure 31: Percentage of publications in each area (original articles and reviews) compared to the institute as a whole



Figure 32: Percentage of publications ranked Q1 and D1 in their category (JCR) by area

ACTIVE PROJECTS



Figure 33: Active competitive research projects at the regional, national, and international level by scientific area/research units

The percentage of competitive research projects in 2025 conducted by each research area/unit is as follows:

Research Area	Research projects total assets	% of total research projects
Area 1	118	30%
Onco-Hemat. Unit	50	13%
Area 3	104	27%
Area 4	58	15%
IBIMA Tech Area	47	12%
Area 8	17	4%

IBIMA Rare area is a multidisciplinary area of the IBIMA Plataforma BIONAND formed by groups that also belong to other areas. The area is not included in this last figure and table so as not to distort the total number of active projects.

CLINICAL TRIALS

The clinical trials conducted in each scientific area/research unit of the IBIMA Plataforma BIONAND during the past year are as follows:



Figure 34: Distribution of active clinical trials by research areas/unit

AREA 1. CARDIOVASCULAR DISEASES, OBESITY, AND DIABETES. ENVIRONMENTAL DETERMINANTS AND LIFESTYLE.

Coordinator: Ricardo Gómez Huelgas. Assistant Coordinator: Rosa Bernal López

Scientific Production



Figure 35: Number of publications, number of publications led, and Impact Factor of Area 1



Figure 37: Percentage of publications in Q1 and D1 from Area 1

Selection of the five most relevant publications in the area in 2025:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-02	Mela, V; Heras, V; Iesmantaite, M; García-Martín, ML; Bernal, M; Posligua-García, JD; Subiri-Verdugo, A; Martínez-Montoro, JI; Gómez-Pérez, AM; Banderas, B; Indias, IM; Tinahones, FJ	Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis	GUT	26,2	D1	2025
A-01	Romero-Zerbo, SY; Valverde, N; Claros, S; Zamorano-Gonzalez, P; Boraldi, F; Lofaro, FD; Lara, E; Pavia, J; Garcia-Fernandez, M; Gago, B; Martin-Montañez, E	New molecular mechanisms to explain the neuroprotective effects of insulin-like growth factor II in a cellular model of Parkinson's disease	JOURNAL OF ADVANCED RESEARCH	13	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-02	Mela, V; Martín-Reyes, F; Oliva-Olivera, W; Cantarero-Cuenca, A; Sánchez-García, A; Sancho-Marín, R; González-Jimenez, A; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sanchez-Gallegos, P; Martínez-Moreno, JM; Tinahones, FJ; García-Fuentes, E; Garrido-Sánchez, L	Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	2025
A-02	Linares-Pineda, TM; Lendinez-Jurado, A; Piserra-López, A; Suárez-Arana, M; Pozo, M; Molina-Vega, M; Picón-César, MJ; Morcillo, S	Longitudinal DNA methylation profiles in saliva of offspring from mothers with gestational diabetes: associations with early childhood growth patterns	CARDIOVASCULAR DIABETOLOGY	10.6	D1	2025
A-02	Martínez-Montoro, JI; Cornejo-Pareja, I; Díaz-López, A; Sureda, A; Toledo, E; Abete, I; Babio, N; Tur, JA; Martinez-Gonzalez, MA; Martínez, JA; Fitó, M; Salas-Salvadó, J; Tinahones, FJ; PREDIMED Plus Investigators	Effect of an intensive lifestyle intervention on cystatin C-based kidney function in adults with overweight and obesity: From the PREDIMED-Plus trial	JOURNAL OF INTERNAL MEDICINE	9.2	D1	2025

118 Active research projects

219 Clinical trials

CIMO ONCO-HEMATOLOGY UNIT

Coordinator: Melissa García Caballero. Assistant Coordinator: Elisa Matas Rico / Julia Alcaide García

Scientific Production



Figure 37: No. publications, no. publications led, and Impact Factor from CIMO Onco-Hematology Unit



Figure 38: Percentage of Q1 and D1 publications from the CIMO Onco-Hematology Unit

Selection of the five most relevant publications from the Unit in 2025:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-21	Escamilla-Sanchez, A; López-Villodres, JA; Alba-Tercedor, C; Ortega-Jiménez, MV; Rius-Díaz, F; Sanchez-Varo, R; Bermúdez, D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	12.6	D1	2025
BE-17	Anaya, MJG; Tudela, AC; Gómez-Millán, J; Ocón, MJL; Rodríguez, HJ; Ríos, IG	Once-weekly ultra-hypofractionated radiation therapy for breast cancer: Outcomes from a single-institution real-world cohort	BREAST	7.9	D1	2025
B-04	García-Criado, F; Seoane, P; Rojano, E; Ranea, JAG; Perkins, JR	Advancing edge-based clustering and graph embedding for biological network analysis: a case study in RASopathies	BRIEFINGS IN BIOINFORMATICS	7.7	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-21	García-Delgado, R; Moreno-Carrasco, G; Carrasco-Gomariz, M; García-Segovia, S; Flores, RMO; Torres-González, J; Gallego-Fuillerat, G; Lopez-Villodres, JA; Escamilla-Sánchez, A	Impact of iron chelation therapy on mitochondrial function, vascular integrity and inflammation in transfusion-dependent myelodysplastic syndromes	FRONTIERS IN IMMUNOLOGY	5.9	Q1	2025
B-01	Comino-Méndez, I; Velasco-Suelto, J; Pascual, J; López-López, E; Quirós-Ortega, ME; Gaona-Romero, C; Martín-Muñoz, A; Losana, P; Heredia, Y; Alba, E; Guerrero-Zotano, A	Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer	BREAST CANCER RESEARCH	5.6	Q1	2025

AREA 3. NEUROSCIENCES, CHRONICITY, AGING, AND HEALTH IN VULNERABLE POPULATIONS.

Coordinator: Antonia Serrano Criado, Deputy Coordinator: Patricia Moreno Peral.

Scientific Production



Figure 39: No. publications, no. publications led, and Impact Factor from Area 3



Figure 40: Percentage of publications in Q1 and D1 from Area 3

Selection of the five most relevant publications in the area in 2025:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-07	Romero-Zerbo, SY; Valverde, N; Claros, S; Zamorano-Gonzalez, P; Boraldi, F; Lofaro, FD; Lara, E; Pavia, J; Garcia-Fernandez, M; Gago, B; Martin-Montañez, E	New molecular mechanisms to explain the neuroprotective effects of insulin-like growth factor II in a cellular model of Parkinson's disease	JOURNAL OF ADVANCED RESEARCH	13	D1	2025
C-09	Escamilla-Sanchez, A; López-Villodres, JA; Alba-Tercedor, C; Ortega-Jiménez, MV; Rius-Díaz, F; Sanchez-Varo, R; Bermúdez, D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	12.6	D1	2025
C-06	López-Gambero, AJ; Vargas, A; Fernández-Arjona, MD; Rubio, L; de Ceglia, M; Vera-Fernández, C; Campillo-Calatayud, A; Rivera, P; Fonseca, FRD; Barrios, V; Chowen, JA; Argente, J; Suárez, J	Alteration of IGF-1 bioavailability due to PAPPA2 deficiency leads to sex-specific metabolic disturbances	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-06	de Ceglia, M; Botticelli, L; Di Bonaventura, EM; Fuentes, AV; Di Bonaventura, MVM; de Fonseca, FR; Cifani, C	Targeting the endocannabinoid/paracannabinoid systems in binge eating behavior: Efficacy of dual ligands in a preclinical model	PHARMACOLOGICAL RESEARCH	10.5	D1	2025
C-09	Caceres-Palomo, L; Sanchez-Mejias, E; Trujillo-Estrada, L; Perez-Moreno, JJ; Lopez-Oliva, E; Lim, TE; Deflitch, L; Chang, SH; Kampman, L; Corces, MR; Blurton-Jones, M; Moreno-Gonzalez, I; Pascual, A; Vitorica, J; Garcia-Leon, JA; Gutierrez, A	Human iPSC-derived APOE4/4 Alzheimers disease astrocytes exhibit a senescent and pro-inflammatory state that compromises neuronal support	JOURNAL OF NEUROINFLAMMATION	10.1	D1	2025



AREA 4. AUTOIMMUNE DISEASES, INFECTIOUS DISEASES, INFLAMMATION, AND ALLERGY.

Coordinator: Cristobalina Mayorga Mayorga, Adjunct Coordinator: Mercedes Robles Díaz

Scientific Production



Figure 41: No. publications, no. publications led, and Impact Factor from Area 4



Figure 42: Percentage of publications in Q1 and D1 from Area 4

Selection of the five most relevant publications in the area in 2025:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-04	Gómez, F; Pérez-Sánchez, N; Macías-Camero, A; Núñez, R; Contreras, N; Cañas, JA; Jiménez-Sánchez, IM; Díez-Echave, P; Barbas, C; Guéant, JL; Barber, D; Vieths, S; Scheurer, S; Villaseñor, A; Rodríguez-Nogales, A; Mayorga, C; Torres, MJ	Multi-omics analysis of a prebiotic intervention with pectin in lipid transfer proteins (LTPs) allergic patients	CARBOHYDRATE POLYMERS	12.5	D1	2025
D-05	Bessone, F; Hernandez, N; Medina-Caliz, I; García-Cortés, M; Schinoni, MI; Mendizabal, M; Chiodi, D; Nunes, V; Ridruejo, E; Pazos, X; Santos, G; Fassio, E; Parana, R; Reggiardo, V; Tanno, H; Sanchez, A; Tanno, F; Montes, P; Tagle, M; Arrese, M; Brahm, J; Girala, M; Lizarzabal, MI; Carrera, E; Zerega, A; Bianchi, C; Reyes, L; Arnedillo, D; Cordone, A; Gualano, G; Jaureguizahar, F; Rifrani, G; Robles-Díaz, M; Ortega-Alonso, A; Pinazo-Bandera, JM; Stephens, C; Sanabria-Cabrera, J; Bonilla-Toyos, E; Niu, H; Alvarez-Alvarez, I; Lucena, MI; Andrade, RJ	Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY	12.2	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-04	Bogas, G; Ariza, A; Vázquez-Revuelta, P; Labella, M; Madrigal-Burgaleta, R; Fernández-Santamaría, R; Calvo-Serrano, S; Villar-Chamorro, E; Martín-Clavo, S; Lebrón-Martín, C; Mayorga, C; Doña, I; Torres, MJ	Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes	ALLERGY	12	D1	2025
D-04	Fernandez-Santamaria, R; Salas, M; Ariza, A; Jiménez, MA; González-Mendiola, MR; Sanchez, ML; Boteanu, C; Mayorga, C; Fernandez, TD; Torres, MJ; Laguna, JJ	Basophil Activation Test Positivity Decreases With Time in Immediate Allergic Reactions to Proton Pump Inhibitors	ALLERGY	12	D1	2025
D-04	Gelincik, A; Brockow, K; Çelik, GE; Demir, S; Diaz, ID; Ebo, DG; Mayorga, C; Labella, M; Sabato, V; Jaen, MJT	Diagnosis of Quinolone Hypersensitivity: An EAACI Position Paper	ALLERGY	12	D1	2025



Active research projects



Clinical trials

AREA 6 IBIMA TECH: HEALTH TECHNOLOGY AND INNOVATION.

Coordinator: Antonio Ignacio Cuesta Vargas. Assistant coordinator: Francisco Ángel Moreno Dueñas

Scientific Production



Figure 43: Number of publications, number of publications led, and Impact Factor for the IBIMA Tech Area



Figure 44: Percentage of publications in Q1 and D1 from the IBIMA Tech Area

Selection of the five most relevant publications in the area in 2025:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-10	Benitez-Martin, C; Najera, F; Perez-Inestrosa, E	Simultaneous dual-colour labelling of mitochondria and lysosomes: An indolium-based approach	SENSORS AND ACTUATORS B-CHEMICAL	7.7	D1	2025
F-02	Mármol-Rivera, JA; Fernández-Rodríguez, JD; Asenjo, B; López-Rubio, E	Latent diffusion for arbitrary zoom MRI super-resolution	EXPERT SYSTEMS WITH APPLICATIONS	7.5	D1	2025
F-15	Segura-Ortiz, Adrian; Gimenez-Orenga, Karen; Garcia-Nieto, Jose; Oltra, Elisa; Aldana-Montes, Jose F	Multifaceted evolution focused on maximal exploitation of domain knowledge for the consensus inference of Gene Regulatory Networks.	COMPUTERS IN BIOLOGY AND MEDICINE	6.3	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-03	Pérez-Sánchez, L; Sénchez-Ramírez, A; Leuermann, J; Molina-Fernández, I	Optical Camera-Based Multiplexed Photonic Sensor System With Ultralow Detection Limit for Biomedical Applications	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.9	D1	2025
F-14	Escriche-Escuder, A; García-Almeida, JM; Vegas-Aguilar, IM; Pajares, B; Alba, E; Trinidad-Fernández, M; Roldán-Jiménez, C; Cuesta-Vargas, AI	Effect of a 12-week exercise program on phase angle in women with breast cancer	SUPPORTIVE CARE IN CANCER	3	D1	2025



AREA 7. NANODIAGNOSTICS.

Coordinator: María Luisa García Martín

Scientific Production



Figure 45: Number of publications, number of publications led, and Impact Factor from Area 7.



Figure 46: Percentage of publications in Q1 and D1 in Area 7.

Selection of the five most relevant publications in the area in 2025:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
G-01	Perez-Carrasco, Virginia; Soriano-Lerma, Ana; Guzzi, Cinzia; Garcia-Martin, Maria Luisa; Tello, Maria J.; Linde-Rodriguez, Angel; Sanchez-Martin, Victoria; Ortiz-Gonzalez, Matilde; Gutierrez-Fernandez, Jose; Alarcon-Riquelme, Marta E.; Soriano, Miguel; Maranon, Concepcion; Garcia-Salcedo, Jose A.	Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	BIOMARKER RESEARCH	11.5	D1	2025
G-01	Caro, Carlos; Paez-Munoz, Jose M.; Pernia Leal, Manuel; Carayol, Marta; Feijoo-Cuaresma, Monica; Garcia-Martin, Maria L.	Metabolically-Driven Active Targeting of Magnetic Nanoparticles Functionalized with Glucuronic Acid to Glioblastoma: Application to MRI-Tracked Magnetic Hyperthermia Therapy	ADVANCED HEALTHCARE MATERIALS	9.6	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
G-01	Mela, Virginia; Heras, Violeta; Iesmantaite, Monika; Garcia-Martin, Maria Luisa; Bernal, Manuel; Posligua-Garcia, Joel D.; Subiri-Verdugo, Alba; Martinez-Montoro, Jose Ignacio; Gomez-Perez, Ana Maria; Banderas, Borja; Moreno Indias, Isabel; Tinahones, Francisco J.	Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis	GUT	26.2	D1	2025
G-01	Caro, Carlos; Arias-Ramos, Nuria; Urbano-Gamez, Jesus David; Gonzalez-Alday, Raquel; Lopez-Larrubia, Pilar; Garcia-Martin, Maria Luisa	A multiparametric perspective on C6 and F98 cell lines in orthotopic rat models for glioblastoma research	SCIENTIFIC REPORTS	3.9	Q1	2025
G-01	Avasthi, A; Fernandez-Afonso, Y; Gutiérrez, L; de la Fuente, JM; Leal, MP; Caro, C; Garcia-Martin, ML	Protein corona as the key factor governing the in vivo fate of magnetic nanoparticles	BIOMATERIALS SCIENCE	5.7	Q2	2025



Active research projects

AREA 8. NANOSYSTEMS AND ADVANCED THERAPIES

Coordinator: Elena González Muñoz

Scientific Production



Figure 47: No. publications, no. publications led, and Impact Factor from Area 8



Figure 48: Percentage of publications in Q1 and D1 from Area 8

Selection of the five most relevant publications in the area in 2025:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
HE-01	Ducic, T; Pereiro, E; Ninkovic, M; Sperling, S; Rohde, V; Fernández-González, C; Algarra, M; González-Muñoz, E	Single-cell in situ mapping of glioblastoma and astrocyte cell lines treated with a carbon dot-mediated riluzole nanotherapeutic agent: a live-cell μFTIR and soft X-ray tomography approach	JOURNAL OF NANOBIOTECHNOLOGY	12.6	D1	2025
H-03	Ruiz-Villalba, A; Pardo-Saganta, A	Emerging concepts and novel mechanisms in organ fibrosis	NPJ REGENERATIVE MEDICINE	6.5	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
H-02	Maaloul, A; Manríquez, CP; Decara, J; Marí-Beffa, M; alvarez-Torres, D; Redoli, SL; Martínez-Albardonedo, B; Araya-Rojas, M; Fajardo, V; Díaz, RTA	Biological Effects of Polysaccharides from Bovistella utriformis as Cytotoxic, Antioxidant, and Antihyperglycemic Agents: In Vitro and In Vivo Studies	PHARMACEUTICS	5.5	D1	2025
HE-01	Ducic, T; Rodriguez-Yañez, F; Gonzalez-Muñoz, E	Synchrotron radiation FTIR microspectroscopy enables measuring dynamic cell identity patterning during human 3D differentiation	FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY	4.3	Q1	2025
H-03	Oliveira, CC; Cordoba, J; Pearson, JR; Guruceaga, E; Marín-Sedeño, E; Lopez-Moreno, M; Guadix, JA; García-Caballero, M; Pérez-Pomares, JM; Ruiz-Villalba, A	Revealing the complexity of the epicardial secretome	SCIENTIFIC REPORTS	3.9	Q1	2025



Active research projects

5.2. RESEARCH GROUPS

AREA 1. CARDIOVASCULAR DISEASES, OBESITY, AND DIABETES. ENVIRONMENTAL DETERMINANTS AND LIFESTYLE

CONSOLIDATED GROUPS

A-01. ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY.

LR Gabriel Olveira Fuster Gabriel. Co-LR Javier Bermúdez Silva

Priority line of research: Obesity, diabetes, and clinical nutrition.

Other lines:

1. Obesity and translational diabetes: adipose tissue and beta cell metabolism:
   - Pathophysiology of the pancreatic islet in type 2 diabetes.
   - Prevention of type 2 diabetes and the inflammatory processes that underlie and precede so-called “beta-cell failure”
   - Role of angiogenesis in the regulation of adipose tissue expansion in relation to obesity and type 2 diabetes.
   - Role of angiogenic microRNAs in the regulation of white, brown, and beige adipose tissue functionality
   - Role of microbiota in obesity and type 2 diabetes
   - Study of the cause-effect relationship between obesity and mental illnesses
   - Thymic adipose tissue as a source of angiogenesis for blood vessel neogeneration in older adult subjects with ischemic heart disease.
2. New approaches in clinical-experimental research in diabetes and metabolism and clinical nutrition applied to chronic diseases:
   - type 1 diabetes, new technology, biomarkers, and psychosociological approach
   - Clinical nutrition and dietetics applied to artificial nutrition
   - Surgical morbid obesity: clinical experimental models
   - Hypogonadism and glomerulopathy associated with obesity.
   - Clinical nutrition in chronic diseases (cystic fibrosis and bronchiectasis, cancer, and neurological diseases)
   - New methods for the assessment of nutritional status and their prognostic value
3. Epidemiology and risk factors for diabetes and related metabolic diseases
   - Epidemiology of diabetes mellitus, obesity, and related metabolic diseases in Spain and Andalusia (prevalence and incidence)
   - Study of new prognostic ecological markers (environmental pollution) for hydrocarbon metabolism abnormalities.
   - Study of biomarkers predictive of diabetes and metabolic diseases (e.g. mRNA, genetic, epigenetic, and biochemical biomarkers).
   - Epidemiology of thyroid diseases in Spain and iodine deficiency disorders.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-01	Soria-Utrilla, V; Vero, C; Romero-Zerbo, SY; Adarve-Castro, A; López-Urdiales, R; Herranz-Antolín, S; García-Almeida, JM; García-Malpartida, K; Ferrer-Gómez, M; Moreno-Borreguero, A; Luengo-Pérez, LM; Alvarez-Hernández, J; Aragón-Valera, C; Ocón-Bretón, MJ; García-Manzanares, A; Bretón-Lesmes, I; Serrano-Aguayo, P; Pérez-Ferre, N; López-Gómez, JJ; Olivares-Alcolea, J; Moreno-Martínez, M; Tejera-Pérez, C; García-Arias, S; Abad-González, AL; Alhambra-Expósito, MR; Zugasti-Murillo, A; Parra-Barona, J; Torrejón-Jaramillo, S; Abuin, J; Fernández-García, JC; Olveira, G	Biomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial	CLINICAL NUTRITION	7.4	D1	2025
A-01	Martínez-Montoro, JI; Aparicio-Sánchez, JJ; Pimentel, B; Juárez-Campo, M; Alamillo, ML; Fernández-García, JC	Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study	DIABETES RESEARCH AND CLINICAL PRACTICE	7.4	D1	2025
A-01	Padial, M; Rebollo, A; Jiménez-Salcedo, T; López, V; Avesani, CM; Lindholm, B; Qureshi, AR; Olveira, G	A Pilot Clinical Trial of a Nutrition Education Program on Quality of Life in CKD	CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY	7.1	D1	2025
A-01	Gutiérrez, P; Jiménez, L; Martínez, J; Alba, C; Girón, MV; Olveira, G; Ruiz-Esteban, P; Olveira, C	Dry eye disease and morphological changes in the anterior chamber in people with cystic fibrosis	JOURNAL OF CYSTIC FIBROSIS	6	Q1	2025
A-01	Mucarzel, F; Peláez, PG; Utrilla, VS; Jiménez, RF; Candia, FP; Torralvo, FJS; Peláez, RB; Almeida, JMG; Olveira, G	Sex-specific CT-derived muscle and fat phenotypes in colon cancer: implications for nutritional and metabolic assessment	FRONTIERS IN NUTRITION	5.1	Q1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
52	33%	67%	23%	249



Networks and Ciber:
CIBERDEM CB07/08/0019 Diabetes and Associated Metabolic Diseases (ISCIII).

Competitive HR contracts funded in 2025:
2 Sara Borrell Contracts (ISCIII)
3 Río Hortega Contract (ISCIII).
2 PFIS Contracts (ISCIII)
1 i-PFIS contract (ISCIII).
1 Contract for the intensification of research activity in the SNS (ISCIII)
1 Juan de la Cierva Contract (AEI)
4 Nicolás Monardes SAS contracts (Action C).
1 Investiga C Program Contract (SAS).
1 Contract for long-term reinforcement of the SAS (Action B).
1 Contract for the incorporation of clinical-research professionals into SAS clinical units.

A-02. OBESITY, DIABETES, AND THEIR COMORBIDITIES: PREVENTION AND TREATMENT.

LR Francisco Tinahones Madueño. Co-LR Manuel Macias González. Co-LR Isabel Moreno Indias

Priority line of research: Study of metabolic diseases: diabetes and obesity

Other lines:

1. Gut microbiota, insulin resistance, and obesity.
2. Role of adipobiology in metabolic diseases.
3. Metabolic effect of bariatric surgery.
4. Environmental factors in the genesis of obesity and diabetes.
5. Novel cellular and molecular mechanisms of inflammation in metabolic diseases: obesity, diabetes, and cancer
6. Genetic and epigenetic factors in the prevention, progression, and treatment of diabetes.
7. PREDIMED PLUS study.
8. Dietetic-therapeutic approach to obesity: role of ketosis, intermittent fasting, physical exercise, and chronobiology.
9. Mitochondrial fitness in metabolic diseases.
10. Endocrine-metabolic complications of obesity: NFALD.
11. Hyperlipoproteinemia, insulin resistance, and atherosclerotic disease.
12. Analysis of biomarkers of response to a weight loss intervention.
13. Immunity of metabolic diseases.
14. Role of gestation and lactation in the onset of metabolic diseases

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-02	Mela, V; Heras, V; Iesmantaite, M; García-Martín, ML; Bernal, M; Posligua-García, JD; Subiri-Verdugo, A; Martínez-Montoro, JI; Gómez-Pérez, AM; Banderas, B; Indias, IM; Tinahones, FJ	Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis	GUT	26	D1	2025
A-02	Mela, V; Martín-Reyes, F; Oliva-Olivera, W; Cantarero-Cuenca, A; Sánchez-García, A; Sancho-Marín, R; González-Jimenez, A; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sanchez-Gallegos, P; Martínez-Moreno, JM; Tinahones, FJ; García-Fuentes, E; Garrido-Sánchez, L	Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery	METABOLISM-CLINICAL AND EXPERIMENTAL	12	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-02	Linares-Pineda, TM; Lendinez-Jurado, A; Piserra-López, A; Suárez-Arana, M; Pozo, M; Molina-Vega, M; Picón-César, MJ; Morcillo, S	Longitudinal DNA methylation profiles in saliva of offspring from mothers with gestational diabetes: associations with early childhood growth patterns	CARDIOVASCULAR DIABETOLOGY	11	D1	2025
A-02	Martínez-Montoro, JI; Cornejo-Pareja, I; Díaz-López, A; Sureda, A; Toledo, E; Abete, I; Babio, N; Tur, JA; Martinez-Gonzalez, MA; Martínez, JA; Fitó, M; Salas-Salvadó, J; Tinahones, FJ; PREDIMED Plus Investigators	Effect of an intensive lifestyle intervention on cystatin C-based kidney function in adults with overweight and obesity: From the PREDIMED-Plus trial	JOURNAL OF INTERNAL MEDICINE	9.2	D1	2025
A-02	Martínez-Montoro, JI; Bandera, B; Gutiérrez-Bedmar, M; Gómez-Pérez, AM; Macías-González, M; Moreno-Indias, I; Tinahones, FJ	Effect of a ketogenic diet, time-restricted eating, or alternate-day fasting on weight loss in adults with obesity: a randomized clinical trial	BMC MEDICINE	8.3	D1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
83	42%	77%	31%	506



Networks and Ciber:

CA20128 (PIMENTO): Promoting Innovation of fermented foods (European Commission)
CA20117 (Mye-InfoBank) - Conversion of Myeloid Cell Molecular Profiles into Biomarkers of Inflammation and Cancer (European Commission)
CA23151 (Medi-CaSE) - Mediterranean Cancer Screening and Early Diagnosis Network (European Commission)
CA23110 (INFOGUT) - International networking on in vitro colon models simulating gut microbiota mediated interactions (European Commission)

CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer (European Commission)
CA23146(EURO-VALDI-NET) - European vascular liver diseases network (European Commission)
CA22114 (TREARURE) - Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development (European Commission)
CA20110 (exRNA-PATH) - RNA communication across kingdoms: new mechanisms and strategies in pathogen control (European Commission)
CERT22/00034. Networked State Consortium for the Development of Medicines for Advanced Therapies
CIBEROBN CB06/03/0018 Physiopathology of Obesity and Nutrition (ISCIII)

Competitive HR contracts funded in 2025:
2 PFIS Contracts (ISCIII)
1 Río Hortega Contract (ISCIII)
1 Juan Rodés Contract (ISCIII)
2 Sara Borrell Contracts (ISCIII)
4 Miguel Servet I Contracts(ISCIII)
2 Miguel Servet II Contracts (ISCIII)
3 Nicolás Monardes SAS contracts (Action C).

A-03. CARDIOVASCULAR RESEARCH FOR HEALTH.

LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas, Co-LR Francisco Javier Pavón Morón

Lines of research:
1. Ischemic heart disease: New preventive, diagnostic, and therapeutic approaches.
2. Biomarkers and risk factors for cardiovascular disease.
3. Valvular and aortic diseases: Molecular and genetic bases.
4. Pulmonary hypertension and rare diseases.
5. Cardiometabolic diseases: sexual dimorphism and lifestyles.
6. Clinical and translational research in arrhythmias, cardiomyopathies, and heart failure.
7. New information and communication technology in cardiovascular research.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-03	Robles-Mezcua, Ainhoa; Januzzi, James L; Pavon-Moron, Francisco Javier; Rodriguez-Capitan, Jorge; Lopez-Garrido, Miguel A; Cruzado-Alvarez, Concepcion; Robles-Mezcua, Maria; Gutierrez-Bedmar, Mario; Couto-Mallon, David; Rueda-Calle, Eloy C; Barreiro-Perez, Manuel; Sanchez, Pedro L; Gomez-Doblas, Juan Jose; Jimenez-Navarro, Manuel F; Garcia-Pinilla, Jose M	Effects of sacubitril/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniques.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	2025
A-03	Jiménez-Salva, M; Carmona-Segovia, A; Molina-Ramos, AI; García-Rodríguez, L; Puyol-Ruiz, F; Doncel-Abad, V; Romero-Cuevas, M; Serrano, A; Muñoz-García, A; Flores-López, M; Ortega-Gómez, A; Gutiérrez-Bedmar, M; Rodríguez-Capitán, J; Jiménez-Navarro, M; Pavón-Morón, FJ	Older adults with acute coronary syndrome: the impact of frailty and nutritional status on in-hospital complications	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	2025
A-03	Segovia, ADMC; Becerra-Muñoz, VM; Arjona, MJJ; Velasco, VN; Ochoa, N; Barberà, JA; López-Meseguer, M; Asencio, JMM; Blanco, I; Subias, PE	Real-life use of validated quality of life questionnaires in patients with pulmonary arterial hypertension in Spain: a cross-sectional study	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-03	Thurnhofer-Hemsi, K; García-Aguilar, I; Fernández-Rodriguez, JD; López-Rubio, E	Representation of Molecules by Sequences of Instructions	JOURNAL OF CHEMICAL INFORMATION AND MODELING	5.3	Q1	2025
A-03	Medina-Vera, D; Martín-Chaves, L; Sánchez-Marín, L; Díaz-Ottaviano, M; Gavito, AL; Popova, O; Sánchez-Quintero, MJ; Rodríguez-Capitán, J; de Fonseca, FR; Jiménez-Navarro, MF; Serrano, A; Pavón-Morón, FJ	Maladaptive stress-coping behavior in CX3CR1-deficient mice: Impact of adolescent stress and alcohol exposure on neuroimmune responses and inflammation	NEUROPHARMACOLOGY	4.6	Q1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
55	38%	69%	25%	346



Networks and Ciber:

CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (European Commission)

CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities (European Commission)

(European Commission)

CA20137 (VOICES) - Making Young Researchers' Voices Heard for Gender Equality (European Commission)

CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure (European Commission)

CA19101 (DE-PASS) - Determinants of Physical Activities in Settings (European Commission)

CA24112 Implementation of Tear Fluid Biomarkers in Precision Medicine (TEAR-Precision) (European Commission)

CIBERCV CB16/11/00360 Cardiovascular Diseases (ISCIII)

Competitive HR contracts funded in 2025:

1 Contract ERC GRANT 2023 (Juan Rodés Contract - ISCIII)

2 PFIS Contracts (ISCIII)

2 Río Hortega Contracts (ISCIII)

1 Contract for the intensification of research activity in the SNS (ISCIII)

1 Contract for the annual reinforcement of the research activity in the SAS clinical units (Action A)

1 Nicolás Monardes SAS Contract (Action C).

A-06. DIABETES, OBESITY, AND OTHER VASCULAR RISK FACTORS. SYSTEMIC AUTOIMMUNE DISEASES.

LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal López

Priority line of research: Diabetes, obesity, and other cardiovascular risk factors

Other lines:

1. Systemic Autoimmune Diseases
2. Chronic diseases Older Adult Diseases
3. Thromboembolic disease

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-06	Trenas, A; Perez-Velasco, MA; Bernal-López, MR; López-Carmona, MD; Gómez-Doblas, JJ; Martinez-Esteban, MD; Bouarich, O; Garcia-Casares, N; Fernández-Garcia, D; de Lucas, MDG; Gómez-Huelgas, R; Perez-Belmonte, LM	Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	Q1	2025
A-06	Florido-Santiago, M; Pérez-Belmonte, LM; Lara, JP; Millán-Gomez, M; Pérez-Velasco, MA; Osuna-Sánchez, J; García-Casares, N; Gomez-Huelgas, R; Blanco-Reina, E; Barbancho, MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	2.8	Q2	2025
A-06	Vargas-Molina, S; García-Sillero, M; Maroto-Izquierdo, S; Baz-Valle, E; Bautista-Mayorga, B; Murri, M; Schoenfeld, BJ; Benítez-Porres, J	Cluster sets and traditional sets elicit similar muscular hypertrophy: a volume and effort-matched study in resistance-trained individuals	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY	2.7	Q2	2025
A-06	Vargas-Molina, S; García-Sillero, M; Jiménez-García, JD; Carbone, L; Bonilla, DA; Petro, JL; Romance, R; Benítez-Porres, J	Effects of a Nonlinear Program on Different Health Parameters in the Elderly	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH	2.6	Q2	2025
A-06	Castro, N; Benítez-Porres, J; Carbone, L; Chulvi, I; Bonilla, DA; Petro, JL; Peña, J; Vargas-Molina, S	Effects of Hip-Dominant Strength Exercises on Post-Activation Performance Enhancement	APPLIED SCIENCES-BASEL	2.5	Q2	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
19	68%	26%	16%	68



Networks:
CA21147 (ENOTTA) - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (European Commission)

Competitive HR contracts funded in 2025:
1 PFIS Contract (ISCIII)

1 Río Hortega Contract (ISCIII)

1 Contract for the intensification of research activity in the SNS (ISCIII)

1 Contract for the annual reinforcement of the research activity in the SAS clinical units (Action A)

1 Nicolás Monardes SAS Contract (Action C).

A-07. TRANSLATIONAL RESEARCH IN CARDIOVASCULAR DISEASE.

LR José Antonio González Correa. Co-LR José Pedro de la Cruz Cortés

Priority line of research: Translational research on the effect of olive oil polyphenols on vascular inflammation and micro-and macroagiopathic complications in patients with type 2 diabetes

Other lines of research:

1. Evaluation of biomarkers and risk factors related to the progression of diabetic retinopathy
2. Evaluation of the level of response to antiplatelet therapy with acetylsalicylic acid in patients with type 2 diabetes in primary care
3. Characterization of functional fractions of olives, formulation of new products, and analysis of their effects
4. Intensification of pharmacovigilance activities through an organizational change and training intervention in a primary care clinical management unit (UGC)

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-07	Escamilla-Sanchez, A; López-Villodres, JA; Alba-Tercedor, C; Ortega-Jiménez, MV; Rius-Díaz, F; Sanchez-Varo, R; Bermúdez, D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	13	D1	2025
A-07	García-Delgado, R; Moreno-Carrasco, G; Carrasco-Gomariz, M; García-Segovia, S; Flores, RMO; Torres-González, J; Gallego-Fuillerat, G; Lopez-Villodres, JA; Escamilla-Sánchez, A	Impact of iron chelation therapy on mitochondrial function, vascular integrity and inflammation in transfusion-dependent myelodysplastic syndromes	FRONTIERS IN IMMUNOLOGY	5.9	Q1	2025
A-07	Ruiz-Malagon, AJ; Herraiz-Vilela, M; Serrano-Pino, R; García-Avila, P; Díaz-Suárez, L; Carmona-Segovia, AD; Becerra-Munoz, VM; Jiménez-Navarro, M; Arranz-Salas, I; Lopez-Villodres, JA; Fernández-Castañer, A; Gutiérrez-Martínez, F; Rodríguez-González, FJ; Camargo-Camero, R; Alcaín-Martínez, G; Rodríguez-Díaz, C; García-Fuentes, E; Sánchez-Quintero, MJ; Lopez-Gomez, C	Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease	WORLD JOURNAL OF GASTROENTEROLOGY	5.4	Q1	2025
A-07	Gavilán, P; Gavilán, JC; Clavijo, E; Viciana, I; Gonzalez-Correa, JA	A prediction model for complications caused by portal hypertension or liver cancer in a Spanish cohort of chronic hepatitis B patients	REVISTA CLINICA ESPANOLA	1.7	Q2	2025
A-06	Castro, N; Benítez-Porres, J; Carbone, L; Chulvi, I; Bonilla, DA; Petro, JL; Peña, J; Vargas-Molina, S	Effects of Hip-Dominant Strength Exercises on Post-Activation Performance Enhancement	APPLIED SCIENCES-BASEL	2.5	Q2	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
4	25%	75%	25%	26



A-09. RESEARCH IN ARTERIOSCLEROSIS, CARDIOVASCULAR PREVENTION, METABOLISM, AND NEUROLOGICAL DISEASES.

LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares

Priority line of research: Diseases of plasma lipoprotein metabolism

Other lines:

1. Rare diseases. PXE, Turner, Familial Chylomicronemia Syndromes
2. Epidemiology, stratification, and prevention of cardiovascular risk
3. Use of PET/CT imaging, 3T MRI, and ultrasound in the evaluation of atherosclerotic disease
4. Cognitive Impairment, Alzheimer's Disease, and Vascular Risk
5. Neurological Diseases and Vascular Risk

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-09	Florido-Santiago, M; Pérez-Belmonte, LM; Lara, JP; Millán-Gomez, M; Pérez-Velasco, MA; Osuna-Sánchez, J; García-Casares, N; Gomez-Huelgas, R; Blanco-Reina, E; Barbancho, MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	2.8	Q2	2025
A-09	Gonzalez-Alegre, J; Arespa-Castello, M; Sánchez-Chaparro, MA	Is Honesty the Fee for Vulnerability? Gender-Based Evaluation of Workers' Sick Leave Determinants Around the COVID-19 Pandemic	JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE	1.4	Q3	2025
A-09	Ariza, MJ; Coca-Prieto, I; Rioja, J; Muñiz-Grijalvo, O; Zambón-Rados, D; Blanco-Echevarría, A; Arrobas-Velilla, T; Delgado-Lista, J; León-Jiménez, D; Casañas-Martínez, M; Alvarez-Sala, LA; Gutiérrez-Carrasquilla, L; Sánchez-Gil, J; Domènech, M; González-Jiménez, A; Benítez-Toledo, MJ; Espíldora-Hernández, J; de Victoria, EOM; Sánchez-Chaparro, MA; Valdivielso, P	Pathogenicity assessment of genetic variants identified in patients with severe hypertriglyceridemia: Novel cases of familial chylomicronemia syndrome from the Dyslipidemia Registry of the Spanish Atherosclerosis Society	GENETICS IN MEDICINE	6.2	Q1	2025
A-09	Urbinati, F; Bueno, JAR; Real, PS; Redondo-López, MC; Ortega, AS; García-Arnés, JA; Bedmar, MG; Alba-Linero, C; García-Casares, N	Retinal structure and vasculature changes and their relationship with mild cognitive impairment in type 2 diabetes	JOURNAL OF ALZHEIMERS DISEASE	3.1	Q2	2025
A-09	Ettaghadouini, DA; Gallego-Fuentes, P; Chica-Villa, A; Fontalba-Navas, A; Pérez-Costillas, L; Gutiérrez-Bedmar, M; García-Casares, N	Study on mental health and motivation in undergraduate medical students at the Faculty of Medicine, University of Malaga	EDUCACION MEDICA			2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
12	58%	33%	25%	45





Networks:
RICORS-ICTUS, Cerebral Vascular Diseases (ISCIII)

A-10. EPIDEMIOLOGY, PHYSICAL ACTIVITY, ACCELEROMETRY, and NUTRITION (EpiPHAAN).

LR Julia Wärnberg. Co-LR Napoleón Pérez Farinós

Priority line:
Prevention of cardiovascular disease through Mediterranean diet, physical activity, and behavioral therapy (PREDIMED-Plus)

Other lines:
1. Objective measurement of physical activity and sleep through accelerometry.
2. Health promotion, healthy lifestyle habits. Nutritional epidemiology.
3. Childhood obesity and its determinants.
4. Epidemiology and prevention of non-communicable diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-10	Real-Pérez, M; Fernández-García, JC; Gavala-González, J	Effects of a 6-month rowing training program in breast cancer survivors	PLOS ONE	2.6	Q2	2025
A-10	Mayorga-Vega, L; Jimenez-Cebrian, AM; Barón-López, FJ; Montiel-Luque, A; Benavente-Marin, JC; Warnberg, J	Reliability of the use of foot pressure pain threshold in adults: a test-retest analysis	PEERJ	2.4	Q2	2025
A-10	Ruiz-Sánchez, FJ; Martins, MD; Losa-Iglesias, ME; Becerro-de-Bengoa-Vallejo, R; Gómez-Salgado, J; Saavedra-García, MA; López-López, D; Jiménez-Cebrián, AM	Static Plantar Pressure Distribution Measured Using PodoPrint Aluminum Platform in Multiple Sclerosis Patients: A Case-Control Study	JOURNAL OF FOOT AND ANKLE RESEARCH	2.2	Q2	2025
A-10	Prados, JME; Cortés-Rodriguez, A; Losa-Iglesias, ME; Gómez-Salgado, J; Vallejo, RBD; Saavedra-Garcia, MA; López, DL; Jiménez-Cebrián, AM	Mental health and Crohn's disease: evaluating depression through a case-referent study	REVISTA DA ASSOCIACAO MEDICA BRASILEIRA	1.3	Q2	2025
A-10	Cortes-Rodríguez, A; Alves-Gomes, L; Losa-Iglesias, ME; Gomez-Salgado, J; Becerro-de-Bengoa-Vallejo, R; Saavedra-García, MA; Lopez-Lopez, D; Jiménez-Cebrián, AM	Repercussion of kinesiophobia in ankylosing spondylitis: a case-control study	GACETA MEDICA DE MEXICO	0.8	Q3	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
13	54%	38%	15%	53



A-11. NEPHROLOGY AND RENAL TRANSPLANTATION.

LR Verónica López Jiménez. Co-LR Juana Alonso Titos.

Priority line of research: Strategies to reduce the main complications after renal transplantation (cardiovascular, metabolic, and infectious complications) and the evaluation of risk factors and transplant outcomes.

Other lines:

1. Cardiovascular disease and LVH in renal patients.
2. Post-transplant diabetes and chronic graft dysfunction.
3. Immunosuppressive strategies.
4. Survival analysis and predictive models of mortality in renal patients.
5. Renal senescence and Klotho expression.
6. Evaluation, management, and analysis of risk factors for infectious complications in solid organs after transplantation.
7. Analysis of new biomarkers of renal function, mainly chemokines in urine.
8. Analysis of lymphocyte subpopulations involved in cellular rejection by means of fine-needle aspiration (FNA) biopsy and flow cytometry.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-11	Moreso, F; Miñano, JAP; Fructuoso, AS; Jacas, C; Alegret, M; Ferrer, M; Colmenero, J; Belmonte, AA; Jiménez, VL; Pascual, S; Blanca, AM; Galiano, APV; Cachero, A; Rivero, A; Crespo, M; Cuadrado, A; Marcos, AC; Diéguez, MLG; Alvarez, CA; Kareaga, NM; Martinez, JMA; Pagano, G; Santana, EN; Torres, IB; Flores, IP; Alonso-Titos, J; Rodríguez-Soler, M; Alarcón, LM; Alvarez, TMG; Castelló, IB; Gonzalez-Vilatarsana, E; Miras, F; Bravo, MAG	Development and validation of the Neuro-Score: a specific scale to detect and monitor cognitive impairment in kidney or liver transplant recipients	AMERICAN JOURNAL OF TRANSPLANTATION	8.2	D1	2025
A-11	Padial, M; Rebollo, A; Jiménez-Salcedo, T; López, V; Avesani, CM; Lindholm, B; Qureshi, AR; Olveira, G	A Pilot Clinical Trial of a Nutrition Education Program on Quality of Life in CKD	CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY	7.1	D1	2025
A-11	Trenas, A; Perez-Velasco, MA; Bernal-López, MR; López-Carmona, MD; Gómez-Doblas, JJ; Martinez-Esteban, MD; Bouarich, O; Garcia-Casares, N; Fernández-Garcia, D; de Lucas, MDG; Gómez-Huelgas, R; Perez-Belmonte, LM	Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	D1	2025
A-11	Gutiérrez, P; Jiménez, L; Martínez, J; Alba, C; Girón, MV; Olveira, G; Ruiz-Esteban, P; Olveira, C	Dry eye disease and morphological changes in the anterior chamber in people with cystic fibrosis	JOURNAL OF CYSTIC FIBROSIS	6	Q1	2025
A-11	Garcia-Cosio Carmena, Maria Dolores; Farrero, Marta; Blasco Peiro, Maria Teresa; Crespo, Marta; Delgado Jimenez, Juan; Diaz Molina, Beatriz; Fernandez Rivera, Constantino; Garrido Bravo, Iris Paula; Lopez Jimenez, Veronica; Melilli, Edoardo; Mirabet Perez, Sonia; Perez Tamajon, Maria Lourdes; Rangel Sousa, Diego; Rodrigo, Emilio; Cruzado, Josep Maria; Hernandez Marrero, Domingo	Management of Kidney Disease in Heart Transplant Patients: A National Delphi Survey-based Consensus Expert Paper.	Transplantation	5.1	D1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
8	13%	88%	50%	42



Networks:

RICORS2040 (KIDNEY DISEASE), Inflammation and Immunopathology of Organs and Systems (ISCIII)

A-17. ANIMAL MODELS IN CARDIOVASCULAR RESEARCH.

LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero

Priority line of research: Etiology and pathophysiology of bicuspid aortic valve disease and congenital coronary artery anomalies

Other lines:

1. Animal models of atherosclerosis
2. Vascular growth: angiogenesis and arteriogenesis
3. Embryonic development of the cardiovascular system
4. Comparative anatomy and evolution of the cardiovascular system

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-17	Pozo-Vilumbrales, B; Martín-Chaves, L; López-Unzu, MA; Soto-Navarrete, MT; Pavón-Morón, FJ; Rodríguez-Capitán, J; Fernández, B	Unraveling the molecular complexity of bicuspid aortopathy: Lessons from comparative proteomics	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE	4.2	Q1	2025
A-17	Soto-Navarrete, MT; Pozo-Vilumbrales, B; López-Unzu, MA; Martín-Chaves, L; Durán, AC; Fernández, B	Endocardial-to-mesenchymal transition underlies cardiac outflow tract septation and bicuspid aortic valve formation in the Syrian hamster model	SCIENTIFIC REPORTS	3.9	Q1	2025
A-17	Sánchez-Quintero, M; Iboleón, A; Chaves, LM; Vilumbrales, BP; Carmona-Segovia, ADM; López, PM; Romero-Cuevas, M; Rodríguez-Capitán, J; Becerra-Muñoz, VM; Pavón-Morón, FJ; Murri, M	Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement	BIOLOGICS-TARGETS & THERAPY	3.4	Q2	2025

Scientific production and research activity:

Articles	%Art. Led	% Q1	% D1	IF
3	67%	67%		12



A-19. MULTIDISCIPLINARY PEDIATRIC RESEARCH GROUP

LR Isabel Leiva Gea, Co-LR David Moreno Pérez

Priority line of research: Microbiota in patients who have undergone an appendectomy, microbiota after ketogenic diet in refractory epilepsy, microbiota in immunodeficiencies, microbiota in critical patients.

Other lines:

1. Diabetes and technology
2. Epidemiology in diabetes
3. Growth
4. Obesity
5. Autoimmunity and inflammatory bowel disease
6. Neonatal cystic fibrosis screening
7. Bronchiolitis. Risk factors in the Bayesian model
8. Teleassistance in complex chronic patients
9. Antibiotic resistance

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-19	Leiva-Gea, L; Lendínez-Jurado, A; Sánchez-Palomino, P; Delgado-Ramos, B; Corte-Torres, MD; Leiva-Gea, I; Leiva-Gea, A	Guided Bone Regeneration Using a Modified Occlusive Barrier with a Window: A Case Report	BIOMIMETICS	3.9	Q1	2025
A-19	Moreno-Pérez, D; Korobova, A; Croche-Santander, FD; Cordón-Martínez, A; Díaz-Morales, O; Martínez-Campos, L; Pérez-González, E; Martínez-Padilla, MD; Santos-Pérez, JL; Brioso-Galiana, J; Sánchez-Códez, MI; Del Diego-Salas, J; Rivera-Izquierdo, M; Lorusso, N	Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023-2024 Season in Andalusia, Spain (NIRSEGRAND)	VACCINES	3.4	Q2	2025
A-19	Porcel-Chacón, R; Tapia-Ceballos, L; Ariza-Jimenez, AB; Gómez-Perea, A; Jiménez-Hinojosa, JM; López-Siguero, JP; Leiva-Gea, I	Differences in Metabolic Control Between Different Insulin Use Patterns in Pediatric Patients with Type 1 Diabetes Through Intermittent Glucose Monitoring	DISEASES	3	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-19	Leiva-Gea, I; Moreno-Jabato, F; Ariza-Jimenez, AB; Lendinez-Jurado, A; Gómez-Perea, A; Romero-Perez, MD; Garcia-Garcia, E; Mata, MAS; Martinez-Moya, G; Momblan, J; Lechuga-Sancho, AM; Gómez-Vida, JM; Mier-Palacios, M; Ranchal-Perez, MD; Vivas-González, G; Cabeza, PC; Fernández-Hernández, E; Jimenez-Martin, AP; Guarino-Narváez, J; de Vera-Gómez, PR; Martinez-Brocca, MA	Glycemic Analysis and Stratification of Pediatric Patients with Type 1 Diabetes Using isCGM in Southern Spain: Insights from the Andiacare Digital Platform	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025
A-19	Madrid-Rodríguez, A; Peláez-Cantero, MJ; Lendínez-Jurado, A; Suárez-Carrasco, A; Godoy-Molina, E; Gámez-Ruiz, A; Corripio-Mancera, A; Ramón-Telo, Y; García-Ruiz, A; Leiva-Gea, I	Assessing the Impact of a Telemedicine Program on Caregivers of Children With Complex Chronic Conditions: Pre-Post Intervention Study	JMIR PEDIATRICS AND PARENTING	2.3	Q2	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
18	44%	61%	22%	98



Networks:

CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections in adolescents (European Commission)

CA21168 (JIR-CliPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies adolescents (European Commission)

A-21. RESEARCH ON ORGAN PROTECTION IN THE PERIOPERATIVE PERIOD OF HEART SURGERY

LR José Luis Guerrero Orriach. Co-LR José Cruz Mañas

Priority line of research: Cardioprotection with halogenated compounds

Other lines:
1. Organ protection in heart surgery
2. Anesthesia and cancer
3. Opioid-free anesthesia

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-21	Guerrero-Orriach, JL; Carmona-Luque, MD; Rodriguez-Capitan, MJ; Quesada-Muñoz, G	MicroRNA-197-3p Transfection: Variations in Cardiomyocyte Gene Expression with Anaesthetics Drugs in a Model of Hypoxia/Reperfusion	PHARMACEUTICALS	4.8	Q1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
1	100%	100%	0%	5





Networks:
CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care

A-23. PREVENTIVE MEDICINE AND PUBLIC HEALTH

LR. Mario Gutiérrez Bedmar. Co-LR Rosa López Gigosos

Priority line of research: Preventive medicine and public health

Other lines:
1. Epidemiology and prevention of chronic diseases
2. Vaccines
3. International Health
4. Emerging diseases
5. Nosocomial infection
6. Pollution and environmental health
7. Occupational health
8. Immunosenescence

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-23	Cueto-Galán, R; Fontalba-Navas, A; Gutiérrez-Bedmar, M; Ruiz-Canela, M; Martínez-González, MA; Alves, L; Babio, N; Fitó, M; Ros, E; Fiol, M; Estruch, R; Arós, F; Serra-Majem, L; Pintó, X; Muñoz-Bravo, C; García-Rodríguez, A; Gómez-Gracia, E	Adherence to the Mediterranean diet to prevent or delay hepatic steatosis: a longitudinal analysis within the PREDIMED study	FRONTIERS IN NUTRITION	5.1	Q1	2025
A-23	Muñoz-Bravo, C; Marín-Burdallo, I; González-Herrera, L; Torres, CGP; Lozano-Lorca, M; Jiménez-Moleón, JJ; Olmedo-Requena, R	Copper in colorectal cancer patients: a systematic review and meta-analysis	CARCINOGENESIS	2.9	Q2	2025
A-23	Ortega, LR; Tapias, JM; Fernández, MJF; Jiménez-Navarro, M; Ortega-Gómez, A; Romero-Cuevas, M; Gómez-Doblas, JJ	In-Hospital Mortality and Costs of Added Morbidity in Heart Failure Patients at a University Hospital: A Retrospective Cross-Sectional Study	JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE	2.3	Q2	2025
A-23	Hurtado-Prieto, A; Mariscal-López, E; Gutierrez-Bedmar, M; López-Gigosos, R	Reversed sex disparities in heart failure mortality in Spain, 2000-2023: a population-based analysis of older adults	FRONTIERS IN PUBLIC HEALTH	3.4	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-23	Ruiz-Canela, M; Corella, D; Martinez-González, MA; Babio, N; Martinez, JA; Forga, L; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Santos-Lozano, JM; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Martin-Sánchez, V; Riera-Mestre, A; Delgado-Rodriguez, M; Matia-Martin, P; Vidal, J; Vázquez, C; Daimiel, L; Buil-Cosiales, P; Shyam, S; Sorli, JV; Castañer, O; Garcia-Rios, A; Torres-Collado, L; Gómez-Gracia, E; Zulet, MA; Konieczna, J; Casas, R; Cano-Ibáñez, N; Tojal-Sierra, L; Bernal-López, RM; Toledo, E; Garcia-Gavilán, J; Fernández-Carrión, R; Goday, A; Arenas-Larriva, AP; González-Palacios, S; Schroeder, H; Ros, E; Fitó, M; Hu, FB; Tinahones, FJ; Salas-Salvadó, J	Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes A Secondary Analysis of a Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE	15	D1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
19	21%	63%	32%	99



EMERGING GROUPS

AE-25. NEFROCONSULTOR.

Lines of research

1. Referral to the nephrology department from non-specialized care
2. Glomerular diseases, renal tubular dysfunction

ASSOCIATED GROUPS

AA-04. INTENSIVE CARE MEDICINE

LR María Antonia Estecha Foncea

Lines of research:

1. Care circuits and mortality
2. Biotechnology in critically ill patients with multiple organ dysfunction syndrome
3. Critical patient safety
4. Organ and tissue donation
5. Professional and user participation
6. Care circuits and mortality
7. Biotechnology in critically ill patients with multiple organ dysfunction syndrome
8. Critical patient safety
9. Organ and tissue donation
10. Professional and user participation

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
AA-04	Sánchez-Quintero, M; Iboleón, A; Chaves, LM; Vilumbrales, BP; Carmona-Segovia, ADM; López, PM; Romero-Cuevas, M; Rodríguez-Capitán, J; Becerra-Muñoz, VM; Pavón-Morón, FJ; Murri, M	Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement	BIOLOGICS-TARGETS & THERAPY	3.4	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
AA-04	Jimenez-López, R; Martin-Chaves, L; Gutierrez-Garcia, AM; Carmona-Segovia, AD; Mora-Ordoñez, B; Sánchez-Garcia, AM; Fernández-Romero, L; Murri, M; Sánchez-Quintero, MJ; Berteli-Garcia, G; Sánchez-Chaparro, MA; Bodi, V; Rodriguez-Capitán, J; Jimenez-Navarro, M; Pavón-Morón, FJ; Romero-Trevejo, JL	Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy	FRONTIERS IN MEDICINE	3	Q1	2025
AA-04	Simón-Frapolli, VJ; López-Montalbán, A; Vegas-Aguilar, IM; Generoso-Piñar, M; Fernández-Jiménez, R; Cornejo-Pareja, IM; Sánchez-García, AM; Martínez-López, P; Nuevo-Ortega, P; Reina-Artacho, C; Estecha-Foncea, MA; Gómez-González, AM; González-Jiménez, MB; Avanesi-Molina, E; Tinahones-Madueño, FJ; García-Almeida, JM	Relationship Between Vitamin D Levels with In-Hospital Complications and Morphofunctional Recovery in a Cohort of Patients After Severe COVID-19 Across Different Obesity Phenotypes	NUTRIENTS	5	Q1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
3		67%		11



AA-15. HEART AND VASCULAR DISEASE

LR Cristobal Urbano Carrillo

Lines of research:

1. Cardiovascular epidemiology
2. Heart failure
3. Cardiac interventionism
4. Congenital heart diseases
5. Pre-transplant evaluation of solid organs.
6. Heart and kidney failure
7. Systems of processes and organizational methods

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
AA-15	Aybar, MJT; Larrubia-Valle, JI; Berdún, CP; Carmona-Segovia, AD; Pavón-Morón, FJ; Jiménez-Navarro, MF	At the heart of the classroom: student perspective on teaching methods in Cardiology	SPANISH JOURNAL OF MEDICAL EDUCATION	0.7	Q3	2025
AA-15	Ruiz-Molina, Y; Padial, M; Martin-Bravo, MD; Garcia-Olivares, M; Porras, N; Chicharro, A; Mora-Robles, J; González-Jiménez, A; Sasso, CV; Olveira, G	Targeting Lymphedema in Overweight Breast Cancer Survivors: A Pilot Randomized Controlled Trial of Diet and Exercise Intervention	NUTRIENTS	5	Q1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
2		50%		6



AA-20. RESEARCH GROUP ON CARE IN MÁLAGA (INVESCUIDA)

LR Cipriano Viñas. Co-LR Antonio Jesús Núñez Montenegro

Priority line of research: Attention to chronicity.

Other lines:

1. Care of patients with chronic wounds.
2. Complications associated with the use of vascular devices: phlebitis, bacteremia, thrombosis, etc. An innovation project funded in 2018 began to be implemented in 2019
3. Clinical practice guidelines for pressure ulcers in pediatrics and neonatology.
4. Care of ostomies.
5. Validation of the "ESCENDE" Tool (Developmentally Sensitive Neonatal Nursing Care Scale) to determine the level of care intensity in the neonatal intensive care unit
6. Prevention of infections in neonatal intensive care units
7. Psychological intervention in palliative care patients

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
AA-20	Bujalance-Hoyos, J; de Luna-Rodríguez, ME; González-Escobosa, AC; Oña-González, AM; Sánchez-Gómez, S; Zamudio-Sánchez, A; Blanco-Mavillard, I	Implementation of a multimodal strategy via a mobile application to reduce catheter failure in patients with vascular access devices in Spain (CUIDAVEN Study): a pre-post intervention study	ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL	4.4	Q1	2025
AA-20	García-Ortega, MA; García-Piñero, JM; Gomez-González, AJ; Medina-Lopez, R; González-García, M; Montero-García, AJ; Morales-Gil, IM	Impact of an Early Discharge Hospital-at-Home Program on Length of Stay and Clinical Outcomes in Preterm Infants: A Case-Control Study	CHILDREN-BASEL	2.1	Q2	2025
AA-20	Bujalance-Hoyos, J; de Luna-Rodriguez, ME; González-Escobosa, AC; Ona-González, AM; Alvarez, MJF; Suárez, RL	CuidaVen®, an app for the care of people with vascular access. A care innovation project	ENFERMERIA CLINICA	1.1	Q3	2025
AA-20	Sánchez-Lozano, MA; Padilla, AMM; Montilla, JS; Arana, AR; Gil, MJM; Jurado, SJ; Subirats, MB	Development and implementation of a computerised registry for the assessment and monitoring of cancer patients	REVISTA ESPANOLA DE SALUD PUBLICA	0.8	Q4	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
4	50%	25%		8



AA-22. BIOPSYCHOSOCIAL INTERVENTION IN COMPLEX PROCESSES IN HEALTH SYSTEMS.

LR Eduardo Sánchez Guerrero

Priority line of research: Syndemic constructs for the bio-psycho-social model (MBPS)

Other lines:

1. Semiotics, topography, functionality, and nosology (BPS System)
2. ICD-11 and ICF ontologies and Dual MBPS Diagnosis
3. MBPS modulation systems
4. Capabilities and potentialities. Determinants of health
5. Cultural and bioactive physiological configurators MBPS

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
AA-22	Martín-Valero, R; Vega-Morales, AV Sr; Martín-Vega, FJ; Rodriguez-Huguet, M; Rodríguez-Martínez, MC; Vinolo-Gil, MJ	Effectiveness of Augmented Reality in the Teaching of Health University Students: Quasi-Experimental Study	JMIR SERIOUS GAMES	4.1	Q1	2025
AA-22	Ortega-Prados, P; González-Sánchez, M; Galán-Mercant, A	Innovative Rehabilitation of an Anterior Cruciate Ligament Tear in a Football Player: Muscle Chain Approach-A Case Study	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025
AA-22	Gonzalez-Sanchez, M; Reina-Ruiz, AJ; Molina-Torres, G; Trzcinska, SK; Carrasco-Vega, E; Lochmannová, A; Galán-Mercant, A	Structural and Psychometric Properties of Neck Pain Questionnaires Through Patient-Reported Outcome Measures: A Systematic Review	MEDICINA-LITHUANIA	2.4	Q1	2025
AA-22	Rodríguez-Martínez, MC; Correia, F; García-Pérez, P	Analysis of Occupational Needs in Refugees and Applicants for International Protection: Scoping Review	SOCIETIES	1.6	Q2	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
4	50%	75%	0%	11

EXTERNAL ASSOCIATED GROUPS

AA-24. VASCULAR RISK AND CHRONIC DISEASES

LR: Miguel Ángel García Ordóñez. Co-LR: Jesus Olmedo Llanes

Lines of research:

1. Vascular risk factors and cardiovascular disease
2. Type 2 diabetes mellitus
3. Hypertension
4. Dyslipidemia
5. Complex chronic diseases
6. Chronicity and frailty
7. Pluripathological patients

Scientific production and research activity:



Networks:

CA20104 (PhysAgeNet) - Network on evidence-based physical activity in old age (European Commission)
CA22169 (EU-METAHEART) - EUropean network to tackle METAbolic alterations in HEART failure (European Commission)

CIMO ONCO-HEMATOLOGY UNIT

CONSOLIDATED GROUPS

B-01. CLINICAL AND TRANSLATIONAL RESEARCH IN CANCER

LR Emilio Alba Conejo. Co-LR Iñaki Comino Méndez

Lines of research:

1. Clinical-translational research in breast, prostate, gynecological, digestive, and germ cell cancers.
2. Translational research in the identification of epigenetic/genetic markers of early stages of cancer.
3. Research in the use of new diagnostic techniques (liquid biopsy...) and markers.
4. Research on the relationship between microbiota and cancer.
5. Research using real world data.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-01	Comino-Méndez, I; Velasco-Suelto, J; Pascual, J; López-López, E; Quirós-Ortega, ME; Gaona-Romero, C; Martín-Muñoz, A; Losana, P; Heredia, Y; Alba, E; Guerrero-Zotano, A	Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer	BREAST CANCER RESEARCH	5.6	Q1	2025
B-01	García-Corbacho, J; Indacochea, A; Victoria, I; Moreno, D; Angelats, L; Navarro, AEG; Mezquita, L; Brasó-Maristany, F; Galván, P; Mellado, B; Viñolas, N; Sauri, T; Nogué, M; Adamo, B; Maurel, J; Pineda, E; Gaba, L; Reig, O; Basté, N; Sanfeliu, E; Juan, ME; Prat, A; Schettini, F	Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study	CANCER IMMUNOLOGY IMMUNOTHERAPY	5.1	Q1	2025
B-01	Laborda-Illanes, A; Boutriq, S; Aranega-Martín, L; Castellano-Castillo, D; Sánchez-Alcoholado, L; Plaza-Andrades, I; Peralta-Linero, J; Alba, E; Fernández-García, JC; González-González, A; Queipo-Ortuño, MI	Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-01	Godoy-Ortíz, A; Lendínez-Sánchez, G; Zalabardo, M; Pascual, J; Lopez-Pascual, A; Cantero, A; Ribelles, N; Iglesias, M; Villar, E; Pajares, B; Díaz-Redondo, T; Domínguez-Recio, ME; Carabantes, F; Bermejo, MJ; Rueda-Domínguez, A; Alba, E; Sánchez-Muñoz, A	Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy	FRONTIERS IN ONCOLOGY	3.3	Q2	2025
B-01	Escrivá-de-Romani, S; Cejalvo, JM; Alba, E; Friedmann, J; Rodríguez-Lescure, A; Savard, MF; Pezo, RC; Gion, M; Ruiz-Borrego, M; Hamilton, E; Pluard, T; Webster, M; Beeram, M; Linden, H; Saura, C; Shpektor, D; Salim, B; Harvey, P; Hurvitz, SA	Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study	LANCET ONCOLOGY	36	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
22	23%	73%	18%	149



Ciber:

CIBERONC CB16/12/00481 Cancer (ISCIII)

Competitive HR contracts funded in 2025:

1 MARIE SKLODOWSKA-CURIE Contract (EC)

1 Sara Borrell Contract (ISCIII)

1 Contract for the Training of University Personnel - FPU.

1 Ramón y Cajal contract.

1 Juan de la Cierva Contract (AEI)

1 Contract for Technical Support Staff from the Ministry of Science and Innovation.

1 Pre-doctoral contract from the Spanish Association Against Cancer

1 Grant for Returning Young Researchers from the Spanish Society of Medical Oncology.

1 Contract for long-term reinforcement of the SAS (Action B).

1 Regional Government of Andalusia Postdoctoral Contract

B-04. MOLECULAR BASES OF BIOLOGICAL SYSTEMS (SIBIUMA)

LR Miguel Ángel Medina Torres

Lines of research:

1. Angiogenesis and tumor microenvironment: Identification and characterization of angiogenesis modulators. Metabolism in the tumor microenvironment.
2. Metabolism of biogenic amines and polyamines in health and disease.
3. Bioinformatics and networks: Interactome, disease network, and drug modeling with predictive methods.
4. Bioinformatics workflows for automation of genomic analysis. Analysis of transposon expression in cancer.
5. Applications of lines 1-4 to rare diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-04	García-Criado, F; Seoane, P; Rojano, E; Ranea, JAG; Perkins, JR	Advancing edge-based clustering and graph embedding for biological network analysis: a case study in RASopathies	BRIEFINGS IN BIOINFORMATICS	7.7	D1	2025
B-04	Díaz-Santiago, E; Moya-García, AA; Pérez-García, J; Yahyaoui, R; Orengo, C; Pazos, F; Perkins, JR; Ranea, JAG	Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks	FRONTIERS IN PHARMACOLOGY	4.8	Q1	2025
B-04	García-Criado, F; Hurtado-García, L; Rojano, E; Esteban-Martos, A; Pérez-García, J; Seoane, P; Ranea, JAG	Integrative Transcriptomic and Network-Based Analysis of Neuromuscular Diseases	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025
B-04	Dakhli, N; López-Jiménez, A; Cárdenas, C; Hraoui, M; Dhaouafi, J; Bernal, M; Sebai, H; Medina, MA	Urtica dioica Aqueous Leaf Extract: Chemical Composition and In Vitro Evaluation of Biological Activities	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025
B-04	Mela, V; Heras, V; Iesmantaite, M; García-Martín, ML; Bernal, M; Posligua-García, JD; Subiri-Verdugo, A; Martínez-Montoro, JI; Gómez-Pérez, AM; Banderas, B; Indias, IM; Tinahones, FJ	Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis	GUT	26	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
14	50%	100%	29%	90



Active projects



Patents applied for

Ciber and networks:
CA23146(EURO-VALDI-NET) - European vascular liver diseases network (European Commission)
CIBERER CB06/07/0046 Rare Diseases (ISCIII)

B-05. TRANSLATIONAL RESEARCH IN CANCER IMMUNOTHERAPY.

LR Antonio Rueda Domínguez. Co-LR. Isabel Barragan Mallofret

Priority line of research: Oncology and hematology.

Other lines of research: Cancer immunotherapy.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-05	Hutchings, M; Sureda, A; Bosch, F; Larsen, TS; Corradini, P; Avigdor, A; Terol, MJ; Dominguez, AR; Pinto, A; Skarbnik, A; Cordoba, R; Jorgensen, JM; Zinzani, PL; Leung, W; Bottos, A; Li, DH; Relf, J; Tandon, M; Sellam, G; Gritti, G	Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/ Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial	JOURNAL OF CLINICAL ONCOLOGY	43	D1	2025
B-05	Fodil-Cherif, S; Hadoux, J; Mercier, O; Benitez, JC; Durand, A; Lasolle, H; Perrier, M; Jannin, A; Laboureau, S; Le Bras, M; Chabre, O; Gaujoux, S; Rouiller, LG; Hentic, O; Du Boullay, H; Haissaguerre, M; Kinn, H; Lecomte, T; Goudet, P; Girard, N; Scoazec, JY; Besse, B; Faron, M; Baudin, E	Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks	JOURNAL OF THORACIC ONCOLOGY	21	D1	2025
B-05	Provencio, M; Cobo, M; Rodriguez-Abreu, D; Carcereny, E; Castro, RL; Bruno, MF; Bernabé, R; Bosch-Barrera, J; Massuti, B; Sánchez, A; Ortega, AL; Guirado, M; del Barco, E; Camps, C; Lázaro-Quintela, M; Dómine, M; Sala, MA; Medina, K; González-Larriba, JL; Aparisi, F; Oramas, J; Aguiar, D; Cerezo, S; Losada, B; Ruano-Ravina, A; Cantero, A; Ospina-Serrano, AV; Calvo, V	Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain	LANCET REGIONAL HEALTH-EUROPE	13	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-05	Guardamagna, M; Berciano-Guerrero, MA; Lavado-Valenzuela, R; Auclin, É; Onieva-Zafra, JL; Plaza-Andrades, I; Oliver, J; Garrido-Aranda, A; Perez-Ruiz, E; Alvarez, M; Ocaña, MC; Queipo-Ortuño, MI; Barragán, I; Rueda-Dominguez, A	Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma	SCIENTIFIC REPORTS	3.9	Q1	2025
B-05	García-Aranda, M; Onieva, MA; Martín-García, D; Quirós, R; López, I; Padilla-Ruiz, M; Téllez, T; Martínez-Gálvez, B; Hortas, ML; García-Galindo, A; González-Gomariz, J; Armañanzas, R; Rivas-Ruiz, F; Serrano, A; Barragán-Mallofret, I; Redondo, M	KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients	SCIENTIFIC REPORTS	3.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
15	20%	80%	40%	140



Competitive HR contracts funded in 2025:

1 Juan de la Cierva Contract (AEI)

2 Nicolás Monardes SAS contracts (Action C).

1 Contract for research personnel in training, Agents of the Andalusian Knowledge System.

1 Junior Clinical Contract (AECC)

1 Senior Clinical Contract (AECC)

B-07. CANCEROMICS.

LR Javier Márquez Gómez. Co-LR José Manuel Matés Sánchez

Priority line of research: Functional genomics and cancer proteomics

Other lines of research:

1. Cellular and molecular bases of glutamate synthesis in brain
2. New antitumor strategies and therapies based on glutaminase isoenzymes
3. Transgenic animal models with amino acid metabolism deficits
4. Heterologous expression of recombinant human proteins with therapeutic and biotechnological value

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-07	de los Santos-jiménez, J; Campos-Sandoval, JA; Rosales, T; Ko, B; Alonso, FJ; Márquez, J; Deberardinis, RJ; Matés, JM	Glutaminase-2 Expression Induces Metabolic Changes and Regulates Pyruvate Dehydrogenase Activity in Glioblastoma Cells	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025
B-07	Martínez-Padilla, A; Márquez, J; Huerta, MA; Roza, C; Cisneros, E	Loss of Glutaminase 1 in Small Sensory Neurons Prevents Nerve Injury Induced Mechanical Allodynia: Insights From Conditional Knockout Mice	EUROPEAN JOURNAL OF PAIN	3.4	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
2	50%	100%		8



B-10. SKIN CANCER.

LR María Victoria de Gálvez Aranda. Co-LR Enrique Herrera Acosta

Priority line of research: Research on the processes involved in the development of skin cancer and other diseases that arise from overexposure to solar radiation and research on prevention through the development of photoprotection tools.

Other lines:

1. Studies of the mechanisms involved in the development of skin cancer with a specific search for new prognostic factors as well as a therapeutic approach.
2. Research on the effects of biologic therapy on psoriasis and other dermatoses.
3. Analysis of the etiopathogenesis of photodermatosis for a comprehensive approach to prevention and treatment measures.
4. Research on the mechanisms involved in the generation of photoaging hyperpigmentation and a comprehensive approach to photoprotection strategies to prevent them.
5. Measurement of ultraviolet, visible, and IR solar and artificial radiation in order to generate algorithms for solar and artificial exposure that are safe and for preventive purposes.
6. Non-intrusive technology-based research on the analysis of sun damage to the skin and topical photoprotection tools.
7. Research on new topical photoprotectors based on natural substances.
8. Development of solar and artificial radiation measurement tools based on specific sensors and development of new technology for photodiagnosis and phototherapy.
9. Development of communication strategies for sun damage prevention.

Scientific production and research activity:



Clinical studies



Patents applied for

B-11. GENITOURINARY ONCOLOGY TRANSLATIONAL RESEARCH GROUP

LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico

Priority line of research: Genetic and molecular epidemiology of genitourinary cancer

Other lines of research:

1. Development of new antineoplastic molecules in genitourinary tumors
2. Oncogenesis and taxonomy of genitourinary tumors
3. Prognostic and predictive biomarkers in genitourinary cancer
4. Advanced therapies in urologic oncology
5. Lysophosphatidic acid and autotaxin-mediated signaling in genitourinary tumors

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-11	Olmos, D; Lorente, D; Jambrina, A; Tello-Velasco, D; Ovejero-Sánchez, M; Gonzalez-Ginel, I; Romero-Laorden, N; Nunes-Carneiro, D; Balongo, M; Gutierrez-Pecharromán, AM; Llácer, C; Prieto, JD; Perez-Argüelles, D; Arco, FAD; Miguel-Masiá, J; Ruiz-Vico, M; Santos, R; Esteban-Villarrubia, J; Gonzalez-Billalabeitia, E; Jürgens, A; Capone, C; Trevisan, M; Van Sanden, S; Stulnig, G; Hernández, D; López-Casas, PP; Rodriguez-Antolin, A; Castellano, DE; Herrera-Imbroda, B; Castro, E	BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes	ANNALS OF ONCOLOGY	65	D1	2025
B-11	Necchi, A; Guerrero-Ramos, F; Crispen, PL; Herrera-Imbroda, B; Garje, R; Powles, T; Peyton, CC; Pradere, B; Ku, JH; Shore, N; Bögemann, M; Preston, MA; Xylinas, E; Llano, CSD; Hasan, M; Stitou, H; Bhanvadia, S; Sweiti, H; Psutka, S	TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial	LANCET ONCOLOGY	36	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-11	Borza, R; Matas-Rico, E; Perrakis, A; Moolenaar, WH	Unlocking the signaling potential of GPI-anchored proteins through lipolytic cleavage	TRENDS IN CELL BIOLOGY	18	D1	2025
B-11	Pilo, J; Rego-Calvo, A; García-Flores, LA; Arranz-Salas, I; Alvarez-Mancha, AI; Izquierdo, AG; Crujeiras, AB; Alcaide, J; Ortega-Castan, M; Boughanem, H; Macías-González, M	Unraveling TNXB Epigenetic Alterations Through Genome-Wide DNA Methylation Analysis and Their Implications for Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025
B-11	Castillo, LC; Belenchón, IR; Sanz, IP; Marenco, RS; Claro, AVO; Martínez, NS; López, RM; Soto, AJ; Ossorio, JLA; Galisteo, EG; Valiente, JC; Imbroda, BH; Jiménez, JM; Casas, JAV; Rodríguez, A; Ortiz, AS; Hernández, JPC; Gómez, EG	Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence	PROSTATE	2.5	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
5	0%	80%	60%	127





Competitive HR contracts funded in 2025:

1 junior clinician of the Spanish Association Against Cancer (AECC)

1 Pre-doctoral contract from the Spanish Association Against Cancer

1 grant for predoctoral contracts for the training of doctors from the State Research Agency.

B-12. COMPUTATIONAL INTELLIGENCE IN BIOMEDICINE.

LR José Manuel Jerez Aragonés

Lines of research:

1. Clinical informatics
2. Clinical data mining
3. Clinical bioinformatics

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-12	Sánchez-Lozano, MA; Padilla, AMM; Montilla, JS; Arana, AR; Gil, MJM; Jurado, SJ; Subirats, MB	Development and implementation of a computerised registry for the assessment and monitoring of cancer patients	REVISTA ESPANOLA DE SALUD PUBLICA	0.8	Q4	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1	100%			1



B-14. TRANSLATIONAL RESEARCH GROUP IN CANCER AND OTHER PREVALENT CHRONIC DISEASES.

LR Maximino Redondo Bautista. Co-LR Marilina García Aranda

Lines of research:

1. Evaluation of health services in oncologic diseases
2. Study of inhibitor of apoptosis proteins in cancer
3. Study of biomarkers of immunoediting and response to immunotherapy in cancer and health outcomes attributable to said immunotherapy.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-14	García-Aranda, M; Onieva, MA; Martín-García, D; Quirós, R; López, I; Padilla-Ruiz, M; Téllez, T; Martínez-Gálvez, B; Hortas, ML; García-Galindo, A; González-Gomariz, J; Armañanzas, R; Rivas-Ruiz, F; Serrano, A; Barragán-Mallofret, I; Redondo, M	KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients	SCIENTIFIC REPORTS	3.9	Q1	2025
B-14	García-Aranda, M; Abitei, C; Martín-García, D; Fúnez, R; Rivas-Ruiz, F; Robles-Lasarte, M; Alcaide-Garcia, J; Téllez, T; Aguirre, U; Borrero-Martín, JJ; del Cura, I; Suárez-Varela, MMM; Quintana, JM; Redondo, M	Long-term prognostic value of apoptotic index in colorectal cancer: a 5-year multicentre cohort study	PATHOLOGY	3	Q2	2025
B-14	Martín-García, D; García-Aranda, M; Varela-Moreno, E; Padilla-Ruiz, M; Zarcos-Pedrinaci, I; Rivas-Ruiz, F; Téllez, T; García-Gutiérrez, S; González, N; Rivero, A; Sarasqueta, C; Perestelo-Pérez, L; Castells, X; Quintana, JM; Sala, M; Redondo, M	Patient-attributable delay and its impact on two-year survival in breast cancer: A multicenter prospective cohort study	EJSO	2.9	Q1	2025
B-14	Alcaide-Garcia, J; Boughanem, H; García-Aranda, M; Rivas-Ruiz, F; Aguirre, U; García, DM; Padilla-Ruiz, M; Varela-Moreno, E; Robles-Lasarte, M; Baré, M; del Cura, I; Varela, MMM; Quintana, JM; Macías, M; Redondo, M	Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients	COLORECTAL DISEASE	2.7	Q1	2025
B-14	Quero, C; Martín-García, D; Rivas-Ruiz, F; García-Aranda, M; Redondo, M	Comparison of oncological care in a hospital center before and after the integration of specialized oncology services	CLINICAL & TRANSLATIONAL ONCOLOGY	2.5	Q3	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
8	75%	63%	13%	29



Networks:

CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care

CA21139 (IMPROVE) - 3Rs concepts to improve the quality of biomedical science

CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer

CA23119 (SENESCENCE2030) - Targeting Cell Senescence to Prevent Age-Related Diseases

Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS), RD24-0005-0016 (ISCIII)

B-22. EMERGING ANTITUMOR ADAPTATION THERAPIES

LR: Manuel Cobo Dols. Co-LR Inmaculada Ales Diaz

Lines of research:
Immuno-oncology biomarkers and precision medicine: Agnostic in non-cutaneous solid tumors

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-22	Ahn, MJ; Tanaka, K; Paz-Ares, L; Cornelissen, R; Girard, N; Pons-Tostivint, E; Baz, DV; Sugawara, S; Cobo, M; Perol, M; Mascaux, C; Poddubskaya, E; Kitazono, S; Hayashi, H; Hong, MH; Felip, E; Hall, R; Juan-Vidal, O; Brungs, D; Lu, S; Garassino, M; Chargualaf, M; Zhang, Y; Howarth, P; Uema, D; Lisberg, A; Sands, J	Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study	JOURNAL OF CLINICAL ONCOLOGY	43	D1	2025
B-22	Herbst, RS; Cho, BC; Zhou, CC; Burotto, M; Dols, MC; Sendur, MAN; Moiseyenko, V; Casarini, I; Nishio, M; Hui, RN; Pons-Tostivint, E; Dudnik, J; Ahmed, S; Okpara, CE; Dutcus, C; Yin, LN; Luo, YW; Chirovsky, D; Bhagwati, N; Abreu, DR	Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study	JOURNAL OF THORACIC ONCOLOGY	21	D1	2025
B-22	Peters, S; Paz-Ares, LG; Reck, M; Carbone, DP; Brahmer, JR; Borghaei, H; Lu, S; O'Byrne, KJ; John, T; Ciuleanu, TE; Schenker, M; Caro, RB; Nishio, M; Cobo, M; Lee, JS; Zurawski, B; Pluzanski, A; Aoyama, T; Tschaika, M; Devas, V; Grootendorst, DJ; Ramalingam, SS	Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis	JOURNAL OF THORACIC ONCOLOGY	21	D1	2025
B-22	Hochmair, M; Schenker, M; Dols, MC; Kim, TM; Ozyilkan, O; Smagina, M; Leonova, V; Kato, T; Fedenko, A; De Angelis, F; Rittmeyer, A; Gray, JE; Greystoke, A; Aggarwal, H; Huang, QL; Zhao, B; Lara-Guerra, H; Nadal, E	Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy	JOURNAL OF THORACIC ONCOLOGY	21	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-22	Jurado, JM; Gutiérrez, V; Cantero, A; Berciano-Guerrero, MA; Padilla, A; Pérez-Ruiz, E; Montesa, A; Carabantes, F; Cobo, M	Association Between Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
16	6%	75%	38%	167



Competitive HR contracts funded in 2025:
1 junior clinician of the Spanish Association Against Cancer (AECC)

EMERGING GROUPS

BE-03. HEMATOLOGY AND HEMATOTHERAPY.

LR Francisco José López Jaime

Priority line of research:
Study of genetic/genomic profiles with an influence on the diagnosis, treatment, and survival of adult and pediatric patients with hematologic neoplasms. Individualized treatment and quality of life.

Other lines:

1. Transplantation of hematopoietic stem cells in adult and pediatric patients:
   - Home-based hematopoietic stem cell transplantation and quality of life.
   - Study of variables involved in graft-versus-host disease.
   - Study of chimerism in allogeneic hematopoietic stem cell transplantation using new technologies (real-time PCR and digital PCR), prognostic implications, and prediction of relapse.
2. CAR-T (Chimeric Antigen Receptor-T) cell therapy: efficacy and quality of life studies.
3. Study of rare hematologic-based diseases: diagnosis and individualized treatment.
4. Hemostasis and Thrombosis: Clinical and laboratory approach to new therapies for patients with hemophilia. Digital tools for the management and analysis of information in hemophilia. Immune thrombocytopenia. Thrombophilic states of genetic and acquired origin. Thrombosis in oncohematology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-03	Marco-Rico, A; Calvo-Villas, JM; López-Jaime, FJ; Hirnyk, MC; Hernández, MDN; Martín, SH; Entrena-Ureña, L; Marcellini-Antonio, S; Díaz-Jordán, BL; Jurado-Herrera, S; Pérez-González, NF; García-Díaz, C; García-Candel, F; Fernández-Bello, I; Marco-Vera, P	Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study	JOURNAL OF BLOOD MEDICINE	2.7	Q2	2025
BE-03	Wheeler, AP; Abraham, A; Barnes, C; Frandsen, RB; d'Oiron, R; Eichler, H; Hampton, K; López-Jaime, FJ; Lyu, CJ; Tavares, CMM; Nogami, K; Sutton, C; Windyga, J; Zulfikar, B; Castaman, G	Real-World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End-of-Study Results From the explorer6 Non-Interventional Study	HAEMOPHILIA	3	Q2	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
2	0%	0%	0%	6



BE-15. PATHOLOGICAL ANATOMY.

LR Isabel Hierro. Co-LR Rafael E. Carvia Ponsaillé

Priority line of research: Anatomic pathological factors of prognostic value or decisive for the therapeutic approach in oncology

Other lines:

1. Anatomic pathological studies of autoimmune, infectious, or inflammatory diseases with prognostic or therapeutic value.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-15	Martínez-Montoro, JI; Sancho-Marín, R; Ocaña-Wilhelmi, L; Arranz-Salas, I; Ruiz-Campos, N; García-López, MJ; Tinahones, FJ; Gutiérrez-Repiso, C	Gastric microbiota-specific signatures in adults with obesity and Helicobacter pylori-negative gastritis	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	3.6	Q1	2025
BE-15	Ruiz-Malagon, AJ; Herraiz-Vilela, M; Serrano-Pino, R; García-Avila, P; Díaz-Suárez, L; Carmona-Segovia, AD; Becerra-Munoz, VM; Jiménez-Navarro, M; Arranz-Salas, I; Lopez-Villodres, JA; Fernández-Castañer, A; Gutiérrez-Martínez, F; Rodríguez-González, FJ; Camargo-Camero, R; Alcaín-Martínez, G; Rodríguez-Díaz, C; García-Fuentes, E; Sánchez-Quintero, MJ; Lopez-Gomez, C	Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease	WORLD JOURNAL OF GASTROENTEROLOGY	5.4	Q1	2025
BE-15	Martin-Reyes, F; Kentaoui-Bousellam, I; Ruiz-Malagón, AJ; Ho-Plágaro, A; López-Gómez, C; Herraiz-Vilela, M; Alcain-Martínez, G; Camargo-Camero, R; Martos-VanDussen, JV; Camacho-Martel, L; Gutiérrrez-Martínez, F; Arranz-Salas, I; Ortega-Jimenez, MV; Escamilla-Sánchez, A; Daza-González, JJ; Sanchiz-Cardenas, E; Rivas-Becerra, J; García-Fuentes, E; Rodríguez-Pacheco, F; Rodriguez-Diaz, C	Mesenteric adipose tissue in Crohn's disease alters the immune response of the ileal mucosa and increases angiogenesis and fibrosis	SCIENTIFIC REPORTS	3.9	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-15	Pilo, J; Rego-Calvo, A; García-Flores, LA; Arranz-Salas, I; Alvarez-Mancha, AI; Izquierdo, AG; Crujeiras, AB; Alcaide, J; Ortega-Castan, M; Boughanem, H; Macías-González, M	Unraveling TNXB Epigenetic Alterations Through Genome-Wide DNA Methylation Analysis and Their Implications for Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
4		100%		18

BE-17. CLINICAL, MOLECULAR, AND TECHNOLOGICAL RESEARCH IN RADIATION ONCOLOGY.

LR Jaime Gómez-Millán Barrachina. Co-LR María Jesús García Anaya

Priority line of research: Prognostic and predictive factors of response to ionizing radiation in upper aerodigestive tract and gynecologic tumors.

Other lines:

1. New techniques in cancer treatment with radiotherapy Etiopathogenesis of mucositis
2. Immunologic factors associated with response in SBRT

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-17	Anaya, MJG; Tudela, AC; Gómez-Millán, J; Ocón, MJL; Rodríguez, HJ; Ríos, IG	Once-weekly ultra-hypofractionated radiation therapy for breast cancer: Outcomes from a single-institution real-world cohort	BREAST	7.9	D1	2025
BE-17	Fernández-Forné, A; Fernández-Jiménez, R; Toledo-Serrano, MD; Jiménez-Rodríguez, H; Muñoz-Lupiáñez, M; Ruiz-López, MA; García-Almeida, JM; De la Peña-fernández, L; Queipo-Ortuño, MI; Gómez-Millán, J	Impact of Nutritional Status on Severe Radiation-Induced Mucositis in Oropharyngeal Cancer Patients Undergoing Chemo-Radiotherapy	NUTRIENTS	5	Q1	2025
BE-17	Montero-Benitez, MZ; Carmona-Llanos, A; Fernández-Jiménez, R; Román-Jobacho, A; Gómez-Millán, J; Modamio-Molina, J; Cabrera-Cesar, E; Vegas-Aguilar, I; Amaya-Campos, MD; Tinahones, FJ; Molina-Montes, E; Cayón-Blanco, M; García-Almeida, JM	AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques	CANCERS	4.4	Q2	2025
BE-17	Lozano-Borbalas, Alicia; Jordi-Ollero, Olivia; Marruecos, Jordi; Farre, Nuria; Planas, Isabel; Toledo, Maria Dolores; Mesia, Ricard; Navarro-Martin, Arturo	Impact of clinical and dosimetric factors on severe oral mucositis in head and neck cancer: insights from a phase II clinical trial	FRONTIERS IN ONCOLOGY	3.3	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-17	Salvador, Segado-Guillot; Jesus, Garcia-Anaya Maria; Dolores, Toledo-Serrano Maria; Angel, Calvo-Tudela; Patricia, Prieto-Granados; Dolores, Torres-Tabanera Maria; Antonio, Medina-Carmona Jose; Jaime, Gomez-Millan	Hypofractionated Accelerated Radiotherapy for Head and Neck Cancer in Fragile Patients	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK	2.2	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
5	60%	40%	20%	23



BE-18. VASCULAR BIOLOGY, TUMOR MICROENVIRONMENT & TARGET DISCOVERY.

LR Melissa García Caballero

Priority line of research: Study of the tumor microenvironment, characterization of endothelial reprogramming, identification of new therapeutic targets, and development of new drugs

Other lines: Study of diseases that depend on deregulated lymph/angiogenesis

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-18	Oliveira, CC; Cordoba, J; Pearson, JR; Guruceaga, E; Marín-Sedeño, E; Lopez-Moreno, M; Guadix, JA; García-Caballero, M; Pérez-Pomares, JM; Ruiz-Villalba, A	Revealing the complexity of the epicardial secretome	SCIENTIFIC REPORTS	3.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1		100%		4



Networks:
CA21154 (TRANSLACORE) - Translational control in Cancer European Network (European Commission)
CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer (European Commission)

Competitive HR contracts funded in 2025:
1 Pre-doctoral contract from the Spanish Association Against Cancer
1 Pre-doctoral contract for doctoral training (AEI).

BE-19. RADIOBIOLOGY.

LR Miguel José Ruiz Gómez

Lines of research:
1. Molecular markers of antineoplastic drug resistance, radiation, and cellular aging
2. Effect of electromagnetic fields. Evaluation of cell damage and mechanisms of repair and resistance.
3. Molecular radiobiology
4. Study of chronological and replicative cellular aging and its relationship with the effects and molecular mechanisms of resistance to drugs and physical agents
5. Biological and environmental dosimetry

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-19	García-Cañizares, VM; González-Vidal, A; Burgos-Molina, AM; Mercado-Sáenz, S; Sendra-Portero, F; Ruiz-Gómez, MJ	Common Molecular Mechanisms and Biomarkers in Breast, Colon and Ovarian Cancer	APPLIED SCIENCES-BASEL	2.5	Q2	2025
BE-19	Rodríguez-García, M; Burgos-Molina, AM; González-Vidal, A; Sendra-Portero, F; Bernal, M; Ruiz-Gómez, MJ	Molecular mechanisms of radiation resistance in colorectal cancer: in silico identification of AURKA, BIRC5 and PLK1 proteins as potential biomarkers	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY	2.4	Q1	2025
BE-19	González-Vidal, A; Mercado-Sáenz, S; Lopez-Diaz, B; Burgos-Molina, AM; González-Pedrosa, MP; Sendra-Portero, F; Ruiz-Gomez, MJ	Radiation and SARS-CoV-2 effects on the microbiota, immune system and health	INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY	0.5	Q4	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
3	100%	33%	0%	5



BE-21. HEMATOLOGY AND IMMUNOLOGY.

LR Regina García Delgado. Co-LR Alejandro Escamilla Sánchez

Lines of research:

1. Multidisciplinary translational study to evaluate clinical, biological, and immunological profiles in patients with hematological malignancies.
2. Lymphoproliferative neoplasms (NHL).
3. Related myeloproliferative neoplasms (MPN).
4. Precision medicine for hematological malignancies.
5. Immunotherapy for hematological malignancies.
6. New therapeutic targets for hematological malignancies.
7. Tumor microenvironment and progression of hematologic malignancies.
8. Translational research and knowledge transfer.
9. Psycho-oncology and patient well-being.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-21	Escamilla-Sanchez, A; López-Villodres, JA; Alba-Tercedor, C; Ortega-Jiménez, MV; Rius-Díaz, F; Sanchez-Varo, R; Bermúdez, D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	13	D1	2025
BE-21	García-Delgado, R; Moreno-Carrasco, G; Carrasco-Gomariz, M; García-Segovia, S; Flores, RMO; Torres-González, J; Gallego-Fuillerat, G; Lopez-Villodres, JA; Escamilla-Sánchez, A	Impact of iron chelation therapy on mitochondrial function, vascular integrity and inflammation in transfusion-dependent myelodysplastic syndromes	FRONTIERS IN IMMUNOLOGY	5.9	Q1	2025
BE-21	Fontalba-Navas, A; Echeverria, R; Larrea-Killinger, C; Gracia-Arnaiz, M; Soar, C; Arrebola, JP	Association Between the Healthy Eating Index and the Body Mass Index of Older Adults: An Analysis of Food Frequency and Preferences	NUTRIENTS	5	Q1	2025
BE-21	García-Delgado, R; Luque-Lupiáñez, E; Mora-Infante, D; Ortíz-Flores, RM; Cidoncha-Morcillo, B; Torres-González, J; Fontalba-Navas, A; Escamilla-Sánchez, A	Translational Insights into Interferon Alpha's Effects on Immunomolecular Dynamics in Philadelphia-Negative Myeloproliferative Neoplasms	CANCERS	4.4	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-21	Ruiz-Centeno, C; Cueto-Galán, R; Pena-Andreu, JM; Fontalba-Navas, A	Problematic internet use and its relationship with eating disorders	FRONTIERS IN PUBLIC HEALTH	3.4	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
9	67%	67%	11%	43



Networks:

CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer (European Commission)

BE-23. NEW HORIZONS FOR ONCOLOGY PATIENTS.

LR: Miguel Ángel Berciano Guerrero / Co-LR Julia Alcaide García.

Lines of research:

1. Translational research in cancer.
2. Cell therapy in solid tumors.
3. New drugs and strategies for cancer
4. Cross-sectional and multidisciplinary research in oncology patients.
5. Long-term cancer survivors.
6. Artificial intelligence applied to medical oncology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-23	Guardamagna, M; Berciano-Guerrero, MA; Lavado-Valenzuela, R; Auclin, É; Onieva-Zafra, JL; Plaza-Andrades, I; Oliver, J; Garrido-Aranda, A; Perez-Ruiz, E; Alvarez, M; Ocaña, MC; Queipo-Ortuño, MI; Barragán, I; Rueda-Dominguez, A	Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma	SCIENTIFIC REPORTS	3.9	Q1	2025
BE-23	Alcaide-Garcia, J; Boughanem, H; García-Aranda, M; Rivas-Ruiz, F; Aguirre, U; García, DM; Padilla-Ruiz, M; Varela-Moreno, E; Robles-Lasarte, M; Baré, M; del Cura, I; Varela, MMM; Quintana, JM; Macías, M; Redondo, M	Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients	COLORECTAL DISEASE	2.7	Q1	2025
BE-23	Cerezuela-Fuentes, P; de la Rosa, CA; Crespo, G; Berciano-Guerrero, MA; Soria, A; Muñoz-Couselo, E; Castro, RL; Majem, M; de Miguel, PA; Manzano, JL; Bellido, L; Lecumberri, MJ; Subias, MC; Guzmán, JCV; Hernández, B; Espinosa, E; Puértolas, T; Sanz, LG; Martínez, JM; Abril, VP; Algarra, SM; Márquez-Rodas, I	Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study	MELANOMA RESEARCH	1.9	Q3	2025
BE-23	André, T; Shiu, KK; Kim, TW; Jensen, BV; Jensen, LH; Punt, CJA; Smiths, D; Garcia-Carbonero, R; Alcaide-Garcia, J; Gibbs, P; de la Fouchardiere, C; Rivera, F; Elez, E; Le, DT; Yoshino, T; Zuo, Y; Fogelmans, D; Adelbergs, D; Diaz, LA	Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study	ANNALS OF ONCOLOGY	65	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BE-23	Arance, A; Berciano-Guerrero, MA; Guo, J; Carlino, MS; Ascierto, PA; Burotto, M; Mortier, L; Queirolo, P; Chiarion-Sileni, V; Schachter, J; Zhang, X; Martin-Liberal, J; Del Vecchio, M; Okpara, CE; Dutcus, C; Zhang, J; Diede, SJ; Neff, T; Long, GV	Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma	ANNALS OF ONCOLOGY	65	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
15	20%	53%	13%	175



ASSOCIATED GROUPS

BA-16. QUALITY AND SAFETY IN LABORATORY AND HEMATOLOGY CARE.

LR Adolfo Romero Ruiz

Lines of research:

1. Clinical safety.
2. Pre-blood test.
3. Hematology.
4. Clinical analysis.
5. Care.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BA-16	Romero-Arana, A; Romero-Sibajas, N; Arroyo-Bello, E; Romero-Ruiz, A; Gómez-Salgado, J	Monitoring and Follow-Up of Patients on Vitamin K Antagonist Oral Anticoagulant Therapy Using Artificial Intelligence: The AIto-Control Project	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025
BA-16	Romero-Arana, A; González-Rodríguez, MJ; Sánchez-Vega, P; García-Iglesias, JJ; Gómez-Salgado, J; Romero, A	Educational program to improve knowledge and therapeutic range for self-controlled anticoagulated patients	ATENCION PRIMARIA	1.6	Q2	2025
BA-16	Sánchez-Lozano, MA; Padilla, AMM; Montilla, JS; Arana, AR; Gil, MJM; Jurado, SJ; Subirats, MB	Development and implementation of a computerised registry for the assessment and monitoring of cancer patients	REVISTA ESPANOLA DE SALUD PUBLICA	0.8	Q4	2025
BA-16	Romero-Arana, A; Martín-Pereira, J; Fagundo-Rivera, J; Gómez-Salgado, J; Romero-Ruiz, A	Importance of the pre-analytical phase of sample collection in the evaluation of the clinical laboratory support process	EDUCACION MEDICA			2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
BA-16	Iboleon-Jimenez, A; Sánchez-Quintero, MJ; Carmona-Segovia, ADM; Sojo, B; Fernández-Ramos, AM; García-Rodríguez, L; Molina-Ramos, AI; García-Pinilla, JM; Jimenez-Navarro, M; Ortega-Gomez, A	Circulating mitochondrial biomarkers in acute coronary syndrome	FRONTIERS IN MEDICINE	3	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
6	67%	33%	0%	10



BA-20. ONCOLOGY AND BENIGN PATHOLOGY.

LR Jorge Contreras Martínez

Lines of research:

1. Priority line: Prostate tumors, head and neck tumors, brain tumors, breast tumors, pediatric and adolescent tumors, hyperthermia treatment
2. Other lines: Benign diseases (skin tumors, rheumatologic diseases). Degenerative diseases (Alzheimer's disease)

Scientific production and research activity



AREA 3. NEUROSCIENCES, CHRONICITY, AGING, AND HEALTH IN VULNERABLE POPULATIONS.

CONSOLIDATED GROUPS

C-01. NEUROIMMUNOLOGY AND NEUROINFLAMMATION.

Co-LR Pedro Serrano Castro, Co-LR Guillermo Estivill, Co-LR Laura Leyva

Priority lines of research:

1. Neuroimmunology of multiple sclerosis
2. Neuroinflammatory basis of epilepsy

Other lines:

1. Advanced therapies in neurological diseases.
2. Neuromodulation techniques of brain circuits.
3. Psychopharmacology applied in experimental models of diseases with a neuroinflammatory component: Stroke.
4. Personalized medicine in neurology and new therapeutic perspectives.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-01	Ciano-Petersen, NL; Villagrán-García, M; Muñiz-Castrillo, S; Farina, A; Vogrig, A; Goncalves, D; Nicole, F; Rogemond, V; Picard, G; Aubart, M; Psimaras, D; Oliver, B; Serrano-Castro, PJ; Joubert, B; Honnorat, J	Relapses in Anti-NMDAR Encephalitis: Clinical Characterization and Predictive Features	NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION	8.4	D1	2025
C-01	Moreno-Madrid, Isabel; Romero-Imbroda, Jesus; Reyes-Bueno, Jose Antonio; Arrabal-Gomez, Carlos; Diaz-Casares, Amelia; Diaz-Sanchez, Estela; Barbancho-Fernandez, Miguel Angel; Fuxe, Kjell; Borroto-Escuela, Dasiel; Serrano-Castro, Pedro; Narvaez, Manuel	Peripheral expression of NPY1R-based heteroreceptor complexes reflects hippocampal neuroimmune status: Novel biomarkers for early Alzheimer's disease detection.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	2025
C-01	Brichette-Mieg, I; Alonso-Torres, A; Aliaga-Gaspar, P; Rodríguez-Bada, JL; Reyes-Garrido, V; Urbaneja-Romero, P; Muñoz, C; Díaz-Sánchez, M; Martín-Montañez, E; Cabello-Porras, MD; Oliver-Martos, B; Leyva, L	Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification	FRONTIERS IN IMMUNOLOGY	5.9	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-01	Aguilar-Castillo, MJ; Estivill-Torrús, G; García-Martín, G; Cabezudo-García, P; López-Moreno, Y; Ortega-Pinazo, J; Ramírez-García, T; Ciano-Petersen, NL; Serrano-Castro, PJ	Inflammatory Drug-Resistant Epilepsy Index (IDREI) as a Molecular Compound Biomarker in Focal Epilepsies	BIOMOLECULES	4.8	Q1	2025
C-01	Avila-Gámiz, F; Pérez-Cano, AM; Pérez-Berlanga, JM; Zambrana-Infantes, EN; Mañas-Padilla, MC; Gil-Rodríguez, S; Tronel, S; Santín, LJ; de Guevara-Miranda, DL	Sequential physical and cognitive training disrupts cocaine-context associations via multi-level stimulation of adult hippocampal neurogenesis	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
27	37%	74%	22%	124



Networks:

CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (European Commission).

Competitive HR contracts funded in 2025:

1 Contract for long-term reinforcement of the SAS (Action B).

1 Nicolás Monardes SAS Contract (Action C).

C-02. MENTAL HEALTH, SERVICES, AND PRIMARY CARE (SAMSERAP).

LR Juan Ángel Bellón Saameño. Co-LR Patricia Moreno Peral

Lines of research:

1. Develop and validate risk algorithms to predict the onset of common mental illnesses.
2. Design, develop, and evaluate innovative programs for the prevention of common mental illnesses.
3. Generate evidence on the effectiveness, cost-effectiveness, and acceptance of prevention programs for common mental illnesses.
4. Evaluate the implementation of programs for the prevention of common mental illnesses.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-02	Ho, PTN; Vernooij, MW; Voortman, T; Rodriguez-Ayllon, M; Neitzel, J	Objective physical activity and Alzheimer's disease burden in the population-based Rotterdam Study	ALZHEIMERS & DEMENTIA	11	D1	2025
C-02	Ballesteros, A; Flores-Lopez, M; Sánchez-Torres, AM; Gil-Berrozpe, GJ; Moreno-Izco, L; Gavito, A; Serrano, A; de Fonseca, FR; Cuesta, MJ	Exploring Vascular Endothelial Growth Factor and Other Blood-Brain Barrier Biomarkers in Cognition of First-Episode Psychosis: An Observational Study	JOURNAL OF CLINICAL PSYCHIATRY	4.6	D1	2025
C-02	Sánchez-Marín, L; Jiménez-Castilla, V; Flores-López, M; Navarro, JA; Gavito, A; Blanco-Calvo, E; Santín, LJ; Pavón-Morón, FJ; de Fonseca, FR; Serrano, A	Sex-specific alterations in emotional behavior and neurotransmitter systems in LPA1 receptor-deficient mice	NEUROPHARMACOLOGY	4.6	Q1	2025
C-02	Equinet L, Enthoven C, Jansen PW, Rodriguez-Ayllon M.	The longitudinal association between sport participation and self-esteem in youth in the Netherlands: The role of sport type	JOURNAL OF SCIENCE AND MEDICINE IN SPORT	3.4	Q1	2025
C-02	Flores-López, M; Herrera-Imbroda, J; Requena-Ocaña, N; García-Marchena, N; Araos, P; Verheul-Campos, J; Ruiz, JJ; Pastor, A; de la Torre, R; Bordallo, A; Pavón-Morón, FJ; Fonseca, FRD; Serrano, A	Exploratory study on plasma Acylglycerol and Acylethanolamide dysregulation in substance use and attention-deficit/hyperactivity disorder: Implications for novel biomarkers in dual diagnosis	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
14	21%	79%	29%	58



Networks:

CA23153 (YouthDMH) - Digital Mental Health for Young People (European Commission)

RICAPPS, Research Network on Primary Care for Addictions (ISCIII)

Competitive HR contracts funded in 2025:

1 PFIS Contract (ISCIII)

1 Sara Borrell Contract (ISCIII)

2 Pre-doctoral contracts for university professor training from the Ministry of Universities.

1 Pre-doctoral contract for the training of doctors from the State Research Agency.

2 Contracts for research personnel in training for agents of the Andalusian Knowledge System.

1 Contract for the incorporation of postdoctoral researchers to groups in the health and research centers of the SSPA.

C-03. BASIC, CLINICAL, AND EPIDEMIOLOGICAL RESEARCH ON MENTAL HEALTH GROUP.

LR Jose Guzmán Parra, Co-LR: Jessica Goodman Casanova, Co-LR Jesús Herrera Imbroda

Priority line of research: Genetic psychiatry: analysis of genetic variables associated with the expression of the bipolar I and II phenotype in a cohort of families with high aggregation.

Other lines of research:

1. Genetic underpinnings, biomarkers, and personalized treatments in mental health and addiction.
2. Psychological interventions using new information and communication technologies (e-Mental Health).
3. Care, safety, and participation of individuals, families, and communities in mental health care.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-03	Herrera-Imbroda, J; Carbonel-Aranda, V; García-Illanes, Y; Aguilera-Serrano, C; Bordallo-Aragón, A; García-Spínola, E; Torres-Campos, D; Villagrán, JM; García-Sanchez, JA; Mayoral-Cleries, F; Guzmán-Parra, J	An Exploratory Study about Factors and Outcomes Associated with the Experience of Coercive Measures in Mental Health Settings	PSYCHIATRIC QUARTERLY	2.9	Q2	2025
C-03	Hurtado, MM; Villena, A; Quemada, C; Morales-Asencio, JM	Personal relationships during and after an initial psychotic episode. First-person experiences	JOURNAL OF MENTAL HEALTH	3.2	Q1	2025
C-03	Herrera-Imbroda, J; Carbonell-Aranda, V; Guerrero-Pertinez, G; Basnestein-Fonseca, P; Anderberg, P; Varela-Moreno, E; Cuesta-Vargas, A; Garolera, M; Lemmens, E; Berglund, JS; Mayoral-Cleries, F; Goodman-Casanova, JM; Guzman-Parra, J	Temporal Associations Between Cognitive Impairment and Depression in Older Adults: A Longitudinal Analysis	EUROPEAN JOURNAL OF INVESTIGATION IN HEALTH PSYCHOLOGY AND EDUCATION	2.6	Q2	2025
C-03	Ramírez-Martín, A; Sirignano, L; Foo, JC; Streit, F; Frank, J; Witt, SH; Rietschel, M; Mayoral-Cleries, F; Moreno-Küstner, B; Guzmán-Parra, J	The relationships between impulsivity and mood in bipolar disorder: An ecological momentary assessment study	PLOS ONE	2.6	Q2	2025
C-03	Villena, A; Hurtado, MM; Gómez, C; Amor, G; Vega, A; Morales-Asencio, JM	Users remain overlooked: Shared decision-making processes for people with anxiety disorders	JOURNAL OF PSYCHIATRIC AND MENTAL HEALTH NURSING	2.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
22	27%	59%	27%	136





Networks:

CA19101 (DE-PASS) - Determinants of Physical Activities in Settings (European Commission)

CA22114 (TREARURE) - Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development (European Commission)

CA23153 (YouthDMH) - Digital Mental Health for Young People (European Commission)

Competitive HR contracts funded in 2025:

1 Río Hortega Contract (ISCIII)

1 Juan Rodés Contract (ISCIII)

1 Contract for the annual reinforcement of research activity in the clinical units of the SAS.

1 Contract for long-term reinforcement of the SAS (Action B).

1 Contract for the incorporation of postdoctoral researchers to groups in the health and research centers of the SSPA.

C-05. DEGENERATION AND REGENERATION OF THE CENTRAL NERVOUS SYSTEM.

LR Antonio J. Jiménez Lara

Lines of research:

1. Experimental studies on possible stem cell therapies in the treatment of fetal-neonatal hydrocephalus
2. Long-term conditioning of microglia

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-05	León-Rodríguez, A; Grondona, JM; Marín-Wong, S; López-Aranda, MF; López-Avalos, MD	Long-term reprogramming of primed microglia after moderate inhibition of CSF1R signaling	GLIA	5.1	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1	100%	100%		5



Competitive HR contracts funded in 2025:

1 predoctoral contract for the training of university professors FPU

1 Beatriz Galindo research contract (AEI)

C-06. NEUROPSYCHOPHARMACOLOGY.

LR Fernando Rodríguez de Fonseca. Co-LR: Antonia María Serrano Criado. Co-LR: Juan Suárez Pérez

Priority line of research: Study of the biological basis of the behavior and pathophysiology of highly prevalent degenerative diseases. These include addiction disorders (drug abuse), eating disorders (obesity, diabetes, dyslipidemia), Alzheimer's disease, as well as anxiety and depression syndromes throughout their course and in disease models (psychiatric comorbidity).

Other lines:

1. Alcoholic and non-alcoholic steatohepatitis
2. Neuropsychopharmacology of neurodegenerative diseases (ischemia, Parkinson's disease)
3. Metabolic programming during development and growth (obesity, diabetes)
4. Development of new therapeutic chemical entities or new indications for existing drugs.
5. Pharmacological evaluation of food for special medical purposes (FSMPs).

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-06	López-Gambero, AJ; Vargas, A; Fernández-Arjona, MD; Rubio, L; de Ceglia, M; Vera-Fernández, C; Campillo-Calatayud, A; Rivera, P; Fonseca, FRD; Barrios, V; Chowen, JA; Argente, J; Suárez, J	Alteration of IGF-1 bioavailability due to PAPPA2 deficiency leads to sex-specific metabolic disturbances	METABO-LISM-CLINICAL AND EXPERIMEN-TAL	12	D1	2025
C-06	de Ceglia, M; Botticelli, L; Di Bonaventura, EM; Fuentes, AV; Di Bonaventura, MVM; de Fonseca, FR; Cifani, C	Targeting the endocannabinoid/paracannabinoid systems in binge eating behavior: Efficacy of dual ligands in a preclinical model	PHARMACOLOGI-CAL RESEARCH	11	D1	2025
C-06	de Ceglia, M; Tovar, R; Rodriguez-Pozo, M; Vargas, A; Gavito, A; Suarez, J; Baixeras, E; de Fonseca, FR; Decara, J	A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models	BIOCHEMICAL PHARMACOLOGY	5.6	D1	2025
C-06	de Ceglia, M; Romano, A; Di Bonaventura, MVM; Gavito, A; Botticelli, L; Di Bonaventura, EM; Friuli, M; Cifani, C; de Fonseca, FR; Gaetani, S	Cafeteria Diet Abstinence Induces Depressive Behavior and Disrupts Endocannabinoid Signaling in Dopaminergic Areas: A Preclinical Study	CURRENT NEURO-PHARMACOLOGY	5.3	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-06	Pacheco-Sánchez, B; Melgar-Locatelli, S; López-Merchán, R; Benítez-Marín, MJ; Blasco-Alonso, M; González-Mesa, E; Tovar, R; Rubio, P; Suárez, J; Sanjuan, C; de Fonseca, FR; Alén, F; de Ceglia, M; Rivera, P	Gestational saccharin consumption disrupts gut-brain axis glucose homeostasis control in adolescent offspring rats in a sex-dependent manner	BIOLOGY OF SEX DIFFERENCES	5.1	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
36	67%	67%	17%	151





Networks:

CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants development (European Commission)

CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development (European Commission)

CA24130 (PSY-NET): Psychedelic renaissance: turn on, tune in and drop in (European Commission)

RIAPAd, Research Network on Primary Care for Addictions, RD24/0003/0012 (ISCIII).

Competitive HR contracts funded in 2025:

2 Río Hortega Contracts (ISCIII)

1 i-PFIS Contract (ISCIII)

3 Sara Borrell Contracts (ISCIII)

1 Miguel Servet Contract (ISCIII)

1 Ramón y Cajal contract (AEI).

2 Nicolás Monardes SAS contracts (Action C).

C-07. BASIC AND APPLIED ASPECTS OF NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES.

LR Zaida Diaz Cabiale, Co-LR José Pablo Lara Muñoz. Co-LR María Inmaculada García Fernández

Priority line of research:

Basic biomedical aspects of neurotransmission and regeneration in the central nervous system to aspects applied to clinical and therapeutic approaches to neuropsychiatric and neurodegenerative diseases from different approaches but which converge on the study of basic mechanisms that will allow for the development of new diagnostic and therapeutic tools for the treatment of these diseases.

Other lines:

1. Study the role of neuropeptides in key areas of the central nervous system (CNS) for the mediation of behavioral functions associated with anxiety, depression, and fear
2. Analyze the functional interaction of the opioid and dopaminergic systems during opioid dependence in areas related to the learning and consolidation of addictive behavioral habits.
3. Delve deeper into the molecular and cellular bases involved (such as oxidative stress) in the genesis of neurodegenerative processes such as aging and Parkinson's disease and study the neuroprotective effects of IGF-II.
4. Early diagnosis, monitoring, and intervention in neurodegenerative and neuropsychiatric diseases and through autonomic and cognitive assessment techniques. Basic and applied aspects.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-07	Romero-Zerbo, SY; Valverde, N; Claros, S; Zamorano-Gonzalez, P; Boraldi, F; Lofaro, FD; Lara, E; Pavia, J; Garcia-Fernandez, M; Gago, B; Martin-Montañez, E	New molecular mechanisms to explain the neuroprotective effects of insulin-like growth factor II in a cellular model of Parkinson's disease	JOURNAL OF ADVANCED RESEARCH	13	D1	2025
C-07	Flores-Gomez, Marta; Cantero-Garcia, Noelia; Pineda-Gomez, Juan Pedro; Moh-Ahmed, Amel; Flores-Burgess, Antonio; Diaz-Cabiale, Zaida; Millon, Carmelo	Galanin(1-15) and Naltrexone: A novel approach for alcohol use disorder in rats, involving the mesolimbic system.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	2025
C-07	Cantero-García, N; Flores-Burgess, A; Flores-Gomez, M; Pineda-Gomez, JP; Ramos, MC; Diaz, C; Millon, C; Díaz-Cabiale, Z	Intranasal Galanin (1-15) modulates alcohol self-administration and depressive-like behavior in rats and shows a favorable safety profile	FRONTIERS IN PHARMACOLOGY	4.8	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-07	Pineda-Gómez, JP; Millón, C; Cantero-García, N; Flores-Gómez, M; de Guevara-Miranda, DL; Flores-Burgess, A; Diaz-Cabiale, Z	A new pharmacological strategy against treatment-resistant depression	PROGRESS IN NEURO-PSYCHO-PHARMACOLOGY & BIOLOGICAL PSY-CHIATRY	3.9	Q1	2025
C-07	Florido-Santiago, M; Pérez-Belmonte, LM; Lara, JP; Millán-Gomez, M; Pérez-Velasco, MA; Osuna-Sánchez, J; García-Casares, N; Gomez-Huelgas, R; Blanco-Reina, E; Barbancho, MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERI-ATRIC PSYCHIATRY	2.8	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
16	50%	69%	31%	84



Active projects



Patents applied for

Competitive HR contracts funded in 2025:
1 predoctoral contract for the training of university professors FPU.

C-08. MAEPAP. MULTIMORBIDITY, ADHERENCE, ECONOMIC EVALUATION, AND PALLIATIVE CARE IN PRIMARY CARE.

LR Francisca Leiva Fernández, Co-LR: Antonio García Ruiz

Priority line of research: Research on clinical, educational, and economic aspects of multimorbidity, polymedication and treatment adherence in primary care

Other lines:

1. Identification of health professionals' educational needs on multimorbidity and polymedication.
2. Evaluation of training interventions on multimorbidity, polymedication, and treatment adherence for health professionals.
3. Creation and validation of a questionnaire to assess the beliefs of patients with COPD on inhalation therapy.
4. Validation of the mental model of disease in patients with COPD in our setting.
5. Research on health outcomes (treatment adherence, quality of life, pulmonary function) in patients with COPD.
6. Evaluation of the effectiveness of educational interventions in patients with COPD to improve inhaler technique and treatment adherence.
7. Educational impact of a journal club on the acquisition of evidence-based medicine and nursing skills.
8. Evaluation and improvement of teaching quality in specialized health training.
9. Financial assessment of health technology (including drugs).
10. Drug management: from efficacy to effectiveness to efficiency.
11. Development of the IDC-Pal tool: Diagnostic Instrument for Complexity in Palliative Care (PC), in a shared-care model.
12. Development of a multidisciplinary care plan for the last days of life.
13. Validation and cultural adaptation of the "Conversation guide for serious illness."
14. Research on volunteering in palliative care.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-08	Soler, NGA; Trujillo, LG; García-Ruiz, AJ	Cost of Quality of Life in Advanced Parkinson's Disease: Efficient Strategies for Disease Assessment	REVISTA DE NEUROLOGIA	0.8	Q4	2025
C-08	Moreno, SMG; Sánchez, FJ; Soler, NGA; Ruiz, FR; Garcia-Ruiz, AJ	Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches	BMJ OPEN	2.3	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-08	Blundell, DB; Soler, NGA	Quality Management in Spanish Community Pharmacy: Implementation of ISO 9001	JOURNAL OF EVALUATION IN CLINICAL PRACTICE	2.1	Q2	2025
C-08	Nieto-Gómez, P; Castaño-Amores, C; García-Ruiz, AJ; Oliva-Moreno, J	Determinants of time to access to EMA-approved cancer drugs in Spanish NHS in the past decade: a two cohorts study	HEALTH POLICY	3.4	D1	2025
C-08	Escamilla-Sanchez, A; López-Villodres, JA; Alba-Tercedor, C; Ortega-Jiménez, MV; Rius-Díaz, F; Sanchez-Varo, R; Bermúdez, D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	13	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
11	27%	45%	18%	41



C-09. NEUROPATHOLOGY OF ALZHEIMER'S DISEASE (NEUROAD).

LR Antonia Gutiérrez Pérez

Priority line of research: Neuroinflammation and glial response in Alzheimer's disease

Other lines:

1. Decipher new pathogenic mechanisms involved in Alzheimer's disease that will allow greater translational success to symptoms in humans. Impact of risk factors. Identification of biomarkers and therapeutic targets.
2. Develop new animal models of Alzheimer's disease that better recapitulate human disease. Preclinical studies in *in vivo* models of new therapeutic strategies and evaluation of drugs.
3. Development of *in vitro* models of Alzheimer's disease using patient-derived iPSCs. Studies of pathogenic mechanisms and evaluation of new drugs in human cellular platforms.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-09	Escamilla-Sanchez, A; López-Villodres, JA; Alba-Tercedor, C; Ortega-Jiménez, MV; Rius-Díaz, F; Sanchez-Varo, R; Bermúdez, D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	13	D1	2025
C-09	Caceres-Palomo, L; Sanchez-Mejias, E; Trujillo-Estrada, L; Perez-Moreno, JJ; Lopez-Oliva, E; Lim, TE; Deflitch, L; Chang, SH; Kampman, L; Corces, MR; Blurton-Jones, M; Moreno-Gonzalez, I; Pascual, A; Vitorica, J; Garcia-Leon, JA; Gutierrez, A	Human iPSC-derived APOE4/4 Alzheimers disease astrocytes exhibit a senescent and pro-inflammatory state that compromises neuronal support	JOURNAL OF NEUROINFLAMMATION	10	D1	2025
C-09	Andreo-Lopez, J; Nuñez-Diaz, C; Huynh, KD; Nguyen, MMT; Da Cunha, C; Cantero-Molina, FJ; Campos-Moreno, C; Zimbone, S; Bellia, F; Giuffrida, ML; Trujillo-Estrada, L; Garcia-Leon, JA; Bettinetti-Luque, M; Gamez, N; Valdes, C; Morales, R; Forner, S; Martini, AC; Gutierrez, A; Laferla, FM; Baglietto-Vargas, D	Human and Mouse Alzheimer's Seeds Differentially Affect Amyloid Deposition and Microglia-Dependent Plaque Response in Aged Mice	AGING CELL	7.1	D1	2025
C-09	Crouzet, C; Xie, DF; Nuqui, MNL; Hasselman, J; Phan, T; Wilson, RH; Baglietto-Vargas, D; Da Cunha, C; Davtyan, H; Forner, S; Jullienne, A; Bazrafkan, A; Laferla, FM; Obenaus, A; Blurton-Jones, M; Akbari, Y; Green, KN; Choi, B	Cerebrovascular alterations in a mouse model of late-onset Alzheimer's disease	NEUROPHOTONICS	3.8	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-09	Vegas-Gomez, L; Pizarro, M; Garcia-Martin, J; Arredondo-Alcala, MA; Bustamante, B; Gonzalez-Silva, C; Matus, S; Diaz-Espinoza, R; Gutierrez, A; Morales, R; Duran-Aniotz, C; Moreno-Gonzalez, I	Peripheral administration of blood from tau transgenic animals exacerbates brain tau-associated pathology	PLOS ONE	2.6	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
5	80%	60%	60%	36



Ciber:
CIBERNED Neurodegenerative Diseases CB06/05/1116 (ISCIII)

Competitive HR contracts funded in 2025:
1 contract for hiring a predoctoral researcher for the training of university professor (FPU)

1 Contract for pre-doctoral research staff under the University of Málaga's Plan.

C-11. VULNERABILITY AND RESILIENCE TO CHRONIC PAIN: IMPLICATIONS FOR PSYCHOLOGICAL INTERVENTION.

LR María Carmen Ramírez Maestre

Priority line of research: Coping styles and strategies and vulnerability to pain: individual differences and implications for psychological intervention.

Other lines:

1. Variables psicosociales de vulnerabilidad y protección implicadas en el proceso de cronificación del dolor / *The role of psychosocial variables of vulnerabaility and protection in pain chronification.*
2. Patrones de actividad y gestión de metas/ *Patterns of activity and goal management strategies.*
3. Variables predictoras del abuso de opioides y medicación coadyuvante en los pacientes con dolor crónico no oncológico: desarrollo de una escala de detección y clasificación de riesgo / *Predictive variables of opioid and coadjuvant drug abuse in patients with chronic non-oncologic pain: Development of an instrument to assess and classify risk of abuse.*
4. Trastorno de estrés postraumático y dolor crónico como entidades comórbidas: análisis de factores transdiagnósticos / *Post-traumatic stress disorder and chronic pain as comorbid entities: Analysis of transdiagnostic factors*.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-11	Esteve, R; Ramirez-Maestre, C; Serrano-Ibáñez, ER; López-Martinez,AE	Impulsivity Is Related to Prescription Opioid Misuse in People With Chronic Pain Through Pain Catastrophizing and Emotional Distress	PAIN RESEARCH & MANAGEMENT	3	Q2	2025
C-11	Barrado-Moreno, V; Esteve, R; López-Martínez, AE; Ramirez-Maestre, C	Measuring psychological flexibility and inflexibility: further psychometric evidence of the Multidimensional Psychological Flexibility Inventory short form (MPFI-24) in Spanish population	CURRENT PSYCHOLOGY	2.6	Q1	2025
C-11	Ramírez-Maestre, C; Esteve, R; Serrano-Ibáñez, ER; López-Martínez, AE	Prescription opioid misuse in people with chronic noncancer pain: A multi-variable analysis of sociodemographic, clinical, and psychological factors	PLOS ONE	2.6	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-11	de la Vega, R; Yokoyama, K; Daniels, K; Palermo, TM	Unwanted or negative treatment reactions in digital psychological interventions for adolescents with chronic pain	JOURNAL OF PEDIATRIC PSYCHOLOGY	2.1	Q3	2025
C-11	de la Vega, R; Chaves, E; Lund, T; Koocher, GP; Caes, L	Ethical Issues in International Research in Pediatric Psychology: Challenges and Opportunities	JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS	1.9	Q3	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
10	70%	50%		29



Competitive HR contracts funded in 2025:
1 Ramón y Cajal contract (AEI).

C-12. COGNITIVE NEUROSCIENCE: APHASIA AND RELATED DISORDERS (UNCA).

LR Guadalupe Dávila Arias

Priority line of research: Post-stroke aphasia

Other lines:
1. Post-stroke aphasia
2. Validation of diagnostic tests in aphasia and related cognitive and behavioral disorders
3. Design of therapeutic strategies for speech and language disorders
4. Language learning in healthy subjects and individuals with aphasia
5. Echo, imitation, contagion, and repetition and their importance in normal and pathological language.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-12	Gutiérrez-Cordero, I; García-Orza, J	Disassembling an experimental artifact in aphasia: Why phonemic errors with words and semantic errors with numbers?	CORTEX	3.3	Q1	2025
C-12	Berthier, ML; Moreno-Torres, I; Verhoeven, J; Dávila, G	Revisiting the boundaries of different altered accents profiles	CORTEX	3.3	Q1	2025
C-12	Gutiérrez-Cordero, I; García-Orza, J	sunflower: an R package for handling multiple response attempts and conducting error analysis in aphasia and related disorders	FRONTIERS IN PSYCHOLOGY	2.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
3	100%	100%		10



Competitive HR contracts funded in 2025:
1 Ramón y Cajal contract (AEI).

C-13. CHRONICITY, DEPENDENCY, CARE, AND HEALTH SERVICES.

LR José Miguel Morales Asencio

Priority line of research: Multidisciplinary models of care and interventions in individuals with chronic diseases and multimorbidity as well as in situations of dependency.

Other lines:

1. Health inequalities in the caregivers of individuals with multimorbidity and dependence.
2. Clinical safety in individuals with chronic disease, multimorbidity, and dependence.
3. Improving the effectiveness of health care for individuals with chronic diseases and their caregivers (methods and instruments for evidence-based healthcare, design and implementation of clinical practice guidelines).

The spectrum ranges from interventions and models of care for people with chronic pain or type II diabetes mellitus, prevention of adverse events in this population, development and analysis of services for individuals with multimorbidity (case management, transitional care, etc.), or the health impact of the role of family caregiver in the medium-and long-term, among other examples.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-13	Bujalance-Hoyos, J; de Luna-Rodríguez, ME; González-Escobosa, AC; Oña-González, AM; Sánchez-Gómez, S; Zamudio-Sánchez, A; Blanco-Mavillard, I	Implementation of a multimodal strategy via a mobile application to reduce catheter failure in patients with vascular access devices in Spain (CUIDAVEN Study): a pre-post intervention study	ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL	4.4	Q1	2025
C-13	León-Campos, A; Quemada-González, C; Gutiérrez-Rodríguez, L; Pérez-Ardanaz, B; García-Mayor, S; Kaknani-Uttumchandani, S; Martí-García, C	The Impact of Video-Assisted Debriefing on Fostering Self-Critical Thinking in Mental Health Nursing Students	JOURNAL OF NURSING MANAGEMENT	4	D1	2025
C-13	Julià-Móra, JM; Calafell-Vert, M; Rosal-Obrador, FR; Blanco-Mavillard, I; Miró-Bonet, M	Perceptions of care and family support from patients and family caregivers during the COVID-19 pandemic: a phenomenological study in Spain	BMC NURSING	3.9	D1	2025
C-13	Hurtado, MM; Villena, A; Quemada, C; Morales-Asencio, JM	Personal relationships during and after an initial psychotic episode. First-person experiences	JOURNAL OF MENTAL HEALTH	3.2	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-13	Villena, A; Hurtado, MM; Gómez, C; Amor, G; Vega, A; Morales-Asencio, JM	Users remain overlooked: Shared decision-making processes for people with anxiety disorders	JOURNAL OF PSYCHIATRIC AND MENTAL HEALTH NURSING	2.9	Q1	2025

Scientific production and research activity

Articles	%Art. led.	% Q1	% D1	IF
22	68%	55%	23%	59



Active projects



Patents applied for

Networks:

CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research (European Commission)

CA21168 (JIR-CliPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies (European Commission)

CA24107 (SAFE-ICU) - Patient SAFety Related Outcome Measures in European ICUs (European Commission)

C-14. CHRONIC DISEASES AND AGING.

LR Maria Dolores Martin Escalante/Co-LR Julian Olalla Sierra

Lines of research:

1. Chronic cardiovascular diseases
2. Quality and evaluation of healthcare outcomes in chronic diseases and aging.
3. Infectious diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-14	García-Aranda, M; Onieva, MA; Martín-García, D; Quirós, R; López, I; Padilla-Ruiz, M; Téllez, T; Martínez-Gálvez, B; Hortas, ML; García-Galindo, A; González-Gomariz, J; Armañanzas, R; Rivas-Ruiz, F; Serrano, A; Barragán-Mallofret, I; Redondo, M	KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients	SCIENTIFIC REPORTS	3.9	Q1	2025
C-14	Martín-García, D; García-Aranda, M; Varela-Moreno, E; Padilla-Ruiz, M; Zarcos-Pedrinaci, I; Rivas-Ruiz, F; Téllez, T; García-Gutiérrez, S; González, N; Rivero, A; Sarasqueta, C; Perestelo-Pérez, L; Castells, X; Quintana, JM; Sala, M; Redondo, M	Patient-attributable delay and its impact on two-year survival in breast cancer: A multicenter prospective cohort study	EJSO	2.9	Q1	2025
C-14	Alcaide-Garcia, J; Boughanem, H; García-Aranda, M; Rivas-Ruiz, F; Aguirre, U; García, DM; Padilla-Ruiz, M; Varela-Moreno, E; Robles-Lasarte, M; Baré, M; del Cura, I; Varela, MMM; Quintana, JM; Macías, M; Redondo, M	Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients	COLORECTAL DISEASE	2.7	Q1	2025
C-14	Olivares-Navarro, P; Pérez-Rodríguez, MT; Goikoetxea-Agirre, AJ; Reguera-Iglesias, JM; León, E; Mantecón, MA; Pulido-Navazo, A; Boix-Palop, L; Retamar-Gentil, P; Armiñanzas-Castillo, C; Fernández-Natal, I; Jover-Sáenz, A; Jiménez, AD; Fernández-Suárez, J; Martín-Aspas, A; Smithson-Amat, A; Carrasco, AB; Natera-Kindelán, C; Pérez-Crespo, PM; Hernández, IL; López-Cortés, LE; Rodríguez-Baño, J	Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort	INFECTION	3.6	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-14	Izquierdo, R; Suárez-García, I; Gómez-García, T; Marco-Sánchez, C; Puente-Ferreiro, J; Moreno, C; Diaz, A; Cabello-Clotet, N; Vinuesa, D; Blanco, JL; Melús, E; Gómez-Ayerbe, C; Olalla, J; Riera, M; Bernardino, JI; de Quirós, JCDB; Moreno, S; Jarrín, I	Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain	HIV MEDICINE	3.2	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
13	0%	23%	0%	32



C-16. MATERNAL-FETAL MEDICINE, EPIGENETICS, WOMEN'S HEALTH CONDITIONS, AND REPRODUCTIVE HEALTH RESEARCH GROUP .

LR Ernesto González Mesa. Co-LR Jesús Salvador Jiménez López

Priority line of research: Research in the field of reproductive health.

Other lines:

1. Perinatal exposure and psychoevolutionary development.
2. Prematurity, prognostic markers of fetal neurodevelopment, mood disorders in the perinatal period, multiple pregnancy, and reproductive pathology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-16	Arias, IN; Frías, LC; Gonzalez, MM; Cárdenas, LB; Lopez, JSJ	Diagnosis and Management of Struma Ovarii in Pregnancy: A Case Report	LIFE-BASEL	3.4	Q1	2025
C-16	Moral-Moral, CM; Porras-Caballero, L; Blasco-Alonso, M; Cuenca-Marín, C; Monis-Rodriguez, S; Gonzalez-Mesa, E; Narbona-Arias, I; Jimenez-Lopez, JS	Diagnostic Challenges and Perinatal Outcomes: A Case Series on a Retrospective Study	DIAGNOSTICS	3.3	Q1	2025
C-16	Narbona-Arias, I; Blasco-Alonso, M; Monis-Rodriguez, S; Muñoz, CG; González-Mesa, E; Lubián-López, DM; Jimenez-López, J	More than a Diagnosis: How Prenatal Identification of Cantú Syndrome Transformed a Family's Medical Narrative	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025
C-16	Guerra, CL; Morente, LS; Hidalgo, FJM; Romero, MN; Espada, GC; Jimenez-Lopez, JS	The Manchester Procedure as a Uterine-Preserving Alternative for Uterine Prolapse Due to Cervical Elongation: A Short-and Mid-Term Clinical Analysis	MEDICINA-LITHUANIA	2.4	Q1	2025
C-16	Linares-Pineda, TM; Lendinez-Jurado, A; Piserra-López, A; Suárez-Arana, M; Pozo, M; Molina-Vega, M; Picón-César, MJ; Morcillo, S	Longitudinal DNA methylation profiles in saliva of offspring from mothers with gestational diabetes: associations with early childhood growth patterns	CARDIOVASCULAR DIABETOLOGY	11	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
12	42%	83%	17%	49



Networks:

CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development.

CA21108 (NETSKINMODELS) - European Network for Skin Engineering and Modeling.

Competitive HR contracts funded in 2025:

1 Beatriz Galindo research contract (AEI)

1 Contract for doctoral research personnel for agents of the Andalusian Knowledge System.

C-18. FORENSIC MEDICINE, TOXICOLOGY, AND FORENSIC ODONTOLOGY.

LR. Stella Martín de las Heras, Co-LR Leticia Olga Rubio Lamia

Priority line of research: Gender violence, forensic odontology, mineralized samples subjected to thermal stress, forensic toxicology

Other lines:

1. Forensic genetics, medical ethics, training and education in medicine and health sciences

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-18	López-Gambero, AJ; Vargas, A; Fernández-Arjona, MD; Rubio, L; de Ceglia, M; Vera-Fernández, C; Campillo-Calatayud, A; Rivera, P; Fonseca, FRD; Barrios, V; Chowen, JA; Argente, J; Suárez, J	Alteration of IGF-1 bioavailability due to PAPPA2 deficiency leads to sex-specific metabolic disturbances	METABOLISM-CLINICAL AND EXPERIMENTAL	12	D1	2025
C-18	Rodríguez-Pozo, M; Pacheco-Sánchez, B; Ben Rabaa, M; De Ceglia, M; Melgar-Locatelli, S; Santos, I; de Fonseca, FR; Suárez, J; Rivera, P	Perinatal Ethanol Exposure Induces Astrogliosis and Decreases GRP55/PEA-Mediated Neuroprotection in Hippocampal Astrocytes of the 3xTg Alzheimer's Animal Model	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025
C-18	Vadas, E; López-Gambero, AJ; Vargas, A; Rodríguez-Pozo, M; Rivera, P; Decara, J; Serrano, A; Martín-de-las-Heras, S; de Fonseca, FR; Suárez, J	Region-Specific Impact of Repeated Synthetic Cannabinoid Exposure and Withdrawal on Endocannabinoid Signaling, Gliosis, and Inflammatory Markers in the Prefrontal Cortex and Hippocampus	BIOMOLECULES	4.8	Q1	2025
C-18	Fernández-López, R; Andreasen, K; Ankerstjerne, L; Martín-de-las-Heras, S; Rasch, V; Megías, JL; Linde, DS; de-León-de-León, S; Schei, B; Wu, CS; Oviedo-Gutiérrez, A; Zapata-Calvente, AL	Prevalence and associated factors of intimate partner violence against pregnant women who attend antenatal care in Denmark and Spain: A digital screening approach	ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA	3.1	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-18	Martín-Martín, J; Santos, I; Gaitán-Arroyo, MJ; Suarez, J; Rubio, L; Martín-de-las-Heras, S	Dental color measurement to estimate age in adults: a systematic review and meta-analysis	FORENSIC SCIENCE MEDICINE AND PATHOLOGY	1.4	Q3	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
5	40%	80%	20%	26



Networks:

CA22106 (MDVI): Migrant Disaster Victim Identification (European Commission)

CA24147 (AID-AgE) Artificial Intelligence Driven Dental AgEstimation Network (European Commission)

C-22. Receptomics and Signaling Networks in Brain Diseases.

LR Dasiel Óscar Borroto Escuela, Co-LR Manuel Narváez Peláez

Lines of research:

1. Functional mapping of interactions between GPCRs, RTKs, and other receptors in neuropsychiatric and neurodegenerative diseases.
2. Development of new therapeutic strategies targeting receptor heterocomplexes.
3. Advanced receptomics: dynamic analysis of receptomes during aging and the progression of brain diseases.
4. Application of high-resolution technologies for the *in situ* study of signaling networks.
5. Structural bioinformatics and data mining for the analysis of receptor-receptor interaction networks (GPCR-Hetnet) and the design of interaction modulators.
6. Pharmacological screening of molecules that modulate receptor heterocomplexes.
7. Receptomics and neuroinflammation: Implications for glia-neuron communication.
8. Interactomics applied to the discovery of new diagnostic and prognostic biomarkers

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-22	Moreno-Madrid, Isabel; Romero-Imbroda, Jesus; Reyes-Bueno, Jose Antonio; Arrabal-Gomez, Carlos; Diaz-Casares, Amelia; Diaz-Sanchez, Estela; Barbancho-Fernandez, Miguel Angel; Fuxe, Kjell; Borroto-Escuela, Dasiel; Serrano-Castro, Pedro; Narvaez, Manuel	Peripheral expression of NPY1R-based heterore-ceptor complexes reflects hippocampal neuroim-mune status: Novel bio-markers for early Alzhei-mer's disease detection.	Biomedicine & pharma-cotherapy = Biomedecine & pharmaco-therapie	7.5	D1	2025
C-22	Moreno-Madrid, I; Arrabal-Gomez, C; Romero-Imbroda, J; Díaz-Casares, A; Fuxe, K; Borroto-Escuela, D; Serrano-Castro, P; Narváez, M	Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor com-plexes without affecting neuroplasticity or depres-sive-like behaviour	JOURNAL OF PSYCHO-PHARMA-COLOGY	5.5	D1	2025
C-22	Farías-Cea, A; Pérez, L; Leal, C; Segura, K; Hernández, V; Atiés-Pérez, C; Martínez, LM; Hödar-Salazar, M; Reyes-Parada, M; Sotomayor-Zárate, R; Rojas-Hidalgo, F; Julio-Pieper, M; Bravo, JA; Borroto-Escuela, DO; Iturriaga-Vásquez, P	Distinct Swimming Be-havioral Phenotypes Following Serotonin and Dopamine Transporter Modulation in the Adult Zebrafish Novel Tank Div-ing Test (NTT)	PHARMA-CEUTICALS	4.8	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
3	67%	100%	67%	18

Competitive HR contracts funded in 2025:

2 Emergia grant contracts for research staff.

1 Contract for a pre-doctoral research fellow under the University of Málaga's Plan.

EMERGING GROUPS

CE-17. TECHNOLOGY AND INNOVATION IN EMERGENCY DEPARTMENTS AND HOSPITALIZATION.

LR. Carmen Ortiz García. Co-LR Ángela García de la Torre. Co-LR Begoña Mora Ordoñez

Priority line of research: Safety and well-being in emergency department and hospitalization patient care

Other lines:

1. Development of shared healthcare scenarios and technical and organizational innovation
2. Detection of vital and social risk or prevention of health problems and their sequelae
3. Participation in the third-sector health system or associations of expatients/users

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CE-17	Jimenez-López, R; Martin-Chaves, L; Gutierrez-Garcia, AM; Carmona-Segovia, AD; Mora-Ordoñez, B; Sánchez-Garcia, AM; Fernández-Romero, L; Murri, M; Sánchez-Quintero, MJ; Berteli-Garcia, G; Sánchez-Chaparro, MA; Bodi, V; Rodriguez-Capitán, J; Jimenez-Navarro, M; Pavón-Morón, FJ; Romero-Trevejo, JL	Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy	FRONTIERS IN MEDICINE	3	Q1	2025
CE-17	Santotoribio, JD; Corral-Pérez, J; Nuñez-Jurado, D; Fatela-Cantillo, D; García-De La Torre, A; Orantes-Maroto, G; Del Valle-Vázquez, L; Del Castillo-Otero, D; Maira-Gonzalez, N; Cobos-Díaz, A; Guerrero, JM; Lopez-Saez, JB	Malignant pleural effusion risk based on a novel tool using homocysteine and carcinoembryonic antigen in pleural fluid: A multicenter study	CLINICAL BIOCHEMISTRY	2.1	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
2	0%	50%	0%	5



CE-20. OPHTHALMOLOGY.

LR Carlos Rocha de Lossada

Lines of research:

1. Cornea.
2. Retina.
3. Uveitis.
4. Pediatric ophthalmology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CE-20	Rocha-de-Lossada, C; Burguera, N; Fernández, J; Ribeiro, F; Ursell, P; Serrano-Castro, PJ; Dick, HB	Cataract Surgery in Cognitive Impairment: Navigating the Accessibility Challenge in European Healthcare	OPHTHALMOLOGY AND THERAPY	3.2	Q1	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
1	100%	100%		3

CE-21. FRAILTY, AGING, COMPLEX CHRONICITY, AND TEACHING.

LR Marina García Gámez

Lines of research:

1. Fragility Research.
2. Research on aging in the population.
3. Research on complex chronic diseases.
4. Research in the field of health teaching.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CE-21	Casals, C; Fernáandez-Ordoñnez, E; Vázquez-Sánchez, MA; Guerra-Marmolejo, C; Sánchez-Ojeda, MA; López-Leiva, I; García-Gámez, M	Spanish cultural adaptation of the avoidance questionnaire for adolescents (AQA) in undergraduate nursing students	TEACHING AND LEARNING IN NURSING	1.7	Q2	2025
CE-21	Campos, RR; Asencio, JMM; Parra, MRI; Gámez, MG	Validation in Spanish of the GAIN instrument for its application in caregivers of patients with multimorbidity in the home environment	ENFERMERIA CLINICA	1.1	Q3	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
2	100%	0%	0%	3





CE-23. Podology, Inclusive Health, and Equality (PODOSALUD_IG).

LR Ana Belén Ortega Ávila

Lines of research:

1. Research in Podology.
2. Gender perspective in healthcare.
3. Inclusive health: Vulnerable populations
4. Sexuality and self-esteem.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CE-23	Cervera-Garvi, P; Ortiz-Romero, M; Gordillo-Fernandez, LM; Garcia-Paya, I; Ortega-Avila, AB; Diaz-Miguel, S	Translation into Spanish, Transcultural Adaptation and Validation of the Foot Function Index Revised Short Form (FFI_RSF) Questionnaire	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025
CE-23	Gambero, LC; Gijón-Noguerón, GA; Miguel, SD; Barón-López, J; Raquel, CT	Wrist Joint Restriction: Impact on Foot Pressure, Center of Gravity, and the Role of the Dominant Hand	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025
CE-23	Martinez-Rico, M; Gijon-Nogueron, G; Ortega-Avila, AB; Roche-Seruendo, LE; Climent-Pedrosa, A; Deschamps, K; Sanchis-Sales, E	Effect of different custom-made foot orthotics on foot joint stiffness in individuals with structural hallux limitus: A quasi-experimental study	CLINICAL BIOMECHANICS	1.4	Q3	2025
CE-23	Martinez-Sebastian, C; Evans, AMF; Ramos-Petersen, L; Molina-Garcia, C; Gómez-Carrión, A; Gijon-Nogueron, G	The Relationship Between Foot Posture, Validated Foot and Ankle Tests, and Hypermobility in Paediatric Population: A Cross-Sectional Study	JOURNAL OF PAEDIATRICS AND CHILD HEALTH	1.4	Q3	2025
CE-23	Marchena-Rodriguez, A; Garcia-Medina, J; Sanchez-Morilla, S; Cervera-Garvi, P; Ortiz-Romero, M; Ortega-Avila, AB	Methodological Quality of Cross-Cultural Adaptations of the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale	JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION	0.6	Q4	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
13	54%	38%	0%	29



CE-24. Comprehensive Women's Health with a Gender Perspective (SIMGE).

LR Shakira Kaknani Uttumchandani, Co-LR Eloísa Fernández Ordóñez

Lines of research:

1. Sexual, reproductive, and perinatal health from a gender perspective
2. Violence against women and its impact on health
3. Women's health and well-being throughout the life cycle
4. Social determinants and gender inequalities in health
5. Safety, quality of care, and evidence-based practice in women's health

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CE-24	Perez, DV; Navarro, M; Segura-Segura, B; Wendelbo, R; Bandres-Ciga, S; Arraez, MA; Arraez, C; Rodriguez-Losada, N	Neuroprotective Effects of Low-Dose Graphenic Materials on SN4741 Embryonic Stem Cells Against ER Stress and MPTP-Induced Oxidative Stress	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025
CE-24	León-Campos, A; Quemada-González, C; Gutiérrez-Rodríguez, L; Pérez-Ardanaz, B; García-Mayor, S; Kaknani-Uttumchandani, S; Martí-García, C	The Impact of Video-Assisted Debriefing on Fostering Self-Critical Thinking in Mental Health Nursing Students	JOURNAL OF NURSING MANAGEMENT	4	D1	2025
CE-24	García-Ortega, MA; García-Piñero, JM; Gomez-González, AJ; Medina-Lopez, R; González-García, M; Montero-García, AJ; Morales-Gil, IM	Impact of an Early Discharge Hospital-at-Home Program on Length of Stay and Clinical Outcomes in Preterm Infants: A Case-Control Study	CHILDREN-BASEL	2.1	Q2	2025
CE-24	Casals, C; Fernáandez-Ordoñnez, E; Vázquez-Sánchez, MA; Guerra-Marmolejo, C; Sánchez-Ojeda, MA; López-Leiva, I; García-Gámez, M	Spanish cultural adaptation of the avoidance questionnaire for adolescents (AQA) in undergraduate nursing students	TEACHING AND LEARNING IN NURSING	1.7	Q2	2025

Scientific production and research activity:

Articles	%Art. Led.	% Q1	% D1	IF
4	75%	50%	25%	13



ASSOCIATED GROUPS

CA-10. CAUSAL COGNITION GROUP.

LR David Luque Ruiz, Co-LR Pedro Luis Cobos Cano.

Lines of research:

1. Associative learning mechanisms.
2. Learning systems involved in the acquisition and extinction of conditioned fear.
3. Cerebral bases of the reinforcement learning system.
4. Individual differences in reinforcement learning as a marker of vulnerability to anxiety disorders.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CA-10	Martínez-Lopez, P; Vázquez-Millán, A; Garre-Frutos, F; Luque, D	Assessing the validity evidence for habit measures based on time pressure	BEHAVIOR RESEARCH METHODS	3.9	D1	2025
CA-10	Molinero, S; Martínez-López, P; Morís, J; Quintero, MJ; Cobos, PL; López, FJ; Luque, D	The degraded contingency test fails to detect habit induction in humans	PLOS ONE	2.6	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
2	100%	50%	50%	7



Competitive HR contracts funded in 2025:

1 contract for personnel predoctoral researcher for training of university professor (FPU)

EXTERNAL ASSOCIATED GROUPS

CA-15. PALLIATIVE CARE.

LR Pilar Barnestein Fonseca

Principal line of research:

Clinical, educational, and economic aspects of palliative care.

Other lines:

1. Improving the quality of care for patients and their families through research and innovation
2. Expand the interdisciplinary and comprehensive approach to the care of patients with cancer and other advanced-stage diseases
3. Promote competitive research projects, whether public or private, national or EU-wide.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CA-15	Kodba-Ceh, H; Lunder, U; Asgeirsdóttir, GH; Barnestein-Fonseca, P; Bakan, M; Haugen, DF; Halfdanardottir, SI; Joshi, M; Mcglinchey, T; Romarheim, E; Tripodoro, VA; Veloso, VI; Martín, EV; van der Heide, A; Zambrano, SC; Yildiz, B; Rasmussen, BH; iLIVE Project Consortium	End-of-life care decision-making from perspectives of patients, family members and healthcare professionals in 10 countries: a qualitative study within the iLIVE project	MORTALITY	1	Q2	2025
CA-15	Barnestein-Fonseca, P; Víbora-Martín, E; Ruiz-Torreras, I; Gómez-García, R; Martín-Roselló, ML	Perceived usefulness of new technologies in palliative care volunteering: mixed-methods study with stakeholders	BMC PALLIATIVE CARE	3	Q1	2025
CA-15	Schelin, MEC; Hedman, C; Barnestein-Fonseca, P; Egloff, M; Ellershaw, J; Haugen, DF; Fischer, C; Joshi, M; Korfage, IJ; Lunder, U; Mason, S; Simon, J; Tripodoro, VA; Yildiz, B; Zambrano, SC; Eychmueller, S; van Zuylen, L; van der Heide, A; Fürst, CJ	Recruitment, follow-up and survival in an 11-country cohort study of patients at the end of life and their relatives	PLOS ONE	2.6	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CA-15	Herrera-Imbroda, J; Carbonell-Aranda, V; Guerrero-Pertinez, G; Basnestein-Fonseca, P; Anderberg, P; Varela-Moreno, E; Cuesta-Vargas, A; Garolera, M; Lemmens, E; Berglund, JS; Mayoral-Cleries, F; Goodman-Casanova, JM; Guzman-Parra, J	Temporal Associations Between Cognitive Impairment and Depression in Older Adults: A Longitudinal Analysis	EUROPEAN JOURNAL OF INVESTIGATION IN HEALTH PSYCHOLOGY AND EDUCATION	2.6	Q2	2025
CA-15	Aguiar-Leiva, VP; Leiva-Fernández, F; Martín-Roselló, ML; Gomez-Garcia, R; Fernandez-Lopez, A; Barnestein-Fonseca, P; Morales-Asencio, JM	Validation of a questionnaire to assess complexity of palliative care needs in primary care in Malaga, Spain: a study protocol	BMJ OPEN	2.3	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
5	20%	20%		11.5

CA-19. DIGCOMPSALUD. DIGITAL COMPETENCE FOR LIFELONG LEARNING.

LR Carmen Aránzazu Bermúdez Martín

Lines of research:

1. Artificial intelligence in the study of older adults
2. Dependence and frailty
3. Improvements in health care

Other lines:

Digital competence, open science, educational technology, digital transformation, curriculum design, lifelong learning, virtual library, school for patient, health technology, open education, digital health.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CA-19	Florido-Santiago, M; Pérez-Belmonte, LM; Lara, JP; Millán-Gomez, M; Pérez-Velasco, MA; Osuna-Sánchez, J; García-Casares, N; Gomez-Huelgas, R; Blanco-Reina, E; Barbancho, MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	2.8	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1				2.8



AREA 4. AUTOIMMUNE DISEASES, INFECTIOUS DISEASES, INFLAMMATION, AND ALLERGY.

CONSOLIDATED GROUPS

D-01. CLINICAL RESEARCH GROUP ON HIV INFECTION, ENDOVASCULAR INFECTION, AND BACTEREMIA.

LR Jesús Santos González. Co-LR Rosario Palacios Muñoz

Priority line of research: HIV infection

Other lines of research:

1. HIV/HCV infection
2. Other sexually transmitted infections
3. Endovascular infections and bacteremia
4. Osteoarticular infections
5. International health and imported infections

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-01	Palom-Grau, C; Cuervo, G; Muñoz, P; Arriaza, MM; Martínez-Sellés, M; González-Ramallo, V; de Alarcón, A; Poyato-Borrego, M; Rodríguez-García, R; Rodríguez-Esteban, MA; Fariñas, MC; González-Rico, C; Goenaga, MA; Ojeda-Burgos, G; Goikoetxea-Agirre, AJ; Calderón-Parra, J; López-Azor, JC; García-Vázquez, E; Loeches, B; Quintana, E; de la Mària , CG; Llopis, J; Miró, JM	A Contemporary Picture of Coagulase-Negative Staphylococcal Endocarditis A Nationwide GAMES Cohort Study	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	22	D1	2025
D-01	Fichtenbaum, CJ; Malvestutto, C; Watanabe, MG; Smith, ED; Ribaudo, HJ; Mccallum, S; Fitch, K; Currier, JS; Diggs, MR; Chu, SM; Aberg, JA; Lu, M; Valencia, J; Gómez-Ayerbe, C; Brar, I; Madruga, JV; Bloomfield, GS; Douglas, PS; Zanni, M; Grinspoon, SK	Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	LANCET HIV	13	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-01	Labiod, N; Sanchez-Seco, MP; Goikoetxea, J; Zurita, ND; Norman, FF; Martínez, MM; Alonso, PA; Hernández-Betancor, A; Sempere-Alcocer, MA; Moure, Z; Ocete, MD; Vicente, MR; de la Calle-prieto, F; Gallego, M; Domingo, LC; Galán, JC; Camprubí-Ferrer, D; Meilán, C; Perez-Hernandez, I; Cabezon, I; Hernández, FJ; Bernal, E; Vázquez, A	Case series of Oropouche fever among travellers returning from Cuba to Spain, 2024	EUROSURVEILLANCE	7.8	D1	2025
D-01	Pita-Martínez, C; Jiménez-Sousa, MA; Martinez-Picado, J; Rodríguez, CEG; Fariñas, C; Galindo, P; Roca-Oporto, C; Santos, J; Muñoz-García, P; Rava, M; Resino, S; Martín-Escolano, R	Immune and senescence profiles associated with non-AIDS-defining cancer risk in people with HIV: a case-cohort study	FRONTIERS IN IMMUNOLOGY	5.9	Q1	2025
D-01	Palacios, R; Gómez-Ayerbe, C; Martín-Cortés, S; González-Jiménez, A; López-Jódar, M; Pérez-Hernández, IA; Santos, J	Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study	JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY	3.6	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
11	9%	45%	27%	69



Networks:

CA21164 (ADVANCE-TB) - Towards an improvement in diagnostics and treatment strategies for TB control (European Commission)

CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections in (European Commission)

CA20128 (PIMENTO) - Promoting Innovation of fermented foods (European Commission)

D-03. INFLAMMATORY AND AUTOIMMUNE DISEASES.

LR Antonio Fernández Nebro. Co-LR Natalia Mena Vázquez

Priority line of research: Immunologically mediated inflammatory diseases

Other lines:

1. Microbiota in inflammatory diseases
2. Cardiovascular risk in inflammatory diseases
3. Nursing care in osteoarticular diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-03	Cano-García, L; García-Studer, A; Manrique-Arija, S; Ortiz-Marquez, F; Redondo-Rodríguez, R; Borregón-Garrido, P; Mena-Vázquez, N; Fernández-Nebro, A	Identifying inflammatory phenotypes associated with lung involvement in systemic sclerosis: k-means clustering approach	FRONTIERS IN IMMUNOLOGY	5.9	Q1	2025
D-03	Mena-Vázquez, N; García-Studer, A; Ortiz-Márquez, F; Manrique-Arija, S; Mucientes, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Redondo-Rodriguez, R; Cano-García, L; Fernández-Nebro, A	Longitudinal Assessment of Body Composition and Inflammatory Status in Rheumatoid Arthritis During TNF Inhibitor Treatment: A Pilot Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	2025
D-03	Mucientes, A; Núñez, GMM; Mena-Vázquez, N; Lisbona-Montañez, JM; Manrique-Arija, S; González-Jiménez, A; Ruiz-Limón, P; Garcia-Studer, A; Ortiz-Márquez, F; Cano-García, L; Fernández-Nebro, A	Analysis of epigenetic biomarkers for diagnosis and assessment of severity in rheumatoid arthritis: a cross-sectional study	ARTHRITIS RESEARCH & THERAPY	4.6	Q1	2025
D-03	Cano-García, L; García-Studer, A; Manrique-Arija, S; Ortiz-Márquez, F; Redondo-Rodríguez, R; Borregón-Garrido, P; Mena-Vázquez, N; Fernández-Nebro, A	Accrual of organ damage and one-year mortality in systemic sclerosis: A prospective observational study	SEMINARS IN ARTHRITIS AND RHEUMATISM	4.4	Q1	2025
D-03	Mena-Vázquez, N; Ortiz-Márquez, F; Ramírez-García, T; Cabezudo-García, P; García-Studer, A; Mucientes-Ruiz, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Redondo-Rodríguez, R; Manrique-Arija, S; Cano-García, L; Serrano-Castro, PJ; Fernández-Nebro, A	Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis	FRONTIERS IN MEDICINE	3	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
12	50%	83%	0%	44



Networks:
RICORS INFLAMMATORY DISEASES REI, RD24-0007-0036 (ISCIII)

Competitive HR contracts funded in 2025:
1 PFIS Contract (ISCIII)
1 Sara Borrell Contract (ISCIII)

D-04. ALLERGIC DISEASES TO DRUGS AND ALLERGENS.

LR María José Torres Jaén, Co-LR: Lina Mayorga Mayorga

Priority line of research: Study of allergic reactions

Other lines:

1. Drug hypersensitivity reactions mediated by specific immunological mechanisms, such as IgE or T cells.
2. Drug hypersensitivity reactions mediated by other mechanisms.
3. Food allergies.
4. Allergic respiratory diseases: rhinitis and asthma
5. Specific immunomodulatory treatments: Immunotherapy and desensitization.
6. Development of nanomaterials for diagnosis and treatment.
7. Validation and clinical implementation of biomarkers for allergic reactions

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-04	Gómez, F; Pérez-Sánchez, N; Macías-Camero, A; Núñez, R; Contreras, N; Cañas, JA; Jiménez-Sánchez, IM; Díez-Echave, P; Barbas, C; Guéant, JL; Barber, D; Vieths, S; Scheurer, S; Villaseñor, A; Rodríguez-Nogales, A; Mayorga, C; Torres, MJ	Multi-omics analysis of a prebiotic intervention with pectin in lipid transfer proteins (LTPs) allergic patients	CARBOHYDRATE POLYMERS	13	D1	2025
D-04	Bogas, G; Ariza, A; Vázquez-Revuelta, P; Labella, M; Madrigal-Burgaleta, R; Fernández-Santamaría, R; Calvo-Serrano, S; Villar-Chamorro, E; Martín-Clavo, S; Lebrón-Martín, C; Mayorga, C; Doña, I; Torres, MJ	Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes	ALLERGY	12	D1	2025
D-04	Fernandez-Santamaria, R; Salas, M; Ariza, A; Jiménez, MA; González-Mendiola, MR; Sanchez, ML; Boteanu, C; Mayorga, C; Fernandez, TD; Torres, MJ; Laguna, JJ	Basophil Activation Test Positivity Decreases With Time in Immediate Allergic Reactions to Proton Pump Inhibitors	ALLERGY	12	D1	2025
D-04	Gelincik, A; Brockow, K; Çelik, GE; Demir, S; Diaz, ID; Ebo, DG; Mayorga, C; Labella, M; Sabato, V; Jaen, MJT	Diagnosis of Quinolone Hypersensitivity: An EAACI Position Paper	ALLERGY	12	D1	2025
D-04	Labella, M; de Guzmán, JR; Diez-Echave, P; Salas, M; Fernández-Santamaría, R; Mayorga, C; Doña, I; Torres, MJ	Direct Single-Dose Drug-Provocation Test Is Safe for Delabelling Penicillin Low-Risk Reactions in Adults	ALLERGY	12	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
30	43%	83%	70%	280



Networks:
RICORS INFLAMMATORY DISEASES REI RD24/0007/0024 (ISCIII)

Competitive HR contracts funded in 2025:
1 MARIE SKLODOWSKA-CURIE Contract: POSTDOCTORAL FELLOWSHIPS - EUROPEAN FELLOWSHIPS (European Commission).

7 PFIS Contracts (ISCIII)

4 Río Hortega Contracts (ISCIII)

3 Juan Rodés Contracts (ISCIII)

1 Sara Borrell Contract (ISCIII)

2 Ramón y Cajal Contracts from the State Research Agency.

1 Pre-doctoral contract for the training of doctors from the State Research Agency.

1 Contract for the annual reinforcement of research activity in the clinical units of the SAS.

1 Contract for long-term reinforcement of the SAS (Action B).

2 Contract for the incorporation of clinical-research professionals to the clinical units of the Andalusian Health Service.

3 Nicolás Monardes SAS contracts (Action C).

D-05. HEPATOGASTROENTEROLOGY, PHARMACOLOGY, AND TRANSLATIONAL CLINICAL THERAPEUTICS.

LR Raúl J. Andrade Bellido, Co-LR Eduardo García Fuentes, Co-LR Mercedes Robles Díaz

Lines of research:

1. Epidemiological research, causality, and genetic factors and identification of biomarkers in hepatotoxicity.
2. Etiopathogenesis and new treatments in inflammatory bowel disease
3. Etiopathogenesis, clinical course and noninvasive diagnosis in nonalcoholic fatty liver disease

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-05	Bessone, F; Hernandez, N; Medina-Caliz, I; García-Cortés, M; Schinoni, MI; Mendizabal, M; Chiodi, D; Nunes, V; Ridruejo, E; Pazos, X; Santos, G; Fassio, E; Parana, R; Reggiardo, V; Tanno, H; Sanchez, A; Tanno, F; Montes, P; Tagle, M; Arrese, M; Brahm, J; Girala, M; Lizarzabal, MI; Carrera, E; Zerega, A; Bianchi, C; Reyes, L; Arnedillo, D; Cordone, A; Gualano, G; Jaureguizahar, F; Rifrani, G; Robles-Díaz, M; Ortega-Alonso, A; Pinazo-Bandera, JM; Stephens, C; Sanabria-Cabrera, J; Bonilla-Toyos, E; Niu, H; Alvarez-Alvarez, I; Lucena, MI; Andrade, RJ	Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY	12	D1	2025
D-05	Mela, V; Martín-Reyes, F; Oliva-Olivera, W; Cantarero-Cuenca, A; Sánchez-García, A; Sancho-Marín, R; González-Jimenez, A; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sanchez-Gallegos, P; Martínez-Moreno, JM; Tinahones, FJ; García-Fuentes, E; Garrido-Sánchez, L	Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery	METABOLISM-CLINICAL AND EXPERIMENTAL	12	D1	2025
D-05	Di Zeo-Sánchez, DE; Diaz-Alberola, I; Pinazo-Bandera, JM; García-Cortés, M; Sanabria-Cabrera, J; Robles-Díaz, M; Alvarez-Alvarez, I; Lucena, MI; Andrade, RJ; Villanueva-Paz, M; Stephens, C	Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD)	BRITISH JOURNAL OF PHARMACOLOGY	7.7	D1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-05	Ruiz-Malagon, AJ; Herraiz-Vilela, M; Serrano-Pino, R; García-Avila, P; Díaz-Suárez, L; Carmona-Segovia, AD; Becerra-Munoz, VM; Jiménez-Navarro, M; Arranz-Salas, I; Lopez-Villodres, JA; Fernández-Castañer, A; Gutiérrez-Martínez, F; Rodríguez-González, FJ; Camargo-Camero, R; Alcaín-Martínez, G; Rodríguez-Díaz, C; García-Fuentes, E; Sánchez-Quintero, MJ; Lopez-Gomez, C	Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease	WORLD JOURNAL OF GASTROENTEROLOGY	5.4	Q1	2025
D-05	Martin-Reyes, F; Kentaoui-Bousellam, I; Ruiz-Malagón, AJ; Ho-Plágaro, A; López-Gómez, C; Herraiz-Vilela, M; Alcain-Martínez, G; Camargo-Camero, R; Martos-VanDussen, JV; Camacho-Martel, L; Gutiérrrez-Martínez, F; Arranz-Salas, I; Ortega-Jimenez, MV; Escamilla-Sánchez, A; Daza-González, JJ; Sanchiz-Cardenas, E; Rivas-Becerra, J; García-Fuentes, E; Rodríguez-Pacheco, F; Rodriguez-Diaz, C	Mesenteric adipose tissue in Crohn's disease alters the immune response of the ileal mucosa and increases angiogenesis and fibrosis	SCIENTIFIC REPORTS	3.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
26	50%	65%	19%	129





Networks and Ciber:

CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities.
CIBEREHD CB07/04/2008 Liver and Digestive Diseases (ISCIII)

Competitive HR contracts funded in 2025:
1 i-PFIS Contract (ISCIII)
2 Río Hortega Contracts (ISCIII)
1 Juan Rodés Contract (ISCIII)
2 Miguel Servet Contracts (ISCIII)
1 Pre-doctoral contract for the training of doctors from the State Research Agency.
1 Contract for university professor training from the Ministry of Science, Innovation, and Universities.
1 Contract for the incorporation of clinical-research professionals into SAS clinical units (Action B).
1 Nicolás Monardes SAS Contract (Action C).
1 Contract for the incorporation of postdoctoral researchers to groups in the health and research centers of the SSPA.
1 Contract for the hiring of clinical care professionals at SAS centers (Investiga C Program).

EMERGING GROUPS

DE-02. GROUP FOR THE STUDY OF INFECTIOUS DISEASES.

LR José María Reguera

Priority line of research: HIV infection

Other lines:
1. Endovascular infection
2. Multidrug-resistant bacteria
3. Identification of NTM by means of MALDITOF

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
DE-02	Varisco, B; Pérez-Crespo, PMM; Retamar-Gentil, P; Hernandez, IL; Farinas-Alvarez, MC; Fernández-Natal, I; Pérez-Rodríguez, MT; Aguirre, AJG; Sánchez-Calvo, JM; Martín, LB; León-Jiménez, E; García, DV; Reguera-Iglesias, JM; Bahamonde-Carrasco, A; Fernandez-Suárez, J; Rodríguez-Baño, J; López-Cortés, LE; ROBACREIPI GEIH SEIMC SAEI Grp	Mortality predictors and definition proposal for complicated coagulase-negative Staphylococcus bacteraemia: a multicentre prospective cohort study	CLINICAL MICROBIOLOGY AND INFECTION	8.5	D1	2025
DE-02	Sobrino, B; Luque, S; Velasco-Arnaiz, E; González, RL; Del Pozo, JL	Gram-positive infections in special populations. Expert view on the role of dalbavancin	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	3.8	Q1	2025
DE-02	Olivares-Navarro, P; Pérez-Rodríguez, MT; Goikoetxea-Agirre, AJ; Reguera-Iglesias, JM; León, E; Mantecón, MA; Pulido-Navazo, A; Boix-Palop, L; Retamar-Gentil, P; Armiñanzas-Castillo, C; Fernández-Natal, I; Jover-Sáenz, A; Jiménez, AD; Fernández-Suárez, J; Martín-Aspas, A; Smithson-Amat, A; Carrasco, AB; Natera-Kindelán, C; Pérez-Crespo, PM; Hernández, IL; López-Cortés, LE; Rodríguez-Baño, J	Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort	INFECTION	3.6	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
DE-02	Mancheño-Losa, M; Murillo, O; Benavent, E; Sorlí, L; Riera, M; Cobo, J; Benito, N; Morata, L; Ribera, A; Sobrino, B; Fernández-Sampedro, M; Múñez, E; Bahamonde, A; Barbero, JM; del Toro, MD; Villa, J; Rigo-Bonnin, R; Luque, S; García-Luque, I; Oliver, A; Esteban, J; Lora-Tamayo, J	Efficacy and safety of colistin plus beta-lactams for bone and joint infection caused by fluoroquinolone-resistant gram-negative bacilli: a prospective multicenter study	INFECTION	3.6	Q2	2025
DE-02	Rojo-Martín, MD; Ruiz-Mesa, JD; Mediavilla-Gradolph, C; Marín-Arriaza, M; Halbardier-Carretero, A; Serrano-Sánchez, J; Márquez-Gómez, I; de Toro-Peinado, I; Caballero-Martínez, LF; García-Barrionuevo, A; Palop-Borrás, B	The role of microbiological markers in the progression of Clostridioides difficile infection	REVISTA ARGENTINA DE MICROBIOLOGIA	2.1	Q3	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
6	33%	33%	17%	24



Clinical studies

DE-07. INFLAMMATION IN CRITICALLY ILL PATIENTS.

LR Manuel Enrique Herrera Gutierrez. Co-LR Emilio Curiel Balsera

Priority line of research: Study of the inflammatory response and treatment measures.

Other lines:

1. Inflammatory response in different scenarios: Extracorporeal surgery, acute kidney disease, acute liver disease.
2. Extracorporeal organ support.
3. Ischemic heart disease.
4. Ischemic/hemorrhagic brain disease.

Scientific production and research activity



Active projects



Clinical studies

DE-08. HEPATOGASTROENTEROLOGY, ENDOSCOPY, AND GASTROINTESTINAL SURGERY.

LR Miguel Jiménez Pérez. Co-LR Julio Santoyo Santoyo

Priority line of research: Liver diseases: viral, metabolic, and toxic. Liver transplantation. Gastrointestinal oncology.

Other lines:

1. Inflammatory bowel disease
2. Digestive endoscopy

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
DE-08	Mela, V; Martín-Reyes, F; Oliva-Olivera, W; Cantarero-Cuenca, A; Sánchez-García, A; Sancho-Marín, R; González-Jimenez, A; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sanchez-Gallegos, P; Martínez-Moreno, JM; Tinahones, FJ; García-Fuentes, E; Garrido-Sánchez, L	Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery	METABOLISM-CLINICAL AND EXPERIMENTAL	12	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1		100%	100%	12



Active projects



Clinical studies

DE-09. IMMUNE RESPONSE TO VIRAL INFECTIONS.

LR Juan José Borrego García. Co-LR José Manuel Jiménez Guardeño. Co-LR Ana María Ortega Prieto

Priority line of research: Study of the immune response to viral infections and the mechanisms of viral immunopathology.

Other lines:

1. Study of viruses of high biomedical relevance:
2. Coronavirus (SARS-CoV-1, SARS-CoV-2, NL63-CoV)
3. Human immunodeficiency virus (HIV)
4. Influenza virus

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Year
DE-09	Santamaria-Castro, I; Leiva-Rebollo, R; Marín-Wong, S; Jimenez-Guardeño, JM; Ortega-Prieto, AM	Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies	MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS	7.8	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1	100%	100%	100%	8



Active projects

Competitive HR contracts funded in 2024:

1 Ramón y Cajal Contract from the State Research Agency.

1 Miguel Servet Contract (ISCIII)

1 contract for the incorporation of Post-doctorates from the Junta of Andalusia.

DE-10. OPHTHALMOLOGY.

LR Rafael Luque Aranda. Co-LR Carmen Alba Linero

Priority line of research: Autoimmune diseases, infectious diseases and ocular allergies

Other lines:

1. Ocular involvement in neurological diseases
2. Ocular involvement in cardiovascular disease

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Year
DE-10	Gutiérrez, P; Jiménez, L; Martínez, J; Alba, C; Girón, MV; Olveira, G; Ruiz-Esteban, P; Olveira, C	Dry eye disease and morphological changes in the anterior chamber in people with cystic fibrosis	JOURNAL OF CYSTIC FIBROSIS	6	Q1	2025
DE-10	Sánchez-Fernández, B; Zamorano-González, P; Martín-Montañez, E; Alba-Linero, C; Rius-Díaz, F; García-Fernandez, M; Luque-Aranda, R; García-Basterra, I	Oxidative Stress and Inflammatory Biomarkers in Aqueous Humor and Blood of Patients with Leber's Hereditary Optic Neuropathy	ANTIOXIDANTS	6.6	Q1	2025
DE-10	Zamorano-Martin, F; Rebollo-Ramírez, W; Ballesteros-Sánchez, A; Alba-Linero, C; Ortiz-Perez, S; Tovilla-Canales, JL; Nava-Castañeda, A	Punctal occlusion versus artificial tears and lid hygiene in the management of Dry Anophthalmic Socket Syndrome: a randomized controlled trial	ORBIT-THE INTERNATIONAL JOURNAL ON ORBITAL DISORDERS-OCULOPLASTIC AND LACRIMAL SURGERY	0.8	Q4	2025
DE-10	Urbinati, F; Bueno, JAR; Real, PS; Redondo-López, MC; Ortega, AS; García-Arnés, JA; Bedmar, MG; Alba-Linero, C; García-Casares, N	Retinal structure and vasculature changes and their relationship with mild cognitive impairment in type 2 diabetes	JOURNAL OF ALZHEIMERS DISEASE	3.1	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
4	50%	50%	0%	17



Networks:
Collaborating Clinical Group in the Inflammatory Diseases Ricors RICORS-REI (ISCIII).

DE-11. PULMONOLOGY.

LR Jose Luis Velasco Garrido

Lines of research:

1. Immune mechanisms and endophenotypes of severe asthma.
2. Prognostic impact of nutritional status on disease progression.
3. Prevalence and progression of malnutrition and sarcopenia in patients with pulmonary fibrosis.
4. Safety and efficacy of biologic treatments for asthma.

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Year
DE-11	Montero-Benitez, MZ; Carmona-Llanos, A; Fernández-Jiménez, R; Román-Jobacho, A; Gómez-Millán, J; Modamio-Molina, J; Cabrera-Cesar, E; Vegas-Aguilar, I; Amaya-Campos, MD; Tinahones, FJ; Molina-Montes, E; Cayón-Blanco, M; García-Almeida, JM	AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques	CANCERS	4.4	Q2	2025
DE-11	Sanmartin-Sánchez, A; Fernández-Jimenez, R; Olivares-Alcolea, J; Cabrera-Cesar, E; Espildora-Hernández, F; Vegas-Aguilar, I; Amaya-Campos, MD; Simón-Frapolli, VJ; Villaplana-Garcia, M; Cornejo-Pareja, I; Sánchez-Garcia, A; Murri, M; Guirado-Peláez, P; Vidal-Suárez, A; Garrido-Sánchez, L; Tinahones, FJ; Velasco-Garrido, JL; Garcia-Almeida, JM	Cachexia Phenotyping Through Morphofunctional Assessment and Mitocondrial Biomarkers (GDF-15 and PGC-1α) in Idiopathic Pulmonary Fibrosis	NUTRIENTS	5	Q1	2025
DE-11	Cabrera-César, E; Fernández-Jiménez, R; Lopez-Garcia, J; Sanmartín-Sánchez, A; Cano-Gamonoso, MB; Agüero, IA; Espíldora-Hernández, F; Garcia, LFD; Vega-Aguilar, I; Amaya-Campos, MD; Tinahones, FJ; Garcia-Almeida, JM; Velasco-Garrido, JL	Malnutrition, Sarcopenia, and Malnutrition Sarcopenia Syndrome in Idiopathic Pulmonary Fibrosis	ADVANCES IN RESPIRATORY MEDICINE	2.3	Q2	2025
DE-11	Sanmartín-Sánchez, A; Fernández-Jiménez, R; Cabrera-César, E; Espíldora-Hernández, F; Vegas-Aguilar, I; Amaya-Campos, MD; Palmas-Candia, FX; Olivares-Alcolea, J; Simón-Frapolli, VJ; Cornejo-Pareja, I; Sánchez-García, A; Murri, M; Guirado-Peláez, P; Vidal-Suárez, A; Garrido-Sánchez, L; Tinahones, FJ; Velasco-Garrido, JL; García-Almeida, JM	The Nutritional Phenotyping of Idiopathic Pulmonary Fibrosis Through Morphofunctional Assessment: A Bicentric Cross-Sectional Case-Control Study	LIFE-BASEL	3.4	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
4	25%	50%	0%	15



ASSOCIATED GROUPS

DA-06. IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMID).

LR Rosa García Portales. Co-LR María del Carmen Ordóñez Cañizares

Lines of research:

1. Comorbidity, prevalence and impact of immune-mediated inflammatory diseases.
2. Biotherapies and targeted therapies in rheumatoid arthritis, psoriatic arthritis, spondyloarthropathies, and uveitis.
3. Pharmacogenetics.

Scientific production and research activity



Networks:

Collaborating Clinical Group in the Inflammatory Diseases Ricors RICORS-REI (ISCIII).

AREA 6. IBIMA TECH: HEALTH TECHNOLOGY AND INNOVATION AREA.

F-02. COMPUTATIONAL INTELLIGENCE AND IMAGE ANALYSIS.

LR Ezequiel López Rubio, Co-LR Esteban José Palomo Ferrer

Lines of research:

1. Neurocomputing.
2. Digital image analysis.
3. Intelligent decision support systems.
4. Computational learning.
5. Grouping analysis.
6. Decision making.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-02	Mármol-Rivera, JA; Fernández-Rodríguez, JD; Asenjo, B; López-Rubio, E	Latent diffusion for arbitrary zoom MRI super-resolution	EXPERT SYSTEMS WITH APPLICATIONS	7.5	D1	2025
F-02	Rodríguez-Rodríguez, JA; Molina-Cabello, MA; Benítez-Rochel, R; López-Rubio, E	Consensus-Based 3D View Generation from Noisy Images	INTERNATIONAL JOURNAL OF NEURAL SYSTEMS	6.4	Q1	2025
F-02	Thurnhofer-Hemsi, K; García-Aguilar, I; Fernández-Rodriguez, JD; López-Rubio, E	Representation of Molecules by Sequences of Instructions	JOURNAL OF CHEMICAL INFORMATION AND MODELING	5.3	Q1	2025
F-02	Lima, MSPD Jr; Ortiz-de-Lazcano-Lobato, JM; Lopez-Rubio, E	Training-Free Few-Shot Image Classification via Kernel Density Estimation with CLIP Embeddings	MATHEMATICS	2.2	D1	2025
F-02	Díaz-Gaxiola, E; Yee-Rendon, A; Vega-Lopez, IF; Campos-Leal, JA; García-Aguilar, I; López-Rubio, E; Luque-Baena, RM	Experimental Assessment of YOLO Variants for Coronary Artery Disease Segmentation from Angiograms	ELECTRONICS	2.6	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
9	89%	56%	33%	38



Competitive HR contracts funded in 2025:
1 i-PFIS Contract (ISCIII)

F-03. COMMUNICATIONS ENGINEERING.

LR Iñigo Molina Fernández

Lines of research:

1. R&D in telecommunication networks, systems, and services.
2. Signal processing in biomedicine.
3. e-Health.
4. Biosensors.
5. Applications of adaptive optics in ophthalmology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-03	Imas, JJ; Del Villar, I; Halir, R; Wangüemert-Pérez, JG; Ortega-Moñux, A; Matías, IR; Molina-Fernández, I	A systemic model for lossy mode resonances (LMRs)	OPTICS AND LASER TECHNOLOGY	5	Q1	2025
F-03	Pérez-Sánchez, L; Sénchez-Ramírez, A; Leuermann, J; Molina-Fernández, I	Optical Camera-Based Multiplexed Photonic Sensor System With Ultralow Detection Limit for Biomedical Applications	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.9	D1	2025
F-03	Arshad, A; Zabit, U; Bernal, O; Deleau, C; Halir, R	Robust integrated optical feedback interferometry via variable optical attenuation	OPTICS EXPRESS	3.3	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
3	100%	67%	33%	14



F-04. MAPIR (MACHINE PERCEPTION AND INTELLIGENT ROBOTICS GROUP).

LR Javier González Jiménez. Co-LR Francisco Ángel Moreno Dueñas

Priority line of research: Use of robotic technology to improve the independence of older adults in their homes

Other lines of research:

1. Development and research on robotic telepresence systems that allow for extending independent living and social interaction among older adults. This system is designed so that a family member, caregiver, or healthcare professional can virtually visit the user's home, experiencing an interaction very similar to a conventional in-person visit.
2. Development of automatic, safe navigation systems in small settings as well as systems for friendly interaction among older adults with a certain degree of cognitive frailty who live alone in their homes. This interaction seeks to alleviate the feeling of loneliness by contributing to users' independence and well-being.
3. Development and research in sensor networks and algorithms for sensing activity in the environment as well as physiological parameters of individuals (patients who are chronic, at risk, in rehabilitation, etc.) for the purpose of monitoring and control by public health professionals (doctors, nurses, social workers, etc.).

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-04	Luperto, M; Romeo, M; Lunardini, F; Monroy, J; García, DH; Abbate, C; Cangelosi, A; Ferrante, S; Gonzalez-Jimenez, J; Basilico, N; Borghese, NA	Exploring the Viability of Socially Assistive Robots for At-Home Cognitive Monitoring: Potential and Limitations	INTERNATIONAL JOURNAL OF SOCIAL ROBOTICS	3.7	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1				3.7



Competitive HR contracts funded in 2025:
1 predoctoral contract for the training of university professors (FPU).

F-05. MEDICAL ROBOTICS.

LR. Victor Fernando Muñoz Martínez

Priority line: Development of robotic assistants for laparoscopic surgery

Other lines:

1. Design of surgical robots.
2. Instrument movement control.
3. Automated surgical planning.
4. Fault-tolerant control architectures
5. Development of human-machine interfaces
6. Telesurgery
7. Medical devices
8. Digital twins

Scientific production and research activity



Competitive HR contracts funded in 2025:
1 predoctoral contract for the training of university professors (FPU).

F-09. ELECTRONICS FOR INSTRUMENTATION AND SYSTEMS.

LR Fernando Vidal Verdú.

Lines of research:

1. Research in electronics and instrumentation
2. Bioinformatics/Biomedicine
3. Applications in rehabilitation and assistance systems
4. Use of artificial intelligence techniques in diagnostic systems
5. Identification of correlations between genetic data and diseases

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-09	Martínez-Cesteros, J; Domínguez-Gimeno, S; Castellanos-Ramos, J; Sánchez-Durán, JA; Medrano-Sánchez, C	Characterization and Comparison of Piezoresistive Materials and Their Performance on Pressure-Sensitive Mats	IEEE SENSORS JOURNAL	4.5	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1		100%		5



F-10. BIOMIMETIC DENDRIMERS AND PHOTONIC LABORATORY.

LR Ezequiel Pérez-Inestrosa. Co-LR Francisco Nájera Albendín

Priority line of research: Preparation of dendrimeric structures to emulate multivalent bioactive macromolecules and visualize their interactions

Other lines:

1. Synthesis of new suitably functionalized dendrimer and dendron systems.
2. Preparation of solid supports (nanoparticles) for their functionalization with dendrimer systems.
3. Synthesis of fluorescent markers for dendrimeric systems.
4. Design and synthesis of sensors for biomedical information processing.
5. Design and synthesis of sensors for biomedical information processing.
6. Development of carbohydrate-based multivalent systems to mimic and interfere in the role played by natural oligosaccharides in biological processes related to pathogen infection, immunity, and cancer.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-10	Benitez-Martin, C; Najera, F; Perez-Inestrosa, E	Simultaneous dual-colour labelling of mitochondria and lysosomes: An indolium-based approach	SENSORS AND ACTUATORS B-CHEMICAL	7.7	D1	2025
F-10	Torres-Olea, B; Pérez-Merchán, A; Zampieri, C; Luna-León, R; Reina, JJ; Moreno-Tost, R; Cecilia, JA; García-Sancho, C; Maireles-Torres, P	Novel method for the production of Zr-doped Beta-zeolites and their use in the production of 5-(hydroxymethyl) furfural etherified biofuels	CATALYSIS TODAY	5.3	Q1	2025
F-10	Matamoros, E; Perez, EMS; Cintas, P; Light, ME; Palacios, JC	Reverse Anomeric Effects in Pyranose and Furanose Isomers in Schiff Bases of d-Galactosamine	JOURNAL OF ORGANIC CHEMISTRY	3.6	Q1	2025
F-10	Montoro-Leal, P; Guerrero, MDL; Mena-Herrera, L; Alonso, EV; Ruiz-Sánchez, AJ; Jiménez-Pérez, R	Selective electrochemical sensor for bisphenol A detection in wastewater using molecularly imprinted polymers on sustainable magnetic graphene oxide	MICROCHIMICA ACTA	5.3	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
4	50%	100%	25%	22



Active projects



Patents applied for

Competitive HR contracts funded in 2025:
1 Contract to promote research consolidation from the State Research Agency.

F-14. CLINIMETRICS IN PHYSICAL THERAPY.

LR Antonio Ignacio Cuesta Vargas

Priority line of research: Develop and validate instruments for clinical assessment and diagnosis that incorporate biomechanics, physiology, psychometrics, and clinical signs

Other lines:

1. Development, validation, and sensitivity to change of instruments for measuring outcomes in clinical sciences.
2. Physiology and biomechanics applied to musculoskeletal (dys)function. Preclinical studies.
3. Multimodal health promotion interventions in chronic conditions. Clinical studies.
4. Health solutions based on portable information and communication technologies. Telemedicine and mHealth. Translational studies and innovation.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-14	Sánchez-Pastor, A; Bravo, C; Henríquez-Jurado, JM; Alcaraz-Ruíz, L; Trinidad-Fernández, M	Effect of high-intensity exercise on functional capacity, cardiorespiratory function and quality of life in patients with colorectal cancer: a systematic review and meta-analysis	SUPPORTIVE CARE IN CANCER	3	D1	2025
F-14	Ramírez-Pérez, L; Cuesta-Vargas, AI	Shoulder Muscle Activity Through Surface Electromyography and Estimation of Physiological Fatigue Using the T-Fast Test in Patients With Glenohumeral Instability: A Cross-Sectional Study	PHYSIOTHERAPY RESEARCH INTERNATIONAL	1.8	Q2	2025
F-14	Garrido-Cervera, JA; Ruiz-Granados, MI; Cuesta-Vargas, AI; Sánchez-Guarnido, AJ	Patient-Reported Outcome Measures (PROMs) for Recovery in Mental Health: A Scoping Review	COMMUNITY MENTAL HEALTH JOURNAL	1.7	Q3	2025
F-14	Garrido-Cervera, JA; Ruiz-Granados, MI; Cuesta-Vargas, AI; Sánchez-Guarnido, AJ	Validation study for the individual recovery outcomes counter (I.ROC) in a	EUROPEAN JOURNAL OF PSYCHIATRY	1.5	Q3	2025
F-14	Ramirez-Pérez, L; Cuesta-Vargas, A	In-vivo stability shoulder assessment during push-ups using force plates in young adults	REVISTA IBEROAMERICANA DE CIENCIAS DE LA ACTIVIDAD FISICA Y EL DEPORTE	0.7	Q4	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
23	74%	22%	9%	51



Networks:
CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care

F-15. DATA AND KNOWLEDGE MANAGEMENT, INTEGRATION, AND ANALYSIS (KHAOS).

LR José F. Aldana Montes, Co-LR Ismael Navas Delgado

Priority line of research: (Big) data analytics (management, integration, and analysis of data and big data)

Other lines:
1. Clinical data management
2. Electronic medical records

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-15	Segura-Ortiz, Adrian; Gimenez-Orenga, Karen; Garcia-Nieto, Jose; Oltra, Elisa; Aldana-Montes, Jose F	Multifaceted evolution focused on maximal exploitation of domain knowledge for the consensus inference of Gene Regulatory Networks.	Computers in biology and medicine	6.3	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1	100%	100%	100%	6



F-16. INNOVATIVE THERAPIES AND NEW TECHNOLOGIES IN THE MUSCULOSKELETAL SYSTEM.

LR Enrique Guerado Parra

Lines of research:

1. Clinical research in orthopedic and traumatological surgery
2. Genomics in diseases of the musculoskeletal system
3. Cellular processes in osteogenesis

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-16	Passini-Sánchez, J; Gómez-Palomo, JM; Martínez-Crespo, A; Zamora-Navas, P	Factors associated with in-hospital and 12-month mortality in patients undergoing hip arthroplasty for femoral neck fracture	CLINICAL MEDICINE	2.1	Q2	2025
F-16	Cano-Obando, L; Gomez-Palomo, J M; Galan-Romero, A; Gonzalez-Garcia, C; Zamora-Navas, P	How does multidisciplinary collaboration with an internal medicine physician influence mortality in hip fracture patients?	Revista espanola de cirugia ortopedica y traumatologia			2025
F-16	Gómez-Palomo, JM; Martínez-Crespo, A; Passini-Sánchez, J; Ignatyev-Simonov, N; Zamora-Navas, P; Guerado, E	Quality of life and cost-utility analysis in patients with femoral neck fracture: a propensity score matching study comparing monopolar hemiarthroplasty and total hip arthroplasty	QUALITY OF LIFE RESEARCH	2.7	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
3	100%			5



Active projects



Patents applied for

GROUP F-19. ARTIFICIAL INTELLIGENCE AND SOCIAL RESEARCH.

LR José Ignacio Peláez Sánchez, Co-LR José Antonio Gómez Ruiz

Priority lines of research:

1. Artificial Intelligence
2. Big Data
3. Data Sciences
4. Decision Making
5. Opinion Mining
6. Digital Society
7. Sociology of the family
8. Comparative Social Structure

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-19	Vaccaro-Witt, GF; Bernal, H; Heredia, SG; Cabrera, FE; Peláez, JI	Effect of Informational Divergence on the Mental Health of the Population in Crisis Situations: A Study in COVID-19	SOCIETIES	1.6	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1	100%			2



Active projects

EMERGING GROUPS

FE-17. HANDRESEARCHTEAM.

LR Raquel Cantero Téllez. Co-LR Javier García Orza

Priority line of research: Use of new technologies and innovative treatments for hand injuries.

Other lines:

1. New treatments in the conservative and post-surgical approach to hand injuries. Wrist and hand proprioception.
2. Thumb conditions.
3. Psychological aspects of hand injuries.
4. Influence of traumatic, neurological, and rheumatic hand injuries on activities of daily living.
5. Biomechanical and anatomical foundations of hand conditions.
6. Effectiveness of the use of orthoses for objective and functional improvement of the hand.
7. Study of the hand in musicians.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
FE-17	Cervera-Garvi, P; Ortiz-Romero, M; Gordillo-Fernandez, LM; Garcia-Paya, I; Ortega-Avila, AB; Diaz-Miguel, S	Translation into Spanish, Transcultural Adaptation and Validation of the Foot Function Index Revised Short Form (FFI_RSF) Questionnaire	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025
FE-17	Gambero, LC; Gijón-Noguerón, GA; Miguel, SD; Barón-López, J; Raquel, CT	Wrist Joint Restriction: Impact on Foot Pressure, Center of Gravity, and the Role of the Dominant Hand	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	2025
FE-17	Sanchez-Morilla, S; Cervera-Garvi, P; Ramirez-Perez, L; Garcia-Paya, I; Diaz-Miguel, S; Ortega-Avila, AB	In Vivo Assessment of Ankle Stability During Dynamic Exercises: Scoping Review	HEALTHCARE	2.7	Q2	2025
FE-17	Campos-Cano, A; Ortega-Avila, AB; Diaz-Miguel, S; Castillo-Domínguez, A; Lopezosa-Reca, E; Gijon-Nogueron, G; Ramos-Petersen, L; Reinoso-Cobo, A	Patients' Experiences Following Osteoarticular Foot Surgery for Rheumatoid Arthritis-Related Deformities: A Qualitative Study	MEDICINA-LITHUANIA	2.4	Q1	2025
FE-17	Cantero-Tellez, R; Rider, J; Cruz-Gambero, L; Villafañe, JH; Valdes, K	Kinesiophobia, catastrophizing, and the duration of immobilization: A prospective study on factors associated with shoulder disability following wrist-hand injuries	JOURNAL OF HAND THERAPY	1.8	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
5	60%	60%	0%	13





Networks:
CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research (European Commission)

Competitive HR contracts funded in 2025:
1 predoctoral contract for the training of university professors (FPU).

FE-18. REHABILITATION, INNOVATION, AND QUALITY OF LIFE.

LR Lorena Aguilar Cano, Co-LR: Francisco Luna Cabrera

Priority line of research: Neurorehabilitation, digital health, and technological innovation.

Other lines:

1. Cardiac rehabilitation
2. Respiratory rehabilitation
3. Mobility aids
4. Promotion of physical exercise

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
FE-18	Ruiz-Molina, Y; Padial, M; Martin-Bravo, MD; Garcia-Olivares, M; Porras, N; Chicharro, A; Mora-Robles, J; González-Jiménez, A; Sasso, CV; Olveira, G	Targeting Lymphedema in Overweight Breast Cancer Survivors: A Pilot Randomized Controlled Trial of Diet and Exercise Intervention	NUTRIENTS	5	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1		100%		5



GROUP FE-20. ARTIFICIAL INTELLIGENCE IN MEDICAL IMAGING.

LR Francisco Sendra Portero

Lines of research:

1. Development and application of artificial intelligence (AI) tools to assist in diagnostic imaging through the automatic segmentation and quantification of brain volumes, the diagnosis of otosclerosis, and the evaluation of tumors in the cervicofacial region.
2. Research on New AI Applications in Medical Imaging: Explore and develop new applications of AI in various areas of medical imaging, such as prostate MRI, breast imaging, and osteoarticular radiology.
3. Education and Training in AI Applied to Radiology: Leverage our teaching experience to develop educational programs that prepare professionals in the effective use of AI tools in clinical practice.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
FE-20	García-Cañizares, VM; González-Vidal, A; Burgos-Molina, AM; Mercado-Sáenz, S; Sendra-Portero, F; Ruiz-Gómez, MJ	Common Molecular Mechanisms and Biomarkers in Breast, Colon and Ovarian Cancer	APPLIED SCIENCES-BASEL	2.5	Q2	2025
FE-20	Rodríguez-García, M; Burgos-Molina, AM; González-Vidal, A; Sendra-Portero, F; Bernal, M; Ruiz-Gómez, MJ	Molecular mechanisms of radiation resistance in colorectal cancer: in silico identification of AURKA, BIRC5 and PLK1 proteins as potential biomarkers	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY	2.4	Q1	2025
FE-20	González-Vidal, A; Mercado-Sáenz, S; Lopez-Diaz, B; Burgos-Molina, AM; González-Pedrosa, MP; Sendra-Portero, F; Ruiz-Gomez, MJ	Radiation and SARS-CoV-2 effects on the microbiota, immune system and health	INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY	0.5	Q4	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
3		33%		5



GROUP FE-22. EDUCATION, SPORTS, INNOVATION, AND HEALTH.

LR Alfonso Castillo Rodríguez.

Lines of research:

1. Characteristics, development, and quality of life in children, adolescents, adults, and older adults.
2. Research and development in artificial intelligence to create systems that promote health, education, and sports.
3. Physical activity, health, and nutrition.
4. Factors related to sports and cognitive performance.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
FE-22	González-Fernández, FT; Martínez-Aranda, LM; Sanz-Matesanz, M; Quiñones-Rodríguez, Y; Castillo-Rodríguez, A	Impact of Four-Match Congestion on the Well-Being of Under-16 Male Soccer Players	SPORTS	2.9	Q1	2025
FE-22	Vargas-Molina, S; García-Sillero, M; Jiménez-García, JD; Carbone, L; Bonilla, DA; Petro, JL; Romance, R; Benítez-Porres, J	Effects of a Nonlinear Program on Different Health Parameters in the Elderly	SPORTS HEALTH-A MULTIDISCI-PLINARY AP-PROACH	2.6	Q2	2025
FE-22	Molina-Molina, R; Sánchez-Abselam, O; González-Fernández, FT; Castillo-Rodriguez, A; Onetti-Onetti, W	Analysis of physical characteristics and their relationship with cognitive function in semi-professional female soccer players. A case study	REVISTA IBEROAMERICANA DE CIENCIAS DE LA ACTIVIDAD FISICA Y EL DEPORTE	0.7	Q4	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
3	67%	33%		6

Competitive HR contracts funded in 2025:
1 predoctoral contract for the training of university professors (FPU).

ASSOCIATED GROUPS

FA-07. RESEARCH IN ORTHOPEDIC SURGERY AND TRAUMATOLOGY.

LR Antonio Leiva Gea

Lines of research:

1. Chondral injuries, new therapies in orthopedic surgery and traumatology
2. Autologous chondrocyte implantation.
3. Osteosynthesis.
4. Biomechanical optimization of orthopedic surgery and traumatology procedures.
5. Elongation of bone segments in dysplasias.
6. Infection in orthopedic surgery and traumatology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
FA-07	Leiva-Gea, L; Sánchez-Palomino, P; Lendínez-Jurado, A; Corte-Torres, MD; Leiva-Gea, I; Leiva-Gea, A	Effectiveness of Titanium Occlusive Barriers in Guided Bone Regeneration: A Prospective Analysis of Vertical and Horizontal Bone Augmentation	BIOMIMETICS	3.9	Q1	2025
FA-07	Leiva-Gea, L; Lendínez-Jurado, A; Sánchez-Palomino, P; Delgado-Ramos, B; Corte-Torres, MD; Leiva-Gea, I; Leiva-Gea, A	Guided Bone Regeneration Using a Modified Occlusive Barrier with a Window: A Case Report	BIOMIMETICS	3.9	Q1	2025
FA-07	Muñoz-Sánchez, MA; Martínez-Crespo, A; Tara-Abad, C; Ríos-Morón, M; Montañez-Heredia, E; Gómez-Palomo, JM	Is age an advantage? Improved outcomes after medial unicompartmental knee arthroplasty in patients aged ≥70 years	JOURNAL OF EXPERIMENTAL ORTHOPAEDICS	2.7	Q1	2025
FA-07	Gómez-Palomo, JM; Martínez-Crespo, A; Passini-Sánchez, J; Ignatyev-Simonov, N; Zamora-Navas, P; Guerado, E	Quality of life and cost-utility analysis in patients with femoral neck fracture: a propensity score matching study comparing monopolar hemiarthroplasty and total hip arthroplasty	QUALITY OF LIFE RESEARCH	2.7	Q2	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
FA-07	Gómez-Palomo, JM; Zamora-Mogollo, A; Tara-Abad, C; Diez-Izquierdo, M; García-Vera, JJ; Martínez-Crespo, A	Impact of navigation on functional and radiological outcomes after total knee arthroplasty: a retrospective analysis of one hundred and ninety cases	INTERNATIONAL ORTHOPAEDICS	2.6	Q2	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
9	56%	44%	11%	31





FA-08. OTOTECH.

LR Alfonso Gago Calderón

Lines of research:

1. Research and development of technological devices for otology. Implantable hearing aids
2. Evaluation of hearing treatment quality.

Scientific production and research activity



AREA 7. NANODIAGNOSTICS.

G-01. BIOMEDICAL MAGNETIC RESONANCE LABORATORY (BMRL).

LR María Luisa García Martín

Lines of research:

1. Development of multifunctional magnetic nanomaterials for tumor theranostics.
2. Magnetic resonance metabolomics of tissue and biofluid biopsies for the identification of diagnostic, prognostic, and treatment response biomarkers.

Other lines:

1. Magnetic nanoparticles as contrast agents for magnetic resonance imaging (MRI).
2. Magnetic nanoparticles for magnetic hyperthermia therapy.
3. Multifunctional nanomaterials for multimodal imaging and/or tumor therapy.
4. Magic angle spinning MRI metabolomics for breast and brain tumor biopsies.
5. Biofluid metabolomics using high-resolution MRI in multiple sclerosis and other autoimmune diseases.
6. Biofluid metabolomics using high resolution MRI in cancer.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
G-01	Caro, C; Paez-Muñoz, JM; Leal, MP; Carayol, M; Feijoo-Cuaresma, M; Garcia-Martín, ML	Metabolically-Driven Active Targeting of Magnetic Nanoparticles Functionalized with Glucuronic Acid to Glioblastoma: Application to MRI-Tracked Magnetic Hyperthermia Therapy	ADVANCED HEALTHCARE MATERIALS	9.6	D1	2025
G-01	Avasthi, A; Fernandez-Afonso, Y; Gutiérrez, L; de la Fuente, JM; Leal, MP; Caro, C; Garcia-Martin, ML	Protein corona as the key factor governing the in vivo fate of magnetic nanoparticles	BIOMATERIALS SCIENCE	5.7	Q2	2025
G-01	Caro, C; Arias-Ramos, N; Urbano-Gámez, JD; González-Alday, R; López-Larrubia, P; García-Martín, ML	A multiparametric perspective on C6 and F98 cell lines in orthotopic rat models for glioblastoma research	SCIENTIFIC REPORTS	3.9	Q1	2025

Group	Authors	Article Title	Source Title	IF	Q/D	Year
G-01	Mela, V; Heras, V; Iesmantaite, M; García-Martín, ML; Bernal, M; Posligua-García, JD; Subiri-Verdugo, A; Martínez-Montoro, JI; Gómez-Pérez, AM; Banderas, B; Indias, IM; Tinahones, FJ	Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis	GUT	26	D1	2025
G-01	Perez-Carrasco, V; Soriano-Lerma, A; Guzzi, C; Garcia-Martin, ML; Tello, MJ; Linde-Rodriguez, A; Sánchez-Martin, V; Ortiz-González, M; Gutierrez-Fernández, J; Alarcón-Riquelme, ME; Soriano, M; Marañón, C; Garcia-Salcedo, JA	Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	BIOMARKER RESEARCH	12	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
10	30%	80%	30%	82



AREA 8. NANOSYSTEMS AND ADVANCED THERAPIES.

H-02. SKELETAL BIOMEDICINE LABORATORY.

LR Iván Durán Jiménez. Co-LR Fabiana Csukasi

Priority line of research: Precision medicine in skeletal diseases.

Other lines:

1. Study of disease mechanisms and precision therapies in skeletal dysplasias
2. Study of skeletal stem cell differentiation and metabolism
3. Development of a transcriptomic atlas of the skeleton
4. Gene therapy and gene editing aimed at bone diseases.
5. Study of the influence of cellular stress and inflammation on the skeleton
6. Skeletal tissue engineering. Development of biomaterials and organoids.
7. Therapies based on mesenchymal stem cell secretomes.
8. Use of zebrafish as a model for skeletal diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
H-02	Maaloul, A; Manríquez, CP; Decara, J; Marí-Beffa, M; alvarez-Torres, D; Redoli, SL; Martínez-Albardonedo, B; Araya-Rojas, M; Fajardo, V; Díaz, RTA	Biological Effects of Polysaccharides from Bovistella utriformis as Cytotoxic, Antioxidant, and Antihyperglycemic Agents: In Vitro and In Vivo Studies	PHARMACEUTICS	5.5	D1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
1		100%	100%	6



Networks:
CA22170 (TENET) - TEndon Regeneration NETwork
Competitive HR contracts funded in 2025:
1 MARIE SKLODOWSKA-CURIE Contract: POSTDOCTORAL FELLOWSHIPS (European Commission).

H-03. DEVELOPMENT AND CARDIOVASCULAR DISEASE.

LR Jose María Pérez Pomares

Priority line of research: Study of the embryonic foundations of cardiovascular disease. Study of the cellular and molecular mechanisms of cardiovascular pathophysiology

Other lines:

1. Embryonic cardiovascular development.
2. Cardiovascular repair and regeneration.
3. Fibrosis in the context of cardiomyopathies.
4. Cardiovascular histopathology.
5. Differentiation of cardiovascular progenitor cells.
6. Vascular pathology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
H-03	Ruiz-Villalba, A; Pardo-Saganta, A	Emerging concepts and novel mechanisms in organ fibrosis	NPJ REGENERATIVE MEDICINE	6.5	Q1	2025
H-03	Oliveira, CC; Cordoba, J; Pearson, JR; Guruceaga, E; Marín-Sedeño, E; Lopez-Moreno, M; Guadix, JA; García-Caballero, M; Pérez-Pomares, JM; Ruiz-Villalba, A	Revealing the complexity of the epicardial secretome	SCIENTIFIC REPORTS	3.9	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
2	100%	100%		10





Competitive HR contracts funded in 2025:

1 Ramón y Cajal contract (AEI).

1 Beatriz Galindo contract (AEI)

EMERGING GROUP

HE-01. CELL REPROGRAMMING (iPSCs) AND CELL MODELS OF DISEASE FOR BIOMEDICAL APPLICATIONS.

LR Elena González Muñoz

Priority line of research: Cellular reprogramming (iPSCs) and generation of cellular models of disease for biomedical applications.

Other lines: Regenerative medicine and personalized medicine

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
HE-01	Ducic, T; Pereiro, E; Ninkovic, M; Sperling, S; Rohde, V; Fernández-González, C; Algarra, M; González-Muñoz, E	Single-cell in situ mapping of glioblastoma and astrocyte cell lines treated with a carbon dot-mediated riluzole nanotherapeutic agent: a live-cell μFTIR and soft X-ray tomography approach	JOURNAL OF NANOBIOTECHNOLOGY	13	D1	2025
HE-01	Ducic, T; Rodriguez-Yañez, F; Gonzalez-Muñoz, E	Synchrotron radiation FTIR microspectroscopy enables measuring dynamic cell identity patterning during human 3D differentiation	FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY	4.3	Q1	2025

Scientific production and research activity

Articles	%Art. Led.	% Q1	% D1	IF
2	100%	100%	50%	17





Networks:

CA21151 (HAPLO-iPS) - Generation of Human Induced Pluripotent Stem Cells from Haplo-Selected Cord Blood Samples (European Commission)

CA20140 (CorEuStem) - The European Network for Stem Cell Core Facilities (European Commission)

FUNDING

The following graph shows changes in the revenue obtained by IBIMA Plataforma BIONAND over the last 5 years. This revenue is the sum of competitive and non-competitive grants (donations, agreements, and service provision agreements) obtained by the Institute in addition to the invoicing generated by the clinical studies performed.

Figure 49: Changes in revenue obtained (2021–2025)

As can be seen in the graph, the revenue obtained by or awarded to IBIMA Plataforma BIONAND has increased or remained steady over the years. This means that the institute is a consolidated project with a clear vocation for growth. Its existence generates synergies that translate into sustained growth.



Figure 50: Changes in competitive versus non-competitive revenue (2021–2025)

Comparing competitive and non-competitive revenue obtained, it can be observed that both types of revenue have increased or remained steady with similar figures for both revenue types.
On analyzing expenditures, the proportion is the same, though non-competitive revenue was slightly lower, as shown in the following table for the 2025 fiscal year; It shows 50% of each type of revenue:



Figure 51: Revenue spent 2025: Competitive vs non-competitive

In turn, the following shows revenue spent broken down by the nature of the revenue:

Description of funding body	2025 budget	Spent 2025	%
Competitive	**10,218,101**	**11349644**	**50%**
Competitive Private Grants	258,867	358168	2%
CSYC	469,449	593864	3%
CUII	533,609	506413	2%
FPS	19,481	42340	0%
International EUROPEAN	670,674	824069	4%
ISCIII	5,839,931	6260579	28%
MINISTRY OF ECONOMY, TRADE, AND BUSINESS	763,041	1062614	5%
MINISTRY OF EDUCATION AND VOCATIONAL TRAINING	24,559	23530	0%
MINISTRY OF HEALTH, SOCIAL SERVICES, AND EQUALITY	25,138	20754	0%
Other Revenue	0	7164	0%
Other public bodies	410,163	381826	2%
SAS	1,203,189	1268321	6%
Non-competitive	**10,591,379**	**11361760**	**50%**
CSYC	300,000	300000	1%
CUII	300,000	300000	1%
Donations/Agreements	1,424,500	1232022	5%
Clinical Studies	6,979,436	7582868	33%
Provision of Services	1,047,442	1406870	6%
SAS	120,000	120000	1%
UMA	420,000	420000	2%
Total	**20,809,480**	**22711404**	**100%**

Eighty-five percent of the resources are allocated to research and the rest to funding both management and scientific structures:



Figure 52: Revenue spent 2025: Research versus Structures

The sources of funding for structural revenues are as follows:

Description of structural revenue	2025 budget	Spent 2025	%
Competitive Private Grants	8,862	22302	1%
CSYC	361,805	372644	12%
CUII	446,276	445211	14%
Donations/Agreements	129,500	130109	4%
FPS	2,541	4163	0%
International EUROPEAN	92,484	121253	4%
ISCIII	733,660	768822	24%
MINISTRY OF ECONOMY, TRADE, AND BUSINESS	83,254	130353	4%
MINISTRY OF EDUCATION AND VOCATIONAL TRAINING	0	214	0%
MINISTRY OF HEALTH, SOCIAL SERVICES, AND EQUALITY	3,279	2943	0%
Other Revenue	0	7164	0%
Other public bodies	3,061	182	0%
Provision of Services	357,442	408462	13%
SAS	350,900	344000	11%
UMA	420,000	420000	13%
Total	**€2,993,064.23**	**€3,177,822.00**	**100%**

The revenues that fund the structural expenses of IBIMA's budget are shown below:

Operating expenses	PTO 2025	12/31/2025	VAR	Funding source	Total
Personnel Expenditures	1,362,298	1472735	110438	HR grants and cofunding	589,282
				Indirect costs (OH)	883,454
Purchasing	115,000	196188	359822	Invoicing for services	196,188
External Services	896,834 229976	1030262 35866	-86836 -223120	Member contributions	1,030,262
				Invoicing for services	35,866
Central Services Operating Expenses (Structure Cost)	319,184	336149	22858	Invoicing for services	16,335
IBIMA Plataforma BIONAND Plan Grants	258,297	212114	22858	Indirect costs (OH)	211,712
				Member contributions	109,738
Total Operating Expenses:	2,923,292	3071199	123555	Total Operating Expenses:	3,072,836

The expenses of the profit and loss account are shown in the following chart:



Figure 53: Revenue spent 2025

Balance sheet of the managing entity:

ASSET	2025	2024
A) NON-CURRENT ASSETS	**€21,698,450**	**€18,128,481**
I. Intangible assets	€1,095,141.00	€1,143,717.00
II. Historical Patrimony Assets	€-	€-
III. Tangible assets	€12,296,123.00	€11,059,010.00
VI. Long-term financial investments	€8,307,186.00	€5,925,754.00
B) CURRENT ASSETS	**€65,087,473**	**€56,821,010**
II. Inventory	€38,334.00	€80,598.00
IV. Users and other debtors of the institute's activity	€6,484,310.00	€3,632,729.00
V. Trade debtors and other accounts receivable	€8,681,242.00	€11,045,738.00
VII. Short-term financial investments	€41,210,933.00	€37,509,732.00
VIII. Short-term accruals	€54,392.00	€35,266.00
IX. Cash and other cash equivalents	€8,618,262.00	€4,516,947.00
TOTAL ASSETS (A+B)	**€86,785,923**	**€74,949,491**

NET EQUITY AND LIABILITIES	2025	2024
A) NET EQUITY	**15,361,024**	**€14,293,913**
A-1) Equity	€1,148,568.00	€1,148,568.00
I. Endowment/Social Fund	€6010.00	€6010.00
II. Reserves	€1,142,558.00	€1,142,558.00
IV. Fiscal year surplus	€ -	€ -
A-3) grants, donations, and bequests received	€14,212,456.00	€13,145,345.00
I. Grants	€6,573,790.00	€6,593,693.00
III. Donations and bequests	€7,638,666.00	€6,551,652.00
B) NON-CURRENT LIABILITIES	**€10,412,477**	**€8,266,698**
I. Long-term reserves	€344,462.00	€443,639.00
II. Long-term debts	€10,068,015.00	€7,823,059.00
C) CURRENT LIABILITIES	**€61,012,422**	**€52,388,880**
II. Short-term reserves	€-	€33,142.00
III. Short-term debts	€30,372,521.00	€28,065,974.00
VII. Trade creditors and other accounts payables	€3,683,530.00	€2,384,585.00
VIII. Short-term accruals	€26,956,371.00	€21,905,179.00
TOTAL NET EQUITY AND LIABILITIES (A+B+C)	**€86,785,923**	**€74,949,491**

EDUCATION

Doctoral Programs of the University of Málaga for the 2024–2025 school year, regulated by Royal Decree 99/2011 dated January 28, 2011 and modifications to Royal Decree 576/2023, dated July 4, 2023.

Biomedicine, Translational Research, and New Technologies in Health

Lines of Research:

- Cardiometabolic and Renal Disease Research
- Systemic Diseases
- Advances in Skin, Inflammatory, and Oncologic Disease Research
- Molecular Biology of Cancer. Its Importance in Diagnosis and Treatment
- Genomics Applied to Medicine
- Clinical and Experimental Pharmacology, New Therapies and Technologies
- Basic and Applied Neuroscience
- Clinical, Technological, and Experimental Research in Radiobiology, Medical Imaging, Hearing, and Vision.
- Epidemiology and Public Health
- Surgery, Obstetrics, and Gynecology.

Advanced Biotechnology

Lines of Research:

- Bioengineering and tissue regeneration
- Neurogenesis
- Glutamatergic neurotransmission
- Plant-pathogen interaction
- Plant biotechnology
- Improvement and biotechnology of fruit and vegetable species
- Biotechnology of aquatic systems
- Electrophysiology of aquatic plants

Cellular and Molecular Biology

Lines of Research:

- Molecular biology
- Systems biology
- Neurobiology
- Microbiology
- Developmental biology

Health Sciences

Lines of Research:

- Prevention of cardiovascular disease and obesity
- Chronicity, care, dependency, and evaluation of health and social-health services
- Clinimetrics and physical therapy
- Biomechanics and chronic musculoskeletal processes
- Mental and occupational health in social, health, and emergency contexts

Chemistry and Chemical Technologies. Materials and Nanotechnology

Lines of Research:

- Biochemistry and organic chemistry
- Chemical-physical methods in materials science and technology
- Functional materials
- Materials and processes for sustainability, energy, and the environment
- Chemical engineering and environmental technology

Psychology

Lines of Research:

- Biological foundations of behavior.
- Psychology of basic processes
- Methodological applications Methodology in Social and Health Sciences.
- Developmental and educational psychology
- Psychology of social intervention
- Clinical and health psychology
- Physical activity, performance, management, and health

Information Technology

Lines of Research:

- Software Engineering
- Security, Networks, and Embedded Systems
- Bioevolutionary and Bioinspired Algorithms
- Parallel Architectures and Algorithms
- Computational Intelligence
- Intelligent Systems

Master's Degrees at the University of Málaga in the 2024–2025 academic year

Physician

- University Master's Degree University in Health Economics, Health Management, and the Rational Use of Medicines.

Health Sciences

- University Master's Degree in New Research Trends in Health Sciences.
- University Master's Degree in Global Health.
- University Master's Degree in International Health.
- Interdisciplinary master's degree in palliative care.
- Master's degree in morphofunctional assessment of disease-related malnutrition.
- Master's degree in emotional intelligence and positive psychology.

- Master's degree in extrahospital care and medical air evacuation in emergencies and catastrophes.
- Master's degree in adult and pediatric critical care nursing.
- Master's degree in physical therapy in pelvic floor dysfunction.
- Master's degree in interdisciplinary palliative care.

Psychology and Speech Therapy

- Master's Degree University in General Health Psychology.
- Master's Degree in Physical Activity and Sports Research

Other **University Expert Certificates** in which IBIMA Plataforma BIONAND researchers have participated are the following:

- Interdisciplinary University Expert Certificate in Palliative and End-of-Life Care,
- University Expert Certificate in clinical research and clinical trials monitoring.
- University Expert Certificate in Emotional Well-being and Effective Communication in Health.
- University Expert Certificate in therapeutic exercise and functional rehabilitation in physical therapy.
- University Expert Certificate in Clinical Electrocardiography and Treatment of Cardiac Arrythmias.
- University Expert Certificate in Vertigo and Dizziness: from functional evaluation to treatment approach.
- University Expert Certificate in Pediatric Physical Therapy.

DOCTORAL THESES

The following table lists the theses supervised by IBIMA Plataforma BIONAND researchers:

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
A-01	Ana María Lago Sampedro	Niveles séricos del factor de crecimiento del endotelio vascular b (vegfb) en la cohorte di@bet. es y su relación con la incidencia de enfermedades metabólicas prevalentes	NO	Rojo Martínez, Gemma	García Escobar, Eva
A-01	Ana Muñoz Montiel	Efectos de la rehabilitación respiratoria en el paciente con enfermedad pulmonar obstructiva crónica: valoración del riesgo cardiovascular, marcadores de inflamación, estrés oxidativo y calidad de vida	NO	Olveira Fuster, Casilda	Doménech Del Río, Adolfo
A-02	Rocío Fernández Jiménez	Factores pronósticos de la valoración morfofuncional® en pacientes con fibrosis pulmonar idiopática: sarcopenia y mortalidad a 12 meses	NO	García Almeida, Jose Manuel	Tinahones Madueño, Francisco José

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
A-03	Ainhoa Robles Mezcua	Efecto del tratamiento con sacubitril/valsartán sobre la fibrosis y el remodelado cardiaco en la insuficiencia cardiaca con fracción de eyección reducida: estudio integrado de biomarcadores moleculares y técnicas de imagen	NO	José Manuel García Pinilla	
A-06	Jaime Sanz Cánovas	Análisis descriptivo de pacientes con insuficiencia cardiaca hospitalizados por covid-19 en españa. registro semicovid-19	NO	Ricardo Gómez Huelgas	Luis Miguel Pérez Belmonte
A-06	Michele Ricci	Eficacia y seguridad de los inhibidores de la sglt-2 en pacientes con diabetes mellitus tipo 2 e insuficiencia cardiaca. estudios en vida real para el uso intrahospitalario, estrategias de simplificación terapéutica y desprescripción	NO	Gómez Huelgas, Ricardo	Pérez Belmonte, Luis Miguel
A-06	Guillermo Ropero Luis	Características de los pacientes hospitalizados con hipercalcemia en españa	NO	Ruiz Cantero, Alberto	Gómez Huelgas, Ricardo
A-07	Paula Gavilán Franco	Modelo de predicción del desarrollo de carcinoma hepatocelular en infección crónica por el virus de la hepatitis b	NO	González Correa, José Antonio	Clavijo Frutos, Encarnación
A-19	Alfonso Lendínez Jurado	Análisis de datos metabólicos y calidad de vida del tratamiento con asa cerrada en pacientes pediátricos con diabetes mellitus tipo 1	NO	Leiva Gea, Isabel María	Blasco Alonso, Javier
A-19	María Del Carmen López Castillo	Broncoscopia flexible en las unidades de cuidados intensivos en situaciones especiales: uci pediátrica y neonatología	NO	María De Gracia Espinosa Fernández	Pilar Caro Aguilera
A-19	María Fuensanta Martos Lirio	Evaluación de resultados de control metabólico de población pediátrica con diabetes mellitus tipo 1 vinculado a la adherencia del paciente y al uso de plataforma de gestión	NO	Leiva Gea, Isabel María	Bellido Estévez, Inmaculada
A-23	Sandra María López Fernández	Epidemiología de leishmaniosis en la provincia de málaga	NO	Eduardo Martínez Manzanares	
AA-04	María Del Pilar Nuevo Ortega	Desarrollo de un modelo predictivo de gravedad en el paciente con covid-19 asociado a sus características basales, demográficas y factores cardiovasculares	NO	Pilar Martínez López	Manuel Francisco Jimenez Navarro

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
AA-22	Patricia García Pérez	Intervención temprana de terapia ocupacional en el proceso de alta hospitalaria tras un ictus	NO	Rodríguez Martínez, María Del Carmen	DE LA CRUZ COSME, CARLOS
AA-22	Álvaro Jesús Reina Ruiz	Efectividad de la restricción de flujo sanguíneo en trastornos musculoesqueléticos y análisis de las herramientas de dolor de cuello para la valoración subjetiva del efecto.	YES	Manuel González Sánchez	
AA-22	Francisco Javier Martinez Barrios	Avances en el tratamiento de las úlceras crónicas en la enfermedad de pie diabético: una actualización basada en metaanálisis	YES	María Ruiz Muñoz	
B-01	Ana Godoy Ortiz	Descifrando la heterogeneidad en cáncer de mama her2-positivo: análisis integrativo de datos ómicos y clínicos	NO	Alfonso Sánchez Munoz	Emilio Alba Conejo
B-01	Tatiana Cano Barbadilla	Caracterización patobiológica y predicción de respuesta a neoadyuvancia en el cáncer vesical utilizando la inmunohistoquímica como marcador subrogado de subtipos moleculares	NO	Álvarez Perez, Martina	Hierro Martin, Isabel
B-04	Jose Córdoba Caballero	Aplicación de redes de expresión y regulación para el análisis de enfermedades raras	NO	Pedro Seoane Zonjic	Juan Antonio García Ranea
B-04	Federico García Criado	Predicción bioinformática de vías moleculares compensatorias en enfermedades raras y cáncer para su tratamiento.	YES	Pedro Seoane Zonjic	Juan Antonio García Ranea
B-12	Fernando Gallego Donoso	Large language models for biomedical entity recognition and normalization in low-resource languages and settings	YES	Francisco Javier Vere-das Navarro	
BE-15	Ana Isabel Álvarez Mancha	Evaluación del proceso diagnóstico de la patología nodular tiroidea en una consulta monográfica de alta resolución. concordancia entre citología y biopsia tiroidea	NO	Mancha Doblas, Isabel	Gallego Dominguez, Elena
BE-19	Alejandro González Vidal	Mecanismos moleculares de resistencia a radiación ionizante, envejecimiento celular, estrés oxidativo y 5-fluorouracilo	NO	Miguel José Ruiz Gómez	
BE-19	Antonio Adarve Castro	Localización de patología paratiroidea por pruebas de imagen y evaluación de la densidad mineral ósea mediante análisis de texturas en pacientes con hiperparatiroidismo primario	NO	Ruiz Gómez, Miguel José	Domínguez Pinos, Dolores
BE-21	María García Fortes	Impacto de comorbilidades individuales en el pronóstico de los pacientes con mielofibrosis	NO	Sánchez Chaparro, Miguel Ángel	
BE-23	Antonio Zamudio Sanchez	Necesidades y expectativas de los largos supervivientes de cáncer	NO	Adolfo Romero Ruiz	Maria Rosa Iglesias Parra
C-01	Jose Carlos Arrabal Gomez	Sinergia npy1r-trkb inducida por ketamina: neurogénesis y modulación afectivo-cognitiva en el hipocampo ventral y dorsal	NO	Narváez Peláez, Manuel	Serrano Castro, Pedro Jesus
C-01	Angela Ros Sanjuan	Quality of life in children with hydrocephalus treated with endoscopic third ventriculostomy	YES	Arráez Sanchez, Miguel Ángel	Ros López, Bienvenido
C-03	Almudena Ramirez Martin	Impulsividad, toma de decisiones y conducta de riesgo en el trastorno bipolar: estudio en familias con múltiples casos	NO	Moreno Kustner, Berta	Guzmán Parra, José
C-05	Ana León Rodríguez	Consequences of microglial priming in the hypothalamus. pharmacologic modulation by csf1 receptor inhibition	YES	María Dolores López Ávalos	Jesús Mateos Grondona
C-06	Juan Antonio Navarro Galera	Evaluación farmacológica del d-pinitol como modulador de la insulina: desarrollo de un nuevo concepto de edulcorante funcional	YES	Rodríguez De Fonseca, Fernando	Baixeras Llano, Elena
C-07	Estela Díaz Sánchez	Region-specific modulation of neuronal activity, neurogenesis, and behavior: implications for novel treatments in depression and cognitive decline	YES	Narváez Peláez, Manuel	
C-07	Laura García Durán	Papel del fragmento n-terminal (1-15) de galanina en el trastorno depresivo mayor: interacciones con el escitalopram y el ejercicio físico en un modelo de depresión inducido en animales	YES	Millón Peñuela, Carmelo	Diaz Cabiale, Zaida
C-08	Victor Manuel Cotta Luque	Evaluación de la eficacia de dos intervenciones educativas sobre las técnicas de inhalación en pacientes con enfermedad pulmonar obstructiva crónica. estudio tiepoc.	NO	Antonio García Ruiz	Barnestein Fonseca, María Pilar
C-09	Laura Cáceres Palomo	Desarrollo de precursores neurales, astrocitos y microglía derivados de células madre pluripotentes inducidas (ipscs) humanas como modelos celulares para el estudio de la enfermedad de alzheimer	YES	Antonia Gutiérrez Pérez	Juan Antonio García León

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
C-09	Laura Vegas Gómez	Estudio de la depresión como factor de riesgo de la enfermedad de alzheimer	YES	Inés Moreno Gonzalez	
C-11	Victoria Barrado Moreno	La flexibilidad e inflexibilidad psicológica como variables relacionadas con el mal uso de los opioides de prescripción en personas con dolor crónico no oncológico [psychological flexibility and inflexibility as variables related to the misuse of prescrip	YES	Rosa Esteve Zarazaga	Carmen Ramírez Maestre
C-13	Marta Morales Puerto	Evaluación del delirio en urgencias. adaptación y validación española de las escalas 4at y bcam	NO	León Campos, Álvaro	García Mayor, Silvia
C-13	Francisco Javier Canca Sánchez	Validación de un método tridimensional para el ajuste del calzado en la prevención del dolor podológico	NO	Ana Belén Ortega Ávila	José Carlos Canca Sánchez
C-13	Javier Matías Soto	Los factores psicosociales en la experiencia del dolor crónico musculoesquelético	YES	Alejandro Luque Suarez	
C-16	Fuensanta Guerrero Del Cueto	Bronquiolitis en el hospital materno-infantil de málaga: antes y después del covid-19	NO	Isabel María Leiva Gea	
C-16	Isidoro Narbona Arias	Evaluación de resultados del programa de diagnóstico prenatal de cromosomopatias, genopatías y enfermedades raras de nuestro centro. tendencias en el diagnóstico prenatal invasivo en el hospital materno infantil: tres décadas de cambio de 1994 a 2024	NO	Ernesto González Mesa	Jesús Salvador Jiménez López
C-16	Manuel Angel Gómez Castellano	Clampaje temporal sistemático de las arterias uterinas para la prevención de la hemorragia durante la cesárea. resultados de implantación en la morbilidad materna	NO	Jiménez López, Jesús Salvador	Sabonet Morente, Lorena
CE-23	Daniel Aguilar Núñez	Estudio transversal de la fascia plantar. repercusiones biomecanicas, morfológicas e histopatológicas.	NO	Cervera Garvi, Pablo	Navarro Ledesma, Santiago
CE-23	George Alan Banwell	The conservative management of posterior tibialis tendon dysfunction	YES	Gijon Nogueron, Gabriel Antonio	Gatt, Alfred
CE-23	María Gámez Guijarro	¿Disminuyen los tratamientos biológicos el dolor en el pie y mejoran significativamente la calidad de vida en pacientes con artritis reumatoide?	YES	Gijon Nogueron, Gabriel Antonio	Lopezosa Reca, Eva

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
D-04	Rocío Sáenz De Santa María García	Optimización en el diagnóstico y manejo de pacientes con reacciones de hipersensibilidad a antiinflamatorios no esteroideos	NO	María José Torres Jaén	Inmaculada Doña Diaz
D-05	Daniel Enrique Di Zeo Sanchez	Nuevas aproximaciones fisiopatológicas al daño hepático inducido por fármacos (dili): eje intestino-hígado, huella inmunológica y avances en herramientas diagnósticas	YES	María Isabel Lucena Gonzalez	Camilla Stephens
DE-08	María Martínez Burgos	Análisis de los factores predictores de recidiva de hepatocarcinoma tras trasplante hepático: 20 años de experiencia de un equipo de trasplante	NO	Jimenéz Pérez, Miguel	Santoyo Santoyo, Julio
DE-09	Claudia Sánchez González	Validez del factor v en el diagnóstico de la disfunción precoz de injerto tras el trasplante hepático	NO	Fernández Aguilar, José Luis	Sánchez Pérez, Belinda
DE-10	Juan Marín Nieto	Mascarillas faciales y endoftalmitis tras inyecciones intravítreas en el período covid	NO	García Basterra, Ignacio	Jimenez Navarro, Manuel Francisco
DE-10	Álvaro Santos Ortega	Repercusión funcional y estructural retiniana del deterioro cognitivo leve en pacientes con y sin diabetes	YES	Carmen Alba Linero	Natalia García Casares
F-02	Rosa María Maza Quiroga	Regression of the rician noise level in 3d magnetic resonance images based on benford's law	YES	Ezequiel López Rubio	Domingo López Rodríguez
F-03	Carlos Pérez Armenta	Advanced periodic topologies for next-generation silicon photonics	YES	Alejandro Ortega Moñux	Juan Gonzalo Wangüemert Perez
F-04	José Ojeda Morala	Probabilistic methods for robotic gas source localization	NO	Javier Gonzalez Monroy	Javier González Jimenez
F-14	José Antonio Garrido Cervera	Validación de la versión española del cuestionario de recuperación i.roc en pacientes con trastorno mental severo.	NO	Antonio Ingnacio Cuesta Vargas	
F-14	Jose Luis Matez Bandera	Advances in indoor semantic mapping for mobile robotics	YES	González Jimenez, Javier	Gonzalez Monroy, Javier
F-14	Jaime Gomariz Ruiz	Características psicométricas, grupos de síntomas y cateteres venosos en enfermedad renal crónica avanzada	NO	Gutiérrez Sánchez, Daniel	Perez Cruzado, David
F-14	Tomas Ponce Garcia	Anaerobic fitness in crossfit®: assessment, performance prediction and sex differences	NO	Garcia Romero, Jeronimo Carmelo	Benítez Porres, Javier

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
F-14	Miguel Ortega Castillo	Avances en el manejo de las tendinopatías de miembro superior: progresión del ejercicio terapéutico y evaluación funcional	NO	Cuesta Vargas, Antonio Ignacio	Trinidad Fernández, Manuel
F-16	Alejandro Espejo Reina	Estudio biomecánico de las consecuencias de la lesión de la raíz anterior del menisco lateral y del efecto de su reparación	NO	Guerado Parra, Enrique	Prado Novoa, María
FE-18	Fabio Lodi Rizzini	Efectos de un programa de rehabilitación cardíaca sobre la calidad del sueño en pacientes cardiópatas con y sin insuficiencia cardiaca	NO	Salinas Sánchez, Pablo	Gómez González, María Adela

IBIMA Plataforma BIONAND Educational Program

Educational activities organized by IBIMA in 2025:

- Science in times of disinformation: keep quiet or communicate.
- Webinar: Identify and capture new opportunities for research funding.
- XI IBIMA-RARE Conferences.
- Málaga Care Conferences.
- Welcome to HUVV and HURM residents.
- Visit to the institute by biochemistry students.
- Farmaindustria Conference “Bringing science to schools.”
- Visit for Biology Olympiad Students to IBIMA.
- Visit by patients from the Familial Chylomicronemia Syndrome Association.
- 5th Scientific Conference: Women in Neuroscience. International Day of Women and Girls in Science.
- Citizen Participation Talk - Collaboration with OPPLUS.
- European Researchers’ Night.
- Visit by the Crohn’s Disease Patients Association to the institute.
- Visit by the Andalusian Association of Biotechnologists (AsBAn) to the institute.
- Open-house for professional training and high school students from various centers.
- International Seminar “Personalized Cancer Medicine.”
- Digital PCR Seminar with QIAcuity One 5 Plex, in collaboration with Werfen.
- Talk: Host-microbe interaction in the gut-liver axis during health and disease. Dr. Naiara Beraza (Quadram Institute, Norwich, United Kingdom).
- The 6 Steps to Mindfulness: tools for transforming pain into well-being, chronic illness into health, and stress into calm.
- Training workshops on cell biology and microscopy.
- Talk: “Blastocyst Complementation: A Strategy for Organ Generation.” D. Xabier López-Aranguren
- Talk “Human brown adipose tissue research - from imaging to cells” Dr. Kirsi Virtanen, Turku PET Center.
- Talk “**Omic** talks, seq tech: From the foundations of genomics to multiomics.”
- Talk on Omic Talks: Space Transciotimics comes to IBIMA.
- Introduction to the gender perspective in biomedical research.
- Training on procedures and protocols regarding equality and harassment.
- 27th Edition of the Online Course on Good Clinical Practice Guidelines.
- Introduction of the new radioactive room.
- Basic statistics in biomedical research and research methodology.
- Planning, implementation, and monitoring of a clinical trial. Role of the IBIMA-FIMABIS structures and units.
- Application for REC assessment. Practical information, required documents, and submission of an application through the SICEIA and CTIS portals.
- Basic and classical statistics: Tests for normality, homoscedasticity, skewness, and classical tests.
- Practicing R: Introduction to R and RStudio.
- Understanding my data - Transcriptomics: Basic concepts, workflows, and interpretation.
- Calculating sample size: Introduction to G*Power.
- Talk on artificial intelligence in cardiovascular pharmacotherapy.
- Narrative bibliometrics: Application of DORA-COARA principles in the evaluation of scientific production in the health sciences.
- Conference on innovation and technology transfer in biomedicine. Computer applications.
- 3rd Endometriosis Conference.
- Screening of the documentary film “La Vida en Una Gota [Life in One Drop],” directed by Pedro Lendínez.
- Online informational session on creating narrative scientific CVs.
- Training program on research methods.
- Epidemiological investigation of outbreaks and epidemics.
- Update for users of animals in biomedical research: Stages in the project application process.
- Ongoing training for the proper handling of laboratory animals.
- Workshop on industrial property strategy and patent searches.
- Visit from the NAMBIOSIS company.
- 8th Málaga Alzheimer’s Conference.
- Spanish Society of Clinical Nutrition and Metabolism (SENPE).
- Incorporating a gender perspective into health R&D&I projects. When and how.
- 1st Conference on Giftedness.
- Specific training at the province’s AGS facilities (regional hospitals and primary care centers).
- 4th conference on raising awareness regarding rare diseases, on neonatal screening in Jaén.
- Talk “Scalable, accessible single cell with parse Biosciences evercode”
- Biobank course: Support structures for biomedical research.
- Second series of research and innovation sessions at Costa del Sol University Hospital.
- Nanosystems and advanced therapies symposium.
- Clinical research session, ethics committee, ethical aspects of clinical research and data collection.
- Scientific conferences: Moving toward the future
- 1st Conference on Adolescence: Crisis and opportunity — Imbrain Chair

COMMUNICATIONS

8

In 2025, IBIMA Plataforma BIONAND has strengthened its presence on social networks through an organic and professional strategy on Facebook, Instagram, LinkedIn, and X. It has more than 20,600 followers across these platforms. In addition, it was agreed to open a new account to establish a presence on TikTok.

In total, **69 press releases** were published in coordination with the Regional Ministry of Health, Presidency, and Emergencies; Foundation for Progress and Health, the University of Málaga, and the Regional University Hospital of Málaga, Virgen de la Victoria University Hospital, and Costa del Sol University Hospital. A certain degree of impact in the media has been achieved, with nearly 1,800 media mentions.

The reach, interaction, and performance in social media profiles, as well as the main repercussions in the written and digital press, are listed below.

IMPACT ON SOCIAL NETWORKS:

FACEBOOK:

- Total followers: 2,341
- New followers: +432
- Visualizations: 556,576
- Interactions with content: 29,135
- Clicks on the link: 18,670





INSTAGRAM:

- Total followers: 3,665
- Visualizations: 649,660
- Interactions with content: 2,471



LINKEDIN:

- Account active as of April 17, 2024
- Followers: 10,230
- Reactions: 2410
- Impressions/Interactions: 148,210
- Ongoing publications with institutional, scientific, and informative content
- Total clicks: 15,280
- Publications with high organic virality rate



X (TWITTER):

- Current followers: 4,368
- Total publications: 8,859

IMPACT ON THE MEDIA:

- Press releases issued: 69
- Press releases published on sspa.juntadeandalucia.es: 37
- Total media impact: 1,775 news items (digital and paper)
- Impacts in the written press: 150 direct references to IBIMA
- Impacts in Diario SUR: 86 news items
- Impacts in La Opinión de Málaga: 75 news items
- Impacts in Málaga Hoy: 60 news items
- Impacts in Europa Press: 138
- Más de 60 intervenciones registradas en Televisión, fundamentalmente en los programas: Salud Ahora, Málaga Aquí y Ahora (ambos de Canal Málaga TV) y Conciencia o Tesis, ambos de Canalsur TV.
- Coordination with CIBER, the Regional Government of Andalusia, the Progress and Health Foundation, the University of Málaga (UMA), and public hospitals in Málaga, among other institutions.

	TOTAL IMPACTS	IMPACTS IN PRINT MEDIA
IBIMA	1364	103
BIONAND (WITHOUT IBIMA)	860	61
BIOMEDICAL RESEARCH INSTITUTE OF MÁLAGA, NOT IBIMA	1302	95
BIOMEDICAL INSTITUTE OF MALAGA	56	11
IBIMA BIONAND	918	65
BIOMEDICINE INSTITUTE OF MALAGA	296	18
IBIMA Plataforma BIONAND	899	65

Some of the most significant news items of 2025:

- A study in Málaga confirms that intermittent fasting leads to greater weight loss than a traditional diet (December 2025) https://www.malagahoy.es/malaga/estudio-malaga-confirma-ayunar-dias-adelgaza-dieta-tradicional_0_2005437397.html
- Málaga Opens a Clinical Trials Unit and Establishes Itself as a “National Leader in Research” (November 2025): https://www.diariosur.es/malaga-capital/malaga-estrena-nueva-unidad-ensayos-clinicos-consolida-20251115142157-nt.html
- IBIMA has secured €32 million to fund 366 research projects in 2024 (October 2025): https://www.diariosur.es/malaga/ibima-capta-millones-impulsar-366-proyectos-investigacion-20251006165132-nt.html
- A blood test paves the way for detecting Alzheimer’s before the first symptoms appear (September 2025)https://www.antena3.com/noticias/salud/analisis-sangre-abre-puerta-detectar-alzheimer-antes-primeros-sintomas_202511286929929e6e5e5012dcd2337f.html
- A €1.7 million grant from the European Union will enable Juan Luis Paris to develop a revolutionary technology at IBIMA for controlling cell therapies from outside the body (September 2025): https://biotech-spain.com/es/articles/una-ayuda-de-la-uni-n-europea-de-1-7-millones-de-euros-permitir-a-juan-luis-paris-desarrollar-en-ibima-una-tecnolog-a-revolucionaria-para-controlar-terapias-celulares-desde-fuera-del-cuerpo/
- Málaga unveils Spain’s first olfactometer, which will advance research on neurodegenerative diseases (July 2025): https://cadenaser.com/andalucia/2025/07/22/malaga-estrena-el-primer-olfatometro-de-espana-lo-que-permitira-avanzar-en-investigacion-de-enfermedades-neurodegenerativas-ser-malaga/
- Málaga unites to fight cancer: Goal of raising €100,000 for research: https://www.laopiniondemalaga.es/malaga/2025/07/14/malaga-une-luchar-cancer-objetivo-recaudar-119685888.html
- IBIMA is driving a “pioneering” therapy to treat “brittle bone disease” (June 2025: https://www.malagahoy.es/malaga/ibima-impulsa-terapia-pionera-tratar-enfermedad-huesos-cristal_0_2004060311.html
- Research and sports: IBIMA and the Regional Hospital raise €13,700 at the 2nd 7-a-side Soccer Tournament (March 2025) https://www.laopiniondemalaga.es/malaga/2025/03/31/ibima-hospital-regional-torneo-futbol-115885748.html
- Nearly 200 patients will benefit each year from the new Phase I Clinical Trials Unit in Málaga (February 2025): https://www.laopiniondemalaga.es/malaga/2025/02/26/unidad-ensayos-clinicos-hospital-civil-ibima-114713682.html

Una nueva unidad de ensayos clínicos posiciona a Málaga como «referente en investigación»

Este nuevo espacio se ha puesto en marcha en el Hospital Civil junto con el Ibima, gracias a una inversión de más de 450.000 euros

CRISTINA PINTO

MÁLAGA. El Hospital Civil de Málaga inauguró ayer un nuevo espacio referente en la investigación biomédica: la Unidad de Investigación Clínica de Fase II-III del Hospital Universitario Regional de Málaga, que comenzará a funcionar «de forma inminente» mañana lunes. Esto completa el ciclo y amplía las capacidades del centro en ensayos clínicos de fases avanzadas tras inaugurarse la primera el pasado febrero. Y, según destacó el consejero de Sanidad de la Junta de Andalucía, Antonio Sanz: «Esto convierte a Málaga en un referente nacional e internacional de la investigación biomédica y pionera en cubrir el ciclo completo de desarrollo clínico dentro del sistema sanitario público».

Con esta nueva unidad –que ha supuesto una inversión de 469.000 euros–, el Regional de Málaga y el Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Ibima Plataforma Bionand) tendrán la posibilidad de ampliar sus investigaciones y ofrecer a los pacientes una atención más especializada. La inversión de esta nueva unidad, financiada por el Instituto de Salud Carlos III con fondos NextGeneration EU, cuenta con más de 500 metros cuadrados distribuidos en un hospital de día con diez puestos asistenciales, ocho consultas médicas y salas de posicionamiento, monitorización y seguimiento clínico.



Inauguración de la nueva unidad biomédica, ayer en el Hospital Civil. MARILÚ BÁEZ

Seguridad y tolerancia

Con la puesta en marcha de esta nueva infraestructura se pretende aumentar la capacidad de reclutamiento y seguimiento de pacientes, «mejorando los estándares de calidad, seguridad y trazabilidad en la investigación clínica». Aunque, sobre todo, como se detalló en la presentación, ha sido concebida para determinar la seguridad, tolerancia y dosis óptima de los tratamientos en sus primeras administraciones en humanos.

Actualmente, el Ibima registra 778 estudios clínicos activos, de los que 520 son ensayos con medicamentos y 180 corresponden a Fases I y II. Según destacó el consejero Antonio Sanz, «estos últimos cuatro años, la actividad investigadora ha crecido un 31%, consolidando la posición de este hospital como referente nacional en investigación clínica precoz».

Durante la inauguración, Antonio Sanz reiteró en varias ocasiones «el interés especial» que tenía porque se pusiera en marcha esta unidad. «A veces no se le da la importancia suficiente y la investigación nos resultado demasiado ajena; pero eso es una gran injusticia porque son una parte esencial para abordar los mejores tratamientos a los paciente. Este nuevo espacio tendrá un impacto directo en muchas enfermedades, terapias y soluciones a través de nuevos fármacos», aclaró el consejero de Sanidad.

Málaga desarrolla más de 700 estudios clínicos sobre el cáncer

Día Mundial de la Investigación en Cáncer.

Los proyectos de la provincia avanzan gracias a la financiación pública y privada y el esfuerzo de los profesionales

CRISTINA PINTO



Desde su diagnóstico, Rafael participa en una investigación para compartir sus datos con Estados Unidos y lograr mejoras en el tratamiento

El mismo oncólogo Antonio Rueda, también presidente del Comité Técnico de la Asociación Española contra el Cáncer de Málaga (AECC), al hacer balance sobre la investigación en cáncer en Málaga, valora la evolución de los profesionales, proyectos y grandes apuestas que se están haciendo en la provincia. Según los datos que aporta a este periódico el Ibima Plataforma Bionand, actualmente se desarrollan en la provincia 765 estudios clínicos sobre cáncer, 284 de ellos son ensayos en fases tempranas.

«Cabe destacar que la investigación malagueña hace once años, cuando yo empecé, no teníamos casi ni un euro porque no había investigadores. Ahora sí que son muchos profesionales de calidad los que están trabando en diferentes proyectos y ensayos para poder avanzar en los tratamientos de la enfermedad», analiza el oncólogo Antonio Rueda, que llega a afirmar en varias ocasiones que «Málaga es una de las provincias punpia que tenían en ese momento, posiblemente no estaría contando esto ahora. Si no hubiese participado en ese ensayo clínico, estaría muerto», confiesa tajante Rafael mientras muestra una sonrisa y los ojos brillosos, a pesar de todo.

Puede decir que está vivo y que es capaz de contarlo. Y, sobre todo, que su experiencia con la enfer-

Expertos del Ibima en gripe aviar: «No se ha documentado ninguna transmisión de persona a persona»

Salud confirma que nunca se ha producido un positivo en humanos en Andalucía, y que los «raros» contagios en el ámbito internacional han partido de los animales

JOSÉ ANTONIO SAU



José Manuel Jiménez Guardeño y Ana María Ortega Prieto. SUR

MÁLAGA. La noticia saltó el 3 de septiembre, cuando el Ayuntamiento de Málaga cerró el Parque de Huelín como medida preventiva tras ser halladas muertas unas veinte aves, fallecimientos que podrían deberse a la gripe aviar. Asimismo, se reforzó la vigilancia en otros espacios frecuentados por aves y se enviaron muestras de los animales y del agua de estanque al Centro de Análisis y Diagnóstico de la Fauna Silvestre de la Junta de Andalucía que, a su vez, los remitió al Laboratorio Nacional de Referencia para Influenza Aviar, aunque, de momento, no se conocen los resultados. Además, Sevilla ha cerrado tres parques por el mismo motivo, aunque en este caso se conoce que la causa ha sido, efectivamente, esta enfermedad. Pero ¿hay riesgo de contagio a personas? Es lo que se denomina zoonosis. Los doctores Ana María Ortega Prieto y José Manuel Jiménez Guardeño, biólogos y coinvestigadores responsables del grupo emergente 'Respuesta inmune frente a enfermedades virales' del Instituto de Investigación Biomédica de Málaga (IBIMA Plataforma Bionand), aclaran las cuestiones planteadas por SUR al respecto de esta crisis sanitaria.

La Consejería de Salud y Consumo, de cualquier forma, confirmó ayer a este periódico que nunca se ha producido la transmisión de la gripe aviar de ave a humano en Andalucía, es decir, nadie se ha contagiado de esta patología en la autonomía. Pero ¿qué es la gripe aviar? «La gripe aviar es una enfermedad infecciosa vírica muy contagiosa que afecta principalmente a las aves silvestres y de corral. Algunas variantes, como las de alta patogenidad, producen brotes de alta mortalidad, pudiendo producir la muerte de un elevado número de aves en un corto periodo de tiempo», explica el doctor Juan Miguel Jiménez Guardeño.

Lo cierto es que hay preocupación en la ciudadanía. Los grupos de asociaciones de vecinos se llenan estos días de fotografías de palomas y gaviotas fallecidas. ¿Qué medidas precautorias hay que tomar tras la situación creada en los parques? La doctora Ortega Prieto explica que el cierre de estas zonas «es una medida preventiva habitual que permite recoger muestras para su análisis, la correcta limpieza y desinfección del lugar y evitar que personas o mascotas entren en contacto» con aves enfermas o muertas. Para prevenir posibles casos de gripe aviar, «es importante evitar el contacto» con los ejemplares fallecidos o enfermos y avisar a las autoridades competentes.

La gripe aviar causa en las aves «falta de apetito, decaimiento, falta de coordinación, alteraciones respiratorias, hinchazón en la cabeza y cuello y la muerte», explica Jiménez Guardeño, mientras que Ana Ortega Prieto dice que, aunque afectan principalmente a aves, «se ha descrito también que pueden infectar a distintas especies de mamíferos, incluyendo a los humanos. El riesgo de contagios desde aves es muy raro y, hasta el momento, no se ha documentado transmisión de persona a persona». En humanos, la enfermedad varía desde síntomas similares a la gripe estacional (dolor de cabeza, muscular, fiebre, tos y fatiga; hasta síntomas más graves con complicaciones respiratorias que, en algunos pacientes, «pueden llegar a ser mortales», agrega.

Mutación

De cualquier forma, ¿es un escenario posible que el virus mutara para infectar a humanos? «Los virus de la gripe tienen una elevada facilidad para mutar y generar virus distintos. Aunque las infecciones de aves a humanos son raras, sabemos que pueden ocurrir de manera esporádica. Por lo tanto, este escenario es posible, pero resulta muy difícil saber si llegará a producirse o cuándo podría ocurrir», explica la doctora Ortega Prieto.

¿Podría haber una pandemia? **Advierten de que para prevenir posibles casos de gripe aviar, «es importante evitar el contacto» con los ejemplares fallecidos**

fectadas. Estos casos son muy poco frecuentes y, hasta la fecha, no se ha detectado transmisión de persona a persona. En cuanto a la posibilidad de una nueva pandemia en los próximos años, el riesgo existe, ya que cualquier virus de la gripe aviar podría evolucionar y adaptarse en humanos». «Lo que sí nos han enseñado la pandemia del Covid-19 es la importancia de mantener una vigilancia global constante para anticiparnos a este tipo de amenazas», añade.

En este sentido, la investigación no para de avanzar con el fin de impedir una futura transmisión masiva en humanos. «Las líneas de investigación se centran en varios frentes. Por un lado, es importante trabajar en la vigilancia temprana de brotes en aves y humanos para detectar posibles mutaciones que puedan afectar a la transmisibilidad del virus. Por otro lado, se está poniendo mucho esfuerzo en desarrollar vacunas más eficaces y universales, así como tratamientos que puedan actuar frente a distintas cepas del virus», dice la doctora Ortega Prieto.

Ambos expertos dicen no tener noticias de contagios en humanos en Málaga. «Lo recomendable es que el Ayuntamiento continúe con las medidas de bioseguridad y vigilancia ya implementadas en esa zona y en el resto de zonas verdes de la ciudad. Lo siguiente es confirmar en el laboratorio las causas del brote y sería importante activar un protocolo de seguimiento para las personas que hayan podido estar en contacto directo con las aves afectadas».



Imagen de los investigadores que se reunieron en IBIMA Plataforma Bionand la semana pasada. sur

Un proyecto del Ibima usará una molécula de la algarroba para prevenir el alzhéimer

Intervendrán nutricionalmente a pacientes con pérdida de memoria administrándoles ese componente

JOSÉ ANTONIO SAU

ca de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND) acogió el pasado 24 de abril la reunión de lanzamiento del proyecto Nutricia, una iniciativa pionera que aglutinó, en un encuentro de alto nivel, a investigadores de instituciones punteras como la Erasmus Medical University de Róterdam, la Sapienza University de Roma, y las empresas biotecnológicas Holisum y Euronutra, firmas todas ellas miembros del consorcio in-

cilitar el ingreso de glucosa en estas para que puedan utilizarla como energía) y los desequilibrios metabólicos como factores clave en el desarrollo del deterioro cognitivo y el envejecimiento cerebral. «Estamos asistiendo a un cambio de paradigma en la comprensión de los factores que contribuyen al deterioro cognitivo. La resistencia a la insulina, tradicionalmente ligada a la diabetes tipo 2, está demostrando tener un impacto directo sobre

«La insulina es una hormona que no sólo actúa en el músculo, el tejido graso o el hígado para regular el almacenamiento de energía y retirar glucosa de la sangre. También regula, en el cerebro, el funcionamiento neuronal y la vitalidad e, incluso, la reparación, por así decirlo, del tejido cerebral», recalca el investigador. De esta forma, se ha comprobado que las personas con resistencia a la insulina, es decir, en aquellos en los que esta depósito de las proteínas que se acumulan anómalamente en el alzhéimer», aclara el investigador. Una de ellas, cuando se acumula, provoca «neurotoxicidad, muerte neuronal y deterioro cognitivo», afirma.

La base del proyecto europeo es, de hecho, identificar elementos nutricionales para hacer intervenciones que puedan modificar esa alteración metabólica cerebral y conseguir un envejecimiento más saludable. Con «Euronutra, una empresa malagueña, investigamos desde hace ocho años una molécula que está presente en la vaina del algarrobo que se llama D-pinitol; es capaz de activar la señal de insulina y corregirla en el cerebro», reseña.

«Hemos hecho ya varios estudios y tenemos patentes con Euronutra que permiten proteger y explotar la idea de que el D-pinitol incorporado a la nutrición podría mejorar la resistencia a la insulina y prevendría o atenuaría el deterioro cognitivo», aclara. El Hospital Regional, en concreto el equipo del doctor Pedro Serrano, jefe de la Unidad Clínica de Neurología, va a reclutar a personas que acuden al neurólogo por la «sensación objetiva de que están perdiendo memoria». Así, «vamos a combinar una intervención nutricional con D-pinitol junto con los cuidados habituales que se hacen a estas personas que acuden con la sensación subjetiva de que están perdiendo memoria». Se les va a seguir durante dos años y se van a monitorizar determinadas proteínas que, si se miden en sangre, indicarían un inicio de alzhéimer. Si toman D-pinitol, la acumulación de estas proteínas desaparecería.

En Róterdam se va a hacer un estudio retrospectivo, examinan-

Martes 30.09.25
SUR

«Ningún científico investiga para que le den premios, pero me alegra que se reconozcan el sacrificio y el esfuerzo»

Melissa García Caballero, investigadora y profesora de la UMA, recibe el Premio Nacional de Investigación para Jóvenes 2025

JOSÉ ANTONIO SAU

MÁLAGA. Melissa García Caballero (Montecorto, Málaga, 40 años), científica del Departamento de Biología Molecular y Bioquímica de la Universidad de Málaga (UMA), ha sido galardonada con el Premio Nacional de Investigación para Jóvenes 2025, en la modalidad 'Gabriela Morreale, en Medicina y Ciencias de la Salud', una distinción que otorga el Ministerio de Ciencia, Innovación y Universidades que está considerada como la más importante del país en el ámbito de la I+D+i. En declaraciones a SUR, ha explicado que «ningún científico investiga para que le den premios, pero está bien que se pongan en valor el sacrificio y el esfuerzo».

Estos premios cuentan con veinte modalidades distintas, dotadas cada una con 30.000 euros. En concreto, la profesora de la Facultad de Ciencias de la UMA ha sido reconocida en esta categoría por «su originalidad, excelencia y la orientación traslacional de su investigación en biología vascular y microambiente tumoral utilizando aproximaciones innovadoras y tecnologías de vanguardia de imagen y modelos 3D».

García Caballero ha señalado que el galardón fue comunicado por la ministra de Ciencia, Innovación y Universidades, Diana Morant, el pasado viernes. «Me llamó la ministra y me quedé un poco bloqueada. Hasta tuvo que decirme: 'Soy yo, soy yo'. Me dio mucha alegría, la ministra fue muy cercana, y me puse muy contenta, a la vez que perpleja», ha explicado a SUR.

El premio galardona su trayectoria científica, los trabajos liderados, la investigación realizada dentro y fuera de España y el liderazgo demostrado en estos proyectos. En su opinión, en Málaga



Melissa García Caballero. SUR

«se hace muy buena ciencia y se está avanzando mucho en la investigación» con relación a hace algunos años. «Estamos cada vez mejor posicionados», declara. También se refiere, claro está, a España.

Ella misma pasó unos años en un periodo postdoctoral en Bélgica, ya que antes era casi esencial salir de España para investigar, pero ahora, aclara, «no es obligatorio salir de España para investigar», aunque, eso sí, ella lo recomienda a los jóvenes investigadores, «sobre todo a nivel personal, más que científico. Creas así tu propia red de contactos y colaboradores, pero además, salir de tu burbuja de confort te hace enfrentarte a dificultades y problemas que aprendes a resolverlos por ti mismo». Recuerda que ahora hay grupos muy punteros en Andalucía, Madrid, Barcelona, en el norte de España y en otras comunidades.

García Caballero es bióloga de formación e hizo la tesis en el Departamento de Biología Molecular y Bioquímica, centrando sus esfuerzos en identificar nuevas moléculas capaces de inhibir la generación de vasos sanguíneos (angiogénesis) y el crecimiento tumoral. Después realizó una larga estancia postdoctoral en Bélgica, donde se dedicó mucho esfuerzo en estudiar la formación de vasos linfáticos, el metabolismo vascular y su relación con diversas patologías. A su vuelta a España se ha centrado en comprender la biología vascular del cáncer y cómo las células tumorales invaden la vasculatura tumoral dando lugar al desarrollo de metástasis. «La experiencia adquirida a lo largo de mi trayectoria y la amplia formación en biología vascular y cáncer han impulsado el desarrollo de proyectos que integran estas diferentes perspectivas», declara la premiada bióloga, que es además investigadora principal del Grupo BE18 y Coordinadora de la Unidad de Onco-Hematología-CIMA del Instituto de Investigación Biomédica de Málaga (IBIMA Plataforma BIONAND).

Este año, en los premios el 55% de los galardonados han sido mujeres. «Seis de cada diez premiadas son chicas, y se ha dado, por ejemplo, a una en física. Se han roto los estereotipos y se hace menos patente la brecha de género», recalca a SUR.

Currículo

Melissa García Caballero es investigadora 'Beatriz Galindo' junior del Departamento de Biología Molecular y Bioquímica de la Universidad de Málaga desde 2021. Licenciada y doctora (2013) en Biología por la UMA, comenzó su etapa postdoctoral como becaria 'Marie Curie' en el 'Laboratory of Tumors and Developmental Biology-GIGA Cancer' de la Universidad de Lieja (Bélgica). En 2017 inició su segunda estancia en el 'Laboratory of Angiogenesis and Vascular Metabolism' (Universidad Católica de Lovaina, Bélgica), junto al profesor Peter Carmeliet.





CONCIENCIA

Descifrar la enfermedad de Alzheimer

En Málaga, un grupo de científicos están demostrando en laboratorio la incidencia que tienen otras enfermedades en el origen y el desarrollo del alzhéimer.

Más noticias destacadas en la web de **"Conciencia"** y el programa completo en la plataforma **CanalSur Más.**

Descárgate la App de **CanalSur Más** en: **Play Store** y **Apple Store.**

CANAL SUR MEDIA | 2 noviembre 2025

COMMON RESEARCH SUPPORT SERVICES (ECAI)

9

The IBIMA Plataforma BIONAND spaces dedicated to research total **10,307 m²**. **They are distributed** between the Regional University Hospitals (General H., Maternal H., and Civil H.) and the Virgen de la Victoria University Hospital (including a space in the Valle del Guadalhorce Hospital) the Málaga-Guadalhorce Primary Care Healthcare District, and the University of Málaga, by virtue of agreements signed for the use of spaces and/or shared use, as well as the Málaga TechPark building.

The following is a description of the Shared Research Support Services (ECAIs for their initials in Spanish) that support the various research groups and are necessary for carrying out the institute's activity.

Shared Research Support Services (ECAI, for its initials in Spanish)

- **CLINICAL RESEARCH AND CLINICAL STUDIES** (7th floor of the Regional University Hospital of Málaga (HURM), Early Phase Units at the HUVV and HRUM).
- **METHODOLOGICAL AND STATISTICAL ADVISORY SERVICE**
- **GENOMICS** (node in the Malaga TechPark building, node in the IBIMA laboratory at the HUVV, and node on the 1st floor of the UMA Bioinnovation building at Málaga TechPark)
- **PROTEOMICS** (SCAI building of the UMA on the Teatinos Campus)
- **CELL THERAPY AND GMP ROOMS** (7th floor HURM)
- **BIOBANK** (basement of pavilions 5 and 6 of the Civil H.)
- **ANIMAL EXPERIMENTATION** (Málaga TechPark building and Animal Experimentation Center at the UMA, Teatinos Campus).
- **BIOINFORMATICS** (Malaga TechPark and UMA building, Bioinnovation building in the Málaga TechPark).
- **CELL BIOLOGY (CYTOMETRY AND CULTURES)** (Málaga TechPark building and laboratories 1, 2, and 3 in the hospitals)
- **NANOIMAGING** (Málaga TechPark building).
- **HISTOLOGY** (Málaga TechPark building).
- **CHEMISTRY** (Málaga TechPark building).

Common Research Spaces (Laboratories):

- Laboratory 1. Location: Civil Hospital (HRUM), basements of pavilions 2, 5, and 6.
- Laboratory 2. Location: Virgen de la Victoria University Hospital.
- Laboratory 3 or Regenerative Medicine Laboratory (LMR, for its initials in Spanish). Location: Basement of the HRUM Administration Wing.
- Phase I Clinical Trials Unit: Virgen de la Victoria University Hospital and the Regional University Hospital of Málaga.
- Phase II-III Clinical Trials Unit: Virgen de la Victoria University Hospital and the Regional University Hospital of Málaga.
- Laboratories of the Málaga TechPark building.

Common Research Spaces in the School of Medicine (Pharmacology Laboratory and Legal and Forensic Medicine Department Laboratory), School of Health Sciences (Experimental and Human Movement Laboratory), School of Sciences (BIO-267 Laboratory and the Cellular Biology, Animal and Plant Physiology, and Department of Organic Chemistry laboratories), School of Psychology (Basic Physiology and Psychobiology and Social Sciences Methodology Laboratory), and the Industrial Engineering Higher Technical School (3D printing for research support (LIPSI)), all located on the Teatinos Campus of the University of Málaga.

PRIMARY CARE research space: Two offices on the 2nd floor of the Civil Hospital.

CLINICAL STUDIES

We conduct research to contribute to improving citizens' health. Our commitment is shared with industry leaders, who rely on our institute to conduct their clinical trials thanks to the robustness of our healthcare system, the high level of training of our professionals, and our state-of-the-art infrastructure for the optimal execution of our clinical research activity.

Independent Clinical Research and Clinical Trials Unit (UICEC, for its initials in Spanish)

IBIMA Plataforma BIONAND's Clinical Research and Clinical Trials Unit is a multidisciplinary support structure for the research groups at the institute — the Regional and Virgen de la Victoria University Hospitals of Málaga and primary care — to conduct clinical research studies.
The IBIMA UICEC forms part of the Spanish Clinical Research Network (SCReN) and partially funded by the Carlos III Institute of Health (PT23/00137). On the European level, SCReN forms part of ECRIN, the European Clinical Research Infrastructure Network. SCReN is a national hub and supports and manages international multicenter clinical trials.

Services:

- Methodological and regulatory scientific advising.
- Management and administrative processing.
- Coordination and scientific management of clinical research.
- Scientific management of clinical research.
- Performing studies: Pre-start-up of clinical trials, conduct, finalization, and close-out.
- Monitoring.
- Pharmacovigilance.

Coordinator: Ms. María Isabel Lucena González, Scientific Director of UICEC.
Personnel in 2025: 10 Professionals

Clinical Studies Unit of the Regional University Hospital of Málaga

The aim of the Clinical Studies Unit of the Regional University Hospital of Málaga is to foster and promote observational studies and national and international clinical trials at the center in order to generate knowledge and improve patient health.

Services:

- Technical and administrative support to promote and dynamize the management and conduct of clinical trials and commercial observational studies.
- Promote the research activity of the clinical units of both consolidated and emerging units.
- Increase the number of commercial, national, and international clinical studies.
- Resolution of incidents that hinder the conduct of clinical studies.
- Optimize contract management and metrics/timing.

Phase I Clinical Trials Unit

The Phase I Clinical Research Unit at the Regional University Hospital of Málaga is located on the first floor of Pavillion 8 of the Civil Hospital. The unit features modern, high-capacity facilities and immediate access to key hospital resources, such as the ICU. Its facilities include a patient reception area, a nursing station, three examination rooms, a day hospital, operating rooms, and a technical room, among others.

Coordinator: Mr. Francisco Carabantes Ocón
Personnel in 2025: 1 Technician

Clinical Studies Unit of the Virgen de la Victoria University Hospital in Málaga

The aim of the Clinical Studies Unit of the Virgen de la Victoria University Hospital Málaga is to foster and promote national and international observational studies and clinical trials at the center in order to generate knowledge and improve patient health.
Some of the unit's most notable pieces of equipment include the FibroScan, a body composition analyzer, and a metabolic cart for measuring energy expenditure and the respiratory quotient.

Services:
Technical and administrative support to promote and dynamize the management and conduct of clinical trials and commercial observational studies.

- Promote the research activity of the clinical units of both consolidated and emerging units.
- Increase the number of commercial, national, and international clinical studies.
- Resolution of incidents that hinder the conduct of clinical studies.
- Optimize contract management and metrics/timing.
- Manage the infrastructure of the Phase II/III clinical research care area.

Phase II/III clinical research care area

Area that measures more than 600 square meters for phase II and III clinical research. It has a total of ten consultation rooms, a samples collection room, a day hospital, and sample processing rooms.
Coordinator: Mr. Manuel F. Jiménez Navarro
Responsible for Clinical Trials: Rafael Jiménez López
Personnel in 2025: 1 Technician

Phase I Clinical Trials Unit

The Phase I Clinical Research Unit of the Virgen de la Victoria University Hospital can be directly accessed from outside the hospital. It has a user reception area, a consultation room for samples collection, a nursing station, two consultation rooms, a day hospital, and two double rooms.
The unit complies with the definitive standards of the Early Phase Clinical Trials Unit Standards Manual, with advanced quality certification by the Andalusian Healthcare Quality Agency.

Coordinator: Mr. Javier García Corbacho.

Main results of the ECAI in 2025:

No. of active independent clinical trials	No. of new independent clinical trials	No. of new early phase (I-II) clinical trials	Revenue from clinical trials (€)
371	42	106	€14,142,215.98

Location: This platform is located on the first floor (Phase I Clinical Trials Unit) and on the 2nd floor (Phase II/III Clinical Research Care Area) of the Virgen de la Victoria University Hospital, the first floor of pavilion 8 of the Civil Hospital, and on the 7th floor of Pavilion A of the Regional University Hospital of Málaga.

METHODOLOGICAL AND STATISTICAL ADVISORY SERVICE

The aim of this research advisory unit for research groups is focused on fulfilling the full potential to generate data that are crucial to detect, solve, and prevent problems related to patients' health. It offers specialized biomathematical support that adds rigor and takes special care in design, implementation, and analysis. It provides scientific support that bridges the gap between clinical and translational research.

Services:

- **Methodological and epidemiological advising:** Methodological advising and/or review of research protocols, analysis of the grounds for rejecting projects, review of scientific articles.
- **Statistical advising:** sampling and sample size calculation, descriptive analysis of data, inferential analysis (bivariate and multivariate), support in the use of free software for statistical data analysis (R-project), and review of scientific articles.
- **Advising to research groups:** gathering knowledge about the work conducted in the research groups to support starting lines of research or clinical innovation and identify and promote possible inter-unit, inter-center, and international collaborations. Support for groups' research personnel in the exploitation of their data as well as in the dissemination of their experimental results in national and international forums. Advising for research groups on their research interests in order to define objectives and outline appropriate strategies to achieve them.
- **Educational activities:** education on research methodology, the use of free software for statistical data analysis, advanced statistics, preparation of a scientific manuscript for publication in peer-reviewed scientific journals, critical reading of scientific literature, and specific educational courses according to researchers' needs.

Coordinator: Rita Pérez González

GENOMICS

IBIMA's Genomics Unit, the BIONAND Platform, has taken a strategic leap forward this year, consolidating its role as a key infrastructure for biomedical research, personalized medicine, and technology transfer to the healthcare setting. The Unit has strengthened its technical, organizational, and scientific capabilities, positioning itself as an advanced hub for the development of complex, high-impact genomics projects.





One of the most significant milestones has been advances in solid tumor molecular diagnostics in collaboration with hospitals in Málaga. The consolidation of local pipelines based on NGS Oncomine platforms enables progress toward an integrated model that encompasses clinical sample processing, nucleic acid extraction, library preparation, sequencing, molecular analysis, and interpretation of results. This advance increases the technological autonomy of the IBIMA-hospital network, thus reduces reliance on outsourcing, and strengthens precision oncology.

This period has also been marked by significant technological upgrades. The addition of the DNBSEQ-T1+ system and the MGISP-Smart 8 robot has increased local PE150 sequencing capacity, automation, and scalability. Along with the launch of the Genexus system, the unit now has a more robust infrastructure to tackle both research projects and targeted sequencing workflows with translational and clinical potential.

The scientific portfolio has expanded significantly with the introduction or consolidation of techniques such as low-cost 3'RNA-seq, Chromium GEM-X/ Flex, Stereo-seq spatial transcriptomics on FFPE samples, human and mitochondrial exome sequencing, shotgun/16S metagenomics, bulk ATAC-seq, 5-base DNA libraries for methylation, Olink Protein-seq Reveal, Maxwell workflows for complex clinical samples, and advanced quality control services using Qubit and TapeStation. This expansion allows for providing support for multiomics, translational, and personalized medicine projects.

The activity recorded reflects growing demand: 1,486 samples, 24 services managed with a total revenue of €72,661, and 35 proposals attended to. These figures demonstrate the unit's capacity for client acquisition and consultation.

In addition, progress has been made in internal organization to address the challenge of ISO 15189 certification, which is currently underway. Improvements have been implemented in sample traceability systems, service tracking, inventory control, technical documentation, and the structuring of molecular information. Actions have also been implemented in the areas of training, visibility, and talent recruitment, including activities related to single-cell technologies, spatial transcriptomics, targeted sequencing, the OPE 2025/228 recruitment process for a Genomics ECAI Technician, and hosting students for training placements. During this period, the team was strengthened with the incorporation of a new laboratory technician, helping to increase operational capacity and the stability of technical workflows. In addition, the OMICs Talks seminar series was promoted. There were four sessions held on key technologies such as MGI sequencing, spatial transcriptomics/Stereo-seq, Protein Seq/Olink, and Illumina, creating opportunities for staying up-to-date on technology, interaction with researchers, and the dissemination of new skills. The Unit also hosted four students in training activities: two undergraduate students and two vocational training students. This reinforces its role as a specialized setting for practical training on advanced genomic technologies.

Overall, it has been a period of decisive consolidation and expansion. The combination of new equipment, new techniques, hospital collaboration, molecular circuits, training activities, and organizational improvements positions the Genomics Unit as an essential infrastructure for accelerating translational research, strengthening personalized medicine, and establishing the institute as a leader in advanced biomedical genomics.

Scientific Coordinator: Dr. Isabel Moreno Indias
Technical Coordinator: Daniel Alameda
Personnel in 2025: 2 Technicians
Location: This platform's main headquarters is located at the IBIMA Plataforma BIONAND building in Malaga TechPark. It also has spaces in the basement of Pavilion 5 of the Civil Hospital (Regional University Hospital of Málaga) and in the laboratory on the 1st floor of the Virgen de la Victoria University Hospital.

PROTEOMICS

This research support platform provides scientific and technical support and advising to the university community and other public and private institutions in the identification and characterization of proteins and other biomolecules, primarily through mass spectrometry techniques.
Mass spectrometry is based on the differential behavior of ionized molecules as they pass through electrical and magnetic fields. This technique allows ions to be separated based on their mass-to-charge ratio (m/z) and subsequently detected.

Services offered:

- Sample preparation:
  - Protein extraction.
  - Desalting and concentration of samples.
  - Peptide purification through RP-HPLC.
  - Manual and automated enzymatic digestion of proteins in gel and in solution.
  - Preparation of histological sections for MALDI-Imaging.
  - Sample preparation for MALDI-Imaging of colonies.
- Chromatographic techniques:
  - HPLC: High Performance Liquid Chromatography.
  - FPLC: Fast Protein Liquid Chromatography.
  - TLC: Thin-layer Chromatography.
- Mass spectrometry:
  - Determination of protein molecular masses.
  - Identification of proteins in purified samples and complex mixtures.
  - Relative protein quantification by: LFQ, TMT, SILAC.
  - Study of post-translational modifications.
  - Analysis of protein profiles.
  - Study of the spatial distribution and relative abundance of analytes in intact samples of animal or plant tissues through MALDI-Imaging.
  - Study of bacterial metabolite profiles in microbial colonies and/or biofilms through MALDI-Imaging.
- Immunoassays:
  - Simultaneous detection and quantification of different secreted proteins (cytokines, chemokines, growth factors, etc.) by means of immunoassays based on Luminex technology.

Applications:

- Disease diagnosis and prognosis.
- Identification of therapeutic targets for the development of new drugs and vaccines.
- Determination of molecular mechanisms involved in disease pathogenesis.
- Molecular classification of tumors.
- Studies of drug distribution in tissues.
- Identification of microorganisms.
- Ecological and evolutionary studies.

Main results in 2025:

- A total of 41 requests for analysis corresponding to different research projects were attended to.
- Nine scientific publications and two contributions to scientific conferences were made.
- The completion of 5 Bachelor's Degree Final Project's Degree Theses (TFM) and 1 Doctoral Thesis were collaborating on.
- Four training and teaching support activities were conducted.
- Three scientific dissemination actions were carried out.
- Sixteen training actions were completed by the three department technicians.
- Two new techniques or services were added to the catalog of services.

Scientific articles:

1. Pozo-Vilumbrales B, Martín-Chaves L, López-Unzu MA, Soto-Navarrete MT, Pavón-Morón FJ, Rodríguez-Capitán J, Fernández Corujo B. *Unraveling the molecular complexity of bicuspid aortopathy: Lessons from comparative proteomics.* Biochim Biophys Acta Mol Basis Dis. 2025;167679. doi:10.1016/j.bbadis.2025.167679.
2. Medina-Vera D, Martín-Chaves L, Sánchez-Marín L, Díaz-Ottaviano M, Gavito AL, Popova O, Sánchez-Quintero MJ, Rodríguez-Capitán J, Rodríguez de Fonseca F, Jiménez-Navarro MF, Serrano A, Pavón-Morón FJ. *Maladaptive stress-coping behavior in CX3CR1-deficient mice: Impact of adolescent stress and alcohol exposure on neuroimmune responses and inflammation.* Neuropharmacology. 2025;275:110503. doi:10.1016/j.neuropharm.2025.110503.
3. Rojas-Velis N, Cárdenas-García C, Pérez E, Toledo JR, Medina MÁ, Astuya-Villalón A, Abdala-Díaz RT. *In Vitro Evaluation of the Healing Potential and Proteomic Study of Quercus robur L. Leaf Extracts in Human Keratinocytes.* Molecules. 2025;30(10):2152. doi:10.3390/molecules30102152.
4. Dakhli N, López-Jiménez A, Cárdenas C, Hraoui M, Dhaouafi J, Bernal M, Sebai H, Medina MÁ. *Urtica dioica Aqueous Leaf Extract: Chemical Composition and In Vitro Evaluation of Biological Activities.* Int J Mol Sci. 2025;26(3):1220. doi:10.3390/ijms26031220.
5. Porras-Perales O, Sánchez-Marín L, Medina-Vera D, Flores-López M, Martín-Chaves L, Boccalon M, Requena-Ocaña N, García-Marchena N, Reviriego R, Santín LJ, Martin-Fardon R, Jiménez-Navarro M, Rodríguez de Fonseca F, Serrano A, Pavón-Morón FJ. *Sex-specific dysregulation of the CX3CL1/CX3CR1 axis following cocaine exposure: Translational evidence for a potential biomarker of abstinence.* Prog Neuropsychopharmacol Biol Psychiatry. 2025;141:111482. doi:10.1016/j.pnpbp.2025.111482.
6. Jiménez-López R, Martín-Chaves L, Gutiérrez-García ÁM, Carmona-Segovia ADM, Mora-Ordoñez B, Sánchez-García AM, Fernández-Romero L, Murri M, Sánchez-Quintero MJ, Berteli-García G, Sánchez-Chaparro MÁ, Bodí V, Rodríguez-Capitán J, Jiménez-Navarro M, Pavón-Morón FJ, Romero-Trevejo

JL. *Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy.* Front Med (Lausanne). 2025;12:1631334. doi:10.3389/fmed.2025.1631334.
7. Porras-Perales Ó, Segovia-Reyes J, Crespo-Delgado Á, Ruiz-González D, Flores-López M, Medina-Vera D, Sánchez-Marín L, Martín-Chaves L, Requena-Ocaña N, Molina-Ramos AI, Ruiz-Ruiz JJ, Rodríguez de Fonseca F, Jiménez-Navarro M, Rodríguez-Capitán J, Pavón-Morón FJ, Serrano A. *Distinct cardiac troponin alterations in patients with cocaine and alcohol use disorders during abstinence for cardiovascular risk assessment.* Sci Rep. 2025;15(1):21887. doi:10.1038/s41598-025-08041-y.
8. Pérez-Lorente AI, Molina-Santiago C, Vela D, Corcía, Stincone P, Hierrezuelo J, Grifé M, Pakkir Shah AK, de Vicente A, Petras D, Romero D. *The offensive role of the Bacillus extracellular matrix in driving metabolite-mediated dialogue and adaptive strategies with pathogenic fungi.* 2025.
9. Grifé-Ruiz M, Hierrezuelo-León J, de Vicente A, Pérez-García A, Romero D. *Diversification of Lipopeptide Analogues Drives Versatility in Biological Activities.* 2025.

Contributions to scientific conferences and forums:

1. Gevers-Montoro C, Cárdenas García C, Álvarez Galovich L, Roza C, Kawchuk G, Piché M, Ortega-De Mues A. *Proteomic Insights into Chronic Low Back Pain: Identifying Disease Signatures and Spinal Manipulative Therapy Predictors.* World Federation of Chiropractic Biennial Congress 2025. Copenhague (Dinamarca), 15–18 mayo 2025.
2. II Jornadas de Proteómica en Biomedicina – Red de Proteómica de Investigación Biomédica de Andalucía (IPROTEA). 3–4 abril 2025.

Doctoral Theses and Final Degree Projects:

Doctoral Thesis:

1. León Rodríguez A. *Consequences of microglial priming in the hypothalamus. Pharmacologic modulation by CSF1 receptor inhibition.* Doctoral Program, University of Málaga, September 2025.

Final Degree Project (TFG):

1. Antúnez Muñoz I. *Evaluación de biomarcadores plasmáticos cardiovasculares en hombres y mujeres profesionales de emergencias sanitarias en un contexto de estrés.* Degree in Medicine, University of Málaga, 2024/2025 academic year. Tutor: Manuel Jiménez-Navarro. External collaborators: Laura Martín-Chaves and Antonia Serrano Criado.
2. Ahmed Haddouchi N. *Papel de la inflamación en la patología de aneurisma aórtico torácico (válvula aórtica tricúspide versus válvula aórtica bicúspide).* Degree in Medicine, University of Málaga, 2024/2025 academic year. Tutor: Manuel Jiménez-Navarro. External collaborators: Laura Martín-Chaves and Francisco Javier Pavón-Morón.
3. Sánchez Pérez M. *Apolipoproteínas en plasma de pacientes propuestos a cirugía cardiovascular: dimorfismo sexual y alteraciones asociadas con aneurisma aórtico torácico y válvula aórtica bicúspide.* Degree in Medicine, University of Málaga, 2024/2025 academic year. Tutor: Manuel Jiménez-Navarro. External collaborators: Laura Martín-Chaves and Francisco Javier Pavón-Morón.
4. Cárdenas Vela CU. *Modulación del metabolismo de las poliaminas en células tumorales por compuestos antiangiogénicos* y análogos de poliaminas. Final Degree Project in biological, University of Málaga year.
5. Blanco V. *Exploración del riesgo aterosclerótico en el contexto de MASLD.* Final Degree Project in Biochemistry, University of Málaga, 2024/2025 academic year. Tutor: Beatriz Martínez. External collaborators: Lourdes Garrido Sánchez

Training and teaching support activities:

1. Theoretical class and visit for students in the Master's Program in Advanced Biotechnology in the course "Separation and Analysis of Biomolecules," Faculty of Sciences, University of Málaga. January 24, 2025.
2. Theoretical class and practical visit for Bachelor's Degree in Health Engineering students in the course "Biotechnology," Universidad de Málaga. March 24, 2025.
3. Theoretical class and practical visit to Bachelor's Degree in Health Engineering students in the subject "Genomics, Proteomics, and Metabolomics), University of Málaga. May 20, 2025.
4. Educational visit by high school students from the Anatomical Pathology Laboratory at IES Litoral.

Informational activities:

1. Visit and talk for students participating in the IEScience program (middle and high school students), University of Málaga. March 14, 2025.
2. Visit and talk for students in the clinical laboratory vocational training program. June 27, 2025.
3. Visit and talk for students at IES Los Colegiales in Antequera (12th grade). March 20, 2025.

Coordinator: Mr. Javier Marquez Gómez
Personnel in 2025: 3 Technicians
Location: This platform is located in the Proteomics Unit, 2nd floor of the Central Research Support Services (SCAI) building of the University of Málaga. Teatinos Campus.

CELL CULTURE AND CYTOMETRY

CELL CULTURE

The Cell Culture Unit provides the institute's research groups and other public or private institutions the possibility of culturing and maintaining cells (mainly murine and human), including both primary cultures and established cell lines, offering advising from specialized personnel and the conduct of assays with guaranteed flexibility and adaptation to specific requirements.

Services

GENERAL:

- Maintenance and disinfection of biosafety hoods.
- Maintenance and disinfection of incubators.
- Regular change of water in CO2 incubators.
- Maintenance and disinfection of thermostatic baths.
- Periodic analysis of mycoplasma contamination in incubators.
- Solid waste disposal and treatment and disposal of liquid waste.
- Equipment and facilities for the use of viral vectors in cell culture.
- Daily control of temperature and CO2 in incubators.
- Annual certification of cabins and incubators.

SPECIFIC:

- Advice on the acquisition and maintenance of cell lines.
- Cryopreservation of samples.
- Analysis of mycoplasma contamination.

Scientific Coordinator: Dr. Elena González Muñoz
Personnel in 2025: 1 Technician in charge , shared with the Animal Housing Unit.

Main results 2025:

- Service to 15 research groups under the terms of the services offered.
- Education and training on the correct use of the unit for the personnel of 15 research groups (19 users).
- User management using a calendar in Clustermarket as well as billing of services rendered to internal and external entities.
- Maintenance and verification services have been performed for the cabins and incubators in use.
- The technician training was conducted as part of the Advanced Biosafety Training Workshop, held in person at CNB, CBMSO, CIAL, and CSIC-UAM in October 2025.

DISSEMINATION:

1. 10 Visits organized for high school and vocational training students.

CYTOMETRY

The main objective of this unit is to provide support for the conduct of research studies carried out by the different groups that form part of the Institute or other research centers through scientific advising, sample analysis, and presentation of results in the field of flow cytometry.
The unit's primary mission is to provide efficient, quality service in order to promote and carry out research.

The catalog of services includes, among others:

- Analysis of cell populations via fluorescence:
  - Identification of cell populations through intracellular or extracellular antigen labeling.
  - Cell viability, cell cycle, and apoptosis studies using vital dyes (Annexin-V/Propidium Iodide, TUNEL, mitochondrial membrane potential determination, sub-G0 peak detection, etc.).
  - Studies of oxidative stress using fluorescent probes.
  - Determination of cell proliferative index using labeled nucleoside analogs (BrdU).
  - Fluorescent protein-guided gene expression studies (GFP, YFP...).
  - Quantification of cytokines and other soluble proteins.
  - Intracellular Ca2+ mobilization studies.
- Spectral analysis: Provides the possibility to analyze up to 40 colors
- Cell sorting from single cells collected in tubes or plates

Scientific Coordinator: Dr. Elena González Muñoz
Personnel in 2025: 1 Technician specialized in cytometry and cell separation.

Main results 2025:

- Incorporation of new techniques and protocols according to user demand. Several cytometry panels, both spectral and conventional, have been designed and optimized to meet the requirements of the researchers' projects.
- The technique of cell separation via cytometry has been performed in the separating spectral cytometer at the request of users.
- 16 new users have requested services from the cytometry unit, including both independent users of the analyzer and users of the spectral cytometry and cell separation services offered by the specialist technician. Currently, the unit routinely provides services to 13 IBIMA and UMA research units.
- Eight users were trained to use the cytometer analyzer correctly and autonomously.
- Advising has been provided on experiment design and results analysis to different research groups that have requested it, both from IBIMA and from the UMA and companies.
- At the request of the researchers, a service for processing and staining samples has been introduced within the unit itself.
- The hiring of an improved maintenance service for the spectral cytometer was negotiated and the terms of the contract have been established.
- The transfer a flow cytometry instrument from another IBIMA laboratory has been requested so that it can be used more once it forms part of the flow cytometry unit.

DISSEMINATION:

Several visits organized by IBIMA knowledge area and education area: for high school and vocational training students, undergraduate Biology students (University of Málaga), and representatives of other entities, as well as occasional visits by researchers from other institutions throughout the year.

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

CELL THERAPY AND GMP ROOMS

The institute's Cell Production Unit (UPC) has **three rooms authorized for the aseptic manufacture of advanced therapy drugs according to GMP** (Good Manufacturing Practices) **standards** . The facilities meet the quality and safety requirements necessary for aseptic drug manufacturing. The facilities meet the quality and safety requirements for the aseptic manufacture of medicines according to the Spanish Agency of Medicines and Medical Devices (AEMPS) guidelines since 2012. It is part of the Andalusian Network for the Design and Translation of Advanced Therapies (RADyTTA), whose objective is to promote the development and application in clinical practice of the results obtained from research in the fields of cell, tissue, gene, and nanomedicine therapy.

In addition, through the RADyTTA, the unit belongs to the RICORS Network of Advanced Therapies (TERAV) and the Networked State Consortium for Advanced Therapies (CERTERA), which aims to establish the scientific collaborations necessary for the clinical development of safe and effective advanced academic therapies, and the coordination of networked technological structures that facilitate the translation of these therapies to the National Health System in order to facilitate their clinical translation and patients' access to them.

This unit is authorized by the Spanish Agency of Medicines and Medical Devices for the **manufacture of cell therapy drugs based on expanded adult mesenchymal adipose tissue-derived stem cells (ADSCs) for autologous or allogeneic use** as well as the conduct of the corresponding quality controls according to the European Pharmacopoeia (Ph. Eur) for use in clinical trials in diseases that do not have or do not adequately respond to conventional treatments, such as amyotrophic lateral sclerosis (ALS), structural fecal incontinence, or acute cerebral infarction or stroke, and severe SARS-CoV-2 pneumonia.

In addition, it manufactures drugs for compassionate use procedures with prior authorization from the AEMPS for the following diseases:

- Graft-versus-host disease (GVHD)
- Neurological diseases: ALS, multiple sclerosis
- Fecal incontinence
- Pediatric craniosynostosis

It pioneered the First External Quality Program in Advanced Therapies (www.eqa-atmp.com), which aims to standardize and verify the quality of the tests and techniques used in the manufacture of advanced therapy drugs.

The ECAI is currently collaborating with the University of Málaga on the creation of a 3D bioprinting platform for the preclinical evaluation of customized implants manufactured by bioprinting for the surgical correction of critical cranio-maxillofacial defects in pediatric patients. Furthermore, within the framework of the State Network Consortium for the Development of Advanced Therapy Drugs (CERTERA, for its initials in Spanish), the Cell Production Unit, together with researchers from the Histology Group at the University of Granada's School of Medicine, is optimizing the manufacturing process for peripheral nerve implants, a product developed by the aforementioned department at the University of Granada.

Services:

- Isolation of adult mesenchymal stem cells derived from adipose tissue, in vitro expansion to obtain the dose assigned according to protocol, and subsequent packaging.
- Quality controls for cell therapy trials.
- Environmental and surface microbiological control of facilities with ISO classification: air volumetrics, with settle plates; of surfaces using contact plates.
- Grading of thermal equipment: refrigerators, freezers, stoves, etc.
- Microbiological control testing of cellular products (Ph. Eur. 2.6.27), Mycoplasma (Ph. Eur. 2.6.7), endotoxins (Ph. Eur. 2.6.14), characterization of cellular products (Ph. Eur. 2.7.24), cell count and viability (Ph. Eur. 2.7.29), promotion of cell growth in culture and cell population doublings, genetic stability of ATMPs, cell recovery rate after thawing.
- Potency assay by estimating the immunosuppressive capacity of mesenchymal cells.
- Methodological, scientific, and technical advising on cell therapy clinical trials.
- Management, evaluation, and advising on trial documentation.
- Education on an introduction to cell therapy.
- External Quality Assurance Program in Advanced Therapies.

Coordinator: Dr. Antonio Rodríguez Acosta
Personnel in 2025: 3 Technicians
Main results 2025:

- In 2025, 25 batches of hAD-MSCs-based drugs were manufactured for compassionate use for patients with GVHD (allogeneic treatment).
- Quality control tests were performed the Grenoble Tissue Center (France) and for the Regional Transfusion Center of Málaga.
- Seven batches of drugs were manufactured for a multicenter, randomized, double-blind, Phase IIb clinical trial to evaluate the safety and efficacy of intralesional administration of two doses of expanded allogenic adipose tissue-derived stem cells (ADSCs) conditioned in hyaluronic acid hydrogel as a treatment for patients with fecal incontinence.
- Since 2012, it has been actively collaborating with the RADyTTA, the Graduate School, and the University of Granada to offer a Master's Degree in Manufacturing of Advanced Therapy Medicinal Products.
- Collaboration with the International University of Andalusia in the teaching of the Master's Degree in Advanced Biotechnology.
- Personnel linked to the Unit participate as teachers and workplace tutors in the Cell Culture Specialization Course (IES Litoral).
- In 2025, teaching was done in the Expert Diploma in Clinical Research and Clinical Trials Monitoring (IBIMA/ciber and SCReN Platform).
- It has become part of the EATRIS European platform and the ISCIII's 3D Printing and Bioprinting HUB platform.
- It has joined the Networked State Consortium for Advanced Therapies (CERTERA).
- Participates in a "A multicenter clinical trial with mesenchymal stromal cells in adult and pediatric patients with steroid-refractory acute GVHD to validate an immunomodulatory potency assay that associates with treatment efficacy ICI23/00085." Coordinating LR Rafael Duarte Palomino, Puerta del Hierro Hospital Foundation
- Dissemination activities conducted in 2025:
  - UMA Divulga 2025 Conference.
  - Medical and Health Communication Contest (The Conversation)
- Lecture at the "Scientific Communication" course at Cayetano Heredia University in Peru.
- Theoretical and practical course on technological updates for production in an NCF environment (TERAV+ Network)

Location: This platform is located in the Cleanroom, 7th floor of Pavilion A of the Regional University Hospital of Málaga.

BIOBANK

One of the institute's research support structures is the Provincial Biobank of Málaga, which in turn belongs to the Andalusian Public Health System Biobank. It is a unique biobank structure in terms of its potential and capacity for obtaining, transforming, preserving, and distributing samples for research purposes. It comprises 26 nodes located in SSPA (Andalusian Public Health Service) health centers. The Provincial Biobank of Málaga comprises 3 nodes: the Regional University Hospital of Málaga, the Virgen de la Victoria University Hospital, and the Costa del Sol University Hospital in Marbella. It also has the support of the regional hospitals and the Axarquia, Ronda, and Antequera Hospitals.

It is registered and authorized by the competent authorities with file number B.0001601 dated 16/09/2020 and owned by the Regional Ministry of Health and Families of the Regional Government of Andalusia (the Biobank of the Costa del Sol University Hospital, it has its own record, B.0000414, ownership: Costa del Sol Public Company, 12/03/2012, pending update), in accordance with the provisions of Article 13. Creation and Organization of the Andalusian Public Healthcare System Network Biobank according to **Decree 1/2013**, of January 8, regulating the authorization for the creation and operation of biobanks for biomedical research purposes, creating the Andalusian Biobank Registry and the Andalusian Public Healthcare System Biobank. The Provincial Biobank of Málaga was started 16 years ago. Since its inception, it has worked to become what it is today: a platform of services for provincial researchers, most of whom belong to the Institute, that allows users to carry out their projects with the assurance that the biobank guarantees that the ethical, legal, and technical requirements for biological samples and their associated data are met.

Services:

- Provision of samples and data for research projects.
- Management of samples and data for clinical trials in collaboration with the Clinical Trials Platform of Málaga.
- Processing of samples.
  - New: Organoid unit
- Preservation of samples at different temperatures.
- Technical, scientific, ethical, and quality advising on the collection, storage, and management of human samples in biomedical research.
- Files for diagnostic confirmation.
- Real-time web-based remote equipment monitoring.
-

Work is underway to improve the management of clinical specimens in collaboration with the Anatomical Pathology Department, optimize services for clinical studies, and establish collections of samples and/or strategic data to support the identified needs.

The manners in which the biobank provides these services are:

- Requests for sample provision: activation of circuits for sample collection, delivery of samples or data, and their custody in the biobank.
- Requests for services outside the biobank's organizational scope:
  - Custody: use of facilities for sample conservation.
  - Processing: processing of samples for researchers

Provincial Coordinator: Tatiana Díaz Córdoba
Personnel in 2025: Six technicians at the three hospitals where the biobank is located.
Main results 2025:

Services provided to research projects:

2025	HRUM	HUVV	HUCS
New Donors	373	379	12
No. of initial samples registered	4574	7800	1332
No. of new donations	1452	1575	255
No. of total brr distributed	3889	3829	92
No. of applications received	57	46	2
No. of CMUs attended to	20	14	15
No. of researchers	101	77	17

1. Sample collection and receipt.

NEW DONORS



Note 1: it should be noted that these data are only counted when we can assign donors, i.e. they have signed the biobank informed consent form.

NEW DONATIONS



NUMBER OF INITIAL SAMPLES REGISTERED



2. Use, distribution, and tracking of bioresources

NUMBER OF TOTAL SAMPLES DISTRIBUTED



3. Requests

NUMBER OF TOTAL REQUESTS RECEIVED (LOCAL AND FROM THE NETWORK)



NUMBER OF REQUESTS RECEIVED BY TYPE OF REQUEST



Note: 94 are services and 11 only based on the Biobank management model.

Services provided to clinical trials:

	2020	2021	2022	2023	2024	2025
Number of first visits attended to	65	60	70	77	68	86
No. active trials (cumulative)	161	237	290	370	380	431
No. of requests attended to (samples for clinical trials)	725	790	634	658	706	644
No. of samples/blocks without samples	51	37	27	37	54	53
%	7.6	5.77	5.60	5.33	7.50	8.2
Mean biobank management time (days)	1.2	0.83	1.04	0.88	0.82	1.35
Mean actual response time (days)	1.9	1.37	1.65	1.35	1.28	1.57
Maximum actual response time (days)	6.8	5.75	4.75	5.17	5.1	7
No. of samples outside hospitals without the Málaga biobank	36	55	38	40	42	14
No. of samples from hospitals outside of Málaga	0	4	3	2	3	5
Number of complete blocks delivered	532	1013	905	2167	566	297
Number of times slices have been delivered	153	245	87	172	248	170
TOTAL	691	1258	992	2339	814	467
Express biopsies attended to	ND	ND	ND	84	104	60

Resources and infrastructure:

The biobank's resources and infrastructure have increased significantly in the last 3 years, which shows that it is a consolidated unit with a clear vocation for expansion and growth, generating the synergies necessary for the ongoing development of the structure according to demand. In this sense, the institute continues to provide important support to this unit: it covers the costs of equipment maintenance and repair, commits to acquiring the necessary equipment for the structure, and provides its technicians with the necessary tools to advance in their professional careers.

At present, its facilities cover 346 m^2, of which 230 m^2 correspond to 4 cryopreservation rooms. The remainder is divided into 4 sample reception and registration areas and 3 processing laboratories. All of its locations have the necessary equipment for the transformation of the biological sample and their conservation according to the standard operating procedures. The cryopreservation rooms have equipment for preserving samples at -196 ºC (11), -80 ºC (44), -20 ºC (5), 4 ºC (5), and room temperature (5). It features digital temperature monitoring, validation with an external probe, 24/7 alarm management, connection to a power generator, independent air conditioning, CO2 and O2 detection, forced ventilation activation, etc.

In addition, there are internal and external maintenance plans for all available equipment as well as a comprehensive emergency plan. The sample processing laboratories are also equipped with IIA biological safety laminar flow cabinets (2), microtome, tissue safe, refrigerated centrifuges (2), and other laboratory equipment.

Invoicing for services:

Invoicing for services provided during the 2025 financial year was done entirely through the Andalusian Public Foundation for Progress and Health and totaled €5,365.05.

Quality:

- The Biobank's certification was renewed in 2025 according to the ISO 9001-2015 standard. The unit is certified under the UNE-EN ISO 9001:2015 Standard and participates in the creation of national guidelines for the UNE-EN ISO 20387 accreditation of biobanks, under the coordination of the national platform. The ISO 9001 renewal and the transition to ISO 20387 raise the unit's standards. The improvement in document traceability through nSIBAI ensures that 100% of operations comply with the standard's requirements.
- Infrastructure Qualification: A critical area has been the qualification of refrigeration and storage equipment. The integrity of biological samples and their associated data is a non-negotiable requirement of the pharmaceutical industry and biomedical research. Therefore, considerable effort has been made in validating every link in the chain of custody. Finally, for UNE-ISO 20387 accreditation, an assessment was initiated in the last quarter of 2025 to determine the scope of this accreditation for the Málaga Node, following the successful accreditation of the Coordination Node in 2025.

Research projects led and collaborations:

1. National Platform for Biobanks, Biomodels, and 3D Printing, PT23/00049, ISCIII. Total amount: €287,680. Duration: 3 years.
2. Participation as a member of the collaborating team in the AES2025 call for proposals in the research projects category, titled "Impact of Iron Overload on Myelodysplastic Syndrome: Effects on Chromatin and microRNAs," PI25/02073.

Internationalization of the structure:

The Biobank, Organoids, 3D Printing, and Animal Biomodel Platform provides services to IBIMA researchers to conduct their research activity in international and national networks. The international networks that IBIMA participates in are:

6.1.- European Biobanking research infrastructure **(BBMRI-ERIC)** (https://www.bbmri-eric.eu): European research infrastructure for biobanks, which brings together the main actors in the field of biobanks to promote biomedical research. This network offers a variety of services.
Since October 2025, Spain has been a full member of BBMRI-ERIC, the European Infrastructure for Biobanks and Biomolecular Resources. The Carlos III Health Institute (ISCIII) represents Spain, contributing more than 50 biobanks and specialized units and promoting national and international biomedical research.

- **Change in Status:** After four years as an observer, Spain has consolidated its position within BBMRI-ERIC so as to be able to participate with full voting rights in its governing bodies.
- **National Coordination:** Representation is provided by the ISCIII through the Biobank and Biomodel Platform, which comprises biobanks, animal models, organoids, and 3D printing.
- **Benefits:** Greater access to high-quality tools, data management, training, and European collaboration networks, promoting high-quality research.
- **Legal Basis:** The Official State Gazette (BOE) dated May 22, 2025 formalized this commitment, which is reflected in the ISCIII's framework.

This integration aims to position Spain as a strategic European hub for research and the use of biological samples and associated data.
In Málaga, work is done in full alignment with national and European strategies as part of this network of networks. Within it, we excel in:

- **Quality:** co-leading one of the working groups (Development of the UNE guidelines for the implementation of ISO 20387 for biobanks).
- **Strengthening citizen participation**, as a competitively selected member of the working group:
  - "7.2 Improve stakeholder engagement by continuing to strengthen the Stakeholder Forum Patients and Citizens' Pillar"

6.2.—ISBER stands for the International Society for Biological and Environmental Repositories. It is the only global organization dedicated to addressing the scientific, technical, legal, and ethical issues facing biobanks and sample repositories.
Principal Functions of ISBER

- **Global Harmonization:** It connects professionals across six continents to standardize the handling of biological and environmental samples.
- **Reference Guidelines:** It publishes key international standards, such as the Good Practice: Recommendations for Biobanks guideline. In 2025, the Málaga Biobank participated in the Spanish translation of the 5th Edition of ISBER's Good Practices (BP5), which is of great interest to the Spanish-speaking biobanking community.
- **Education and Networking:** It organizes global conferences and regional symposia to train researchers and technicians.
- **Technological innovation:** It serves as a forum for showcasing new conservation products and technologies.

6.3.-European Infrastructure for Translational Medicine **(EATRIS)** (https://eatris.eu): European infrastructure formed by more than 80 cutting-edge translational medicine research institutes. It has 4 platforms; IBIMA participates in 2 of them: Advanced Therapies Platform and Biomarkers Platform, providing cutting-edge technologies and synergies to advance the development of innovative therapies, vaccines, and diagnostics. The platform collaborates by offering collections of samples and associated clinical data to the scientific community and promoting direct international collaborations. A member of the team has been selected for a training program within EATRIS Plus that aims to forge ties and exchange knowledge, the foundation of all collaborative networking.

Training and Research Activities:

Type	Number
3.1.-Training Provided	13
Training Received	14
3.2.-Communications at conferences	6
3.3.-Participation in research projects	2
3.4.-Outreach activities	6

Among the **training provided**, the following is noteworthy:

- Tutor for 1 student; FCT Internship for Advanced Vocational Training in the Anatomic Pathology and Cytodiagnostics Laboratory. Atlántida Institute. 270 hours. 03/24/2025-06/17/2025.
- Tutor for two students participating in a dual-track internship program as part of the Cell Culture Specialization Course. IES Litoral 204 hours. 03/12/2025-05/30/2025
- Participation as lecturer in **I Expert Diploma in Clinical Research and Clinical Trials Monitoring. 15.00 ECTS**. 2024-2025 school year. Participation in 1 cancer clinical trial.
- Participation in teaching for the **Master's Degree in Biomedical Research on Diabetes and Obesity**. 60 ECTS credits. 2022-2023 school year. Participation in 1 cancer clinical trial.
- Online Clinical Session (Webinar): Biobank of the Andalusian Public Healthcare System in the clinical field. IAVANTE. 10/16/2024 III Ed.
- Online Course: "Management of samples for research" organized by the SSPA biobank, accredited by the Andalusian Healthcare Quality Agency (ACSA).
- Organization and speaker for the 1st and 2nd editions of the course on support structures for biomedical research organized by the training unit of the Virgen de la Victoria University Hospital. GESFORMA.
- Speaker at the 2nd series of sessions of the HUCS Research Unit. "Best Practices in the Management of Biological Samples and the Operation of Biobanks for Biomedical Research." 10/15/2025.

Among the **training provided**, the following is noteworthy:

- 2025-2026 school year. Specialization Course in Cell Cultures. 600 hours. Cesur.
- 01/14/2025 Course: "Incident and Nonconformity Management Focused on Audits." 5 hours. Online. SSPA Biobank.
- 01/15/2025. "Gene Expression Microarrays." 62 hours. Online. IFAPES
- 01/06/2025: "MOLECULAR BIOLOGY TECHNIQUES APPLIED TO ANATOMIC PATHOLOGY." 30 hours. Online. TECNOS.
- 01/06/2025: FUNDAMENTAL PRINCIPALS OF BIOETHICS. ETHICAL DILEMMAS AND CODE OF ETHICS. 50 hours. Online. Regional Ministry of Health of the Regional Government of Galicia.
- 01/06/2025 PATIENT AUTONOMY, INFORMATION, AND CLINICAL DOCUMENTATION. LAW 41/2002, OF NOVEMBER 14. 50 hours. Online. Regional Ministry of Health of the Regional Government of Galicia.

- 01/17/2025 REGISTRATION AND RECEIPT OF REQUESTS THROUGH THE RESEARCHER PORTAL AND CATALOG OF SAMPLES AND DATA FROM THE SSPA BIOBANK. 5 hours. Online. SSPA Biobank.
- 02/19/2025: Theoretical and Practical Foundations of Cytogenetics and Flow Cytometry in the Characterization of Multipotent and Pluripotent Cells. 20 hours. In person. SSPA Biobank.

Conferences:

- Attendance at the 11th CONFERENCE OF THE NATIONAL ASSOCIATION OF RESEARCH ETHICS COMMITTEES (ANCEI) "Ethical Safeguards for the Advancement of Health Technology." In-person, Salamanca:

  POSTER:

  – Strategies to ensure proper completion of informed consent within a biobank.

  POSTER:

  – Ethical aspects of creating strategic collections within a biobank.

  ORAL PRESENTATION:

  – INTELLIGENCE AND BIG DATA: New challenges for Research Ethics Committees in Andalusia. 11th ANCEI Conference
- Attendance at the 3rd Platforms Conference organized by the ISCIII:

  POSTER: THE SSPA BIOBANK IN THE ERC-2023-STG PROGRAM – ERC STARTING GRANTS, ORACLE PROJECT:

  – Essential support for research on predicting acute myocardial infarction using artificial intelligence: 3rd ISCIII Platforms Conference.

  POSTER: Spanish translation of the 5th edition of ISBER's Good Practices: an example of a collective effort. 3rd ISCIII Platforms Conference.

  POSTER: Optimization of traceability and management of biological samples from clinical trials through the biobank information system (BIMS). 3rd ISCIII Platforms Conference.
- Attendance at the BBMRI-ERIC ACADEMY SYMPOSIUM Conference "Ethical, Legal, and Societal Aspects in View of Recent EU Legislation."

Dissemination activities:

As dissemination activities of the Biobank ECAI to the public, the following should be mentioned:

1. **Conference** International Day of Women and Girls in Science. Outreach session at IES Litoral, Málaga.
2. **Conference** with the LUKIS Foundation, a national patient association.
3. **Outreach session** at IES Los Boliches, Fuengirola.
4. Coordination and implementation of **workshops** for the 2025 European Researchers' Night.
5. Guest **speaker** at the 12th Sjögren's Syndrome Public Awareness and Scientific Conference.
6. **Open house** with patient associations: Málaga Lupus and Autoimmune Diseases Association (ALMA), AFIBROMA Fibromyalgia Association "WE ARE NOT INVISIBLE," Spanish Association Against Cancer in Málaga, Málaga Association of Anticoagulated and Coronary Patients (APAM), Málaga Parkinson's Association, Spanish Association for People with Obesity and the Treatment of Obesity (ASEPO), Héroes Foundation, Andalusian Sjögren's Syndrome Association, Adima – Diabetes Málaga, and Alerma.

Other notable results:

- Adaptation a SSPA of the Biobank Information System for clinical trials management.
- It is important to note that during the 2024–2025 period, the unit faced external environmental and energy challenges. Far from being setbacks, these incidents served as real-world tests for safety protocols, thereby strengthening the Emergency Plan.

- Notable new services and innovations introduced include the creation and implementation of the **Donor Portal** , developed thanks to autonomous community funding received for this competitive public innovation project. This portal facilitates real-time citizen participation in biomedical research in an easy and accessible way. Donors can consult the results of the research projects they have participated in, manage their informed consent forms, and consult the availability of samples, among other options. The results of this project have been protected through an intellectual property registration. The project received the IBIMA Plataforma BIONAND 2022 Award for innovations transferred to clinical practice for the results obtained. The **Researcher's Portal** was also created (Intellectual Property Registry FIMABIS-21008) in coordination with the SSPA biobank, which makes it possible to manage the entirety of an application online. In addition, the ECAI is working to better the website so as to improve user access to the platform.
- Achievement of the objectives contained in the public-private agreement between Biobanco and the company 300K Solution (Ref. AC23303).
- User satisfaction was greater than 8.5.

In conclusion, in light of the results obtained in 2025, the Biobank ECAI has established itself not only as an essential infrastructure for scientific support, but also as a strategic hub for innovation and sustainability within the hospital setting and the research institute. The consolidation of invoicing procedures and the involvement of the entire technical team ensure a structure that is approaching self-sufficiency. Furthermore, securing competitive national funding and agreements with companies (such as 300K Solutions) ensures long-term viability. The implementation of advanced services (new protocols for high-volume PBMC isolation and organoid protocols) positions the ECAI as a highly specialized unit capable of meeting the most demanding requirements of precision medicine.

Also noteworthy is the development of specific procedures for including the service in commercial clinical trial agreements, which facilitates the work of hospital researchers and makes the center more attractive to the pharmaceutical industry.

Finally, agreements with patient associations (e.g., the Lukis Foundation) and collaboration with the Provincial Ethics Committee reinforce the Biobank's image as an organization committed to ethics and which is close to the public.

Location: This platform is located in the basement of Pavilion 5 of the Civil Hospital, in the research laboratory on the first floor of the Virgen de la Victoria University Hospital, and at the institute's research facilities at the Costa del Sol University Hospital.

ANIMAL EXPERIMENTATION (UMA)

Maintenance, breeding, and housing of the animals used in different experimental procedures in ongoing research projects.

Services offered:

- Acquisition of animal models.
- Mouse/rat breeding and maintenance, transgenic models.
- Technical support service for performing experimental procedures.
- Advising on regulatory requirements for animal experimentation.
- Facilities:
  - Breeding unit for animals with an SPF biological barrier,
  - 3 laboratories for processing samples and preparing reagents.
  - Service for booking and using facilities for animal surgical procedures.
  - Service for booking and using facilities for performing behavioral studies.
- Advising:
  - Service or advising on experimental and behavioral procedures.
  - Service or advising for breeding and reproduction.
  - Advising on animal welfare and standardization of animal models.
- Training:
  - Training on basic experimental techniques.
  - Use of experimental, surgical, and behavioral devices.

Coordinator: Mr. Ricardo González Carrascosa
Personnel in 2025: 2 caretaker technicians, 3 breeding and procedures technicians, 4 assistants, 1 team leader, and 1 administrative assistant.
Location: This platform is located in the University of Málaga Animal Experimentation building.

ANIMAL EXPERIMENTATION (PTA BUILDING)

The animal housing service in the IBIMA Plataforma BIONAND building is a research support service authorized by the Regional Ministry of Agriculture and Fishing of the Regional Government of Andalusia in 2013. It is registered in the Andalusian Livestock Farm Registry (REGA) with code ES290670001687. Its objective is to provide housing for experimental animals, facilities, material, equipment, and advising necessary to conduct pre-clinical trials on the technologies and products developed at the center both for research groups and companies. The service has the necessary facilities and equipment to work with rats, mice, and zebrafish.

Rodent housing services:

The rodent facility has the capacity to house approximately 170 rats and 2,200 mice, and this capacity can be expanded.

Services offered:

- Housing of laboratory rats and mice.
- Centralized supply of animal diets, shavings, sawdust, cages, racks, feeding bottles, etc.
- Provision of special diets for specific physiological or pathological studies.
- Type II special biological waste management service.
- Maintenance and care of animals in special conditions (temperature, light, humidity, sterile environment, etc.) during the conduct of the experiments that require them.
- Technical support service for performing experimental procedures (animal handling, routes of administration, sample collection, etc.).
- Rat and mouse breeding and maintenance service.

Zebrafish housing services:

Zebrafish housing in the center was authorized by the Regional Ministry of Agriculture and Fisheries in 2014. It has capacity to hold around 2000 zebrafish in 2 racks with 50 tanks each, with the possibility of expanding this capacity in the future.

Services offered:

- Zebrafish housing.
- Advising on zebrafish handling, linecrossing, growth, and development
- Maintenance of zebrafish wild-type lines.

The animal housing facility has its own Animal Experimentation Ethics Committee that includes 5 members responsible for evaluating all animal experimentation projects to be carried out in the center. Approval must be requested from the Regional Ministry of Agriculture, Fisheries, Water, and Rural Development.

Results:

- In 2025, the animal housing ECAI provided services for eight animal experimentation projects, all of which involved mice.
- The IBIMA Plataforma BIONAND Animal Experimentation Ethics Committee (CEEA) evaluated four animal experimentation projects in 2025.

Scientific Manager: Mr. José María Pérez Pomares
Personnel in 2025: 2 Technicians. One is shared with the Cell Culture ECAI.
Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

BIOINFORMATICS

The Bioinformatics ECAI aims to serve as a research support unit, focusing especially on the methodological support of projects, the conduct of bioinformatics analyses, and the promotion of technological innovation.

NOTABLE SERVICES

GENOMICS

- Detection of variants: SNPs, InDels, rare variants.
- Association studies on genomic data (DNA-Seq, ATAQ-Seq, CHIP-Seq). Identification of variants associated with phenotypes (Quantitative Trait Loci (QTL)): GWAS (Genome Wide Association Study), ExWAS (Exome Wide Association Study), Targeted Association Study, Candidate Gene-Based Association Study.
- Variant annotation.

TRANSCRIPTOMICS

- Association studies on gene expression data (bulk RNA-Seq, small RNA-Seq, single-cell RNA-Seq). Identification of differentially expressed genes (DEGs) across phenotypes.
- Analysis of mRNA-miRNA interactions.
- Analysis of gene-gene interaction networks.

EPIGENOMICS AND METHYLATION

- Association studies using epigenomic data: EWAS (Epigenome Wide Association Study.
- Specialization in association studies using methylation and hydroxymethylation array data (Infinium HumanMethylation450K BeadChip, Infinium MethylationEPIC v1.0 BeadChip, Infinium MethylationEPIC v2.0 BeadChip). Identification of differentially methylated sites and regions across phenotypes (DMP, Differentially Methylated Positions; DMS, Differentially Methylated Sites; DMR, Differentially Methylated Regions).

MULTI-OMIC INTEGRATION VIA MIXOMICS

- Integration of data from various omic sources across different phenotypes.
- Identification of eQTLs (expression Quantitative Trait Loci): integration of gene expression data and genomic data.
- Identification of eQTMs (expression Quantitative Trait Methylation): integration of methylation data and genomic data.
- Integration of gene expression data and differentially methylated regions.

MACHINE LEARNING

- Dimensionality reduction analysis.
- Selection of sets of predictor variables and biomarkers: comparison and reduction of the number of predictor variables.
- Creation, comparison, and analysis of predictive models (classification and regression).
- Unsupervised clustering analysis.

DATABASE

- Design, development, management, and maintenance of databases, electronic data collection forms, and surveys in REDCap (www.project-redcap.org).
- Database and information management system auditing: refactoring, cleaning, standardization.
- Management and advising for the REDCap data management platform integrated into the Andalusian Health Service.

DATA MANAGEMENT PLAN

- Support for planning data protection from the design phase of the project or research study
- Support with the creation or review of the DATA MANAGEMENT PLAN.
- Creation of data protection impact assessments (DPIA).
- Preparation and management of data for distribution to repositories.
- Editing data for use in a data space.

GENERAL SERVICES

Proteomics and Metabolomics:

- Association studies using protein abundance/expression data.
- Analysis of post-translational modifications.
- Analysis of cytokine arrays.

Metagenomics and Microbiome:

- Taxonomic analysis of the microbiota: taxonomic groups and communities.
- Studies of relative abundance associated with phenotypes.

Enrichment analysis:

- Functional and structural enrichment studies using gene ontology, KEGG (Kyoto Encyclopedia of Genes and Genomes), Reactome, and hiPathia (HIgh throughput PATHway Interpretation and Analysis).

OTHER SERVICES

- Phenotypic quality assessment of patient and disease cohorts.
- Script design and process automation.
- Design of specialized tools, programs, and applications for biomedical research.
- Specialized consulting on bioinformatics tools for research.
- Consulting, assistance, and graphical and statistical support.
- Methodological consulting on experimental design and analysis.

Novelties 2025:

Services have been restructured to include new service areas such as:

- Machine learning
- Data Management Plan: including the development of EPID
- Data space management
- Analysis of gene-gene interaction networks
- Extraction and analysis of data from BPS.
- 4 specialized training courses were held
- Two dissemination actions on REDcap were carried out.

Coordinator: Mr. Andrés González Jiménez
Personnel in 2025: 3 technicians, distributed as follows:
- 1 specialist technical coordinator
- 2 specialist bioinformatics technician.

Main results 2025:

No. of services provided	No. of services in collaboration with other ECAIs	Interprovincial collaborations	Participation in international networks	Groups contacted to offer services	Hours of training provided
84	3	3	4	20	28

Distribution of services provided by subject area:



Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

CELLULAR BIOLOGY LABORATORIES

These laboratories offer the following services:

Cytometry Service:

- Cellular immunophenotyping. Characterization of cell subpopulations, activation status, receptor expression, and cellular mediators
- Cell separator

Cell Culture Service:

- Preparation and aliquoting of specific antibiotics for culture media, inactivation, and storage of fetal bovine serum. Preparation of culture media as well as medium for freezing cells and pipette maintenance.
- Processing of different biological samples: cell separation by density gradient, obtaining serum and plasma.
- Obtaining and isolation of primary cultures and cell lines
- Lymphocyte isolation and labeling for cell proliferation studies
- Cell freezing

Immunochemistry Department:

- Immunoassays

These laboratories offer comprehensive shared facilities for the institute's various research groups and potential external users. All researchers affiliated with the IBIMA Plataforma BIONAND have access to the facilities, which include a system for reserving equipment or services.

Coordinators: Ms. Cristobalina Mayorga, Mr. Manuel Macías, and Mr. Fernando Rodríguez de Fonseca.
Personnel in 2025: 3 Technicians
Location: These laboratories are located in pavilions 5 and 6 of the Civil Hospital, in the Regenerative Medicine laboratory of the Regional University Hospital of Málaga, and in the laboratory on the 1st floor of the Virgen de la Victoria University Hospital.

HISTOLOGY

The main objective of this platform is to provide support and scientific-technical advising for the processing of histological samples in the field of biomedical research.
Services:

- Sample preparation:
  - Fixation using cryosubstitution and aldehydes
  - Embedding in paraffin, resin, or OCT
  - Histochemistry of basic stains
  - Immunohistochemistry for antibody tissue labeling
- Histological slices:
  - Using the EXaC hard section method
  - Using conventional paraffin microtomy
  - Using a cryostat for cryosections
- Image acquisition and processing:
  - Sample analysis advising
  - Automated image acquisition using a slide loader up to 40x in brightfield, darkfield, and polarization.
  - Fluorescence image acquisition.
  - Histomorphometry
  - Brightfield, fluorescence, or polarization image analysis.

Coordinator: Iván Durán
Personnel in 2025: 1 Technician
Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

NANOIMAGING UNIT

The Nanoimaging Unit has been designed and optimized to provide highly varied, integrated technological support for biomedical research, with a special emphases on research based on nanotechnology, offering advanced services to internal and external users. This facility is accredited as a Singular Scientific and Technological Infrastructure (ICTS), as a node of the ICTS NANBIOSIS.

The unit brings together a wide range of state-of-the-art technologies and is divided into five departments, all of which are staffed by technical specialists:

- **Small animal preclinical imaging service.** Small animal (preclinical) imaging is a vital tool in biomedical research that allows for studying biological processes and potential drugs in animal models using non-invasive methods. This service offers some of the most relevant preclinical imaging types: magnetic resonance imaging (MRI), in vivo (In vivo Xtreme) bioluminescence and fluorescence imaging, nuclear imaging (PET/SPECT)), and X-ray computed tomography (CT). These techniques are essential for the preclinical evaluation and characterization of new diagnostic and therapeutic agents. The combined use of these technologies and new highly specific imaging probes are the basis of molecular imaging.
- **Magnetic resonance imaging (MRI).** This service is equipped with two high-resolution NMR spectrometers: a 400 MHz NMR spectrometer for routine experiments and a spectrometer with a larger magnetic field, 600 MHz, dedicated to high-resolution magic angle NMR spectroscopy (HR-MAS) and conventional spectroscopy of samples that require greater sensitivity. It also has a TD-NMR analyzer for low-field magnetic relaxivity measurements (1.44 T).
- **Electron Microscopy.** The service offers access to conventional transmission electron microscopy (TEM), Cryo-EM and Tomography, and high-resolution environmental scanning electron microscopy (SEM). In addition, the service has an outstanding infrastructure for preparing samples through cryo-immobilization. All equipment has been optimized for biological and nanomedical applications. Although biological and medical applications are the main objective of this service, it can also be used in other scientific and engineering fields, including quality control studies, failure analysis, etc.
- **Optical microscopy.** This facility houses an excellent range of optical microscopy facilities designed to support high quality biomedical research. The equipment includes conventional, confocal, multiphoton, and super-resolution microscopes as well as advanced processing software, such as IMARIS. **Magnetometry**, This service has a vibrating sample magnetometer (VSM) for characterizing the magnetic properties (magnetization, coercivity, magnetic susceptibility, hysteresis loop) of various materials, including ferromagnetic, paramagnetic, diamagnetic, and superparamagnetic materials.

Radioactive Facility (IRA3243), which consists of four rooms:

- **Molecular Nuclear Imaging.** The PET/SPECT/CT equipment is located here
- **Quality control and radiopharmacy.** For the production of new radiopharmaceuticals and their quality controls.
- **X-rays:** Room with an irradiator and In vivo Xtreme bioluminescence, fluorescence, and X-ray equipment
- **Radiochemistry.** For the radioactive labeling of molecules.

The equipment included in the different services of the unit is listed below:

1. SMALL ANIMAL PRECLINICAL IMAGING SERVICE:

- **Bruker MRI 9.4T:** Multinuclear imaging and spectroscopy system. Magnetic resonance imaging (MRI) is a very versatile technique that offers excellent morphological, functional, and physiological information.

In addition, significant advances made over the past few years in the development of highly sensitive contrast agents using nanotechnology approaches have brought MRI into the field of molecular imaging.

- **Bruker Albira SI:** Trimodal positron emission tomography, single-photon emission computed tomography, and X-ray computed tomography (PET/SPECT/CT) system. Positron emission tomography (PET) is a non-invasive diagnostic technique that allows for taking images of the animal's body that show the activity and metabolism of the body's organs. Radioactively-labeled substances that are distributed throughout the body are used. Single-photon emission computed tomography (SPECT) uses gamma rays that produce radioactive isotopes. These isotopes are introduced into the animal's body as part of biologically active molecules. The procedure is similar to that of positron emission tomography (PET), but in SPECT, it is the isotope that directly produces the gamma ray, while in PET, the isotope produces a positron which is then annihilated by an electron to produce the two gamma rays. These two gamma rays exit in opposite directions and their simultaneous detection makes it possible to locate the isotope in a more precise manner than in SPECT. However, SPECT is simpler because it can use isotopes that are easier to obtain and have a longer half-life.
- Computed tomography (CT) allows for taking high-quality 3D imaging of preclinical animal models based on the reconstruction of 2D X-ray images captured at different angles. Albira uses dedicated beds for mice and rats with built-in anesthetic gas. Different image-capturing modes allow users to balance capture time and image quality. The Albira software package automates the reconstruction process, while the PMOD software that is included allows users to perform advanced analysis and export data to popular formats such as DICOM. It allows for the possibility of combining CT data with fluorescence.
- **Bruker In-Vivo Xtreme**: Multimodal imaging system for rats and mice, BRUKER. The In-Vivo Xtreme is a multimodal optical and X-ray system for small animal imaging designed to combine sensitivity, speed, and flexibility for the widest range of molecular imaging applications. Equipped with a high-performance 58 mm f/1.3 lens and a 4MP back-illuminated CCD camera, the In-Vivo Xtreme is suitable for demanding intravital bioluminescence and fluorescence imaging challenges.

2. MAGNETIC RESONANCE SERVICE:

- **Bruker Avance 600 MHz NMR spectrometer**: High resolution spectrometer equipped with Prodigy TCI liquid cryoprobe, TXI room temperature probe, and HR-MAS (high-resolution magic angle spinning) probe. In biomedicine, the use of liquid state NMR studies has expanded from classical metabolic studies that use enriched stable isotope tracers to more recent applications in biofluid metabolomics (urine, plasma, CSF).
- Solid-state NMR, HR-MAS, allows for obtaining high-resolution spectra from intact tissue, i.e. without the need for any metabolite extraction procedure. HR-MAS spectroscopy is widely used for metabolomic studies, especially in cancer research, in which the metabolic profile (metabolome) of tumor biopsies can be characterized using only a few milligrams of intact tissue (tissue biopsy). The HR-MAS technique can also be used to characterize the structure and elucidate partially insoluble compounds.
- **Bruker Ascend 400 MHz NMR spectrometer**: High resolution spectrometer equipped with a BBFO Plus probe optimized for the direct detection of X-nuclei in the ^{31}P to ^{15}N range. Liquid NMR is a fundamental tool in both chemistry and biomedical research. Its applications in chemistry range from the elucidation of small molecule structures to studies of protein-ligand interactions.
- **Bruker Minispec (TD-RMN)**: This piece of equipment allows for measuring magnetic relaxation times, T1 and T2, at clinical fields, 1.44T. Relaxation measurements are fundamental in characterizing the magnetic compounds developed as MRI contrast agents.

3. OPTICAL MICROSCOPY SERVICE:

- **Zeiss LSM980 NLO Multiphoton Confocal Microscope:** Multiphoton confocal microscope with conventional and resonant scanning. Multiphoton (or two-photon) microscopy takes advantage of the near-simultaneous absorption of two or more photons that act to excite a fluorescent molecule with the combined energy of both photons. In practice, this means that low-energy infrared light can be used to see fluorescent molecules that are normally excited by high-energy blue and ultraviolet light. Using this method, fluorescent molecules can be visualized at much greater depths than with conventional microscopy. Infrared light is also much less damaging to living tissue than UV or blue excitation, making it ideal for viewing model organisms or tissue explants. The Zeiss LSM 980 NLO microscope combines confocal and multiphoton modes in one machine and it can easily switch between different modes.
- **Leica HyD SP5 Confocal Microscope**: Confocal microscope with conventional and resonant scanning. Confocal laser scanning microscopy is a very popular technique that uses a combination of laser illumination and a mask through a pinhole to ensure that only focal plane fluorescence reaches the detector. This avoids the characteristic blurring typical of conventional fluorescence microscopy and allows images to be captured as detailed optical slices and then used to build 3D models. Confocal microscopy is one of the most versatile techniques available in optical microscopy.
- **Nikon Eclipse TIRF/N-STORM fluorescence microscope**: This conventional fluorescent microscope is equipped with incubators for timelapse studies on live samples. Fluorescence microscopy offers a wide range of tools to visualize microscopic events. For many purposes, conventional widefield fluorescence microscopy remains the best choice. The CCD detectors used for conventional microscopy are usually more sensitive than the photomultiplier tubes used in confocal microscopes. As the camera captures the entire field of view simultaneously, it also allows for faster imaging. Examples where conventional microscopy may be more appropriate include visualization of individual molecules, receptors, or small organisms, such as bacteria and yeasts. The TIRF (Total Internal Reflection Fluorescence) technique combines the sensitivity of conventional fluorescence with selective illumination to enhance the contrast of features in close proximity to the coverslip. In addition, this equipment allows for performing super-resolution spectroscopy based on STORM (STochastic Optical Reconstruction Microscopy). Historically, the intrinsic diffraction of light has made it difficult to use fluorescence to distinguish structures less than 200 nm away. Super-resolution microscopy refers to techniques that selectively activate fluorescent molecules to map their position up to 10 times more accurately than conventional fluorescent microscopy. The Nikon N-Storm system is capable of locating molecules with a resolution of up to 20 nm.
- **Basic Nikon Eclipse Ti fluorescence microscope**: Conventional fluorescence microscope with incubators for timelapse studies on live samples.
- Perkin Elmer Operetta HCS (High-Content Screening) equipment: High-content screening (HCS) attempts to bridge the gap between microscopy and cytometry by providing large amounts of statistically useful and phenotypically rich data. High-content screening combines automated microscopy with customizable algorithms capable of detecting and quantifying many different types of phenotypic information in fixed and live cells. The HCS Operetta combines the quality of a spinning disk confocal microscope with Harmony HCS software, which contains many common algorithms such as nuclei and cell detection as well as the ability to detect complex phenotypes automatically using machine learning.

4. ELECTRON MICROSCOPY SERVICE:

- **Thermo Scientific-FEI Tecnai G2 20 Twin Transmission Electron Microscope:** In addition to the conventional applications of transmission electron microscopy, this equipment allows for more advanced studies, such as tomography-ET, cryo-ET, cryo-tomography, and EDS (Energy-Dispersive X-ray Spectroscopy).

- **Thermo Scientific-FEI Quanta 250 FEG Scanning Electron Microscope:** One of the most notable features of this equipment is that it is equipped to perform studies in environmental mode, ESEM (environmental scanning electron microscopy), wet-STEM (scanning transmission electron microscopy), and EDS (energy dispersive X-ray spectroscopy).

5. MAGNETOMETRY DEPARTMENT

- **VAM Lake Shore Cryotonics 8604 Magnetometer**: With this equipment, magnetization measurements at room temperature and as a function of temperature (between 2 and 400 K), determination of magnetic transition temperatures (Curie, Neel) in the previous range, magnetic granulometry for studies of small metallic particles and magnetic oxides; cyclic measurements of hysteresis; permeability; coercivity for soft materials; permanent magnets up to magnetic fields of 7 Teslas; and obtaining magnetization curves after cooling with and without a field (FC/ZFC curves).

6. SAMPLE PREPARATION ROOMS:

Electron Microscopy Service:

- Vitrobot Mark IV from Thermo Scientific-FEI, for sample preparation in aqueous solution for cryo-ET.
- LEICA EM UC7 Ultramicrotome, with LEICA EM FC7 cryoultramicrotomy module.
- LEICA EM AFS2 low-temperature freeze substitution and sample inclusion equipment with a LEICA EM FSP automatic reagent dispensing system.
- LEICA EM HPM 100 high-pressure freeze fixation equipment
- LEICA EM SCD 500 high-vacuum sample coating and metal coating system
- Glass knife preparation equipment for cryo-ultramicrotomy, LEICA EM KMR3 (cutting) and LEICA EM MP (mounting for collecting slices)
- LEICA DM1000 conventional optical microscope
- LEICA S4 E stereomicroscope with LEICA L2 illumination system
- Laboratory for embedding samples in resin (shared use laboratory)

Nuclear Magnetic Resonance Service:

- Class II biosafety hood
- Cold room (common use area)

7. RADIOACTIVE EQUIPMENT ROOMS:

- **Precision X-RAD 220XL irradiator.** Compact cabinet X-ray irradiator for higher energy irradiation studies, ideal for delivering high doses in biology and materials science. This system can be used to irradiate in vivo (rats and mice) and in vitro (cell cultures) models.

Scientific Manager: Dr. María Luisa García Martín
Coordinator: Dr. Mónica Feijóo Cuaresma
Personnel in 2025: 5 Technicians
Main results 2025:

- A total of 40 requests were responded to, with a total turnover of 87,000 euros.
- Twenty-eight training activities were carried out.
- Twenty teaching support activities were carried out.
- The unit was cited in 6 scientific articles published in 2025.
- More than 35 users belonging to 20 research groups used the Nanoimaging Unit's services.

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

CHEMISTRY

The unit's mission is to provide services to researchers from the IBIMA Plataforma BIONAND and associated laboratories as well as to visitors from other research institutes. We also contributed to conducing research projects and promoting cooperation among groups.

This service offers infrastructure and equipment for the synthesis and physical and chemical characterization of molecules and nanomaterials as well as for the evaluation of their interaction with biological samples. The platform is equipped with:

- Particle Analyzer by Dynamic Light Scattering (DLS) Particle Analyzer Malvern Nano ZS90 ZetaSizer
- NTA, Nanoparticle Tracking Analysis
- Four-glove dry chamber
- Varian UV-Vis Absorption Spectrometer (CARY-100 BIO-MELT)
- PerkinElmer LS-55 Plate Fluorescence Spectrometer
- FT/IR Infrared Spectrometer Jasco PS-4000
- HPLC chromatograph with UV-Vis and refractive index detectors. JASCO LC-2000-PLUS
- FPLC chromatograph with UV-Vis and electrochemical detectors. JASCO UV-2075
- GPC WATERS chromatograph: gel permeation or molecular exclusion chromatograph with photo diode array UV-Vis spectrometry detector, refractive index detector, light scattering detector, and fraction collector.
- MBraun MB-SPS-800 5-solvent drying system
- Lan Technics Polarimeter
- Melting point meter
- Liberty Blue 2.0 Peptide Synthesizer
- Agilent Cytation 5 Multimodal Plate Reader

Scientific Manager: José Juan Reina
Location: IBIMA Plataforma BIONAND building in Málaga TechPark.

The IBIMA Plataforma BIONAND center has chemical synthesis laboratories duly equipped with safety cabins, rotary evaporators, safety cabinets, etc. The Chemistry Platform is located at IBIMA Plataforma BIONAND and comprises several facilities/spaces:

- General Chemistry Laboratory (floor 1)
- Chemistry Unit (floor -1).

Operation:

- User self-service (own use).
- You must log in to most equipment with a username/password.
- This requires prior user authorization by the person in charge of the unit (request by email) after confirming that the user has mastered and knows how to operate the equipment to be used.
- Access to the Chemistry Unit room requires authorization to enter with a card.

ANNEXES

PUBLICATIONS

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-01	Padial, M; Rebollo, A; Jiménez-Salcedo, T; López, V; Avesani, CM; Lindholm, B; Qureshi, AR; Olveira, G	A Pilot Clinical Trial of a Nutrition Education Program on Quality of Life in CKD	CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY	7.1	D1	Article	2025
A-01	Soria-Utrilla, V; Vero, C; Romero-Zerbo, SY; Adarve-Castro, A; López-Urdiales, R; Herranz-Antolín, S; García-Almeida, JM; García-Malpartida, K; Ferrer-Gómez, M; Moreno-Borreguero, A; Luengo-Pérez, LM; Alvarez-Hernández, J; Aragón-Valera, C; Ocón-Bretón, MJ; García-Manzanares, A; Bretón-Lesmes, I; Serrano-Aguayo, P; Pérez-Ferre, N; López-Gómez, JJ; Olivares-Alcolea, J; Moreno-Martínez, M; Tejera-Pérez, C; García-Arias, S; Abad-González, AL; Alhambra-Expósito, MR; Zugasti-Murillo, A; Parra-Barona, J; Torrejón-Jaramillo, S; Abuin, J; Fernández-García, JC; Olveira, G	Biomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial	CLINICAL NUTRITION	7.4	D1	Article	2025
A-01	Llauradó. G; Cedo. L; Climent. E; Badia. J; Rojo-Martínez. G; Roux. JFL; Yanes. O; Vinaixa. M; Granado-Casas. M; Mauricio. D; Fernández-Veledo. S; Vendrell. J	Circulating short-chain fatty acids and Mediterranean food patterns. A potential role for the prediction of type 2 diabetes risk: The Di@bet.es Study	BMC MEDICINE	8.3	D1	Article	2025
A-01	Hernáez. A; Camps-Vilaró. A; Polo-Alonso. S; Subirana. I; Ramos. R; de Cid. R; Rodríguez-Artalejo. F; Elosua. R; Chirlaque. MD; Amiano. P; Bermúdez-López. M; Guevara. M; Cinza-Sanjurjo. S; Sánchez. MJ; de León. AC; Laclaustra. M; Rojo-Martinez. G; Guembe-Suescun. MJ; Perez-Gomez. B; Vega-Alonso. T; Toran-Monserrat. P; Lora-Pablos. D; Huerta. JM; Valdivielso. JM; Degano. IR; Felix-Redondo. FJ; Gandarillas. AM; Valdes. S; Mundet-Tuduri. X; Sánchez. PL; Martín-Sánchez. V; Rigo. F; Alonso-Sampedro. M; Moreno-Iribas. C; Martín-Escudero. JC; Delgado. E; Grau. M; Urrutia. I; Ovejero. D; Quintela. I; Martí-Lluch. R; Blay. N; Banegas. JR; Tizón-Marcos. H; Gómez. JH; Aizpurua. A; Castro-Boqué. E; Delfrade. J; Prieto-Díaz. MA; Rodríguez-Barranco. M; Almeida-González. D; Moreno-Franco. B; Oualla-Bachiri. W; Sayón-Orea. C; Plans-Beriso. E; Lozano. JE; López-Lifante. VM; Cancelas-Navia. P; Cabrera-Castro. N; Cambray. S; Zacarías-Pons. L; Fernández-Bergés. D; Donoso-Navarro. E; Maldonado-Araque. C; Franch-Nadal. J; Dorado-Díaz. PI; Villarín-Castro. A; Frontera-Juan. G; Gude. F; Andueza. N; Téllez-Plaza. M; Ares-Blanco. J; Cruz. R; Ribas-Aulinas. M; Barretina. J; Guallar-Castillón. P; Caínzos-Achirica. M; Colorado-Yohar. SM; Llorente. A; Diaz-Tocados. JM; Ardanaz. E; Micó-Pérez. RM; Fernandez-Martinez. NF; Rodríguez-Pérez. MD; Cenarro. A; Calle-Pascual. AL; Marrugat. J	Cohort profile: the CORDELIA study (Collaborative cOhorts Reassembled Data to study mEchanisms and Longterm Incidence of chronic diseAses)	EUROPEAN JOURNAL OF EPIDEMIOLOGY	5.9	D1	Article	2025
A-01	Romero-Zerbo. SY; Valverde. N; Claros. S; Zamorano-Gonzalez. P; Boraldi. F; Lofaro. FD; Lara. E; Pavia. J; Garcia-Fernandez. M; Gago. B; Martin-Montañez. E	New molecular mechanisms to explain the neuroprotective effects of insulin-like growth factor II in a cellular model of Parkinson's disease	JOURNAL OF ADVANCED RESEARCH	13	D1	Article	2025
A-01	Oscullo. G; Bekki. A; Olveira. C; Girón. R; García-Clemente. M; Maíz. L; Sibila. O; Golpe. R; Rodríguez-Hermosa. JL; Barreiro. E; Méndez. R; Prados. C; Rodríguez-López. J; de la Rosa. D; Martínez-García. MA	Persistent Blood Eosinophilia and Eosinopenia: Relationship with Outcomes in Bronchiectasis	ARCHIVOS DE BRONCONEUMOLOGIA	9.2	D1	Article	2025
A-01	Martínez-García. MA; Olveira. C; Girón. R; García-Clemente. M; Máiz. L; Sibila. O; Golpe. R; Rodríguez-Hermosa. JL; Barreiro. E; Méndez. R; Prados. C; Rodríguez-López; Oscullo. G; de la Rosa. D	Reliability of blood eosinophil count in steady-state bronchiectasis	PULMONOLOGY	6.4	D1	Article	2025
A-01	Martínez-Montoro. JI; Aparicio-Sánchez. JJ; Pimentel. B; Juárez-Campo. M; Alamillo. ML; Fernández-García. JC	Screening. prevalence. and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study	DIABETES RESEARCH AND CLINICAL PRACTICE	7.4	D1	Article	2025
A-01	Mela. V; Martín-Reyes. F; Oliva-Olivera. W; Cantarero-Cuenca. A; Sánchez-García. A; Sancho-Marín. R; González-Jimenez. A; Tomé. M; Moreno-Ruiz. FJ; Soler-Humanes. R; Fernández-Serrano. JL; Sanchez-Gallegos. P; Martínez-Moreno. JM; Tinahones. FJ; García-Fuentes. E; Garrido-Sánchez. L	Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-01	Guerrini. A; Dalla Rovere. L; Fernández-Jiménez. R; Hardy-Añón. C; Herola-Cobos. C; Garcia-Olivares. M; Fernández. JA; Sánchez. FH; Jiménez. VM; Aguilar. IV; Castro. AA; Khazrai. YM; Campa. F; García-Almeida. JM	The usefulness of the updated bioelectrical impedance vector analysis references for assessing malnutrition. sarcopenia and predicting mortality in hospitalized patients	CLINICAL NUTRITION	7.4	D1	Article	2025
A-01	Beato-Víbora. PI; Chico. A; Moreno-Fernandez. J; Azriel-Mira. S; Nattero-Chávez. L; Mora. RV; Alonso-Carril. N; Simó-Servat. O; Aguilera-Hurtado. E; Céspedes. LMR; de Adana. MR; Domínguez. M; Márquez-Pardo. R; Díaz-Soto. G; Martínez-Brocca. MA; Fernández. KA; Buesa. MA; Hernández. MC; Quirós. C	Transitioning between automated insulin delivery systems: A focus on personalisation	DIABETES RESEARCH AND CLINICAL PRACTICE	7.4	D1	Article	2025
A-01	Biagetti. B; Asanza. EC; García-Feijoo. P; Araujo-Castro. M; Berrocal. VR; Serra. G; Guerrero-Pérez. F; Cámara. R; Lamas. C; García. MDO; Vicente. A; Echarri. AI; Villar-Taibo. R; Rodríguez. MDM; Pérez-López. C; González-Molero. I; Ramirez. MNS; Hurtado. AG; Capristan-Diaz. V; Simo-Servat. A; Gallach. M; Pérez. ES; Rosa. VG; Civantos. S; Martinez-Saez. E; Garcia-Arabehety. J; Torre. EM; Aulinas. A; Iglesias. P; Díez. JJ; Bernabéu. I; Alvarez-Escolá. C; Puig-Domingo. M; Neuroendocrinology Area of the Spanish Society Endocrinology	Trends and Outcomes in Pituitary Apoplexy Management: A Spanish Observational Multicenter Study	NEUROSURGERY	3.9	D1	Article	2025
A-01	Navarro-Cerdán. JR; Pons-Suñer. P; Arnal. L; Arlandis. J; Llobet. R; Perez-Cortes. JC; Lara-Hernández. F; Moya-Valera. C; Quiroz-Rodriguez. ME; Rojo-Martinez. G; Valdés. S; Montanya. E; Calle-Pascual. AL; Franch-Nadal. J; Delgado. E; Castaño. L; García-García. AB; Chaves. FJ	A machine learning approach for type 2 diabetes diagnosis and prognosis using tailored heterogeneous feature subsets	MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING	2.6	Q2	Article	2025
A-01	Rehues. P; Guardiola. M; Amigo. N; Rojo-Martinez. G; Mallol-Parera. R; Ribalta. J	A Robust Multivariate Approach Unveils a 1H-NMR-Based Spectral Metabolomics Signature Predictive of Cardiovascular Disease in People with Type 2 Diabetes: A Prospective Di@bet.es Cohort Study	JOURNAL OF PROTEOME RESEARCH	3.6	Q2	Article	2025
A-01	Asanza. EC; Biroli. A; Pérez-López. C; Araujo-Castro. M; Cámara. R; Guerrero-Pérez. F; Vicente. A; Lamas. C; Serra. G; Echarri. AI; Ollero. MD; Molero. I; Villar-Taibo. R; Rodríguez. MDM; Feijoo. PG; Berrocal. VR; Sánchez. N; Hurtado. AG; Capristan-Díaz. V; Simó-Servat. A; Gallach. M; Pérez. ES; Rosa. VG; Modino. SC; Torre. EM; Aulinas. A; Iglesias. P; Diez. JJ; Rodriguez-Hernández. V; Puig-Pérez. A; Blangini. E; Bernabéu. I; Alvarez-Escolá. C; Sarria-Estrada. S; Puig-Domingo. M; Abelló. FA; Martínez-Sáez. E; Biagetti. B	Age-related differences in the clinical features and management of pituitary apoplexy: a cohort study	EUROPEAN JOURNAL OF ENDOCRINOLOGY	5.2	Q1	Article	2025
A-01	Andreo-López. MC; Contreras-Bolívar. V; Martínez-Heredia. L; Andújar-Vera. F; Becerra-García. D; González-Cejudo. T; González-Salvatierra. S; García-Fontana. C; García-Fontana. B; Muñoz-Torres. M	Alkaline Phosphatase as a Potential Biomarker of Muscle Function: A Pilot Study in Patients with Hypophosphatasia	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
A-01	Yang. CA; Batross. J; Ramirez. LAG; Chandler. J; Walker. D; Tran. V; Jones. DP; Olveira. G; Ziegler. TR; Tangpricha. V; Alvarez. JA	Assessment of the metabolome across the glucose tolerance spectrum in adults with cystic fibrosis hospitalized for pulmonary exacerbations	RESPIRATORY MEDICINE	3.1	Q2	Article	2025
A-01	Cuesta-Vargas. A; Arjona-Caballero. JM; Olveira. G; Román. DD; Bellido-Guerrero. D; García-Almeida. JM	Automatic Analysis of Ultrasound Images to Estimate Subcutaneous and Visceral Fat and Muscle Tissue in Patients with Suspected Malnutrition	DIAGNOSTICS	3.3	Q1	Article	2025
A-01	Díaz-Santiago. E; Moya-García. AA; Pérez-García. J; Yahyaoui. R; Orengo. C; Pazos. F; Perkins. JR; Ranea. JAG	Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks	FRONTIERS IN PHARMACOLOGY	4.8	Q1	Article	2025
A-01	Maruri-Aransolo. A; Quintana. E; Michelena-Gonzalez. M; Pastor-Vivero. MD; Alvarez. A; Girón. R; Alarcón. T; Luna-Paredes. C; Máiz. L; Vicente. S; de Valbuena. MR; Prados. MC; Castillo-Corullón. S; Selma. MJ; Solé. A; Cols-Roig. M; Mondéjar-López. P; Ruiz. EP; Olveira. C; Aguilera. PC; Ruiz. PB; Causapé. CL; Figuerola. J; Asensio. O; Caballero-Pérez. JD; Canton. R	Bronchopulmonary colonization patterns in Spanish people with cystic fibrosis: Results of a national multicentre study	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.5	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-01	Reyes-Garcia. R; Moreno-Pérez. O; Guillen-Morote. C; Modrego-Pardo. I; Doulatram-Gamgaram. VK; Cases. CC; Mendoza. NA; Tejera-Pérez. C; Cárdenas-Salas. J; Martínez-Fuster. S; Lardiés-Sánchez. B; Márquez-Pardo. R; Pinés. P; Tejera-Muñoz. A; Fernández-García. JC	Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide. Multicentre. Retrospective. Observational Study (Women_ENDO2S-RWD Substudy)	NUTRIENTS	5	Q1	Article	2025
A-01	García. IR; Pérez. NP; Torres. FG; Delgado. LO; Torralvo. FJS; López. MP; Marzalo. CF; Olveira. G	Comparison of the digestive tolerance of an oligomeric versus a polymeric oral nutritional supplement in people with anorexia nervosa. A randomised crossover clinical trial	EUROPEAN JOURNAL OF CLINICAL NUTRITION	3.3	Q2	Article	2025
A-01	Padial. M; Avesani. CM; García-Testal. A; Cana-Poyatos. A; Lindholm. B; Segura-Ortí. E	Dietary Needs. Barriers. and Facilitators Among Patients on Hemodialysis and Their Caregivers: The GoodRENal Project in Spain	JOURNAL OF RENAL NUTRITION	3.2	Q1	Article	2025
A-01	Gutiérrez. P; Jiménez. L; Martínez. J; Alba. C; Girón. MV; Olveira. G; Ruiz-Esteban. P; Olveira. C	Dry eye disease and morphological changes in the anterior chamber in people with cystic fibrosis	JOURNAL OF CYSTIC FIBROSIS	6	Q1	Article	2025
A-01	Moreno-Pérez. O; Reyes-Garcia. R; Guillen-Morote. C; Doulatram-Gamgaram. VK; Cases. CC; Mendoza. NA; Tejera-Pérez. C; Cárdenas-Salas. J; Martínez-Fuster. S; Lardiés-Sánchez. B; Márquez-Pardo. R; Pinés. P; Tejera-Muñoz. A; Fernández-García. JC; Modrego-Pardo. I	Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide. multicentre. retrospective. observational study (Renal_ENDO2S-RWD substudy)	CLINICAL KIDNEY JOURNAL	4.6	Q1	Article	2025
A-01	Vinicki. M; Pribic. T; Vuckovic. F; Frkatovic-Hodzic. A; Plaza-Andrades. I; Tinahones. F; Raffaele. J; Fernández-García. JC; Lauc. G	Effects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome	GEROSCIENCE	5.4	Q1	Article	2025
A-01	Barreiro. SC; Pelegrín. BG; Beneyto. BQ; Solana. CF; Aznar. CM; Rojo-Martínez. G; Torre. EM; Peralta. FG	Estimation of the incidence and prevalence of type 1 diabetes mellitus in children under 15 years of age in Spain	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.8	Q3	Article	2025
A-01	Lopez-Campos. JL; Tamayo. PG; Girón. MV; Delgado-Pecellín. I; Olveira. G; Carrasco. L; Reinoso-Arija. R; Olveira. C; Quintana-Gallego. E	Evaluation of Alpha1 Antitrypsin Deficiency-Associated Mutations in People with Cystic Fibrosis	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
A-01	Laborda-Illanes. A; Boutriq. S; Aranega-Martín. L; Castellano-Castillo. D; Sánchez-Alcoholado. L; Plaza-Andrades. I; Peralta-Linero. J; Alba. E; Fernández-García. JC; González-González. A; Queipo-Ortuño. MI	Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
A-01	Alonso. SP; Valdes. S; Doulatram-Gamgaram. VK	GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives	MEDICINA CLINICA	2.1	Q2	Article	2025
A-01	Barranco-Altirriba. M; Granado-Casas. M; Yanes. O; Capellades. J; Junza. A; Franch-Nadal. J; Vendrell. J; Llaurado. G; Valdés. S; García-Escobar. E; Bermúdez-Lopez. M; Valdivielso. JM; Lopez-Lifante. VM; Herrero-Alonso. C; Falguera. M; Vilanova. MB; Arteaga. I; Torán-Monserrat. P; Perera-Lluna. A; Castelblanco. E; Mauricio. D	Guanine and pregnenolone sulfate are associated with incident type 2 diabetes in two independent populations	FRONTIERS IN ENDOCRINOLOGY	4.6	Q1	Article	2025
A-01	Díaz-Cerezo. S; Artime. E; Redondo-Anton. J; Duque. N; Spaepen. E; Cruz. MAM; Arnas-Leon. C; Olveira. G; Rodríguez. IR; Alagarda. MTJ; Valdés. N; Merchante. AA; Masmiquel. L; Santos. MRD	Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study	PATIENT PREFERENCE AND ADHERENCE	2	Q2	Article	2025
A-01	Gil-Rodriguez. S; Berdugo-Gómez. M; Claros. S; Romero-Zerbo. SY; Mañas-Padilla. MC; Gómez-Roldán. MD; Blanco-Calvo. E; Garcia-Fernández. M; Santin. LJ	IGF2 modulates behavioral and hippocampal changes induced by chronic cocaine exposure during adolescence in mice	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR	2.5	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-01	Díez. JJ; Anda. E; Pérez-Corral. B; Paja. M; Alcázar. V; Sánchez-Ragnarsson. C; Orois. A; Romero-Lluch. AR; Sambo. M; Oleaga. A; Caballero. A; Alhambra. MR; Urquijo. V; Delgado-Lucio. AM; Fernández-García. JC; Doulatram-Gamgaram. VK; Dueñas-Disotuar. S; Martín. T; Peinado. M; Sastre. J	Impaired renal function in patients with permanent hypoparathyroidism after thyroidectomy: analysis of a nationwide cohort in Spain	ENDOCRINE	2.9	Q2	Article	2025
A-01	Soria-Utrilla. V; Piñar-Gutierrez. A; Sánchez-Torralvo. FJ; Adarve-Castro. A; Porras. N; Jimenez-Sánchez. A; Quintana-Gallego. ME; Olveira. C; Girón. MV; Olveira. G; Garcia-Luna. PP	Integrating Imaging and Nutrition: Chest CT Muscle Analysis in Adults with Cystic Fibrosis	NUTRIENTS	5	Q1	Article	2025
A-01	Martin-Reyes. F; Kentaoui-Bousellam. I; Ruiz-Malagón. AJ; Ho-Plágaro. A; López-Gómez. C; Herraiz-Vilela. M; Alcain-Martínez. G; Camargo-Camero. R; Martos-VanDussen. JV; Camacho-Martel. L; Gutiérrrez-Martínez. F; Arranz-Salas. I; Ortega-Jimenez. MV; Escamilla-Sánchez. A; Daza-González. JJ; Sanchiz-Cardenas. E; Rivas-Becerra. J; García-Fuentes. E; Rodríguez-Pacheco. F; Rodriguez-Diaz. C	Mesenteric adipose tissue in Crohn's disease alters the immune response of the ileal mucosa and increases angiogenesis and fibrosis	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
A-01	Biagetti. B; Asanza. EC; Pérez-López. C; Araujo-Castro. M; Camara. R; Guerrero-Pérez. F; Vicente. A; Lamas. C; Serra. G; Echarri. AI; Ollero. MD; Molero. IG; Villar-Taibo. R; Rodríguez. MDM; García-Feijoo. P; Berrocal. VR; Ramirez. MNS; Hurtado. AG; Capristan-Díaz. V; Simó-Servat. A; Gallach. M; Perez. ES; Rosa. VG; Civantos. S; Asensio-Wandosell. D; Martinez-Saez. E; Torre. EM; Aulinas. A; Iglesias. P; Diez. JJ; Bernabéu. I; Alvarez-Escolá. C; Puig-Domingo. M	Pituitary Apoplexy: Comorbidities. Management. and Outcomes-A Spanish Observational Multicenter Study	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.1	Q1	Article	2025
A-01	Alonso. SP; Colomo. N; Lago-Sampedro. A; Maldonado-Araque. C; García-Fuentes. E; Gutiérrez-Repiso. C; Tapia-Guerrero. MJ; Rueda. I; Sánchez. PO; Oualla-Bachiri. W; Calle-Pascual. A; Castaño. L; Delgado-Alvarez. E; Menéndez-Torre. E; Franch-Nadal. J; Urrutia. I; Girbés. J; Chaves. FJ; Montanya. E; Rojo-Martínez. G; Valdés. S	Population-based national incidence of thyroid dysfunction in Spain	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
A-01	Biagetti. B; Asanza. EC; Pérez-López. C; Berrocal. VR; Vicente. A; Lamas. C; Guerrero-Pérez. F; Simó-Servat. A; Serra. G; Echarri. AI; Ollero. MD; Molero. IG; Villar-Taibo. R; Rodríguez. MDM; García-Feijoo. P; Ramirez. MNS; Hurtado. AG; Capristan-Díaz. V; Camara. R; Gallach. M; Perez. ES; Rosa. VG; Civantos-Modino. S; Martinez-Saez. E; Torre. EM; Aulinas. A; Iglesias. P; Diez. JJ; Bernabéu. I; Alvarez-Escolá. C; Puig-Domingo. M; Araujo-Castro. M	Predictors of conversion to surgery in pituitary apoplexy: Insights from a Spanish multicenter observational study	JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY	3.3	Q2	Article	2025
A-01	Biagetti. B; Cardona-Arias. A; Torre. EM; Aulinas. A; Ruz-Caracuel. I; Centeno. RG; Gonzalez. L; Echarri. AI; Rodriguez. MDM; Paja. M; Guerrero-Perez. F; Castano. JP; Garcia. MDO; Novo-Rodriguez. C; Tenorio-Jimenez. C; Villar-Taibo. R; Bernabeu. I; Diaz-Lopez. E; Calatayud. M; Alvarez-Escola. C; Rojas-Marcos. PM; Recio-Cordova. JM; Lozano-Aida. C; Roca. QA; Aviles. MD; Mezquita. EL; Argueso. MF; Molero. IG; Alberoa. I; Idrobo. C; Achote. E; Martinez-Saez. E; Marazuela. M; Puig-Domingo. M; Hanzu. F; Araujo-Castro. M	Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION	3.5	Q2	Article	2025
A-01	Perea. V; Quirós. C; Herrera-Arranz. MT; Azriel-Mira. S; Wägner. AM; Beato-Vibora. P; Soldevila. B; Barquiel. B; Pardo. RM; Díaz-Soto. G; Picón. MJ; Colomo. N; Amigó. J; Climent. E; Durán-Martínez. M; Corcoy. R; Codina. M; Cuesta. M; Guedes. BV; Vinagre. I	Pregnancy outcomes with the pregestational use of Minimed 780G compared to Minimed 640G: findings from a multicenter cohort study	ACTA DIABETOLOGICA	2.9	Q2	Article	2025
A-01	Araujo-Castro. M; García-Centeno. R; González. L; Nobre. EL; Severino. MD; Goi. J; Pena. MMP; Torre. EM; Aida. CL; Novoa-Testa. I; Cordido. F; Sánchón. R; Guerrero-Pérez. F; Rodríguez. RO; Rodríguez-Jiménez. B; García. MDO; Echarri. AI; Simó-Servat. A; Rodríguez. MDM; Novo-Rodríguez. C; Calatayud. M; Villar-Taibo. R; Bernabéu. I; Tenorio-Jimenéz. C; Molero. IG; Iglesias. P; Blanco. C; De Lara. FVO; Aulinas. A; Roca. QA; Fano. MP; Martínez. AR; Cardoso. LM; Marques. P; Giustina. A; Marazuela. M; Puig-Domingo. M; Biagetti. B	Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly	PITUITARY	3.4	Q2	Article	2025
A-01	Climent. E; Hevilla. F; Padial. M; Barril-Cuadrado. G; Blanca. M; Jiménez-Salcedo. T; López-Picasso. M; Nogueira-Pérez. A; Olveira. G	Psychobiotic Protection of Nutritional Supplements and Probiotics in Patients Undergoing Hemodialysis: A Randomized Trial	NUTRIENTS	5	Q1	Article	2025
A-01	Dalla Rovere. L; Fernández-Jiménez. R; Guerrini. A; García-Olivares. M; Herola-Cobos. C; Hardy-Añón. C; Awol-Tanko. R; Hernandez-Sanchez. A; García-Almeida. JM	Role of Bioimpedance Phase Angle and Hand Grip Strength in Predicting 12-Month Mortality in Patients Admitted with Haematologic Cancer	CANCERS	4.4	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-01	Mucarzel. F; Peláez. PG; Utrilla. VS; Jiménez. RF; Candia. FP; Torralvo. FJS; Peláez. RB; Almeida. JMG; Olveira. G	Sex-specific CT-derived muscle and fat phenotypes in colon cancer: implications for nutritional and metabolic assessment	FRONTIERS IN NUTRITION	5.1	Q1	Article	2025
A-01	Fernandez-Garcia. Jose Carlos	Strategic health action and other calls for proposals	Nutricion hospitalaria	1.1	Q4	Review	
A-01	Oualla-Bachiri. W; Lago-Sampedro. A; García-Escobar. E; Maldonado-Araque. C; Doulatram-Gamgaram. V; García-Vivanco. M; Martín-Llorente. F; Garrido. JL; Delgado. E; Chaves. FJ; Castaño. L; Calle-Pascual. A; Franch-Nadal. J; Olveira. G; Valdés. S; Rojo-Martínez. G	Surfactant Protein D Mediates the Association Between Smoking and Type 2 Diabetes Mellitus Incidence in the Spanish Adult Population: Di@bet.es Study	JOURNAL OF XENOBIOTICS	4.4	Q1	Article	2025
A-01	Ruiz-Molina. Y; Padial. M; Martin-Bravo. MD; Garcia-Olivares. M; Porras. N; Chicharro. A; Mora-Robles. J; González-Jiménez. A; Sasso. CV; Olveira. G	Targeting Lymphedema in Overweight Breast Cancer Survivors: A Pilot Randomized Controlled Trial of Diet and Exercise Intervention	NUTRIENTS	5	Q1	Article	2025
A-01	Lago-Sampedro. A; Oualla-Bachiri. W; Maldonado-Araque. C; Valdés. S; González-Molero. I; Doulatram-Gamgaram. V; Delgado. E; Chaves. FJ; Castaño. L; Calle-Pascual. A; Franch-Nadal. J; Rojo-Martínez. G; García-Serrano. S; García-Escobar. E	The Interactive Effects of Fruit Intake Frequency and Serum miR-484 Levels as Biomarkers for Incident Type 2 Diabetes in a Prospective Cohort of the Spanish Adult Population: The Di@bet.es Study	BIOMEDICINES	3.9	Q1	Article	2025
A-01	Hysaj. O; Efthimiou. O; Collet. TH; Cappola. AR; Alwan. H; Gussekloo. J; Chaker. L; Kavousi. M; Azizi. F; Köttgen. A; Selvin. E; Trompet. S; Walsh. JP; Brown. SJ; Iacoviello. M; Dullaart. RPF; Bakker. SJL; Sgarbi. JA; Ittermann. T; Völzke. H; Benseñor. IM; Valdés. S; Maldonado-Araque. C; Psaty. BM; Wolters. FJ; Åsvold. BO; Del Giovane. C; Rodondi. N	Thyroid antibody status. thyroid function. and the risk of coronary heart disease and stroke: an individual participant data analysis from 14 cohorts	EUROPEAN JOURNAL OF ENDOCRINOLOGY	5.2	Q1	Review	2025
A-01	Araujo-Castro. M; Torre. EM; Lozano-Aida. C; Garcia-Centeno. R; Fernandez. LG; Idrobo. C; Achote-Rea. E; Echarri. AI; Rodriguez-Argullo. MDM; Paja. M; Guerrero-Perez. F; Castano. JP; Garcia. MDO; Novo-Rodriguez. C; Tenorio-Jimenez. C; Villar-Taibo. R; Bernabeu. I; Diaz-Lopez. E; Calatayud. M; Alvarez-Escola. C; Rojas-Marcos. PM; Recio-Cordova. JM; Aulinas. A; Roca. QA; Aviles. MD; Mezquita. EL; Fernandez-Argueeso. M; Molero. IG; Ruz-Caracuel. I; Aldecoa. I; Garcia. J; Martinez-Saez. E; Hanzu. F; Marazuela. M; Puig-Domingo. M; Biagetti. B	Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.1	Q1	Article	2025
A-01	Oscullo. G; Méndez. R; Olveira. C; Giron. R; Garcia-Clemente. M; Máiz. L; Sibila. O; Golpe. R; Rodríguez-Hermosa. JL; Barreiro. E; Prados. C; Rodríguez-Lopez. J; de la Rosa. D; Martinez-Garcia. MA	What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?-data from the RIBRON registry	JOURNAL OF THORACIC DISEASE	1.9	Q3	Article	2025
A-02	Soria-Utrilla. V; Vero. C; Romero-Zerbo. SY; Adarve-Castro. A; López-Urdiales. R; Herranz-Antolín. S; García-Almeida. JM; García-Malpartida. K; Ferrer-Gómez. M; Moreno-Borreguero. A; Luengo-Pérez. LM; Alvarez-Hernández. J; Aragón-Valera. C; Ocón-Bretón. MJ; García-Manzanares. A; Bretón-Lesmes. I; Serrano-Aguayo. P; Pérez-Ferre. N; López-Gómez. JJ; Olivares-Alcolea. J; Moreno-Martínez. M; Tejera-Pérez. C; García-Arias. S; Abad-González. AL; Alhambra-Expósito. MR; Zugasti-Murillo. A; Parra-Barona. J; Torrejón-Jaramillo. S; Abuin. J; Fernández-García. JC; Olveira. G	Biomarkers of oxidation. inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial	CLINICAL NUTRITION	7.4	D1	Article	2025
A-02	Boughanem. H; Párraga-Viúdez. MJ; Ojeda-Rodríguez. A; Romero-Cabrera. JL; Narváez. ERD; Lopez-Moreno. A; Torres-Peña. JD; Macías-González. M; Alcalá-Díaz. JF; Larriva. APAD; Pérez-Martínez. P; Delgado-Lista. J; Lopez-Miranda. J; Rangel-Zuñiga. OA	Circulating long non-coding RNAs as predictors of type 2 diabetes mellitus development: results from the CORDIOPREV study	CARDIOVASCULAR DIABETOLOGY	10.6	D1	Article	2025
A-02	Kulecka. M; O'Sullivan. J; Fitzgerald. R; Velikonja. A; Huseyin. CE; Laserna-Mendieta. EJ; Ruiz-Limón. P; Eckenberger. J; Vidal-Marin. M; Truppel. BA; Singh. R; Naik. S; Croft. NM; Temko. A; Zomer. A; MacSharry. J; Melgar. S; Deb. P; Sanderson. IR; Claesson. MJ	Combining mucosal microbiome and host multi-omics data shows prognostic potential in paediatric ulcerative colitis	NATURE COMMUNICATIONS	15.7	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-02	Shyam. S; Gómez-Martínez. C; Ni. JQ; Gaforio. JJ; Martínez-González. MA; Corella. D; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Lapetra. J; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Martín-Sánchez. V; Pintó. X; Delgado-Rodríguez. M; Matía-Martín. P; Vidal. J; Vázquez. C; Daimiel. L; Ros. E; Fernandez-Aranda. F; Hernández-Cacho. A; Buil-Cosiales. P; Sorli. J; Castañer. O; Garcia-Rios. A; Oncina-Canovas. A; Pérez-Farinós. N; Nafria. M; Casas. R; Martínez-Diz. S; Tojal-Sierra. L; Gómez-Pérez. AM; Toledo. E; Fernández-Carrión. R; Bayón. AM; Torres-Peña. JD; Compañ-Gabucio. L; Vázquez-Ruiz. Z; Babio. N; Fitó. M; Salas-Salvadó. J	COVID-19 and Cognitive Decline in Older Adults with High-Cardiovascular Risk: A Post Hoc Analysis	AGING AND DISEASE	6.9	D1	Article	2025
A-02	Escriche-Escuder. A; García-Almeida. JM; Vegas-Aguilar. IM; Pajares. B; Alba. E; Trinidad-Fernández. M; Roldán-Jiménez. C; Cuesta-Vargas. AI	Effect of a 12-week exercise program on phase angle in women with breast cancer	SUPPORTIVE CARE IN CANCER	3	D1	Article	2025
A-02	Martínez-Montoro. JI; Bandera. B; Gutiérrez-Bedmar. M; Gómez-Pérez. AM; Macías-González. M; Moreno-Indias. I; Tinahones. FJ	Effect of a ketogenic diet. time-restricted eating. or alternate-day fasting on weight loss in adults with obesity: a randomized clinical trial	BMC MEDICINE	8.3	D1	Article	2025
A-02	Martínez-Montoro. JI; Cornejo-Pareja. I; Díaz-López. A; Sureda. A; Toledo. E; Abete. I; Babio. N; Tur. JA; Martinez-Gonzalez. MA; Martínez. JA; Fitó. M; Salas-Salvadó. J; Tinahones. FJ; PREDIMED Plus Investigators	Effect of an intensive lifestyle intervention on cystatin C-based kidney function in adults with overweight and obesity: From the PREDIMED-Plus trial	JOURNAL OF INTERNAL MEDICINE	9.2	D1	Article	2025
A-02	Trenas. A; Perez-Velasco. MA; Bernal-López. MR; López-Carmona. MD; Gómez-Doblas. JJ; Martinez-Esteban. MD; Bouarich. O; Garcia-Casares. N; Fernández-Garcia. D; de Lucas. MDG; Gómez-Huelgas. R; Perez-Belmonte. LM	Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction. type 2 diabetes and obesity: a real-world study	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	D1	Article	2025
A-02	Pascual-Gonzalez. Mario; Jimenez-Partinen. Ariadna; Palomo. Esteban J; Lopez-Rubio. Ezequiel; Ortega-Gomez. Almudena	Hyperparameter optimization of YOLO models for invasive coronary angiography lesion detection and assessment.	Computers in biology and medicine	6.3	D1	Article	2025
A-02	Vázquez-Lorente. H; Hernández-Cacho. A; García-Gavilán. JF; Li. J; Ruiz-Canela. M; Belzer. C; Vioque. J; Corella. D; Fitó. M; Vidal. J; Konstanti. P; Moreno-Indias. I; Torres-Collado. L; Coltell. O; Martínez-González. MA; Clish. C; Castañer. O; Liang. LM; Babio. N; Dennis. C; Martínez-Montoro. JI; Atzeni. A; Tinahones. FJ; Hu. FB; Salas-Salvadó. J	Inflammatory dietary potential and gut microbiota in older adults with overweight or obesity and metabolic syndrome	FOOD RESEARCH INTERNATIONAL	8	D1	Article	2025
A-02	Gutierrez-Repisd. C; Diaz-González. BV; Garcia-López. MJ; Alvarez-Perez. J; Garrido-Sánchez. L; Moreno-Indias. I; Bautista-Castaño. I; Serra-Majem. L; Tinahones. FJ	Influence of taste and smell perception on weight loss induced by sleeve gastrectomy and its association with gut microbiota	SURGERY FOR OBESITY AND RELATED DISEASES	3.8	D1	Article	2025
A-02	Linares-Pineda. TM; Lendinez-Jurado. A; Piserra-López. A; Suárez-Arana. M; Pozo. M; Molina-Vega. M; Picón-César. MJ; Morcillo. S	Longitudinal DNA methylation profiles in saliva of offspring from mothers with gestational diabetes: associations with early childhood growth patterns	CARDIOVASCULAR DIABETOLOGY	10.6	D1	Article	2025
A-02	Ni. JQ; Hernández-Cacho. A; Nishi. SK; Babio. N; Belzer. C; Konstati. P; Vioque. J; Corella. D; Castañer. O; Vidal. J; Moreno-Indias. I; Torres-Collado. L; Coltell. O; Fito. M; Ruiz-Canela. M; Wang. DD; Tinahones. FJ; Salas-Salvado. J	Mediterranean diet. gut microbiota. and cognitive decline in older adults with obesity/overweight and metabolic syndrome: a prospective cohort study	BMC MEDICINE	8.3	D1	Article	2025
A-02	Boughanem. H; Torres-Peña. JD; Arenas-de Larriva. AP; Romero-Cabrera. JL; Gómez-Luna. P; Martín-Piedra. L; Rodríguez-Cantalejo. F; Tinahones. FJ; Serrano. EMY; Soehnlein. O; Perez-Martinez. P; Delgado-Lista. J; López-Miranda. J	Mediterranean diet. neutrophil count. and carotid intima-media thickness in secondary prevention: the CORDIOPREV study	EUROPEAN HEART JOURNAL	35.7	D1	Article	2025
A-02	Mela. V; Heras. V; Iesmantaite. M; García-Martín. ML; Bernal. M; Posligua-García. JD; Subiri-Verdugo. A; Martínez-Montoro. JI; Gómez-Pérez. AM; Banderas. B; Indias. IM; Tinahones. FJ	Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis	GUT	26.2	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-02	Hernández-Cacho. A; García-Gavilán. JF; Atzeni. A; Konstanti. P; Belzer. C; Vioque. J; Corella. D; Fitó. M; Vidal. J; Mela. V; Liang. LM; Torres-Collado. L; Coltell. O; Babio. N; Clish. C; Hernando-Redondo. J; Martínez-González. MA; Wang. FL; Moreno-Indias. I; Ni. JQ; Dennis. C; Ruiz-Canela. M; Tinahones. FJ; Hu. FB; Salas-Salvadó. J	Multi-omics approach identifies gut microbiota variations associated with depression	NPJ BIOFILMS AND MICROBIOMES	9.2	D1	Article	2025
A-02	Gomez-Casado. G; Jimenez-Gonzalez. A; Rodriguez-Muñoz. A; Tinahones. FJ; González-Mesa. E; Murri. M; Ortega-Gomez. A	Neutrophils as indicators of obesity-associated inflammation: A systematic review and meta-analysis	OBESITY REVIEWS	7.4	D1	Review	2025
A-02	Ni. JQ; Nishi. SK; Babio. N; Belzer. C; Konstati. P; Vioque. J; Corella. D; Castañer. O; Vidal. J; Moreno-Indias. I; Torres-Collado. L; Guillem-Saiz. P; Fitó. M; Ruiz-Canela. M; Hernández-Cacho. A; Tinahones. FJ; Salas-Salvadó. J	Nut consumption. gut microbiota. and cognitive function: findings from a prospective study in older adults at risk of cognitive decline	AGE AND AGEING	7.1	D1	Article	2025
A-02	Benítez-Ruiz. L; Repiso. CG; Tinahones. FJ; García-Casares. N	Obesity. Olfaction and Cognition: A Systematic Review	CURRENT OBESITY REPORTS	11	D1	Review	2025
A-02	Lorenzo. PM; Izquierdo. AG; Sajoux. I; Nuñez-Garcia. M; Gomez-Arbelaez. D; Zulet. MA; Abete. I; Baltar. J; de Luis. D; Tinahones. FJ; Martinez. JA; Casanueva. FF; Crujeiras. AB	Obesity-related osteopontin protein and methylation blood levels are differentially modulated by a very low-calorie ketogenic diet or bariatric surgery	CLINICAL NUTRITION	7.4	D1	Article	2025
A-02	Jiménez-Salva. M; Carmona-Segovia. A; Molina-Ramos. AI; García-Rodríguez. L; Puyol-Ruiz. F; Doncel-Abad. V; Romero-Cuevas. M; Serrano. A; Muñoz-García. A; Flores-López. M; Ortega-Gómez. A; Gutiérrez-Bedmar. M; Rodríguez-Capitán. J; Jiménez-Navarro. M; Pavón-Morón. FJ	Older adults with acute coronary syndrome: the impact of frailty and nutritional status on in-hospital complications	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	Article	2025
A-02	Toledo. M; Martínez-Martínez. S; Van Hul. M; Laudo. B; Eyre. E; Pelicaen. R; Puel. A; Altirriba. J; Gómez-Valadés. AG; Inderhees. J; Moreno-Indias. I; Pozo. M; Chivite. I; Milà-Guasch. M; Haddad-Tóvolli. R; Obri. A; Fos-Domènech. J; Tahiri. I; Llana. SR; Ramírez. S; Monelli. E; Schwaninger. M; Cani. PD; Nogueiras. R; Claret. M	Rapid modulation of gut microbiota composition by hypothalamic circuits in mice	NATURE METABOLISM	20.8	D1	Article	2025
A-02	Martínez-Montoro. JI; Aparicio-Sánchez. JJ; Pimentel. B; Juárez-Campo. M; Alamillo. ML; Fernández-García. JC	Screening. prevalence. and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study	DIABETES RESEARCH AND CLINICAL PRACTICE	7.4	D1	Article	2025
A-02	Mela. V; Martín-Reyes. F; Oliva-Olivera. W; Cantarero-Cuenca. A; Sánchez-García. A; Sancho-Marín. R; González-Jimenez. A; Tomé. M; Moreno-Ruiz. FJ; Soler-Humanes. R; Fernández-Serrano. JL; Sanchez-Gallegos. P; Martínez-Moreno. JM; Tinahones. FJ; García-Fuentes. E; Garrido-Sánchez. L	Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	Article	2025
A-02	Guerrini. A; Dalla Rovere. L; Fernández-Jiménez. R; Hardy-Añón. C; Herola-Cobos. C; Garcia-Olivares. M; Fernández. JA; Sánchez. FH; Jiménez. VM; Aguilar. IV; Castro. AA; Khazrai. YM; Campa. F; García-Almeida. JM	The usefulness of the updated bioelectrical impedance vector analysis references for assessing malnutrition. sarcopenia and predicting mortality in hospitalized patients	CLINICAL NUTRITION	7.4	D1	Article	2025
A-02	Ruiz-Canela. M; Corella. D; Martinez-González. MA; Babio. N; Martinez. JA; Forga. L; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Santos-Lozano. JM; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Martin-Sánchez. V; Riera-Mestre. A; Delgado-Rodriguez. M; Matia-Martin. P; Vidal. J; Vázquez. C; Daimiel. L; Buil-Cosiales. P; Shyam. S; Sorli. JV; Castañer. O; Garcia-Rios. A; Torres-Collado. L; Gómez-Gracia. E; Zulet. MA; Konieczna. J; Casas. R; Cano-Ibáñez. N; Tojal-Sierra. L; Bernal-López. RM; Toledo. E; Garcia-Gavilán. J; Fernández-Carrión. R; Goday. A; Arenas-Larriva. AP; González-Palacios. S; Schroeder. H; Ros. E; Fitó. M; Hu. FB; Tinahones. FJ; Salas-Salvadó. J	Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes A Secondary Analysis of a Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE	15.4	D1	Article	2025
A-02	Vegas-Aguilar. I; Fernández-Jiménez. R; Cornejo-Pareja. I; Amaya-Campos. MD; Guirado-Peláez. P; Montero-Madrid. N; Vidal-Suarez. A; Martín-Fontalba. MA; Simon-Frapolli. V; Tinahones. FJ; García-Almeida. JM	Adherence to β-hydroxy-β-methylbutyrate-Enriched Oral Nutritional Supplements Enhances Survival and Nutritional Recovery in Malnourished Outpatients: Prognostic Insights	NUTRIENTS	5	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-02	Montero-Benitez. MZ; Carmona-Llanos. A; Fernández-Jiménez. R; Román-Jobacho. A; Gómez-Millán. J; Modamio-Molina. J; Cabrera-Cesar. E; Vegas-Aguilar. I; Amaya-Campos. MD; Tinahones. FJ; Molina-Montes. E; Cayón-Blanco. M; García-Almeida. JM	AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia. and Its Correlation with Morphofunctional Assessment Techniques	CANCERS	4.4	Q2	Article	2025
A-02	Mucientes. A; Núñez. GMM; Mena-Vázquez. N; Lisbona-Montañez. JM; Manrique-Arija. S; González-Jiménez. A; Ruiz-Limón. P; Garcia-Studer. A; Ortiz-Márquez. F; Cano-García. L; Fernández-Nebro. A	Analysis of epigenetic biomarkers for diagnosis and assessment of severity in rheumatoid arthritis: a cross-sectional study	ARTHRITIS RESEARCH & THERAPY	4.6	Q1	Article	2025
A-02	Quetglas-Llabrés. MM; Díaz-López. A; Bouzas. C; Monserrat-Mesquida. M; Salas-Salvadó. J; Ruiz-Canela. M; Martínez. JA; Santos-Lozano. JM; García. S; Estruch. R; López-Miranda. J; Romaguera. D; Tinahones. FJ; García-Fernández. M; Mas-Fontao. S; Matía-Martín. P; Vioque. J; Bueno. A; Babio. N; Tur. JA; Sureda. A	Association Between Oxidative-Inflammation Biomarkers and Incident Chronic Kidney Disease in People with High Cardiovascular Risk: A Nested Case-Control Study	ANTIOXIDANTS	6.6	Q1	Article	2025
A-02	Cuesta-Vargas. A; Arjona-Caballero. JM; Olveira. G; Román. DD; Bellido-Guerrero. D; García-Almeida. JM	Automatic Analysis of Ultrasound Images to Estimate Subcutaneous and Visceral Fat and Muscle Tissue in Patients with Suspected Malnutrition	DIAGNOSTICS	3.3	Q1	Article	2025
A-02	Hinojosa-Nogueira. D; Díaz-Perdigones. CM; García-López. MJ; Marcos. A; Portillo. MP; Lamuela-Raventós. RM; Subiri-Verdugo. A; Nova. E; Milton-Laskibar. I; Galkina. P; Tinahones. FJ; Moreno-Indias. I	Beer-Derived (Poly)phenol Metabolism in Individuals With and Without Metabolic Syndrome: A Comparative Dietary Intervention	MOLECULES	4.6	Q2	Article	2025
A-02	Sanmartin-Sánchez. A; Fernández-Jimenez. R; Olivares-Alcolea. J; Cabrera-Cesar. E; Espildora-Hernández. F; Vegas-Aguilar. I; Amaya-Campos. MD; Simón-Frapolli. VJ; Villaplana-Garcia. M; Cornejo-Pareja. I; Sánchez-Garcia. A; Murri. M; Guirado-Peláez. P; Vidal-Suárez. A; Garrido-Sánchez. L; Tinahones. FJ; Velasco-Garrido. JL; Garcia-Almeida. JM	Cachexia Phenotyping Through Morphofunctional Assessment and Mitocondrial Biomarkers (GDF-15 and PGC-1α) in Idiopathic Pulmonary Fibrosis	NUTRIENTS	5	Q1	Article	2025
A-02	Paulí. S; Oliveras-Cañellas. N; Moreno-Navarrete. JM; Castells-Nobau. A; Ortega. FJ; Rodriguez-Hermosa. JI; Castro. E; Zhang. BR; Zhou. Y; Gómez-Ambrosi. J; Crujeiras. AB; Rangel-Zuñiga. OA; Garrido-Sanchez. L; Becerril. S; Pardo. M; Romero-Cabrera. JL; Gutierrez-Repiso. C; Carreira. MC; Macias-Gonzalez. M; Martinez-Olmos. MA; Frühbeck. G; Seoane. LM; López-Miranda. J; Tinahones. FJ; Diéguez. C; Mayneris-Perxachs. J; Fernández-Real. JM	Cellular composition and transcriptomics of subcutaneous adipose tissue linked to blood glycated haemoglobin	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	3.6	Q1	Article	2025
A-02	Iboleon-Jimenez. A; Sánchez-Quintero. MJ; Carmona-Segovia. ADM; Sojo. B; Fernández-Ramos. AM; García-Rodríguez. L; Molina-Ramos. AI; García-Pinilla. JM; Jimenez-Navarro. M; Ortega-Gomez. A	Circulating mitochondrial biomarkers in acute coronary syndrome	FRONTIERS IN MEDICINE	3	Q1	Article	2025
A-02	Sánchez-Quintero. M; Iboleón. A; Chaves. LM; Vilumbrales. BP; Carmona-Segovia. ADM; López. PM; Romero-Cuevas. M; Rodríguez-Capitán. J; Becerra-Muñoz. VM; Pavón-Morón. FJ; Murri. M	Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement	BIOLOGICS-TARGETS & THERAPY	3.4	Q2	Article	2025
A-02	Vargas-Molina. S; García-Sillero. M; Maroto-Izquierdo. S; Baz-Valle. E; Bautista-Mayorga. B; Murri. M; Schoenfeld. BJ; Benítez-Porres. J	Cluster sets and traditional sets elicit similar muscular hypertrophy: a volume and effort-matched study in resistance-trained individuals	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY	2.7	Q2	Article	2025
A-02	Gomez-Casado. G; Alonso-Titos. J; Gonzalez-Mesa. E; Ortega-Gomez. A	Compatibility of Post-Kidney Transplant Immunosuppression Therapy with Lactation	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Review	2025
A-02	Boughanem. H; de Larriva. APA; Camargo. A; Torres-Peña. JD; Ojeda-Rodriguez. A; Alcala-Diaz. JF; Romero-Cabrera. JL; Rangel-Zuñiga. OA; Rodríguez-Cantalejo. F; Soehnlein. O; Macias-Gonzalez. M; Tinahones. FJ; Perez-Martinez. P; Delgado-Lista. J; López-Miranda. J	Decreased Neutrophils Are Associated With Reduced Risk of Type 2 Diabetes Incidence: Results From the CORDIOPREV Study	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.1	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-02	Vázquez-Lorente. H; Ni. JQ; Paz-Graniel. I; Toledo. E; Corella. D; Castañer. O; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Lapetra. J; Serra-Majem. L; Bouzalmate-Hajjaj. A; Tur. JA; Pérez. RMM; Fanlo. M; Delgado-Rodríguez. M; Bustelo. AB; Vidal. J; Vázquez. C; Daimiel. L; Ros. E; Fernández-Aranda. F; Rognoni. T; Babio. N; Asensio. EM; Pérez-Vega. KA; Garcia-Rios. A; Compañ-Gabucio. L; Cueto-Galán. R; Zulet. MA; Nafria. M; Casas. R; Cano-Ibáñez. N; Tojal-Sierra. L; Gómez-Pérez. AM; Goñi. N; Sorli. JV; Zomeño. MD; Arenas-Larriva. AP; Jiménez-Sellés. P; Basterra-Gortari. J; Fitó. M; Salas-Salvadó. J	Dietary vitamin D intake and 2-year changes in cognitive function in older adults with overweight or obesity and metabolic syndrome	GEROSCIENCE	5.4	Q1	Article	2025
A-02	Jimenez-López. R; Martin-Chaves. L; Gutierrez-Garcia. AM; Carmona-Segovia. AD; Mora-Ordoñez. B; Sánchez-Garcia. AM; Fernández-Romero. L; Murri. M; Sánchez-Quintero. MJ; Berteli-Garcia. G; Sánchez-Chaparro. MA; Bodi. V; Rodriguez-Capitán. J; Jimenez-Navarro. M; Pavón-Morón. FJ; Romero-Trevejo. JL	Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy	FRONTIERS IN MEDICINE	3	Q1	Article	2025
A-02	Carmona-Bayonas. A; alvarez-Escolá. C; Navarro. IB; Cubero. JH; Cruz. MAM; Garcia-Centeno. R; Iglesias. C; Garcia-Donas. J; Picón. MJ; Paja. M; Batanero. LG; García. L; Gordoa. TA; López. C; Hanzu. F; Martínez-Trufero. J; Febrero. B; Saiz-López. P; Carrera. CB; Cajal. TR; Veiguela. B; Gressani. O; Valdes. N; Jimenez-Fonseca. P	Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.1	Q1	Article	2025
A-02	Boughanem. H; Gutierrez-Mariscal. FM; Larriva. APAD; Torres-Peña. JD; Romero-Cabrera. JL; Rangel-Zuñiga. OA; García-Fernández. H; Podadera-Herreros. A; Rodríguez-Cantalejo. F; Soehnlein. O; Macias-Gonzalez. M; Tinahones. FJ; Serrano. EMY; Perez-Martinez. P; Delgado-Lista. J; López-Miranda. J	Effect of long-term Mediterranean versus low-fat diet on neutrophil count. and type 2 diabetes mellitus remission in patients with coronary heart disease: results from the CORDIOPREV study	NUTRITION & DIABETES	5.2	Q1	Article	2025
A-02	Garrigós. M; García-Ruiz. O; Enkvist. CR; García-López. MJ; Moreno-Indias. I; Ruiz-López. MJ; Veiga. J; Figuerola. J; Videvall. E; de la Puente. J	Effects of avian Plasmodium exposure on the microbiota of Culex pipiens	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
A-02	Vinicki. M; Pribic. T; Vuckovic. F; Frkatovic-Hodzic. A; Plaza-Andrades. I; Tinahones. F; Raffaele. J; Fernández-García. JC; Lauc. G	Effects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome	GEROSCIENCE	5.4	Q1	Article	2025
A-02	de la Fuente-Vivas. D; Cappitelli. V; García-Gómez. R; Valero-Díaz. S; Amato. C; Rodriguéz. J; Duro-Sánchez. S; von Kriegsheim. A; Grusch. M; Lozano. J; Arribas. J; Casar. B; Crespo. P	ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility	MOLECULAR ONCOLOGY	4.5	Q2	Article	2025
A-02	Gomez-Casado. G; Saldaña-Garcia. N; Gonzalez-Mesa. E; Ortega-Gomez. A	Etiology of Delayed Lactogenesis in Obesity	BIOMEDICINES	3.9	Q1	Review	2025
A-02	Rodríguez-Capitán. J; Márquez-Camas. P; Carmona-Carmona. J; Moñino. DFA; Chaparro-Muñoz. M; Soler-González. M; del Río. MG; de la Iglesia. TE; Segovia-Reyes. J; Murri. M; Salguero. JRL; Couto-Mallón. D; Romero-Cuevas. M; Pavón-Morón. FJ; Gutiérrez-Bedmar. M; Jiménez-Navarro. M	Etiology of tricuspid regurgitation and mortality: a multicenter cohort study	CLINICAL RESEARCH IN CARDIOLOGY	3.7	Q1	Article	2025
A-02	Ortiz-Samur. NS; Vijaya. AK; Burokas. A; Mela. V	Exploring the Role of Microglial Cells in the Gut-Brain Axis Communication: A Systematic Review	JOURNAL OF NEUROCHEMISTRY	4	Q2	Review	2025
A-02	Jimenez-Fonseca. P; Alvarez-Escola. C; Navarro. IB; Cubero. JH; Fernández. LG; Cruz. MAM; Iglesias. C; García-Donas. J; Picón. MJ; Paja. M; Batanero. LG; García. L; Molina. J; Maté. RJ; Aller. J; Romero. MDT; Salas. JC; Gutiérrez-Buey. G; Zunzunegui. NE; Navarro. M; Lecumberri. MJ; Valdés. N; Carmona-Bayonas. A	External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy	EUROPEAN JOURNAL OF ENDOCRINOLOGY	5.2	Q1	Article	2025
A-02	Yilmaz. B; Alvanoudi. P; Kalogeropoulou. A; Santa. D; Bulmus-Tüccar. T; Nikolaou. A; Moreno-Indias. I; Ruiz-Limon. P; Gutierrez-Repiso. C; Hillesheim. E; Meslier. V; Mayo. B; Malagon. J; Chassard. C; Pracer. S; Vergeres. G; Mantzouridou. FT	Fermented dairy product consumption and blood lipid levels in healthy adults: a systematic review	FRONTIERS IN NUTRITION	5.1	Q1	Review	2025
A-02	Martínez-Montoro. JI; Sancho-Marín. R; Ocaña-Wilhelmi. L; Arranz-Salas. I; Ruiz-Campos. N; García-López. MJ; Tinahones. FJ; Gutiérrez-Repiso. C	Gastric microbiota-specific signatures in adults with obesity and Helicobacter pylori-negative gastritis	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	3.6	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-02	Artime. Esther; Hillman. Natalia; Tinahones. Francisco J; Perez. Antonio; Gimenez. Margarita; Duque. Natalia; Rubio-De Santos. Miriam; Diaz-Cerezo. Silvia; Redondo-Anton. Jennifer; Spaepen. Erik; Perez. Francisco; Conget. Ignacio	Glucometrics and Patient-Reported Outcomes in Individuals With Type 1 Diabetes Mellitus: Insights From the Correlation of Time in Range (CorrelaTIR) Study in Real-World Settings.	Cureus	0		Article	2025
A-02	Monroy. G; Picón-César. MJ; García-Alemán. J; Tinahones. FJ; Martínez-Montoro. JI	Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study	DIABETES TECHNOLOGY & THERAPEUTICS	6.3	Q1	Article	2025
A-02	Ruiz-Limón. P; Mena-Vázquez. N; Moreno-Indias. I; Lisbona-Montañez. JM; Mucientes. A; Manrique-Arija. S; Redondo-Rodriguez. R; Cano-García. L; Tinahones. FJ; Fernández-Nebro. A	Gut dysbiosis is associated with difficult-to-treat rheumatoid arthritis	FRONTIERS IN MEDICINE	3	Q1	Article	2025
A-02	Cornejo-Pareja. I; Kerr. KW; Ramirez. M; Camprubi-Robles. M; Vegas-Aguilar. IM; Fernandez-Jimenez. R; Amaya-Campos. M; Martinez-Martinez. A; Martinez-Martin. J; Garcia-Almeida. JM	Healthcare Resource Utilization During a Multimodal Nutritional Program with Oral Nutritional Supplements in Malnourished Outpatients	NUTRIENTS	5	Q1	Article	2025
A-02	Jiménez. RF; García-Rey. S; Aguilar. IMV; Jiménez-Sánchez. A; Madrid. NM; Cuellar. MCR; Galán. A; Domínguez. PG; León. RG; Zamora. P; Moreno-Domínguez. R; Sansó. RD; García-Luna. PP; Almeida. JMG	Impact of an oral nutritional supplement on the recovery of the nutritional status of older patients with fragility hip fracture: Controlled and randomized clinical trial	CLINICAL NUTRITION ESPEN	2.6	Q3	Article	2025
A-02	Fernández-Forné. A; Fernández-Jiménez. R; Toledo-Serrano. MD; Jiménez-Rodríguez. H; Muñoz-Lupiáñez. M; Ruiz-López. MA; García-Almeida. JM; De la Peña-fernández. L; Queipo-Ortuño. MI; Gómez-Millán. J	Impact of Nutritional Status on Severe Radiation-Induced Mucositis in Oropharyngeal Cancer Patients Undergoing Chemo-Radiotherapy	NUTRIENTS	5	Q1	Article	2025
A-02	Mena-Vázquez. N; Ortiz-Márquez. F; Ramirez-García. T; Gillis-Onieva. C; Cabezudo-García. P; García-Studer. A; Mucientes. A; Lisbona-Montañez. JM; Borregón-Garrido. P; Ruiz-Limón. P; Manrique-Arija. S; Cano-García. L; Serrano-Castro. PJ; Fernández-Nebro. A	Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis	FRONTIERS IN MEDICINE	3	Q1	Article	2025
A-02	Ortega. LR; Tapias. JM; Fernández. MJF; Jiménez-Navarro. M; Ortega-Gómez. A; Romero-Cuevas. M; Gómez-Doblas. JJ	In-Hospital Mortality and Costs of Added Morbidity in Heart Failure Patients at a University Hospital: A Retrospective Cross-Sectional Study	JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE	2.3	Q2	Article	2025
A-02	Pedro-Botet. J; Arrieta. F; Botana. M; Gimeno-Orna. JA; Martinez-Montoro. JI; de Victoria. EOM; Ribalta. J; Sánchez-Margalet. V; Pérez-Pérez. A	Lipid-lowering drug therapy for reducing cardiovascular risk in diabetes. A clinical view of the Cardiovascular Disease Working Group of the Spanish Diabetes Society	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.8	Q3	Article	2025
A-02	Mena-Vázquez. N; García-Studer. A; Ortiz-Márquez. F; Manrique-Arija. S; Mucientes. A; Lisbona-Montañez. JM; Borregón-Garrido. P; Ruiz-Limón. P; Redondo-Rodriguez. R; Cano-García. L; Fernández-Nebro. A	Longitudinal Assessment of Body Composition and Inflammatory Status in Rheumatoid Arthritis During TNF Inhibitor Treatment: A Pilot Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
A-02	Alcaide-Garcia. J; Boughanem. H; García-Aranda. M; Rivas-Ruiz. F; Aguirre. U; García. DM; Padilla-Ruiz. M; Varela-Moreno. E; Robles-Lasarte. M; Baré. M; del Cura. I; Varela. MMM; Quintana. JM; Macías. M; Redondo. M	Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients	COLORECTAL DISEASE	2.7	Q1	Article	2025
A-02	Cabrera-César. E; Fernández-Jiménez. R; Lopez-Garcia. J; Sanmartín-Sánchez. A; Cano-Gamonoso. MB; Agüero. IA; Espíldora-Hernández. F; Garcia. LFD; Vega-Aguilar. I; Amaya-Campos. MD; Tinahones. FJ; Garcia-Almeida. JM; Velasco-Garrido. JL	Malnutrition. Sarcopenia. and Malnutrition Sarcopenia Syndrome in Idiopathic Pulmonary Fibrosis	ADVANCES IN RESPIRATORY MEDICINE	2.3	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-02	Hernando-Redondo. J; Hernáez. A; Sanllorente. A; Pintó. X; Estruch. R; Salas-Salvadó. J; Corella. D; Arós. F; Martínez-González. MA; Subirana. I; Muñoz-Aguayo. D; Malcampo. M; Serra-Majem. L; Romaguera. D; Lapetra. J; Ros. E; Tinahones. F; Lamuela-Raventos. RM; Gómez-Gracia. E; Fitó. M; Castañer. O	Mediterranean Diet Modulates Gene Expression of Cholesterol Efflux Receptors in High-Risk Cardiovascular Patients	MOLECULAR NUTRITION & FOOD RESEARCH	4.2	Q2	Article	2025
A-02	Iboleon-Jimenez. A; Contreras-Muñoz. A; Peláez-Berdún. C; Franco-Hita. R; Sesmero. A; Robles-Mezcua. A; Garcia-Pinilla. JM; Jimenez-Navarro. M; Murri. M	Mitochondria. Sex. and Cardiovascular Disease: A Complex Interplay	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2025
A-02	Romero-Gómez. M; Escalada. J; Noguerol. M; Pérez. A; Carretero. J; Crespo. J; Mascort. JJ; Aguilar. I; Tinahones. F; Canones. P; Gómez-Huelgas. R; de Luis. D; Trullos. IG; Aller. R; Rubio. MA	Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis	GASTROENTEROLOGIA Y HEPATOLOGIA	1.9	Q3	Article	2025
A-02	Joaquín. C; Bretón. I; Ocón-Bretón. MJ; Zabalegui. A; Bellido. D; Martín. PM; Martínez-Olmos. MA; Zugasti. A; Riestra. M; Botella. F; García-Almeida. JM	Nutritional and Physical Rehabilitation in Post-Critical Coronavirus Disease 2019 (COVID-19) Ambulatory Patients: The NutriEcoMuscle Study	NUTRIENTS	5	Q1	Article	2025
A-02	Shyam. S; Nishi. SK; Ni. JQ; Martínez-González. MA; Corella. D; Schröder. H; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Lapetra. J; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Sánchez. VM; Pintó. X; Delgado-Rodríguez. M; Matía-Martín. P; Vidal. J; Vázquez. C; Daimiel. L; Ros. E; Gaforio. JJ; Ruiz-Canela. M; Fernández-Carrión. R; Goday. A; Garcia-Rios. A; Torres-Collado. L; Cueto-Galán. R; Zulet. MA; Prohens. L; Casas. R; Castillo-Hermoso. MA; Tojal-Sierra. L; Gomez-Pérez. AM; García-Arellano. A; Sorli. JV; Castañer. O; Arenas-Larriva. AP; Oncina-Cánovas. A; Goñi. L; Fitó. M; Babio. N; Salas-Salvadó. J	Pasta Consumption and Cardiometabolic Risks in Older Adults with Overweight/Obesity: A Longitudinal Analysis	JOURNAL OF THE AMERICAN NUTRITION ASSOCIATION	2.6	Q3	Article	2025
A-02	Alonso. SP; Colomo. N; Lago-Sampedro. A; Maldonado-Araque. C; García-Fuentes. E; Gutiérrez-Repiso. C; Tapia-Guerrero. MJ; Rueda. I; Sánchez. PO; Oualla-Bachiri. W; Calle-Pascual. A; Castaño. L; Delgado-Alvarez. E; Menéndez-Torre. E; Franch-Nadal. J; Urrutia. I; Girbés. J; Chaves. FJ; Montanya. E; Rojo-Martínez. G; Valdés. S	Population-based national incidence of thyroid dysfunction in Spain	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
A-02	Perea. V; Quirós. C; Herrera-Arranz. MT; Azriel-Mira. S; Wägner. AM; Beato-Vibora. P; Soldevila. B; Barquiel. B; Pardo. RM; Díaz-Soto. G; Picón. MJ; Colomo. N; Amigó. J; Climent. E; Durán-Martínez. M; Corcoy. R; Codina. M; Cuesta. M; Guedes. BV; Vinagre. I	Pregnancy outcomes with the pregestational use of Minimed 780G compared to Minimed 640G: findings from a multicenter cohort study	ACTA DIABETOLOGICA	2.9	Q2	Article	2025
A-02	Paz-López. G; Linares-Pineda. TM; González-Jiménez. A; Sancho-Marín. R; Ocaña-Wilhelmi. L; Tinahones. FJ; Morcillo. S; Gutiérrez-Repiso. C	Pre-operative DNA methylation marks as predictors of weight loss outcomes after sleeve gastrectomy	MOLECULAR METABOLISM	6.6	Q1	Article	2025
A-02	Rubín-García. M; Vitelli-Storelli. F; Alvarez-Alvarez. L; Fitó. M; Vázquez-Ruiz. Z; Salas-Salvadó. J; Corella. D; Serra-Majem. L; Warnberg. J; Romaguera. D; Estruch. R; Pintó. X; Martínez. JA; Vázquez. C; Vidal. J; Tur. JA; Alonso-Gómez. AM; Ros. E; Vioque. J; López-Miranda. J; Bueno-Cavanillas. A; Tinahones. FJ; Lapetra. J; Daimiel. L; Delgado-Rodríguez. M; Matía-Martín. P; Babio. N; Schröder. H; Lamuela-Raventós. RM; Martin-Sánchez. V; Zamora-Ros. R	Prospective association of changes in (poly) phenol intake. body weight and physical activity with inflammatory profile	NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES	3.7	Q1	Article	2025
A-02	Oliva-Olivera. W; Ravnsborg. T; Le Boiteux. E; Garcia-Fuentes. E; Garrido-Sánchez. L; Jensen. ON; Tinahones. FJ	Regulated cell death environments drive fibroinflammatory reprogramming in surviving adipose-derived stem cells	APOPTOSIS	8.1	Q1	Article	2025
A-02	Simón-Frapolli. VJ; López-Montalbán. A; Vegas-Aguilar. IM; Generoso-Piñar. M; Fernández-Jiménez. R; Cornejo-Pareja. IM; Sánchez-García. AM; Martínez-López. P; Nuevo-Ortega. P; Reina-Artacho. C; Estecha-Foncea. MA; Gómez-González. AM; González-Jiménez. MB; Avanesi-Molina. E; Tinahones-Madueño. FJ; García-Almeida. JM	Relationship Between Vitamin D Levels with In-Hospital Complications and Morphofunctional Recovery in a Cohort of Patients After Severe COVID-19 Across Different Obesity Phenotypes	NUTRIENTS	5	Q1	Article	2025
A-02	Dalla Rovere. L; Fernández-Jiménez. R; Guerrini. A; García-Olivares. M; Herola-Cobos. C; Hardy-Añón. C; Awol-Tanko. R; Hernandez-Sanchez. A; García-Almeida. JM	Role of Bioimpedance Phase Angle and Hand Grip Strength in Predicting 12-Month Mortality in Patients Admitted with Haematologic Cancer	CANCERS	4.4	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-02	Rubín-Garía. M; Vitelli-Storelli. F; Toledo. E; Alvarez-Alvarez. L; Martínez-González. MA; Corella. D; Salas-Salvadó. J; Zomeño. MD; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Santos-Lozano. JM; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Pintó. X; Gaforio. JJ; Matía-Martín. P; Vidal. J; Mas-Fontao. S; Daimiel. L; Ros. E; Vázquez-Ruiz. Z; de la Puente. MF; Alvarez-Sala. A; Pérez-Vegaj. A; García-Rios. A; González-Palacios. S; Gómez-Pérez. A; Zulet. MA; Chaplin. A; Casas. R; Cano-Ibañez. N; Tojal-Sierra. L; Cueto-Galán. R; Buil-Cosiales. P; Gutiérrez-Carrasquilla. L; Sorli. J; Malcampo. M; Ortiz-Morales. AM; Mira-Castejón. LA; Rios. S; Fitó. M; Martín-Sánchez. V	Sex differences in (poly)phenol intake patterns and cardiovascular risk in Spanish adult population at high risk of cardiovascular disease: Cross-sectional findings	NUTRITION	3	Q2	Article	2025
A-02	Mucarzel. F; Peláez. PG; Utrilla. VS; Jiménez. RF; Candia. FP; Torralvo. FJS; Peláez. RB; Almeida. JMG; Olveira. G	Sex-specific CT-derived muscle and fat phenotypes in colon cancer: implications for nutritional and metabolic assessment	FRONTIERS IN NUTRITION	5.1	Q1	Article	2025
A-02	Perdigones. CMD; Nogueira. DH; Muñoz. AR; Verdugo. AS; Vilches-Pérez. A; Mela. V; Tinahones. FJ; Indias. IM	Taxonomic and functional characteristics of the gut microbiota in obesity: A systematic review	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.8	Q3	Review	2025
A-02	Atzeni. A; Hernández-Cacho. A; Khoury. N; Babio. N; Belzer. C; Vioque. J; Corella. D; Fitó. M; Clish. C; Vidal. J; Konstanti. P; Gonzales-Palacios. S; Coltell. O; Goday. A; Indias. IM; Chilleron. SC; Ruiz-Canela. M; Tinahones. FJ; Hu. FB; Salas-Salvadó. J	The link between ultra-processed food consumption. fecal microbiota. and metabolomic profiles in older mediterranean adults at high cardiovascular risk	NUTRITION JOURNAL	3.8	Q2	Article	2025
A-02	Sanmartín-Sánchez. A; Fernández-Jiménez. R; Cabrera-César. E; Espíldora-Hernández. F; Vegas-Aguilar. I; Amaya-Campos. MD; Palmas-Candia. FX; Olivares-Alcolea. J; Simón-Frapolli. VJ; Cornejo-Pareja. I; Sánchez-García. A; Murri. M; Guirado-Peláez. P; Vidal-Suárez. A; Garrido-Sánchez. L; Tinahones. FJ; Velasco-Garrido. JL; García-Almeida. JM	The Nutritional Phenotyping of Idiopathic Pulmonary Fibrosis Through Morphofunctional Assessment: A Bicentric Cross-Sectional Case-Control Study	LIFE-BASEL	3.4	Q1	Article	2025
A-02	Pilo. J; Rego-Calvo. A; García-Flores. LA; Arranz-Salas. I; Alvarez-Mancha. AI; Izquierdo. AG; Crujeiras. AB; Alcaide. J; Ortega-Castan. M; Boughanem. H; Macías-González. M	Unraveling TNXB Epigenetic Alterations Through Genome-Wide DNA Methylation Analysis and Their Implications for Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
A-02	Heras. V; Mela. V; Kompella. P; Rojano. E; Paz-López. G; Hurtado-García. L; Ortega-Gomez. A; García-López. MJ; García-Martín. ML; Ranea. JAG; Tinahones. FJ; Moreno-Indias. I	β-Hydroxybutyrate Reduces Body Weight by Modulating Fatty Acid Oxidation and Beiging in the Subcutaneous Adipose Tissue of DIO Mice	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
A-03	Paradies. V; Masiero. G; Rubboli. A; Van Beusekom. HMM; Costa. F; Capranzano. P; Degrauwe. S; Gorog. DA; Jorge. CM; Buchanan. GL; Alasnag. M; Trabattoni. D; Fraccaro. C; Sibbing. D; Dudek. D; Vilahur. G; Chieffo. A; Mehran. R; Capodanno. D; Barbato. E; Siller-Matula. JM	Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis	EUROINTERVENTION	9.5	D1	Article	2025
A-03	Paradies. V; Masiero. G; Rubboli. A; Van Beusekom. HMM; Costa. F; Capranzano. P; Degrauwe. S; Gorog. DA; Jorge. CM; Buchanan. GL; Alasnag. M; Trabattoni. D; Fraccaro. C; Sibbing. D; Dudek. D; Vilahur. G; Chieffo. A; Mehran. R; Capodanno. D; Barbato. E; Siller-Matula. JM	Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.	EUROPEAN HEART JOURNAL	35.7	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-03	Mora-Ayestarán. N; Ochoa. JP; Gómez-González. C; Navarro-Peñalver. M; Gallego-Delgado. M; Larrañaga-Moreira. JM; Robles-Mezcua. A; Basurte-Elorz. MT; Rodriguez-Palomares. JF; Climent-Paya. V; Jiménez-Jaímez. J; Mogollón-Jiménez. MV; García-Granja. PE; García-Alvarez. A; Peña-Peña. ML; Barredo. MA; Ripoll-Vera. T; Palomino-Doza. J; Bayes-Genis. A; Tirón. C; Fernández. AI; Sabater-Molina. M; Toranzo. I; Crespo-Leiro. MG; Doncel-Abad. V; Lacuey-Lecumberri. G; Limeres-Freire. J; García-Alvarez. M; Cabrera-Borrego. E; El Maalem. ZKA; Vilches. S; González-López. E; Villacorta. E; García-Pinilla. JM; Barriales-Villa. R; Gimeno-Blanes. JR; Garcia-Pavia. P; Domínguez. F	Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure	EUROPEAN HEART JOURNAL	35.7	D1	Article	2025
A-03	Costa. F; Doblas. JJG; Expósito. AD; Adamo. M; D'Ascenzo. F; Koltowski. L; Saba. L; Mendieta. G; Gragnano. F; Calabrò. P; Badimon. L; Ibañez. B; Mehran. R; Angiolillo. DJ; Lüscher. T; Capodanno. D	Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives	EUROPEAN HEART JOURNAL	35.7	D1	Review	2025
A-03	Laudani. C; Giacoppo. D; Occhipinti. G; Galli. M; Greco. A; Spagnolo. M; Ortega-Paz. L; Costa. F; Angiolillo. DJ; Capodanno. D	Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes	JACC-CARDIOVASCULAR INTERVENTIONS	11.4	D1	Article	2025
A-03	Alexander. JH; Lydon. EJ; Piccini. JP; Viethen. T; Oldgren. J; Goodman. SG; Steffel. J; Russo. AM; van Gelder. IC; Ferdinand. KC; Lopes. RD; Mundl. H; Benczur. B; Gómez-Doblas. JJ; Glikson. M; Goudev. A; Grove. EL; Halvorsen. S; Kiviniemi. T; Martin. AC; Sandhu. RK; Vinereanu. D; Rockhold. FW; Caso. V; Coppolecchia. R; Patel. MR	Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial	JAMA CARDIOLOGY	14.1	D1	Article	2025
A-03	Costa. F; Salinas. P; Iannaccone. M; Cerrato. E; Márquez. DT; Misra. S; Götzinger. F; Carciotto. G; Silipigni. S; Becerra-Muñoz. VM; Mennuni. M; Stagno. A; Bottari. A; Pavani. M; Varbella. F; Alonso-Briales. JH; Jurado-Román. A; Secemsky. EA; Mahfoud. F; Micari. A	Catheter-based techniques for pulmonary embolism treatment	EUROINTERVENTION	9.5	D1	Review	2025
A-03	Robles-Mezcua. Ainhoa; Januzzi. James L; Pavon-Moron. Francisco Javier; Rodriguez-Capitan. Jorge; Lopez-Garrido. Miguel A; Cruzado-Alvarez. Concepcion; Robles-Mezcua. Maria; Gutierrez-Bedmar. Mario; Couto-Mallon. David; Rueda-Calle. Eloy C; Barreiro-Perez. Manuel; Sanchez. Pedro L; Gomez-Doblas. Juan Jose; Jimenez-Navarro. Manuel F; Garcia-Pinilla. Jose M	Effects of sacubitril/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniques.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	Article	2025
A-03	Trenas. A; Perez-Velasco. MA; Bernal-López. MR; López-Carmona. MD; Gómez-Doblas. JJ; Martinez-Esteban. MD; Bouarich. O; Garcia-Casares. N; Fernández-Garcia. D; de Lucas. MDG; Gómez-Huelgas. R; Perez-Belmonte. LM	Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction. type 2 diabetes and obesity: a real-world study	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	D1	Article	2025
A-03	Yun. S; Comín-Colet. J; Calero-Molina. E; Hidalgo. E; José-Bazán. N; Marcos. MC; Soria. T; Llàcer. P; Fernández. C; Garcia-Pinilla. JM; Cruzado. C; González-Franco. A; García-Marina. EM; Morales-Rull. JL; Solé. C; García-Romero. E; Núñez. J; Civera. J; Fernández. C; Faraudo. M; Moliner. P; Formiga. F; Bagudá. JD; Zegri-Reiriz. I; Verdú-Rotellar. JM; Vela. E; Monterde. D; Piera-Jiménez. J; Carot-Sans. G; Enjuanes. C	Evaluation of mobile health technology combining telemonitoring and teleintervention versus usual care in vulnerable-phase heart failure management (HERMeS): a multicentre. randomised controlled trial	LANCET DIGITAL HEALTH	24.1	D1	Article	2025
A-03	Pérez-Solé. N; de Dios. E; Gavara. J; Ríos-Navarro. C; Marcos-Garces. V; Merenciano. H; Climent. J; López-Bueno. L; Payá. A; de la Espriella. R; Bayés-Genís. A; Jiménez-Navarro. M; Marín. F; Núnez. J; Sanchis. J; Bodí. V	NT-proBNP to guide risk stratification after cardiac rehabilitation in patients with ST-segment elevation myocardial infarction	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	D1	Article	2025
A-03	Jiménez-Salva. M; Carmona-Segovia. A; Molina-Ramos. AI; García-Rodríguez. L; Puyol-Ruiz. F; Doncel-Abad. V; Romero-Cuevas. M; Serrano. A; Muñoz-García. A; Flores-López. M; Ortega-Gómez. A; Gutiérrez-Bedmar. M; Rodríguez-Capitán. J; Jiménez-Navarro. M; Pavón-Morón. FJ	Older adults with acute coronary syndrome: the impact of frailty and nutritional status on in-hospital complications	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	Article	2025
A-03	Segovia. ADMC; Becerra-Muñoz. VM; Arjona. MJJ; Velasco. VN; Ochoa. N; Barberà. JA; López-Meseguer. M; Asencio. JMM; Blanco. I; Subias. PE	Real-life use of validated quality of life questionnaires in patients with pulmonary arterial hypertension in Spain: a cross-sectional study	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-03	Núñez. J; Miñana. G; de la Espriella. R; Zegrí-Reiriz. I; Comín-Colet. J; Gracia. JR; Morales-Rull. JL; Llàcer. P; Diez-Villanueva. P; Bagudá. JD; Cortes. Cé; Goirigolzarri-Artaza. J; García-Pinilla. JM; Barrios. E; Díaz. SD; Jiménez-Marrero. S; Restrepo-Córdoba. MA; Testani. J; Marcos. MC	Salt repletion and diuretic response: The role of serum chloride. A post-hoc analysis of the SALT-HF trial on furosemide and hypertonic saline solution administration in ambulatory patients with worsening heart failure	EUROPEAN JOURNAL OF HEART FAILURE	10.8	D1	Article	2025
A-03	Aybar. MJT; Larrubia-Valle. JI; Berdún. CP; Carmona-Segovia. AD; Pavón-Morón. FJ; Jiménez-Navarro. MF	At the heart of the classroom: student perspective on teaching methods in Cardiology	SPANISH JOURNAL OF MEDICAL EDUCATION	0.7	Q3	Article	2025
A-03	Exposito. AD; Cabeza. AIP; Camas. PM; Mezcua. AR; Pinilla. JMG	Cardiac contractility modulation as a novel therapeutic approach in transthyretin amyloid cardiomyopathy to improve eligibility to stabilizer therapy: a case report	EUROPEAN HEART JOURNAL-CASE REPORTS	0.8	Q4	Article	2025
A-03	Iboleon-Jimenez. A; Sánchez-Quintero. MJ; Carmona-Segovia. ADM; Sojo. B; Fernández-Ramos. AM; García-Rodríguez. L; Molina-Ramos. AI; García-Pinilla. JM; Jimenez-Navarro. M; Ortega-Gomez. A	Circulating mitochondrial biomarkers in acute coronary syndrome	FRONTIERS IN MEDICINE	3	Q1	Article	2025
A-03	Sánchez-Quintero. M; Iboleón. A; Chaves. LM; Vilumbrales. BP; Carmona-Segovia. ADM; López. PM; Romero-Cuevas. M; Rodríguez-Capitán. J; Becerra-Muñoz. VM; Pavón-Morón. FJ; Murri. M	Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement	BIOLOGICS-TARGETS & THERAPY	3.4	Q2	Article	2025
A-03	De Heredia. APLF; Ortiz. MR; Llergo. JT; Bailen. MC; De Castro. MS; de la Mata. MF; Exposito. AD; Cabeza. AIP; Ortega. MD; Fortesi. MG; Valenzuela. IF; Muñoz. MC; Fernández. AR; Almodóvar. AMR; Cubiles. IAD; Martínez. FE; Huelva. FJC; Fernandez. JJS; Rubio. DM; Andalusian Soc Cardiol	Clinical profile and cardiovascular events in patients with atrial fibrillation and hematologic malignancies with recent initiation of targeted therapy: Real-life data from CANAC-FA registry	CURRENT PROBLEMS IN CARDIOLOGY	3.3	Q2	Review	2025
A-03	Cerrato. E; Piedimonte. G; Franzino. M; Marengo. G; Bollati. M; Zecchino. S; Rutigliano. D; Soriano. F; Leoncini. M; Mangione. R; Sagazio. E; Maiellaro. F; Jeva. F; Ussia. GP; Scudiero. F; Franzè. A; Barbero. U; Calderone. D; Nicolino. A; Ugo. F; La Manna. A; Costa. F; Mazzarotto. P; Amat-Santos. IJ; Varbella. F	Contemporary Use of Coils During Percutaneous Coronary Intervention: Insights From the Multicenter COILSEAL Registry	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS	1.9	Q3	Article	2025
A-03	Iuvara. G; Franzino. M; Carciotto. G; De Ferrari. T; Lo Giudice. S; Pallante. F; Giannino. F; Ajello. M; Tomasi. S; Sciortino. L; Monciino. G; Licandri. W; Caminiti. R; Virga. V; Costa. F; Micari. A; Vizzari. G	Coronary Intravascular Imaging: A Comprehensive Review of Techniques. Applications. and Future Directions	MEDICINA-LITHUANIA	2.4	Q1	Review	2025
A-03	Bertolín-Boronat. C; Marcos-Garcés. V; Merenciano-González. H; Mas. MLM; Alberola. JIC; Perez. N; López-Bueno. L; Argente. MCE; Reig. MV; Benito. AA; Rubio. AP; Rios-Navarro. C; de Dios. E; Gavara. J; Jimenez-Navarro. MF; Chorro. FJ; Sanchis. J; Bodi. V	Depression. Anxiety. and Quality of Life in a Cardiac Rehabilitation Program Without Dedicated Mental Health Resources Post-Myocardial Infarction	JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE	2.3	Q2	Article	2025
A-03	Porras-Perales. O; Segovia-Reyes. J; Crespo-Delgado. A; Ruiz-González. D; Flores-López. M; Medina-Vera. D; Sánchez-Marín. L; Martín-Chaves. L; Requena-Ocaña. N; Molina-Ramos. AI; Ruiz-Ruiz. JJ; de Fonseca. FR; Jiménez-Navarro. M; Rodríguez-Capitán. J; Pavón-Morón. FJ; Serrano. A	Distinct cardiac troponin alterations in patients with cocaine and alcohol use disorders during abstinence for cardiovascular risk assessment	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
A-03	Jimenez-López. R; Martin-Chaves. L; Gutierrez-Garcia. AM; Carmona-Segovia. AD; Mora-Ordoñez. B; Sánchez-Garcia. AM; Fernández-Romero. L; Murri. M; Sánchez-Quintero. MJ; Berteli-Garcia. G; Sánchez-Chaparro. MA; Bodi. V; Rodriguez-Capitán. J; Jimenez-Navarro. M; Pavón-Morón. FJ; Romero-Trevejo. JL	Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy	FRONTIERS IN MEDICINE	3	Q1	Article	2025
A-03	Marcos. MC; de la Espriella. R; Zegri-Reiriz. I; Llacer. P; Gracia. JR; Comín-Colet. J; Morales-Rull. JL; Diez-Villanueva. P; Baguda. JD; Jimenez-Marrero. S; Cortés. CO; Restrepo-Córdoba. MA; García-Pinilla. JM; Barrios. E; Díaz. SD; Núñez. J	Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis	ESC HEART FAILURE	3.7	Q1	Article	2025
A-03	Esteban-Fernández. A; Lopez-Fernández. S; Pastor-Pérez. FJ; Pérez-Rivera. JA; Bonilla-Palomas. JL; Cobo-Marcos. M; García-Pinilla. JM; Almenar-Bonet. L; Fluviá-Brugués. P; Bermúdez-Jiménez. FJ; Goena-Vives. C; Lopez-Lopez. A; Gomez-Otero. I	Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients	BMC CARDIOVASCULAR DISORDERS	2.3	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-03	Ruberti. A; Cepas-Guillén. P; Echarte-Morales. J; Arzamendi. D; Moñivas. V; Carrasco-Chinchilla. F; Pan. MN; Nombela-Franco. L; Pascual. I; Guerreiro. CE; Benito-González. T; Pérez. R; Gomez-Blázquez. I; Amat-Santos. IJ; Flores-Umanzor. E; Cruz-González. I; Sánchez-Recalde. A; Alvarez. ABC; Barreiro-Pérez. M; Sanchis. L; Li. CH; Caneiro-Queija. B; del Trigo. M; Martínez-Carmona. JD; Mesa. D; Quevedo. PJ; Avanzas. P; Estévez-Loureiro. R; Freixaa. X	Efficacy of transcatheter edge-to-edge repair for cardiac implantable electronic device-associated tricuspid regurgitation: insights from the TRI-SPA registry	REVISTA ESPANOLA DE CARDIOLOGIA	4.9	Q1	Article	2025
A-03	Rodríguez-Capitán. J; Márquez-Camas. P; Carmona-Carmona. J; Moñino. DFA; Chaparro-Muñoz. M; Soler-González. M; del Río. MG; de la Iglesia. TE; Segovia-Reyes. J; Murri. M; Salguero. JRL; Couto-Mallón. D; Romero-Cuevas. M; Pavón-Morón. FJ; Gutiérrez-Bedmar. M; Jiménez-Navarro. M	Etiology of tricuspid regurgitation and mortality: a multicenter cohort study	CLINICAL RESEARCH IN CARDIOLOGY	3.7	Q1	Article	2025
A-03	Flores-López. M; Herrera-Imbroda. J; Requena-Ocaña. N; García-Marchena. N; Araos. P; Verheul-Campos. J; Ruiz. JJ; Pastor. A; de la Torre. R; Bordallo. A; Pavón-Morón. FJ; Fonseca. FRD; Serrano. A	Exploratory study on plasma Acylglycerol and Acylethanolamide dysregulation in substance use and attention-deficit/hyperactivity disorder: Implications for novel biomarkers in dual diagnosis	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
A-03	Dafaalla. M; Costa. F; Kontopantelis. E; Bagur. R; Iannaccone. M; Bironzo. P; Roubi. SR; De Filippo. O; D'Ascenzo. F; Mamas. MA	External Validation of the PRECISE-DAPT Cancer Score in Patients With Acute Myocardial Infarction	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS	1.9	Q3	Article	2025
A-03	Bertolín-Boronat. C; Marcos-Garcés. V; Merenciano-González. H; Mas. MLM; Alberola. JIC; Perez. N; Bueno. LL; Argente. MCE; Reig. MV; Benito. AA; Rubio. AP; Ríos-Navarro. C; de Dios. E; Gavara. J; Jiménez-Navarro. MF; Chorro. FJ; Sanchis. J; Bodi. V	Familial Hypercholesterolemia Screening in a Cardiac Rehabilitation Program After Myocardial Infarction	CARDIOGENETICS	0.9	Q4	Article	2025
A-03	Ruiz-Malagon. AJ; Herraiz-Vilela. M; Serrano-Pino. R; García-Avila. P; Díaz-Suárez. L; Carmona-Segovia. AD; Becerra-Munoz. VM; Jiménez-Navarro. M; Arranz-Salas. I; Lopez-Villodres. JA; Fernández-Castañer. A; Gutiérrez-Martínez. F; Rodríguez-González. FJ; Camargo-Camero. R; Alcaín-Martínez. G; Rodríguez-Díaz. C; García-Fuentes. E; Sánchez-Quintero. MJ; Lopez-Gomez. C	Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease	WORLD JOURNAL OF GASTROENTEROLOGY	5.4	Q1	Article	2025
A-03	Sisinni. A; Freixa. X; Arzamendi. D; Palomero. VM; Carrasco-Chinchilla. F; Pan. M; Nombela-Franco. L; Pascual. I; Benito-González. T; Estevez-Loureiro. R	Impact of Precapillary Component of Pulmonary Pressure in Tricuspid Transcatheter Edge-to-Edge Repair Results From TRI-SPA	JACC-ADVANCES	0		Article	2025
A-03	Ortega. LR; Tapias. JM; Fernández. MJF; Jiménez-Navarro. M; Ortega-Gómez. A; Romero-Cuevas. M; Gómez-Doblas. JJ	In-Hospital Mortality and Costs of Added Morbidity in Heart Failure Patients at a University Hospital: A Retrospective Cross-Sectional Study	JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE	2.3	Q2	Article	2025
A-03	Dafaalla. M; Costa. F; Jia. HB; Wijeysundera. H; Rashid. M; Graham. MM; Wojakowski. W; Chieffo. A; Mintz. GS; Mamas. MA	Ischaemic and bleeding risk after ST-elevation myocardial infarction in patients with active cancer: a nationwide study	EUROPEAN HEART JOURNAL OPEN	0		Article	2025
A-03	Casas. G; Ródenas-Alesina. E; Limeres. J; Badia-Molins. C; Larrañaga-Moreira. JM; Mirelis. JG; Navarrete-Navarro. J; Martín-Jiménez. J; Alcalá-López. JE; González-Carrillo. J; Teis. A; Soler-Fernández. R; Teixidó-Turà. G; Gutiérrez-García. L; Fernández-Alvarez. P; Muñoz-Cabello. P; Barrabés. JA; Tirón. C; Palomino-Doza. J; García-Pinilla. JM; Bayés-Genís. A; Ripoll-Vera. T; Jiménez-Jáimez. J; Villacorta. E; Gimeno-Blanes. JR; Zorio. E; García-Pavía. P; Barriales-Villa. R; Guala. A; Petersen. SE; Ferreira-González. I; Rodríguez-Palomares. JF	Left ventricular ejection fraction decline and cardiovascular events in suspected cardiomyopathy with excessive trabeculation: toward precision medicine	REVISTA ESPANOLA DE CARDIOLOGIA	4.9	Q1	Article	2025
A-03	Bertolín-Boronat. C; Merenciano-González. H; Marcos-Garcés. V; Mas. MLM; Alberola. JIC; Civera. JM; Reig. MV; Hueso. MR; Carmona. PC; Perez. N; López-Bueno. L; Díaz. BD; Martínez. IM; Rubio. AP; Ríos-Navarro. C; de Dios. E; Gavara. J; Jiménez-Navarro. MF; Sanchis. J; Bodi. V	Low-Density Lipoprotein Cholesterol Reduction and Therapeutic Adherence During Cardiac Rehabilitation After Myocardial Infarction	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
A-03	Medina-Vera. D; Martín-Chaves. L; Sánchez-Marín. L; Díaz-Ottaviano. M; Gavito. AL; Popova. O; Sánchez-Quintero. MJ; Rodríguez-Capitán. J; de Fonseca. FR; Jiménez-Navarro. MF; Serrano. A; Pavón-Morón. FJ	Maladaptive stress-coping behavior in CX3CR1-deficient mice: Impact of adolescent stress and alcohol exposure on neuroimmune responses and inflammation	NEUROPHARMACOLOGY	4.6	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-03	Iboleon-Jimenez. A; Contreras-Muñoz. A; Peláez-Berdún. C; Franco-Hita. R; Sesmero. A; Robles-Mezcua. A; Garcia-Pinilla. JM; Jimenez-Navarro. M; Murri. M	Mitochondria. Sex. and Cardiovascular Disease: A Complex Interplay	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2025
A-03	Ramos-Polo. R; Ras-Jiménez. MD; Carbajales. MDB; Jovells-Vaqué. S; Garcia-Pinilla. JM; Cobo-Marcos. M; de Juan-Bagudá. J; Fonseca. C; Manzano. JF; Cosa. AE; Yun-Viladomat. S; Enjuanes. C; Orduña. MT; Comin-Colet. J	Myocardial Performance Improvement After Iron Replacement in Heart Failure Patients: The IRON-PATH II Echo-Substudy	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
A-03	Echarte-Morales. J; Cepas-Guillén. P; Arzamendi. D; Moñivas. V; Carrasco-Chinchilla. F; Pan. M; Nombela-Franco. L; Pascual. I; Benito-González. T; Pérez. R; Gómez-Blázquez. I; Amat-Santos. IJ; Cruz-González. I; Sánchez-Recalde. A; Caneiro-Queija. B; Alvarez. ABC; Barreiro-Pérez. M; Sanchis. L; Li. CH; del Trigo. M; Martínez-carmona. JD; Mesa. D; Jiménez. P; Avanzas. P; Freixa. X; Estévez-Loureiro. R	One-Year Recurrent Tricuspid Regurgitation After Successful Transcatheter Edge to Edge Repair: The TRI-SPA Registry	AMERICAN JOURNAL OF CARDIOLOGY	2.1	Q3	Article	2025
A-03	García-Pavía. P; García-Pinilla. JM; Lozano-Bahamonde. A; Yun. SR; García-Quintana. A; Gavira-Gómez. JJ; Aibar-Arregui. MA; Barge-Caballero. G; Villota. JN; Bernal. L; Tarilonte. P	Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study	REVISTA ESPANOLA DE CARDIOLOGIA	4.9	Q1	Article	2025
A-03	Verheul-Campos. J; Sanchez-Marin. L; López. Y; Gavito. AL; Grandes. P; Serrano. P; Guerricagoitia. I; Estivill-Torrús. G; Rodriguez-Arias. M; Miñarro. J; Pavón-Morón. FJ; Suárez. J; Serrano. A; de Fonseca. FR	Prior restraint stress counteracts memory deficits associated with adolescent alcohol exposure by targeting both the hippocampal endocannabinoid and glutamatergic systems	DRUG AND ALCOHOL DEPENDENCE	3.6	Q1	Article	2025
A-03	Sánchez-Marín. L; Canoluk. B; Verheul-Campos. J; Gavito. AL; Reviriego. R; Pavón-Morón. FJ; Serrano. A; De Fonseca. FR	Prior stress history shapes adolescent alcohol-induced transcriptional changes in striatal glutamatergic and endocannabinoid pathways	ADICCIONES	1.8	Q3	Article	2025
A-03	Pérez-Solé. N; de Dios. E; Monmeneu. JV; López-Lereu. MP; Gavara. J; Ríos-Navarro. C; Marcos-Garces. V; Merenciano. H; Bonanad. C; Cánoves. J; Platero. F; Ventura. A; Moratal. D; Bayés-Genís. A; Sanz. J; Jiménez-Navarro. M; Martínez-Dolz. L; Sanchis. J; Núñez. J; Bodí. V	Prognostic role of persistent angina after percutaneous revascularization in chronic coronary syndrome with altered angiography and stress CMR	REVISTA ESPANOLA DE CARDIOLOGIA	4.9	Q1	Article	2025
A-03	Perez. MS; Rodriguez-Capitan. J; Requena-Ibanez. JA; Santos-Gallego. CG; Zafar. MU; Escolar. G; Mancini. D; Mitter. S; Lam. D; Contreras. JP; Fergus. I; Atallah-Lajam. F; Abascal. V; Lala. A; Moreno. P; Moss. N; Lerakis. S; Sanz. J; Fuster. V; Badimon. JJ	Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes	CARDIOVASCULAR DRUGS AND THERAPY	3.1	Q2	Review	2025
A-03	Sisinni. A; Barreiro-Perez. M; Freixa. X; Arzamendi. D; Moñivas. V; Carrasco-Chinchilla. F; Pan. M; Nombela-Franco. L; Pascual. I; Benito-González. T; Perez. R; Gómez-Blázquez. I; Amat-Santos. IJ; Cruz-González. I; Sánchez-Recalde. A; Alvarez. ABC; Sanchis. L; Caneiro-Queija. B; Li. CH; del Trigo. M; Martínez-Carmona. JD; Mesa. D; Pozo. E; Avanzas. P; Cepas-Guillén. P; Estévez-Loureiro. R	Real-World Experience in Tricuspid Transcatheter Edge-to-Edge Repair: Transcatheter Tricuspid Valve Repair in Spain Registry	JOURNAL OF THE AMERICAN HEART ASSOCIATION	5.3	Q1	Article	2025
A-03	Thurnhofer-Hemsi. K; García-Aguilar. I; Fernández-Rodriguez. JD; López-Rubio. E	Representation of Molecules by Sequences of Instructions	JOURNAL OF CHEMICAL INFORMATION AND MODELING	5.3	Q1	Article	2025
A-03	Tajes. M; Ras-Jimenez. MD; Girona. J; Ramos-Polo. R; Guardiola. M; Garcia-Pinilla. JM; Ribalta. J; Cobo-Marcos. M; Masana. L; de Juan-Bagudá. J; Fonseca. C; Enjuanes. C; Vázquez-Carrera. M; Comin-Colet. J; Rodriguez-Calvo. R	Serum Growth Differentiation Factor 15 (GDF15) Levels Reflect Ischemic Etiology in Heart Failure Patients with Iron Deficiency: A Cross-Sectional Study	BIOMOLECULES	4.8	Q1	Article	2025
A-03	Sánchez-Marín. L; Jiménez-Castilla. V; Flores-López. M; Navarro. JA; Gavito. A; Blanco-Calvo. E; Santín. LJ; Pavón-Morón. FJ; de Fonseca. FR; Serrano. A	Sex-specific alterations in emotional behavior and neurotransmitter systems in LPA1 receptor-deficient mice	NEUROPHARMACOL-OGY	4.6	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-03	Porras-Perales. O; Sánchez-Marín. L; Medina-Vera. D; Flores-López. M; Martín-Chaves. L; Boccalon. M; Requena-Ocaña. N; García-Marchena. N; Reviriego. R; Santín. LJ; Martin-Fardon. R; Jiménez-Navarro. M; de Fonseca. FR; Serrano. A; Pavón-Morón. FJ	Sex-specific dysregulation of the CX3CL1/CX3CR1 Axis following cocaine exposure: Translational evidence for a potential biomarker of abstinence	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
A-03	de Dios. E; Forteza. MJ; Perez-Sole. N; Molina-Garcia. T; Gavara. J; Marcos-Garces. V; Jimenez-Navarro. M; Ruiz-Sauri. A; Rios-Navarro. C; Bodi. V	Temporal and Spatial Dynamics in the Regulation of Myocardial Metabolism During the Ischemia-Reperfusion Process	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
A-03	Ugo. F; Franzino. M; Massaro. G; Maltese. L; Cavallino. C; Abdirashid. M; Benedetto. D; Costa. F; Rametta. F; Sangiorgi. GM	The Role of IVUS in Coronary Complications	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS	1.9	Q3	Review	2025
A-03	Molina-Cabello. MA; Serrano-Angulo. J; Benito-Picazo. J; Thurnhofer-Hemsi. K	Toward Questionnaire Complexity Reduction by Decreasing the Questions	APPLIED SCIENCES-BASEL	2.5	Q2	Article	2025
A-03	Pozo-Vilumbrales. B; Martín-Chaves. L; López-Unzu. MA; Soto-Navarrete. MT; Pavón-Morón. FJ; Rodríguez-Capitán. J; Fernández. B	Unraveling the molecular complexity of bicuspid aortopathy: Lessons from comparative proteomics	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE	4.2	Q1	Article	2025
A-06	Trenas. A; Perez-Velasco. MA; Bernal-López. MR; López-Carmona. MD; Gómez-Doblas. JJ; Martinez-Esteban. MD; Bouarich. O; Garcia-Casares. N; Fernández-Garcia. D; de Lucas. MDG; Gómez-Huelgas. R; Perez-Belmonte. LM	Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction. type 2 diabetes and obesity: a real-world study	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	D1	Article	2025
A-06	Lancellotti. TES; Avena. MV; Funes. AK; Bernal-López. MR; Gómez-Huelgas. R; Fornes. MW	Exploring the impact of lipid stress on sperm cytoskeleton: insights and prospects	NATURE REVIEWS UROLOGY	14.6	D1	Review	2025
A-06	Uyaroglu. OA; Ruza. I; Skrha. J; Patoulias. D; Bevc. S; Bojadjiev. BI; Gómez-Huelgas. R; Bojunga. J; Lesniak. W; Carretero-Gómez. J; Wacker. J; Pérez-Belmonte. LM; Dicker. D; Petreski. T; Marín-León. I	Treatment of hospitalized patient with hyperglycemia: An EFIM critically appraised and adapted guideline	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	D1	Article	2025
A-06	Ropero-Luis. G; Ruiz-Cantero. A; Gómez-Huelgasb. R	Analysis of hypercalcemia in hospitalized patients in Spain from 2001 through 2015	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.8	Q3	Article	2025
A-06	Florido-Santiago. M; Pérez-Belmonte. LM; Lara. JP; Millán-Gomez. M; Pérez-Velasco. MA; Osuna-Sánchez. J; García-Casares. N; Gomez-Huelgas. R; Blanco-Reina. E; Barbancho. MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	2.8	Q2	Article	2025
A-06	Hernández-Negrín. H; Bernal-López. MR; López-Sampalo. A; Rubio-Rivas. M; Aguilar-García. JA; Gómez-Uranga. A; Carnevali. M; Taboada-Martínezh. ML; Ramos-Rincón. JM; Gómez-Huelgas. R	Cardiovascular profile of systemic lupus erythematosus patients hospitalized for COVID-19 in Spain: Analysis of the SEMI-COVID-19 Registry	MEDICINA CLINICA	2.1	Q2	Article	2025
A-06	Avena. MV; Funes. AK; Monclus. MA; Boarelli. PV; Barbisan. LF; Bernal-López. MR; Gómez-Huelgas. R; Lancellotti. TES; Fornés. MW	Cholesterol and SREBP2 Dynamics During Spermatogenesis Stages in Rabbits: Effects of High-Fat Diet and Protective Role of Extra Virgin Olive Oil	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
A-06	Vargas-Molina. S; García-Sillero. M; Maroto-Izquierdo. S; Baz-Valle. E; Bautista-Mayorga. B; Murri. M; Schoenfeld. BJ; Benítez-Porres. J	Cluster sets and traditional sets elicit similar muscular hypertrophy: a volume and effort-matched study in resistance-trained individuals	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY	2.7	Q2	Article	2025
A-06	Franco. MEP; Puente-García. A; Pérez-Belmonte. LM; Pérez. N; Ellingson. S; Tornero. F	Comprehensive management of chronic kidney disease in the old population	CURRENT MEDICAL RESEARCH AND OPINION	2.2	Q2	Review	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-06	Vargas-Molina. S; García-Sillero. M; Jiménez-García. JD; Carbone. L; Bonilla. DA; Petro. JL; Romance. R; Benítez-Porres. J	Effects of a Nonlinear Program on Different Health Parameters in the Elderly	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH	2.6	Q2	Article	2025
A-06	Castro. N; Benítez-Porres. J; Carbone. L; Chulvi. I; Bonilla. DA; Petro. JL; Peña. J; Vargas-Molina. S	Effects of Hip-Dominant Strength Exercises on Post-Activation Performance Enhancement	APPLIED SCIENCES-BASEL	2.5	Q2	Article	2025
A-06	Pérez-Velasco. MA; Bernal-López. MR; Trenas. A; Ricci. M; López-Carmona. MD; de Lucas. MDG; Gómez-Huelgas. R; Pérez-Belmonte. LM	Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction. obesity and type 2 diabetes	MEDICINA CLINICA	2.1	Q2	Article	2025
A-06	Silva-Soto. MA; Carrillo-Fernández. P; Lancellotti. ETS; Medina-Jiménez. E; Alba. JFM; Catena-Granados. N; López-Carmona. MD; Pérez-Belmonte. LM; Lain. NP; Hernández. AIG; Gómez-Huelgas. R; Bernal-Lopez. MR	Extra Virgin Olive Oil Phenolic Compounds: Modulating Mitochondrial Function and Protecting Against Chronic Diseases-A Narrative Review	NUTRIENTS	5	Q1	Review	2025
A-06	Pérez-Velasco. MA; Osuna-Sánchez. J; Millán-Gómez. M; Ricci. M; López-Sampalo. A; Bernal-López. MR; Gómez-Huelgas. R; Pérez-Belmonte. LM	In-hospital linagliptin for management simplification and hypoglycemia reduction in very old patients with type 2 diabetes	MEDICINA CLINICA	2.1	Q2	Article	2025
A-06	Carrasco-Fernández. L; García-Sillero. M; García-Romero. J; Benítez-Porres. J	Lower Limb Injuries in Women's Handball. Protocols. and Most Common Tests: A Systematic Review	TRANSLATIONAL SPORTS MEDICINE	1.9	Q2	Review	2025
A-06	Romero-Gómez. M; Escalada. J; Noguerol. M; Pérez. A; Carretero. J; Crespo. J; Mascort. JJ; Aguilar. I; Tinahones. F; Canones. P; Gómez-Huelgas. R; de Luis. D; Trullos. IG; Aller. R; Rubio. MA	Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis	GASTROENTEROLOGIA Y HEPATOLOGIA	1.9	Q3	Article	2025
A-06	Hernández-Negrin. H; Paredes-Ruiz. D; Moreno-Torres. V; Ruiz-Arruza. I; Ruiz-Irastorza. G	No association between socioeconomic deprivation and cardiovascular risk or damage in systemic lupus erythematosus within a universal healthcare system: a cohort study from the Basque Country	REVISTA CLINICA ESPANOLA	1.7	Q2	Article	2025
A-06	De Lucas. MDG; Perez-Belmonte. L; Aviles-Bueno. B; Jimenez-Millan. A; Ruiz. FR; Miramontes-Gonzalez. JP	Results of semaglutide in patients older than 70 years. a real-world study of efficacy and safety	MINERVA ENDOCRINOLOGY	2	Q3	Article	2025
A-06	Ponce-García. T; García-Romero. J; Carrasco-Fernández. L; Castillo-Domínguez. A; Benítez-Porres. J	Sex differences in anaerobic performance in CrossFit® athletes: a comparison of three different all-out tests	PEERJ	2.4	Q2	Article	2025
A-07	Escamilla-Sanchez. A; López-Villodres. JA; Alba-Tercedor. C; Ortega-Jiménez. MV; Rius-Díaz. F; Sanchez-Varo. R; Bermúdez. D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	12.6	D1	Article	2025
A-07	Gavilán. P; Gavilán. JC; Clavijo. E; Viciana. I; Gonzalez-Correa. JA	A prediction model for complications caused by portal hypertension or liver cancer in a Spanish cohort of chronic hepatitis B patients	REVISTA CLINICA ESPANOLA	1.7	Q2	Article	2025
A-07	Ruiz-Malagon. AJ; Herraiz-Vilela. M; Serrano-Pino. R; García-Avila. P; Díaz-Suárez. L; Carmona-Segovia. AD; Becerra-Munoz. VM; Jiménez-Navarro. M; Arranz-Salas. I; Lopez-Villodres. JA; Fernández-Castañer. A; Gutiérrez-Martínez. F; Rodríguez-González. FJ; Camargo-Camero. R; Alcaín-Martínez. G; Rodríguez-Díaz. C; García-Fuentes. E; Sánchez-Quintero. MJ; Lopez-Gomez. C	Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease	WORLD JOURNAL OF GASTROENTEROLOGY	5.4	Q1	Article	2025
A-07	García-Delgado. R; Moreno-Carrasco. G; Carrasco-Gomariz. M; García-Segovia. S; Flores. RMO; Torres-González. J; Gallego-Fuillerat. G; Lopez-Villodres. JA; Escamilla-Sánchez. A	Impact of iron chelation therapy on mitochondrial function. vascular integrity and inflammation in transfusion-dependent myelodysplastic syndromes	FRONTIERS IN IMMUNOLOGY	5.9	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-09	Trenas. A; Perez-Velasco. MA; Bernal-López. MR; López-Carmona. MD; Gómez-Doblas. JJ; Martinez-Esteban. MD; Bouarich. O; Garcia-Casares. N; Fernández-Garcia. D; de Lucas. MDG; Gómez-Huelgas. R; Perez-Belmonte. LM	Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction. type 2 diabetes and obesity: a real-world study	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	D1	Article	2025
A-09	Benítez-Ruiz. L; Repiso. CG; Tinahones. FJ; García-Casares. N	Obesity. Olfaction and Cognition: A Systematic Review	CURRENT OBESITY REPORTS	11	D1	Review	2025
A-09	Ariza. MJ; Coca-Prieto. I; Rioja. J; Muñiz-Grijalvo. O; Zambón-Rados. D; Blanco-Echevarría. A; Arrobas-Velilla. T; Delgado-Lista. J; León-Jiménez. D; Casañas-Martínez. M; Alvarez-Sala. LA; Gutiérrez-Carrasquilla. L; Sánchez-Gil. J; Domènech. M; González-Jiménez. A; Benítez-Toledo. MJ; Espíldora-Hernández. J; de Victoria. EOM; Sánchez-Chaparro. MA; Valdivielso. P	Pathogenicity assessment of genetic variants identified in patients with severe hypertriglyceridemia: Novel cases of familial chylomicronemia syndrome from the Dyslipidemia Registry of the Spanish Atherosclerosis Society	GENETICS IN MEDICINE	6.2	D1	Article	2025
A-09	Florido-Santiago. M; Pérez-Belmonte. LM; Lara. JP; Millán-Gomez. M; Pérez-Velasco. MA; Osuna-Sánchez. J; García-Casares. N; Gomez-Huelgas. R; Blanco-Reina. E; Barbancho. MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	2.8	Q2	Article	2025
A-09	Hermida-Ameijeiras. A; Blasco-Alonso. J; Carrillo-Linares. JL; González-Dieguez. ML; Pastor-Rosado. J; Morales-Conejo. M; Bellusci. M; Mercadal-Hally. M	Childhood to adult transition in youth patients with lysosomal acid lipase deficiency: 43 recommendations from experts	ORPHANET JOURNAL OF RARE DISEASES	3.5	Q2	Article	2025
A-09	Jimenez-López. R; Martin-Chaves. L; Gutierrez-Garcia. AM; Carmona-Segovia. AD; Mora-Ordoñez. B; Sánchez-Garcia. AM; Fernández-Romero. L; Murri. M; Sánchez-Quintero. MJ; Berteli-Garcia. G; Sánchez-Chaparro. MA; Bodi. V; Rodriguez-Capitán. J; Jimenez-Navarro. M; Pavón-Morón. FJ; Romero-Trevejo. JL	Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy	FRONTIERS IN MEDICINE	3	Q1	Article	2025
A-09	Gonzalez-Alegre. J; Arespa-Castello. M; Sánchez-Chaparro. MA	Is Honesty the Fee for Vulnerability? Gender-Based Evaluation of Workers' Sick Leave Determinants Around the COVID-19 Pandemic	JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE	1.4	Q3	Article	2025
A-09	Marin-Gracia. M; Ciano-Petersen. NL; Cabezudo-Garcia. P; Fernández-Sánchez. V; Salazar-Benitez. JA; Muñoz-Zea. R; Vidal-Denis. M; Garcia-Martin. G; Postigo-Pozo. MJ; Garcia-Casares. N; Gutierrez-Cardo. A; Serrano-Castro. PJ	Late-onset Rasmussen encephalitis: 3 illustrative cases and a review of the literature	NEUROLOGIA	3.1	Q2	Review	2025
A-09	Castillo. LC; Belenchón. IR; Sanz. IP; Marenco. RS; Claro. AVO; Martínez. NS; López. RM; Soto. AJ; Ossorio. JLA; Galisteo. EG; Valiente. JC; Imbroda. BH; Jiménez. JM; Casas. JAV; Rodríguez. A; Ortiz. AS; Hernández. JPC; Gómez. EG	Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence	PROSTATE	2.5	Q2	Article	2025
A-09	Sagues. E; Alfaro. F; Ramos-Rodríguez. R; García-Casares. N	Resting-state functional connectivity alterations in post-stroke cognitive impairment: a systematic review	BRAIN IMAGING AND BEHAVIOR	2.4	Q3	Review	2025
A-09	Urbinati. F; Bueno. JAR; Real. PS; Redondo-López. MC; Ortega. AS; García-Arnés. JA; Bedmar. MG; Alba-Linero. C; García-Casares. N	Retinal structure and vasculature changes and their relationship with mild cognitive impairment in type 2 diabetes	JOURNAL OF ALZHEIMERS DISEASE	3.1	Q2	Article	2025
A-09	Ettaghadouini. DA; Gallego-Fuentes. P; Chica-Villa. A; Fontalba-Navas. A; Pérez-Costillas. L; Gutiérrez-Bedmar. M; García-Casares. N	Study on mental health and motivation in undergraduate medical students at the Faculty of Medicine. University of Malaga	EDUCACION MEDICA			Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-10	Shyam. S; Gómez-Martínez. C; Ni. JQ; Gaforio. JJ; Martínez-González. MA; Corella. D; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Lapetra. J; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Martín-Sánchez. V; Pintó. X; Delgado-Rodríguez. M; Matía-Martín. P; Vidal. J; Vázquez. C; Daimiel. L; Ros. E; Fernandez-Aranda. F; Hernández-Cacho. A; Buil-Cosiales. P; Sorli. J; Castañer. O; Garcia-Rios. A; Oncina-Canovas. A; Pérez-Farinós. N; Nafria. M; Casas. R; Martínez-Diz. S; Tojal-Sierra. L; Gómez-Pérez. AM; Toledo. E; Fernández-Carrión. R; Bayón. AM; Torres-Peña. JD; Compañ-Gabucio. L; Vázquez-Ruiz. Z; Babio. N; Fitó. M; Salas-Salvadó. J	COVID-19 and Cognitive Decline in Older Adults with High-Cardiovascular Risk: A Post Hoc Analysis	AGING AND DISEASE	6.9	D1	Article	2025
A-10	Ruiz-Canela. M; Corella. D; Martinez-González. MA; Babio. N; Martinez. JA; Forga. L; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Santos-Lozano. JM; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Martin-Sánchez. V; Riera-Mestre. A; Delgado-Rodriguez. M; Matia-Martin. P; Vidal. J; Vázquez. C; Daimiel. L; Buil-Cosiales. P; Shyam. S; Sorli. JV; Castañer. O; Garcia-Rios. A; Torres-Collado. L; Gómez-Gracia. E; Zulet. MA; Konieczna. J; Casas. R; Cano-Ibáñez. N; Tojal-Sierra. L; Bernal-López. RM; Toledo. E; Garcia-Gavilán. J; Fernández-Carrión. R; Goday. A; Arenas-Larriva. AP; González-Palacios. S; Schroeder. H; Ros. E; Fitó. M; Hu. FB; Tinahones. FJ; Salas-Salvadó. J	Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes A Secondary Analysis of a Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE	15.4	D1	Article	2025
A-10	Ahmadnezhad. L; López-López. D; Becerro-de-Bengoa-Vallejo. R; Jiménez-Cebrián. AM; Losa-Iglesias. ME; Casado-Hernández. I; Alves-Gomes. L; Navarro-Flores. E	Adaptation and validation of the Persian version of the foot Health Status Questionnaire in patients with plantar pain: evaluation of test-retest	ANNALS OF MEDICINE	4.3	Q1	Article	2025
A-10	Vázquez-Lorente. H; Ni. JQ; Paz-Graniel. I; Toledo. E; Corella. D; Castañer. O; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Lapetra. J; Serra-Majem. L; Bouzalmate-Hajjaj. A; Tur. JA; Pérez. RMM; Fanlo. M; Delgado-Rodríguez. M; Bustelo. AB; Vidal. J; Vázquez. C; Daimiel. L; Ros. E; Fernández-Aranda. F; Rognoni. T; Babio. N; Asensio. EM; Pérez-Vega. KA; Garcia-Rios. A; Compañ-Gabucio. L; Cueto-Galán. R; Zulet. MA; Nafria. M; Casas. R; Cano-Ibáñez. N; Tojal-Sierra. L; Gómez-Pérez. AM; Goñi. N; Sorli. JV; Zomeño. MD; Arenas-Larriva. AP; Jiménez-Sellés. P; Basterra-Gortari. J; Fitó. M; Salas-Salvadó. J	Dietary vitamin D intake and 2-year changes in cognitive function in older adults with overweight or obesity and metabolic syndrome	GEROSCIENCE	5.4	Q1	Article	2025
A-10	Real-Pérez. M; Fernández-García. JC; Gavala-González. J	Effects of a 6-month rowing training program in breast cancer survivors	PLOS ONE	2.6	Q2	Article	2025
A-10	Ramírez-Pérez. L; Moreno-Morales. N	Identifying Key Factors in Adherence and Dropouts in Active Physiotherapy in Children with Acute Leukemia: A Systematic Review with Meta-Analysis and Meta-Regression	HEALTHCARE	2.7	Q2	Review	2025
A-10	Prados. JME; Cortés-Rodriguez. A; Losa-Iglesias. ME; Gómez-Salgado. J; Vallejo. RBD; Saavedra-Garcia. MA; López. DL; Jiménez-Cebrián. AM	Mental health and Crohn's disease: evaluating depression through a case-referent study	REVISTA DA ASSOCIACAO MEDICA BRASILEIRA	1.3	Q2	Article	2025
A-10	Shyam. S; Nishi. SK; Ni. JQ; Martínez-González. MA; Corella. D; Schröder. H; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Lapetra. J; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Sánchez. VM; Pintó. X; Delgado-Rodríguez. M; Matía-Martín. P; Vidal. J; Vázquez. C; Daimiel. L; Ros. E; Gaforio. JJ; Ruiz-Canela. M; Fernández-Carrión. R; Goday. A; Garcia-Rios. A; Torres-Collado. L; Cueto-Galán. R; Zulet. MA; Prohens. L; Casas. R; Castillo-Hermoso. MA; Tojal-Sierra. L; Gomez-Pérez. AM; García-Arellano. A; Sorli. JV; Castañer. O; Arenas-Larriva. AP; Oncina-Cánovas. A; Goñi. L; Fitó. M; Babio. N; Salas-Salvadó. J	Pasta Consumption and Cardiometabolic Risks in Older Adults with Overweight/Obesity: A Longitudinal Analysis	JOURNAL OF THE AMERICAN NUTRITION ASSOCIATION	2.6	Q3	Article	2025
A-10	Rubín-García. M; Vitelli-Storelli. F; Alvarez-Alvarez. L; Fitó. M; Vázquez-Ruiz. Z; Salas-Salvadó. J; Corella. D; Serra-Majem. L; Warnberg. J; Romaguera. D; Estruch. R; Pintó. X; Martínez. JA; Vázquez. C; Vidal. J; Tur. JA; Alonso-Gómez. AM; Ros. E; Vioque. J; López-Miranda. J; Bueno-Cavanillas. A; Tinahones. FJ; Lapetra. J; Daimiel. L; Delgado-Rodríguez. M; Matía-Martín. P; Babio. N; Schröder. H; Lamuela-Raventós. RM; Martin-Sánchez. V; Zamora-Ros. R	Prospective association of changes in (poly) phenol intake. body weight and physical activity with inflammatory profile	NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES	3.7	Q1	Article	2025
A-10	Mayorga-Vega. L; Jimenez-Cebrian. AM; Barón-López. FJ; Montiel-Luque. A; Benavente-Marin. JC; Warnberg. J	Reliability of the use of foot pressure pain threshold in adults: a test-retest analysis	PEERJ	2.4	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-10	Cortes-Rodríguez. A; Alves-Gomes. L; Losa-Iglesias. ME; Gomez-Salgado. J; Becerro-de-Bengoa-Vallejo. R; Saavedra-García. MA; Lopez-Lopez. D; Jiménez-Cebrián. AM	Repercussion of kinesiophobia in ankylosing spondylitis: a case-control study	GACETA MEDICA DE MEXICO	0.8	Q3	Article	2025
A-10	Rubín-Garía. M; Vitelli-Storelli. F; Toledo. E; Alvarez-Alvarez. L; Martínez-González. MA; Corella. D; Salas-Salvadó. J; Zomeño. MD; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Santos-Lozano. JM; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Pintó. X; Gaforio. JJ; Matía-Martín. P; Vidal. J; Mas-Fontao. S; Daimiel. L; Ros. E; Vázquez-Ruiz. Z; de la Puente. MF; Alvarez-Sala. A; Pérez-Vegaj. A; García-Rios. A; González-Palacios. S; Gómez-Pérez. A; Zulet. MA; Chaplin. A; Casas. R; Cano-Ibañez. N; Tojal-Sierra. L; Cueto-Galán. R; Buil-Cosiales. P; Gutiérrez-Carrasquilla. L; Sorli. J; Malcampo. M; Ortiz-Morales. AM; Mira-Castejón. LA; Rios. S; Fitó. M; Martín-Sánchez. V	Sex differences in (poly)phenol intake patterns and cardiovascular risk in Spanish adult population at high risk of cardiovascular disease: Cross-sectional findings	NUTRITION	3	Q2	Article	2025
A-10	Ruiz-Sánchez. FJ; Martins. MD; Losa-Iglesias. ME; Becerro-de-Bengoa-Vallejo. R; Gómez-Salgado. J; Saavedra-García. MA; López-López. D; Jiménez-Cebrián. AM	Static Plantar Pressure Distribution Measured Using PodoPrint Aluminum Platform in Multiple Sclerosis Patients: A Case-Control Study	JOURNAL OF FOOT AND ANKLE RESEARCH	2.2	Q2	Article	2025
A-11	Padial. M; Rebollo. A; Jiménez-Salcedo. T; López. V; Avesani. CM; Lindholm. B; Qureshi. AR; Olveira. G	A Pilot Clinical Trial of a Nutrition Education Program on Quality of Life in CKD	CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY	7.1	D1	Article	2025
A-11	Moreso. F; Miñano. JAP; Fructuoso. AS; Jacas. C; Alegret. M; Ferrer. M; Colmenero. J; Belmonte. AA; Jiménez. VL; Pascual. S; Blanca. AM; Galiano. APV; Cachero. A; Rivero. A; Crespo. M; Cuadrado. A; Marcos. AC; Diéguez. MLG; Alvarez. CA; Kareaga. NM; Martinez. JMA; Pagano. G; Santana. EN; Torres. IB; Flores. IP; Alonso-Titos. J; Rodríguez-Soler. M; Alarcón. LM; Alvarez. TMG; Castelló. IB; Gonzalez-Vilatarsana. E; Miras. F; Bravo. MAG	Development and validation of the Neuro-Score: a specific scale to detect and monitor cognitive impairment in kidney or liver transplant recipients	AMERICAN JOURNAL OF TRANSPLANTATION	8.2	D1	Article	2025
A-11	Trenas. A; Perez-Velasco. MA; Bernal-López. MR; López-Carmona. MD; Gómez-Doblas. JJ; Martinez-Esteban. MD; Bouarich. O; Garcia-Casares. N; Fernández-Garcia. D; de Lucas. MDG; Gómez-Huelgas. R; Perez-Belmonte. LM	Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction. type 2 diabetes and obesity: a real-world study	EUROPEAN JOURNAL OF INTERNAL MEDICINE	6.1	D1	Article	2025
A-11	Garcia-Cosio Carmena. Maria Dolores; Farrero. Marta; Blasco Peiro. Maria Teresa; Crespo. Marta; Delgado Jimenez. Juan; Diaz Molina. Beatriz; Fernandez Rivera. Constantino; Garrido Bravo. Iris Paula; Lopez Jimenez. Veronica; Melilli. Edoardo; Mirabet Perez. Sonia; Perez Tamajon. Maria Lourdes; Rangel Sousa. Diego; Rodrigo. Emilio; Cruzado. Josep Maria; Hernandez Marrero. Domingo	Management of Kidney Disease in Heart Transplant Patients: A National Delphi Survey-based Consensus Expert Paper.	Transplantation	5.1	D1	Article	2025
A-11	Gomez-Casado. G; Alonso-Titos. J; Gonzalez-Mesa. E; Ortega-Gomez. A	Compatibility of Post-Kidney Transplant Immunosuppression Therapy with Lactation	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Review	2025
A-11	Gutiérrez. P; Jiménez. L; Martínez. J; Alba. C; Girón. MV; Olveira. G; Ruiz-Esteban. P; Olveira. C	Dry eye disease and morphological changes in the anterior chamber in people with cystic fibrosis	JOURNAL OF CYSTIC FIBROSIS	6	Q1	Article	2025
A-11	Climent. E; Hevilla. F; Padial. M; Barril-Cuadrado. G; Blanca. M; Jiménez-Salcedo. T; López-Picasso. M; Nogueira-Pérez. A; Olveira. G	Psychobiotic Protection of Nutritional Supplements and Probiotics in Patients Undergoing Hemodialysis: A Randomized Trial	NUTRIENTS	5	Q1	Article	2025
A-11	De Lucas. MDG; Perez-Belmonte. L; Aviles-Bueno. B; Jimenez-Millan. A; Ruiz. FR; Miramontes-Gonzalez. JP	Results of semaglutide in patients older than 70 years. a real-world study of efficacy and safety	MINERVA ENDOCRINOLOGY	2	Q3	Article	2025
A-17	Sánchez-Quintero. M; Iboleón. A; Chaves. LM; Vilumbrales. BP; Carmona-Segovia. ADM; López. PM; Romero-Cuevas. M; Rodríguez-Capitán. J; Becerra-Muñoz. VM; Pavón-Morón. FJ; Murri. M	Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement	BIOLOGICS-TARGETS & THERAPY	3.4	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-17	Soto-Navarrete. MT; Pozo-Vilumbrales. B; López-Unzu. MA; Martín-Chaves. L; Durán. AC; Fernández. B	Endocardial-to-mesenchymal transition underlies cardiac outflow tract septation and bicuspid aortic valve formation in the Syrian hamster model	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
A-17	Pozo-Vilumbrales. B; Martín-Chaves. L; López-Unzu. MA; Soto-Navarrete. MT; Pavón-Morón. FJ; Rodríguez-Capitán. J; Fernández. B	Unraveling the molecular complexity of bicuspid aortopathy: Lessons from comparative proteomics	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE	4.2	Q1	Article	2025
A-19	Núñez. O; Olmedo. C; Moreno-Perez. D; Lorusso. N; Martínez. SF; Villalba. PEP; Gutierrez. A; Garcia. MA; Latasa. P; Sancho. R; Mendioroz. J; Martinez-Marcos. M; Platón. EM; Rivera. MVG; Perez-Martinez. O; alvarez-Gil. R; Wagner. ER; Gonzalez-Coviella. NL; Zornoza. M; Barranco. MI; Pacheco. MD; Río. VA; Jaume. MF; Arance. RM; Sancho. BA; Diaz. MM; Batalla. N; Andreu. C; Castilla. J; Cenoz. MG; Ibáñez. AF; Huerta. MH; Pérez. ACI; Sáenz. BB; Lamas. J; Hermoso. L; Cobo. SC; Cuesta. MG; Montenegro. S; Domínguez. M; Jarrín. I; Limia. A; Pastor-Barriuso. R; Monge. S	Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study. Spain. 2023/24 season	EUROSURVEILLANCE	7.8	D1	Article	2025
A-19	Linares-Pineda. TM; Lendinez-Jurado. A; Piserra-López. A; Suárez-Arana. M; Pozo. M; Molina-Vega. M; Picón-César. MJ; Morcillo. S	Longitudinal DNA methylation profiles in saliva of offspring from mothers with gestational diabetes: associations with early childhood growth patterns	CARDIOVASCULAR DIABETOLOGY	10.6	D1	Article	2025
A-19	Oulego-Erroz. I; De Castro-Vecino. MD; González-Cortés. R; Alonso-Ojembarrena. A; Rodriguez-Nuñez. A; Palanca-Arias. D; Quesada-Ortega. U; Sanchiz-Cardenas. S; Murillo-Pozo. MA; López-González. J; Sánchez-Yáñez. P; Valencia-Ramos. J; de la Ballina. AF; Chaves-Caro. N; Borrego-Domínguez. R; Sánchez-Porras. M; Rodríguez-Martínez. M; Carballo-Martín. PJ; Bermúdez-Barrezueta. L; Rodríguez-Fanjul. J; Vivanco-Allende. A; Rodríguez-Campoy. P; Vega-Puyal. L; Gil-Antón. J; Sánchez-Martínez. I; Pérez-Quevedo. O; Muñoyerro-Sesmero. M; de Suso. LBG; Mayordomo-Colunga. J	Lung Ultrasound Score. Severity of Acute Lung Disease. and Prolonged Mechanical Ventilation in Children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE	19.4	D1	Article	2025
A-19	Boneh. RS; Navas-López. VM; Hussey. S; Pujol-Muncunill. G; Lawrence. S; Rolandsdotter. H; Otley. A; Martin-de-Carpi. J; Abramas. L; Herrador-López. M; Castillo. NE; Chen. M; Hurley. M; Wingate. K; Olen. O; Rääf. TE; Yaakov. M; Wierdsma. N; Van Limbergen. J; Wine. E	Modified Crohn's Disease Exclusion Diet Maintains Remission in Pediatric Crohn's Disease: Randomized Controlled Trial	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY	12.2	D1	Article	2025
A-19	Madrid-Rodríguez. A; Peláez-Cantero. MJ; Lendínez-Jurado. A; Suárez-Carrasco. A; Godoy-Molina. E; Gámez-Ruiz. A; Corripio-Mancera. A; Ramón-Telo. Y; García-Ruiz. A; Leiva-Gea. I	Assessing the Impact of a Telemedicine Program on Caregivers of Children With Complex Chronic Conditions: Pre-Post Intervention Study	JMIR PEDIATRICS AND PARENTING	2.3	Q2	Article	2025
A-19	Guerrero-del-Cueto. F; Lobato-Lopez. S; Lozano-Duran. D; Sanchez-Duran. B; Ramirez-Martin. L; Esteban-San-Narciso. B; Sosa-Hernandez. S; Martin-Pedraz. L; Moreno-Perez. D; Leiva-Gea. I; Nuñez-Cuadros. E	Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre-and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital	PEDIATRIC PULMONOLOGY	2.3	Q2	Article	2025
A-19	Hermida-Ameijeiras. A; Blasco-Alonso. J; Carrillo-Linares. JL; González-Dieguez. ML; Pastor-Rosado. J; Morales-Conejo. M; Bellusci. M; Mercadal-Hally. M	Childhood to adult transition in youth patients with lysosomal acid lipase deficiency: 43 recommendations from experts	ORPHANET JOURNAL OF RARE DISEASES	3.5	Q2	Article	2025
A-19	Porcel-Chacón. R; Tapia-Ceballos. L; Ariza-Jimenez. AB; Gómez-Perea. A; Jiménez-Hinojosa. JM; López-Siguero. JP; Leiva-Gea. I	Differences in Metabolic Control Between Different Insulin Use Patterns in Pediatric Patients with Type 1 Diabetes Through Intermittent Glucose Monitoring	DISEASES	3	Q2	Article	2025
A-19	Leiva-Gea. L; Sánchez-Palomino. P; Lendínez-Jurado. A; Corte-Torres. MD; Leiva-Gea. I; Leiva-Gea. A	Effectiveness of Titanium Occlusive Barriers in Guided Bone Regeneration: A Prospective Analysis of Vertical and Horizontal Bone Augmentation	BIOMIMETICS	3.9	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-19	Gomez-Casado. G; Saldaña-Garcia. N; Gonzalez-Mesa. E; Ortega-Gomez. A	Etiology of Delayed Lactogenesis in Obesity	BIOMEDICINES	3.9	Q1	Review	2025
A-19	Martinez-Brocca. MA; Bellido. V; Cardona-Hernandez. R; Castaño. L; Conget. I; Fernández. A; Gila. ALG; Leiva-Gea. I; Mauricio. D	Executive summary. Screening. staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED. SEEN and SEEP	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.8	Q3	Article	2025
A-19	Martinez-Brocca. Maria Asuncion; Bellido. Virginia; Cardona-Hernandez. Roque; Castano. Luis; Conget. Ignacio; Fernandez. Alberto; Gomez Gila. Ana Lucia; Leiva-Gea. Isabel; Mauricio. Didac	Executive summary. Screening. staging and follow-up of type 1 diabetes in preclinical stages: consensus of the scientific societies SED. SEEN and SEEP.	ANALES DE PEDIATRIA	2.1	Q2	Article	2025
A-19	Leiva-Gea. I; Moreno-Jabato. F; Ariza-Jimenez. AB; Lendinez-Jurado. A; Gómez-Perea. A; Romero-Perez. MD; Garcia-Garcia. E; Mata. MAS; Martinez-Moya. G; Momblan. J; Lechuga-Sancho. AM; Gómez-Vida. JM; Mier-Palacios. M; Ranchal-Perez. MD; Vivas-González. G; Cabeza. PC; Fernández-Hernández. E; Jimenez-Martin. AP; Guarino-Narváez. J; de Vera-Gómez. PR; Martinez-Brocca. MA	Glycemic Analysis and Stratification of Pediatric Patients with Type 1 Diabetes Using isCGM in Southern Spain: Insights from the Andiacare Digital Platform	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
A-19	Leiva-Gea. L; Lendínez-Jurado. A; Sánchez-Palomino. P; Delgado-Ramos. B; Corte-Torres. MD; Leiva-Gea. I; Leiva-Gea. A	Guided Bone Regeneration Using a Modified Occlusive Barrier with a Window: A Case Report	BIOMIMETICS	3.9	Q1	Article	2025
A-19	Gómez-Perea. A; Lendínez-Jurado. A; Gallego-Gutiérrez. S; Guerrero-Del-Cueto. F; García-Ruiz. A; de la Torre. C; Cardona-Díaz. F; Leiva-Gea. I	Improvement in Glucometric Outcomes After Control-IQ Initiation in Pediatric and Adolescent Type 1 Diabetes Patients: The Impact of Basal Time in Range	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
A-19	Moreno-Pérez. D; Korobova. A; Croche-Santander. FD; Cordón-Martínez. A; Díaz-Morales. O; Martínez-Campos. L; Pérez-González. E; Martínez-Padilla. MD; Santos-Pérez. JL; Brioso-Galiana. J; Sánchez-Códez. MI; Del Diego-Salas. J; Rivera-Izquierdo. M; Lorusso. N	Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023-2024 Season in Andalusia. Spain (NIRSEGRAND)	VACCINES	3.4	Q2	Article	2025
A-19	Saso-Jiménez. L; Urrutia. I; Calvo. B; Bilbao. JR; Gómez-Gila. AL; Leiva-Gea. I; Jiménez-Sanchis. A; Rica. I; Castano. L; Martínez. R; Collaborative Working Grp	Searching for Monogenic Autoimmune Etiology in Patients With Type 1 Diabetes Onset Before 30 Months of Age	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.1	Q1	Article	2025
A-19	Martín-Hernández. E; Bellusci. M; Pérez-Mohand. P; Medina. PC; Blasco-Alonso. J; Morais-López. A; de las Heras. J; Olivas. SMM; Dougherty-de Miguel. L; Couce. ML; Villarroya. EC; Jiménez. MCG; Moreno-Lozano. PJ; Vives. I; Gil-Campos. M; Stanescu. S; Ceberio-Hualde. L; Camprodón. M; Cortès-Saladelafont. E; López-Urdiales. R; Hurtado. MM; Armenteros. AMM; Córcoles. CS; Peña-Quintana. L; Ruiz-Pons. M; Alcalde. C; Castellanos-Pinedo. F; Dios. E; Barrio-Carreras. D; Martín-Cazaña. M; García-Peris. M; Andrade. JD; García-Volpe. C; de los Santos. M; García-Cazorla. A; del Toro. M; Felipe-Rucián. A; Monroy. MJC; Sánchez-Pintos. P; Matas. A; Ortega. DG; Martín-Rivada. A; Bergua. A; Belanger-Quintana. A; Vitoria. I; Yahyaoui. R; Pérez. B; Morales-Conejo. M; Quijada-Fraile. P	Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry	NUTRIENTS	5	Q1	Article	2025
A-21	Guerrero-Orriach. JL; Carmona-Luque. MD; Rodriguez-Capitan. MJ; Quesada-Muñoz. G	MicroRNA-197-3p Transfection: Variations in Cardiomyocyte Gene Expression with Anaesthetics Drugs in a Model of Hypoxia/Reperfusion	PHARMACEUTICALS	4.8	Q1	Article	2025
A-23	Fernández-Duval. G; Razquin. C; Wang. FL; Yun. H; Hu. J; Guasch-Ferré. M; Rexrode. K; Balasubramanian. R; García-Gavilán. J; Ruiz-Canela. M; Clish. CB; Corella. D; Gómez-Gracia. E; Fiol. M; Estruch. R; Lapetra. J; Fitó. M; Serra-Majem. L; Ros. E; Liang. LM; Dennis. C; Asensio. EM; Castañer. O; Planes. FJ; Salas-Salvadó. J; Hu. FB; Toledo. E; Martínez-González. MA	A multi-metabolite signature robustly predicts long-term mortality in the PREDIMED trial and several US cohorts	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	Article	2025
A-23	Martínez-Montoro. JI; Bandera. B; Gutiérrez-Bedmar. M; Gómez-Pérez. AM; Macías-González. M; Moreno-Indias. I; Tinahones. FJ	Effect of a ketogenic diet. time-restricted eating. or alternate-day fasting on weight loss in adults with obesity: a randomized clinical trial	BMC MEDICINE	8.3	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-23	Robles-Mezcua. Ainhoa; Januzzi. James L; Pavon-Moron. Francisco Javier; Rodriguez-Capitan. Jorge; Lopez-Garrido. Miguel A; Cruzado-Alvarez. Concepcion; Robles-Mezcua. Maria; Gutierrez-Bedmar. Mario; Couto-Mallon. David; Rueda-Calle. Eloy C; Barreiro-Perez. Manuel; Sanchez. Pedro L; Gomez-Doblas. Juan Jose; Jimenez-Navarro. Manuel F; Garcia-Pinilla. Jose M	Effects of sacubitril/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniques.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	Article	2025
A-23	Lopez-Solís. R; Castro-Barquero. S; Donat-Vargas. C; Corrado. M; Arancibia-Riveros. C; Martínez-González. MA; Salas-Salvado. J; Sorlí. JV; Serra-Majem. L; Fito. M; Pinto. X; Fiol. M; Lapetra. J; Gomez-Gracia. E; Toledo. E; Ramírez-Sabio. JB; Babio. N; Estruch. R; Ros. E; Lamuela-Raventos. RM	Lycopene intake and prostate cancer risk in men at high cardiovascular risk: a prospective cohort study	BMC MEDICINE	8.3	D1	Article	2025
A-23	Jiménez-Salva. M; Carmona-Segovia. A; Molina-Ramos. AI; García-Rodríguez. L; Puyol-Ruiz. F; Doncel-Abad. V; Romero-Cuevas. M; Serrano. A; Muñoz-García. A; Flores-López. M; Ortega-Gómez. A; Gutiérrez-Bedmar. M; Rodríguez-Capitán. J; Jiménez-Navarro. M; Pavón-Morón. FJ	Older adults with acute coronary syndrome: the impact of frailty and nutritional status on in-hospital complications	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	Article	2025
A-23	Ruiz-Canela. M; Corella. D; Martinez-González. MA; Babio. N; Martinez. JA; Forga. L; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Santos-Lozano. JM; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Martin-Sánchez. V; Riera-Mestre. A; Delgado-Rodriguez. M; Matia-Martin. P; Vidal. J; Vázquez. C; Daimiel. L; Buil-Cosiales. P; Shyam. S; Sorli. JV; Castañer. O; Garcia-Rios. A; Torres-Collado. L; Gómez-Gracia. E; Zulet. MA; Konieczna. J; Casas. R; Cano-Ibáñez. N; Tojal-Sierra. L; Bernal-López. RM; Toledo. E; Garcia-Gavilán. J; Fernández-Carrión. R; Goday. A; Arenas-Larriva. AP; González-Palacios. S; Schroeder. H; Ros. E; Fitó. M; Hu. FB; Tinahones. FJ; Salas-Salvadó. J	Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes A Secondary Analysis of a Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE	15.4	D1	Article	2025
A-23	Cueto-Galán. R; Fontalba-Navas. A; Gutiérrez-Bedmar. M; Ruiz-Canela. M; Martínez-González. MA; Alves. L; Babio. N; Fitó. M; Ros. E; Fiol. M; Estruch. R; Arós. F; Serra-Majem. L; Pintó. X; Muñoz-Bravo. C; García-Rodríguez. A; Gómez-Gracia. E	Adherence to the Mediterranean diet to prevent or delay hepatic steatosis: a longitudinal analysis within the PREDIMED study	FRONTIERS IN NUTRITION	5.1	Q1	Article	2025
A-23	Muñoz-Bravo. C; Marín-Burdallo. I; González-Herrera. L; Torres. CGP; Lozano-Lorca. M; Jiménez-Moleón. JJ; Olmedo-Requena. R	Copper in colorectal cancer patients: a systematic review and meta-analysis	CARCINOGENESIS	2.9	Q2	Article	2025
A-23	Vázquez-Lorente. H; Ni. JQ; Paz-Graniel. I; Toledo. E; Corella. D; Castañer. O; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Lapetra. J; Serra-Majem. L; Bouzalmate-Hajjaj. A; Tur. JA; Pérez. RMM; Fanlo. M; Delgado-Rodríguez. M; Bustelo. AB; Vidal. J; Vázquez. C; Daimiel. L; Ros. E; Fernández-Aranda. F; Rognoni. T; Babio. N; Asensio. EM; Pérez-Vega. KA; Garcia-Rios. A; Compañ-Gabucio. L; Cueto-Galán. R; Zulet. MA; Nafria. M; Casas. R; Cano-Ibáñez. N; Tojal-Sierra. L; Gómez-Pérez. AM; Goñi. N; Sorli. JV; Zomeño. MD; Arenas-Larriva. AP; Jiménez-Sellés. P; Basterra-Gortari. J; Fitó. M; Salas-Salvadó. J	Dietary vitamin D intake and 2-year changes in cognitive function in older adults with overweight or obesity and metabolic syndrome	GEROSCIENCE	5.4	Q1	Article	2025
A-23	Rodríguez-Capitán. J; Márquez-Camas. P; Carmona-Carmona. J; Moñino. DFA; Chaparro-Muñoz. M; Soler-González. M; del Río. MG; de la Iglesia. TE; Segovia-Reyes. J; Murri. M; Salguero. JRL; Couto-Mallón. D; Romero-Cuevas. M; Pavón-Morón. FJ; Gutiérrez-Bedmar. M; Jiménez-Navarro. M	Etiology of tricuspid regurgitation and mortality: a multicenter cohort study	CLINICAL RESEARCH IN CARDIOLOGY	3.7	Q1	Article	2025
A-23	Ortega. LR; Tapias. JM; Fernández. MJF; Jiménez-Navarro. M; Ortega-Gómez. A; Romero-Cuevas. M; Gómez-Doblas. JJ	In-Hospital Mortality and Costs of Added Morbidity in Heart Failure Patients at a University Hospital: A Retrospective Cross-Sectional Study	JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE	2.3	Q2	Article	2025
A-23	López-Laguna. N; Toledo. E; Hershey. MS; Babio. N; Sorlí. JV; Ros. E; Muñoz. MA; Estruch. R; Lapetra. J; Muñoz-Bravo. C; Fiol. M; Bautista-Castaño. I; Pinto. X; Ortega-Azorín. C; Hernando-Redondo. J; Salas-Salvado. J; Tojal-Sierra. L; Martínez-González. MA; Ruiz-Canela. M	Life's Simple 7 and Risk of Peripheral Artery Disease: Results from the PREDIMED Study and an Updated Meta-Analysis	NUTRIENTS	5	Q1	Article	2025
A-23	Hernando-Redondo. J; Hernáez. A; Sanllorente. A; Pintó. X; Estruch. R; Salas-Salvadó. J; Corella. D; Arós. F; Martínez-González. MA; Subirana. I; Muñoz-Aguayo. D; Malcampo. M; Serra-Majem. L; Romaguera. D; Lapetra. J; Ros. E; Tinahones. F; Lamuela-Raventos. RM; Gómez-Gracia. E; Fitó. M; Castañer. O	Mediterranean Diet Modulates Gene Expression of Cholesterol Efflux Receptors in High-Risk Cardiovascular Patients	MOLECULAR NUTRITION & FOOD RESEARCH	4.2	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
A-23	Shyam. S; Nishi. SK; Ni. JQ; Martínez-González. MA; Corella. D; Schröder. H; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Lapetra. J; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Sánchez. VM; Pintó. X; Delgado-Rodríguez. M; Matía-Martín. P; Vidal. J; Vázquez. C; Daimiel. L; Ros. E; Gaforio. JJ; Ruiz-Canela. M; Fernández-Carrión. R; Goday. A; Garcia-Rios. A; Torres-Collado. L; Cueto-Galán. R; Zulet. MA; Prohens. L; Casas. R; Castillo-Hermoso. MA; Tojal-Sierra. L; Gomez-Pérez. AM; García-Arellano. A; Sorli. JV; Castañer. O; Arenas-Larriva. AP; Oncina-Cánovas. A; Goñi. L; Fitó. M; Babio. N; Salas-Salvadó. J	Pasta Consumption and Cardiometabolic Risks in Older Adults with Overweight/Obesity: A Longitudinal Analysis	JOURNAL OF THE AMERICAN NUTRITION ASSOCIATION	2.6	Q3	Article	2025
A-23	Ruiz-Centeno. C; Cueto-Galán. R; Pena-Andreu. JM; Fontalba-Navas. A	Problematic internet use and its relationship with eating disorders	FRONTIERS IN PUBLIC HEALTH	3.4	Q1	Article	2025
A-23	Urbinati. F; Bueno. JAR; Real. PS; Redondo-López. MC; Ortega. AS; García-Arnés. JA; Bedmar. MG; Alba-Linero. C; García-Casares. N	Retinal structure and vasculature changes and their relationship with mild cognitive impairment in type 2 diabetes	JOURNAL OF ALZHEIMERS DISEASE	3.1	Q2	Article	2025
A-23	Hurtado-Prieto. A; Mariscal-López. E; Gutierrez-Bedmar. M; López-Gigosos. R	Reversed sex disparities in heart failure mortality in Spain. 2000-2023: a population-based analysis of older adults	FRONTIERS IN PUBLIC HEALTH	3.4	Q1	Article	2025
A-23	Rubín-Garía. M; Vitelli-Storelli. F; Toledo. E; Alvarez-Alvarez. L; Martínez-González. MA; Corella. D; Salas-Salvadó. J; Zomeño. MD; Martínez. JA; Alonso-Gómez. AM; Wärnberg. J; Vioque. J; Romaguera. D; López-Miranda. J; Estruch. R; Tinahones. FJ; Santos-Lozano. JM; Serra-Majem. L; Bueno-Cavanillas. A; Tur. JA; Pintó. X; Gaforio. JJ; Matía-Martín. P; Vidal. J; Mas-Fontao. S; Daimiel. L; Ros. E; Vázquez-Ruiz. Z; de la Puente. MF; Alvarez-Sala. A; Pérez-Vegaj. A; García-Rios. A; González-Palacios. S; Gómez-Pérez. A; Zulet. MA; Chaplin. A; Casas. R; Cano-Ibañez. N; Tojal-Sierra. L; Cueto-Galán. R; Buil-Cosiales. P; Gutiérrez-Carrasquilla. L; Sorli. J; Malcampo. M; Ortiz-Morales. AM; Mira-Castejón. LA; Rios. S; Fitó. M; Martín-Sánchez. V	Sex differences in (poly)phenol intake patterns and cardiovascular risk in Spanish adult population at high risk of cardiovascular disease: Cross-sectional findings	NUTRITION	3	Q2	Article	2025
A-23	Ettaghadouini. DA; Gallego-Fuentes. P; Chica-Villa. A; Fontalba-Navas. A; Pérez-Costillas. L; Gutiérrez-Bedmar. M; García-Casares. N	Study on mental health and motivation in undergraduate medical students at the Faculty of Medicine. University of Malaga	EDUCACION MEDICA	0		Article	2025
AA-04	Sánchez-Quintero. M; Iboleón. A; Chaves. LM; Vilumbrales. BP; Carmona-Segovia. ADM; López. PM; Romero-Cuevas. M; Rodríguez-Capitán. J; Becerra-Muñoz. VM; Pavón-Morón. FJ; Murri. M	Circulating PGC-1 and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement	BIOLOGICS-TARGETS & THERAPY	3.4	Q2	Article	2025
AA-04	Jimenez-López. R; Martin-Chaves. L; Gutierrez-Garcia. AM; Carmona-Segovia. AD; Mora-Ordoñez. B; Sánchez-Garcia. AM; Fernández-Romero. L; Murri. M; Sánchez-Quintero. MJ; Berteli-Garcia. G; Sánchez-Chaparro. MA; Bodi. V; Rodriguez-Capitán. J; Jimenez-Navarro. M; Pavón-Morón. FJ; Romero-Trevejo. JL	Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy	FRONTIERS IN MEDICINE	3	Q1	Article	2025
AA-04	Simón-Frapolli. VJ; López-Montalbán. A; Vegas-Aguilar. IM; Generoso-Piñar. M; Fernández-Jiménez. R; Cornejo-Pareja. IM; Sánchez-García. AM; Martínez-López. P; Nuevo-Ortega. P; Reina-Artacho. C; Estecha-Foncea. MA; Gómez-González. AM; González-Jiménez. MB; Avanesi-Molina. E; Tinahones-Madueño. FJ; García-Almeida. JM	Relationship Between Vitamin D Levels with In-Hospital Complications and Morphofunctional Recovery in a Cohort of Patients After Severe COVID-19 Across Different Obesity Phenotypes	NUTRIENTS	5	Q1	Article	2025
AA-15	Aybar. MJT; Larrubia-Valle. JI; Berdún. CP; Carmona-Segovia. AD; Pavón-Morón. FJ; Jiménez-Navarro. MF	At the heart of the classroom: student perspective on teaching methods in Cardiology	SPANISH JOURNAL OF MEDICAL EDUCATION	0.7	Q3	Article	2025
AA-15	Ruiz-Molina. Y; Padial. M; Martin-Bravo. MD; Garcia-Olivares. M; Porras. N; Chicharro. A; Mora-Robles. J; González-Jiménez. A; Sasso. CV; Olveira. G	Targeting Lymphedema in Overweight Breast Cancer Survivors: A Pilot Randomized Controlled Trial of Diet and Exercise Intervention	NUTRIENTS	5	Q1	Article	2025
AA-20	Bujalance-Hoyos. J; de Luna-Rodriguez. ME; González-Escobosa. AC; Ona-González. AM; Alvarez. MJF; Suárez. RL	CuidaVen®. an app for the care of people with vascular access. A care innovation project	ENFERMERIA CLINICA	1.1	Q3	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
AA-20	Sánchez-Lozano. MA; Padilla. AMM; Montilla. JS; Arana. AR; Gil. MJM; Jurado. SJ; Subirats. MB	Development and implementation of a computerised registry for the assessment and monitoring of cancer patients	REVISTA ESPANOLA DE SALUD PUBLICA	0.8	Q4	Article	2025
AA-20	García-Ortega. MA; García-Piñero. JM; Gomez-González. AJ; Medina-Lopez. R; González-García. M; Montero-García. AJ; Morales-Gil. IM	Impact of an Early Discharge Hospital-at-Home Program on Length of Stay and Clinical Outcomes in Preterm Infants: A Case-Control Study	CHILDREN-BASEL	2.1	Q2	Article	2025
AA-20	Bujalance-Hoyos. J; de Luna-Rodríguez. ME; González-Escobosa. AC; Oña-González. AM; Sánchez-Gómez. S; Zamudio-Sánchez. A; Blanco-Mavillard. I	Implementation of a multimodal strategy via a mobile application to reduce catheter failure in patients with vascular access devices in Spain (CUIDAVEN Study): a pre-post intervention study	ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL	4.4	Q1	Article	2025
AA-22	Rodríguez-Martínez. MC; Correia. F; García-Pérez. P	Analysis of Occupational Needs in Refugees and Applicants for International Protection: Scoping Review	SOCIETIES	1.6	Q2	Review	2025
AA-22	Martín-Valero. R; Vega-Morales. AV Sr; Martín-Vega. FJ; Rodriguez-Huguet. M; Rodríguez-Martínez. MC; Vinolo-Gil. MJ	Effectiveness of Augmented Reality in the Teaching of Health University Students: Quasi-Experimental Study	JMIR SERIOUS GAMES	4.1	Q1	Article	2025
AA-22	Ortega-Prados. P; González-Sánchez. M; Galán-Mercant. A	Innovative Rehabilitation of an Anterior Cruciate Ligament Tear in a Football Player: Muscle Chain Approach-A Case Study	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
AA-22	Gonzalez-Sanchez. M; Reina-Ruiz. AJ; Molina-Torres. G; Trzcinska. SK; Carrasco-Vega. E; Lochmannová. A; Galán-Mercant. A	Structural and Psychometric Properties of Neck Pain Questionnaires Through Patient-Reported Outcome Measures: A Systematic Review	MEDICINA-LITHUANIA	2.4	Q1	Review	2025
B-01	Capdevila. J; Hernando. J; Molina-Cerrillo. J; Viñuales. MB; Garcia-Carbonero. R; Teulé. A; Custodio. A; Jimenez-Fonseca. P; Lopez. C; Hierro. C; Carmona-Bayonas. A; Alonso. V; Llanos. M; Sevilla. I; García-Alvarez. A; Alonso-Gordoa. T; Jiménez. IG; Anton-Pascual. B; Sánchez. AM; Grande. E	Cabozantinib plus Atezolizumab in Advanced. Progressive Endocrine Malignancies: A Multicohort. Basket. Phase II Trial (CABATEN/GETNE-T1914)	CLINICAL CANCER RESEARCH	10.2	D1	Article	2025
B-01	Escriche-Escuder. A; García-Almeida. JM; Vegas-Aguilar. IM; Pajares. B; Alba. E; Trinidad-Fernández. M; Roldán-Jiménez. C; Cuesta-Vargas. AI	Effect of a 12-week exercise program on phase angle in women with breast cancer	SUPPORTIVE CARE IN CANCER	3	D1	Article	2025
B-01	Paul. ED; Huraiová. B; Valková. N; Matyasovska. N; Gábrisová. D; Gubová. S; Ignácaková. H; Ondris. T; Gala. M; Barroso. L; Bendiková. S; Bila. J; Buranovská. K; Drobná. D; Krchnáková. Z; Kryvokhyzha. M; Lovisek. D; Mamoilyk. V; Mancikova. V; Vojtassáková. N; Ristová. M; Comino-Méndez. I; Andrasina. I; Morozov. P; Tuschl. T; Pareja. F; Kather. JN; Cekan. P	The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer	NATURE COMMUNICATIONS	15.7	D1	Article	2025
B-01	Escrivá-de-Romani. S; Cejalvo. JM; Alba. E; Friedmann. J; Rodríguez-Lescure. A; Savard. MF; Pezo. RC; Gion. M; Ruiz-Borrego. M; Hamilton. E; Pluard. T; Webster. M; Beeram. M; Linden. H; Saura. C; Shpektor. D; Salim. B; Harvey. P; Hurvitz. SA	Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive. HER2-positive metastatic breast cancer: primary results from atwo-part. multicentre. single-arm. phase 2a study	LANCET ONCOLOGY	35.9	D1	Article	2025
B-01	Hinte. LC; Ghosh. A; Castellano-Castillo. D; Wolfrum. C; von Meyenn. F	An epigenome atlas of mouse adipocytes	MOLECULAR METABOLISM	6.6	Q1	Article	2025
B-01	Guardamagna. M; Berciano-Guerrero. MA; Lavado-Valenzuela. R; Auclin. É; Onieva-Zafra. JL; Plaza-Andrades. I; Oliver. J; Garrido-Aranda. A; Perez-Ruiz. E; Alvarez. M; Ocaña. MC; Queipo-Ortuño. MI; Barragán. I; Rueda-Dominguez. A	Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma	SCIENTIFIC REPORTS	3.9	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
B-01	Cottu. P; Cheeseman. S; Hall. P; Woeckel. A; Scholz. CW; Bria. E; Orlandi. A; Ribelles. N; Vallet. M; Niklas. N; Hogg. C; Aggarwal. S; Moreira. J; Lucerna. M; Collin. SM; Logue. A; Long. GH	Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records	BREAST CANCER RESEARCH AND TREATMENT	3	Q2	Article	2025
B-01	García-Corbacho. J; Indacochea. A; Victoria. I; Moreno. D; Angelats. L; Navarro. AEG; Mezquita. L; Brasó-Maristany. F; Galván. P; Mellado. B; Viñolas. N; Sauri. T; Nogué. M; Adamo. B; Maurel. J; Pineda. E; Gaba. L; Reig. O; Basté. N; Sanfeliu. E; Juan. ME; Prat. A; Schettini. F	Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study	CANCER IMMUNOLOGY IMMUNOTHERAPY	5.1	Q1	Article	2025
B-01	Coakley. MF; Pascual. J; O'Reilly. S	Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians	BJC REPORTS	0		Article	2025
B-01	Boronat-Toscano. A; Queipo-Ortuño. MI; Monfort-Ferré. D; Suau. R; Vaño-Segarra. I; Valldosera. G; Cepero. C; Astiarraga. B; Clua-Ferré. L; Plaza-Andrade. I; Aranega-Martín. L; Cabrinety. L; de Barbarà. CA; Castellano-Castillo. D; Moliné. A; Caro. A; Domènech. E; Sánchez-Herrero. JF; Benaiges-Fernandez. R; Fernández-Veledo. S; Vendrell. J; Ginés. I; Sumoy. L; Manyé. J; Menacho. M; Serena. C	Dialister-driven succinate accumulation is associated with disease activity and postoperative recurrence in Crohn's disease	WORLD JOURNAL OF GASTROENTEROLOGY	5.4	Q1	Article	2025
B-01	Vinicki. M; Pribic. T; Vuckovic. F; Frkatovic-Hodzic. A; Plaza-Andrades. I; Tinahones. F; Raffaele. J; Fernández-García. JC; Lauc. G	Effects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome	GEROSCIENCE	5.4	Q1	Article	2025
B-01	Nadal. E; Martín-Martorell. P; Benítez. JC; Sala. MA; Cedrés. S; Alvarez. C; Dómine. M; Sais. E; Saigí. M; López. R; Vilà. L; Massutí. B; García-Campelo. R; Mesas-Ruiz. A; Insa. A; Plans-Marín. S; Hijazo-Pechero. S; Muñoz-Pinedo. C; Brenes. J; Provencio. M	Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma	LUNG CANCER	4.4	Q1	Article	2025
B-01	Guardamagna. M; Zamorano. E; Albarrán-Artahona. V; Mesas. A; Benitez. JC	Emerging Techniques of Translational Research in Immuno-Oncology: A Focus on Non-Small Cell Lung Cancer	CANCERS	4.4	Q2	Review	2025
B-01	Laborda-Illanes. A; Boutriq. S; Aranega-Martín. L; Castellano-Castillo. D; Sánchez-Alcoholado. L; Plaza-Andrades. I; Peralta-Linero. J; Alba. E; Fernández-García. JC; González-González. A; Queipo-Ortuño. MI	Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
B-01	Comino-Méndez. I; Velasco-Suelto. J; Pascual. J; López-López. E; Quirós-Ortega. ME; Gaona-Romero. C; Martín-Muñoz. A; Losana. P; Heredia. Y; Alba. E; Guerrero-Zotano. A	Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer	BREAST CANCER RESEARCH	5.6	Q1	Article	2025
B-01	Fernández-Forné. A; Fernández-Jiménez. R; Toledo-Serrano. MD; Jiménez-Rodríguez. H; Muñoz-Lupiáñez. M; Ruiz-López. MA; García-Almeida. JM; De la Peña-fernández. L; Queipo-Ortuño. MI; Gómez-Millán. J	Impact of Nutritional Status on Severe Radiation-Induced Mucositis in Oropharyngeal Cancer Patients Undergoing Chemo-Radiotherapy	NUTRIENTS	5	Q1	Article	2025
B-01	López-Miranda. E; Pérez-García. JM; Gión. M; Ribelles. N; Cortez-Castedo. P; Alonso-Romero. JL; García. MM; González-Santiago. S; Bermejo. B; Morales. S; Carañana. V; Garrigós. L; Fernández-Pinto. M; Garcia-Vicente. S; García-Sanz. A; Mena-Molina. A; Boix. O; Alcalá-López. D; Llombart-Cussac. A; Cortés. J	Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial	BREAST CANCER RESEARCH	5.6	Q1	Article	2025
B-01	Gaona-Romero. C; Domínguez-Recio. ME; Comino-Méndez. I; Ortega-Jiménez. MV; Lavado-Valenzuela. R; Alba. E	Luminal and Basal Subtypes Across Carcinomas: Molecular Programs Beyond Tissue of Origin	CANCERS	4.4	Q2	Review	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
B-01	Andúlar. JMC; de la Peña. FA; Vila. MM; Pascual. J; Tolos. P; Pages. C; Cuenca. N; Zotano. AG	Optimizing therapeutic approaches for HR+/HER2advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression	CANCER DRUG RESISTANCE	5.2	Q1	Review	2025
B-01	Godoy-Ortíz. A; Lendínez-Sánchez. G; Zalabardo. M; Pascual. J; Lopez-Pascual. A; Cantero. A; Ribelles. N; Iglesias. M; Villar. E; Pajares. B; Díaz-Redondo. T; Domínguez-Recio. ME; Carabantes. F; Bermejo. MJ; Rueda-Domínguez. A; Alba. E; Sánchez-Muñoz. A	Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy	FRONTIERS IN ONCOLOGY	3.3	Q2	Article	2025
B-01	García-Saenz. JA; Rodríguez-Lescure. A; Cruz. J; Albanell. J; Alba. E; Llombart. A	Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence	TARGETED ONCOLOGY	4	Q2	Review	2025
B-01	Capdevila. J; Tafuto. S; Krogh. M; Teulé. A; Garcia-Carbonero. R; Klümpen. HJ; Cremer. B; Sevilla. I; Eriksson. B; Tabaksblat. E; Metges. JP; Reed. NS; Schrader. J; Navarro. V; Valentí. V; Hernando. J; Colao. AM; Vestermark. L; Carnaghi. C; Knigge. UP; Jimenez-Fonseca. P; Benavent. M; de Vos-Geelen. J; Venerito. M; Von Werder. A; Jann. H; Rinke. A; Smith. D; Hörsch. D; Starling. N; Ruszniewski. P; Baudin. E; Caroli-Bosc. FX; Manzano. JL; Martín. M; Scarpa. A; Lawlor. RT; Ragulan. C; Ps. H; Sadanandam. A; Carmona-Bayonas. A; Salazar. R	Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial	ESMO OPEN	8.3	Q1	Article	2025
B-04	Ocaña. MC; Bernal. M; Quesada. AR; Medina. MA	A primer on metabolic contributions in tumor angiogenic microenvironment	BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER	8.3	D1	Review	2025
B-04	García-Criado. F; Seoane. P; Rojano. E; Ranea. JAG; Perkins. JR	Advancing edge-based clustering and graph embedding for biological network analysis: a case study in RASopathies	BRIEFINGS IN BIOINFORMATICS	7.7	D1	Article	2025
B-04	Sánchez-Molina. A; Bernal. M; Posligua-García. JD; Pérez-Pulido. AJ; de Cubas. L; Hidalgo. E; Valdivieso. MH; Salas-Pino. S; Daga. RR	Hydroxyurea induces an oxidative stress response that triggers ER expansion and cytoplasmic protein aggregation	PLOS BIOLOGY	7.2	D1	Article	2025
B-04	Mela. V; Heras. V; Iesmantaite. M; García-Martín. ML; Bernal. M; Posligua-García. JD; Subiri-Verdugo. A; Martínez-Montoro. JI; Gómez-Pérez. AM; Banderas. B; Indias. IM; Tinahones. FJ	Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis	GUT	26.2	D1	Article	2025
B-04	Pitarch. B; Chagoyen. M; Ranea. JAG; Pazos. F	A review on Gene Ontology evaluations	DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION	3.6	Q1	Review	2025
B-04	Díaz-Santiago. E; Moya-García. AA; Pérez-García. J; Yahyaoui. R; Orengo. C; Pazos. F; Perkins. JR; Ranea. JAG	Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks	FRONTIERS IN PHARMACOLOGY	4.8	Q1	Article	2025
B-04	Cervantes-Santos. JA; Villar-Luna. H; Bojórquez-Orozco. AM; Díaz-Navarro. JE; Arce-Leal. AP; Santos-Cervantes. ME; Claros. MG; Méndez-Lozano. J; Rodríguez-Negrete. EA; Leyva-López. NE	Huanglongbing as a Persistent Threat to Citriculture in Latin America	BIOLOGY-BASEL	3.5	Q1	Review	2025
B-04	García-Criado. F; Hurtado-García. L; Rojano. E; Esteban-Martos. A; Pérez-García. J; Seoane. P; Ranea. JAG	Integrative Transcriptomic and Network-Based Analysis of Neuromuscular Diseases	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
B-04	Serrano. JJ; Medina. MA	Metabolic Reprogramming at the Edge of Redox: Connections Between Metabolic Reprogramming and Cancer Redox State	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
B-04	Entrenas-García. C; Suarez-Cárdenas. JM; Fernández-Rodríguez. R; Bautista. R; Claros. MG; Garrido. JJ; Zaldívar-López. S	miR-215 Modulates Ubiquitination to Impair Inflammasome Activation and Autophagy During Salmonella Typhimurium Infection in Porcine Intestinal Cells	ANIMALS	2.7	Q1	Article	2025
B-04	Rodríguez-García. M; Burgos-Molina. AM; González-Vidal. A; Sendra-Portero. F; Bernal. M; Ruiz-Gómez. MJ	Molecular mechanisms of radiation resistance in colorectal cancer: in silico identification of AURKA. BIRC5 and PLK1 proteins as potential biomarkers	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY	2.4	Q1	Article	2025
B-04	Dakhli. N; López-Jiménez. A; Cárdenas. C; Hraoui. M; Dhaouafi. J; Bernal. M; Sebai. H; Medina. MA	Urtica dioica Aqueous Leaf Extract: Chemical Composition and In Vitro Evaluation of Biological Activities	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
B-04	Rodríguez-Rivero. M; Medina. MA	Vitamin D as a Systemic Regulatory Axis: From Homeostasis to Multiorgan Disease	BIOMEDICINES	3.9	Q1	Review	2025
B-04	Heras. V; Mela. V; Kompella. P; Rojano. E; Paz-López. G; Hurtado-García. L; Ortega-Gomez. A; García-López. MJ; García-Martín. ML; Ranea. JAG; Tinahones. FJ; Moreno-Indias. I	□-Hydroxybutyrate Reduces Body Weight by Modulating Fatty Acid Oxidation and Beiging in the Subcutaneous Adipose Tissue of DIO Mice	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
B-05	Sarno. Francesca; Tenorio. Jair; Perea. Sofia; Medina. Laura; Pazo-Cid. Roberto; Juez. Ignacio; Garcia-Carbonero. Rocio; Feliu. Jaime; Guillen-Ponce. Carmen; Lopez-Casas. Pedro P.; Guerra. Carmen; Duran. Yolanda; Lopez-Acosta. Jose Francisco; Alonso. Carolina; Esquivel. Estrella; Dopazo. Ana; Akshinthala. Dipikaa; Muthuswamy. Senthil K.; Lapunzina. Pablo; Bockorny. Bruno; Hidalgo. Manuel	A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial	CLINICAL CANCER RESEARCH	10.2	D1	Article	2025
B-05	Fodil-Cherif. S; Hadoux. J; Mercier. O; Benitez. JC; Durand. A; Lasolle. H; Perrier. M; Jannin. A; Laboureau. S; Le Bras. M; Chabre. O; Gaujoux. S; Rouiller. LG; Hentic. O; Du Boullay. H; Haissaguerre. M; Kinn. H; Lecomte. T; Goudet. P; Girard. N; Scoazec. JY; Besse. B; Faron. M; Baudin. E	Characterization. Prognosis. and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE. ENDOCAN RENATEN. and RYTHMIC Networks	JOURNAL OF THORACIC ONCOLOGY	20.8	D1	Article	2025
B-05	Hutchings. M; Sureda. A; Bosch. F; Larsen. TS; Corradini. P; Avigdor. A; Terol. MJ; Dominguez. AR; Pinto. A; Skarbnik. A; Cordoba. R; Jorgensen. JM; Zinzani. PL; Leung. W; Bottos. A; Li. DH; Relf. J; Tandon. M; Sellam. G; Gritti. G	Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial	JOURNAL OF CLINICAL ONCOLOGY	43.4	D1	Article	2025
B-05	Provencio. M; Cobo. M; Rodriguez-Abreu. D; Carcereny. E; Castro. RL; Bruno. MF; Bernabé. R; Bosch-Barrera. J; Massuti. B; Sánchez. A; Ortega. AL; Guirado. M; del Barco. E; Camps. C; Lázaro-Quintela. M; Dómine. M; Sala. MA; Medina. K; González-Larriba. JL; Aparisi. F; Oramas. J; Aguiar. D; Cerezo. S; Losada. B; Ruano-Ravina. A; Cantero. A; Ospina-Serrano. AV; Calvo. V	Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain	LANCET REGIONAL HEALTH-EUROPE	13	D1	Article	2025
B-05	Dall'Olio. Filippo G.; Zrafi. Wael; Roelants. Veronique; Ambrosini. Valentina; Fourquet. Aloyse; Mitea. Cristina; Passiglia. Francesco; Bauckneht. Matteo; Bonardel. Gerald; Conci. Nicole; Benitez. Jose Carlos; Arena. Vincenzo; Namour. Celine; Naigeon. Marie; Monnet. Isabelle; Beshiri. Kristi; Hoton. Delphine; Dursun. Safiye; Danlos. Francois Xavier; Argalia. Giulia; Aldea. Mihaela; Rovera. Guido; Derosa. Lisa; Iebba. Valerio; Gietema. Hester A.; Gounant. Valerie; Lacroix. Valerie; Remon. Jordi; Gautheret. Daniel; Chaput. Nathalie; Job. Bastien; Kannouche. Patricia L.; Velasco-Nuno. Monica; Zitvogel. Laurence; Cella. Eugenia; Chicharo de Freitas. Jose Reinaldo; Vasseur. Damien; Bettaieb. Mohamed Aymen; Tagliamento. Marco; Hendriks. Lizza; Italiano. Antoine; Planchard. David; Marabelle. Aurelien; Barlesi. Fabrice; Novello. Silvia; De Andreis. Desiree; Aboubakar Nana. Frank; Ardizzoni. Andrea; Zalcman. Gerard; Garcia. Camilo; Besse. Benjamin	Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates	CLINICAL CANCER RESEARCH	10.2	D1	Article	2025
B-05	Anaya. MJG; Tudela. AC; Gómez-Millán. J; Ocón. MJL; Rodríguez. HJ; Ríos. IG	Once-weekly ultra-hypofractionated radiation therapy for breast cancer: Outcomes from a single-institution real-world cohort	BREAST	7.9	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
B-05	Jurado. JM; Gutiérrez. V; Cantero. A; Berciano-Guerrero. MA; Padilla. A; Pérez-Ruiz. E; Montesa. A; Carabantes. F; Cobo. M	Association Between Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
B-05	Guardamagna. M; Berciano-Guerrero. MA; Lavado-Valenzuela. R; Auclin. É; Onieva-Zafra. JL; Plaza-Andrades. I; Oliver. J; Garrido-Aranda. A; Perez-Ruiz. E; Alvarez. M; Ocaña. MC; Queipo-Ortuño. MI; Barragán. I; Rueda-Dominguez. A	Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
B-05	Brandao. Mariana; Prisciandaro. Elena; Xenophontos. Eleni; Mariolo. Alessio; Sadeghi. Amir H.; Filippi. Andrea R.; Levy. Antonin; Bandura. Artur; Caramella. Caroline; Dickhoff. Chris; de Margerie-Mellon. Constance; Faivre-Finn. Corinne; Portik. Daniel; Sanchez-Lorente. David; De Ruysscher. Dirk; Smit. Egbert; Gobbini. Elisa; Fadel. Elie; Ruffini. Enrico; Olmetto. Emanuela; Cortiula. Francesco; Bahce. Idris; Houda. Ilias; Opitz. Isabelle; Naidoo. Jarushka; Edwards. John; Remon. Jordi; Benitez. Jose Carlos; Trujillo. Juan Carlos; Derks. Jules; Amrane. Karim; Hartemink. Koen J.; Stathopoulos. Konstantinos; Hendriks. Lizza E. L.; Iglesias. Manoli; Occhipinti. Mario; Guckenberger. Matthias; Levra. Niccolo Giaj; Girard. Nicolas; Reguart. Noemi; Mercier. Olaf; Bironzo. Paolo; Hofman. Paul; Petersen. Rene Horsleben; De Angelis. Riccardo; Abgral. Ronan; Terrisse. Safae; Popat. Sanjay; Pierret. Thomas; Blum. Torsten Gerriet; Ricardi. Umberto; Dionisi. Valeria; Berghmans. Thierry; Dingemans. Anne-Marie C.	Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group	LUNG CANCER	4.4	Q1	Article	2025
B-05	Nadal. E; Martín-Martorell. P; Benítez. JC; Sala. MA; Cedrés. S; Alvarez. C; Dómine. M; Sais. E; Saigí. M; López. R; Vilà. L; Massutí. B; García-Campelo. R; Mesas-Ruiz. A; Insa. A; Plans-Marín. S; Hijazo-Pechero. S; Muñoz-Pinedo. C; Brenes. J; Provencio. M	Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma	LUNG CANCER	4.4	Q1	Article	2025
B-05	Guardamagna. M; Zamorano. E; Albarrán-Artahona. V; Mesas. A; Benitez. JC	Emerging Techniques of Translational Research in Immuno-Oncology: A Focus on Non-Small Cell Lung Cancer	CANCERS	4.4	Q2	Review	2025
B-05	Fernández-Forné. A; Fernández-Jiménez. R; Toledo-Serrano. MD; Jiménez-Rodríguez. H; Muñoz-Lupiáñez. M; Ruiz-López. MA; García-Almeida. JM; De la Peña-fernández. L; Queipo-Ortuño. MI; Gómez-Millán. J	Impact of Nutritional Status on Severe Radiation-Induced Mucositis in Oropharyngeal Cancer Patients Undergoing Chemo-Radiotherapy	NUTRIENTS	5	Q1	Article	2025
B-05	García-Aranda. M; Onieva. MA; Martín-García. D; Quirós. R; López. I; Padilla-Ruiz. M; Téllez. T; Martínez-Gálvez. B; Hortas. ML; García-Galindo. A; González-Gomariz. J; Armañanzas. R; Rivas-Ruiz. F; Serrano. A; Barragán-Mallofret. I; Redondo. M	KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
B-05	Godoy-Ortíz. A; Lendínez-Sánchez. G; Zalabardo. M; Pascual. J; Lopez-Pascual. A; Cantero. A; Ribelles. N; Iglesias. M; Villar. E; Pajares. B; Díaz-Redondo. T; Domínguez-Recio. ME; Carabantes. F; Bermejo. MJ; Rueda-Domínguez. A; Alba. E; Sánchez-Muñoz. A	Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy	FRONTIERS IN ONCOLOGY	3.3	Q2	Article	2025
B-05	Gumà. J; Palazón-Carrión. N; Rueda-Domínguez. A; Sequero. S; Calvo. V; García-Arroyo. R; Gómez-Codina. J; Llanos. M; Martínez-Banaclocha. N; Provencio. M	SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025)	CLINICAL & TRANSLATIONAL ONCOLOGY	2.5	Q3	Article	2025
B-07	de los Santos-jiménez. J; Campos-Sandoval. JA; Rosales. T; Ko. B; Alonso. FJ; Márquez. J; Deberardinis. RJ; Matés. JM	Glutaminase-2 Expression Induces Metabolic Changes and Regulates Pyruvate Dehydrogenase Activity in Glioblastoma Cells	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
B-07	Martínez-Padilla. A; Márquez. J; Huerta. MA; Roza. C; Cisneros. E	Loss of Glutaminase 1 in Small Sensory Neurons Prevents Nerve Injury Induced Mechanical Allodynia: Insights From Conditional Knockout Mice	EUROPEAN JOURNAL OF PAIN	3.4	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
B-11	Olmos. D; Lorente. D; Jambrina. A; Tello-Velasco. D; Ovejero-Sánchez. M; Gonzalez-Ginel. I; Romero-Laorden. N; Nunes-Carneiro. D; Balongo. M; Gutierrez-Pecharromán. AM; Llácer. C; Prieto. JD; Perez-Argüelles. D; Arco. FAD; Miguel-Masiá. J; Ruiz-Vico. M; Santos. R; Esteban-Villarrubia. J; Gonzalez-Billalabeitia. E; Jürgens. A; Capone. C; Trevisan. M; Van Sanden. S; Stulnig. G; Hernández. D; López-Casas. PP; Rodriguez-Antolin. A; Castellano. DE; Herrera-Imbroda. B; Castro. E	BRCA1/2 and homologous recombination repair alterations in high-and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes	ANNALS OF ONCOLOGY	65.4	D1	Article	2025
B-11	Necchi. A; Guerrero-Ramos. F; Crispen. PL; Herrera-Imbroda. B; Garje. R; Powles. T; Peyton. CC; Pradere. B; Ku. JH; Shore. N; Bögemann. M; Preston. MA; Xylinas. E; Llano. CSD; Hasan. M; Stitou. H; Bhanvadia. S; Sweiti. H; Psutka. S	TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised. open-label phase 2 trial	LANCET ONCOLOGY	35.9	D1	Article	2025
B-11	Borza. R; Matas-Rico. E; Perrakis. A; Moolenaar. WH	Unlocking the signaling potential of GPI-anchored proteins through lipolytic cleavage	TRENDS IN CELL BIOLOGY	18.1	D1	Article	2025
B-11	Castillo. LC; Belenchón. IR; Sanz. IP; Marenco. RS; Claro. AVO; Martínez. NS; López. RM; Soto. AJ; Ossorio. JLA; Galisteo. EG; Valiente. JC; Imbroda. BH; Jiménez. JM; Casas. JAV; Rodríguez. A; Ortiz. AS; Hernández. JPC; Gómez. EG	Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence	PROSTATE	2.5	Q2	Article	2025
B-11	Pilo. J; Rego-Calvo. A; García-Flores. LA; Arranz-Salas. I; Alvarez-Mancha. AI; Izquierdo. AG; Crujeiras. AB; Alcaide. J; Ortega-Castan. M; Boughanem. H; Macías-González. M	Unraveling TNXB Epigenetic Alterations Through Genome-Wide DNA Methylation Analysis and Their Implications for Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
B-12	Sánchez-Lozano. MA; Padilla. AMM; Montilla. JS; Arana. AR; Gil. MJM; Jurado. SJ; Subirats. MB	Development and implementation of a computerised registry for the assessment and monitoring of cancer patients	REVISTA ESPANOLA DE SALUD PUBLICA	0.8	Q4	Article	2025
B-14	Monreal-Bartolome. A; Castro. A; Perez-Ara. MA; Gili. M; Mayoral. F; Hurtado. MM; Moreno. EV; Botella. C; García-Palacios. A; Baños. RM; López-Del-Hoyo. Y; García-Campayo. J; Montero-Marin. J	Efficacy of a Blended Low-Intensity Internet-Delivered Psychological Program in Patients With Multimorbidity in Primary Care: Randomized Controlled Trial	JOURNAL OF MEDICAL INTERNET RESEARCH	6	D1	Article	2025
B-14	Quero. C; Martín-García. D; Rivas-Ruiz. F; García-Aranda. M; Redondo. M	Comparison of oncological care in a hospital center before and after the integration of specialized oncology services	CLINICAL & TRANSLATIONAL ONCOLOGY	2.5	Q3	Article	2025
B-14	García-Aranda. M; Onieva. MA; Martín-García. D; Quirós. R; López. I; Padilla-Ruiz. M; Téllez. T; Martínez-Gálvez. B; Hortas. ML; García-Galindo. A; González-Gomariz. J; Armañanzas. R; Rivas-Ruiz. F; Serrano. A; Barragán-Mallofret. I; Redondo. M	KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
B-14	Alcaide-Garcia. J; Boughanem. H; García-Aranda. M; Rivas-Ruiz. F; Aguirre. U; García. DM; Padilla-Ruiz. M; Varela-Moreno. E; Robles-Lasarte. M; Baré. M; del Cura. I; Varela. MMM; Quintana. JM; Macías. M; Redondo. M	Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients	COLORECTAL DISEASE	2.7	Q1	Article	2025
B-14	García-Aranda. M; Abitei. C; Martín-García. D; Fúnez. R; Rivas-Ruiz. F; Robles-Lasarte. M; Alcaide-Garcia. J; Téllez. T; Aguirre. U; Borrero-Martín. JJ; del Cura. I; Suárez-Varela. MMM; Quintana. JM; Redondo. M	Long-term prognostic value of apoptotic index in colorectal cancer: a 5-year multicentre cohort study	PATHOLOGY	3	Q2	Article	2025
B-14	Martín-García. D; García-Aranda. M; Varela-Moreno. E; Padilla-Ruiz. M; Zarcos-Pedrinaci. I; Rivas-Ruiz. F; Téllez. T; García-Gutiérrez. S; González. N; Rivero. A; Sarasqueta. C; Perestelo-Pérez. L; Castells. X; Quintana. JM; Sala. M; Redondo. M	Patient-attributable delay and its impact on two-year survival in breast cancer: A multicenter prospective cohort study	EJSO	2.9	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
B-14	Herrera-Imbroda. J; Carbonell-Aranda. V; Guerrero-Pertinez. G; Basnestein-Fonseca. P; Anderberg. P; Varela-Moreno. E; Cuesta-Vargas. A; Garolera. M; Lemmens. E; Berglund. JS; Mayoral-Cleries. F; Goodman-Casanova. JM; Guzman-Parra. J	Temporal Associations Between Cognitive Impairment and Depression in Older Adults: A Longitudinal Analysis	EUROPEAN JOURNAL OF INVESTIGATION IN HEALTH PSYCHOLOGY AND EDUCATION	2.6	Q2	Article	2025
B-14	Alicia. LB; Angeles. OGM; Desirée. MG; Maximino. R; Marilina. GA	Utility of Protein Markers in COVID-19 Patients	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Review	2025
B-22	Bogas. G; Ariza. A; Vázquez-Revuelta. P; Labella. M; Madrigal-Burgaleta. R; Fernández-Santamaría. R; Calvo-Serrano. S; Villar-Chamorro. E; Martín-Clavo. S; Lebrón-Martín. C; Mayorga. C; Doña. I; Torres. MJ	Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes	ALLERGY	12	D1	Article	2025
B-22	Ahn. MJ; Tanaka. K; Paz-Ares. L; Cornelissen. R; Girard. N; Pons-Tostivint. E; Baz. DV; Sugawara. S; Cobo. M; Perol. M; Mascaux. C; Poddubskaya. E; Kitazono. S; Hayashi. H; Hong. MH; Felip. E; Hall. R; Juan-Vidal. O; Brungs. D; Lu. S; Garassino. M; Chargualaf. M; Zhang. Y; Howarth. P; Uema. D; Lisberg. A; Sands. J	Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized. Open-Label Phase III TROPION-Lung01 Study	JOURNAL OF CLINICAL ONCOLOGY	43.4	D1	Article	2025
B-22	Timilsina. M; Buosi. S; Torrente. M; Provencio. M; Cobo. M; Abreu. DR; Castro. RL; Carcereny. E; Curry. E; Novácek. V	Large language model vs. traditional machine learning: Evaluating predictive models for early detection of tumor relapse	EXPERT SYSTEMS WITH APPLICATIONS	7.5	D1	Article	2025
B-22	Herbst. RS; Cho. BC; Zhou. CC; Burotto. M; Dols. MC; Sendur. MAN; Moiseyenko. V; Casarini. I; Nishio. M; Hui. RN; Pons-Tostivint. E; Dudnik. J; Ahmed. S; Okpara. CE; Dutcus. C; Yin. LN; Luo. YW; Chirovsky. D; Bhagwati. N; Abreu. DR	Lenvatinib Plus Pembrolizumab. Pemetrexed. and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study	JOURNAL OF THORACIC ONCOLOGY	20.8	D1	Article	2025
B-22	Peters. S; Paz-Ares. LG; Reck. M; Carbone. DP; Brahmer. JR; Borghaei. H; Lu. S; O'Byrne. KJ; John. T; Ciuleanu. TE; Schenker. M; Caro. RB; Nishio. M; Cobo. M; Lee. JS; Zurawski. B; Pluzanski. A; Aoyama. T; Tschaika. M; Devas. V; Grootendorst. DJ; Ramalingam. SS	Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis	JOURNAL OF THORACIC ONCOLOGY	20.8	D1	Article	2025
B-22	Hochmair. M; Schenker. M; Dols. MC; Kim. TM; Ozyilkan. O; Smagina. M; Leonova. V; Kato. T; Fedenko. A; De Angelis. F; Rittmeyer. A; Gray. JE; Greystoke. A; Aggarwal. H; Huang. QL; Zhao. B; Lara-Guerra. H; Nadal. E	Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy	JOURNAL OF THORACIC ONCOLOGY	20.8	D1	Article	2025
B-22	Pundole. X; Younan. D; Critchlow. CW; Puntis. SR; Soohoo. M; Anderson. ES; Najdi. R; Horinouchi. H; Calvo. V; Cobo. M; Lopez-Castro. R; Bernabe. R; Cho. J; Desai. PA; Ahn. MJ; Provencio. M	A Multi-Country Study of the Clinical Course of Extensive-Stage Small Cell Lung Cancer: A Six-Study Analysis of Real-World Treatment Patterns and Outcomes	CLINICAL EPIDEMIOLOGY	3.2	Q1	Article	2025
B-22	Jurado. JM; Gutiérrez. V; Cantero. A; Berciano-Guerrero. MA; Padilla. A; Pérez-Ruiz. E; Montesa. A; Carabantes. F; Cobo. M	Association Between Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
B-22	Provencio. M; Cobo. M; Rodriguez-Abreu. D; Carcereny. E; Calvo. V; Castro. RL; Bernabé. R; Bruno. MF; Bosch-Barrera. J; del Barco. E; Medina. K; Sanchez-Hernandez. A; Suay. G; Ortega. AL; Vázquez. S; Lazaro-Quintela. M; Guirado. M; Estival. A; Blanco. M; Cantero. A; Massutí. B	Biomarker landscape in advanced NSCLC: insights from a national prospective registry	LUNG CANCER	4.4	Q1	Article	2025
B-22	Peled. N; Tufman. A; Sequist. LV; Pasello. G; Wang. Q; Antonuzzo. L; Larriba. JG; Valdivieso. SM; Dols. MC; Milella. M; Dudnik. J; Martín-Martorell. P; Aranda. IB; Huang. D; Palicio. NV; Scimone. A; Bria. E; Servidio. L; Pimentel. R; Ganiyu. AA; Zhao. J	COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib	ESMO OPEN	8.3	Q1	Article	2025
B-22	Sabaté. JM; Beato-Zambrano. C; Cobo. M; Lemaire. A; Montesarchio. V; Serna-Montros. J; Namane. R; Baccarelli. SM; Rico-Villademoros. F	Naloxegol for the Treatment of Opioid-Induced Constipation in Patients with Cancer Pain: A Pooled Analysis of Real-World Data	CANCERS	4.4	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
B-22	Carbone. DP; Ciuleanu. TE; Cobo. M; Schenker. M; Zurawski. B; Menezes. J; Richardet. E; Felip. E; Cheng. Y; Juan-Vidal. O; Alexandru. A; Mizutani. H; Reinmuth. N; Lu. S; Reck. M; John. T; Scherpereel. A; De Marchi. P; Aoyama. T; Sathyanarayana. P; Grootendorst. DJ; Hu. N; Ip. V; Hung. YH; Paz-Ares. LG	Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final. 6-year outcomes from CheckMate 9LA	ESMO OPEN	8.3	Q1	Article	2025
B-22	Varela. M; Teixidó. C; Alvarez-Fernández. C; Arasanz. H; Peralta. S; Lázaro. M; Calvo. V; Alvarez. R; Baena. J; Valdivia. J; Arriola. E; Bernabé. R; Isla. D; Camacho. C; Massutí. B; Blasco. A; García. T; Cobo. M; Campayo. M; Hijazo-Pechero. S; Callejo. A; Dominguez. M; Nadal. E	Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study	TRANSLATIONAL LUNG CANCER RESEARCH	3.5	Q1	Article	2025
B-22	Godoy-Ortíz. A; Lendínez-Sánchez. G; Zalabardo. M; Pascual. J; Lopez-Pascual. A; Cantero. A; Ribelles. N; Iglesias. M; Villar. E; Pajares. B; Díaz-Redondo. T; Domínguez-Recio. ME; Carabantes. F; Bermejo. MJ; Rueda-Domínguez. A; Alba. E; Sánchez-Muñoz. A	Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy	FRONTIERS IN ONCOLOGY	3.3	Q2	Article	2025
B-22	Macarulla. T; Muñoz. A; de Castro. EM; Castillo. A; Cano. MT; Castet. F; Vidal. R; Ferrández. A; Ghanem. I; Ales. I; Vera. R; Lobo. M; Adeva. J; Melian. M; Gallego. I; Laquente. B; Montes. AF; Peinado. P; Paredes. BG; Pazo. R; Escobar. IG; de Mena. IR; Carrato. A; Aranda. E	Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry	ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY	0		Article	2025
B-22	Solomon. Benjamin J.; Tan. Daniel S. W.; de Castro. Gilberto; Cobo. Manuel; Garassino. Marina Chiara; Zhang. Jun; Johnson. Bruce E.; Lee. Jay M.; Garrido. Pilar; Butler. Andrew A.; Pelletier. Marc R.; Savchenko. Alexander; Ji. Lexiang; Brase. Jan C.; Caparica. Rafael; Demanse. David; Wu. Jincheng; Bossen. Claudia; Mok. Tony	The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials	CANCER RESEARCH COMMUNICATIONS	3.3	Q2	Article	2025
BA-16	Iboleon-Jimenez. A; Sánchez-Quintero. MJ; Carmona-Segovia. ADM; Sojo. B; Fernández-Ramos. AM; García-Rodríguez. L; Molina-Ramos. AI; García-Pinilla. JM; Jimenez-Navarro. M; Ortega-Gomez. A	Circulating mitochondrial biomarkers in acute coronary syndrome	FRONTIERS IN MEDICINE	3	Q1	Article	2025
BA-16	Sánchez-Lozano. MA; Padilla. AMM; Montilla. JS; Arana. AR; Gil. MJM; Jurado. SJ; Subirats. MB	Development and implementation of a computerised registry for the assessment and monitoring of cancer patients	REVISTA ESPANOLA DE SALUD PUBLICA	0.8	Q4	Article	2025
BA-16	Romero-Arana. A; González-Rodríguez. MJ; Sánchez-Vega. P; García-Iglesias. JJ; Gómez-Salgado. J; Romero. A	Educational program to improve knowledge and therapeutic range for self-controlled anticoagulated patients	ATENCION PRIMARIA	1.6	Q2	Article	2025
BA-16	Romero-Arana. A; Martín-Pereira. J; Fagundo-Rivera. J; Gómez-Salgado. J; Romero-Ruiz. A	Importance of the pre-analytical phase of sample collection in the evaluation of the clinical laboratory support process	EDUCACION MEDICA	0		Article	2025
BA-16	Santotoribio. JD; Corral-Pérez. J; Nuñez-Jurado. D; Fatela-Cantillo. D; García-De La Torre. A; Orantes-Maroto. G; Del Valle-Vázquez. L; Del Castillo-Otero. D; Maira-Gonzalez. N; Cobos-Díaz. A; Guerrero. JM; Lopez-Saez. JB	Malignant pleural effusion risk based on a novel tool using homocysteine and carcinoembryonic antigen in pleural fluid: A multicenter study	CLINICAL BIOCHEMISTRY	2.1	Q2	Article	2025
BA-16	Romero-Arana. A; Romero-Sibajas. N; Arroyo-Bello. E; Romero-Ruiz. A; Gómez-Salgado. J	Monitoring and Follow-Up of Patients on Vitamin K Antagonist Oral Anticoagulant Therapy Using Artificial Intelligence: The AIto-Control Project	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
BE-03	Marco-Rico. A; Calvo-Villas. JM; López-Jaime. FJ; Hirnyk. MC; Hernández. MDN; Martín. SH; Entrena-Ureña. L; Marcellini-Antonio. S; Díaz-Jordán. BL; Jurado-Herrera. S; Pérez-González. NF; García-Díaz. C; García-Candel. F; Fernández-Bello. I; Marco-Vera. P	Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study	JOURNAL OF BLOOD MEDICINE	2.7	Q2	Article	2025
BE-03	Wheeler. AP; Abraham. A; Barnes. C; Frandsen. RB; d'Oiron. R; Eichler. H; Hampton. K; López-Jaime. FJ; Lyu. CJ; Tavares. CMM; Nogami. K; Sutton. C; Windyga. J; Zulfikar. B; Castaman. G	Real-World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End-of-Study Results From the explorer6 Non-Interventional Study	HAEMOPHILIA	3	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
BE-15	Martínez-Montoro. JI; Sancho-Marín. R; Ocaña-Wilhelmi. L; Arranz-Salas. I; Ruiz-Campos. N; García-López. MJ; Tinahones. FJ; Gutiérrez-Repiso. C	Gastric microbiota-specific signatures in adults with obesity and Helicobacter pylori-negative gastritis	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	3.6	Q1	Article	2025
BE-15	Ruiz-Malagon. AJ; Herraiz-Vilela. M; Serrano-Pino. R; García-Avila. P; Díaz-Suárez. L; Carmona-Segovia. AD; Becerra-Munoz. VM; Jiménez-Navarro. M; Arranz-Salas. I; Lopez-Villodres. JA; Fernández-Castañer. A; Gutiérrez-Martínez. F; Rodríguez-González. FJ; Camargo-Camero. R; Alcaín-Martínez. G; Rodríguez-Díaz. C; García-Fuentes. E; Sánchez-Quintero. MJ; Lopez-Gomez. C	Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease	WORLD JOURNAL OF GASTROENTEROLOGY	5.4	Q1	Article	2025
BE-15	Martin-Reyes. F; Kentaoui-Bousellam. I; Ruiz-Malagón. AJ; Ho-Plágaro. A; López-Gómez. C; Herraiz-Vilela. M; Alcain-Martínez. G; Camargo-Camero. R; Martos-VanDussen. JV; Camacho-Martel. L; Gutiérrrez-Martínez. F; Arranz-Salas. I; Ortega-Jimenez. MV; Escamilla-Sánchez. A; Daza-González. JJ; Sanchiz-Cardenas. E; Rivas-Becerra. J; García-Fuentes. E; Rodríguez-Pacheco. F; Rodriguez-Diaz. C	Mesenteric adipose tissue in Crohn's disease alters the immune response of the ileal mucosa and increases angiogenesis and fibrosis	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
BE-15	Pilo. J; Rego-Calvo. A; García-Flores. LA; Arranz-Salas. I; Alvarez-Mancha. AI; Izquierdo. AG; Crujeiras. AB; Alcaide. J; Ortega-Castan. M; Boughanem. H; Macías-González. M	Unraveling TNXB Epigenetic Alterations Through Genome-Wide DNA Methylation Analysis and Their Implications for Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
BE-17	Anaya. MJG; Tudela. AC; Gómez-Millán. J; Ocón. MJL; Rodríguez. HJ; Ríos. IG	Once-weekly ultra-hypofractionated radiation therapy for breast cancer: Outcomes from a single-institution real-world cohort	BREAST	7.9	D1	Article	2025
BE-17	Montero-Benitez. MZ; Carmona-Llanos. A; Fernández-Jiménez. R; Román-Jobacho. A; Gómez-Millán. J; Modamio-Molina. J; Cabrera-Cesar. E; Vegas-Aguilar. I; Amaya-Campos. MD; Tinahones. FJ; Molina-Montes. E; Cayón-Blanco. M; García-Almeida. JM	AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia. and Its Correlation with Morphofunctional Assessment Techniques	CANCERS	4.4	Q2	Article	2025
BE-17	Salvador. Segado-Guillot; Jesus. Garcia-Anaya Maria; Dolores. Toledo-Serrano Maria; Angel. Calvo-Tudela; Patricia. Prieto-Granados; Dolores. Torres-Tabanera Maria; Antonio. Medina-Carmona Jose; Jaime. Gomez-Millan	Hypofractionated Accelerated Radiotherapy for Head and Neck Cancer in Fragile Patients	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK	2.2	Q2	Article	2025
BE-17	Lozano-Borbalas. Alicia; Jordi-Ollero. Olivia; Marruecos. Jordi; Farre. Nuria; Planas. Isabel; Toledo. Maria Dolores; Mesia. Ricard; Navarro-Martin. Arturo	Impact of clinical and dosimetric factors on severe oral mucositis in head and neck cancer: insights from a phase II clinical trial	FRONTIERS IN ONCOLOGY	3.3	Q2	Article	2025
BE-17	Fernández-Forné. A; Fernández-Jiménez. R; Toledo-Serrano. MD; Jiménez-Rodríguez. H; Muñoz-Lupiáñez. M; Ruiz-López. MA; García-Almeida. JM; De la Peña-fernández. L; Queipo-Ortuño. MI; Gómez-Millán. J	Impact of Nutritional Status on Severe Radiation-Induced Mucositis in Oropharyngeal Cancer Patients Undergoing Chemo-Radiotherapy	NUTRIENTS	5	Q1	Article	2025
BE-18	Oliveira. CC; Cordoba. J; Pearson. JR; Guruceaga. E; Marín-Sedeño. E; Lopez-Moreno. M; Guadix. JA; García-Caballero. M; Pérez-Pomares. JM; Ruiz-Villalba. A	Revealing the complexity of the epicardial secretome	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
BE-19	García-Cañizares. VM; González-Vidal. A; Burgos-Molina. AM; Mercado-Sáenz. S; Sendra-Portero. F; Ruiz-Gómez. MJ	Common Molecular Mechanisms and Biomarkers in Breast. Colon and Ovarian Cancer	APPLIED SCIENCES-BASEL	2.5	Q2	Article	2025
BE-19	Rodríguez-García. M; Burgos-Molina. AM; González-Vidal. A; Sendra-Portero. F; Bernal. M; Ruiz-Gómez. MJ	Molecular mechanisms of radiation resistance in colorectal cancer: in silico identification of AURKA. BIRC5 and PLK1 proteins as potential biomarkers	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY	2.4	Q1	Article	2025
BE-19	González-Vidal. A; Mercado-Sáenz. S; Lopez-Diaz. B; Burgos-Molina. AM; González-Pedrosa. MP; Sendra-Portero. F; Ruiz-Gomez. MJ	Radiation and SARS-CoV-2 effects on the microbiota. immune system and health	INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY	0.5	Q4	Review	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
BE-21	Escamilla-Sanchez. A; López-Villodres. JA; Alba-Tercedor. C; Ortega-Jiménez. MV; Rius-Díaz. F; Sanchez-Varo. R; Bermúdez. D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	12.6	D1	Article	2025
BE-21	Cueto-Galán. R; Fontalba-Navas. A; Gutiérrez-Bedmar. M; Ruiz-Canela. M; Martínez-González. MA; Alves. L; Babio. N; Fitó. M; Ros. E; Fiol. M; Estruch. R; Arós. F; Serra-Majem. L; Pintó. X; Muñoz-Bravo. C; García-Rodríguez. A; Gómez-Gracia. E	Adherence to the Mediterranean diet to prevent or delay hepatic steatosis: a longitudinal analysis within the PREDIMED study	FRONTIERS IN NUTRITION	5.1	Q1	Article	2025
BE-21	Fontalba-Navas. A; Echeverria. R; Larrea-Killinger. C; Gracia-Arnaiz. M; Soar. C; Arrebola. JP	Association Between the Healthy Eating Index and the Body Mass Index of Older Adults: An Analysis of Food Frequency and Preferences	NUTRIENTS	5	Q1	Article	2025
BE-21	García-Delgado. R; Moreno-Carrasco. G; Carrasco-Gomariz. M; García-Segovia. S; Flores. RMO; Torres-González. J; Gallego-Fuillerat. G; Lopez-Villodres. JA; Escamilla-Sánchez. A	Impact of iron chelation therapy on mitochondrial function. vascular integrity and inflammation in transfusion-dependent myelodysplastic syndromes	FRONTIERS IN IMMUNOLOGY	5.9	Q1	Article	2025
BE-21	Carrasco. GM; Flores. RMO; Delgado. RG; Morcillo. BC; Mas. AIR; Canales. DD; González. MR; Gomariz. MC; Escamilla-Sánchez. A	Impact of Pre-Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis	CANCER MEDICINE	3.1	Q2	Article	2025
BE-21	Martin-Reyes. F; Kentaoui-Bousellam. I; Ruiz-Malagón. AJ; Ho-Plágaro. A; López-Gómez. C; Herraiz-Vilela. M; Alcain-Martínez. G; Camargo-Camero. R; Martos-VanDussen. JV; Camacho-Martel. L; Gutiérrez-Martínez. F; Arranz-Salas. I; Ortega-Jimenez. MV; Escamilla-Sánchez. A; Daza-González. JJ; Sanchiz-Cardenas. E; Rivas-Becerra. J; García-Fuentes. E; Rodríguez-Pacheco. F; Rodriguez-Diaz. C	Mesenteric adipose tissue in Crohn's disease alters the immune response of the ileal mucosa and increases angiogenesis and fibrosis	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
BE-21	Ruiz-Centeno. C; Cueto-Galán. R; Pena-Andreu. JM; Fontalba-Navas. A	Problematic internet use and its relationship with eating disorders	FRONTIERS IN PUBLIC HEALTH	3.4	Q1	Article	2025
BE-21	Ettaghadouini. DA; Gallego-Fuentes. P; Chica-Villa. A; Fontalba-Navas. A; Pérez-Costillas. L; Gutiérrez-Bedmar. M; García-Casares. N	Study on mental health and motivation in undergraduate medical students at the Faculty of Medicine. University of Malaga	EDUCACION MEDICA	0		Article	2025
BE-21	García-Delgado. R; Luque-Lupiáñez. E; Mora-Infante. D; Ortíz-Flores. RM; Cidoncha-Morcillo. B; Torres-González. J; Fontalba-Navas. A; Escamilla-Sánchez. A	Translational Insights into Interferon Alpha's Effects on Immunomolecular Dynamics in Philadelphia-Negative Myeloproliferative Neoplasms	CANCERS	4.4	Q2	Article	2025
BE-23	André. T; Shiu. KK; Kim. TW; Jensen. BV; Jensen. LH; Punt. CJA; Smiths. D; Garcia-Carbonero. R; Alcaide-Garcia. J; Gibbs. P; de la Fouchardiere. C; Rivera. F; Elez. E; Le. DT; Yoshino. T; Zuo. Y; Fogelmans. D; Adelbergs. D; Diaz. LA	Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study	ANNALS OF ONCOLOGY	65.4	D1	Article	2025
BE-23	Arance. A; Berciano-Guerrero. MA; Guo. J; Carlino. MS; Ascierto. PA; Burotto. M; Mortier. L; Queirolo. P; Chiarion-Sileni. V; Schachter. J; Zhang. X; Martin-Liberal. J; Del Vecchio. M; Okpara. CE; Dutcus. C; Zhang. J; Diede. SJ; Neff. T; Long. GV	Randomized. double-blind. phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma	ANNALS OF ONCOLOGY	65.4	D1	Article	2025
BE-23	Cerezuela-Fuentes. P; Gonzalez-Cao. M; Puertolas. T; Manzano. JL; Maldonado. C; Yelamos. O; Berciano-Guerrero. MA; Martin-Liberal. J; Muñoz-Couselo. E; Espinosa. E; Drozdowskyj. A; Berrocal. A; Soria. A; Marquez-Rodas. I; Martin-Algarra. S; Quindos. M; Puig. S	Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis	CLINICAL & TRANSLATIONAL ONCOLOGY	2.5	Q3	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
BE-23	Jurado. JM; Gutiérrez. V; Cantero. A; Berciano-Guerrero. MA; Padilla. A; Pérez-Ruiz. E; Montesa. A; Carabantes. F; Cobo. M	Association Between Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
BE-23	Guardamagna. M; Berciano-Guerrero. MA; Lavado-Valenzuela. R; Auclin. É; Onieva-Zafra. JL; Plaza-Andrades. I; Oliver. J; Garrido-Aranda. A; Perez-Ruiz. E; Alvarez. M; Ocaña. MC; Queipo-Ortuño. MI; Barragán. I; Rueda-Dominguez. A	Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
BE-23	Sánchez-Lozano. MA; Padilla. AMM; Montilla. JS; Arana. AR; Gil. MJM; Jurado. SJ; Subirats. MB	Development and implementation of a computerised registry for the assessment and monitoring of cancer patients	REVISTA ESPANOLA DE SALUD PUBLICA	0.8	Q4	Article	2025
BE-23	Ibáñez. C; Tourís-Lores. M; Montesa. A; López-Campos. F; Ríos. E; Usán. P; Moretones. C; Conde-Estévez. D	Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	3.4	Q2	Review	2025
BE-23	Weichenthal. M; Ellebaek. E; Mangana. J; Asher. N; Gavrilova. I; Kandolf. L; Ugurel. S; Hausschild. A; Meier. F; Leiter. U; Livingstone. E; Gebhardt. C; Gutzmer. R; Ruhlmann. CH; Mahncke-Guldbrandt. L; Haslund. CA; Kopec. S; Teterycz. P; Bender. M; Poudroux. W; Muñoz-Couselo. E; Berciano-Guerrero. MA; Shalamanova. G; Depalo. DK; Brozic. JM; Chiarion-Sileni. V; Arance. A; Ziogas. D; Robert. C; Velde. AOV; Gassama. AA; Shapira. R; Benbetzalel. G; Grynberg. S; Ramelyte. E; Bertoldo. F; Delprete. V; Gaudy-Marqueste. C; Mohr. P; Dummer. R; Ascierto. PA; Gogas. H; Espinosa. E; Lebbé. C; Rutkowski. P; Haanen. J; Schadendorf. D; Svane. IM	Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study	EUROPEAN JOURNAL OF CANCER	7.1	Q1	Article	2025
BE-23	Bujalance-Hoyos. J; de Luna-Rodríguez. ME; González-Escobosa. AC; Oña-González. AM; Sánchez-Gómez. S; Zamudio-Sánchez. A; Blanco-Mavillard. I	Implementation of a multimodal strategy via a mobile application to reduce catheter failure in patients with vascular access devices in Spain (CUIDAVEN Study): a pre-post intervention study	ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL	4.4	Q1	Article	2025
BE-23	Alcaide-Garcia. J; Boughanem. H; García-Aranda. M; Rivas-Ruiz. F; Aguirre. U; García. DM; Padilla-Ruiz. M; Varela-Moreno. E; Robles-Lasarte. M; Baré. M; del Cura. I; Varela. MMM; Quintana. JM; Macías. M; Redondo. M	Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients	COLORECTAL DISEASE	2.7	Q1	Article	2025
BE-23	García-Aranda. M; Abitei. C; Martín-García. D; Fúnez. R; Rivas-Ruiz. F; Robles-Lasarte. M; Alcaide-Garcia. J; Téllez. T; Aguirre. U; Borrero-Martín. JJ; del Cura. I; Suárez-Varela. MMM; Quintana. JM; Redondo. M	Long-term prognostic value of apoptotic index in colorectal cancer: a 5-year multicentre cohort study	PATHOLOGY	3	Q2	Article	2025
BE-23	Mamtani. Ronac; Matsubara. Nobuaki; Pino. Alvaro Montesa; Herranz. Urbano Anido; Sendur. Mehmet A. N.; Gravis. Gwenaelle; Huillard. Olivier; Lee. Hyo Jin; Gafanov. Rustem; Joly. Florence; Bedke. Jens; Sella. Avishay; Chang. Yen-Hwa; Imai. Kentaro; Moreno. Blanca Homet; Xu. Jin Zhi; Alva. Ajjai; Powles. Thomas	Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial	CLINICAL GENITOURINARY CANCER	2.7	Q2	Article	2025
BE-23	García-Alfonso. P; Jimenez-Fonseca. P; Soto-Alsar. J; Baraibar. I; Santos. C; La Casta. A; Ghanem. I; Cortijo. G; Méndez. A; Pazo-Cid. R; Vera. R; Melián. M; Alcaide. J; Graña. B; Páez. D; Gallego. I; Lobo. M; Borregón. M; Montes. A; de Castro. E; Carmona-Bayonas. A; Aranda. E	Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study	ONCOLOGIST	4.2	Q2	Article	2025
BE-23	Cerezuela-Fuentes. P; de la Rosa. CA; Crespo. G; Berciano-Guerrero. MA; Soria. A; Muñoz-Couselo. E; Castro. RL; Majem. M; de Miguel. PA; Manzano. JL; Bellido. L; Lecumberri. MJ; Subias. MC; Guzmán. JCV; Hernández. B; Espinosa. E; Puértolas. T; Sanz. LG; Martínez. JM; Abril. VP; Algarra. SM; Márquez-Rodas. I	Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study	MELANOMA RESEARCH	1.9	Q3	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
BE-23	Pilo. J; Rego-Calvo. A; García-Flores. LA; Arranz-Salas. I; Alvarez-Mancha. AI; Izquierdo. AG; Crujeiras. AB; Alcaide. J; Ortega-Castan. M; Boughanem. H; Macías-González. M	Unraveling TNXB Epigenetic Alterations Through Genome-Wide DNA Methylation Analysis and Their Implications for Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
C-01	Khatib. L; Pique. J; Ciano-Petersen. NL; Criton. G; Birzu. C; Aubart. M; Benaiteau. M; Picard. G; Marignier. R; Carra-Dalliere. C; Ayrignac. X; Psimaras. D; Labauge. PM; Honnorat. J; Cotton. F; Joubert. B	Abnormal Brain MRI in Anti-NMDA Receptor Encephalitis	NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION	8.4	D1	Article	2025
C-01	López-Gambero. AJ; Vargas. A; Fernández-Arjona. MD; Rubio. L; de Ceglia. M; Vera-Fernández. C; Campillo-Calatayud. A; Rivera. P; Fonseca. FRD; Barrios. V; Chowen. JA; Argente. J; Suárez. J	Alteration of IGF-1 bioavailability due to PAPPA2 deficiency leads to sex-specific metabolic disturbances	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	Article	2025
C-01	Moreno-Madrid. I; Arrabal-Gomez. C; Romero-Imbroda. J; Díaz-Casares. A; Fuxe. K; Borroto-Escuela. D; Serrano-Castro. P; Narváez. M	Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour	JOURNAL OF PSYCHO-PHARMACOLOGY	5.5	D1	Article	2025
C-01	Mármol-Rivera. JA; Fernández-Rodríguez. JD; Asenjo. B; López-Rubio. E	Latent diffusion for arbitrary zoom MRI super-resolution	EXPERT SYSTEMS WITH APPLICATIONS	7.5	D1	Article	2025
C-01	Moreno-Madrid. Isabel; Romero-Imbroda. Jesus; Reyes-Bueno. Jose Antonio; Arrabal-Gomez. Carlos; Diaz-Casares. Amelia; Diaz-Sanchez. Estela; Barbancho-Fernandez. Miguel Angel; Fuxe. Kjell; Borroto-Escuela. Dasiel; Serrano-Castro. Pedro; Narvaez. Manuel	Peripheral expression of NPY1R-based heteroreceptor complexes reflects hippocampal neuroimmune status: Novel biomarkers for early Alzheimer's disease detection.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	Article	2025
C-01	Ciano-Petersen. NL; Villagrán-García. M; Muñiz-Castrillo. S; Farina. A; Vogrig. A; Goncalves. D; Nicole. F; Rogemond. V; Picard. G; Aubart. M; Psimaras. D; Oliver. B; Serrano-Castro. PJ; Joubert. B; Honnorat. J	Relapses in Anti-NMDAR Encephalitis: Clinical Characterization and Predictive Features	NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION	8.4	D1	Article	2025
C-01	Agüera-Morales. E; Fernández-Sánchez. VE; Navarro-Mascarell. G; Cabezas-Rodríguez. JA; Peña-Toledo. MA; Reyes-Rodríguez. V; Postigo-Pozo. MJ; Patrignani-Ochoa. G; Geniz-Clavijo. MA; Márquez-Infante. C; Tallon-Aguilar. L; Tinoco-González. J; Padillo-Ruiz. J; Valladares-Sánchez. A; Caballero-Eraso. C; López-Ramírez. C; Alcázar-Caballero. RM; Leyva-Fernández. L; Rodríguez-Acosta. A; Maldonado-Sánchez. R; García-Martín. ML; Somoza-Ramírez. ML; Quijano-Ruiz. B; Macías-Sánchez. MD; Carmona-Sánchez. G; Fernández-López. O; Fernández-Fernández. O	Adipose-derived mesenchymal stem cells for the treatment of Amyotrophic Lateral Sclerosis. A phase I/II safety and efficacy clinical trial	FRONTIERS IN NEUROLOGY	2.8	Q2	Article	2025
C-01	Campanelli. Lorenzo; Galeano. Pablo; Prestia. Federico A; Cuesta. Carolina; Dalmasso. Maria C; Flores-Lopez. Maria; Gona. Cristian; Irureta. Nicolas; Kairiyama. Claudia; Lisso. Julieta; Lopez-Gambero. Antonio Jesus; Mintz. Ines; Medel. Nancy; Campuzano. Karen S; Muchnik. Carolina; Novack. Gisela V; Olivar. Natividad; Quiroga. Ivana; Requena-Ocana. Nerea; Reyes-Bueno. Jose Antonio; Serrano-Castro. Pedro; Sevillano. Zulma; Solis. Patricia; Suarez. Juan; Villella. Ivana; Wukitsevits. Nancy; Castano. Eduardo M; Taragano. Fernando; Kochen. Silvia; Politis. Daniel G; Brusco. Luis I; Rodriguez de Fonseca. Fernando; Morelli. Laura	Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease.	Heliyon	3.6	Q1	Article	2025
C-01	Rocha-de-Lossada. C; Burguera. N; Fernández. J; Ribeiro. F; Ursell. P; Serrano-Castro. PJ; Dick. HB	Cataract Surgery in Cognitive Impairment: Navigating the Accessibility Challenge in European Healthcare	OPHTHALMOLOGY AND THERAPY	3.2	Q1	Review	2025
C-01	Mascaro. RS; Sobrino. TG; Hernandez. AH; Negro. ALP; Jimenez. AA; Pose. AA; Gallego. MDC; Casasnovas. C; Fernandez. CAC; Perez. JE; Cortes. MF; Carrera. MF; Petit. MPG; Munoz. AG; Gutierrez. GG; Martinez. AG; Morales. RJ; Ciano-Petersen. NL; Ulloa. PLM; Hengstl. SM; Sancho. EM; Barrero. FJN; Faubel. FEN; Fernandez. JP; Pascual. SIP; Lucas. JP; Minguez. JP; Perez. MR; Gonzalez. MS; Sotoca. J; Santiago. BR; Garcia, RR; Turon-Sans, J; Carsiy, VV; Mantecona, TS	Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease in Spain	NEUROLOGIA	3.1	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-01	Soler, NGA; Trujillo, LG; García-Ruiz, AJ	Cost of Quality of Life in Advanced Parkinson's Disease: Efficient Strategies for Disease Assessment	REVISTA DE NEUROLOGIA	0.8	Q4	Article	2025
C-01	Brichette-Mieg, I; Alonso-Torres, A; Aliaga-Gaspar, P; Rodríguez-Bada, JL; Reyes-Garrido, V; Urbaneja-Romero, P; Muñoz, C; Díaz-Sánchez, M; Martín-Montañez, E; Cabello-Porras, MD; Oliver-Martos, B; Leyva, L	Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification	FRONTIERS IN IMMUNOLOGY	5.9	Q1	Article	2025
C-01	Pacheco-Sánchez, B; Verheul-Campos, J; Vargas, A; Tovar, R; Rodriguez-Pozo, M; Navarro, JA; López-Gambero, AJ; Baixeras, E; Serrano-Castro, PJ; Suárez, J; Sanjuan, C; Rivera, P; de Fonseca, FR	Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3xTg Humanized Mouse Model of Alzheimer's Disease	NUTRIENTS	5	Q1	Article	2025
C-01	Serrano-Castro, PJ; Caballero-Martínez, F; Campos-Lucas, FJ; Campos-Fernández, D; de Aguilar-Amat, MJ; García, A; Gifreu, A; Santamaría-Rodríguez, I; Poza, JJ; Toledo-Argany, M	Effectiveness and safety of early add-on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV-add study	EPILEPSIA OPEN	2.9	Q2	Article	2025
C-01	Kaswan, ZAM; Bowers, C; Teplyakov, I; Sibtain, A; Munoz-Martin, J; Ahmed, S; Kaffman, L; Giuliano, L; Dietrich, MO; Kaffman, A	Erratic Maternal Care Induces Avoidant-Like Attachment Deficits in a Mouse Model of Early Life Adversity	ENEURO	2.7	Q3	Article	2025
C-01	Blanch, A; Blanco, E	Fluid-crystallised abilities and academic achievement in secondary education and university	EDUCATIONAL PSYCHOLOGY	3	Q1	Article	2025
C-01	Gil-Rodriguez, S; Berdugo-Gómez, M; Claros, S; Romero-Zerbo, SY; Mañas-Padilla, MC; Gómez-Roldán, MD; Blanco-Calvo, E; Garcia-Fernández, M; Santin, LJ	IGF2 modulates behavioral and hippocampal changes induced by chronic cocaine exposure during adolescence in mice	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR	2.5	Q2	Article	2025
C-01	Mena-Vázquez, N; Ortiz-Márquez, F; Ramirez-García, T; Gillis-Onieva, C; Cabezudo-García, P; García-Studer, A; Mucientes, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Manrique-Arija, S; Cano-García, L; Serrano-Castro, PJ; Fernández-Nebro, A	Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis	FRONTIERS IN MEDICINE	3	Q1	Article	2025
C-01	Aguilar-Castillo, MJ; Estivill-Torrús, G; García-Martín, G; Cabezudo-García, P; López-Moreno, Y; Ortega-Pinazo, J; Ramírez-García, T; Ciano-Petersen, NL; Serrano-Castro, PJ	Inflammatory Drug-Resistant Epilepsy Index (IDREI) as a Molecular Compound Biomarker in Focal Epilepsies	BIOMOLECULES	4.8	Q1	Article	2025
C-01	Marin-Gracia, M; Ciano-Petersen, NL; Cabezudo-Garcia, P; Fernández-Sánchez, V; Salazar-Benitez, JA; Muñoz-Zea, R; Vidal-Denis, M; Garcia-Martin, G; Postigo-Pozo, MJ; Garcia-Casares, N; Gutierrez-Cardo, A; Serrano-Castro, PJ	Late-onset Rasmussen encephalitis: 3 illustrative cases and a review of the literature	NEUROLOGIA	3.1	Q2	Review	2025
C-01	Martínez-Padilla, A; Márquez, J; Huerta, MA; Roza, C; Cisneros, E	Loss of Glutaminase 1 in Small Sensory Neurons Prevents Nerve Injury Induced Mechanical Allodynia: Insights From Conditional Knockout Mice	EUROPEAN JOURNAL OF PAIN	3.4	Q1	Article	2025
C-01	Perez, DV; Navarro, M; Segura-Segura, B; Wendelbo, R; Bandres-Ciga, S; Arraez, MA; Arraez, C; Rodriguez-Losada, N	Neuroprotective Effects of Low-Dose Graphenic Materials on SN4741 Embryonic Stem Cells Against ER Stress and MPTP-Induced Oxidative Stress	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
C-01	Verheul-Campos, J; Sanchez-Marin, L; López, Y; Gavito, AL; Grandes, P; Serrano, P; Guerricagoitia, I; Estivill-Torrús, G; Rodriguez-Arias, M; Miñarro, J; Pavón-Morón, FJ; Suárez, J; Serrano, A; de Fonseca, FR	Prior restraint stress counteracts memory deficits associated with adolescent alcohol exposure by targeting both the hippocampal endocannabinoid and glutamatergic systems	DRUG AND ALCOHOL DEPENDENCE	3.6	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-01	Avila-Gámiz, F; Pérez-Cano, AM; Pérez-Berlanga, JM; Zambrana-Infantes, EN; Mañas-Padilla, MC; Gil-Rodríguez, S; Tronel, S; Santín, LJ; de Guevara-Miranda, DL	Sequential physical and cognitive training disrupts cocaine-context associations via multi-level stimulation of adult hippocampal neurogenesis	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
C-01	Sánchez-Marín, L; Jiménez-Castilla, V; Flores-López, M; Navarro, JA; Gavito, A; Blanco-Calvo, E; Santín, LJ; Pavón-Morón, FJ; de Fonseca, FR; Serrano, A	Sex-specific alterations in emotional behavior and neurotransmitter systems in LPA1 receptor-deficient mice	NEUROPHARMACOLOGY	4.6	Q1	Article	2025
C-01	Porras-Perales, O; Sánchez-Marín, L; Medina-Vera, D; Flores-López, M; Martín-Chaves, L; Boccalon, M; Requena-Ocaña, N; García-Marchena, N; Reviriego, R; Santín, LJ; Martin-Fardon, R; Jiménez-Navarro, M; de Fonseca, FR; Serrano, A; Pavón-Morón, FJ	Sex-specific dysregulation of the CX3CL1/CX3CR1 Axis following cocaine exposure: Translational evidence for a potential biomarker of abstinence	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
C-01	Piñar-Morales, R; Durán, R; Bautista-García, A; García-Mansilla, MJ; Aliaga-Gaspar, P; Vives-Montero, F; Barrero-Hernández, FJ	The impact of oxidative stress on symptoms associated with multiple sclerosis	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
C-02	García-Huércano, C; Conejo-Ceron, S; Martínez-Vispo, C; Bellon, JA; Rodríguez-Morejon, A; Tamayo-Morales, O; Moreno-Peral, P	Effectiveness of digital psychological and psychoeducational interventions to prevent anxiety: Systematic review and meta-analysis of randomized controlled trials	PSYCHOLOGICAL MEDICINE	5.5	D1	Review	2025
C-02	Ballesteros, A; Flores-Lopez, M; Sánchez-Torres, AM; Gil-Berrozpe, GJ; Moreno-Izco, L; Gavito, A; Serrano, A; de Fonseca, FR; Cuesta, MJ	Exploring Vascular Endothelial Growth Factor and Other Blood-Brain Barrier Biomarkers in Cognition of First-Episode Psychosis: An Observational Study	JOURNAL OF CLINICAL PSYCHIATRY	4.6	D1	Article	2025
C-02	Ho, PTN; Vernooij, MW; Voortman, T; Rodriguez-Ayllon, M; Neitzel, J	Objective physical activity and Alzheimer's disease burden in the population-based Rotterdam Study	ALZHEIMERS & DEMENTIA	11.1	D1	Article	2025
C-02	Jiménez-Salva, M; Carmona-Segovia, A; Molina-Ramos, AI; García-Rodríguez, L; Puyol-Ruiz, F; Doncel-Abad, V; Romero-Cuevas, M; Serrano, A; Muñoz-García, A; Flores-López, M; Ortega-Gómez, A; Gutiérrez-Bedmar, M; Rodríguez-Capitán, J; Jiménez-Navarro, M; Pavón-Morón, FJ	Older adults with acute coronary syndrome: the impact of frailty and nutritional status on in-hospital complications	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	Article	2025
C-02	Campanelli, Lorenzo; Galeano, Pablo; Prestia, Federico A; Cuesta, Carolina; Dalmasso, Maria C; Flores-Lopez, Maria; Gona, Cristian; Irureta, Nicolas; Kairiyama, Claudia; Lisso, Julieta; Lopez-Gambero, Antonio Jesus; Mintz, Ines; Medel, Nancy; Campuzano, Karen S; Muchnik, Carolina; Novack, Gisela V; Olivar, Natividad; Quiroga, Ivana; Requena-Ocana, Nerea; Reyes-Bueno, Jose Antonio; Serrano-Castro, Pedro; Sevillano, Zulma; Solis, Patricia; Suarez, Juan; Villella, Ivana; Wukitsevits, Nancy; Castano, Eduardo M; Taragano, Fernando; Kochen, Silvia; Politis, Daniel G; Brusco, Luis I; Rodriguez de Fonseca, Fernando; Morelli, Laura	Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease.	Heliyon	3.6	Q1	Article	2025
C-02	Reviriego, R; Flores-López, M; Requena-Ocaña, N; Castilla-Ortega, E; Bordallo, A; De Fonseca, FR; Serrano, A; Garcia-Marchena, N	Characterization of cognitive impairment and contributing factors in patients with substance use disorders: Influence of primary alcohol or cocaine use	ACTA PSYCHOLOGICA	2.7	Q2	Article	2025
C-02	Porras-Perales, O; Segovia-Reyes, J; Crespo-Delgado, A; Ruiz-González, D; Flores-López, M; Medina-Vera, D; Sánchez-Marín, L; Martín-Chaves, L; Requena-Ocaña, N; Molina-Ramos, AI; Ruiz-Ruiz, JJ; de Fonseca, FR; Jiménez-Navarro, M; Rodríguez-Capitán, J; Pavón-Morón, FJ; Serrano, A	Distinct cardiac troponin alterations in patients with cocaine and alcohol use disorders during abstinence for cardiovascular risk assessment	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
C-02	Gómez-Gómez, I; Rodero-Cosano, M; Bellón, JA; Zabaleta-del-Olmo, E; Maderuelo-Fernandez, JA; Moreno-Peral, P; Magallón-Botaya, R; Oliván-Blázquez, B; Casajuana-Closas, M; López-Jiménez, T; Bolíbar, B; Llobera, J; Clavería, A; Sanchez-Perez, A; Motrico, E	Examining the influence of mental health and structural determinants of health on the stage of motivational readiness for health behaviour changes: A path analysis study	JOURNAL OF HEALTH PSYCHOLOGY	2.2	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-02	Flores-López, M; Herrera-Imbroda, J; Requena-Ocaña, N; García-Marchena, N; Araos, P; Verheul-Campos, J; Ruiz, JJ; Pastor, A; de la Torre, R; Bordallo, A; Pavón-Morón, FJ; Fonseca, FRD; Serrano, A	Exploratory study on plasma Acylglycerol and Acylethanolamide dysregulation in substance use and attention-deficit/hyperactivity disorder: Implications for novel biomarkers in dual diagnosis	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
C-02	Uriko, K; Christoforou, A; Motrico, E; Moreno-Peral, P; Akik, BK; Zutic, M; van den Berg, MPL	Paternal peripartum depression: emerging issues and questions on prevention, diagnosis and treatment. A consensus report from the cost action Riseup-PPD	JOURNAL OF REPRODUCTIVE AND INFANT PSYCHOLOGY	1.6	Q2	Article	2025
C-02	Sánchez-Recio, R; Oliván-Blázquez, B; Méndez-López, F; Gascón-Santos, S; Marti-Lluch, R; Zabaleta-Del-Olmo, E; Tamayo-Morales, O; Maderuelo-Fernández, JA; Casajuana, M; López-Jiménez, T; Motrico, E; Gómez-Gómez, I; Sanchez-Perez, A; Rodero-Cosano, ML; Llobera, J; Bellón, JA; Moreno-Peral, P; Bolibar, B; Recio-Rodríguez, JI; Ramos, R; Clavería, A	Self-reported health and depression among EIRA cohort: a moderated mediation model of sex and perceived social support	FRONTIERS IN PSYCHOLOGY	2.9	Q1	Article	2025
C-02	Sánchez-Marín, L; Jiménez-Castilla, V; Flores-López, M; Navarro, JA; Gavito, A; Blanco-Calvo, E; Santín, LJ; Pavón-Morón, FJ; de Fonseca, FR; Serrano, A	Sex-specific alterations in emotional behavior and neurotransmitter systems in LPA1 receptor-deficient mice	NEUROPHARMACOLOGY	4.6	Q1	Article	2025
C-02	Porras-Perales, O; Sánchez-Marín, L; Medina-Vera, D; Flores-López, M; Martín-Chaves, L; Boccalon, M; Requena-Ocaña, N; García-Marchena, N; Reviriego, R; Santín, LJ; Martin-Fardon, R; Jiménez-Navarro, M; de Fonseca, FR; Serrano, A; Pavón-Morón, FJ	Sex-specific dysregulation of the CX3CL1/CX3CR1 Axis following cocaine exposure: Translational evidence for a potential biomarker of abstinence	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
C-02	Equinet L, Enthoven C, Jansen PW, Rodriguez-Ayllon M.	The longitudinal association between sport participation and self-esteem in youth in the Netherlands: The role of sport type	JOURNAL OF SCIENCE AND MEDICINE IN SPORT	3.4	Q1	Article	2025
C-03	López-del-Hoyo, Y; Fernández-Martínez, S; Perez-Aranda, A; Monreal-Bartolom, A; Barceló-Soler, A; Camarero-Grados, L; Armas-Landaeta, C; Guzmán-Parra, J; Carbonell, V; Campos, D; Chen, XY; García-Campay, J	Effectiveness of a Web-Based Self-Guided Intervention (MINDxYOU) for Reducing Stress and Promoting Mental Health Among Health Professionals: Results From a Stepped-Wedge Cluster Randomized Trial	JOURNAL OF MEDICAL INTERNET RESEARCH	6	D1	Article	2025
C-03	Monreal-Bartolome, A; Castro, A; Perez-Ara, MA; Gili, M; Mayoral, F; Hurtado, MM; Moreno, EV; Botella, C; García-Palacios, A; Baños, RM; López-Del-Hoyo, Y; García-Campayo, J; Montero-Marin, J	Efficacy of a Blended Low-Intensity Internet-Delivered Psychological Program in Patients With Multimorbidity in Primary Care: Randomized Controlled Trial	JOURNAL OF MEDICAL INTERNET RESEARCH	6	D1	Article	2025
C-03	Koromina, M; Ravi, A; Panagiotaropoulou, G; Schilder, BM; Humphrey, J; Braun, A; Bidgeli, T; Chatzinakos, C; Coombes, BJ; Kim, J; Liu, XX; Terao, C; O'Connell, KS; Adams, MJ; Adolfsson, R; Alda, M; Alfredsson, L; Andlauer, TFM; Andreassen, OA; Antoniou, A; Baune, BT; Bengesser, S; Biernacka, J; Boehnke, M; Bosch, R; Cairns, MJ; Carr, VJ; Casas, M; Catts, S; Cichon, S; Corvin, A; Craddock, N; Dafnas, K; Dalkner, N; Dannlowski, U; Degenhardt, F; Di Florio, A; Dikeos, D; Fellendorf, FT; Ferentinos, P; Forstner, AJ; Forty, L; Frye, M; Fullerton, JM; Gawlik, M; Gizer, IR; Gordon-Smith, K; Green, MJ; Grigoroiu-Serbanescu, M; Guzman-Parra, J; Hahn, T; Henskens, F; Hillert, J; Jablensky, AV; Jones, L; Jones, I; Jonsson, L; Kelsoe, JR; Kircher, T; Kirov, G; Kittel-Schneider, S; Kogevinas, M; Landén, M; Leboyer, M; Lenger, M; Lissowska, J; Lochner, C; Loughland, C; Macintyre, DJ; Martin, NG; Maratou, E; Mathews, CA; Mayoral, F; Mcelroy, SL; Mcgregor, NW; Mcintosh, A; Mcquillin, A; Michie, P; Mitchell, PB; Moutsatsou, P; Mowry, B; Mueller-Myhsok, B; Myers, RM; Nenadic, I; Nievergelt, CM; Nöthen, MM; Nurnberger, J; Donovan, MO; Donovan, CO; Ophoff, RA; Owen, MJ; Pantelis, C; Pato, C; Pato, MT; Patrinos, GP; Pawlak, JM; Perlis, RH; Porichi, E; Posthuma, D; Ramos-Quiroga, JA; Reif, A; Reininghaus, EZ; Ribasés, M; Rietschel, M; Schall, U; Schofield, PR; Schulze, TG; Scott, L; Scott, RJ; Serretti, A; Smoller, JW; Swiatkowska, B; Artigas, MS; Stein, DJ; Streit, F; Toma, C; Tooney, P; Vawter, MP; Vieta, E; Vincent, JB; Waldman, ID; Weickert, CS; Weickert, T; Witt, SH; Hong, KS; Ikeda, M; Iwata, N; Won, HH; Edenberg, HJ; Ripke, S; Raj, T; Coleman, JRI; Mullins, N	Fine-mapping genomic loci refines bipolar disorder risk genes	NATURE NEUROSCIENCE	20	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-03	O'Connell, KS; Koromina, M; van der Veen, T; Boltz, T; David, FS; Yang, JMK; Lin, KH; Wang, X; Coleman, JRI; Mitchell, BL; McGrouther, CC; Rangan, AV; Lind, PA; Koch, E; Harder, A; Parker, N; Bendl, J; Adorjan, K; Agerbo, E; Albani, D; Alemany, S; Alliey-Rodriguez, N; Als, TD; Andlauer, TFM; Antoniou, A; Ask, H; Bass, N; Bauer, M; Beins, EC; Bigdeli, TB; Pedersen, CB; Boks, MP; Borte, S; Bosch, R; Brum, M; Brumpton, BM; Brunkhorst-Kanaan, N; Budde, M; Bybjerg-Grauholm, J; Byerley, W; Cabana-Domínguez, J; Cairns, MJ; Carpiniello, B; Casas, M; Cervantes, P; Chatzinakos, C; Chen, HC; Clarence, T; Clarke, TK; Claus, I; Coombes, B; Corfield, EC; Cruceanu, C; Cuellar-Barboza, A; Czerski, PM; Dafnas, K; Dale, AM; Dalkner, N; Degenhardt, F; DePaulo, JR; Djurovic, S; Drange, OK; Escott-Price, V; Fanous, AH; Fellendorf, FT; Ferrier, IN; Forty, L; Frank, J; Frei, O; Freimer, NB; Fullard, JF; Garnham, J; Gizer, IR; Gordon, SD; Gordon-Smith, K; Greenwood, TA; Grove, J; Guzman-Parra, J; Ha, TH; Hahn, T; Haraldsson, M; Hautzinger, M; Havdahl, A; Heilbronner, U; Hellgren, D; Herms, S; Hickie, IB; Hoffmann, P; Holmans, PA; Huang, MC; Ikeda, M; Jamain, S; Johnson, JS; Jonsson, L; Kalman, JL; Kamatani, Y; Kennedy, JL; Kim, E; Kim, J; Kittel-Schneider, S; Knowles, JA; Kogevinas, M; Kranz, TM; Krebs, K; Kushner, SA; Lavebratt, C; Lawrence, J; Leber, M; Lee, HJ; Liao, C; Lucae, S; Lundberg, M; MacIntyre, DJ; Maier, W; Maihofer, AX; Malaspina, D; Manchia, M; Maratou, E; Martinsson, L; Mattheisen, M; McGregor, NW; McInnis, MG; McKay, JD; Medeiros, H; Meyer-Lindenberg, A; Millischer, V; Morris, DW; Moutsatsou, P; Mühleisen, TW; O'Donovan, C; Olsen, CM; Panagiotaropoulou, G; Papiol, S; Pardiñas, AF; Park, HY; Perry, A; Pfennig, A; Pisanu, C; Potash, JB; Quested, D; Rapaport, MH; Regeer, EJ; Rice, JP; Rivera, M; Schulte, EC; Senner, F; Shadrin, A; Shilling, PD; Sigurdsson, E; Sindermann, L; Sirignano, L; Siskind, D; Slaney, C; Sloofman, LG; Smeland, OB; Smith, DJ; Sobell, JL; Artigas, MS; Stein, DJ; Stein, F; Su, MH; Sung, H; Swiatkowska, B; Terao, C; Tesfaye, M; Tesli, M; Thorgeirsson, TE; Thorp, JG; Toma, C; Tondo, L; Tooney, PA; Tsai, SJ; Tsermpini, EE; Vawter, MP; Vedder, H; Vreeker, A; Walters, JTR; Winsvold, BS; Witt, SH; Won, HH; Ye, R; Young, AH; Zandi, PP; Zillich, L; Adolfsson, R; Alda, M; Alfredsson, L; Backlund, L; Baune, BT; Bellivier, F; Bengesser, S; Berrettini, WH; Biernacka, JM; Boehnke, M; Borglum, AD; Breen, G; Carr, VJ; Catts, S; Cichon, S; Corvin, A; Craddock, N; Dannlowski, U; Dikeos, D; Etain, B; Ferentinos, P; Frye, M; Fullerton, JM; Gawlik, M; Gershon, ES; Goes, FS; Green, MJ; Grigoroiu-Serbanescu, M; Hauser, J; Henskens, FA; Hjerling-Leffler, J; Hougaard, DM; Hveem, K; Iwata, N; Jones, I; Jones, LA; Kahn, RS; Kelsoe, JR; Kircher, T; Kirov, G; Kuo, PH; Landén, M; Leboyer, M; Li, QS; Lissowska, J; Lochner, C; Loughland, C; Luykx, JJ; Martin, NG; Mathews, CA; Mayoral, F; McElroy, SL; McIntosh, AM; McMahon, FJ; Medland, SE; Melle, I; Milani, L; Mitchell, PB; Morken, G; Mors, O; Mortensen, PB; Müller-Myhsok, B; Myers, RM; Myung, W; Neale, BM; Nievergelt, CM; Nordentoft, M; Nöthen, MM; Nurnberger, JI; O'Donovan, MC; Oedegaard, KJ; Olsson, T; Owen, MJ; Paciga, SA; Pantelis, C; Pato, CN; Pato, MT; Patrinos, GP; Pawlak, JM; Ramos-Quiroga, JA; Reif, A; Reininghaus, EZ; Ribasés, M; Rietschel, M; Ripke, S; Rouleau, GA; Roussos, P; Saito, T; Schall, U; Schalling, M; Schofield, PR; Schulze, TG; Scott, LJ; Scott, RJ; Serretti, A; Smoller, JW; Squassina, A; Stahl, EA; Stefansson, H; Stefansson, K; Stordal, E; Streit, F; Sullivan, PF; Turecki, G; Vaaler, AE; Vieta, E; Vincent, JB; Waldman, ID; Weickert, CS; Weickert, TW; Werge, T; Whiteman, DC; Zwart, JA; Edenberg, HJ; McQuillin, A; Forstner, AJ; Mullins, N; Di Florio, A; Ophoff, RA; Kim, JW; Lee, YK; Kang, JH; Cheon, MJ; Kim, DJ; Aslan, M; Harvey, PD; Andreassen, OA; Huang, GD	Genomics yields biological and phenotypic insights into bipolar disorder	NATURE	48.5	D1	Article	2025
C-03	O'Connell, KS; Adolfsson, R; Andlauer, TFM; Bauer, M; Baune, B; Biernacka, JM; Carpiniello, B; Cichon, S; Craddock, N; Cuellar-Barboza, AB; Dannlowski, U; Degenhardt, F; Dikeos, D; Ferentinos, P; Forstner, AJ; Frye, MA; Fullerton, JM; Grigoroiu-Serbanescu, M; Guzman-Parra, J; Jones, L; Jonsson, L; Kircher, T; Kogevinas, M; Landen, M; Lissowska, J; Lochner, C; Manchia, M; Mayoral, F; Mcelroy, SL; Mcgregor, NW; Meyer-Lindenberg, A; Mitchell, PB; Müller-Myhsok, B; Nöthen, MM; Patrinos, GP; Pawlak, JM; Reif, A; Rietschel, M; Schofield, PR; Schulze, TG; Serretti, A; Smoller, JW; Squassina, A; Stein, DJ; Streit, F; Swiatkowska, B; Tondo, L; Vieta, E; Waldman, ID; Dale, AM; Andreassen, OA	New Genomics Discoveries Across the Bipolar Disorder Spectrum Implicate Neurobiological and Developmental Pathways	BIOLOGICAL PSYCHIATRY	9	D1	Review	2025
C-03	León-Campos, A; Quemada-González, C; Gutiérrez-Rodríguez, L; Pérez-Ardanaz, B; García-Mayor, S; Kaknani-Uttumchandani, S; Martí-García, C	The Impact of Video-Assisted Debriefing on Fostering Self-Critical Thinking in Mental Health Nursing Students	JOURNAL OF NURSING MANAGEMENT	4	D1	Article	2025
C-03	Carbonell-Aranda, V; García-Illanes, Y; Traverso-Rodríguez, M; Bordallo-Aragón, A; Moreno-Kustner, B; Guzmán-Parra, J; Herrera-Imbroda, J	A Transition to Discharge Program for the Reduction of Early Readmission in a Mental Health Inpatient Unit: Study Protocol	PSYCHIATRY INTERNATIONAL	1.1	Q4	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-03	Herrera-Imbroda, J; Carbonel-Aranda, V; García-Illanes, Y; Aguilera-Serrano, C; Bordallo-Aragón, A; García-Spínola, E; Torres-Campos, D; Villagrán, JM; García-Sanchez, JA; Mayoral-Cleries, F; Guzmán-Parra, J	An Exploratory Study about Factors and Outcomes Associated with the Experience of Coercive Measures in Mental Health Settings	PSYCHIATRIC QUARTERLY	2.9	Q2	Article	2025
C-03	Martí-García, C; Quemada-González, C; Aguilera-Serrano, C; Martín, YM; García-Caro, MP	Changing the narrative: A qualitative study on the impact of media portrayals on people with schizophrenia	PLOS ONE	2.6	Q2	Article	2025
C-03	García, IR; Pérez, NP; Torres, FG; Delgado, LO; Torralvo, FJS; López, MP; Marzalo, CF; Olveira, G	Comparison of the digestive tolerance of an oligomeric versus a polymeric oral nutritional supplement in people with anorexia nervosa. A randomised crossover clinical trial	EUROPEAN JOURNAL OF CLINICAL NUTRITION	3.3	Q2	Article	2025
C-03	Flores-López, M; Herrera-Imbroda, J; Requena-Ocaña, N; García-Marchena, N; Araos, P; Verheul-Campos, J; Ruiz, JJ; Pastor, A; de la Torre, R; Bordallo, A; Pavón-Morón, FJ; Fonseca, FRD; Serrano, A	Exploratory study on plasma Acylglycerol and Acylethanolamide dysregulation in substance use and attention-deficit/hyperactivity disorder: Implications for novel biomarkers in dual diagnosis	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
C-03	Lorente-Català, R; Diaz-Garcia, A; Jaen, I; Gili, M; Mayoral, F; Garcia-Campayo, J; López-Del-Hoyo, Y; Castro, A; Hurtado, MM; Planting, CHM; Garcia-Palacios, A	Implementation of Evidence-Based Psychological Treatments to Address Depressive Disorders: A Systematic Review	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Review	2025
C-03	Villalta, L; Elias, M; Llorens, M; Vall-Roqué, H; Romero-González, M; Valencia-Agudo, F	Implementation of the incredible years-ASLD® program in autism and preterm children with communication and/or socialization difficulties in Spain (FIRST STEPS): a feasibility study	CHILDREN AND YOUTH SERVICES REVIEW	1.7	Q1	Article	2025
C-03	Sepúlveda-Muñoz, J; González, CQ; Lara, MMH; García, AMG; Martí-García, C; Pérez-Bryan, JMGH; Morales-Asencio, JM	Management of Psychosis and Schizophrenia by Primary Care GPs: A Cross-Sectional Study in Spain	JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH	2.5	Q2	Article	2025
C-03	Hurtado, MM; Villena, A; Quemada, C; Morales-Asencio, JM	Personal relationships during and after an initial psychotic episode. First-person experiences	JOURNAL OF MENTAL HEALTH	3.2	Q1	Article	2025
C-03	Petri-Romao, P; Martínez-Alés, G; Martinez-Morata, I; Moreno-Küstner, B; Fernández-Jiménez, E; Hecker, I; Melchior, M; Mittendorfer-Rutz, E; Sijbrandij, M; Walter, H; Witteveen, AB; Ayuso-Mateos, JL; Bravo-Ortiz, MF; Kalisch, R; Puhlmann, LMC; Mediavilla, R	Resilience changes and occupational resilience factors among healthcare workers during and after the COVID-19 pandemic: A 2-year prospective cohort study	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
C-03	Ettaghadouini, DA; Gallego-Fuentes, P; Chica-Villa, A; Fontalba-Navas, A; Pérez-Costillas, L; Gutiérrez-Bedmar, M; García-Casares, N	Study on mental health and motivation in undergraduate medical students at the Faculty of Medicine, University of Malaga	EDUCACION MEDICA	0		Article	2025
C-03	Herrera-Imbroda, J; Carbonell-Aranda, V; Guerrero-Pertinez, G; Basnestein-Fonseca, P; Anderberg, P; Varela-Moreno, E; Cuesta-Vargas, A; Garolera, M; Lemmens, E; Berglund, JS; Mayoral-Cleries, F; Goodman-Casanova, JM; Guzman-Parra, J	Temporal Associations Between Cognitive Impairment and Depression in Older Adults: A Longitudinal Analysis	EUROPEAN JOURNAL OF INVESTIGATION IN HEALTH PSYCHOLOGY AND EDUCATION	2.6	Q2	Article	2025
C-03	Ramírez-Martín, A; Sirignano, L; Foo, JC; Streit, F; Frank, J; Witt, SH; Rietschel, M; Mayoral-Cleries, F; Moreno-Küstner, B; Guzmán-Parra, J	The relationships between impulsivity and mood in bipolar disorder: An ecological momentary assessment study	PLOS ONE	2.6	Q2	Article	2025
C-03	Lamarca, M; Romero-Castillejo, A; Balsells-Mejia, S; Lopez-Carrilero, R; Vila-Badia, R; Pousa, E; Grasa, E; Barrigon, M; Birulés, I; Peláez, T; Gutiérrez-Zotes, A; Cabezas, A; Lorente-Rovira, E; Cid, J; Ruiz-Delgado, I; González-Higueras, F; Legido, T; Moreno-Küstner, B; Barajas, A; Ochoa, S	The Role of Sex, Quality of Life, Self-Esteem and Cognitive Insight in Reducing Personal Stigma in Psychosis	CLINICAL PSYCHOLOGY & PSYCHOTHERAPY	2.7	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-03	Mora, F; Ramos-Quiroga, JA; Baca-García, E; Crespo, JM; Gutiérrez-Rojas, L; Madrazo, A; Costillas, LP; Saiz, PA; Tordera, V; Vieta, E	Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects	FRONTIERS IN PSYCHIATRY	3.4	Q1	Article	2025
C-03	Villena, A; Hurtado, MM; Gómez, C; Amor, G; Vega, A; Morales-Asencio, JM	Users remain overlooked: Shared decision-making processes for people with anxiety disorders	JOURNAL OF PSYCHIATRIC AND MENTAL HEALTH NURSING	2.9	Q1	Article	2025
C-05	León-Rodríguez, A; Grondona, JM; Marín-Wong, S; López-Aranda, MF; López-Avalos, MD	Long-term reprogramming of primed microglia after moderate inhibition of CSF1R signaling	GLIA	5.1	Q1	Article	2025
C-06	de Ceglia, M; Tovar, R; Rodriguez-Pozo, M; Vargas, A; Gavito, A; Suarez, J; Baixeras, E; de Fonseca, FR; Decara, J	A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models	BIOCHEMICAL PHARMACOLOGY	5.6	D1	Article	2025
C-06	López-Gambero, AJ; Vargas, A; Fernández-Arjona, MD; Rubio, L; de Ceglia, M; Vera-Fernández, C; Campillo-Calatayud, A; Rivera, P; Fonseca, FRD; Barrios, V; Chowen, JA; Argente, J; Suárez, J	Alteration of IGF-1 bioavailability due to PAPPA2 deficiency leads to sex-specific metabolic disturbances	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	Article	2025
C-06	Maaloul, A; Manríquez, CP; Decara, J; Marí-Beffa, M; alvarez-Torres, D; Redoli, SL; Martínez-Albardonedo, B; Araya-Rojas, M; Fajardo, V; Díaz, RTA	Biological Effects of Polysaccharides from Bovistella utriformis as Cytotoxic, Antioxidant, and Antihyperglycemic Agents: In Vitro and In Vivo Studies	PHARMACEUTICS	5.5	D1	Article	2025
C-06	Ballesteros, A; Flores-Lopez, M; Sánchez-Torres, AM; Gil-Berrozpe, GJ; Moreno-Izco, L; Gavito, A; Serrano, A; de Fonseca, FR; Cuesta, MJ	Exploring Vascular Endothelial Growth Factor and Other Blood-Brain Barrier Biomarkers in Cognition of First-Episode Psychosis: An Observational Study	JOURNAL OF CLINICAL PSYCHIATRY	4.6	D1	Article	2025
C-06	Jiménez-Salva, M; Carmona-Segovia, A; Molina-Ramos, AI; García-Rodríguez, L; Puyol-Ruiz, F; Doncel-Abad, V; Romero-Cuevas, M; Serrano, A; Muñoz-García, A; Flores-López, M; Ortega-Gómez, A; Gutiérrez-Bedmar, M; Rodríguez-Capitán, J; Jiménez-Navarro, M; Pavón-Morón, FJ	Older adults with acute coronary syndrome: the impact of frailty and nutritional status on in-hospital complications	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	Article	2025
C-06	de Ceglia, M; Botticelli, L; Di Bonaventura, EM; Fuentes, AV; Di Bonaventura, MVM; de Fonseca, FR; Cifani, C	Targeting the endocannabinoid/paracannabinoid systems in binge eating behavior: Efficacy of dual ligands in a preclinical model	PHARMACOLOGICAL RESEARCH	10.5	D1	Article	2025
C-06	de Ceglia, M; Rasheed, N; Tovar, R; Pareja-Cerbán, I; Arias-Sáez, A; Gavito, A; Gaetani, S; Cifani, C; de Fonseca, FR; Decara, J	A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
C-06	Castro-Zavala, A; Nieto-Nieves, AE; Melgar-Locatelli, S; Medina-Rodriguez, L; Mañas-Padilla, MC; Castilla-Ortega, E	A persistent increase in gut permeability correlates with emotional dysregulation following maternal separation in male and female mice	BEHAVIOURAL BRAIN RESEARCH	2.3	Q2	Article	2025
C-06	Fernández-Espejo, E; de Fonseca, FR	Association of Hemispheric Asymmetry of Dopamine-Transporter Binding with Risk of Parkinsonian Depression	MOVEMENT DISORDERS CLINICAL PRACTICE	2.7	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-06	Campanelli, Lorenzo; Galeano, Pablo; Prestia, Federico A; Cuesta, Carolina; Dalmasso, Maria C; Flores-Lopez, Maria; Gona, Cristian; Irureta, Nicolas; Kairiyama, Claudia; Lisso, Julieta; Lopez-Gambero, Antonio Jesus; Mintz, Ines; Medel, Nancy; Campuzano, Karen S; Muchnik, Carolina; Novack, Gisela V; Olivar, Natividad; Quiroga, Ivana; Requena-Ocana, Nerea; Reyes-Bueno, Jose Antonio; Serrano-Castro, Pedro; Sevillano, Zulma; Solis, Patricia; Suarez, Juan; Villella, Ivana; Wukitsevits, Nancy; Castano, Eduardo M; Taragano, Fernando; Kochen, Silvia; Politis, Daniel G; Brusco, Luis I; Rodriguez de Fonseca, Fernando; Morelli, Laura	Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease.	Heliyon	3.6	Q1	Article	2025
C-06	de Ceglia, M; Romano, A; Di Bonaventura, MVM; Gavito, A; Botticelli, L; Di Bonaventura, EM; Friuli, M; Cifani, C; de Fonseca, FR; Gaetani, S	Cafeteria Diet Abstinence Induces Depressive Behavior and Disrupts Endocannabinoid Signaling in Dopaminergic Areas: A Preclinical Study	CURRENT NEURO-PHARMACOLOGY	5.3	Q1	Article	2025
C-06	Reviriego, R; Flores-López, M; Requena-Ocaña, N; Castilla-Ortega, E; Bordallo, A; De Fonseca, FR; Serrano, A; Garcia-Marchena, N	Characterization of cognitive impairment and contributing factors in patients with substance use disorders: Influence of primary alcohol or cocaine use	ACTA PSYCHOLOGICA	2.7	Q2	Article	2025
C-06	Martín-Martín, J; Santos, I; Gaitán-Arroyo, MJ; Suarez, J; Rubio, L; Martín-de-las-Heras, S	Dental color measurement to estimate age in adults: a systematic review and meta-analysis	FORENSIC SCIENCE MEDICINE AND PATHOLOGY	1.4	Q3	Review	2025
C-06	Porras-Perales, O; Segovia-Reyes, J; Crespo-Delgado, A; Ruiz-González, D; Flores-López, M; Medina-Vera, D; Sánchez-Marín, L; Martín-Chaves, L; Requena-Ocaña, N; Molina-Ramos, AI; Ruiz-Ruiz, JJ; de Fonseca, FR; Jiménez-Navarro, M; Rodríguez-Capitán, J; Pavón-Morón, FJ; Serrano, A	Distinct cardiac troponin alterations in patients with cocaine and alcohol use disorders during abstinence for cardiovascular risk assessment	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
C-06	Pacheco-Sánchez, B; Verheul-Campos, J; Vargas, A; Tovar, R; Rodriguez-Pozo, M; Navarro, JA; López-Gambero, AJ; Baixeras, E; Serrano-Castro, PJ; Suárez, J; Sanjuan, C; Rivera, P; de Fonseca, FR	Early Oral Administration of D-Chiro-Inositol Reverses Hippocampal Insulin and Glutamate Signaling Deficits in the 3xTg Humanized Mouse Model of Alzheimer's Disease	NUTRIENTS	5	Q1	Article	2025
C-06	Benítez-Marín, MJ; Blasco-Alonso, M; de Fonseca, FD; Jiménez, JS; Rivera, P; González-Mesa, E	Evaluating neuronal damage biomarkers at birth for predicting neurodevelopmental risks in foetal growth restriction	ACTA PAEDIATRICA	2.1	Q2	Review	2025
C-06	de-Sola, J; Mestre-Pintó, JI; Villanueva-Blasco, VJ; Talledo, H; Serrano, A; Rubio, G; de Fonseca, FR	Evolution of Problematic Mobile Phone Use in the Spanish Population over the Last Decade	BEHAVIORAL SCIENCES	2.5	Q2	Article	2025
C-06	Flores-López, M; Herrera-Imbroda, J; Requena-Ocaña, N; García-Marchena, N; Araos, P; Verheul-Campos, J; Ruiz, JJ; Pastor, A; de la Torre, R; Bordallo, A; Pavón-Morón, FJ; Fonseca, FRD; Serrano, A	Exploratory study on plasma Acylglycerol and Acylethanolamide dysregulation in substance use and attention-deficit/hyperactivity disorder: Implications for novel biomarkers in dual diagnosis	PROGRESS IN NEURO-PSYCHOPHAR-MACOLOGY & BIOLOGI-CAL PSYCHIATRY	3.9	Q1	Article	2025
C-06	Pacheco-Sánchez, B; Melgar-Locatelli, S; López-Merchán, R; Benítez-Marín, MJ; Blasco-Alonso, M; González-Mesa, E; Tovar, R; Rubio, P; Suárez, J; Sanjuan, C; de Fonseca, FR; Alén, F; de Ceglia, M; Rivera, P	Gestational saccharin consumption disrupts gut-brain axis glucose homeostasis control in adolescent offspring rats in a sex-dependent manner	BIOLOGY OF SEX DIFFERENCES	5.1	Q1	Article	2025
C-06	Melgar-Locatelli, S; Mañas-Padilla, MD; Rivera, P; Rodriguez-Perez, C; Castilla-Ortega, E	High-Phenolic Cocoa Enhances Drug-Induced Reinstatement of Cocaine-Conditioned Place Preference Independently of Increasing Adult Hippocampal Neurogenesis	FOOD SCIENCE & NUTRITION	3.8	Q2	Article	2025
C-06	Aguilar-Castillo, MJ; Estivill-Torrús, G; García-Martín, G; Cabezudo-García, P; López-Moreno, Y; Ortega-Pinazo, J; Ramírez-García, T; Ciano-Petersen, NL; Serrano-Castro, PJ	Inflammatory Drug-Resistant Epilepsy Index (IDREI) as a Molecular Compound Biomarker in Focal Epilepsies	BIOMOLECULES	4.8	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-06	Medina-Vera, D; Martín-Chaves, L; Sánchez-Marín, L; Díaz-Ottaviano, M; Gavito, AL; Popova, O; Sánchez-Quintero, MJ; Rodríguez-Capitán, J; de Fonseca, FR; Jiménez-Navarro, MF; Serrano, A; Pavón-Morón, FJ	Maladaptive stress-coping behavior in CX3CR1-deficient mice: Impact of adolescent stress and alcohol exposure on neuroimmune responses and inflammation	NEUROPHARMACOLOGY	4.6	Q1	Article	2025
C-06	Campanelli, L; Sendoya, JM; Brody, S; Galeano, P; Do Carmo, S; Cuello, AC; Castaño, EM; Gonzalés-Jimenez, A; Verheul, J; Medina-Vera, D; de Fonseca, FR; Wernersson, R; Morelli, L	New insights into the molecular biology of Alzheimer's-like cerebral amyloidosis achieved through multi-omics approaches	PLOS ONE	2.6	Q2	Article	2025
C-06	Montagud-Romero, S; González-Portilla, M; Mellado, S; Grandes, P; de Fonseca, FR; Pascual, M; Rodríguez-Arias, M	Oleoylethanolamide effects on stress-induced ethanol consumption: A lipid at the crossroads between stress, reward and neuroinflammation	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
C-06	González-Portilla, M; Montagud-Romero, S; de Fonseca, FR; Rodríguez-Arias, M	Oleoylethanolamide restores stress-induced prepulse inhibition deficits and modulates inflammatory signaling in a sex-dependent manner	PSYCHOPHARMACOLOGY	3.3	Q2	Article	2025
C-06	Serrano, M; Saumell-Esnaola, M; Ocerin, G; del Caño, GG; Soria-Gómez, E; Mimenza, A; Puente, N; Bonilla-Del Río, I; Ramos-Uriarte, A; Reguero, L; Christie, BR; de Fonseca, FR; Rodríguez-Arias, M; Gerrikagoitia, I; Grandes, P	Omega-3 Fatty Acids Mitigate Long-Lasting Disruption of the Endocannabinoid System in the Adult Mouse Hippocampus Following Adolescent Binge Drinking	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
C-06	Rodríguez-Pozo, M; Pacheco-Sánchez, B; Ben Rabaa, M; De Ceglia, M; Melgar-Locatelli, S; Santos, I; de Fonseca, FR; Suárez, J; Rivera, P	Perinatal Ethanol Exposure Induces Astrogliosis and Decreases GRP55/PEA-Mediated Neuroprotection in Hippocampal Astrocytes of the 3xTg Alzheimer's Animal Model	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
C-06	Perez-Gutierrez, AM; Flórez, G; Blanco, V; Vázquez, FL; Abelli-Deulofeu, E; Ortega, L; Serrano, A; Arias, F; Navarrete, F; Fonseca, F; Estevez, V; Trigo, JG; Facal, F; Arrojo, M; Manzanares, J; Muga, R; Miquel, L; de Fonseca, FR; Torrens, M; Rubio, G; Costas, J	Predictive performance for alcohol use disorder of polygenic scores based on the general addiction risk factor and problematic alcohol use	DRUG AND ALCOHOL DEPENDENCE	3.6	Q1	Article	2025
C-06	Verheul-Campos, J; Sanchez-Marin, L; López, Y; Gavito, AL; Grandes, P; Serrano, P; Guerricagoitia, I; Estivill-Torrús, G; Rodriguez-Arias, M; Miñarro, J; Pavón-Morón, FJ; Suárez, J; Serrano, A; de Fonseca, FR	Prior restraint stress counteracts memory deficits associated with adolescent alcohol exposure by targeting both the hippocampal endocannabinoid and glutamatergic systems	DRUG AND ALCOHOL DEPENDENCE	3.6	Q1	Article	2025
C-06	Sánchez-Marín, L; Canoluk, B; Verheul-Campos, J; Gavito, AL; Reviriego, R; Pavón-Morón, FJ; Serrano, A; De Fonseca, FR	Prior stress history shapes adolescent alcohol-induced transcriptional changes in striatal glutamatergic and endocannabinoid pathways	ADICCIONES	1.8	Q3	Article	2025
C-06	Vadas, E; López-Gambero, AJ; Vargas, A; Rodríguez-Pozo, M; Rivera, P; Decara, J; Serrano, A; Martín-de-las-Heras, S; de Fonseca, FR; Suárez, J	Region-Specific Impact of Repeated Synthetic Cannabinoid Exposure and Withdrawal on Endocannabinoid Signaling, Gliosis, and Inflammatory Markers in the Prefrontal Cortex and Hippocampus	BIOMOLECULES	4.8	Q1	Article	2025
C-06	Villanueva-Blasco, VJ; Eslava, D; Olave-Porrúa, L; Quintana, JB; de Fonseca, FR	Selective prevention programs for substance and behavioral addictions in adolescents: a systematic review	FRONTIERS IN PSYCHOLOGY	2.9	Q1	Review	2025
C-06	Fernández-Espejo, E; Guerra, MD; Castellano, S; de Fonseca, FR; de Pablos, AM	Serum Myeloperoxidase Activity Is Associated with Hoehn-Yahr Staging and Striatal Dopamine-Transporter Binding in Parkinson's Disease	MOVEMENT DISORDERS CLINICAL PRACTICE	2.7	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-06	Sánchez-Marín, L; Jiménez-Castilla, V; Flores-López, M; Navarro, JA; Gavito, A; Blanco-Calvo, E; Santín, LJ; Pavón-Morón, FJ; de Fonseca, FR; Serrano, A	Sex-specific alterations in emotional behavior and neurotransmitter systems in LPA1 receptor-deficient mice	NEUROPHARMACOLOGY	4.6	Q1	Article	2025
C-06	Porras-Perales, O; Sánchez-Marín, L; Medina-Vera, D; Flores-López, M; Martín-Chaves, L; Boccalon, M; Requena-Ocaña, N; García-Marchena, N; Reviriego, R; Santín, LJ; Martin-Fardon, R; Jiménez-Navarro, M; de Fonseca, FR; Serrano, A; Pavón-Morón, FJ	Sex-specific dysregulation of the CX3CL1/CX3CR1 Axis following cocaine exposure: Translational evidence for a potential biomarker of abstinence	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
C-06	Villanueva-Blasco, VJ; Mateu-Mollá, J; Vázquez-Martínez, A; Rial-Boubeta, A; de Fonseca, FR; Folgar, MI	The Role of Sex and Coping Styles on the Relationship Between Depression and Cannabis Use	INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION	2.5	Q2	Article	2025
C-07	Flores-Gomez, Marta; Cantero-Garcia, Noelia; Pineda-Gomez, Juan Pedro; Moh-Ahmed, Amel; Flores-Burgess, Antonio; Diaz-Cabiale, Zaida; Millon, Carmelo	Galanin(1-15) and Naltrexone: A novel approach for alcohol use disorder in rats, involving the mesolimbic system.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	Article	2025
C-07	Grunenwald, F; Huerta, TJ; Sepulveda, D; Jerez, C; Urbina, V; Carrera, B; Diaz-Espinoza, R; Nova, E; Pacheco, R; Martín-Montañez, E; Gil-Rodriguez, S; Valverde, N; Garcia-Fernandez, M; Aguilera, C; Chana-Cuevas, P; Vidal, RL	IGF2-Reprogrammed Macrophages Ameliorate the Inflammatory Response and Protect Against the Neuroinflammatory Process in Parkinson's Disease Models	AGING CELL	7.1	D1	Article	2025
C-07	Romero-Zerbo, SY; Valverde, N; Claros, S; Zamorano-Gonzalez, P; Boraldi, F; Lofaro, FD; Lara, E; Pavia, J; Garcia-Fernandez, M; Gago, B; Martin-Montañez, E	New molecular mechanisms to explain the neuroprotective effects of insulin-like growth factor II in a cellular model of Parkinson's disease	JOURNAL OF ADVANCED RESEARCH	13	D1	Article	2025
C-07	Moreno-Madrid, Isabel; Romero-Imbroda, Jesus; Reyes-Bueno, Jose Antonio; Arrabal-Gomez, Carlos; Diaz-Casares, Amelia; Diaz-Sanchez, Estela; Barbancho-Fernandez, Miguel Angel; Fuxe, Kjell; Borroto-Escuela, Dasiel; Serrano-Castro, Pedro; Narvaez, Manuel	Peripheral expression of NPY1R-based heteroreceptor complexes reflects hippocampal neuroimmune status: Novel biomarkers for early Alzheimer's disease detection.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	Article	2025
C-07	Merino-Galán, L; Zamarbide, M; Belloso-Iguerategui, A; Alonso-Moreno, MC; Gago, B; Reinares-Sebastián, A; Blesa, J; Dumitriu, D; Quiroga-Varela, A; Rodríguez-Oroz, MC	Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism	NPJ PARKINSONS DISEASE	8.2	D1	Article	2025
C-07	Pineda-Gómez, JP; Millón, C; Cantero-García, N; Flores-Gómez, M; de Guevara-Miranda, DL; Flores-Burgess, A; Diaz-Cabiale, Z	A new pharmacological strategy against treatment-resistant depression	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	3.9	Q1	Article	2025
C-07	Meschian-Coretti, S; Gomez-Palomo, JM; García-Vera, JJ; Salinas-Sánchez, P; Dawid-Milner, MS; Montañez-Heredia, E	Accuracy of medial opening wedge high tibial osteotomy using patient-specific instrumentation: a randomised cadaveric study	EUROPEAN JOURNAL OF ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	1.5	Q3	Article	2025
C-07	Rodríguez-Martínez, MC; Correia, F; García-Pérez, P	Analysis of Occupational Needs in Refugees and Applicants for International Protection: Scoping Review	SOCIETIES	1.6	Q2	Review	2025
C-07	Florido-Santiago, M; Pérez-Belmonte, LM; Lara, JP; Millán-Gomez, M; Pérez-Velasco, MA; Osuna-Sánchez, J; García-Casares, N; Gomez-Huelgas, R; Blanco-Reina, E; Barbancho, MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	2.8	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-07	Brichette-Mieg, I; Alonso-Torres, A; Aliaga-Gaspar, P; Rodríguez-Bada, JL; Reyes-Garrido, V; Urbaneja-Romero, P; Muñoz, C; Díaz-Sánchez, M; Martín-Montañez, E; Cabello-Porras, MD; Oliver-Martos, B; Leyva, L	Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification	FRONTIERS IN IMMUNOLOGY	5.9	Q1	Article	2025
C-07	Gil-Rodriguez, S; Berdugo-Gómez, M; Claros, S; Romero-Zerbo, SY; Mañas-Padilla, MC; Gómez-Roldán, MD; Blanco-Calvo, E; Garcia-Fernández, M; Santin, LJ	IGF2 modulates behavioral and hippocampal changes induced by chronic cocaine exposure during adolescence in mice	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR	2.5	Q2	Article	2025
C-07	García-Ortega, MA; García-Piñero, JM; Gomez-González, AJ; Medina-Lopez, R; González-García, M; Montero-García, AJ; Morales-Gil, IM	Impact of an Early Discharge Hospital-at-Home Program on Length of Stay and Clinical Outcomes in Preterm Infants: A Case-Control Study	CHILDREN-BASEL	2.1	Q2	Article	2025
C-07	Cantero-García, N; Flores-Burgess, A; Flores-Gomez, M; Pineda-Gomez, JP; Ramos, MC; Diaz, C; Millon, C; Díaz-Cabiale, Z	Intranasal Galanin (1-15) modulates alcohol self-administration and depressive-like behavior in rats and shows a favorable safety profile	FRONTIERS IN PHARMACOLOGY	4.8	Q1	Article	2025
C-07	Morales-Luque, C; Carrillo-Franco, L; López-González, MV; González-García, M; Dawid-Milner, MS	Mapping the Neurophysiological Link Between Voice and Autonomic Function: A Scoping Review	BIOLOGY-BASEL	3.5	Q1	Review	2025
C-07	Sánchez-Fernández, B; Zamorano-González, P; Martín-Montañez, E; Alba-Linero, C; Rius-Díaz, F; García-Fernandez, M; Luque-Aranda, R; García-Basterra, I	Oxidative Stress and Inflammatory Biomarkers in Aqueous Humor and Blood of Patients with Leber's Hereditary Optic Neuropathy	ANTIOXIDANTS	6.6	Q1	Article	2025
C-07	Simón-Frapolli, VJ; López-Montalbán, A; Vegas-Aguilar, IM; Generoso-Piñar, M; Fernández-Jiménez, R; Cornejo-Pareja, IM; Sánchez-García, AM; Martínez-López, P; Nuevo-Ortega, P; Reina-Artacho, C; Estecha-Foncea, MA; Gómez-González, AM; González-Jiménez, MB; Avanesi-Molina, E; Tinahones-Madueño, FJ; García-Almeida, JM	Relationship Between Vitamin D Levels with In-Hospital Complications and Morphofunctional Recovery in a Cohort of Patients After Severe COVID-19 Across Different Obesity Phenotypes	NUTRIENTS	5	Q1	Article	2025
C-08	Nieto-Gómez, P; Castaño-Amores, C; García-Ruiz, AJ; Oliva-Moreno, J	Determinants of time to access to EMA-approved cancer drugs in Spanish NHS in the past decade: a two cohorts study	HEALTH POLICY	3.4	D1	Article	2025
C-08	Escamilla-Sanchez, A; López-Villodres, JA; Alba-Tercedor, C; Ortega-Jiménez, MV; Rius-Díaz, F; Sanchez-Varo, R; Bermúdez, D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	12.6	D1	Article	2025
C-08	Cárdenas-Quesada, J; Remesal-Doblado, A; Garrido-Rodríguez, V; Lucena, M; Ginel-Mendoza, L; Cárdenas-Viedma, SL; Sanabria-Cabrera, J	Advancing clinical research in the Spanish primary care service: Challenges, opportunities, and lessons from other European models	EUROPEAN JOURNAL OF GENERAL PRACTICE	2.5	Q1	Article	2025
C-08	Soler, NGA; Trujillo, LG; García-Ruiz, AJ	Cost of Quality of Life in Advanced Parkinson's Disease: Efficient Strategies for Disease Assessment	REVISTA DE NEUROLOGIA	0.8	Q4	Article	2025
C-08	Milanés-Guisado, Y; Jódar-Sánchez, F; Sánchez-Pardo, DJ; Neukam, K; Castro-Gómez, A; López-Cortés, LF	Healthcare resource utilization and related cost of non-HIV comorbidity management in people with HIV in a Spanish cohort from 2007-2016	CURRENT MEDICAL RESEARCH AND OPINION	2.2	Q2	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-08	Gottlieb, H; Seghers, L; Leiva-Fernandez, F; Ghiciuc, CM; Hafez, G; Herdeiro, MT; Petrovic, AT; Novais, T; Schneider, MP; Dima, A; Ekenberg, M; Wettermark, B	Medication adherence in the curricula of future European physicians, pharmacists and nurses - a cross-sectional survey	BMC MEDICAL EDUCATION	3.2	Q1	Article	2025
C-08	Moreno, SMG; Sánchez, FJ; Soler, NGA; Ruiz, FR; Garcia-Ruiz, AJ	Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches	BMJ OPEN	2.3	Q2	Article	2025
C-08	Sánchez-Fernández, B; Zamorano-González, P; Martín-Montañez, E; Alba-Linero, C; Rius-Díaz, F; García-Fernandez, M; Luque-Aranda, R; García-Basterra, I	Oxidative Stress and Inflammatory Biomarkers in Aqueous Humor and Blood of Patients with Leber's Hereditary Optic Neuropathy	ANTIOXIDANTS	6.6	Q1	Article	2025
C-08	Blundell, DB; Soler, NGA	Quality Management in Spanish Community Pharmacy: Implementation of ISO 9001	JOURNAL OF EVALUATION IN CLINICAL PRACTICE	2.1	Q2	Article	2025
C-08	Rivero-de-Aguilar, A; Mascareñas-García, M; Pérez-Rios, M; Llaneza-Gonzalez, MA; Mulero, P; Mendibe, M; Rovira, A; Meca-Lallana, V; García-Ruiz, AJ; Landete, L; Hermida, JRV; Rueda, PC; Ruano-Raviña, A; Puente-Hernandez, M; Varela-Lema, L	Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis	NEUROLOGIA	3.1	Q2	Article	2025
C-08	Aguiar-Leiva, VP; Leiva-Fernández, F; Martín-Roselló, ML; Gomez-Garcia, R; Fernandez-Lopez, A; Barnestein-Fonseca, P; Morales-Asencio, JM	Validation of a questionnaire to assess complexity of palliative care needs in primary care in Malaga, Spain: a study protocol	BMJ OPEN	2.3	Q2	Article	2025
C-09	Andreo-Lopez, J; Nuñez-Diaz, C; Huynh, KD; Nguyen, MMT; Da Cunha, C; Cantero-Molina, FJ; Campos-Moreno, C; Zimbone, S; Bellia, F; Giuffrida, ML; Trujillo-Estrada, L; Garcia-Leon, JA; Bettinetti-Luque, M; Gamez, N; Valdes, C; Morales, R; Forner, S; Martini, AC; Gutierrez, A; Laferla, FM; Baglietto-Vargas, D	Human and Mouse Alzheimer's Seeds Differentially Affect Amyloid Deposition and Microglia-Dependent Plaque Response in Aged Mice	AGING CELL	7.1	D1	Article	2025
C-09	Caceres-Palomo, L; Sanchez-Mejias, E; Trujillo-Estrada, L; Perez-Moreno, JJ; Lopez-Oliva, E; Lim, TE; Deflitch, L; Chang, SH; Kampman, L; Corces, MR; Blurton-Jones, M; Moreno-Gonzalez, I; Pascual, A; Vitorica, J; Garcia-Leon, JA; Gutierrez, A	Human iPSC-derived APOE4/4 Alzheimers disease astrocytes exhibit a senescent and pro-inflammatory state that compromises neuronal support	JOURNAL OF NEUROINFLAMMATION	10.1	D1	Article	2025
C-09	Escamilla-Sanchez, A; López-Villodres, JA; Alba-Tercedor, C; Ortega-Jiménez, MV; Rius-Díaz, F; Sanchez-Varo, R; Bermúdez, D	Instagram as a Tool to Improve Human Histology Learning in Medical Education: Descriptive Study	JMIR MEDICAL EDUCATION	12.6	D1	Article	2025
C-09	Crouzet, C; Xie, DF; Nuqui, MNL; Hasselman, J; Phan, T; Wilson, RH; Baglietto-Vargas, D; Da Cunha, C; Davtyan, H; Forner, S; Jullienne, A; Bazrafkan, A; Laferla, FM; Obenaus, A; Blurton-Jones, M; Akbari, Y; Green, KN; Choi, B	Cerebrovascular alterations in a mouse model of late-onset Alzheimer's disease	NEUROPHOTONICS	3.8	Q2	Article	2025
C-09	Vegas-Gomez, L; Pizarro, M; Garcia-Martin, J; Arredondo-Alcala, MA; Bustamante, B; Gonzalez-Silva, C; Matus, S; Diaz-Espinoza, R; Gutierrez, A; Morales, R; Duran-Aniotz, C; Moreno-Gonzalez, I	Peripheral administration of blood from tau transgenic animals exacerbates brain tau-associated pathology	PLOS ONE	2.6	Q2	Article	2025
C-11	Ibáñez, ERS; Houghton, JL; Ruiz-Párraga, GT; Esteve, R; Ramírez-Maestre, C; López-Martínez, AE	Acceptance and commitment therapy (ACT) for pediatric chronic non-cancer pain: A systematic review	JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE	3	Q1	Review	2025
C-11	Miró, J; Sampietro, A; Monterde, S; Ingelmo, P; Wicksell, RK; Nolla, C; Alonso, M; Lázaro, JJ; Martínez, E; Rubio, P; Sánchez, A; Sánchez, V; Vázquez, A; de la Vega, R; Reinoso-Barbero, F	Development, implementation and evaluation of a digital treatment for adolescents with chronic pain: a protocol for a multi-phase study	FRONTIERS IN DIGITAL HEALTH	3.8	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-11	de la Vega, R; Chaves, E; Lund, T; Koocher, GP; Caes, L	Ethical Issues in International Research in Pediatric Psychology: Challenges and Opportunities	JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS	1.9	Q3	Article	2025
C-11	Esteve, R; Ramirez-Maestre, C; Serrano-Ibáñez, ER; López-Martinez,AE	Impulsivity Is Related to Prescription Opioid Misuse in People With Chronic Pain Through Pain Catastrophizing and Emotional Distress	PAIN RESEARCH & MANAGEMENT	3	Q2	Article	2025
C-11	Barrado-Moreno, V; Esteve, R; López-Martínez, AE; Ramirez-Maestre, C	Measuring psychological flexibility and inflexibility: further psychometric evidence of the Multidimensional Psychological Flexibility Inventory short form (MPFI-24) in Spanish population	CURRENT PSYCHOLOGY	2.6	Q1	Article	2025
C-11	Ramírez-Maestre, C; Esteve, R; Serrano-Ibáñez, ER; López-Martínez, AE	Prescription opioid misuse in people with chronic noncancer pain: A multi-variable analysis of sociodemographic, clinical, and psychological factors	PLOS ONE	2.6	Q2	Article	2025
C-11	Barrado-Moreno, V; Esteve, R; Mccracken, LM; Ramirez-Maestre, C	The Mediating Role of Psychological Flexibility and Inflexibility Between Impulsivity and Opioid Misuse in People With Chronic Noncancer Pain	EUROPEAN JOURNAL OF PAIN	3.4	Q1	Article	2025
C-11	Li, R; Srinakarin, K; de la Vega, R; Murray, CB; Palermo, TM	Treatment expectations and pain-related outcomes in clinical trials of digital cognitive-behavioral therapy for youth with chronic pain	JOURNAL OF PAIN	4	Q1	Article	2025
C-11	de la Vega, R; Yokoyama, K; Daniels, K; Palermo, TM	Unwanted or negative treatment reactions in digital psychological interventions for adolescents with chronic pain	JOURNAL OF PEDIATRIC PSYCHOLOGY	2.1	Q3	Article	2025
C-11	Taygar, AS; Bartels, SL; de la Vega, R; Flink, I; Engman, L; Petersson, S; Johnsson, S; Boersma, K; McCracken, LM; Wicksell, RK	User-Driven Development of a Digital Behavioral Intervention for Chronic Pain: Multimethod Multiphase Study	JMIR FORMATIVE RESEARCH	2.1	Q3	Article	2025
C-12	Gutiérrez-Cordero, I; García-Orza, J	Disassembling an experimental artifact in aphasia: Why phonemic errors with words and semantic errors with numbers?	CORTEX	3.3	Q1	Article	2025
C-12	Berthier, ML; Moreno-Torres, I; Verhoeven, J; Dávila, G	Revisiting the boundaries of different altered accents profiles	CORTEX	3.3	Q1	Article	2025
C-12	Gutiérrez-Cordero, I; García-Orza, J	sunflower: an R package for handling multiple response attempts and conducting error analysis in aphasia and related disorders	FRONTIERS IN PSYCHOLOGY	2.9	Q1	Article	2025
C-13	García-Luque, R; Pimentel, E; Durán, F; Aranda-Gallardo, M; Morales-Asencio, JM	A machine learning-based clinical prediction rule for adverse outcomes in multimorbid patients	INTELLIGENT MEDICINE	6.9	D1	Article	2025
C-13	Julià-Móra, JM; Calafell-Vert, M; Rosal-Obrador, FR; Blanco-Mavillard, I; Miró-Bonet, M	Perceptions of care and family support from patients and family caregivers during the COVID-19 pandemic: a phenomenological study in Spain	BMC NURSING	3.9	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-13	Segovia, ADMC; Becerra-Muñoz, VM; Arjona, MJJ; Velasco, VN; Ochoa, N; Barberà, JA; López-Meseguer, M; Asencio, JMM; Blanco, I; Subias, PE	Real-life use of validated quality of life questionnaires in patients with pulmonary arterial hypertension in Spain: a cross-sectional study	EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING	3.9	D1	Article	2025
C-13	León-Campos, A; Quemada-González, C; Gutiérrez-Rodríguez, L; Pérez-Ardanaz, B; García-Mayor, S; Kaknani-Uttumchandani, S; Martí-García, C	The Impact of Video-Assisted Debriefing on Fostering Self-Critical Thinking in Mental Health Nursing Students	JOURNAL OF NURSING MANAGEMENT	4	D1	Article	2025
C-13	Fernández-Domínguez, JC; Sesé-Abad, A; De Pedro-Gómez, JE; Morales-Asencio, JM; Jiménez-López, R	Unveiling the Context for Implementing Evidence-Based Practice in Spanish Nursing	JOURNAL OF ADVANCED NURSING	3.4	D1	Article	2025
C-13	Ramirez-Martin, Almudena; Poveda Gomez, Francisco; Aranda-Gallardo, Marta; Martin-Bautista, Elena; Rivas Ruiz, Francisco; Garcia-Alegria, Jose Javier	Acceptance and intention to use of a physiological sensor shirt in health field in older patients	Revista espanola de geriatria y gerontologia	0		Article	2025
C-13	Jimenez Martin JM, Morales Fernandez A, Vergara Romero M, Morales Asencio JM	Experiences, Beliefs, and Values of Patients with Chronic Pain Who Attended a Nurse-Led Program: A Descriptive Phenomenological Qualitative Study	NURSING REPORTS	2	Q1	Article	2025
C-13	García-Ortega, MA; García-Piñero, JM; Gomez-González, AJ; Medina-Lopez, R; González-García, M; Montero-García, AJ; Morales-Gil, IM	Impact of an Early Discharge Hospital-at-Home Program on Length of Stay and Clinical Outcomes in Preterm Infants: A Case-Control Study	CHILDREN-BASEL	2.1	Q2	Article	2025
C-13	Fernández-Forné, A; Fernández-Jiménez, R; Toledo-Serrano, MD; Jiménez-Rodríguez, H; Muñoz-Lupiáñez, M; Ruiz-López, MA; García-Almeida, JM; De la Peña-fernández, L; Queipo-Ortuño, MI; Gómez-Millán, J	Impact of Nutritional Status on Severe Radiation-Induced Mucositis in Oropharyngeal Cancer Patients Undergoing Chemo-Radiotherapy	NUTRIENTS	5	Q1	Article	2025
C-13	Bujalance-Hoyos, J; de Luna-Rodríguez, ME; González-Escobosa, AC; Oña-González, AM; Sánchez-Gómez, S; Zamudio-Sánchez, A; Blanco-Mavillard, I	Implementation of a multimodal strategy via a mobile application to reduce catheter failure in patients with vascular access devices in Spain (CUIDAVEN Study): a pre-post intervention study	ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL	4.4	Q1	Article	2025
C-13	Sepúlveda-Muñoz, J; González, CQ; Lara, MMH; García, AMG; Martí-García, C; Pérez-Bryan, JMGH; Morales-Asencio, JM	Management of Psychosis and Schizophrenia by Primary Care GPs: A Cross-Sectional Study in Spain	JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH	2.5	Q2	Article	2025
C-13	Porcel-Gálvez, AM; Morales-Asencio, JM	Methodological approaches to nurse-to-patient ratio planning in healthcare systems: What we know and what remains to be known	ENFERMERIA CLINICA	1.1	Q3	Article	2025
C-13	Hurtado, MM; Villena, A; Quemada, C; Morales-Asencio, JM	Personal relationships during and after an initial psychotic episode. First-person experiences	JOURNAL OF MENTAL HEALTH	3.2	Q1	Article	2025
C-13	Pérez-Ardanaz, B; Gutiérrez-Rodríguez, L; Gómez-González, AJ; Morales-Asencio, JM; Montero-García, A; León-Campos, A	Predictive model for the risk of paediatric intensive care utilization in children with medical complexity: A longitudinal retrospective cohort study	NURSING IN CRITICAL CARE	2.6	Q1	Article	2025
C-13	Coca-Boronat, E; Morales-Asencio, JM; Coca-Gallen, D; Gutiérrez-Rodríguez, L; Lupiáñez-Pérez, I; Guerra-Marmolejo, C; Sáenz-Gomez, J; Pérez-Ardanaz, B	Primary Care Utilization and Prehospital Emergency Demand Among Patients with Multimorbidity in Spain	NURSING REPORTS	2	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-13	Duggan, C; Hernon, O; Simpkin, AJ; Manasek, V; de la Torre-montero, JC; Santos-Costa, P; Moss, JG; Ruhlmann, CH; Taxbro, K; Calero, MAR; Oom, R; Barroca, R; Grady, OO; Daly, J; Blanco-Mavillard, I; Dodlek, N; Charvat, J; Unanue-Arza, S; Krakovska, B; Carr, PJ	Promoting a research agenda for cancer treatment for intravenous devices with clinicians in Europe; the PRACTICE survey	JOURNAL OF CANCER POLICY	2	Q3	Article	2025
C-13	Lopez-Muñoz, C; Aranda-Gallardo, M; Rivas-Ruiz, F; Moya-Suárez, AB; Canca-Sanchez, JC	Survival of multi-pathological inpatients with nutritional risk according to their PROFUND index	ENFERMERIA CLINICA	1.1	Q3	Article	2025
C-13	Cavaggion, C; Navarro-Ledesma, S; Juul-Kristensen, B; Luque-Suarez, A; Voogt, L; Struyf, F	The effect of painful exercise on ultrasonographic outcomes in rotator cuff-related shoulder pain: Secondary analysis of a randomized controlled trial	JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION	1.5	Q2	Article	2025
C-13	Villena, A; Hurtado, MM; Gómez, C; Amor, G; Vega, A; Morales-Asencio, JM	Users remain overlooked: Shared decision-making processes for people with anxiety disorders	JOURNAL OF PSYCHIATRIC AND MENTAL HEALTH NURSING	2.9	Q1	Article	2025
C-13	Reina Campos R, Morales Asencio JM, Iglesias Parra MR, García Gámez M	Validation in Spanish of the GAIN instrument for its application in caregivers of patients with multimorbidity in the home environment	ENFERMERIA CLINICA	1.1	Q3	Article	2025
C-13	Aguiar-Leiva, VP; Leiva-Fernández, F; Martín-Roselló, ML; Gomez-Garcia, R; Fernandez-Lopez, A; Barnestein-Fonseca, P; Morales-Asencio, JM	Validation of a questionnaire to assess complexity of palliative care needs in primary care in Malaga, Spain: a study protocol	BMJ OPEN	2.3	Q2	Article	2025
C-13	Rodriguez-Calero, MA; Carr, PJ; Santos-Costa, P; Blanco-Mavillard, I	Vascular Access Specialist Teams (VAST) as a strategy to address future challenges in intravenous therapy	ENFERMERIA CLINICA	1.1	Q3	Article	2025
C-14	Ramirez-Martin, Almudena; Poveda Gomez, Francisco; Aranda-Gallardo, Marta; Martin-Bautista, Elena; Rivas Ruiz, Francisco; Garcia-Alegria, Jose Javier	Acceptance and intention to use of a physiological sensor shirt in health field in older patients	Revista espanola de geriatria y gerontologia	0		Article	2025
C-14	Hernández-Negrín, H; Bernal-López, MR; López-Sampalo, A; Rubio-Rivas, M; Aguilar-García, JA; Gómez-Uranga, A; Carnevali, M; Taboada-Martínezh, ML; Ramos-Rincón, JM; Gómez-Huelgas, R	Cardiovascular profile of systemic lupus erythematosus patients hospitalized for COVID-19 in Spain: Analysis of the SEMI-COVID-19 Registry	MEDICINA CLINICA	2.1	Q2	Article	2025
C-14	Quero, C; Martín-García, D; Rivas-Ruiz, F; García-Aranda, M; Redondo, M	Comparison of oncological care in a hospital center before and after the integration of specialized oncology services	CLINICAL & TRANSLATIONAL ONCOLOGY	2.5	Q3	Article	2025
C-14	Olivares-Navarro, P; Pérez-Rodríguez, MT; Goikoetxea-Agirre, AJ; Reguera-Iglesias, JM; León, E; Mantecón, MA; Pulido-Navazo, A; Boix-Palop, L; Retamar-Gentil, P; Armiñanzas-Castillo, C; Fernández-Natal, I; Jover-Sáenz, A; Jiménez, AD; Fernández-Suárez, J; Martín-Aspas, A; Smithson-Amat, A; Carrasco, AB; Natera-Kindelán, C; Pérez-Crespo, PM; Hernández, IL; López-Cortés, LE; Rodríguez-Baño, J	Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort	INFECTION	3.6	Q2	Article	2025
C-14	De la Rosa-Riestra, S; Gutiérrez-Gutiérrez, B; López-Hernández, I; Pérez-Rodríguez, MT; Agirre, JG; Plata, A; León, E; Alvarez, MCF; Fernández-Natal, I; Fernández-Suárez, J; Boix-Palop, L; Pedragosa, JC; Jover-Sáenz, A; Calvo, JMS; Martín-Aspas, A; Natera-Kindelán, C; Del Arco-Jiménez, A; Pérez-Crespo, PMM; López-Cortés, LE; Rodríguez-Baño, J	External validation of the predictive ability of Charson, SOFA, Pitt, INCREMENT-ESBL and bloodstream infection mortality Risk for 30-day-mortality in bacteraemia using the PROBAC cohort data	INFECTIOUS DISEASES	2.3	Q3	Article	2025
C-14	García-Aranda, M; Onieva, MA; Martín-García, D; Quirós, R; López, I; Padilla-Ruiz, M; Téllez, T; Martínez-Gálvez, B; Hortas, ML; García-Galindo, A; González-Gomariz, J; Armañanzas, R; Rivas-Ruiz, F; Serrano, A; Barragán-Mallofret, I; Redondo, M	KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients	SCIENTIFIC REPORTS	3.9	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-14	Alcaide-Garcia, J; Boughanem, H; García-Aranda, M; Rivas-Ruiz, F; Aguirre, U; García, DM; Padilla-Ruiz, M; Varela-Moreno, E; Robles-Lasarte, M; Baré, M; del Cura, I; Varela, MMM; Quintana, JM; Macías, M; Redondo, M	Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients	COLORECTAL DISEASE	2.7	Q1	Article	2025
C-14	García-Aranda, M; Abitei, C; Martín-García, D; Fúnez, R; Rivas-Ruiz, F; Robles-Lasarte, M; Alcaide-Garcia, J; Téllez, T; Aguirre, U; Borrero-Martín, JJ; del Cura, I; Suárez-Varela, MMM; Quintana, JM; Redondo, M	Long-term prognostic value of apoptotic index in colorectal cancer: a 5-year multicentre cohort study	PATHOLOGY	3	Q2	Article	2025
C-14	Moreno, SMG; Sánchez, FJ; Soler, NGA; Ruiz, FR; Garcia-Ruiz, AJ	Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches	BMJ OPEN	2.3	Q2	Article	2025
C-14	Martín-García, D; García-Aranda, M; Varela-Moreno, E; Padilla-Ruiz, M; Zarcos-Pedrinaci, I; Rivas-Ruiz, F; Téllez, T; García-Gutiérrez, S; González, N; Rivero, A; Sarasqueta, C; Perestelo-Pérez, L; Castells, X; Quintana, JM; Sala, M; Redondo, M	Patient-attributable delay and its impact on two-year survival in breast cancer: A multicenter prospective cohort study	EJSO	2.9	Q1	Article	2025
C-14	De Lucas, MDG; Perez-Belmonte, L; Aviles-Bueno, B; Jimenez-Millan, A; Ruiz, FR; Miramontes-Gonzalez, JP	Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety	MINERVA ENDOCRINOLOGY	2	Q3	Article	2025
C-14	Izquierdo, R; Suárez-García, I; Gómez-García, T; Marco-Sánchez, C; Puente-Ferreiro, J; Moreno, C; Diaz, A; Cabello-Clotet, N; Vinuesa, D; Blanco, JL; Melús, E; Gómez-Ayerbe, C; Olalla, J; Riera, M; Bernardino, JI; de Quirós, JCDB; Moreno, S; Jarrín, I	Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain	HIV MEDICINE	3.2	Q2	Article	2025
C-14	Lopez-Muñoz, C; Aranda-Gallardo, M; Rivas-Ruiz, F; Moya-Suárez, AB; Canca-Sanchez, JC	Survival of multi-pathological inpatients with nutritional risk according to their PROFUND index	ENFERMERIA CLINICA	1.1	Q3	Article	2025
C-16	Linares-Pineda, TM; Lendinez-Jurado, A; Piserra-López, A; Suárez-Arana, M; Pozo, M; Molina-Vega, M; Picón-César, MJ; Morcillo, S	Longitudinal DNA methylation profiles in saliva of offspring from mothers with gestational diabetes: associations with early childhood growth patterns	CARDIOVASCULAR DIABETOLOGY	10.6	D1	Article	2025
C-16	Gomez-Casado, G; Jimenez-Gonzalez, A; Rodriguez-Muñoz, A; Tinahones, FJ; González-Mesa, E; Murri, M; Ortega-Gomez, A	Neutrophils as indicators of obesity-associated inflammation: A systematic review and meta-analysis	OBESITY REVIEWS	7.4	D1	Review	2025
C-16	Gomez-Casado, G; Alonso-Titos, J; Gonzalez-Mesa, E; Ortega-Gomez, A	Compatibility of Post-Kidney Transplant Immunosuppression Therapy with Lactation	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Review	2025
C-16	Arias, IN; Frías, LC; Gonzalez, MM; Cárdenas, LB; Lopez, JSJ	Diagnosis and Management of Struma Ovarii in Pregnancy: A Case Report	LIFE-BASEL	3.4	Q1	Article	2025
C-16	Moral-Moral, CM; Porras-Caballero, L; Blasco-Alonso, M; Cuenca-Marín, C; Monis-Rodriguez, S; Gonzalez-Mesa, E; Narbona-Arias, I; Jimenez-Lopez, JS	Diagnostic Challenges and Perinatal Outcomes: A Case Series on a Retrospective Study	DIAGNOSTICS	3.3	Q1	Article	2025
C-16	Gomez-Casado, G; Saldaña-Garcia, N; Gonzalez-Mesa, E; Ortega-Gomez, A	Etiology of Delayed Lactogenesis in Obesity	BIOMEDICINES	3.9	Q1	Review	2025
C-16	Benítez-Marín, MJ; Blasco-Alonso, M; de Fonseca, FD; Jiménez, JS; Rivera, P; González-Mesa, E	Evaluating neuronal damage biomarkers at birth for predicting neurodevelopmental risks in foetal growth restriction	ACTA PAEDIATRICA	2.1	Q2	Review	2025
C-16	Pacheco-Sánchez, B; Melgar-Locatelli, S; López-Merchán, R; Benítez-Marín, MJ; Blasco-Alonso, M; González-Mesa, E; Tovar, R; Rubio, P; Suárez, J; Sanjuan, C; de Fonseca, FR; Alén, F; de Ceglia, M; Rivera, P	Gestational saccharin consumption disrupts gut-brain axis glucose homeostasis control in adolescent offspring rats in a sex-dependent manner	BIOLOGY OF SEX DIFFERENCES	5.1	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
C-16	Narbona-Arias, I; Blasco-Alonso, M; Monis-Rodriguez, S; Muñoz, CG; González-Mesa, E; Lubián-López, DM; Jimenez-López, J	More than a Diagnosis: How Prenatal Identification of Cantú Syndrome Transformed a Family's Medical Narrative	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
C-16	Silva, R; Prata, AP; Abreu, W; Brandao, T; Brandao, S; Riklikiene, O; Jarasiunaite-Fedosejeva, G; Mesa, ESG; Isbir, GG; Inci, F; Komurku, B; Uriko, K; Thompson, G	Posttraumatic growth and its associations with perceived stress and core beliefs in women after traumatic childbirth during the COVID-19 pandemic	BIRTH-ISSUES IN PERINATAL CARE	2.5	Q1	Article	2025
C-16	Brandao, T; Brandao, S; Prata, AP; Silva, R; Abreu, W; Riklikiene, O; Jarasiunaite-Fedosejeva, G; González-Mesa, E; Isbir, GG; Inci, F; Akik, BK; Uriko, K; Thomson, G	Posttraumatic Growth in Women After a Childbirth Experience: The Influence of Individual Characteristics and Intrusive and Deliberate Rumination	PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY	2.3	Q2	Article	2025
C-16	Guerra, CL; Morente, LS; Hidalgo, FJM; Romero, MN; Espada, GC; Jimenez-Lopez, JS	The Manchester Procedure as a Uterine-Preserving Alternative for Uterine Prolapse Due to Cervical Elongation: A Short-and Mid-Term Clinical Analysis	MEDICINA-LITHUANIA	2.4	Q1	Article	2025
C-18	López-Gambero, AJ; Vargas, A; Fernández-Arjona, MD; Rubio, L; de Ceglia, M; Vera-Fernández, C; Campillo-Calatayud, A; Rivera, P; Fonseca, FRD; Barrios, V; Chowen, JA; Argente, J; Suárez, J	Alteration of IGF-1 bioavailability due to PAPPA2 deficiency leads to sex-specific metabolic disturbances	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	Article	2025
C-18	Martín-Martín, J; Santos, I; Gaitán-Arroyo, MJ; Suarez, J; Rubio, L; Martín-de-las-Heras, S	Dental color measurement to estimate age in adults: a systematic review and meta-analysis	FORENSIC SCIENCE MEDICINE AND PATHOLOGY	1.4	Q3	Review	2025
C-18	Rodríguez-Pozo, M; Pacheco-Sánchez, B; Ben Rabaa, M; De Ceglia, M; Melgar-Locatelli, S; Santos, I; de Fonseca, FR; Suárez, J; Rivera, P	Perinatal Ethanol Exposure Induces Astrogliosis and Decreases GRP55/PEA-Mediated Neuroprotection in Hippocampal Astrocytes of the 3xTg Alzheimer's Animal Model	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
C-18	Fernández-López, R; Andreasen, K; Ankerstjerne, L; Martín-de-las-Heras, S; Rasch, V; Megías, JL; Linde, DS; de-León-de-León, S; Schei, B; Wu, CS; Oviedo-Gutiérrez, A; Zapata-Calvente, AL	Prevalence and associated factors of intimate partner violence against pregnant women who attend antenatal care in Denmark and Spain: A digital screening approach	ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA	3.1	Q1	Article	2025
C-18	Vadas, E; López-Gambero, AJ; Vargas, A; Rodríguez-Pozo, M; Rivera, P; Decara, J; Serrano, A; Martín-de-las-Heras, S; de Fonseca, FR; Suárez, J	Region-Specific Impact of Repeated Synthetic Cannabinoid Exposure and Withdrawal on Endocannabinoid Signaling, Gliosis, and Inflammatory Markers in the Prefrontal Cortex and Hippocampus	BIOMOLECULES	4.8	Q1	Article	2025
C-22	Moreno-Madrid, I; Arrabal-Gomez, C; Romero-Imbroda, J; Díaz-Casares, A; Fuxe, K; Borroto-Escuela, D; Serrano-Castro, P; Narváez, M	Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour	JOURNAL OF PSYCHO-PHARMACOLOGY	5.5	D1	Article	2025
C-22	Moreno-Madrid, Isabel; Romero-Imbroda, Jesus; Reyes-Bueno, Jose Antonio; Arrabal-Gomez, Carlos; Diaz-Casares, Amelia; Diaz-Sanchez, Estela; Barbancho-Fernandez, Miguel Angel; Fuxe, Kjell; Borroto-Escuela, Dasiel; Serrano-Castro, Pedro; Narvaez, Manuel	Peripheral expression of NPY1R-based heteroreceptor complexes reflects hippocampal neuroimmune status: Novel biomarkers for early Alzheimer's disease detection.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	7.5	D1	Article	2025
C-22	Farías-Cea, A; Pérez, L; Leal, C; Segura, K; Hernández, V; Atiés-Pérez, C; Martínez, LM; Hödar-Salazar, M; Reyes-Parada, M; Sotomayor-Zárate, R; Rojas-Hidalgo, F; Julio-Pieper, M; Bravo, JA; Borroto-Escuela, DO; Iturriaga-Vásquez, P	Distinct Swimming Behavioral Phenotypes Following Serotonin and Dopamine Transporter Modulation in the Adult Zebrafish Novel Tank Diving Test (NTT)	PHARMACEUTICALS	4.8	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
CA-10	Martínez-Lopez, P; Vázquez-Millán, A; Garre-Frutos, F; Luque, D	Assessing the validity evidence for habit measures based on time pressure	BEHAVIOR RESEARCH METHODS	3.9	D1	Article	2025
CA-10	Molinero, S; Martínez-López, P; Morís, J; Quintero, MJ; Cobos, PL; López, FJ; Luque, D	The degraded contingency test fails to detect habit induction in humans	PLOS ONE	2.6	Q2	Article	2025
CE-17	Jimenez-López, R; Martin-Chaves, L; Gutierrez-Garcia, AM; Carmona-Segovia, AD; Mora-Ordoñez, B; Sánchez-Garcia, AM; Fernández-Romero, L; Murri, M; Sánchez-Quintero, MJ; Berteli-Garcia, G; Sánchez-Chaparro, MA; Bodi, V; Rodriguez-Capitán, J; Jimenez-Navarro, M; Pavón-Morón, FJ; Romero-Trevejo, JL	Distinct cytokine profiles in plasma and tears highlight ophthalmologic inflammation in type 2 diabetes without retinopathy	FRONTIERS IN MEDICINE	3	Q1	Article	2025
CE-17	Santotoribio, JD; Corral-Pérez, J; Nuñez-Jurado, D; Fatela-Cantillo, D; García-De La Torre, A; Orantes-Maroto, G; Del Valle-Vázquez, L; Del Castillo-Otero, D; Maira-Gonzalez, N; Cobos-Díaz, A; Guerrero, JM; Lopez-Saez, JB	Malignant pleural effusion risk based on a novel tool using homocysteine and carcinoembryonic antigen in pleural fluid: A multicenter study	CLINICAL BIOCHEMISTRY	2.1	Q2	Article	2025
CE-20	Rocha-de-Lossada, C; Burguera, N; Fernández, J; Ribeiro, F; Ursell, P; Serrano-Castro, PJ; Dick, HB	Cataract Surgery in Cognitive Impairment: Navigating the Accessibility Challenge in European Healthcare	OPHTHALMOLOGY AND THERAPY	3.2	Q1	Review	2025
CE-21	Casals, C; Fernáandez-Ordoñnez, E; Vázquez-Sánchez, MA; Guerra-Marmolejo, C; Sánchez-Ojeda, MA; López-Leiva, I; García-Gámez, M	Spanish cultural adaptation of the avoidance questionnaire for adolescents (AQA) in undergraduate nursing students	TEACHING AND LEARNING IN NURSING	1.7	Q2	Article	2025
CE-21	Campos, RR; Asencio, JMM; Parra, MRI; Gámez, MG	Validation in Spanish of the GAIN instrument for its application in caregivers of patients with multimorbidity in the home environment	ENFERMERIA CLINICA	1.1	Q3	Article	2025
CE-23	Gamez-Guijarro, M; Reinoso-Cobo, A; Pardo-Rios, M; Ortega-Avila, AB; Ramos-Petersen, L; Gijon-Nogueron, G; Lopezosa-Reca, E	Analysis of foot function in terms of different pharmacological treatments in a cohort of patients with rheumatoid arthritis: a longitudinal study	BMC RHEUMATOLOGY	2.5	Q2	Article	2025
CE-23	Moya-Cuenca, C; Gijón-Nogueron, G; Chicharro-Luna, E	Barefoot or Shod? The Impact of Footwear on Children's Gait: A Systematic Review with an Exploratory Meta-Analysis	APPLIED SCIENCES-BASEL	2.5	Q2	Review	2025
CE-23	Martinez-Rico, M; Gijon-Nogueron, G; Ortega-Avila, AB; Roche-Seruendo, LE; Climent-Pedrosa, A; Deschamps, K; Sanchis-Sales, E	Effect of different custom-made foot orthotics on foot joint stiffness in individuals with structural hallux limitus: A quasi-experimental study	CLINICAL BIOMECHANICS	1.4	Q3	Article	2025
CE-23	Campos-Cano, A; Castillo-Dominguez, A; Ortega-Avila, AB; Ramos-Petersen, L; Gijon-Nogueron, G; Perez-Galan, MJ; Reinoso-Cobo, A	Impact of Foot Surgery and Pharmacological Treatments on Functionality and Pain in Rheumatoid Arthritis: A Five-Year Longitudinal Study	HEALTHCARE	2.7	Q2	Article	2025
CE-23	Gracia-Sánchez, A; Cano-García, L; Ramos-Petersen, L; Gijón-Nogueron, G; Zuníca-García, S; Chicharro-Luna, E	Impact of systemic sclerosis on foot skin hydration: A case-control study	JOURNAL OF TISSUE VIABILITY	2.8	Q1	Article	2025
CE-23	Sanchez-Morilla, S; Cervera-Garvi, P; Ramirez-Perez, L; Garcia-Paya, I; Diaz-Miguel, S; Ortega-Avila, AB	In Vivo Assessment of Ankle Stability During Dynamic Exercises: Scoping Review	HEALTHCARE	2.7	Q2	Review	2025
CE-23	Marchena-Rodriguez, A; Garcia-Medina, J; Sanchez-Morilla, S; Cervera-Garvi, P; Ortiz-Romero, M; Ortega-Avila, AB	Methodological Quality of Cross-Cultural Adaptations of the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale	JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION	0.6	Q4	Article	2025
CE-23	Campos-Cano, A; Ortega-Avila, AB; Diaz-Miguel, S; Castillo-Domínguez, A; Lopezosa-Reca, E; Gijon-Nogueron, G; Ramos-Petersen, L; Reinoso-Cobo, A	Patients' Experiences Following Osteoarticular Foot Surgery for Rheumatoid Arthritis-Related Deformities: A Qualitative Study	MEDICINA-LITHUANIA	2.4	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
CE-23	Coca-Boronat, E; Morales-Asencio, JM; Coca-Gallen, D; Gutiérrez-Rodríguez, L; Lupiáñez-Pérez, I; Guerra-Marmolejo, C; Sáenz-Gomez, J; Pérez-Ardanaz, B	Primary Care Utilization and Prehospital Emergency Demand Among Patients with Multimorbidity in Spain	NURSING REPORTS	2	Q1	Article	2025
CE-23	Casals, C; Fernáandez-Ordoñnez, E; Vázquez-Sánchez, MA; Guerra-Marmolejo, C; Sánchez-Ojeda, MA; López-Leiva, I; García-Gámez, M	Spanish cultural adaptation of the avoidance questionnaire for adolescents (AQA) in undergraduate nursing students	TEACHING AND LEARNING IN NURSING	1.7	Q2	Article	2025
CE-23	Martinez-Sebastian, C; Evans, AMF; Ramos-Petersen, L; Molina-Garcia, C; Gómez-Carrión, A; Gijon-Nogueron, G	The Relationship Between Foot Posture, Validated Foot and Ankle Tests, and Hypermobility in Paediatric Population: A Cross-Sectional Study	JOURNAL OF PAEDIATRICS AND CHILD HEALTH	1.4	Q3	Article	2025
CE-23	Cervera-Garvi, P; Ortiz-Romero, M; Gordillo-Fernandez, LM; Garcia-Paya, I; Ortega-Avila, AB; Diaz-Miguel, S	Translation into Spanish, Transcultural Adaptation and Validation of the Foot Function Index Revised Short Form (FFI_RSF) Questionnaire	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
CE-23	Gambero, LC; Gijón-Noguerón, GA; Miguel, SD; Barón-López, J; Raquel, CT	Wrist Joint Restriction: Impact on Foot Pressure, Center of Gravity, and the Role of the Dominant Hand	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
CE-24	León-Campos, A; Quemada-González, C; Gutiérrez-Rodríguez, L; Pérez-Ardanaz, B; García-Mayor, S; Kaknani-Uttumchandani, S; Martí-García, C	The Impact of Video-Assisted Debriefing on Fostering Self-Critical Thinking in Mental Health Nursing Students	JOURNAL OF NURSING MANAGEMENT	4	D1	Article	2025
CE-24	García-Ortega, MA; García-Piñero, JM; Gomez-González, AJ; Medina-Lopez, R; González-García, M; Montero-García, AJ; Morales-Gil, IM	Impact of an Early Discharge Hospital-at-Home Program on Length of Stay and Clinical Outcomes in Preterm Infants: A Case-Control Study	CHILDREN-BASEL	2.1	Q2	Article	2025
CE-24	Perez, DV; Navarro, M; Segura-Segura, B; Wendelbo, R; Bandres-Ciga, S; Arraez, MA; Arraez, C; Rodriguez-Losada, N	Neuroprotective Effects of Low-Dose Graphenic Materials on SN4741 Embryonic Stem Cells Against ER Stress and MPTP-Induced Oxidative Stress	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
CE-24	Casals, C; Fernáandez-Ordoñnez, E; Vázquez-Sánchez, MA; Guerra-Marmolejo, C; Sánchez-Ojeda, MA; López-Leiva, I; García-Gámez, M	Spanish cultural adaptation of the avoidance questionnaire for adolescents (AQA) in undergraduate nursing students	TEACHING AND LEARNING IN NURSING	1.7	Q2	Article	2025
D-01	Palom-Grau, C; Cuervo, G; Muñoz, P; Arriaza, MM; Martínez-Sellés, M; González-Ramallo, V; de Alarcón, A; Poyato-Borrego, M; Rodríguez-García, R; Rodríguez-Esteban, MA; Fariñas, MC; González-Rico, C; Goenaga, MA; Ojeda-Burgos, G; Goikoetxea-Agirre, AJ; Calderón-Parra, J; López-Azor, JC; García-Vázquez, E; Loeches, B; Quintana, E; de la Mària , CG; Llopis, J; Miró, JM	A Contemporary Picture of Coagulase-Negative Staphylococcal Endocarditis A Nationwide GAMES Cohort Study	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	22.3	D1	Article	2025
D-01	Labiod, N; Sanchez-Seco, MP; Goikoetxea, J; Zurita, ND; Norman, FF; Martínez, MM; Alonso, PA; Hernández-Betancor, A; Sempere-Alcocer, MA; Moure, Z; Ocete, MD; Vicente, MR; de la Calle-prieto, F; Gallego, M; Domingo, LC; Galán, JC; Camprubí-Ferrer, D; Meilán, C; Perez-Hernandez, I; Cabezon, I; Hernández, FJ; Bernal, E; Vázquez, A	Case series of Oropouche fever among travellers returning from Cuba to Spain, 2024	EUROSURVEILLANCE	7.8	D1	Article	2025
D-01	Fichtenbaum, CJ; Malvestutto, C; Watanabe, MG; Smith, ED; Ribaudo, HJ; Mccallum, S; Fitch, K; Currier, JS; Diggs, MR; Chu, SM; Aberg, JA; Lu, M; Valencia, J; Gómez-Ayerbe, C; Brar, I; Madruga, JV; Bloomfield, GS; Douglas, PS; Zanni, M; Grinspoon, SK	Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	LANCET HIV	13	D1	Article	2025
D-01	Gavilán, P; Gavilán, JC; Clavijo, E; Viciana, I; Gonzalez-Correa, JA	A prediction model for complications caused by portal hypertension or liver cancer in a Spanish cohort of chronic hepatitis B patients	REVISTA CLINICA ESPANOLA	1.7	Q2	Article	2025
D-01	Frías-García, R; García, PM; Vilchez, MM; Caballero, GC; Rodríguez-García, R; Rodríguez-Esteban, MA; Fariñas-Alvarez, MC; Meda, JMM; Villanueva, AG; Ojeda-Burgos, G; Goikoetxea-Agirre, AJ; Palacios, MB; Martínez-Sellés, M	Body mass index and prognosis of infective endocarditis	INFECTIOUS DISEASES	2.3	Q3	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
D-01	Smith, ED; Malvestutto, C; Ribaudo, HJ; Fichtenbaum, CJ; Aberg, JA; Watanabe, M; Bloomfield, GS; Currier, JS; Chu, SM; Fitch, K; Diggs, MR; Bedimo, R; Valencia, J; Gomez-Ayerbe, C; Brar, I; Madruga, JV; Lu, MT; Douglas, PS; Zanni, M; Grinspoon, SK	Cardiovascular Hazards of Abacavir-Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort	OPEN FORUM INFECTIOUS DISEASES	3.8	Q1	Article	2025
D-01	Estrada, V; Losa, JE; Morillo-Verdugo, R; Pérez-Encinas, M; Santos, J; Castro, A; González, MP; Salinas-Ortega, L	Cost analysis associated with intramuscular versus oral administration of antiretroviral therapy in the management of human immunodeficiency virus infection	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.5	Q2	Article	2025
D-01	Retamar-Gentil, P; Alegre-Albendea, M; De Santis, LV; Caston-Osorio, JJ; Márquez-Gomez, I; Corzo-Delgado, JE; Praena-Segovia, J; Herrero-Rodríguez, C; Esteban-Moreno, MA; Martín-Aspas, A; Jiménez-Aguilar, P; Martínez-Marcos, FJ; Lopez-Cárdenas, S; Ojeda-Burgos, G; Sadyrbaeva-Dolgova, S; Anguita-Santos, F; Baño, JR; Palacios-Baena, ZR	How to use novel antimicrobials beyond official indications: an expert consensus	JAC-ANTIMICROBIAL RESISTANCE	3.3	Q2	Article	2025
D-01	Pita-Martínez, C; Jiménez-Sousa, MA; Martinez-Picado, J; Rodríguez, CEG; Fariñas, C; Galindo, P; Roca-Oporto, C; Santos, J; Muñoz-García, P; Rava, M; Resino, S; Martín-Escolano, R	Immune and senescence profiles associated with non-AIDS-defining cancer risk in people with HIV: a case-cohort study	FRONTIERS IN IMMUNOLOGY	5.9	Q1	Article	2025
D-01	Palacios, R; Gómez-Ayerbe, C; Martín-Cortés, S; González-Jiménez, A; López-Jódar, M; Pérez-Hernández, IA; Santos, J	Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study	JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY	3.6	Q2	Article	2025
D-01	Izquierdo, R; Suárez-García, I; Gómez-García, T; Marco-Sánchez, C; Puente-Ferreiro, J; Moreno, C; Diaz, A; Cabello-Clotet, N; Vinuesa, D; Blanco, JL; Melús, E; Gómez-Ayerbe, C; Olalla, J; Riera, M; Bernardino, JI; de Quirós, JCDB; Moreno, S; Jarrín, I	Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain	HIV MEDICINE	3.2	Q2	Article	2025
D-03	Cano-García, L; García-Studer, A; Manrique-Arija, S; Ortiz-Márquez, F; Redondo-Rodríguez, R; Borregón-Garrido, P; Mena-Vázquez, N; Fernández-Nebro, A	Accrual of organ damage and one-year mortality in systemic sclerosis: A prospective observational study	SEMINARS IN ARTHRITIS AND RHEUMATISM	4.4	Q1	Article	2025
D-03	Mucientes, A; Núñez, GMM; Mena-Vázquez, N; Lisbona-Montañez, JM; Manrique-Arija, S; González-Jiménez, A; Ruiz-Limón, P; Garcia-Studer, A; Ortiz-Márquez, F; Cano-García, L; Fernández-Nebro, A	Analysis of epigenetic biomarkers for diagnosis and assessment of severity in rheumatoid arthritis: a cross-sectional study	ARTHRITIS RESEARCH & THERAPY	4.6	Q1	Article	2025
D-03	Rua-Figueroa, I; Pérez-Veiga, N; Rodríguez-Almaraz, E; Galindo-Izquierdo, M; Erausquin, C; Fernandez-Nebro, A; Itzazelaia, EU; Serrano-Benavente, B; Alén, JC; Manrique-Arija, S; Senabre, JM; Bernal, JA; Narvaez, J; Tomero, E; Aurrecoechea, E; Ibáñez-Barceló, M; Segarra, VT; Sangüesa, C; Freire-González, M; García-Villanueva, MJ; Taboada, VM; Arevalo, M; Morales, CM; Iñiguez, C; Perez, A; Salgado, E; Carrión-Barberà, I; Andreu, JL; Cobo, T; Horcada, L; Bonilla, G; Lozano-Rivas, N; Exposito, L; Montilla, C; Toyos, FJ; Ibarguengoitia-Barrena, O; Pascual, EV; Medina, JN; Menor-Almagro, R; Ivorra, JAR; Jiménez, AM; Nolla, JM; Pego-Reigosa, JM	Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort	LUPUS SCIENCE & MEDICINE	4	Q1	Article	2025
D-03	Kaczmarczyk, B; de la Calle-fabregat, C; Conde, A; Duarte, AC; Mena-Vazquez, N; Fernandez-Nebro, A; Triguero-Martinez, A; Castañeda, S; Sobrin, RDS; Mera-Varela, A; Lopez-Pedrera, C; Escudero-Contreras, A; Vela-Casasempere, P; Molina, M; Narvaez, J; Retuerto-Guerrero, M; Pablos, JL; Sarmiento-Monroy, JC; Sanmarti, R; Gomez-Carrera, L; Bonilla, G; Remuzgo-Martinez, S; Gonzalez-Gay, MA; Leiro-Fernandez, V; Perez-Gomez, N; Vadillo-Font, C; Abasolo, L; Casafont-Sole, I; Mateo-Soria, L; Castillo-Gonzalez, AC; Marras, C; Perez-Pampin, E; Ballestar, E; Gonzalez, A	DNA methylome biomarkers of rheumatoid arthritis-associated interstitial lung disease reflecting lung fibrosis pathways, an exploratory case-control study	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
D-03	Ruiz-Limón, P; Mena-Vázquez, N; Moreno-Indias, I; Lisbona-Montañez, JM; Mucientes, A; Manrique-Arija, S; Redondo-Rodriguez, R; Cano-García, L; Tinahones, FJ; Fernández-Nebro, A	Gut dysbiosis is associated with difficult-to-treat rheumatoid arthritis	FRONTIERS IN MEDICINE	3	Q1	Article	2025
D-03	Cano-García, L; García-Studer, A; Manrique-Arija, S; Ortiz-Marquez, F; Redondo-Rodríguez, R; Borregón-Garrido, P; Mena-Vázquez, N; Fernández-Nebro, A	Identifying inflammatory phenotypes associated with lung involvement in systemic sclerosis: k-means clustering approach	FRONTIERS IN IMMUNOLOGY	5.9	Q1	Article	2025
D-03	Gracia-Sánchez, A; Cano-García, L; Ramos-Petersen, L; Gijón-Nogueron, G; Zuníca-García, S; Chicharro-Luna, E	Impact of systemic sclerosis on foot skin hydration: A case-control study	JOURNAL OF TISSUE VIABILITY	2.8	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
D-03	Mena-Vázquez, N; Ortiz-Márquez, F; Ramirez-García, T; Gillis-Onieva, C; Cabezudo-García, P; García-Studer, A; Mucientes, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Manrique-Arija, S; Cano-García, L; Serrano-Castro, PJ; Fernández-Nebro, A	Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis	FRONTIERS IN MEDICINE	3	Q1	Article	2025
D-03	Mena-Vázquez, N; García-Studer, A; Ortiz-Márquez, F; Manrique-Arija, S; Mucientes, A; Lisbona-Montañez, JM; Borregón-Garrido, P; Ruiz-Limón, P; Redondo-Rodriguez, R; Cano-García, L; Fernández-Nebro, A	Longitudinal Assessment of Body Composition and Inflammatory Status in Rheumatoid Arthritis During TNF Inhibitor Treatment: A Pilot Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
D-03	Morales, E; Rúa-Figueroa, I; Rubio, JLC; Bernabéu, AA; Alonso, RB; Xutgla, MCC; Juárez, GF; Mena-Vázquez, N; Blanco, JJR; Escola, JM; García, FJN; Sopeña, B; Porras, LFQ; Romero-Yusten, S; Laqué, RS	Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis	NEFROLOGIA	2.6	Q2	Article	2025
D-03	Romero-Yuste, S; Macía, M; Dominguez-Alvaro, M; Fernández-Nebro, A; Blasco, M; Narváez, J; Fernández, G; Rúa-Figueroa, I; Luis-Rodríguez, D; Ventosa, B	RESER/NVAN: Spanish Registry of patients with ANCA-associated vasculitis: objectives and methodology	REUMATOLOGIA CLINICA	1.3	Q4	Article	2025
D-03	Altabás-González, I; Rua-Figueroa, I; Roberts, K; Mamani, IL; Mouriño, C; Martinez-Barrio, J; Izquierdo, MG; Calvo-Alén, J; Erausquin, C; Serrano-Benavente, B; Uriarte, E; Tomero, E; Freire-González, M; Blanco, R; Salgado, E; Gomez-Sabater, S; Fernandez-Nebro, A; Sangüesa, C; Narvaez, J; Vázquez, NM; Menor-Almagro, R; de Salazar, JCRG; Aurrecoechea, E; Ibarguengoitia-Barrena, O; Montilla, C; Bonilla, G; Segarra, VT; Juan-Mas, A; García-Villanueva, MJ; Morales, CM; Horcada, L; Lozano-Rivas, N; Iñiguez, C; Arevalo, M; Paredes, B; Exposito, L; Toyos, FJ; Flores-Fernandez, E; Medina, JN; Gil, JJF; Bohorquez, C; Pego-Reigosa, JM	Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality	LUPUS SCIENCE & MEDICINE	4	Q1	Article	2025
D-04	Bogas, G; Ariza, A; Vázquez-Revuelta, P; Labella, M; Madrigal-Burgaleta, R; Fernández-Santamaría, R; Calvo-Serrano, S; Villar-Chamorro, E; Martín-Clavo, S; Lebrón-Martín, C; Mayorga, C; Doña, I; Torres, MJ	Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes	ALLERGY	12	D1	Article	2025
D-04	Fernandez-Santamaria, R; Salas, M; Ariza, A; Jiménez, MA; González-Mendiola, MR; Sanchez, ML; Boteanu, C; Mayorga, C; Fernandez, TD; Torres, MJ; Laguna, JJ	Basophil Activation Test Positivity Decreases With Time in Immediate Allergic Reactions to Proton Pump Inhibitors	ALLERGY	12	D1	Article	2025
D-04	Pascal, M; Chauhan, J; Knol, E; Bianchini, R; Castells, M; de las Vecillas, L; Hartmann, K; Izquierdo, E; Jappe, U; Jimenez-Rodriguez, TW; Levi-Schaffer, F; Mayorga, C; Poli, A; Redegeld, F; Santos, AF; Jensen-Jarolim, E; Bergmann, C; Karagiannis, SN; Bax, HJ	Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology: An EAACI Position Paper	ALLERGY	12	D1	Article	2025
D-04	Montoro, J; Antolín-Amérigo, D; Izquierdo-Domínguez, A; Zapata, JJ; García-Gallardo, M; González, R; Armentia, A; Rondón, C; Fernández, MM; Pedrero, SG; Valero, A	Climate Change-Associated Environmental Factors and Pollutants: Impact on Allergic Diseases, Epidemiology, Severity, and Health Care Burden	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY	6.7	D1	Review	2025
D-04	Cortellini, G; Nakonechna, A; Barbaud, A; Bavbek, S; Calogiuri, G; Dona, I; Kvedariene, V; Martinez, JJL; Liberati, S; Pagani, M; Romano, A	Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper	ALLERGY	12	D1	Article	2025
D-04	Gelincik, A; Brockow, K; Çelik, GE; Demir, S; Diaz, ID; Ebo, DG; Mayorga, C; Labella, M; Sabato, V; Jaen, MJT	Diagnosis of Quinolone Hypersensitivity: An EAACI Position Paper	ALLERGY	12	D1	Article	2025
D-04	Labella, M; de Guzmán, JR; Diez-Echave, P; Salas, M; Fernández-Santamaría, R; Mayorga, C; Doña, I; Torres, MJ	Direct Single-Dose Drug-Provocation Test Is Safe for Delabelling Penicillin Low-Risk Reactions in Adults	ALLERGY	12	D1	Article	2025
D-04	Agache, I; Torres, M; Eguiluz-Gracia, I; Bradatan, E; El Abd, K; Bilo, MB; Rivolta, F; Sangalli, A; Bumbacea, R; Ali, S; Antolin, D; Cuenda, ACL; Albéndiz, V; Oliveira, MM; Nogueira, PJ; Carmona, L; HEAD Study Grp	Economic Impact of Allergic Diseases and Asthma-The HEAD Pan-European Registry	ALLERGY	12	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
D-04	Mayorga, C; Fernandez-Santamaria, R; Çelik, GE; Labella, M; Murdaca, G; Sokolowska, M; Naisbitt, D; Sabato, V	Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report	ALLERGY	12	D1	Article	2025
D-04	Price, OJ; Papadopoulos, NG; Amerigo, DA; Backer, V; Bougault, V; Del Giacco, S; Gawlik, R; Eguiluz-Gracia, I; Heffler, E; Janson, C; Mcdonald, VM; Moreira, A; Simpson, A; Bonini, M	Exercise Recommendations and Practical Considerations for Asthma Management-An EAACI Position Paper	ALLERGY	12	D1	Article	2025
D-04	Nuñez, R; Fernandez-Santamaria, R; Salas, M; Bogas, G; Diez-Echave, P; Mayorga, C; Torres, MJ; Fernandez, TD	Genomic variants association with selective hypersensitivity reactions to amoxicillin and clavulanic acid	ALLERGY	12	D1	Article	2025
D-04	Perez-Carrasco, V; Soriano-Lerma, A; Guzzi, C; Garcia-Martin, ML; Tello, MJ; Linde-Rodriguez, A; Sánchez-Martin, V; Ortiz-González, M; Gutierrez-Fernández, J; Alarcón-Riquelme, ME; Soriano, M; Marañón, C; Garcia-Salcedo, JA	Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	BIOMARKER RESEARCH	11.5	D1	Article	2025
D-04	Céspedes, JA; Pérez-Moreno, AM; Jurado-Escobar, R; Bogas, G; Salas, M; Ariza, A; Muñoz-Cano, R; Mayorga, C; Torres, MJ; Paris, JL	IgG Removal Enhances the Sensitivity of Amoxicillin-Specific IgE Detection in ImmunoCAP and Radioallergosorbent Test	ALLERGY	12	D1	Article	2025
D-04	Testera-Montes, A; Ariza, A; Sola-Martinez, RA; Aranda, CJ; Bentabol-Ramos, G; Sanchez-Torralvo, D; Mayorga, C; Torres, MJ; Eguiluz-Gracia, I; Rondon, C	Investigation of the diagnostic accuracy of basophil activation test for allergic phenotypes of rhinitis	ALLERGY	12	D1	Article	2025
D-04	Gómez, F; Pérez-Sánchez, N; Macías-Camero, A; Núñez, R; Contreras, N; Cañas, JA; Jiménez-Sánchez, IM; Díez-Echave, P; Barbas, C; Guéant, JL; Barber, D; Vieths, S; Scheurer, S; Villaseñor, A; Rodríguez-Nogales, A; Mayorga, C; Torres, MJ	Multi-omics analysis of a prebiotic intervention with pectin in lipid transfer proteins (LTPs) allergic patients	CARBOHYDRATE POLYMERS	12.5	D1	Article	2025
D-04	Klimek, L; Brough, HA; Arasi, S; Toppila-Salmi, S; Bergmann, C; Jutel, M; Bousquet, J; Hox, V; Gevaert, P; Tomazic, PV; Segovia, CR; Cingi, C; Cuevas, M; Gröger, M; Huber, P; Reitsma, S; Rudenko, M; Maza-Solano, J; Gane, S; Karavelia, A; van Gerven, L; Schiappoli, M; Bozkurt, B; Becker, S; Chaker, A; Wollenberg, B; Mösges, R; Huppertz, T; Hagemann, J; Palomares, O; Bärhold, F; Pfaar, O; Del Giacco, S; Bonadonna, P; Moreira, A; Agache, I; Akdis, CA; Fokkens, W; Walusiak-Skorupa, J; de las Vecillas, L; Lozano, MA; Giovannini, M; Untersmayr, E; Feleszko, W; Cianferoni, A; Sahiner, UM; Eguiluz-Gracia, I; Shamji, M; Jaén, MJT	Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity-An EAACI Position Paper	ALLERGY	12	D1	Article	2025
D-04	Agache, I; Adcock, IM; Baraldi, F; Chung, KF; Eguiluz-Gracia, I; Johnston, SL; Jutel, M; Nair, P; Papi, A; Porsbjerg, C; Usmani, OS; Meyers, DA; Zemelka-Wiacek, M; Bleecker, ER	Personalized therapeutic approaches for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	11.2	D1	Review	2025
D-04	Venter, C; Alonso-Coello, P; Beltran, J; Bracchiglione, J; Fernandez-Saenz, K; Riera, P; Solà, I; Arasi, S; Canani, RB; Fleischer, D; Eguiluz-Gracia, I; Meyer, R; Roberts, G; Roth-Walter, F; Santos, AF; Skypala, I; Smith, PK; Sokolowska, M; Torres, MJ; Vassilopoulou, E; Walter, J; O'Mahony, L	Protocol: Scoping review of the association between complementary feeding, growth, and immune health in infants and toddlers-An EAACI guideline paper	PEDIATRIC ALLERGY AND IMMUNOLOGY	4.5	D1	Review	2025
D-04	Gao YD, Wang ZJ, Ogulur I, Li SJ, Yazici D, Li XH, Pat Y, Zheng Y, Babayev H, Zeyneloglu C, Li YC, Ardicli S, Tian WQ, Ardicli O, Chen SW, Bu XT, Lu G, Chang LH, He Y, Guttman-Yassky E, Cabanillas B, Ozdemir C, Kiykim A, Shamji M, Nadeau K, Torres MJ, Akdis M, Akdis CA	The Evolution, Immunopathogenesis and Biomarkers of Type 2 Inflammation in Common Allergic Disorders	ALLERGY	12	D1	Review	2025
D-04	Tontini, C; Radzikowska, U; Aranda, CJ; Tynecka, M; Dolset, MID; Eljaszewicz, A; Cornejo-García, JA; Villaseñor, A; Ariza, A; Contreras, N; López-Rodríguez, JC; Karaguzel, D; Lozano-Ojalvo, D; Castagnoli, R; Eguiluz-Gracia, I; Sokolowska, M; Mayorga, C; Hilger, C; Mortz, CG; Pfaar, O; Barber, D; Escribese, MM; Karaaslan, C	The Use of Omics Sciences in Allergic Diseases From Bench to Bedside: An EAACI Position Paper	ALLERGY	12	D1	Article	2025
D-04	Gao, YD; Wang, ZJ; Ogulur, I; Li, SJ; Yazici, D; Li, XH; Pat, Y; Zheng, Y; Babayev, H; Zeyneloglu, C; Li, YC; Ardicli, S; Tian, WQ; Ardicli, O; Chen, SW; Bu, XT; Lu, G; Chang, LH; He, Y; Guttman-Yassky, E; Cabanillas, B; Ozdemir, C; Kiykim, A; Shamji, M; Nadeau, K; Torres, MJ; Akdis, M; Akdis, CA	Type 2 Immunity and Its Role in Allergic Disorders	ALLERGY	12	D1	Review	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
D-04	Paris, JL; Vora, LK; Pérez-Moreno, AM; Martín-Astorga, MD; Naser, YA; Anjani, QK; Cañas, JA; Torres, MJ; Mayorga, C; Donnelly, RF	Dissolving microneedle array patches containing mesoporous silica nanoparticles of different pore sizes as a tunable sustained release platform	INTERNATIONAL JOURNAL OF PHARMACEUTICS	0		Article	2025
D-04	Berges-Gimeno, MP; Alvarez-Cuesta, E; Atanaskovic-Markovic, M; Attanassi, M; Caffareli, C; Caubet, JC; du Toit, G; Guzman-Melendez, A; Kuyucu, S; Madrigal-Burgaleta, R; Mayorga, L; Powell, E; Ramien, M; Gomes, ER; Mori, F; White, AA; Ansotegui, IJ; Aun, MV; Barbaud, A; Bavbek, S; Bernal-Rubio, L; Chang, YS; Brockow, K; Bustamante, L; Ensina, LFC; Cuesta-Herranz, J; Fernandes, BN; Garvey, LH; Giavina-Bianchi, P; Kidon, MI; Alvarez, ML; Makowska, JS; Marinho, S; Mendoza-Hernández, DA; Pagani, M; Pino, VP; Parisi, CAS; Park, HS; Peter, J; Phillips, EJ; Risma, K; Solano-Solares, E; Tanno, LK; Valluzzi, RL; Vazquez-Revuelta, P; Watts, TJ; Yamaguchi, M	Drug hypersensitivity reactions in children in clinical practice: A WAO Statement	WORLD ALLERGY ORGANIZATION JOURNAL	4.3	Q2	Review	2025
D-04	Del Giacco, S; Canonica, GW; Agache, I; Price, D; Roche, N; Schunemann, H; Allan, K; Ansotegui, I; Barbaglia, S; Bernstein, JA; Bonini, M; Bosnic-Anticevich, S; Bousquet, J; Braido, F; Carter, V; Chong-Neto, HJ; Di Bona, D; Fletton, K; Diaz, SG; Gupta, VA; Hubbard, R; Iaccarino, J; Eguiluz-Gracia, I; Jacomelli, C; Kocks, J; Krishnan, J; Mahler, V; Morais-Almeida, M; Moreles, D; Muti, P; Palkonen, S; Papadopoulos, N; Pawankar, R; Reeb, C; Reddel, H; Rojo, I; Ryan, D; Sodhi, L; Torres, M; Winders, T; Wilson, KC	Expert Perspectives on Next Generation Health Guidelines: How to Integrate RWE in EBM	PRAGMATIC AND OBSERVATIONAL RESEARCH	2.7	Q1	Article	2025
D-04	Himawan, A; Korelidou, A; Pérez-Moreno, AM; Paris, JL; Dominguez-Robles, J; Vora, LK; Permana, AD; Larrañeta, E; Graham, R; Scott, CJ; Donnelly, RF	Formulation and evaluation of PVA-based composite hydrogels: physicochemical, leachables, and in vitro immunogenicity studies	JOURNAL OF MATERIALS CHEMISTRY B	5.8	Q2	Article	2025
D-04	Amo, G; García-Menaya, JM; Martí, M; Gómez-Tabales, J; Cornejo-García, JA; Blanca-López, N; Canto, G; Doña, I; Blanca, M; Torres, MJ; Agúndez, JAG; García-Martín, E; Ayuso, P	Genetic and serum biomarkers of NSAID hypersensitivity reactions	FRONTIERS IN PHARMACOLOGY	4.8	Q1	Article	2025
D-04	Himawan, A; Graham, R; Volpe-Zanutto, F; Li, HH; Pandya, AK; Aisyah, AN; Agustina, R; Paris, JL; Dominguez-Robles, J; Vora, LK; Permana, AD; Scott, CJ; Donnelly, RF	Microneedles From Shape-Preserving Crosslinked Poly(Vinyl Alcohol) Hydrogels: Minimising Interference in Transdermal Proteomics	ADVANCED MATERIALS TECHNOLOGIES	6.2	Q2	Article	2025
D-04	Belmont, AP; Solensky, R; Doña, I; Salas, M; Torres, MJ	Resensitization-Should Repeat Testing Be Performed in Patients Undergoing Penicillin Allergy Evaluations? A Pro-Con Debate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	6.6	Q1	Article	2025
D-04	Romano, A; Valluzzi, RL; Alvarez-Cuesta, E; Ansotegui, I; Asero, R; Barbaud, A; Bartra, J; Bavbek, S; Cahill, KN; Demoly, P; Doña, I; Meléndez, MAG; Kidon, M; Li, LLY; Madrigal-Burgaleta, R; Makowska, JS; Park, HS; Picado, C; Sanak, M; Taniguchi, M; White, AA; Atanaskovic-Markovic, M; Attanasi, M; Aun, MV; Berges-Gimeno, MP; Bernal-Rubio, L; Brockow, K; Bustamante, L; Caffarelli, C; Chang, YS; Chikhladze, M; Ensina, LF; Fernandes, BN; Garvey, LH; Giavina-Bianchi, P; Gómes, E; Kuyucu, S; Labella, M; Mayorga, C; Mori, F; Pagani, M; Palma-Pino, V; Parisi, C; Phillips, E; Powell, E; Ramien, M; Savic, L; Solano-Solares, E; Tanno, LK; Vazquez-Revuelta, P; Watts, T; Yamaguchi, M	Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement	WORLD ALLERGY ORGANIZATION JOURNAL	4.3	Q2	Review	2025
D-04	Quan, PL; Ollé, L; Sabaté--Bresco, M; Guruceaga, E; Laguna, JJ; Doña, I; Muñoz-Cano, R; Perez-Gracia, JL; Martín, M; Gastaminza, G	Variants of the MRGPRX2 Gene Found in Patients With Hypersensitivity to Quinolones and Vancomycin Show Amplified and Drug-Specific Activation Responses In Vitro	CLINICAL AND EXPERIMENTAL ALLERGY	6.4	Q1	Article	2025
D-05	Bessone, F; Hernandez, N; Medina-Caliz, I; García-Cortés, M; Schinoni, MI; Mendizabal, M; Chiodi, D; Nunes, V; Ridruejo, E; Pazos, X; Santos, G; Fassio, E; Parana, R; Reggiardo, V; Tanno, H; Sanchez, A; Tanno, F; Montes, P; Tagle, M; Arrese, M; Brahm, J; Girala, M; Lizarzabal, MI; Carrera, E; Zerega, A; Bianchi, C; Reyes, L; Arnedillo, D; Cordone, A; Gualano, G; Jaureguizahar, F; Rifrani, G; Robles-Díaz, M; Ortega-Alonso, A; Pinazo-Bandera, JM; Stephens, C; Sanabria-Cabrera, J; Bonilla-Toyos, E; Niu, H; Alvarez-Alvarez, I; Lucena, MI; Andrade, RJ	Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY	12.2	D1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
D-05	Di Zeo-Sánchez, DE; Diaz-Alberola, I; Pinazo-Bandera, JM; García-Cortés, M; Sanabria-Cabrera, J; Robles-Díaz, M; Alvarez-Alvarez, I; Lucena, MI; Andrade, RJ; Villanueva-Paz, M; Stephens, C	Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD)	BRITISH JOURNAL OF PHARMACOLOGY	7.7	D1	Article	2025
D-05	Ronca, V; Parente, A; Lytvyak, E; Hansen, BE; Hirschfield, G; Bonder, A; Ebadi, M; Elwir, S; Alsaed, M; Milkiewicz, P; Janik, MK; Marschall, HU; Burza, MA; Efe, C; Caliskan, AR; Harputluoglu, M; Kabaçam, G; Terrabuio, D; Onofrio, FD; Selzner, N; Parés, A; Llovet, L; Akyildiz, M; Arikan, C; Manns, MP; Taubert, R; Weber, AL; Schiano, TD; Haydel, B; Czubkowski, P; Socha, P; Oldak, N; Akamatsu, N; Tanaka, A; Levy, C; Martin, EF; Goel, A; Sedki, M; Jankowska, I; Ikegami, T; Rodriguez, M; Sterneck, M; Sebode, M; Schramm, C; Donato, MF; Colapietro, F; Lohse, A; Andrade, RJ; Patwardhan, VR; van Hoek, B; Biewenga, M; Ueda, Y; Deneau, M; Pedersen, M; Mayo, MJ; Floreani, A; Burra, P; Secchi, MF; Kremer, AE; Beretta-Piccoli, BT; Sciveres, M; Maggiore, G; Jafri, SM; Debray, D; Girard, M; Lacaille, F; Heneghan, M; Mason, AL; Oo, Y; Montano-Loza, AJ	Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival	JHEP REPORTS	7.5	D1	Article	2025
D-05	Mela, V; Martín-Reyes, F; Oliva-Olivera, W; Cantarero-Cuenca, A; Sánchez-García, A; Sancho-Marín, R; González-Jimenez, A; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sanchez-Gallegos, P; Martínez-Moreno, JM; Tinahones, FJ; García-Fuentes, E; Garrido-Sánchez, L	Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	Article	2025
D-05	Ruiz-Malagón, AJ; Rodríguez-Sojo, MJ; Redondo, E; Rodríguez-Cabezas, ME; Gálvez, J; Rodríguez-Nogales, A	Systematic review: The gut microbiota as a link between colorectal cancer and obesity	OBESITY REVIEWS	7.4	D1	Review	2025
D-05	Cárdenas-Quesada, J; Remesal-Doblado, A; Garrido-Rodríguez, V; Lucena, M; Ginel-Mendoza, L; Cárdenas-Viedma, SL; Sanabria-Cabrera, J	Advancing clinical research in the Spanish primary care service: Challenges, opportunities, and lessons from other European models	EUROPEAN JOURNAL OF GENERAL PRACTICE	2.5	Q1	Article	2025
D-05	Niu, H; Alvarez-Alvarez, I; Chen, MJ	Artificial Intelligence: An Emerging Tool for Studying Drug-Induced Liver Injury	LIVER INTERNATIONAL	5.2	Q1	Review	2025
D-05	Florido-Santiago, M; Pérez-Belmonte, LM; Lara, JP; Millán-Gomez, M; Pérez-Velasco, MA; Osuna-Sánchez, J; García-Casares, N; Gomez-Huelgas, R; Blanco-Reina, E; Barbancho, MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	2.8	Q2	Article	2025
D-05	de los Santos-Fernández, RL; Segovia-Zafra, A; Paz-López, G; Matilla-Cabello, G; Niu, H; Alvarez-Alvarez, I; Stephens, C; González-Jiménez, A; Lucena, MI; Andrade, RJ; Medina-Cáliz, I	Epigenetic modifications in drug-induced liver injury: A systematic review	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY	3	Q2	Review	2025
D-05	Bermúdez-Pérez, IV; Alvarez-Alvarez, I; Medina-Cáliz, I; Robles-Diaz, M; Niu, H; Chen, MJ; Andrade, RJ; Lucena, MI; Stephens, C; Gonzalez-Jimenez, A	Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniques	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	3.4	Q2	Review	2025
D-05	Liao, TJ; Xia, MH; Hayashi, P; Pan, BH; Aithal, GP; Lucena, MI; Andrade, RJ; Rule, JA; Lee, WM; Rakela, J; Huang, RL; Chen, MJ	Genetic Variants of GBP4: Reduced Risks for Drug-Induced Acute Liver Failure in Non-Finnish European Population	LIVER INTERNATIONAL	5.2	Q1	Article	2025
D-05	Ruiz-Malagon, AJ; Herraiz-Vilela, M; Serrano-Pino, R; García-Avila, P; Díaz-Suárez, L; Carmona-Segovia, AD; Becerra-Munoz, VM; Jiménez-Navarro, M; Arranz-Salas, I; Lopez-Villodres, JA; Fernández-Castañer, A; Gutiérrez-Martínez, F; Rodríguez-González, FJ; Camargo-Camero, R; Alcaín-Martínez, G; Rodríguez-Díaz, C; García-Fuentes, E; Sánchez-Quintero, MJ; Lopez-Gomez, C	Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease	WORLD JOURNAL OF GASTROENTEROLOGY	5.4	Q1	Article	2025
D-05	Steplewski, K; Walker, L; Coffee, N; Fallon, M; Yonemochi, R; Alpers, D; Rockey, D; Lewis, J; Cohen, E; Caminis, J; Hey-Hadavi, J; Andrade, RJ; Palmer, M	IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials	DRUG SAFETY	3.8	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
D-05	Alonso-Castellano, P; Tugores, A; Mariño, Z; Olveira, A; Berenguer, M; Huarte, MP; Fernández-Ramos, JR; Lázaro-Ríos, M; González-Diéguez, ML; Moreno-Planas, JM; Hernández-Guerra, M; Fernández-Alvarez, P; Delgado-Blanco, M; Pinazo-Bandera, JM; Romero, M; Ampuero, J; Masnou-Ridaura, H; Cachero, A; Vargas, V; Gómez-Camarero, J; Morillas-Ariño, MJ; Molina-Pérez, E; Miralpeix, A; García-Villarreal, L	Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.	DIGESTIVE AND LIVER DISEASE	3.8	Q2	Article	2025
D-05	Vincenzi, B; Yimin, M; Andrade, RJ; Castillo, MM; Akhundova-Unadkat, G; Mato, JM	Management of drug-induced liver injury associated with anti-cancer therapy	FRONTIERS IN PHYSIOLOGY	3.4	Q1	Review	2025
D-05	Martin-Reyes, F; Kentaoui-Bousellam, I; Ruiz-Malagón, AJ; Ho-Plágaro, A; López-Gómez, C; Herraiz-Vilela, M; Alcain-Martínez, G; Camargo-Camero, R; Martos-VanDussen, JV; Camacho-Martel, L; Gutiérrrez-Martínez, F; Arranz-Salas, I; Ortega-Jimenez, MV; Escamilla-Sánchez, A; Daza-González, JJ; Sanchiz-Cardenas, E; Rivas-Becerra, J; García-Fuentes, E; Rodríguez-Pacheco, F; Rodriguez-Diaz, C	Mesenteric adipose tissue in Crohn's disease alters the immune response of the ileal mucosa and increases angiogenesis and fibrosis	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
D-05	García-Cortés, M; Matilla-Cabello, G; Lucena, MI	Methods for causality assessment of idiosyncratic drug-induced liver injury	LIVER INTERNATIONAL	5.2	Q1	Review	2025
D-05	Mansilla, MJG; Sojo, MJR; Lista, AR; Mosqueda, CVA; Malagón, AJR; Plagaro, AH; Gálvez, J; Nogales, AR; Sánchez, MJR	Microbial-Derived Antioxidants in Intestinal Inflammation: A Systematic Review of Their Therapeutic Potential	ANTIOXIDANTS	6.6	Q1	Review	2025
D-05	Devarbhavi, HC; Andrade, RJ	Natural History of Idiosyncratic Drug-Induced Liver Injury and Prognostic Models	LIVER INTERNATIONAL	5.2	Q1	Review	2025
D-05	Laue, T; Ballester, MP; Meoli, L; Grabitz, C; Uson, E; D'Antiga, L; McLin, V; Pujadas, M; Carvalho-Gomes, A; Sahuco, I; Bono, A; D'Amico, F; Viganò, R; Diago, E; Lanseros, BT; Inglese, E; Vazquez, DM; Broekhoven, A; Kikkert, M; Morales, SPT; Myeni, SK; Riveiro-Barciela, M; Palom, A; Zeni, N; Brocca, A; Cussigh, A; Cmet, S; Escudero-García, MD; Stocco, M; Natola, LA; Ieluzzi, D; Paon, V; Sangiovanni, A; Farina, E; Dibenedetto, C; Sánchez-Torrijos, Y; Lucena-Varela, A; Román, E; Sánchez, E; Sánchez-Aldehuelo, R; López-Cardona, J; Jeyanesan, D; Morocho, AE; Canas-Perez, I; Eastgate, C; Di Cola, S; Lapenna, L; Zaccherini, G; Bongiovanni, D; Riva, A; Sharma, R; Tsou, HLP; Harris, N; Zanaga, P; Sayaf, K; Hossain, S; Crespo, J; Robles-Diaz, M; Madejón, A; Degroote, H; Korenjak, M; Verhelst, X; García-Samaniego, J; Andrade, RJ; Iruzubieta, P; Wright, G; Caraceni, P; Merli, M; Patel, VC; Gander, A; Albillos, A; Soriano, G; Donato, MF; Sacerdoti, D; Toniutto, P; Buti, M; Duvoux, C; Grossi, PA; Berg, T; Polak, WG; Puoti, M; Bosch-Comas, A; Belli, LS; Burra, P; Russo, FP; Coenraad, M; Calleja, JL; Perricone, G; Chokshi, S; Berenguer, M; Clària, J; Moreau, R; Fernández, J; Arroyo, V; Angeli, P; Sánchez-Garrido, C; Ampuero, J; Piano, S; Nicastro, E; Rock, N; Shawcross, D; Edwards, L; Mutschler, F; Melk, A; Mehta, G; Baumann, U; Jalan, R	Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults	TRANSPLANTATION DIRECT	1.9	Q3	Article	2025
D-05	Aziez, M; Yanat, B; Rodriguez-Diaz, C; Suharoschi, R; Vulturar, R; Heghes, SC; Guenaoui, N; Ali, AM; Garcia-Fuentes, E; Bribi, N	Pharmacological Potential of Arthrospira platensis in Mitigating Sub-Chronic Colitis: Redox Homeostasis and Gut Microbiota Modulation	CURRENT ISSUES IN MOLECULAR BIOLOGY	3	Q3	Article	2025
D-05	Alonso, SP; Colomo, N; Lago-Sampedro, A; Maldonado-Araque, C; García-Fuentes, E; Gutiérrez-Repiso, C; Tapia-Guerrero, MJ; Rueda, I; Sánchez, PO; Oualla-Bachiri, W; Calle-Pascual, A; Castaño, L; Delgado-Alvarez, E; Menéndez-Torre, E; Franch-Nadal, J; Urrutia, I; Girbés, J; Chaves, FJ; Montanya, E; Rojo-Martínez, G; Valdés, S	Population-based national incidence of thyroid dysfunction in Spain	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
D-05	Da Silva, VC; Tijeras, JAM; Ruíz-Malagón, AJ; Guerra, GCB; Dantas-Medeiros, R; Medeiros, TS; Garcia-Garcia, J; Rodríguez-Nogales, A; Rodríguez-Cabezas, ME; García, F; da Silva, AA Jr; Gálvez, J; Zucolotto, SM	Preclinical evaluation of colon-targeted nanoparticles containing Commiphora leptophloeos extract for treating inflammatory bowel diseases and colitis-associated colorectal cancer	INTERNATIONAL JOURNAL OF PHARMACEUTICS	0		Article	2025
D-05	Oliva-Olivera, W; Ravnsborg, T; Le Boiteux, E; Garcia-Fuentes, E; Garrido-Sánchez, L; Jensen, ON; Tinahones, FJ	Regulated cell death environments drive fibroinflammatory reprogramming in surviving adipose-derived stem cells	APOPTOSIS	8.1	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
D-05	Marín-Romero, A; Di Zeo-Sánchez, DE; Tabraue-Chávez, M; Villanueva-Paz, M; Pinazo-Bandera, JM; Sanabria-Cabrera, J; Garcia-Cortés, M; Diaz-Mochón, JJ; Lucena, MI; Andrade, RJ; Stephens, C; Pernagallo, S	Short communication: miRNA122 interrogation via PCR-Free method to track liver recovery	PLOS ONE	2.6	Q2	Article	2025
D-05	Nunes, V; Schinoni, MI; Bessone, F; Lucena, MI; Medina-Cáliz, I; Hernandez, N; Costa, MCM; Lins, I; Cardoso, AJ; Freire, B; Schiavon, L; Silva, M; Cançado, ER; Paraná, R	Stanozolol-induced Liver Injury: A Distinctive Cholestatic Clinical and Biochemical Phenotype at Presentation	JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY	3.2	Q2	Article	2025
DE-02	Varisco, B; Pérez-Crespo, PMM; Retamar-Gentil, P; Hernandez, IL; Farinas-Alvarez, MC; Fernández-Natal, I; Pérez-Rodríguez, MT; Aguirre, AJG; Sánchez-Calvo, JM; Martín, LB; León-Jiménez, E; García, DV; Reguera-Iglesias, JM; Bahamonde-Carrasco, A; Fernandez-Suárez, J; Rodríguez-Baño, J; López-Cortés, LE; ROBACREIPI GEIH SEIMC SAEI Grp	Mortality predictors and definition proposal for complicated coagulase-negative Staphylococcus bacteraemia: a multicentre prospective cohort study	CLINICAL MICROBIOLOGY AND INFECTION	8.5	D1	Article	2025
DE-02	Olivares-Navarro, P; Pérez-Rodríguez, MT; Goikoetxea-Agirre, AJ; Reguera-Iglesias, JM; León, E; Mantecón, MA; Pulido-Navazo, A; Boix-Palop, L; Retamar-Gentil, P; Armiñanzas-Castillo, C; Fernández-Natal, I; Jover-Sáenz, A; Jiménez, AD; Fernández-Suárez, J; Martín-Aspas, A; Smithson-Amat, A; Carrasco, AB; Natera-Kindelán, C; Pérez-Crespo, PM; Hernández, IL; López-Cortés, LE; Rodríguez-Baño, J	Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort	INFECTION	3.6	Q2	Article	2025
DE-02	Mancheño-Losa, M; Murillo, O; Benavent, E; Sorlí, L; Riera, M; Cobo, J; Benito, N; Morata, L; Ribera, A; Sobrino, B; Fernández-Sampedro, M; Múñez, E; Bahamonde, A; Barbero, JM; del Toro, MD; Villa, J; Rigo-Bonnin, R; Luque, S; García-Luque, I; Oliver, A; Esteban, J; Lora-Tamayo, J	Efficacy and safety of colistin plus beta-lactams for bone and joint infection caused by fluoroquinolone-resistant gram-negative bacilli: a prospective multicenter study	INFECTION	3.6	Q2	Article	2025
DE-02	De la Rosa-Riestra, S; Gutiérrez-Gutiérrez, B; López-Hernández, I; Pérez-Rodríguez, MT; Agirre, JG; Plata, A; León, E; Alvarez, MCF; Fernández-Natal, I; Fernández-Suárez, J; Boix-Palop, L; Pedragosa, JC; Jover-Sáenz, A; Calvo, JMS; Martín-Aspas, A; Natera-Kindelán, C; Del Arco-Jiménez, A; Pérez-Crespo, PMM; López-Cortés, LE; Rodríguez-Baño, J	External validation of the predictive ability of Charson, SOFA, Pitt, INCREMENT-ESBL and bloodstream infection mortality Risk for 30-day-mortality in bacteraemia using the PROBAC cohort data	INFECTIOUS DISEASES	2.3	Q3	Article	2025
DE-02	Sobrino, B; Luque, S; Velasco-Arnaiz, E; González, RL; Del Pozo, JL	Gram-positive infections in special populations. Expert view on the role of dalbavancin	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	3.8	Q1	Review	2025
DE-02	Rojo-Martín, MD; Ruiz-Mesa, JD; Mediavilla-Gradolph, C; Marín-Arriaza, M; Halbardier-Carretero, A; Serrano-Sánchez, J; Márquez-Gómez, I; de Toro-Peinado, I; Caballero-Martínez, LF; García-Barrionuevo, A; Palop-Borrás, B	The role of microbiological markers in the progression of Clostridioides difficile infection	REVISTA ARGENTINA DE MICROBIOLOGIA	2.1	Q3	Article	2025
DE-08	Mela, V; Martín-Reyes, F; Oliva-Olivera, W; Cantarero-Cuenca, A; Sánchez-García, A; Sancho-Marín, R; González-Jimenez, A; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sanchez-Gallegos, P; Martínez-Moreno, JM; Tinahones, FJ; García-Fuentes, E; Garrido-Sánchez, L	Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery	METABOLISM-CLINICAL AND EXPERIMENTAL	11.9	D1	Article	2025
DE-09	Santamaria-Castro, I; Leiva-Rebollo, R; Marín-Wong, S; Jimenez-Guardeño, JM; Ortega-Prieto, AM	Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies	MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS	7.8	D1	Review	2025
DE-10	Gutiérrez, P; Jiménez, L; Martínez, J; Alba, C; Girón, MV; Olveira, G; Ruiz-Esteban, P; Olveira, C	Dry eye disease and morphological changes in the anterior chamber in people with cystic fibrosis	JOURNAL OF CYSTIC FIBROSIS	6	Q1	Article	2025
DE-10	Sánchez-Fernández, B; Zamorano-González, P; Martín-Montañez, E; Alba-Linero, C; Rius-Díaz, F; García-Fernandez, M; Luque-Aranda, R; García-Basterra, I	Oxidative Stress and Inflammatory Biomarkers in Aqueous Humor and Blood of Patients with Leber's Hereditary Optic Neuropathy	ANTIOXIDANTS	6.6	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
DE-10	Zamorano-Martin, F; Rebollo-Ramírez, W; Ballesteros-Sánchez, A; Alba-Linero, C; Ortiz-Perez, S; Tovilla-Canales, JL; Nava-Castañeda, A	Punctal occlusion versus artificial tears and lid hygiene in the management of Dry Anophthalmic Socket Syndrome: a randomized controlled trial	ORBIT-THE INTERNATIONAL JOURNAL ON ORBITAL DISORDERS-OCULOPLASTIC AND LACRIMAL SURGERY	0.8	Q4	Article	2025
DE-10	Urbinati, F; Bueno, JAR; Real, PS; Redondo-López, MC; Ortega, AS; García-Arnés, JA; Bedmar, MG; Alba-Linero, C; García-Casares, N	Retinal structure and vasculature changes and their relationship with mild cognitive impairment in type 2 diabetes	JOURNAL OF ALZHEIMERS DISEASE	3.1	Q2	Article	2025
DE-11	Montero-Benitez, MZ; Carmona-Llanos, A; Fernández-Jiménez, R; Román-Jobacho, A; Gómez-Millán, J; Modamio-Molina, J; Cabrera-Cesar, E; Vegas-Aguilar, I; Amaya-Campos, MD; Tinahones, FJ; Molina-Montes, E; Cayón-Blanco, M; García-Almeida, JM	AI-Assistance Body Composition CT at T12 and T4 in Lung Cancer: Diagnosing Sarcopenia, and Its Correlation with Morphofunctional Assessment Techniques	CANCERS	4.4	Q2	Article	2025
DE-11	Sanmartin-Sánchez, A; Fernández-Jimenez, R; Olivares-Alcolea, J; Cabrera-Cesar, E; Espildora-Hernández, F; Vegas-Aguilar, I; Amaya-Campos, MD; Simón-Frapolli, VJ; Villaplana-Garcia, M; Cornejo-Pareja, I; Sánchez-Garcia, A; Murri, M; Guirado-Peláez, P; Vidal-Suárez, A; Garrido-Sánchez, L; Tinahones, FJ; Velasco-Garrido, JL; Garcia-Almeida, JM	Cachexia Phenotyping Through Morphofunctional Assessment and Mitocondrial Biomarkers (GDF-15 and PGC-1[illegible]) in Idiopathic Pulmonary Fibrosis	NUTRIENTS	5	Q1	Article	2025
DE-11	Cabrera-César, E; Fernández-Jiménez, R; Lopez-Garcia, J; Sanmartín-Sánchez, A; Cano-Gamonoso, MB; Agüero, IA; Espíldora-Hernández, F; Garcia, LFD; Vega-Aguilar, I; Amaya-Campos, MD; Tinahones, FJ; Garcia-Almeida, JM; Velasco-Garrido, JL	Malnutrition, Sarcopenia, and Malnutrition Sarcopenia Syndrome in Idiopathic Pulmonary Fibrosis	ADVANCES IN RESPIRATORY MEDICINE	2.3	Q2	Article	2025
DE-11	Sanmartín-Sánchez, A; Fernández-Jiménez, R; Cabrera-César, E; Espíldora-Hernández, F; Vegas-Aguilar, I; Amaya-Campos, MD; Palmas-Candia, FX; Olivares-Alcolea, J; Simón-Frapolli, VJ; Cornejo-Pareja, I; Sánchez-García, A; Murri, M; Guirado-Peláez, P; Vidal-Suárez, A; Garrido-Sánchez, L; Tinahones, FJ; Velasco-Garrido, JL; García-Almeida, JM	The Nutritional Phenotyping of Idiopathic Pulmonary Fibrosis Through Morphofunctional Assessment: A Bicentric Cross-Sectional Case-Control Study	LIFE-BASEL	3.4	Q1	Article	2025
F-02	Pascual-Gonzalez, Mario; Jimenez-Partinen, Ariadna; Palomo, Esteban J; Lopez-Rubio, Ezequiel; Ortega-Gomez, Almudena	Hyperparameter optimization of YOLO models for invasive coronary angiography lesion detection and assessment.	Computers in biology and medicine	6.3	D1	Article	2025
F-02	Mármol-Rivera, JA; Fernández-Rodríguez, JD; Asenjo, B; López-Rubio, E	Latent diffusion for arbitrary zoom MRI super-resolution	EXPERT SYSTEMS WITH APPLICATIONS	7.5	D1	Article	2025
F-02	Lima, MSPD Jr; Ortiz-de-Lazcano-Lobato, JM; Lopez-Rubio, E	Training-Free Few-Shot Image Classification via Kernel Density Estimation with CLIP Embeddings	MATHEMATICS	2.2	D1	Article	2025
F-02	Rodríguez-Rodríguez, JA; Molina-Cabello, MA; Benítez-Rochel, R; López-Rubio, E	Consensus-Based 3D View Generation from Noisy Images	INTERNATIONAL JOURNAL OF NEURAL SYSTEMS	6.4	Q1	Article	2025
F-02	Lima, MSPD Jr; López-Rubio, E; Ortiz-de-Lazcano-Lobato, M; Fernández-Rodríguez, JD	Enhanced generation of automatically labelled image segmentation datasets by advanced style interpreter deep architectures	PATTERN RECOGNITION LETTERS	3.3	Q2	Article	2025
F-02	Díaz-Gaxiola, E; Yee-Rendon, A; Vega-Lopez, IF; Campos-Leal, JA; García-Aguilar, I; López-Rubio, E; Luque-Baena, RM	Experimental Assessment of YOLO Variants for Coronary Artery Disease Segmentation from Angiograms	ELECTRONICS	2.6	Q2	Article	2025
F-02	García-Aguilar, I; Galeano-Brajones, J; Luna-Valero, F; Carmona-Murillo, J; Fernández-Rodríguez, JD; Luque-Baena, RM	Improving 5 G base station placement through precise rooftop detection using super-resolution diffusion models and satellite image analysis	NATURAL COMPUTING	1.6	Q3	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
F-02	Thurnhofer-Hemsi, K; García-Aguilar, I; Fernández-Rodriguez, JD; López-Rubio, E	Representation of Molecules by Sequences of Instructions	JOURNAL OF CHEMICAL INFORMATION AND MODELING	5.3	Q1	Article	2025
F-02	Molina-Cabello, MA; Serrano-Angulo, J; Benito-Picazo, J; Thurnhofer-Hemsi, K	Toward Questionnaire Complexity Reduction by Decreasing the Questions	APPLIED SCIENCES-BASEL	2.5	Q2	Article	2025
F-03	Pérez-Sánchez, L; Sénchez-Ramírez, A; Leuermann, J; Molina-Fernández, I	Optical Camera-Based Multiplexed Photonic Sensor System With Ultralow Detection Limit for Biomedical Applications	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.9	D1	Article	2025
F-03	Imas, JJ; Del Villar, I; Halir, R; Wangüemert-Pérez, JG; Ortega-Moñux, A; Matías, IR; Molina-Fernández, I	A systemic model for lossy mode resonances (LMRs)	OPTICS AND LASER TECHNOLOGY	5	Q1	Article	2025
F-03	Arshad, A; Zabit, U; Bernal, O; Deleau, C; Halir, R	Robust integrated optical feedback interferometry via variable optical attenuation	OPTICS EXPRESS	3.3	Q2	Article	2025
F-04	Luperto, M; Romeo, M; Lunardini, F; Monroy, J; García, DH; Abbate, C; Cangelosi, A; Ferrante, S; Gonzalez-Jimenez, J; Basilico, N; Borghese, NA	Exploring the Viability of Socially Assistive Robots for At-Home Cognitive Monitoring: Potential and Limitations	INTERNATIONAL JOURNAL OF SOCIAL ROBOTICS	3.7	Q2	Article	2025
F-09	Martínez-Cesteros, J; Domínguez-Gimeno, S; Castellanos-Ramos, J; Sánchez-Durán, JA; Medrano-Sánchez, C	Characterization and Comparison of Piezoresistive Materials and Their Performance on Pressure-Sensitive Mats	IEEE SENSORS JOURNAL	4.5	Q1	Article	2025
F-10	Benitez-Martin, C; Najera, F; Perez-Inestrosa, E	Simultaneous dual-colour labelling of mitochondria and lysosomes: An indolium-based approach	SENSORS AND ACTUATORS B-CHEMICAL	7.7	D1	Article	2025
F-10	Torres-Olea, B; Pérez-Merchán, A; Zampieri, C; Luna-León, R; Reina, JJ; Moreno-Tost, R; Cecilia, JA; García-Sancho, C; Maireles-Torres, P	Novel method for the production of Zr-doped Beta-zeolites and their use in the production of 5-(hydroxymethyl)furfural etherified biofuels	CATALYSIS TODAY	5.3	Q1	Article	2025
F-10	Matamoros, E; Perez, EMS; Cintas, P; Light, ME; Palacios, JC	Reverse Anomeric Effects in Pyranose and Furanose Isomers in Schiff Bases of d-Galactosamine	JOURNAL OF ORGANIC CHEMISTRY	3.6	Q1	Article	2025
F-10	Montoro-Leal, P; Guerrero, MDL; Mena-Herrera, L; Alonso, EV; Ruiz-Sánchez, AJ; Jiménez-Pérez, R	Selective electrochemical sensor for bisphenol A detection in wastewater using molecularly imprinted polymers on sustainable magnetic graphene oxide	MICROCHIMICA ACTA	5.3	Q1	Article	2025
F-14	Escriche-Escuder, A; García-Almeida, JM; Vegas-Aguilar, IM; Pajares, B; Alba, E; Trinidad-Fernández, M; Roldán-Jiménez, C; Cuesta-Vargas, AI	Effect of a 12-week exercise program on phase angle in women with breast cancer	SUPPORTIVE CARE IN CANCER	3	D1	Article	2025
F-14	Sánchez-Pastor, A; Bravo, C; Henríquez-Jurado, JM; Alcaraz-Ruíz, L; Trinidad-Fernández, M	Effect of high-intensity exercise on functional capacity, cardiorespiratory function and quality of life in patients with colorectal cancer: a systematic review and meta-analysis	SUPPORTIVE CARE IN CANCER	3	D1	Article	2025
F-14	Ramírez-Pérez, L; Cuesta-Vargas, AI	Artificial intelligence in the diagnosis of shoulder injuries through magnetic resonance imaging: a scoping review	EVOLUTIONARY INTELLIGENCE	2.6	Q3	Review	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
F-14	Cuesta-Vargas, A; Arjona-Caballero, JM; Olveira, G; Román, DD; Bellido-Guerrero, D; García-Almeida, JM	Automatic Analysis of Ultrasound Images to Estimate Subcutaneous and Visceral Fat and Muscle Tissue in Patients with Suspected Malnutrition	DIAGNOSTICS	3.3	Q1	Article	2025
F-14	Gomariz-Ruiz, Jaime; Perez-Cruzado, David; Gutierrez-Sanchez, Daniel	Cluster of symptoms in kidney failure: A systematic review.	Heliyon	0		Article	2025
F-14	Di Caudo, C; Aranda-Villalobos, P; Rivas-Garcia, M; Molina, LJ; Gutiérrez-Sánchez, D; Calvo, RP; Membrilla-Mesa, M	Cross-cultural adaptation and psychometric testing of the Spanish version of the Spinal Cord Injury Falls Concern Scale (SCI-FCS)	DISABILITY AND REHABILITATION	2	Q2	Article	2025
F-14	Martín-Martín, J; Santos, I; Gaitán-Arroyo, MJ; Suarez, J; Rubio, L; Martín-de-las-Heras, S	Dental color measurement to estimate age in adults: a systematic review and meta-analysis	FORENSIC SCIENCE MEDICINE AND PATHOLOGY	1.4	Q3	Review	2025
F-14	García-Conejo, C; Roldán-Jiménez, C; Cuesta-Vargas, AI	Effect of exercise-based cardiac rehabilitation on dyspnoea in heart failure: A systematic review of assessment tools, outcomes, and FITT parameters	REHABILITACION	0.4	Q4	Review	2025
F-14	Palau, P; Dominguez, E; Minguez, S; Núñez, G; Santas, E; Garcia-Conejo, C; de Amo, I; Marin, P; Flor, C; Lopez, L; Ortega, L; Gabaldon-Sánchez, I; de la Espriella, R; Sanchis, J; Núñez, J	Effect of left bundle branch block on maximal functional capacity in asymptomatic individuals without structural heart disease	REVISTA ESPANOLA DE CARDIOLOGIA	4.9	Q1	Article	2025
F-14	Ramírez-Pérez, L; Cuesta-Vargas, AI	Effectiveness of therapeutic exercise program in shoulder instability: a systematic review and meta-analysis	EUROPEAN JOURNAL OF PHYSIOTHERAPY	1.1	Q3	Review	2025
F-14	Ramírez-Pérez, L; Moreno-Morales, N	Identifying Key Factors in Adherence and Dropouts in Active Physiotherapy in Children with Acute Leukemia: A Systematic Review with Meta-Analysis and Meta-Regression	HEALTHCARE	2.7	Q2	Review	2025
F-14	Gómez-Palomo, JM; Zamora-Mogollo, A; Tara-Abad, C; Diez-Izquierdo, M; García-Vera, JJ; Martínez-Crespo, A	Impact of navigation on functional and radiological outcomes after total knee arthroplasty: a retrospective analysis of one hundred and ninety cases	INTERNATIONAL ORTHOPAEDICS	2.6	Q2	Article	2025
F-14	Ramirez-Perez, L; Su, EYS; Cuesta-Vargas, AI; Kerr, GK	In Vivo (In)Stability Shoulder Assessment in Healthy Active Adults Using Force Plates and a Motion Capture System: A Cross-Sectional Study	SENSORS	3.5	Q2	Article	2025
F-14	Sanchez-Morilla, S; Cervera-Garvi, P; Ramirez-Perez, L; Garcia-Paya, I; Diaz-Miguel, S; Ortega-Avila, AB	In Vivo Assessment of Ankle Stability During Dynamic Exercises: Scoping Review	HEALTHCARE	2.7	Q2	Review	2025
F-14	Ramírez-Pérez, L; Kerr, GK; Cuesta-Vargas, AI	In vivo assessment of shoulder stability in dynamic rehabilitation exercises: A scoping review	GAIT & POSTURE	2.4	Q2	Review	2025
F-14	Ramirez-Pérez, L; Cuesta-Vargas, A	In-vivo stability shoulder assessment during push-ups using force plates in young adults	REVISTA IBEROAMERICANA DE CIENCIAS DE LA ACTIVIDAD FISICA Y EL DEPORTE	0.7	Q4	Article	2025
F-14	Carrasco-Fernández, L; García-Sillero, M; García-Romero, J; Benítez-Porres, J	Lower Limb Injuries in Women's Handball, Protocols, and Most Common Tests: A Systematic Review	TRANSLATIONAL SPORTS MEDICINE	1.9	Q2	Review	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
F-14	Prue, G; Czamanski-Cohen, J; Kassianos, AP; Pilleron, S; Ladas, A; Can, AA; Roldan-Jimenez, C; Degi, CL; Iscan, G; Arslan, S; de Boer, AGEM; Celebic, A; Donate-Martinez, A; Alhambra-Borras, T; Mitrevski, B; Marzorati, C; Pravettoni, G; Grasso, R; Nazik, E; Pawlowska, E; Mucalo, I; Browne, JP; Tripkovic, K; Vojvodic, K; Karekla, M; Moschofidou, M; Bayram, SB; Brandao, T; Arndt, V; Jaswal, P; Semerci, R; Bozkul, G; Sahin, E; Toygar, I; Frountzas, M; Martins, RM; Jefford, M; Keane, D; Hegarty, J	Models of care and associated targeted implementation strategies for cancer survivorship support in Europe: a scoping review protocol	BMJ OPEN	2.3	Q2	Article	2025
F-14	Garrido-Cervera, JA; Ruiz-Granados, MI; Cuesta-Vargas, AI; Sánchez-Guarnido, AJ	Patient-Reported Outcome Measures (PROMs) for Recovery in Mental Health: A Scoping Review	COMMUNITY MENTAL HEALTH JOURNAL	1.7	Q3	Article	2025
F-14	Biro, A; Iantovics, LB; Fekete, L; Fekete, GL	Prototype of a multimodal AI system for vitiligo detection and mental health monitoring	FRONTIERS IN MEDICINE	3	Q1	Article	2025
F-14	Ponce-García, T; García-Romero, J; Carrasco-Fernández, L; Castillo-Domínguez, A; Benítez-Porres, J	Sex differences in anaerobic performance in CrossFit® athletes: a comparison of three different all-out tests	PEERJ	2.4	Q2	Article	2025
F-14	Ramírez-Pérez, L; Cuesta-Vargas, AI	Shoulder Muscle Activity Through Surface Electromyography and Estimation of Physiological Fatigue Using the T-Fast Test in Patients With Glenohumeral Instability: A Cross-Sectional Study	PHYSIOTHERAPY RESEARCH INTERNATIONAL	1.8	Q2	Article	2025
F-14	Garrido-Cervera, JA; Ruiz-Granados, MI; Cuesta-Vargas, AI; Sánchez-Guarnido, AJ	Validation study for the individual recovery outcomes counter (I.ROC) in a	EUROPEAN JOURNAL OF PSYCHIATRY	1.5	Q3	Article	2025
F-15	Segura-Ortiz, Adrian; Gimenez-Orenga, Karen; Garcia-Nieto, Jose; Oltra, Elisa; Aldana-Montes, Jose F	Multifaceted evolution focused on maximal exploitation of domain knowledge for the consensus inference of Gene Regulatory Networks.	Computers in biology and medicine	6.3	D1	Article	2025
F-16	Passini-Sánchez, J; Gómez-Palomo, JM; Martínez-Crespo, A; Zamora-Navas, P	Factors associated with in-hospital and 12-month mortality in patients undergoing hip arthroplasty for femoral neck fracture	MEDICINA CLINICA	2.1	Q2	Article	2025
F-16	Cano-Obando, L; Gomez-Palomo, J M; Galan-Romero, A; Gonzalez-Garcia, C; Zamora-Navas, P	How does multidisciplinary collaboration with an internal medicine physician influence mortality in hip fracture patients?	Revista espanola de cirugia ortopedica y traumatologia	0		Article	2025
F-16	Gómez-Palomo, JM; Martínez-Crespo, A; Passini-Sánchez, J; Ignatyev-Simonov, N; Zamora-Navas, P; Guerado, E	Quality of life and cost-utility analysis in patients with femoral neck fracture: a propensity score matching study comparing monopolar hemiarthroplasty and total hip arthroplasty	QUALITY OF LIFE RESEARCH	2.7	Q2	Article	2025
F-19	Vaccaro-Witt, GF; Bernal, H; Heredia, SG; Cabrera, FE; Peláez, JI	Effect of Informational Divergence on the Mental Health of the Population in Crisis Situations: A Study in COVID-19	SOCIETIES	1.6	Q2	Article	2025
FA-07	Savarirayan, R; Irving, M; Wilcox, WR; Bacino, CA; Hoover-Fong, JE; Harmatz, P; Polgreen, LE; Palm, K; Prada, CE; Kubota, T; Arundel, P; Kotani, Y; Leiva-Gea, A; Bober, MB; Hecht, JT; Legare, JM; Lawrinson, S; Low, A; Sabir, I; Huntsman-Labed, A; Day, JRS	Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study	MED	11.8	D1	Article	2025
FA-07	Meschian-Coretti, S; Gomez-Palomo, JM; García-Vera, JJ; Salinas-Sánchez, P; Dawid-Milner, MS; Montañez-Heredia, E	Accuracy of medial opening wedge high tibial osteotomy using patient-specific instrumentation: a randomised cadaveric study	EUROPEAN JOURNAL OF ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	1.5	Q3	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
FA-07	Leiva-Gea, L; Sánchez-Palomino, P; Lendínez-Jurado, A; Corte-Torres, MD; Leiva-Gea, I; Leiva-Gea, A	Effectiveness of Titanium Occlusive Barriers in Guided Bone Regeneration: A Prospective Analysis of Vertical and Horizontal Bone Augmentation	BIOMIMETICS	3.9	Q1	Article	2025
FA-07	Passini-Sánchez, J; Gómez-Palomo, JM; Martínez-Crespo, A; Zamora-Navas, P	Factors associated with in-hospital and 12-month mortality in patients undergoing hip arthroplasty for femoral neck fracture	MEDICINA CLINICA	2.1	Q2	Article	2025
FA-07	Leiva-Gea, L; Lendínez-Jurado, A; Sánchez-Palomino, P; Delgado-Ramos, B; Corte-Torres, MD; Leiva-Gea, I; Leiva-Gea, A	Guided Bone Regeneration Using a Modified Occlusive Barrier with a Window: A Case Report	BIOMIMETICS	3.9	Q1	Article	2025
FA-07	Cano-Obando, L; Gomez-Palomo, J M; Galan-Romero, A; Gonzalez-Garcia, C; Zamora-Navas, P	How does multidisciplinary collaboration with an internal medicine physician influence mortality in hip fracture patients?	Revista espanola de cirugia ortopedica y traumatologia	0		Article	2025
FA-07	Muñoz-Sánchez, MA; Martínez-Crespo, A; Tara-Abad, C; Ríos-Morón, M; Montañez-Heredia, E; Gómez-Palomo, JM	Is age an advantage? Improved outcomes after medial unicompartmental knee arthroplasty in patients aged ≥70 years	JOURNAL OF EXPERIMENTAL ORTHOPAEDICS	2.7	Q1	Article	2025
FA-07	Gómez-Palomo, JM; Martínez-Crespo, A; Passini-Sánchez, J; Ignatyev-Simonov, N; Zamora-Navas, P; Guerado, E	Quality of life and cost-utility analysis in patients with femoral neck fracture: a propensity score matching study comparing monopolar hemiarthroplasty and total hip arthroplasty	QUALITY OF LIFE RESEARCH	2.7	Q2	Article	2025
FA-07	Gómez-Palomo, JM; Zamora-Mogollo, A; Tara-Abad, C; Diez-Izquierdo, M; García-Vera, JJ; Martínez-Crespo, A	Impact of navigation on functional and radiological outcomes after total knee arthroplasty: a retrospective analysis of one hundred and ninety cases	INTERNATIONAL ORTHOPAEDICS	2.6	Q2	Article	2025
FE-17	Sanchez-Morilla, S; Cervera-Garvi, P; Ramirez-Perez, L; Garcia-Paya, I; Diaz-Miguel, S; Ortega-Avila, AB	In Vivo Assessment of Ankle Stability During Dynamic Exercises: Scoping Review	HEALTHCARE	2.7	Q2	Review	2025
FE-17	Cantero-Tellez, R; Rider, J; Cruz-Gambero, L; Villafañe, JH; Valdes, K	Kinesiophobia, catastrophizing, and the duration of immobilization: A prospective study on factors associated with shoulder disability following wrist-hand injuries	JOURNAL OF HAND THERAPY	1.8	Q2	Article	2025
FE-17	Campos-Cano, A; Ortega-Avila, AB; Diaz-Miguel, S; Castillo-Domínguez, A; Lopezosa-Reca, E; Gijon-Nogueron, G; Ramos-Petersen, L; Reinoso-Cobo, A	Patients' Experiences Following Osteoarticular Foot Surgery for Rheumatoid Arthritis-Related Deformities: A Qualitative Study	MEDICINA-LITHUANIA	2.4	Q1	Article	2025
FE-17	Cervera-Garvi, P; Ortiz-Romero, M; Gordillo-Fernandez, LM; Garcia-Paya, I; Ortega-Avila, AB; Diaz-Miguel, S	Translation into Spanish, Transcultural Adaptation and Validation of the Foot Function Index Revised Short Form (FFI_RSF) Questionnaire	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
FE-17	Gambero, LC; Gijón-Noguerón, GA; Miguel, SD; Barón-López, J; Raquel, CT	Wrist Joint Restriction: Impact on Foot Pressure, Center of Gravity, and the Role of the Dominant Hand	JOURNAL OF CLINICAL MEDICINE	2.9	Q1	Article	2025
FE-18	Ruiz-Molina, Y; Padial, M; Martin-Bravo, MD; Garcia-Olivares, M; Porras, N; Chicharro, A; Mora-Robles, J; González-Jiménez, A; Sasso, CV; Olveira, G	Targeting Lymphedema in Overweight Breast Cancer Survivors: A Pilot Randomized Controlled Trial of Diet and Exercise Intervention	NUTRIENTS	5	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
FE-20	García-Cañizares, VM; González-Vidal, A; Burgos-Molina, AM; Mercado-Sáenz, S; Sendra-Portero, F; Ruiz-Gómez, MJ	Common Molecular Mechanisms and Biomarkers in Breast, Colon and Ovarian Cancer	APPLIED SCIENCES-BASEL	2.5	Q2	Article	2025
FE-20	Rodríguez-García, M; Burgos-Molina, AM; González-Vidal, A; Sendra-Portero, F; Bernal, M; Ruiz-Gómez, MJ	Molecular mechanisms of radiation resistance in colorectal cancer: in silico identification of AURKA, BIRC5 and PLK1 proteins as potential biomarkers	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY	2.4	Q1	Article	2025
FE-20	González-Vidal, A; Mercado-Sáenz, S; Lopez-Diaz, B; Burgos-Molina, AM; González-Pedrosa, MP; Sendra-Portero, F; Ruiz-Gomez, MJ	Radiation and SARS-CoV-2 effects on the microbiota, immune system and health	INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY	0.5	Q4	Review	2025
FE-22	Molina-Molina, R; Sánchez-Abselam, O; González-Fernández, FT; Castillo-Rodriguez, A; Onetti-Onetti, W	Analysis of physical characteristics and their relationship with cognitive function in semi-professional female soccer players. A case study	REVISTA IBEROAMERICANA DE CIENCIAS DE LA ACTIVIDAD FISICA Y EL DEPORTE	0.7	Q4	Article	2025
FE-22	Vargas-Molina, S; García-Sillero, M; Jiménez-García, JD; Carbone, L; Bonilla, DA; Petro, JL; Romance, R; Benítez-Porres, J	Effects of a Nonlinear Program on Different Health Parameters in the Elderly	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH	2.6	Q2	Article	2025
FE-22	González-Fernández, FT; Martínez-Aranda, LM; Sanz-Matesanz, M; Quiñones-Rodríguez, Y; Castillo-Rodríguez, A	Impact of Four-Match Congestion on the Well-Being of Under-16 Male Soccer Players	SPORTS	2.9	Q1	Article	2025
G-01	Caro, C; Paez-Muñoz, JM; Leal, MP; Carayol, M; Feijoo-Cuaresma, M; Garcia-Martín, ML	Metabolically-Driven Active Targeting of Magnetic Nanoparticles Functionalized with Glucuronic Acid to Glioblastoma: Application to MRI-Tracked Magnetic Hyperthermia Therapy	ADVANCED HEALTHCARE MATERIALS	9.6	D1	Article	2025
G-01	Mela, V; Heras, V; Iesmantaite, M; García-Martín, ML; Bernal, M; Posligua-García, JD; Subiri-Verdugo, A; Martínez-Montoro, JI; Gómez-Pérez, AM; Banderas, B; Indias, IM; Tinahones, FJ	Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis	GUT	26.2	D1	Article	2025
G-01	Perez-Carrasco, V; Soriano-Lerma, A; Guzzi, C; Garcia-Martin, ML; Tello, MJ; Linde-Rodriguez, A; Sánchez-Martin, V; Ortiz-González, M; Gutierrez-Fernández, J; Alarcón-Riquelme, ME; Soriano, M; Marañón, C; Garcia-Salcedo, JA	Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	BIOMARKER RESEARCH	11.5	D1	Article	2025
G-01	Avasthi, A; Fernandez-Afonso, Y; Gutiérrez, L; de la Fuente, JM; Leal, MP; Caro, C; Garcia-Martin, ML	Protein corona as the key factor governing the in vivo fate of magnetic nanoparticles	BIOMATERIALS SCIENCE	5.7	Q2	Article	2025
G-01	Caro, C; Arias-Ramos, N; Urbano-Gámez, JD; González-Alday, R; López-Larrubia, P; García-Martín, ML	A multiparametric perspective on C6 and F98 cell lines in orthotopic rat models for glioblastoma research	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
G-01	Gimeno-Ferrero, R; Estruch-Blasco, M; Pajuelo, E; Fernández, I; García-Martín, ML; Leal, MP	Amphiphile-Assisted Synthesis of Ruthenium Nanoparticles for Controlled Release and Enhanced Antibacterial Activity	SMALL METHODS	9.1	Q1	Article	2025
G-01	Castillejos, MC; Zuliani, A; Cova, CM; Caro, C; Noriega, LL; Comaills, V; García-Martín, ML; Gauthier, BR; Khiar, N	Assessing small-sized D-fructose-functionalized micelles for active targeting of triple-negative breast cancer	JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY	4.9	Q1	Article	2025

Grupo	Authors	Article Title	Source Title	FI	Q/D1	Document Type	Publication Year
G-01	Heras, V; Mela, V; Kompella, P; Rojano, E; Paz-López, G; Hurtado-García, L; Ortega-Gomez, A; García-López, MJ; García-Martín, ML; Ranea, JAG; Tinahones, FJ; Moreno-Indias, I	β-Hydroxybutyrate Reduces Body Weight by Modulating Fatty Acid Oxidation and Beiging in the Subcutaneous Adipose Tissue of DIO Mice	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	4.9	Q1	Article	2025
G-01	Gómez-González, E; Núñez, NO; Caro, C; García-Martín, ML; Moreno, JMM; Hamdi, A; López-Larrubia, P; Becerro, AI; Ocaña, M	Sodium lanthanide tungstate-based nanoparticles as bimodal probes for T1-T2 magnetic resonance imaging and X-ray computed tomography	DALTON TRANSACTIONS	3.3	Q1	Article	2025
G-01	Agüera-Morales, E; Fernández-Sánchez, VE; Navarro-Mascarell, G; Cabezas-Rodríguez, JA; Peña-Toledo, MA; Reyes-Rodríguez, V; Postigo-Pozo, MJ; Patrignani-Ochoa, G; Geniz-Clavijo, MA; Márquez-Infante, C; Tallon-Aguilar, L; Tinoco-González, J; Padillo-Ruiz, J; Valladares-Sánchez, A; Caballero-Eraso, C; López-Ramírez, C; Alcázar-Caballero, RM; Leyva-Fernández, L; Rodríguez-Acosta, A; Maldonado-Sánchez, R; García-Martín, ML; Somoza-Ramírez, ML; Quijano-Ruiz, B; Macías-Sánchez, MD; Carmona-Sánchez, G; Fernández-López, O; Fernández-Fernández, O	Adipose-derived mesenchymal stem cells for the treatment of Amyotrophic Lateral Sclerosis. A phase I/II safety and efficacy clinical trial	FRONTIERS IN NEUROLOGY	2.8	Q2	Article	2025
H-02	Maaloul, A; Manríquez, CP; Decara, J; Marí-Beffa, M; alvarez-Torres, D; Redoli, SL; Martínez-Albardonedo, B; Araya-Rojas, M; Fajardo, V; Díaz, RTA	Biological Effects of Polysaccharides from Bovistella utriformis as Cytotoxic, Antioxidant, and Antihyperglycemic Agents: In Vitro and In Vivo Studies	PHARMACEUTICS	5.5	D1	Article	2025
H-03	Ruiz-Villalba, A; Pardo-Saganta, A	Emerging concepts and novel mechanisms in organ fibrosis	NPJ REGENERATIVE MEDICINE	6.5	Q1	Article	2025
H-03	Oliveira, CC; Cordoba, J; Pearson, JR; Guruceaga, E; Marín-Sedeño, E; Lopez-Moreno, M; Guadix, JA; García-Caballero, M; Pérez-Pomares, JM; Ruiz-Villalba, A	Revealing the complexity of the epicardial secretome	SCIENTIFIC REPORTS	3.9	Q1	Article	2025
HE-01	Ducic, T; Pereiro, E; Ninkovic, M; Sperling, S; Rohde, V; Fernández-González, C; Algarra, M; González-Muñoz, E	Single-cell in situ mapping of glioblastoma and astrocyte cell lines treated with a carbon dot-mediated riluzole nanotherapeutic agent: a live-cell μFTIR and soft X-ray tomography approach	JOURNAL OF NANOBIOTECHNOLOGY	12.6	D1	Article	2025
HE-01	Ducic, T; Rodriguez-Yañez, F; Gonzalez-Muñoz, E	Synchrotron radiation FTIR microspectroscopy enables measuring dynamic cell identity patterning during human 3D differentiation	FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY	4.3	Q1	Article	2025

PUBLICATIONS BY EXTERNAL ASSOCIATED GROUPS

Group	Authors	Article Title	Source Title	Document Type	FI	Q	Publication Year
CA-15	Kodba-Ceh, H; Lunder, U; Asgeirsdóttir, GH; Barnestein-Fonseca, P; Bakan, M; Haugen, DF; Halfdanardottir, SI; Joshi, M; Mcglinchey, T; Romarheim, E; Tripodoro, VA; Veloso, VI; Martín, EV; van der Heide, A; Zambrano, SC; Yildiz, B; Rasmussen, BH; iLIVE Project Consortium	End-of-life care decision-making from perspectives of patients, family members and healthcare professionals in 10 countries: a qualitative study within the iLIVE project	MORTALITY	Article	1	Q2	2025
CA-15	Barnestein-Fonseca, P; Víbora-Martín, E; Ruiz-Torreras, I; Gómez-García, R; Martín-Roselló, ML	Perceived usefulness of new technologies in palliative care volunteering: mixed-methods study with stakeholders	BMC PALLIATIVE CARE	Article	3	Q1	2025
CA-15	Schelin, MEC; Hedman, C; Barnestein-Fonseca, P; Egloff, M; Ellershaw, J; Haugen, DF; Fischer, C; Joshi, M; Korfage, IJ; Lunder, U; Mason, S; Simon, J; Tripodoro, VA; Yildiz, B; Zambrano, SC; Eychmueller, S; van Zuylen, L; van der Heide, A; Fürst, CJ	Recruitment, follow-up and survival in an 11-country cohort study of patients at the end of life and their relatives	PLOS ONE	Article	2,6	Q2	2025
CA-15	Herrera-Imbroda, J; Carbonell-Aranda, V; Guerrero-Pertinez, G; Basnestein-Fonseca, P; Anderberg, P; Varela-Moreno, E; Cuesta-Vargas, A; Garolera, M; Lemmens, E; Berglund, JS; Mayoral-Cleries, F; Goodman-Casanova, JM; Guzman-Parra, J	Temporal Associations Between Cognitive Impairment and Depression in Older Adults: A Longitudinal Analysis	EUROPEAN JOURNAL OF INVESTIGATION IN HEALTH PSYCHOLOGY AND EDUCATION	Article	2,6	Q2	2025
CA-15	Aguiar-Leiva, VP; Leiva-Fernández, F; Martín-Roselló, ML; Gomez-Garcia, R; Fernandez-Lopez, A; Barnestein-Fonseca, P; Morales-Asencio, JM	Validation of a questionnaire to assess complexity of palliative care needs in primary care in Malaga, Spain: a study protocol	BMJ OPEN	Article	2,3	Q2	2025
CA-19	Florido-Santiago, M; Pérez-Belmonte, LM; Lara, JP; Millán-Gomez, M; Pérez-Velasco, MA; Osuna-Sánchez, J; García-Casares, N; Gomez-Huelgas, R; Blanco-Reina, E; Barbancho, MA	Assessment of Long-Term Mild and Major Neurocognitive Disorders 48 Months After Cardiac Surgery	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY	Article	2,8	Q2	2025

ACTIVE COMPETITIVE RESEARCH GRANTS IN 2025

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-01	The Effectiveness of MyDiaMate, a Self-guided Web-based App for Mental Health in Type 1 Diabetes: a Multinational Randomized Controlled Trial	MARÍA TERESA ANARTE ORTÍZ	International non-EU	PI	BREAKTHROUGH T1D	2022
A-01	PMP21-00006. ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2	GEMMA ROJO MARTINEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2021
A-01	PI23-00347 Estado de nutrición de selenio en la población española. Relación con la prevalencia e Incidencia de enfermedad tiroidea y diabetes tipo 2. Estudio di@bet.es.IP: SERGIO VALDES HERNANDEZ. COI: GEMMA ROJO MARTINEZ	SERGIO VALDES HERNANDEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-01	IFI20/00034 Contratos I-PFIS: Doctorados IIS-Empresa en ciencias y tecnologías de la salud. Candidato: Marina Padial Barranco, Jefe de Grupo: Gabriel Olveira Fuster	GABRIEL OLVEIRA FUSTER	National	HR	INSTITUTO DE SALUD CARLOS III	2020
A-01	AP177082021 DETECCION PRECOZ Y TRATAMIENTO DE PACIENTES AFECTADOS DE ADRENOLEUCODISTROFIA LIGADA AL CROMOSOMA X: UN ESTUDIO POBLACIONAL PROSPECTIVO.	RAQUEL YAHYAOUI MACIAS	National	PI	FUNDACIÓN MUTUA MADRILEÑA	2021
A-01	4050-22_miR21-AuNPs dirigido específicamente al tejido adiposo como terapia pionera contra la obesidad, la resistencia a la insulina y la diabetes tipo 2	RAJAA EL BEKAY RIZKY	National	PI	FUNDACIÓN PARA LA INNOVACIÓN Y LA PROSPECTIVA EN SALUD EN ESPAÑA	2022
A-01	SANCYD-2017-03 Evaluación del estado nutricional del paciente onco-hematológico hospitalizado. Implantación de un protocolo de cribado y valoración nutricional. Victoria Contreras Bolivar	GABRIEL OLVEIRA FUSTER	Regional	PI	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2017
A-01	CM24-00013 Contrato Rio Hortega.	FRANCISCO JOSÉ TINAHONES MADUEÑO	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-01	FI24-00310 Contratos predoctorales de formación en investigación de salud.	SERGIO VALDES HERNANDEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-01	INN24_03 Secuenciación de sujetos con DM2 para validación de un algoritmo de diagnóstico diferencial entre sujetos con DM2 vs sujetos con MODY-HFN1a. En el camino hacia la aplicación clínica	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2024
A-01	INT24-00051 Contrato Intensificación	JOSÉ CARLOS FERNANDEZ GARCIA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-01	PI-0113-2025 Intervención de Ejercicio Físico Supervisado en Anorexia Nerviosa: Ensayo Clínico sobre Recuperación Morfofuncional, Biomarcadores Moleculares y Salud Psicosocial en Mujeres Jóvenes	GABRIEL OLVEIRA FUSTER	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2025
A-01	BA24-00030 Modelo de éxito para la Incorporación coste-efectiva al sistema sanitario publico de una medicina de precisión en la atención a las personas con diabetes monogenicas	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-01	SENPE PISENIOR 24_01 Cambios en la microbiota, toxinas urémicas y biomarcadores de inflamación tras tratamiento nutricional personalizado en la enfermedad renal crónica avanzada (Ensayo clínico ERCANUT)	GABRIEL OLVEIRA FUSTER	National	PI	SOCIEDAD ESPAÑOLA DE NUTRICIÓN CLÍNICA Y METABOLISMO	2024
A-01	COM_24-02 Necesidades, barreras y facilitadores de la dieta en personas con enfermedad renal crónica y sus cuidadores. Proyecto goodrenal	MARINA PADIAL BARRANCO	Regional	AWARDS	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2024

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-01	C-0033-2024 CONTRATO INVESTIGA C	GABRIEL OLVEIRA FUSTER	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
A-01	CD24-00003 Contrato Sara Borell	GABRIEL OLVEIRA FUSTER	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-01	CM24-00176 Contrato Rio Hortega.	JOSÉ CARLOS FERNANDEZ GARCIA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-01	CM24-00274 Contrato Rio Hortega	GABRIEL OLVEIRA FUSTER	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-01	PI21-01924 Papel de los miARNs exosomales inflamatorios en la comunicación entre tejido adiposo-cerebro. Nuevos mecanismos subyacentes de las comorbilidades neuropsiquiátricas relacionadas con la obesidad	RAJAA EL BEKAY RIZKY	National	PI	INSTITUTO DE SALUD CARLOS III	2021
A-01	INV-CLIN-01-2023 Evaluación del perfil clínico y analítico de los pacientes con diabetes mellitus tipo 2 en Endocrinología: Un estudio multicéntrico nacional (estudio REDIEN).	JOSÉ CARLOS FERNANDEZ GARCIA	National	PI	FUNDACIÓN DE LA SOCIEDAD ESPAÑOLA ENDOCRINOLOGÍA Y NUTRICIÓN	2023
A-01	PID2021-128926OA-I00_REgulación del receptor de cannabinoide tipo 1 en la fisiología del islote humano y en el contexto de la Diabetes de tipo 1	NATALIA COLOMO RODRIGUEZ	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
A-01	CPP2022-010108 MetabPlus: a flexible and efficient multi-IEM Newborn Screening Program.	RAQUEL YAHYAOUI MACIAS	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
A-01	FSEEN22_OBESIDAD_01 Impacto del aceite de oliva virgen extra (AOVE) sobre algunos microRNAs (miRNAs) y su efecto sobre la meta-inflamación y estrés oxidativo en personas con obesidad y prediabetes.	IGNACIO RUIZ GARCIA	National	PI	FUNDACIÓN DE LA SOCIEDAD ESPAÑOLA ENDOCRINOLOGÍA Y NUTRICIÓN	2022
A-01	PI23-01785 Control glucémico y metabólico tras intervención nutricional con AOV de alto contenido en oleocantal y oleaceína en personas con diabetes tipo 2. Un ensayo aleatorizado, doble ciego y controlado. IP: FRANCISCO JAVIER BERMUDEZ SILVA_ COI: MARIA JOSE TAPIA GUERRERO	FRANCISCO JAVIER BERMÚDEZ SILVA	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-01	MA-INV-0031-2022-03 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Gabriel Olveira Fuster	GABRIEL OLVEIRA FUSTER	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
A-01	PI-0141-2024 Cronobiología y cronodisrupción en personas que reciben terapia médica nutricional y su repercusión sobre la calidad de vida de pacientes y cuidadores. Estudio descriptivo y de intervención	GABRIEL OLVEIRA FUSTER	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
A-01	NUTRICION PARENTERAL_23-01 Evaluación del uso de la fórmula de nutrición parenteral tricameral Finomel ® en plantas de hospitalización no críticas	MARÍA JOSÉ TAPIA GUERRERO	Regional	PI	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2023
A-01	PRIBINNOVE25-01 Omplementación clínica del modelo de valoración morfofuncional en pacientes adultos con fibrosis quística tratados con moduladores CFTR (Elexacaftor-Tezacaftor-Ivacaftor).	GABRIEL OLVEIRA FUSTER	Local	AWARDS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
A-01	PMPER24-00011-MLG Una nueva dimensión del cribado neonatal, el proyecto piloto CRINGENES	RAQUEL YAHYAOUI MACIAS	National	PI	INSTITUTO DE SALUD CARLOS III	2024
A-01	RC1-0001-2025 Renovación del Programa Nicolás Monardes 2021.	GEMMA ROJO MARTINEZ	Regional	HR	SERVICIO ANDALUZ DE SALUD	2025
A-01	C1-0005-2023 PROGRAMA NICOLAS MONARDE_CONVOCATORIA 2023	FRANCISCA RODRIGUEZ PACHECO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
A-01	CPC25288_Determinantes e implicaciones de la concentración sérica de lipoproteina(a) en población general y con diabetes. Estudio di@bet.es. D: Inmaculada González Molero.FSEEN 2025	INMACULADA GONZALEZ MOLERO	National	PI	FUNDACIÓN DE LA SOCIEDAD ESPAÑOLA ENDOCRINOLOGÍA Y NUTRICIÓN	2025

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-01	COM_24-01 ¿En Seguridad Alimentaria se considera la fi bra de bambú como ingrediente de los preparados de carne picada?	VERÓNICA GONZÁLEZ ABREU	Regional	AWARDS	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2024
A-01	EDUCACION_23-01 “Establecimiento de un programa de educación nutricional para mejorar la adherencia dietética y la calidad de vida de las personas con enfermedad renal crónica avanzada (ERCA)”	MARINA PADIAL BARRANCO	Regional	AWARDS	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2023
A-01	SENPE-01-2022_FSanchezTorralvo CT-Determined Sarcopenia in GLIM-Defined Malnutrition and Prediction of 6-Month Mortality in Cancer Inpatients	FRANCISCO JOSÉ SANCHEZ TORRALVO	National	AWARDS	SOCIEDAD ESPAÑOLA DE NUTRICIÓN CLÍNICA Y METABOLISMO	2022
A-01	FI21-00040 Contratos predoctorales de formación en investigación de salud. Wasima Oualla Bachiri jefe de grupo Gemma Rojo Martínez.	GEMMA ROJO MARTINEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2021
A-01	PI-01-2021_SANCYD-BAXTER_GOlveira. Hiperglucemia en nutrición parenteral: efecto sobre biomarcadores de inflamación, oxidación y permeabilidad intestinal. Estudio INSUPAR	GABRIEL OLVEIRA FUSTER	Regional	PI	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2021
A-01	PI-02-2021_SANCYD-VEGENAT-OB_IR. Acciones beneficiosas del aceite de oliva virgen extra sobre la meta-inflamación y procesos relacionados en personas con obesidad y pre-diabetes	IGNACIO RUIZ GARCIA	Regional	PI	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2021
A-01	PI-06-2021-SANCYD-NUTRICIA. Evaluación del control glucémico mediante monitorización flash de glucosa (MFG) en pacientes desnutridos con diabetes tipo 2 y suplementos orales: fórmula estándar vs fórmula específica para diabetes	VIYEY KISHORE DOULATRAM GAMGARAM	Regional	AWARDS	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2021
A-01	RBL-0004-1905 Generacion de nuevos ingredientes y alimentos beneficiosos dirigidos a condiciones de riesgo y al bienestar global de personas con cáncer colorrectal-acrónimo Tératrofo. Efecto coadyuvante en pacientes con tratamiento quimioterápico.	GABRIEL OLVEIRA FUSTER	Regional	HR	SERVICIO ANDALUZ DE SALUD	2022
A-01	PMP22-00033 “El primer Estudio de asociación de genoma completo (GWAS) con enfermedad coronaria poblacional a 10 años en más de 100.000 participantes para personalizar la prevención cardiovascular en España”	SERGIO VALDES HERNANDEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022
A-01	RC1-0002-2025 Renovación del Programa Nicolás Monardes 2021. IB:Francisco Javier Bermúdez	FRANCISCO JAVIER BERMÚDEZ SILVA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2025
A-01	CD23-00110 Contrato Sara Borrel 2023_Alicia Gonzalez Gonzalez_Jefe de Grupo: Jose Carlos Fernandez Garcia	JOSÉ CARLOS FERNANDEZ GARCIA	National	HR	INSTITUTO DE SALUD CARLOS III	2023
A-01	COM_24-03 Biomarcadores de oxidación e inflamación y permeabilidad intestinal en personas con diabetes mellitus que reciben nutrición parenteral total: efecto del tipo de fórmula lipídica.	GABRIEL OLVEIRA FUSTER	Regional	AWARDS	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2024
A-01	COM_24-04 Evaluación de la masa muscular en pacientes con neoplasia colorrectal: correlación entre el análisis de tc de abdomen a la altura de l3 y otras medidas antropométricas y funcionales	VIRGINIA SORIA UTRILLA	Regional	AWARDS	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2024
A-01	PI23-00984 Medicina de precisión en diabetes monogénicas: estrategias genómicas, caracterización clínico-genética y costes asociados. IP: CRISTINA MALDONADO ARAQUE CO-IP: MARIA SOLEDAD RUIZ DE ADANA NAVAS	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-01	PR_NUTRI_2025_Características basales y valoración morfofuncional de pacientes adultos con alteraciones de la beta oxidación de ácidos grasos en Andalucía. IP: Viyey Kishore Doulatram Gamgaram.	VIYEY KISHORE DOULATRAM GAMGARAM	Regional	AWARDS	SOCIEDAD ANDALUZA DE ENDOCRINOLOGÍA, DIABETES Y NUTRICIÓN	2025
A-01	FSED_01-2024 Efecto de miRNAs modulados por la exposición a partículas contaminantes PM10 sobre la disfunción de la célula ß pancreática.	CRISTINA MALDONADO ARAQUE	National	PI	SOCIEDAD ESPAÑOLA DE DIABETES	2024
A-01	FSED_02-2024 Determinantes e implicaciones de la concentración sérica de lipoproteina(a) en población general y con diabetes. Estudio di@bet.es.	VIYEY KISHORE DOULATRAM GAMGARAM	National	PI	SOCIEDAD ESPAÑOLA DE DIABETES	2024

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-01	PIP-0002-2025 NEOReact: Validación Clínica de una nueva Herramienta Rectómica para el Cribado Neonatal de Errores Innatos del Metabolismo	MANUEL BERNAL MUÑOZ	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2025
A-01	JDC2024-055752-I Ayuda Juan de la Cierva 2024. Candidato: Flores Martín. Jefe de grupo: Gemma Rojo.	GEMMA ROJO MARTINEZ	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2025
A-01	B-0078-2024 Refuerzo con RRHH de la actividad investigadora en las UC del SAS - Acción BN: Viyei Kishore Doulatram Gamgaram D: Gabriel Olveira Fuster	GABRIEL OLVEIRA FUSTER	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
A-01/A-02	PI20/01559 Glomerulopatía asociada a Obesidad: Evaluación de la eficacia de una dieta de muy bajo contenido calórico o de la inhibición de SGLT2 sobre albuminuria y función renal	JOSÉ CARLOS FERNANDEZ GARCIA	National	PI	INSTITUTO DE SALUD CARLOS III	2020
A-01/A-19	PI21-01042 Detección precoz y tratamiento de niños afectados de adrenoleucodistrofia ligada al X: un estudio poblacional prospectivo	RAQUEL YAHYAOUI MACIAS	National	PI	INSTITUTO DE SALUD CARLOS III	2021
A-01/DE-08	PI23-01818 Enfermedad por hígado graso asociada a disfunción metabólica y diabetes tipo 1. Análisis de factores predictivos y evaluación de potenciales estrategias terapéuticas. IP: JOSE CARLOS FERNANDEZ GARCIA_COI: MIGUEL JIMENEZ PEREZ	JOSÉ CARLOS FERNANDEZ GARCIA	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-01	CIBER-D1 Metabolic fatty liver disease in people with Type 1 Diabetes in Spain. Prevalence, physiological determinants, and clinical relevance	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2023
A-01	Efecto neuroprotector del IGF-II en un modelo celular de enfermedad de Parkinson con acumulación de agregados tóxicos de α-sinucleína	SILVANA YANINA ROMERO ZERBO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2022
A-01	CARACTERIZACIÓN DE LAS ALTERACIONES OFTALMOLÓGICAS EN PACIENTES CON FIBROSIS QUÍSTICA Y BRONQUIECTASIAS NO DEBIDAS A FIBROSIS QUÍSTICA	CASILDA OLVEIRA FUSTER	National	PI	Sociedad Española de Neumología y Cirugía Torácica (Separ)	2023
A-02	Susceptibilidad genética para predecir la pérdida de peso tras cirugía bariátrica.	LOURDES GARRIDO SÁNCHEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022
A-02	Lifestyle Interventions, metabolites, microbiome, and diabetes risk	FRANCISCO JOSÉ TINAHONES MADUEÑO	International non-EU	PI	NATIONAL INSTITUTES OF HEALTH	2020
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	PATRICIA RUIZ LIMON/ ISABEL MORENO INDIAS/CAROLINA GUTIÉRREZ REPISO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
A-02	CA20117 (Mye-InfoBank) - Conversión de perfiles moleculares de células mieloides en biomarcadores de inflamación y cáncer	ALMUDENA ORTEGA GOMEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
A-02	Project COMFORT - Patient-Centric BlOod SaMpling FOr ImpRoved HealThcar	MANUEL MACÍAS GONZÁLEZ	European Union	PI	COMISIÓN EUROPEA	2023
A-02	CA23151 (Medi-CaSE) - Mediterranean Cancer Screening and Early Diagnosis Network	MANUEL MACÍAS GONZÁLEZ	European Union	NETWORKS AND STRUCTURES	COST ASSOCIATION	2023
A-02	CA23110 (INFOGUT) - International networking on in vitro colon models simulating gut microbiota mediated interactions	PATRICIA RUIZ LIMON/ LOURDES GARRIDO SÁNCHEZ/ DANIEL HINOJOSA NOGUEIRA/ CAROLINA GUTIÉRREZ REPISO	European Union	NETWORKS AND STRUCTURES	COST ASSOCIATION	2023
A-02	The Microbiome-Gut-Brain Axis and Personalized Mediterranean Diet Interventions for Alzheimer's Dementia Prevention	FRANCISCO JOSÉ TINAHONES MADUEÑO	International non-EU	PI	NATIONAL INSTITUTES OF HEALTH	2023
A-02	CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer	MANUEL MACÍAS GONZÁLEZ/ DESIRÉE MARTÍN GARCÍA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-02	CA23146(EURO-VALDI-NET) - European vascular liver diseases network	LOURDES GARRIDO SÁNCHEZ	European Union	NETWORKS AND STRUCTURES	COST ASSOCIATION	2023
A-02	CA22114 (TREASURE) - Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants´development	Mª SONSOLES MORCILLO ESPINA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2018
A-02	CA20110 (exRNA-PATH) - RNA communication across kingdoms: new mechanisms and strategies in pathogen control	MARIA MERCEDES CLEMENTE POSTIGO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2020
A-02	FI23-00104 Contratos predoctorales de formación en investigación de salud. BN: GEMA GOMEZ CASADO.IP:ALMUDENA ORTEGA GOMEZ.	ALMUDENA ORTEGA GOMEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2023
A-02	PI21-01864 Definiendo la heterogeneidad en la Diabetes Gestacional: hacia una medicina de precisión. Una ventana crítica para parar el ciclo vicioso de diabetes-obesidad.	Mª SONSOLES MORCILLO ESPINA	National	PI	INSTITUTO DE SALUD CARLOS III	2021
A-02	MS22-00033 Contrato Miguel Servet 2022	VIRGINIA MELA RIVAS	National	HR	INSTITUTO DE SALUD CARLOS III	2022
A-02	RC-0008-2021 Renovación I Acción C (Programa Nicolás Monardes) Convocatoria 2017	SONSOLES MORCILLO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2021
A-02	C-0028-2018 Acciones para el refuerzo con recursos humanos de la actividad investigadora en las Unidades de Gestión Clinica del Servicio Andaluz de Salud 2018. Acción C. Vinculación de investigadores a las UGC del SAS. Programa Nicola Monardes	LOURDES GARRIDO SÁNCHEZ	Regional	HR	SERVICIO ANDALUZ DE SALUD	2018
A-02	ICI23-00019 Efecto de la levotiroxina como terapia adyuvante a la dieta hipocalórica en el tratamiento de la obesidad: ensayo clínico aleatorizado controlado por placebo.	FRANCISCO JOSÉ TINAHONES MADUEÑO	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-02	RC-0001-2018 Acción C Nicolás Monardes	MANUEL MACÍAS GONZÁLEZ	Regional	HR	SERVICIO ANDALUZ DE SALUD	2025
A-02	PI21-01677 Medicina personalizada o de precisión en el abordaje dietético de la obesidad	FRANCISCO JOSÉ TINAHONES MADUEÑO	National	PI	INSTITUTO DE SALUD CARLOS III	2021
A-02	CD22/00144 Contrato Sara Borrell_Violeta Heras Dominguez_Jefe de Grupo Francisco Jose Tinahones Madueño.	FRANCISCO JOSÉ TINAHONES MADUEÑO	National	HR	INSTITUTO DE SALUD CARLOS III	2022
A-02	PI-0108-2022 BÚSQUEDA DE POTENCIALES BIOMARCADORES DE DIAGNÓSTICO / EVOLUCION DE LA ESTEATOHEPATITIS NO ALCOHÓLICA EN PACIENTES CON OBESIDAD MÓRBIDA SOMETIDOS A CIRUGÍA BARIÁTRICA	LOURDES GARRIDO SÁNCHEZ	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2022
A-02	CPII21-00013 Contratos Miguel Servet Tipo II 2021	ISABEL MORENO INDIAS	National	HR	INSTITUTO DE SALUD CARLOS III	2021
A-02	SED-2021-001 DISFUNCIÓN VENTRICULAR E INSUFICIENCIA CARDIACA EN PACIENTES CON DIABETES TIPO 1. PAPEL DE LA MICROBIOTA INTESTINAL EN LA AFECTACIÓN MIOCÁRDICA EN DIABETES TIPO 1.	ANA GOMEZ PEREZ	National	PI	SOCIEDAD ESPAÑOLA DE DIABETES	2021
A-02	SECO_PI23_01 FACTORES PREDICTORES DE LA RESPUESTA A LA CIRUGÍA BARIÁTRICA: PAPEL DE LA COMPOSICIÓN CORPORAL Y LA PÉRDIDA DE PESO PREVIA A LA CIRUGÍA"	LUIS OCAÑA WILHELMI	National	PI	SOCIEDAD ESPAÑOLA DE CIRUGÍA DE LA OBESIDAD	2023
A-02	CP20-00066:Impact of glucose-lowering strategies on gut microbiota. Proyecto Miguel Servet 2020 Carolina Gutierrez Repiso	CAROLINA GUTIÉRREZ REPISO	National	PI	INSTITUTO DE SALUD CARLOS III	2020
A-02	CP20-00066 Contratos Miguel Servet 2020	CAROLINA GUTIERREZ REPISO	National	HR	INSTITUTO DE SALUD CARLOS III	2020
A-02	PI-0288-2024 Hacia la diagnosis de la disfunción del tejido adiposo para el manejo personalizado de la obesidad y las enfermedades metabólicas.	DIEGO FERNANDEZ GARCIA	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-02	SED-2018-02 DIFERENCIAS EN MICROBIOTA ENTRE PACIENTES CON DIABETES MELLITUS GESTACIONAL TRATADAS CON INSULINA FRENTE A AQUELLAS TRATADAS CON METFORMINA Y SU POSIBLE PAPEL EN EL CONTROL METABÓLICO, LA INFLAMACIÓN Y LOS RESULTADOS OBSTÉTRICOS Y PERINATALES. IP: María Molina Vega	MARÍA MOLINA VEGA	National	PI	SOCIEDAD ESPAÑOLA DE DIABETES	2018
A-02	PI24/00674 Cuarto trimestre de embarazo: perfil de riesgo cardiovascular e implicaciones pronósticas a largo plazo en mujeres con Diabetes Gestacional. Biomarcadores epigenéticos como predictores de riesgo.	Mª SONSOLES MORCILLO ESPINA	National	PI	INSTITUTO DE SALUD CARLOS III	2024
A-02	RC1-0002-2023 Renovación II del Programa Nicolás Monardes 2023	MANUEL MACÍAS GONZÁLEZ	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
A-02	CP20-00060 Contratos Miguel Servet 2020	ALMUDENA ORTEGA GOMEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2020
A-02	PI23-01449 Hacia la diagnosis de la disfunción del tejido adiposo para el manejo personalizado de la obesidad y las enfermedades metabólicas_ICornejo_MClemente	ISABEL MARÍA CORNEJO PAREJA	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-02	CPII22-00013 Contratos Miguel Servet Tipo II 2022	MORA MURRI PIERRI	National	HR	INSTITUTO DE SALUD CARLOS III	2022
A-02	PI-0235-2021. miRNoma circulante asociado a diferentes estrategias nutricionales para el abordaje personalizado de la obesidad. NutrimiRs: caracterización y potencial terapéutico.	MARIA MERCEDES CLEMENTE POSTIGO	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2021
A-02	ANPQ23_01 PROYECTO DE VALORACIÓN NUTRICIONAL EN EL PACIENTE PENDIENTE DE CIRUGÍA DE COLON ENFOCADO A LA COMPOSICIÓN CORPORAL (TAC, Ecografía nutricional y Bioimpedancia vectorial) (PROGRAMA DE PREHABILITACIÓN)	MIGUEL DAMAS FUENTES	National	PI	FUNDACIÓN DE LA SOCIEDAD ESPAÑOLA ENDOCRINOLOGÍA Y NUTRICIÓN	2023
A-02	CD21-00131 Contratos Sara Borrell 2021 Libia Alejandra Garcia Flores jefe de grupo Manuel Macías González	MANUEL MACÍAS GONZÁLEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2021
A-02	CP20-00060:Footprint of an early nutritional intervention on breastfeeding mothers in the quality of the breast milk and health of the infant. Proyecto Miguel Servet 2020 Almudena Ortega Gomez	ALMUDENA ORTEGA GOMEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2020
A-02	CM23-00128 Contrato Rio Hortega 2023_Cristina Maria Diaz Perdigones_Jefe de Grupo:Isabel Moreno Indias.	ISABEL MORENO INDIAS	National	HR	INSTITUTO DE SALUD CARLOS III	2023
A-02	OBESIDAD-METABOLISMO_23_01 Papel de la enfermedad por hígado graso asociada a disfunción metabólica (MASLD) como marcador predictivo de remisión de diabetes tras cirugía bariátrica	JOSE IGNACIO MARTINEZ MONTORO	Regional	PI	FUNDACION ANDALUZA DE NUTRICIÓN CLÍNICA Y DIETÉTICA	2023
A-02	CP20-00066 Ayuda permanente Contratos Miguel Servet 2020 Carolina Gutierrez Repiso.	CAROLINA GUTIERREZ REPISO	National	HR	INSTITUTO DE SALUD CARLOS III	2020
A-02	PI24/00347 Mente sana en un cuerpo sano. El ayuno intermitente como herramienta para el mantenimiento del peso a través de la comunicación intestino-cerebro: explorando la microglia y la microbiota como link fundamental.	ISABEL MORENO INDIAS	National	PI	INSTITUTO DE SALUD CARLOS III	2024
A-02	PI-0071-2024 Intervención Nutricional	JOSÉ MANUEL GARCIA ALMEIDA	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
A-02	PI23-01724 Una visión holística para el desarrollo de biomarcadores para NAFLD relacionado con la obesidad. IP:LOURDES GARRIDO SANCHEZ_ COI:JOSE MANUEL GARCIA ALMEIDA	LOURDES GARRIDO SÁNCHEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-02	FI22-00193 Contratos predoctorales de formación en investigación de salud. BN: Alba Subiri Verdugo IP Isabel Morneo Indias	ISABEL MORENO INDIAS	National	HR	INSTITUTO DE SALUD CARLOS III	2022

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-02	JR24-00006 Contrato Juan Rodes	JOSE IGNACIO MARTINEZ MONTORO	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-02	MA-INV-0031-2022-02 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Francisco Tinahones Madueño	FRANCISCO JOSÉ TINAHONES MADUEÑO	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
A-02	MS22-00096 Contrato Miguel Servet 2022	PATRICIA RUIZ LIMON	National	HR	INSTITUTO DE SALUD CARLOS III	2022
A-02	INTAR25-01 Análisis Espacial Avanzado de la Respuesta Inflamatoria e Inmunitaria en el Microambiente Tumoral del Cáncer colorrectal (ST-CRC insight)	CAROLINA MURIEL LOPEZ	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
A-02	PMP22-00073 GENETIC SUSCEPTIBILITY TO PREDICT WEIGHT LOSS AFTER BARIATRIC SURGERY.	FRANCISCO JOSÉ TINAHONES MADUEÑO	National	PI	INSTITUTO DE SALUD CARLOS III	2022
A-02/A-03	PI23-00293 Medicina Personalizada en el Abordaje Dietético de la Insuficiencia Cardiaca. Ayuno intermitente, cetosis y cronobiología. IP: MORA MURRI PIERRI_ COI: JOSE MANUEL GARCIA PINILLA	MORA MURRI PIERRI	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-02/A-09	PI23-01825 Alteraciones del olfato y gusto en la obesidad como potenciales predictores de la perdida de peso y su relación con redes cerebrales. IP:CAROLINA GUTIERREZ REPISO_ COI:NATALIA GARCIA CASARES	CAROLINA GUTIÉRREZ REPISO	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-02/A-10	AVANCES EN MEDICINA DE PRECISIÓN DE LA OBESIDAD: ANÁLISIS MULTIÓMICO Y DINÁMICO PARA EL DESCUBRIMIENTO Y VALIDACIÓN DE BIOMARCADORES PREDICTORES DE PÉRDIDA DE PESO TRAS INTERVENCIÓN EN PERSONAS DE ALTO RIESGO”	DOLORES CORELLA PIQUER	National	PI	INSTITUTO DE SALUD CARLOS III	2021
A-02/B-22	PI24/00245 Evaluación Nutricional, Inflamatoria y Muscular (NIMA) en Pacientes con Cáncer Colorrectal	MANUEL MACÍAS GONZÁLEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2024
A-02/BE-18/C-06/D-04/D-05/DE-09	FORT23/00013 IBIMA FORTALECE 2023	ANTONIA SERRANO CRIADO	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-02/C-16	PI22-01813 El papel de los neutrófilos de leche materna de madres con enfermedades metabólicas tras una intervención nutricional. Impacto en el desarrollo del niño y respuesta a infecciones pulmonares	ALMUDENA ORTEGA GOMEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022
A-03	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	MARIA JOSE SANCHEZ QUINTERO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
A-03	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	MARIA JOSE SANCHEZ QUINTERO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
A-03	ORACLE - Optimize risk prediction after myocardial infarction through artificial intelligence and multidimensional evaluation	FRANCESCO COSTA	European Union	HR	COMISIÓN EUROPEA	2022
A-03	CA20137 (VOICES) - Making Young Researchers’ Voices Heard for Gender Equality	MARIA JOSE SANCHEZ QUINTERO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
A-03	CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure	MARIA JOSE SANCHEZ QUINTERO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2022
A-03	FI23-00016 Contratos predoctorales de formación en investigación de salud.BN: ADA DEL MAR CARMONA SEGOVIA. IP:MANUEL FRANCISCO JIMENEZ NAVARRO.	MANUEL FRANCISCO JIMENEZ NAVARRO	National	HR	INSTITUTO DE SALUD CARLOS III	2023

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-03	PI-0245-2021. Caracterización de Pacientes con Hipertensión Pulmonar Basada en la Función Mitocondrial para el Desarrollo de una Prueba Diagnóstica	JUAN JOSÉ GOMEZ DOBLAS	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2021
A-03	C1-0049-2019 SOLICITUD PARA EL PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2019	FRANCISCO JAVIER PAVÓN MORÓN	Regional	HR	SERVICIO ANDALUZ DE SALUD	2019
A-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	JORGE RODRIGUEZ CAPITAN	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2020
A-03	CA24112 - Implementation of Tear Fluid Biomarkers in Precision Medicine (TEAR-Precision)	MANUEL FRANCISCO JIMENEZ NAVARRO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2025
A-03	PI22/00570 Relación de la microbiota fecal y oral, y sus metabolitos, con la presencia de arterias coronarias lisas, irregulares y con lesión IP Fco Manuel Jimenez obstructiva significativa	MANUEL FRANCISCO JIMENEZ NAVARRO	National	PI	INSTITUTO DE SALUD CARLOS III	2022
A-03	SECFEC-INV-BAS 2318 Evaluación del Riesgo de Cardiopatía Isquémica en Pacientes con Trastorno por Uso de Alcohol en Abstinencia: Determinación de Marcadores de Estrés Cardíaco e Inflamación en Plasma	MANUEL FRANCISCO JIMENEZ NAVARRO	National	PI	SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA	2023
A-03	FI24-00012 Contratos predoctorales de formación en investigación de salud. Becerra	VÍCTOR MANUEL BECERRA MUÑOZ	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-03	CM24-00006 Contrato Rio Hortega.	FRANCESCO COSTA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-03	CM24-00188 Contrato Rio Hortega	FRANCISCO JAVIER PAVÓN MORÓN	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-03	PI23-01192 Eficacia, seguridad y efecto sobre el estado inflamatorio de un programa de telerehabilitación en pacientes con hipertensión arterial pulmonar. IP: VICTOR MANUEL BECERRA MUÑOZ	VÍCTOR MANUEL BECERRA MUÑOZ	National	PI	INSTITUTO DE SALUD CARLOS III	2023
A-03	Proy_Excel_01009 Identificación de marcadores moleculares de aortopatía bicúspide (MaMolAo)	GEMMA SANCHEZ ESPIN	Regional	PI	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2022
A-03	AFFIRMO - ATRIAL FIBRILLATION INTEGRATED APPROACH IN FRAIL, MULTIMORBID, AND POLYMEDICATED OLDER PEOPLE	JORGE RODRIGUEZ CAPITAN	European Union	PI	COMISIÓN EUROPEA	2020
A-03	PI22-01833 Caracterización de Marcadores de Estrés Cardíaco y Quimioquinas en Pacientes con Trastorno por Uso de Alcohol para Evaluar el Riesgo de Cardiopatía Isquémica: Biomarcadores Específicos.	FRANCISCO JAVIER PAVÓN MORÓN	National	PI	INSTITUTO DE SALUD CARLOS III	2022
A-03	JR23-00033 Contratos Juan Rodes 2023 Francesco Costa	FRANCESCO COSTA	National	HR	INSTITUTO DE SALUD CARLOS III	2023
A-03	MA-INV-0031-2022-07 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Francisco Javier Pavón	FRANCISCO JAVIER PAVÓN MORÓN	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
A-03	SAC PI 24_01 Evaluación de marcadores de riesgo cardiovascular en el seguimiento en mujeres con Diabetes Gestacional y su relación con biomarcadores epigenéticos	LUIS GARCIA RODRIGUEZ	Regional	PI	SOCIEDAD ANDALUZA DE CARDIOLOGÍA	2024
A-03	A1-0015-2024 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS).	JUAN JOSÉ GOMEZ DOBLAS	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
A-03	INT23-00033 Contrato intensificación	MANUEL FRANCISCO JIMENEZ NAVARRO	National	HR	INSTITUTO DE SALUD CARLOS III	2023

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-06	Secoiridoides del olivo en la terapia nutricional del lupus eritematoso sistémico: implicaciones epigenéticas. Estudio SerLES	RICARDO GÓMEZ HUELGAS	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2021
A-06	CA21147 (ENOTTA) - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases	MARÍA DEL MAR AYALA GUTIERREZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
A-06	HOR-2025-06 ALADIN - Algal Lutein Against Decline of Intellectual Nimbleness	MARIA ROSA BERNAL LOPEZ	European Union	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2025
A-06	e2-ducass - e2-ducass digital tool intervention: bringing the health literacy to vulnerable populations for promoting physical activity, healthy diet patterns and mental and cardiovascular health	RICARDO GÓMEZ HUELGAS	European Union	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2023
A-06	SAM - Gemelo Digital Inteligente para la prescripción social en atención sanitaria primaria	RICARDO GÓMEZ HUELGAS	European Union	PI	COMISIÓN EUROPEA	2024
A-06	3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory and Allergic Conditions	CARLOS ROMERO GOMEZ	European Union	PI	COMISIÓN EUROPEA	2018
A-06	IDeIBIMA_001_2018 Impacto de la modificación del estilo de vida sobre la función muscular y cognitiva de una población obesa metabólicamente sana de edad avanzada.	RICARDO GÓMEZ HUELGAS	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2018
A-06	C1-0005-2020_Solicitud para el programa Nicolás Monarde. Convocatoria 2020	MARIA ROSA BERNAL LOPEZ	Regional	HR	SERVICIO ANDALUZ DE SALUD	2020
A-06	FI22/00294 Contratos predoctorales de formación en investigación de salud. BN: María de los Ángeles Silva Soto IP Rosa Bernal Lopez	MARIA ROSA BERNAL LOPEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2022
A-06	IHMC22/00011 Impact of lipid stress on sperm cytoskeleton: -omic study and damage reversal strategy through diet	ESTEFANÍA SAEZ LANCELLOTTI	National	HR	INSTITUTO DE SALUD CARLOS III	2022
A-06	CM22/00225 Contrato Rio Hortega 2022 Miguel Angel Perez Velasco_Jefe de Grupo Luis Miguel Perez Belmonte.	LUIS MIGUEL PEREZ BELMONTE	National	HR	INSTITUTO DE SALUD CARLOS III	2022
A-06	A1-0009-2024 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS)	MIGUEL ÁNGEL PEREZ VELASCO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
A-06	A1-0047-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: RICARDO GOMEZ HUELGAS	RICARDO GOMEZ HUELGAS	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
A-06	INT24/00026 Contrato intensificación	LAURA MARTIN PIEDRA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
A-06/A-19	PI-0040-2024 Obesidad Sarcopénica en la Infancia: Un problema emergente con graves consecuencias. Estudio OSIN	MERCEDES RIVERA CUELLO	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
A-07	Eficacia de los polifenoles del aceite de oliva y el ejercicio programado sobre la microangiopatía diabética	JOSÉ ANTONIO GONZÁLEZ CORREA	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
A-07	PI-0137-2024 Estudio traslacional del efecto cardiosaludable de la asociación polifenoles-pectina obtenida del alperujo	ESTHER MARTIN AURIOLES	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
A-07	PS17174 NUTRADAF,ITC-20161265 Caracterización de las fracciones funcionales de la aceituna, formulación de nuevos productos y análisis de sus defectos	JOSÉ PEDRO DE LA CRUZ CORTÉS	National	PI	CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN (CDTI)	2016

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-07	PS17173 NUTRADAF,ITC-20161265 Caracterización de las fracciones funcionales de la aceituna, formulación de nuevos productos y análisis de sus defectos	JOSÉ ANTONIO GONZÁLEZ CORREA	National	PI	CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN (CDTI)	2016
A-09	HOR-2024-01 MDR in AIS - Minimizing Door to Reperfusion Times in Drip and Ship Model for Patients with Acute Ischemic Stroke	CARLOS CRUZ COSME	European Union	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2023
A-09	BAP 01-24 ESTUDIO DEL S0NDROME DE AUTOANTICUERPOS ANTI-LPL Y ANTI-GPIHBP1 EN LA HIPERTRIGLICERIDEMIA GRAVE,	JOSÉ RIOJA VILLODRES	National	PI	FUNDACION ESPAÑOLA DE ARTERIOSCLEROSIS	2024
A-09	BICE 05-20 Caracterización clínica de sujetos con hiperalfalipoproteinemia extrema e identificación de variantes de secuencia en genes candidatos	MARÍA JOSÉ ARIZA CORBO	National	PI	SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS	2020
A-09/ C-22	Depression: From classical neurotransmitters to Neuropeptides.	MANUEL ALEJANDRO NARVÁEZ PELÁEZ	Regional	HR	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2021
A-10	PI-0067-2022. Influencia de los Entornos Obesogénicos Durante una Intervención para la Pérdida de Peso en el contexto andaluz del ensayo PREDIMED-PLUS. (PRE-ENVIRONS ANDALUCÍA)	JULIA WARNBERG	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2022
A-11	RD21-0005-0012 Red de Enfermedaes Inflamatorias IP: Domingo Hernández Marrero	VERÓNICA LOPEZ JIMENEZ	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2021
A-11	PIE25-06 Utilidad de variables de radiómica en imágenes de tc para evaluar el comportamiento tumoral de meningiomas	ALMUDENA PEREZ LARA	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
A-11	PIE25-05 Monitorización de Pacientes Hiperinmunizados tras Trasplante Renal mediante el Análisis de Subpoblaciones de Monocitos CD14 (M1-like y M2-like)	VERÓNICA LOPEZ JIMENEZ	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
A-11	PMP22-00119 Red Nacional de Laboratorios de Función Renal	ELENA GUTIERREZ VILCHEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022
A-11	SEN22_01 Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico: estudio prospectivo, controlado y aleatorizado de grupos paralelos	ARMANDO TORRES RAMIRO	National	PI	SOCIEDAD ESPAÑOLA DE NEFROLOGÍA	2022
A-17	Desarrollo embrionario del origen anatómico de las arterias coronarias en modelos animales	FRANCISCO DE BORJA FERNÁNDEZ CORUJO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
A-17	MA-INV-0031-2022-26 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Borja Fernández Corujo	BORJA FERNANDEZ CORUJO	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
A-19	Estudio de factores predictivos para la alteración del crecimiento intrauterino mediante la identificación de biomarcadores clínicos, metabólicos y metagenómicos	FERNANDO CARDONA DÍAZ	National	PI	-	2022
A-19	Estudios ómicos, medicina personalizada y terapia avanzada para el síndrome STXBP1	MANUEL ÁLVAREZ DOLADO	Regional	PI	CONSEJERÍA DE SALUD Y CONSUMO	2024
A-19	CA21168 (JIR-CliPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	ROCÍO GALINDO ZAVALA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-19	CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	PILAR SANCHEZ YAÑEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
A-19	BECA_SPAO_001 Estudio de factores implicados en el desarrollo de la enfermedad celíaca en niños; detección de potenciales biomarcadores moleculares	VÍCTOR MANUEL NAVAS LOPEZ	Regional	PI	SOCIEDAD ANDALUZA DE PEDIATRÍA DE ANDALUCÍA ORIENTAL	2020
A-19	SEGHNP-2022-01. ANÁLISIS DE LA RESPUESTA FISIOLÓGICA AL AYUNO DE NIÑOS Y ADOLESCENTES CON OBESIDAD, EN COMPARACIÓN CON ADULTOS, Y TRAS UNA INTERVENCIÓN DE RESTRICCIÓN TEMPORAL DE LA INGESTA DE ALIMENTOS	RAFAEL MARTIN MASOT	National	PI	SOCIEDAD ESPAÑOLA DE GASTROENTEROLOGÍA, HEPATOLOGÍA Y NUTRICIÓN PEDIÁTRICA	2022
A-19	PUNI-003_2018:TELEMEDICINA EN LA ATENCIÓN A NIÑOS CRÓNICOS COMPLEJOS-PLURIPATOLÓGICOS Y SUBSIDIARIOS DE CUIDADOS PALIATIVOS PEDIÁTRICOS	AURORA MADRID RODRIGUEZ	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2018
A-19	SEFQ_24_01 ESTIMACIÓN DEL GASTO ENERGÉTICO EN REPOSO EN PACIENTES PEDIÁTRICOS CON FIBROSIS QUÍSTICA EN DIFERENTES FASES LA ENFERMEDAD Y SU TRATAMIENTO: EVALUACIÓN DE LA VALIDEZ DE LAS ECUACIONES PREDICTIVAS.	RAFAEL MARTIN MASOT	National	PI	SOCIEDAD ESPAÑOLA DE FIBROSIS QUISTICA	2023
A-19	AI-01-2024 Desarrollo de una herramienta predictora de respuesta a terapia biológica en niños con enfermedad inflamatoria intestinal	VÍCTOR MANUEL NAVAS LOPEZ	Regional	PI	SOCIEDAD ANDALUZA DE PEDIATRÍA DE ANDALUCÍA ORIENTAL	2024
A-19	BECA_SPAO_2021_Entrenamiento de la fuerza labial y lingual en sujetos pediátricos y su repercusión en la mejora de la disfagia orofaríngea.	VÍCTOR MANUEL NAVAS LOPEZ	Regional	PI	SOCIEDAD ANDALUZA DE PEDIATRÍA DE ANDALUCÍA ORIENTAL	2021
A-19	PI-0070-2024 ESTUDIO A NIVEL DE CÉLULA ÚNICA DE LA RESPUESTA INMUNOLÓGICA SISTÉMICA A LA INGESTA CONTROLADA DE GLUTEN EN LA ENFERMEDAD CELIACA PEDIÁTRICA (CELLiomicS)	RAFAEL MARTIN MASOT	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
A-19	CONECT4CHILDREN - European Paediatric Clinical Trials Network	ESMERALDA NUÑEZ CUADROS	European Union	PI	COMISIÓN EUROPEA	2017
A-19	AI-01-2023. ESTUDIO A NIVEL DE CÉLULA ÚNICA DEL EFECTO DE UNA DIETA SIN GLUTEN EN EL PERFIL INMUNOLÓGICO SISTÉMICO DE PACIENTES PEDIÁTRICOS CON ENFERMEDAD CELÍACA	RAFAEL MARTIN MASOT	Regional	PI	SOCIEDAD ANDALUZA DE PEDIATRÍA DE ANDALUCÍA ORIENTAL	2023
A-19	BECA_SPAO_2022 ANÁLISIS DE LA RESPUESTA FISIOLÓGICA AL AYUNO DE NIÑOS Y ADOLESCENTES CON OBESIDAD, EN COMPARACIÓN CON ADULTOS, Y TRAS UNA INTERVENCIÓN DE RESTRICCIÓN TEMPORAL DE LA INGESTA DE ALIMENTOS	RAFAEL MARTIN MASOT	Regional	PI	SOCIEDAD ANDALUZA DE PEDIATRÍA DE ANDALUCÍA ORIENTAL	2022
A-19	SEGHNP-2021-01. RESTRICCIÓN HORARIA DE LA INGESTA DE ALIMENTOS EN NIÑOS Y ADOLESCENTES CON OBESIDAD Y COMORBILIDADES METABÓLICAS: ESTUDIO PILOTO	VÍCTOR MANUEL NAVAS LOPEZ	National	PI	SOCIEDAD ESPAÑOLA DE GASTROENTEROLOGÍA, HEPATOLOGÍA Y NUTRICIÓN PEDIÁTRICA	2021
A-21	CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care	AIDA RAIGON PONFERRADA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
A-21	AAEAR23_01 “Variación de la recidiva oncológica en el perioperatorio de cirugía tumoral de mama: comparación de anestesia libre de opiáceos e hipnóticos intravenosos vs opiáceos e hipnóticos inhalatorios. Papel de los circRNA como biomarcadores en este grupo de pacientes”.	AIDA RAIGON PONFERRADA	Regional	PI	ASOCIACIÓN ANDALUZA EXTREMEÑA DE ANESTESIOLOGÍA, REANIMACIÓN Y TERAPÉUTICA DEL DOLOR	2023
A-23	La vacunación de los adultos como factor protector para el desarrollo de demencias. Revisión sistemática y metaanálisis	ALBERTO MARISCAL LARRUBIA	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
A-23	HOR-2025-04 ASEPHAI - Developing a pathway to integrate a personalised Far-UVC disinfection system, as a tertiary preventative measure against worsening of patients' health in ICUs.	SILVIA SOLER MENDEZ	European Union	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
AA-20	MSC_007-2017 La aplicación (APPs) del paciente crónico. APPs para valorar la fragilidad de los pacientes crónicos en la Atención Sanitaria, que permite su priorización y la optimización de los recursos en el Sistema Sanitario Público	ANTONIO JESÚS NUÑEZ MONTENEGRO	Local	AWARDS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2017
B-01	CARACTERIZACIÓN GENÓMICA PROFUNDA DEL CÁNCER DE MAMA LOCALIZADO TRATADO CON TERAPIA NEOADYUVANTE USANDO BIOPSIA LÍQUIDA	EMILIO ALBA CONEJO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
B-01	Análisis multifactorial y unicelular del control epigenético modulado por la microbiota en cáncer de mama triple negativo resistente a quimioterapia neoadyuvante	Mª ISABEL QUEIPO ORTUÑO	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
B-01	Modulación epigenética de distintos subtipos hormonales de cáncer de mama por el microbioma intratumoral: Un enfoque a nivel de células individuales	Mª ISABEL QUEIPO ORTUÑO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
B-01	Ayudas para la Formación de Personal Universitario (FPU)	Mª ISABEL QUEIPO ORTUÑO	National	HR	Ministerio de Universidades	2022
B-01	Ayudas para Personal Técnico de Apoyo	ISAAC JESÚS PLAZA ANDRADES	National	HR	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
B-01	Ayudas Juan de la Cierva 2023_PEINADO RODRIGUEZ, FRANCISCO MANUEL	FRANCISCO MANUEL PEINADO RODRIGUEZ	National	HR	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
B-01	Postdoctorales Junta de Andalucía 2024_CASTELLANO CASTILLO, DANIEL	DANIEL CASTELLANO CASTILLO	National	HR	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
B-01	CARABELA-NF1 - CARABELA-NF1: CDK4/6i Resistance and Biomarker Analysis in Neoadjuvant settings from CARABELA trial.	EMILIO ALBA CONEJO	European Union	HR	COMISIÓN EUROPEA	2024
B-01	PI21-00321Impacto del microbioma intestinal e intratumoral en la respuesta a la quimioterapia neoadyuvante en pacientes con cáncer de mama triple negativo (TNBC).	MARÍA ISABEL QUEIPO ORTUÑO	National	PI	INSTITUTO DE SALUD CARLOS III	2021
B-01	SEOM23 PI_01 Hematopoyesis clonal y envejecimiento precoz en largos supervivientes de tumores de células germinales testiculares	LAURA GALVEZ CARVAJAL	National	PI	SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA	2023
B-01	GEIS-2016-01 Clinical, pathological and molecular correlation of endometrial stromal sarcomas accord!ng to WHO 2014 classification	ISABEL SEVILLA GARCIA	National	PI	GEIS - GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS	2016
B-01	CD21-00164 Contratos Sara Borrell 2021 Daniel Castellano Castillo jefe de grupo Emilio Alba Conejo	EMILIO ALBA CONEJO	National	HR	INSTITUTO DE SALUD CARLOS III	2021
B-01	PREDOC-001-2023 Caracterización de subtipos moleculares definidos por PAM50 y estudio del comportamiento clínico del fenotipo basal en distintas localizaciones tumorales.	EMILIO ALBA CONEJO	National	HR	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2022
B-01	SEOM23-RT-01 MAPS-LUNG: Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial sequencing to reveal Lung Cancer Metastatic Landscape.	EMILIO ALBA CONEJO	National	HR	SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA	2023
B-01	RYC2023-044581-I-PI Proyecto Ramon y Cajal.	EMILIO ALBA CONEJO	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
B-01	SAOM22-01-RB "ANÁLISIS MULTIÓMICO EN CÁNCER DE MAMA HER2-POSITIVO: DIFERENCIAS MOLECULARES ENTRE SUBTIPO INTRÍNSECO MOLECULAR HER2-ENRICHED Y NO-ENRIQUECIDO, RELACIÓN CON HETEROGENEIDAD BIOLÓGICA Y RESPUESTA AL TRATAMIENTO"	ANA GODOY ORTIZ	Regional	PI	SOCIEDAD ANDALUZA DE ONCOLOGIA MEDICA	2022
B-01	PI24/00161 Explorando las conexiones entre la microbiota intestinal e intratumoral, los cambios epigenéticos y la resistencia a la terapia endocrina en cáncer de mama con receptor de estrógenos positivo (BC-EPIBIOTA).	BELLA ISABEL PAJARES HACHERO	National	PI	INSTITUTO DE SALUD CARLOS III	2024

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
B-01	SAOM22-01-MR ADN tumoral circulante como biomarcardor predictivo de respuesta en pacientes con linfoma de Hodgkin clásico de novo: estrategia de medicina personalizada	LAURA GALVEZ CARVAJAL	Regional	PI	SOCIEDAD ANDALUZA DE ONCOLOGIA MEDICA	2022
B-01	B-0045-2023 Refuerzo con RRHH de la actividad investigadora en las UC del SAS - Acción B	LAURA GALVEZ CARVAJAL	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
B-01	SEEO-2016-01 Efectividad de una intervención enfermera educativa y seguimiento para la mejora de la fatiga en pacientes de cáncer de mama en revisión	PILAR CAMARERO GOMEZ	National	PI	SOCIEDAD ESPAÑOLA DE ENFERMERIA ONCOLOGICA	2016
B-01	RYC2023-044581-I Contrato Ramon y Cajal.	EMILIO ALBA CONEJO	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
B-04	Integración de fenotipo, genotipo y transcriptómica en una plataforma bioinformática para ayudar en el diagnóstico de enfermedades raras	JUAN ANTONIO GARCÍA RANEA	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
B-04	Destino celular, inflamación, metabolismo y angiogénesis en microambientes patológicos como dianas para enfoques farmacológicos biotecnológicos	MIGUEL ÁNGEL MEDINA TORRES	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
B-04	Epigenética de la memoria inmunitaria: Vacunación por MSP1 y redes reguladoras mediadas por Folatos	ARMANDO REYES PALOMARES	Regional	PI	UNIVERSIDAD DE MÁLAGA	2024
B-04	CA23146(EURO-VALDI-NET) - European vascular liver diseases network	BEATRIZ MARTÍNEZ POVEDA	European Union	NETWORKS AND STRUCTURES	COST ASSOCIATION	2023
B-04	MA-INV-0031-2022-20 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Miguel Angel Medina	MIGUEL ÁNGEL MEDINA TORRES	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
B-04/B-12	Altas de expresión del olivo (OXA) para interrogación prospectiva del olivo en estrés salino	MANUEL GONZALO CLAROS DÍAZ/ FRANCISCO VEREDAS NAVARRO	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
B-05	CLJUN211613ZAFR_Radio-inmunoterapia en cáncer metastásico. JUAN ZAFRA.	MARIA ISABEL BARRAGÁN MALLOFRET	National	HR	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2021
B-05	C1-0003-2023 PROGRAMA NICOLAS MONARDE CONVOCATORIA 2023_ Farmacogenómica y toxocogenomica de precisión en Oncología	FRANCISCO OLIVER MARTOS	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
B-05	Proy_Excel_01002 Farmacogenomica de precisión aplicada al tratamiento de inmunoterapia en Cáncer de pulmón y Cabeza y Cuello.	FRANCISCO JAVIER OLIVER MARTOS	Regional	PI	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2022
B-05	JDC2023-050934-I Ayuda Juan de la Cierva 2023_ Candidato: Alba Rodríguez Martínez Jefe de Grupo: María Isabel Barragán Mallofret	MARIA ISABEL BARRAGÁN MALLOFRET	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
B-05	PREDOC_01691 Integración de ómicas para la identificación de marcadores predictivos de respuesta a inmunoterapia del cáncer.	MARIA ISABEL BARRAGÁN MALLOFRET	Regional	HR	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2021
B-05	RC-0009-2021 Renovación I Acción C (Programa Nicolás Monardes) Convocatoria 2017	ISABEL BARRAGÁN	Regional	HR	SERVICIO ANDALUZ DE SALUD	2021
B-05	SEOM23-PI-GE-01 CARACTERIZACIÓN DE LOS PACIENTES LARGOS SUPERVIVIENTES TRATADOS CON INMUNOTERAPIA.	LAURA MARÍA MEDINA RODRIGUEZ	National	PI	SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA	2023
B-05	MA-INV-0031-2022-14 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Isabel Barragan	MARIA ISABEL BARRAGÁN MALLOFRET	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
B-05	DTS23-00114 EPIPREDICT: Desarrollo de un panel de marcadores epigenéticos en biopsia líquida para la predicción de respuesta y pronóstico en nuevas estrategias inmunoterápicas	MARIA ISABEL BARRAGÁN MALLOFRET	National	PI	INSTITUTO DE SALUD CARLOS III	2023
B-05	GLD23-00137 “MAPS-LUNG: Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial sequencing to reveal Lung Cancer Metastatic Landscape”	ANTONIO RUEDA DOMINGUEZ	National	PI	GILEAD SCIENCES, S.L.U	2023
B-05	PRYES247250BARR Descifrando las firmas epigenéticas de la respuesta abscopal para guiar la inmunoterapia de precisión (EPI-SABR)	MARIA ISABEL BARRAGÁN MALLOFRET	National	PI	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2023
B-05	CI25-20197 Validation of a novel epigenetic decoding of blood DNA to predict clinical benefit of immunotherapy	MARIA ISABEL BARRAGÁN MALLOFRET	National	PI	FUNDACIÓN LA CAIXA	2025
B-05	CLSEN25BENI MAPS-LUNG: Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial sequencing to reveal Lung Cancer Metastatic Landscape	EMILIO ALBA CONEJO	National	HR	FUNDACIÓN CIENTÍFICA DE LA ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2024
B-05/ BE-23	GEM23_01 “Ex vivo characterization of the mechanisms associated with Abscopal Response”.	MIGUEL ÁNGEL BERCIANO GUERRERO	National	PI	GRUPO ESPAÑOL MULTIDISCIPLINAR DE MELANOMA	2023
B-05/B-22	PI22-01816 Biomarcadores de resistencia a la inmunoterapia: integrando Efecto Abscopal y epigenética en una estrategia de medicina de precisión no invasiva.	MARIA ISABEL BARRAGÁN MALLOFRET	National	PI	INSTITUTO DE SALUD CARLOS III	2022
B-07	EL DIALOGO ENTRE GLS Y GLS2 COMO DIANA TERAPEUTICA EN CANCER	JOSÉ MANUEL MATÉS SÁNCHEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
B-07	MA-INV-0031-2022-06 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Javier Marquez	JAVIER MÁRQUEZ GÓMEZ	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
B-11	FPI2022_ARANDA BRAVO, ISMAEL	ELISA MATAS RICO	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
B-11	Optimización de la inmunoterapia en el cáncer de vejiga avanzado mediante la inhibición de la inmunosupresión dependiente de Autotaxina	ELISA MATAS RICO	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
B-11	Evaluación del papel de Autotaxina como factor pronóstico en Cáncer de Vejiga	ELISA MATAS RICO	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
B-11	BRECISE - Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement	BERNARDO HERRERA IMBRODA	European Union	PI	COMISIÓN EUROPEA	2024
B-11	CPP2022-010045 Desarrollo y validación de nuevo sistema automático de predicción, diagnóstico y análisis temprano de patologías del tracto urinario inferior, a través de nuevas técnicas de procesado de señal e investigación de IA usando martwatch (SWALU23)	BERNARDO HERRERA IMBRODA	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
B-11	SEOM_001 GRUPO EMERGENTE: Utilidad pronóstica y predictiva de la co-delección somática de BRCA2-RB1 en cáncer de próstata avanzado	ELENA CASTRO MARCOS	National	PI	SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA	2020
B-11	PID2021-125385OB-I00 Abordando el papel del ATX como una nueva diana terapéutica en el cáncer de vejiga urotelial	ELISA MATAS RICO	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
B-11	LABAE223471MATA: LAB AECC_01 LA SEÑALIZACIÓN POR AUTOTAXINA-ÁCIDO LISOFOSFATIDICO COMO DIANA TERAPEUTICA PARA MEJORAR LA EFICACIA DE LA INMUNOTERAPIA EN EL CÁNCER UROTELIAL DE VEJIGA. LABAE223471MATA	ELISA MATAS RICO	National	PI	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2022
B-11	AECC_JUNIOR_01_Validación de marcadores y nuevas dianas de tratamiento en cáncer urotelia. Candidato. Fernando Alberca	ELISA MATAS RICO	National	HR	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2023
B-11	MA-INV-0031-2022-16 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Elisa Matas	ELISA MATAS RICO	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
B-11	PRDML258709WAND Ayuda Predoctoral AECC Málaga 2025	ELISA MATAS RICO	National	HR	FUNDACIÓN CIENTÍFICA DE LA ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2024
B-12	PID2020-116898RB-I00 INTELIGENCIA ARTIFICIAL PARA PROCESAMIENTO DE LENGUAJE NATURAL DE TEXTO CLÍNICO EN ESPAÑOL PARA ANÁLISIS DE REAL-WORLD-DATA (Text2RWD)	JOSÉ MANUEL JEREZ ARAGONÉS	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
B-12	Diseño de algoritmos de IA y PLN para el análisis automático de información no estructurada contenida en la historia clínica electrónica en salud	JOSÉ MANUEL JEREZ ARAGONÉS	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
B-12	Modelos de Lenguaje (LLM) y de Generación Aumentada por Recuperación (RAG) para la Extracción de Información Objetiva de Textos Oncológicos en Español	LEONARDO FRANCO	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2024
B-14	INTERACT-EUROPE 100	MARILINA GARCIA ARANDA	European Union	PI	COMISIÓN EUROPEA	2023
B-14	CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer	MARILINA GARCIA ARANDA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
B-14	CA21139 (IMPROVE) - 3Rs concepts to improve the quality of biomedical science	MARILINA GARCIA ARANDA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
B-14	CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care	MARÍA PADILLA RUIZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
B-14	CA23119 (SENESCENCE2030) - Targeting Cell Senescence to Prevent Age-Related Diseases	MARILINA GARCIA ARANDA	European Union	NETWORKS AND STRUCTURES	COST ASSOCIATION	2023
B-14	PI21-00252 Estudio del estado de salud y calidad de vida en pacientes supervivientes de cáncer de colon y recto a 12 años de seguimiento post cirugía	MAXIMINO REDONDO BAUTISTA	National	PI	INSTITUTO DE SALUD CARLOS III	2021
B-14	RD21-0016-0015 Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS). IP: Maximino Redondo Bautista	MAXIMINO REDONDO BAUTISTA	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2021
B-14	PI24/01193 DESARROLLO Y EVALUACIÓN DE UNA APLICACIÓN MÓVIL PARA OFRECER SOPORTE PSICOLÓGICO A MUJERES CON CÁNCER DE MAMA Y SUPERVIVIENTES: PROYECTO SERENAPP.	IRENE ZARCOS PEDRINACI	National	PI	INSTITUTO DE SALUD CARLOS III	2024
B-14	RD24-0005-0016 Red de Investigación en Cronicidad, Atención Primaria y Prevención y Promoción de la Salud (RICAPPS)	MAXIMINO REDONDO BAUTISTA	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2024
B-22	CLJUN223421CANT. AYUDAS TALENTO EN EL TERRITORIO: CLÍNICO JUNIOR. Candidata: Alejandra Cantero González. Jefe de Grupo: Manuel Ángel Cobo Dols	MANUEL COBO DOLS	National	HR	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2022
B-22	SOSCLC - Small cell lung cancer: from biology networks to tailored therapy	MANUEL COBO DOLS	National	PI	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2024
BA-16	PNI24_CGEE Evaluación de la efectividad y eficiencia de un programa de seguimiento enfermero en pacientes con insuficiencia cardíaca: un análisis coste-utilidad.	RAFAEL MESA RICO	National	AWARDS	CONSEJO GENERAL ENFERMERÍA DE ESPAÑA	2024
BA-16	CGEE-PI-2021. Influencia en la calidad de vida, adherencia al tratamiento y mejora de conocimientos en pacientes anticoagulados con? anti-vitamina K (AVK)	ADOLFO ROMERO RUIZ	National	AWARDS	CONSEJO GENERAL ENFERMERÍA DE ESPAÑA	2021
BA-20	PS15138 Proyecto Debra - Diffusion Enhanced Brain Radiotherapy	JORGE CONTRERAS MARTINEZ	Regional	PI	FUNDACIÓN CORPORACIÓN TECNOLÓGICA DE ANDALUCIA	2015

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
BE-18	Beatriz Galindo_GARCIA CABALLERO, MELISSA	MELISSA GARCÍA CABALLERO	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
BE-18	Descifrando la interacción entre la vasculatura linfática y las células inmunes en microambientes tumorales para el desarrollo de inmunoterapias mejoradas	MELISSA GARCÍA CABALLERO	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
BE-18	Descifrando la interacción entre la vasculatura linfática y las células inmunes en microambientes tumorales para el desarrollo de inmunoterapias mejoradas	MELISSA GARCÍA CABALLERO	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
BE-18	CA21154 (TRANSLACORE) - Translational control in Cancer European Network	MELISSA GARCÍA CABALLERO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
BE-18	CA21135 (IMMUNO-model) - Modelling immunotherapy response and toxicity in cancer	MELISSA GARCÍA CABALLERO/ ALEJANDRO ESCAMILLA SANCHEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
BE-18	PREDOC-003-2023 Caracterización de la vasculatura tumoral linfática y descubrimiento de prometedoras dianas terapéuticas.	MELISSA GARCÍA CABALLERO	National	HR	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2022
BE-18	INT-F2-2501 PLAN PROPIO F2 Ayuda para fomentar la asistencia a eventos internacionales de posicionamiento	MELISSA GARCÍA CABALLERO	Local	COMPLEMEN-TARY ACTIONS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
BE-18	MA-INV-0031-2022-12 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Melissa García	MELISSA GARCÍA CABALLERO	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
BE-18/C-09/H-02	INTAR25-11 Estudio de la intercomunicación del tejido adiposo con otros órganos periféricos y su implicación en la patogénesis del Alzheimer.	MELISSA GARCÍA CABALLERO	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
BE-19	Elaboración de un protocolo nacional en dosimetría biológica	MIGUEL JOSÉ RUIZ GÓMEZ	National	PI	CONSEJO DE SEGURIDAD NUCLEAR	2022
BE-21	Estudio del infiltrado de linfocitos B en pacientes con melanoma metastásico mediante la validación interna de ¿ |	ALEJANDRO ESCAMILLA SANCHEZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2022
BE-21	PIE25-07 Inmuno-LLC: Evaluación del rol de miRNAs presentes en biopsia líquida de pacientes con leucemia linfática crónica tratados con inhibidores de la BTK.	ALEJANDRO ESCAMILLA SANCHEZ	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
BE-21	INN25_02 Plataforma con IA para la formación en comunicación y prevención de agresiones a profesionales sanitarios mediante pacientes estandarizados virtuales.	ANDRÉS FONTALBA NAVAS	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
BE-23	EUnetCCC JA - The European Comprehensive Cancer Centre Network	ÁLVARO MONTESA PINO	European Union	PI	COMISIÓN EUROPEA	2024
C-01	PID2020-117464RB-I00 EL RECEPTOR LPA1 COMO POSIBLE BIOMARCADOR VULNERABILIDAD A LA DEPRESION. PAPEL EN LA SENSIBILIZACION MICROGLIAL Y EN LOS CAMBIOS NEUROGENICOS INDUCIDOS POR ESTRES JUVENIL	CARMEN PEDRAZA BENÍTEZ	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
C-01	Evaluación de las propiedades antivirales e inmunomoduladoras del receptor de IFN beta soluble en encefalitis herpética y encefalitis NMDAR postherpética	BEGOÑA OLIVER MARTOS	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
C-01	Prevención de la sensibilización cruzada a alcohol y cocaína en la adolescencia: efectos neuroprotectores de la oleoiletanolamida	EDUARDO BLANCO CALVO	National	PI	M.SANIDAD	2021

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-01	Facilitación de la conectividad hicampo-corteza prefrontal ventromedial como herramienta para favorecer la extinción de asociaciones cocaína-contexto	DAVID LADRÓN DE GUEVARA MIRANDA	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-01	Diferencias interindividuales y sexuales en la vulnerabilidad a desarrollar depresión por estrés: Papel bidireccional del eje intestinocerebro.	CARMEN PEDRAZA BENÍTEZ/ MARGARITA PEREZ MARTIN	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
C-01	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	BEATRIZ GARCIA DIAZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
C-01	Unveiling the role of neurokinin-1 receptor in regulating myelination and neuroprotection	BEATRIZ GARCIA DIAZ	International non-EU	PI	CARIPLO FOUNDATION	2023
C-01	ICI19/00027 Ensayo clínico fase IIb para confirmar la seguridad y eficacia de la administración intralesional de dos dosis de células mesenquimales de tejido adiposo alogénicas en pacientes con incotinencia fecal. IP. Laura Leyva Fernández	LAURA LEYVA FERNANDEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2019
C-01	PI21-01668 Biomarcadores pronósticos de evolución clínica en pacientes con esclerosis múltiple remitente recurrente de diagnóstico reciente: volumetría de la médula espinal	LAURA LEYVA FERNANDEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2021
C-01	PI22-00596 Caracterización genética y evaluación funcional de la respuesta de interferón tipo I en pacientes con encefalitis anti-receptor NMDA (IFN-NMDAR).	BEGOÑA OLIVER MARTOS	National	PI	INSTITUTO DE SALUD CARLOS III	2022
C-01	PI22-01141 Papel de los vasos sanguíneos en las alteraciones en el patrón de mielina asociado al abuso de alcohol durante la adolescencia: una nueva vía terapéutica para el tratamiento de las adicciones.	BEATRIZ GARCIA DIAZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022
C-01	PMPER24-00017-MLG SEED-ALS: Synergizing Efforts to Develop and Accelerate Breakthroughs in ALS Research	PEDRO JESÚS SERRANO CASTRO	National	PI	INSTITUTO DE SALUD CARLOS III	2024
C-01	Contratos Predoctorales	PATRICIA CHAVES PEÑA	Regional	HR	-	2021
C-01	IFEQ22_00032 Equipamiento para dotación de equipamiento para ECAI Genómica	PEDRO JESÚS SERRANO CASTRO	National	INFRAESTRUC-TURA	INSTITUTO DE SALUD CARLOS III	2022
C-01	MA-INV-0031-2022-05 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Guillermo Estivill - Eduardo Blanco Calvo	GUILLERMO ESTIVILL TORRÚS	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
C-01	CPP2021-008689 SISTEMA PORTABLE INTELIGENTE DE MONITORIZACIÓN Y TERAPIA PARA TRASTORNOS DEL SUEÑO REM (SMOTTS).	VICTORIA EUGENIA FERNANDEZ SANCHEZ	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
C-01	PMPER24-00018-MLG RED ESPAÑOLA DE NEUROPATÍAS AUTOINMUNES	GUILLERMINA GARCIA MARTIN	National	PI	INSTITUTO DE SALUD CARLOS III	2024
C-01	PMPER24-00007-MLG Creación de un nodo integral para la Distrofia Miotónica tipo 1 en España: registro clínico, mapas genómicos, epigenómicos y proteómicos (DM1-Hub)	Mª ASUNCION MAESTRE MARTINEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2024
C-01	RBL-0001-2023_Renovación 2023 Acción B-Refuerzos de larga duración	PEDRO JESÚS SERRANO CASTRO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
C-01	RC1-0003-2025 Renovación del Programa Nicolás Monardes 2021. IB:Guillermo Estivill Torrús	GUILLERMO ESTIVILL TORRÚS	Regional	HR	SERVICIO ANDALUZ DE SALUD	2025
C-01	ProyExcel_00996 Evaluation of the Lysophosphatidic acid signalling pathway as a high potential target for the Pelizaeus-Merzbacher disease treatment.	BEATRIZ GARCIA DIAZ	Regional	PI	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2022
C-01/C-07	USO DE IGF-II PARA EL TRATAMIENTO DE LAS ALTERACIONES HIPOCAMPALES Y CONDUCTUALES INDUCIDAS POR EL CONSUMO CRONICO DE COCAINA DURANTE LA ADOLESCENCIA	LUIS J SANTÍN	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2020

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-01/C-07	Eficacia neuroprotectora de IGF-II sobre las alteraciones neuronales y conductuales en un modelo experimental de la enfermedad de Parkinson mediado por alfa-SYN.	EDUARDO BLANCO CALVO/ ELISA MARTIN MONTAÑEZ	National	PI	-	2023
C-01/C-07	CPP2021-008512 PRIMER KIT DEL MERCADO PARA EL DIAGNÓSTICO TEMPRANO DE LA ESCLEROSIS MÚLTIPLE EN SANGRE	BEGOÑA OLIVER MARTOS	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
C-02	AC24/00016 TEIDe - Tailored Exercise Interventions for Dementia prEvention: bridging research evidence and primary care practice	JUAN ÁNGEL BELLON SAAMEÑO	European Union	PI	INSTITUTO DE SALUD CARLOS III	2024
C-02	CA23153 (YouthDMH) - Digital Mental Health for Young People	MARIA RODRIGUEZ GARCIA/ SONIA CONEJO CERÓN/ JESSICA MARIAN GOODMAN CASANOVA/ JOSÉ GUZMAN PARRA	European Union	NETWORKS AND STRUCTURES	COST ASSOCIATION	2023
C-02	PI21-01695 Prevención de la ansiedad y depresión por evaluación de riesgos: ensayo controlado aleatorio (El Estudio PANDORA)	JUAN ÁNGEL BELLON SAAMEÑO	National	PI	INSTITUTO DE SALUD CARLOS III	2021
C-02	FI22-00221 Contratos predoctorales de formación en investigación de salud. BN: Carmen María Garrido González IP: Juan Ángel Bellón Saameño	JUAN ÁNGEL BELLON SAAMEÑO	National	HR	INSTITUTO DE SALUD CARLOS III	2022
C-02	CD23-00096 Contrato Sara Borrell 2023_Maria Rodriguez Garcia_Jefe de grupo: Juan Angel Bellon.	JUAN ÁNGEL BELLON SAAMEÑO	National	HR	INSTITUTO DE SALUD CARLOS III	2023
C-02	POSTDOC-21-00620 Incorporación de ayudas posdoctorales. Candidato:Sonia Conejo Cerón Jefe de equipo: Juan Angel Bellon Saameño	JUAN ÁNGEL BELLON SAAMEÑO	Regional	HR	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2021
C-02	FPU22-04269 CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE PROFESORADO UNIVERSITARIO-FPU 2022. CANDIDATA: MARIA CRISTINA GONZALEZ MONROY	JUAN ÁNGEL BELLON SAAMEÑO	National	HR	MINISTERIO DE UNIVERSIDADES	2023
C-02	Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS) IP: Juan Ángel Bellón Saameño	JUAN ÁNGEL BELLON SAAMEÑO	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2021
C-02	PID2020-119652RA-I00 Efectividad de una intervención personalizada a través de internet basada en un algoritmo de riesgo para la prevención universal de la ansiedad. El estudio prevANS.	PATRICIA MORENO PERAL	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
C-02	PREDOC_02151. Impacto de las medidas de aislamiento por COVID-19 en personas mayores con deterioro cognitivo y sus cuidadores.	JUAN ÁNGEL BELLON SAAMEÑO	Regional	HR	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2021
C-02	FPU23_SUAREZ ESCALONA, ELISABET	ELISABET SUÁREZ ESCALONA	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
C-02	PI24/02114 Generando prácticas basadas en la evidencia para la prevención de la depresión: el proyecto PANGEA	JUAN ÁNGEL BELLON SAAMEÑO	National	PI	INSTITUTO DE SALUD CARLOS III	2024
C-02	AP-0614-2024-C5-F2 TeenFit: El Buscador de Apps de Actividad Física para Adolescentes.	MARIA RODRIGUEZ GARCIA	Regional	PI	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.	2024
C-02	AP-0608-2024-C5-F2 Participación ciudadana en la adaptación de una intervención online personalizada para la prevención de los trastornos de ansiedad a población joven adulta: prevent-YA PPI.	FRANCISCA MUÑOZ COBOS	Regional	PI	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.	2024

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-02	RHJ-0024-2024 Intervención transdiagnóstica a través de una app para la prevención de los problemas de ansiedad, depresión y consumo problemático de sustancias en población joven adulta	JUAN ÁNGEL BELLON SAAMEÑO	Regional	HR	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
C-02	PRE2021-098359 AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE DOCTORES 2021.	PATRICIA MORENO PERAL	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
C-02	MA-INV-0031-2022-10 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Juan Ángel Bellón	JUAN ÁNGEL BELLON SAAMEÑO	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
C-03	HOR-2024-02 DADAP - Digitizing and Automating the Diagnostic psychiatric Assessment Process	MARINA ROMERO GONZÁLEZ	European Union	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
C-03	MENTOR - Mental Health Together	JOSÉ GUZMAN PARRA	European Union	PI	COMISIÓN EUROPEA	2023
C-03	CA22114 (TREARURE) - Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants´development	GLORIA MARGARITA GUERRERO PERTÍÑEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2022
C-03	PI21/01328 Eficacia e implementación de un programa online de psicoterapia para la prevención de los efectos de la pandemia de la COVID-19 en la salud mental de los profesionales sociosanitarios	JOSÉ GUZMAN PARRA	National	PI	INSTITUTO DE SALUD CARLOS III	2021
C-03	JR23/00008 Contratos Juan Rodes 2023	JESSICA MARIAN GOODMAN CASANOVA	National	HR	INSTITUTO DE SALUD CARLOS III	2023
C-03	PRIBDIVULGA25-03 “Divulgación en salud mental y arteterapia”	JESSICA MARIAN GOODMAN CASANOVA	Local	AWARDS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
C-03	RHJ-0043-2024 Investigadora Postdoctoral	JOSÉ GUZMAN PARRA	Regional	HR	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
C-03	RBL-0005-2024 Renovación 2024 Acción B-Refuerzos de larga duración. UC Salud Mental.	ANTONIO BORDALLO ARAGON	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
C-03	CM22/00232 Contrato Rio Hortega 2022 Vera Carbonell Aranda_Jefe de Grupo Jose Guzman Parra.	JOSÉ GUZMAN PARRA	National	HR	INSTITUTO DE SALUD CARLOS III	2022
C-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	ANA BELÉN PABA DOTES	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2020
C-03	MA-INV-0031-2022-09 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Fermin Mayoral	FERMÍN MAYORAL CLERIES	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
C-03	A1-0024-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: JOSE GUZMAN PARRAS.	ANTONIO BORDALLO ARAGON	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
C-03	Gilead20-001 Eficacia de un programa de acompañamiento de enfermería para la microeliminación de la hepatitis C en pacientes con diagnóstico psquiátrico grave PSIQUIÁTRICO GRAVE	CASTA QUEMADA GONZALEZ	National	PI	GILEAD SCIENCES EUROPE LTD.	2020
C-03/ C-18	INTAR25-08 Modelos predictivos basados en inteligencia artificial para el riesgo de suicidio en urgencias hospitalarias	JUAN SUÁREZ PÉREZ/ LETICIA OLGA RUBIO LAMIA	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-05	Efectos de la microglía condicionada sobre el eje hipotálamo-hipofisario-adrenal y la respuesta al estrés. Modulación farmacológica con un inhibidor de CSF1R y cannabidiol	MARÍA DOLORES LÓPEZ ÁVALOS	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
C-05	Determinación de los mecanismos celulares/moleculares responsables de la eficacia de una terapia para recuperar el epéndimo tras hemorragias intraventriculares	ANTONIO JESÚS JIMÉNEZ LARA	National	PI	MINISTERIO DE ECONOMÍA	2024
C-05	Beatriz Galindo_LOPEZ ARANDA, MANUEL FRANCISCO	MANUEL FRANCISCO LOPEZ ARANDA	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
C-05	FPU23_ LOPEZ DE SAN SEBASTIAN JAVIER	JAVIER LOPEZ DE SAN SEBASTIAN	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
C-05	MA-INV-0031-2022-25 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Antonio Jesús Jiménez Lara	ANTONIO JESÚS JIMÉNEZ LARA	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
C-06	PID2020-114374RB-I00 Estrategias nutricionales para potenciar la neurogénesis y la función hipocampal: uso de cacao como nuevo tratamiento para las alteraciones cognitivas inducidas por la cocaína (CHOCOvsCOCA)	ESTELA CASTILLA ORTEGA	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
C-06	Análisis del papel neuroprotector del fitocannabinoide no-psicoactivo cannabidiol en defectos del neurodesarrollo por intoxicación etílica: evaluación de las alteraciones morfológicas, neurogénicas y cognitivo-emocionales	JUAN SUÁREZ PÉREZ	Regional	PI	CONSEJERÍA DE TRANSFORMACIÓN ECONÓMICA, INDUSTRIA, CONOCIMIENTO Y UNIVERSIDADES	2022
C-06	Perfil neuropsicológico de la sintomatología depresiva en niños y adolescentes: Implicaciones psicopedagógicas	Mª JESÚS LUQUE ROJAS	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-06	Impacto neuroconductual del entrenamiento cognitivo estructurado: un enfoque en el consumo perjudicial de alcohol y las interacciones cerebro-cuerpo	ESTELA CASTILLA ORTEGA	National	PI	MINISTERIO DE ECONOMÍA	2024
C-06	CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development	ANTONIA SERRANO CRIADO	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2022
C-06	HOR-2025-05 NUTRICIA - NUtritional Therapies for Recovery of Insulin-resistance-mediated Cognitive Impairment and Aging	FERNANDO RODRÍGUEZ FONSECA	European Union	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
C-06	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants´development	ADRIANA CASTRO ZAVALA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2022
C-06	MS19/00068 Contrato Miguel Servet	PATRICIA RIVERA GONZÁLEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2019
C-06	PI22/00427 PAPEL DEL BDNF Y LAS ACILETANOLAMIDAS EN EL DETERIORO COGNITIVO ASOCIADO A LOS TRASTORNOS POR USO DE ALCOHOL: UN ESTUDIO TRASLACIONAL.	FERNANDO RODRÍGUEZ FONSECA	National	PI	INSTITUTO DE SALUD CARLOS III	2022
C-06	202212-32_Towards understanding and predicting treatment resistance in major depression.	FERNANDO RODRÍGUEZ FONSECA	National	PI	FUNDACIÓ LA MARATO DE TV3	2022
C-06	SUBV23/00030: ESTUDIO DE LA ASOCIACIÓN JUEGO PATOLÓGICO-USO ANÓMALO DEL MÓVIL EN LA POBLACIÓN GENERAL ESPAÑOLA: DETERMINANTES SOCIALES E INDIVIDUALES	FERNANDO RODRÍGUEZ FONSECA	National	PI	MINISTERIO DE CONSUMO	2023
C-06	RC1-0001-2023 Renovación II del Programa Nicolás Monardes 2023.	FERNANDO RODRÍGUEZ FONSECA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
C-06	C1-0005-2022 PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2022 CARACTERIZACIÓN DE SISTEMAS DE SEÑALIZACIÓN LIPÍDICOS ASOCIADOS A LA COMORBILIDAD PSIQUIÁTRICA EN LOS TRASTORNOS POR USO DE SUSTANCIAS: IDENTIFICACIÓN DE BIOMARCADORES Y DIANAS TERAPÉUTICAS.	ANTONIA MARIA SERRANO CRIADO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2022

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-06	CP21/00021 Proyecto Miguel Servet 2021 Juan Manuel Decara del Olmo	JUAN MANUEL DECARA DEL OLMO	National	PI	INSTITUTO DE SALUD CARLOS III	2021
C-06	MS21/00021 Contrato Miguel Servet 2021	JUAN MANUEL DECARA DEL OLMO	National	HR	INSTITUTO DE SALUD CARLOS III	2021
C-06	Ayudas Ramón y Cajal 2023_RIVERA GONZÁLEZ, PATRICIA	PATRICIA RIVERA GONZÁLEZ	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
C-06	IFI21/00024: Contratos I-PFIS 2021 Beatriz Pacheco Sánchez. Jefe de grupo: Fernando Rodríguez de Fonseca	FERNANDO RODRÍGUEZ FONSECA	National	HR	INSTITUTO DE SALUD CARLOS III	2021
C-06	CM24/00259 Contrato Río Hortega	ANTONIA SERRANO CRIADO	National	HR	INSTITUTO DE SALUD CARLOS III	2024
C-06	CD24/00124 Contrato Sara Borrell	PATRICIA RIVERA GONZÁLEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2024
C-06	CD24/00041 Contrato Sara Borell	ANTONIA SERRANO CRIADO	National	HR	INSTITUTO DE SALUD CARLOS III	2024
C-06	CM23/00150 Contrato Rio Hortega 2023_ Yolanda Lopez Moreno_Jefe de Grupo: Fernando Rodriguez de Fonseca	FERNANDO RODRÍGUEZ FONSECA	National	HR	INSTITUTO DE SALUD CARLOS III	2023
C-06	MA-INV-0031-2022-08 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Antonia Serrano	ANTONIA SERRANO CRIADO	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
C-06	PRIBDIVULGA25-01 “Fragmentos de lo Invisible: una mirada artística al daño cerebral adquirido”	ESTELA CASTILLA ORTEGA	Local	AWARDS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
C-06	RD24/0003/0012 Red de Investigación de Atención Primaria en Adicciones (RIAPAd)	FERNANDO RODRÍGUEZ FONSECA	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2024
C-06	CD24/00136 Contrato Sara Borell	FERNANDO RODRÍGUEZ FONSECA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
C-06	CA24130 (PSY-NET): Psychedelic renaissance: turn on, tune in and drop in	JUAN SUÁREZ PÉREZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2025
C-06	CPP2024-011828_ENDORADIA-3D: Aplicación de Inteligencia Artificial y Radiómica para la Detección de Focos de Endometriosis Profunda en Imagen Médica. IP: Emilia Villegas.	EMILIA VILLEGAS MUÑOZ	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2025
C-06	PI-0070-2025 CIR-NeuroAPP: Un enfoque integrado de biomarcadores y aplicación móvil para el monitoreo del neurodesarrollo infantil.	PATRICIA RIVERA GONZÁLEZ	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2025
C-07	FPU2023_MORALES LUQUE, CARMEN	CARMEN MORALES LUQUE	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
C-07	Contratos Predoctorales	PABLO ZAMORANO GONZÁLEZ	Regional	HR	-	2021
C-07	Aislamiento social en la pandemia de COVID-19 y consumo de alcohol: Combinación Galanina (1-15)-Naltrexona como estrategia terapéutica.	CARMELO MILLÓN PEÑUELA	National	PI	Plan Nacional Sobre drogas, Ministerio de Sanidad	2022
C-07	Atenuación de los efectos secundarios de los opioides en el control del dolor: implicación de D4R	BELEN GAGO CALDERÓN/ ALICIA RIVERA RAMÍREZ	National	PI	MINISTERIO DE ECONOMÍA	2023
C-07	DEPRESION RESISTENTE AL TRATAMIENTO: UNA NUEVA ESTRATEGIA FARMACOLOGICA UTILIZANDO GALANINA(1-15)	ZAIDA DÍAZ CABIALE	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2020

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-07	Estudio multidimensional de Galanina (1-15) como potenciador de antidepresivos en un modelo animal de depresión resistente al tratamiento	ZAIDA DÍAZ CABIALE	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2024
C-07	Potenciación de la antinocicepción inducida por opioides: estrategia basada en el sistema dopaminérgico	ALICIA RIVERA RAMÍREZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-07	Sindrome de Covid Persistente y Disfunción Autonómica. Estudio Pots Ochos Post Covid	MARC STEFAN DAWID MILNER	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-07	Efecto neuroprotector del IGF-II en enfermedades neurodegenerativas y neuropsiquiátricas con deterioro cognitivo. Papel de receptor IGF-II/M6P	JOSÉ ÁNGEL NARVÁEZ BUENO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-07	MA-INV-0031-2022-24 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Zaida Diaz	ZAIDA DÍAZ CABIALE	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
C-07	PRIBDOCTOR25-01 Premio al mejor expediente de DOCTOR del año en la Universidad de Málaga de IBIMA Plataforma BIONAND.	NOELIA CANTERO GARCÍA	Local	AWARDS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
C-07/C-01	PI24/01816 Descifrando el Papel de los Heterocomplejos Y1R en el Deterioro Cognitivo Inducido por el Síndrome Metabólico: Una Vía hacia Nuevos Biomarcadores y Objetivos Terapéuticos.	PEDRO JESÚS SERRANO CASTRO	National	PI	INSTITUTO DE SALUD CARLOS III	2024
C-08	STOP IATRO - Start Therapeutic OPtimisazion and IATRogenesis prevention on Older People	FRANCISCA LEIVA FERNANDEZ	European Union	PI	COMISIÓN EUROPEA	2023
C-08	PI22-01651 Multimorbilidad en el Sistema Nacional de Salud: Caracterización poblacional e impacto de sus patrones y trayectorias en personas mayores (Proyecto MM-SNS)	FRANCISCA LEIVA FERNANDEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022
C-08	PI-0129-2024 Validación de una versión corta de la herramienta IDC-PAL para su uso en población adulta en Atención Primaria (IDC-Pal-AP). Diseño y estudio de Aceptabilidad de una APP para su uso	FRANCISCA LEIVA FERNANDEZ	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
C-09	Diabetes y Alzheimer. Mecanismos moleculares de coagregación proteica	INÉS MORENO GONZÁLEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2019
C-09	AGREGADOS TAU EN SANGRE. UNA VENTANA A LA PATOGENESIS PERIFERICA Y LA INTERVENCION TERAPEUTICA	INÉS MORENO GONZÁLEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
C-09	Agregación y propagación de tau en la glía, una aproximación inflamacéntrica del inicio de demencia tras una contusión cerebral	INÉS MORENO GONZÁLEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2024
C-09	Impacto del tejido adiposo en la patogénesis de la enfermedad de Alzheimer: Mecanismos moleculares y nuevas dianas terapéuticas	DAVID BAGLIETTO VARGAS	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2024
C-09	Impact of white adipose tissue on tau pathology in transgenic mice	DAVID BAGLIETTO VARGAS	International non-EU	PI	ALZHEIMER'S ASSOCIATION ESTADOS UNIDOS	2022
C-09	Disfunción glial y enfermedad de Alzheimer	ANTONIA GUTIÉRREZ PÉREZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-09	CNS2022-135424 AGREGADOS TAU EN SANGRE. UNA VENTANA A LA PATOGENESIS PERIFERICA Y LA INTERVENCION TERAPEUTICA	INÉS MORENO GONZÁLEZ	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
C-09	Predoctorales Plan Propio 2024_GARCIA MARTIN, JESUS	JESÚS GARCÍA MARTÍN	Regional	HR	UNIVERSIDAD DE MÁLAGA	2024
C-09	FPU2024_GARCÍA MARTÍN, JESÚS	JESÚS GARCÍA MARTÍN	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
C-09	CIBERNED CB06/05/1116. Programa Enfermedad de Alzheimer y otras demencias. Subvención anual (2024) para nuestro grupo CIBERNED	ANTONIA GUTIÉRREZ PÉREZ	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2025
C-09	MA-INV-0031-2022-18 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Antonia Gutierrez	ANTONIA GUTIÉRREZ PÉREZ	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-09	PI24/00274 Modulando el metabolismo/senescencia microglial como terapia modificadora de la patología tau para la enfermedad de Alzheimer y otras taupatías: una evaluación preclínica.	ANTONIA GUTIÉRREZ PÉREZ	National	PI	INSTITUTO DE SALUD CARLOS III	2024
C-09	Propagación de la patología amiloidea en un modelo esporádico de la enfermedad de Alzheimer: descifrando nuevos meanismos patogénicos y dianas terapéuticas	DAVID BAGLIETTO VARGAS	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2019
C-11	Ayudas Ramón y Cajal 2018_VEGA CARRANZA, ROCIO DE LA	ROCÍO DE LA VEGA DE CARRANZA	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2018
C-11	Efectividad e implementación de una intervención digital para el dolor crónico infantil co-diseñada con pacientes (Digital SPA)	ROCÍO DE LA VEGA DE CARRANZA	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2021
C-11	e-Intervención motivacional bimodal para potenciar factores resilientes en pacientes con dolor crónico (e-MOTIDOLOR)	GEMMA TERESA RUIZ PÁRRAGA	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2019
C-11	Perfil psicológico asociado a la complejidad de los síndromes de sensibilización central, comórbido al trauma y al trastorno de estrés postraumático en mujeres.	ELENA ROCÍO SERRANO IBÁÑEZ	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
C-12	Ayudas Ramón y Cajal 2020_LOPEZ BARROSO, DIANA	DIANA LÓPEZ BARROSO	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
C-12	Análisis transdiagnóstico de la ecolalia: de la normalidad a las fases iniciales del deterioro cognitivo	GUADALUPE DÁVILA ARIAS	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-12	Comprendiendo las diferencias interindividuales en el aprendizaje de palabras a través de la neuroimagen y la neuromodulación	DIANA LÓPEZ BARROSO	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
C-12/ FE-20	Automatic assessment of Hypernasality in Spanish language using running Speech	IGNACIO MORENO TORRES SANCHEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
C-13	Interacción de variables de composición corporal en la perfusión y oxigenación tisular periférica de tejidos sometidos a presión	JOSÉ MIGUEL MORALES ASENCIO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-13	Barreras en la atención sexual y reproductiva integral de la población LGBTQ+ en los servicios de atención primaria del distrito sanitario Málaga-Valle del Guadalhorce	SHAKIRA KAKNANI UTTUMCHANDANI	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-13	CA21168 (JIR-CliPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	EVA TIMONET ANDREU	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
C-13	CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research	GABRIEL ANTONIO GIJON NOGUERON/ EVA TIMONET ANDREU/ ANA BELEN ORTEGA AVILA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
C-13	CA24107 (SAFE-ICU) - Patient SAFety Related Outcome Measures in European ICUs	ÁNGELA ORTEGA LOPEZ	European Union	NETWORKS AND STRUCTURES	COST ASSOCIATION	2024
C-13	AP-0245-2020 Componentes de la Gestión de Casos en Demencias: Estudio de Métodos Mixtos (Gecade)	JUAN CARLOS MORILLA HERRERA	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2020
C-13	PI21-01197 Perfusión y Oxigenación Tisular Periférica en zonas de riesgo de deterioro de la integridad cutánea sometidas a tratamiento con Ácidos Grasos Hiperoxigenados vs Aceite de Oliva Virgen	INMACULADA LUPIAÑEZ PEREZ	National	PI	INSTITUTO DE SALUD CARLOS III	2021
C-13	AP-0174-2021-C2-F2 Efectividad de los ácidos grasos hiperoxigenados y aceite de oliva virgen extra en la prevención de las úlceras por presión relacionada con la perfusión y oxigenación tisular periférica.	INMACULADA LUPIAÑEZ PEREZ	Regional	PI	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.	2021
C-13	AP-0244-2020 Calidad de Vida, Salud Física y Mental, y Evaluación Económica de Cuidadores Familiares de Población Infantil Dependiente y Con Enfermedad Crónica: (Seguimiento Cohorte Infaprint)	MAGDALENA CUEVAS FERNANDEZ-GALLEGO	Regional	PI	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.	2019

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-13	AP-0228-2021-C2-F2 Barreras de Autocuidado y Complicaciones micro/macrovasculares asociadas en Diabetes Mellitus tipo 2 (Estudio BACA-DM2).	JORGE CARO BAUTISTA	Regional	PI	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.	2021
C-13	AP-0004-2025 Prevención de úlceras por presión en población dependiente mediante un multisensor inalámbrico para la medición del microclima cutáneo	FRANCISCA VILLA ESTRADA	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2025
C-13	ACT25-01 Modelos predictivos y análisis del contexto para reducir la infección del orificio del catéter venoso central en hemodiálisis (PREDIXITA): Estudio pre-implementación con métodos mixto	IAN BLANCO MAVILLARD	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
C-13	PIS25-03 Medición del microclima cutáneo de zonas sometidas a presión por un dispositivo biométrico para la prevención de úlceras por presión en población dependiente. IP: Inmaculada Lupiáñez Pérez.	INMACULADA LUPIAÑEZ PEREZ	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
C-13	PMP22-00003 Salud pública y Medicina preventiva de precisión combinando exploración física, hábitos de vida e información genómica: monitorización de la pandemia de obesidad a través de extensión de la Cohorte IMPaCT (Obes-IMPaCT)	JORGE CARO BAUTISTA	National	PI	INSTITUTO DE SALUD CARLOS III	2022
C-13	Validation and evaluation of the Cui-DAR Cudeca Plan in people in the last days of life versus conventional care. Asociación Española contra el Cáncer	JOSÉ MIGUEL MORALES ASENCIO	National	PI	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2023
C-13	SEM23-01 Valoración del patrón de alimentación de personas con demencia en la comunidad a través de la escala edinburgh feeding evaluation in dementia scale (edfed). Seguimiento longitudinal.	M.ª CARMEN SAUCEDO FIGUEREDO	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2023
C-13	PMP24/00008-MLG AMBISiON-IMPaCT: Un proyecto de enriquecimiento de la cohorte IMPACT con medidas AMBIentales y de Salud Ocular para la medicina de precisión.	JORGE CARO BAUTISTA	National	PI	INSTITUTO DE SALUD CARLOS III	2024
C-13	PMP24/00012-MLG Incorporación de la información clínica de atención primaria y hospitalaria en la cohorte IMPACT: proyecto IMPACT-IC.	JORGE CARO BAUTISTA	National	PI	INSTITUTO DE SALUD CARLOS III	2024
C-13/ C-02	IMP/00021 Impact Programa de Medicina Predictiva.	JUAN ÁNGEL BELLON SAAMEÑO/ JORGE CARO BAUTISTA	National	PI	INSTITUTO DE SALUD CARLOS III	2020
C-14	PI-0008-2025 Prevención y Respuesta Inmediata en Salud sexual y su Manejo en Andalucía (PRISMA)	INÉS PEREZ CAMACHO	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2025
C-14	PROVIDE - Prediction and prevention of cardiovascular diseases in pre-diabetes and diabetes	Mª DOLORES MARTÍN ESCALANTE	European Union	PI	COMISIÓN EUROPEA	2023
C-16	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants´development	MARÍA FERNANDA LARA CABANÁS/ ERNESTO GONZALEZ MESA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2022
C-16	CA21108 (NETSKINMODELS) - European Network for Skin Engineering and Modeling	MARÍA FERNANDA LARA CABANÁS	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
C-16	El sistema inmune innato de la leche materna; efecto de la dieta y obesidad de la madre.	ERNESTO GONZALEZ MESA	Regional	HR	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2021
C-16	Beatriz Galindo_REYES PALOMARES, ARTURO	ARTURO REYES PALOMARES	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2023

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
C-16	Emergia_LARA CABANAS, MARIA FERNANDA	MARIA FERNANDA LARA CABANAS	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
C-16	Descifrando la modulación redox del metabolismo en el desarrollo embrionario preimplantacional y la reprogramación epigenética: implicaciones para la salud a largo plazo	ARTURO REYES PALOMARES	National	PI	MINISTERIO DE ECONOMÍA	2024
C-16	EMG22-005 Propiedades de la leche materna tras diabetes gestacional: sistema inmune innato y la respuesta del lactante ante infecciones respiratorias	MARTA BLASCO ALONSO	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2022
C-18	CA22106 (MDVI): Migrant Disaster Victim Identification	LETICIA OLGA RUBIO LAMIA/ STELLA MARTIN HERAS, DE LAS	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
C-18	PIE25-01 Implicación del sistema cannabinoide endógeno en la fisiopatología del hueso. IP: Leticia Olga Rubio Lamia.	LETICIA OLGA RUBIO LAMIA	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
C-18	VIOLENCIA DE GÉNERO EN EMBARAZADAS: TIPIFICACIÓN Y CRIBADO EN EL CONTEXTO SANITARIO (VIOLEMB)	STELLA MARTÍN DE LAS HERAS	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
C-18	CA24147 (AID-AgE) Artificial Intelligence Driven Dental AgEstimation Network	LETICIA OLGA RUBIO LAMIA	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2024
C-18	The Social Life of Dead Bodies: A new ethnographic approach to migrant deaths in and around the Mediterranean Sea (SOLID)	STELLA MARTÍN DE LAS HERAS	European Union	PI	COMISIÓN EUROPEA	2024
C-22	Ayudas Emergia 2020_BORROTO ESCUELA, DASIEL OSCAR	DASIEL OSCAR BORROTO ESCUELA	Regional	HR	-	2020
C-22	Emergia_MAUERER, INGRID	INGRID DORIS MAUERER	Regional	HR	-	2021
C-22	Predoctorales Plan Propio 2023_MORENO MADRID, ISABEL	ISABEL MORENO MADRID	Regional	HR	-	2023
C-22	Estudio de la vulnerabilidad de los complejos heteroreceptores de serotoninas en la depresión. Efecto modulatorio potencial de los antidepresivos de espectro rápido	DASIEL OSCAR BORROTO ESCUELA	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
CA-10	FPU23_VAZQUEZ MILLAN, JOSE ANTONIO	JOSE ANTONIO VAZQUEZ MILLAN	Regional	HR	-	2023
CA-10	Estrategias de reducción de recaídas de miedos tras un tratamiento experimental de extinción	FRANCISCO JOSE LOPEZ GUTIERREZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
CA-10	Investigando experimentalmente la formación de nuevos hábitos en humanos	FRANCISCO JOSE LOPEZ GUTIERREZ/ DAVID LUQUE RUIZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
CA-10	Evaluando el equilibrio entre el procesamiento dirigido a metas y habitual a través del curso del aprendizaje	DAVID LUQUE RUIZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2024
CA-10	Aprendizaje de nuevos hábitos en humanos: una perspectiva multiproceso	DAVID LUQUE RUIZ	Regional	PI	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2022
CE-21	AP-0615-2024-C5-F2 Impacto de una intervención basada en un programa ejercicios multicomponente en población mayor adulta prefrágil en Atención Primaria: Un Estudio Cuasiexperimental	ALBERTO GÓMEZ MORENO	Regional	PI	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.	2024

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
CE-21	PIS25-01 Impacto de una intervención basada en un programa ejercicios multicomponente en población mayor adulta pre-frágil en Atención Primaria: Un Estudio Cuasiexperimental. IP: Alberto Gómez Moreno.	ALBERTO GÓMEZ MORENO	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
CE-23	Relación de las características morfoestructurales de los ligamentos del tobillo con la inestabilidad crónica, mecánica y funcional de tobillo	PABLO CERVERA GARVI	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
CE-24	Barreras en la atención sexual y reproductiva integral de la población LGBTQ+ en los servicios de atención primaria del distrito sanitario Málaga-Valle del Guadalhorce	SHAKIRA KAKNANI UTTUMCHANDANI	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
D-01	CA21164 (ADVANCE-TB) - Towards an improvement in diagnostics and treatment strategies for TB control	ISABEL ASCENSIÓN PEREZ HERNANDEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
D-01	CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	CARMEN MARÍA GONZÁLEZ DOMENECH	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
D-01	CA20128 (PIMENTO) - Promoting Innovation of fermented foods	CARMEN MARÍA GONZÁLEZ DOMENECH	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
D-01	Gilead. CPC19043 Convenio para la regulación de beca concedida en el marco de la 1º Convocatoria de Becas “Proyectos sobre Diagnóstico y Derivación del Paciente con VIH al Sistema Nacional de Salud” al proyecto “Estudio de contactos de pacientes con infección por el VIH para mejorar el diagnóstico de la infección oculta y de otras infecciones de transmisión sexual (ITS)	JESÚS SANTOS GONZALEZ	National	PI	GILEAD SCIENCES EUROPE LTD.	2019
D-03	Criterios de cribado de enfermedad pulmonar intersticial difusa en pacientes con artritis reumatoide. Estudio de Validez. VAR-EPIDSER	NATALIA MENA VAZQUEZ	National	PI	SOCIEDAD ESPAÑOLA DE REUMATOLOGÍA	2022
D-03	RD21-0002-0037 Red de Enfermedades Inflamatorias IP: Antonio Fernández Nebro	ANTONIO FERNANDEZ NEBRO	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2021
D-03	FAR-01-23 Identificación de biomarcadores metagenómicos y transcriptómicos para el diagnóstico y pronóstico de Enfermedad Pulmonar Intersticial (EPI) asociada a Artritis Reumatoide (AR)	NATALIA MENA VAZQUEZ	Regional	PI	FUNDACION ANDALUZA DE REUMATOLOGIA	2023
D-03	PMP22-00101 “Validación clínica del algoritmo OPTIBIO para predecir permanencia en remisión en pacientes con artritis reumatoide a tratamiento con terapia biológica (REMRABIT-plus)”,	ANTONIO FERNANDEZ NEBRO	National	PI	INSTITUTO DE SALUD CARLOS III	2022
D-03	FI23-00084 Contratos predoctorales de formación en investigación de salud. BN:JOSE MANUEL LISBONA MONTAÑEZ_IP:ANTONIO FERNANDEZ NEBRO.	ANTONIO FERNANDEZ NEBRO	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-03	PI25_CUIDADOS_01 Impacto de los determinantes en salud en pacientes con artritis reumatoide: estudio desde una perspectiva de género. IP: Laura Cano.	LAURA CANO GARCIA	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
D-03	RD24-0007-0036 Red de Enfermedades Inflamatorias (REI)	ANTONIO FERNANDEZ NEBRO	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2024
D-03	FAR2021-001. Identificación de biomarcadores de Enfermedad Pulmonar Intersticial (EPI) asociada a Artritis Reumatoide (AR)	NATALIA MENA VAZQUEZ	Regional	PI	FUNDACION ANDALUZA DE REUMATOLOGIA	2021
D-03	CD23-00082 Contrato Sara Borrell 2023_Arkaitz Mucientes Ruiz_Jefe de grupo: Antonio Fernandez Nebro	ANTONIO FERNANDEZ NEBRO	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-03	PI22-01207 Análisis integral de datos clínicos, metagenómicos y transcriptómicos para identificar biomarcadores de respuesta a tratamiento Anti-TNF en pacientes con artritis reumatoide	NATALIA MENA VAZQUEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
D-04	Diseño de Nanoestructuras basadas en Dendrímeros y Fármacos para Aplicaciones Biomédicas	Mª ISABEL MONTAÑEZ VEGA	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
D-04	Optimización diagnóstica en alergia a betalactámicos: desarrollo de test in vitro innovadores basados en biotecnología	Mª JOSÉ TORRES JAÉN	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
D-04	PRE-BIT - Understanding the role of B cell phenotypes as a predictor of the efficacy and prognosis of allergen immunotherapy using allergic rhinitis to house dust mite as a model	CRISTOBALINA MAYORGA MAYORGA	European Union	HR	COMISIÓN EUROPEA	2022
D-04	CLIMAIR - Climate change and air contamination: Artificial Intelligence applied on the correlation between air pollutants and non-communicable respiratory diseases in Europe.	IBON EGUILUZ GRACIA	European Union	PI	COMISIÓN EUROPEA	2023
D-04	JARED - Joint Action on REspiratory Diseases	IBON EGUILUZ GRACIA	European Union	PI	COMISIÓN EUROPEA	2024
D-04	CPP2022-009994 Development of a photonic point of care device for multiplexed detection of biomarkers, tryptase, IL-6, and PAF in the events of hypersensitivity during oncological or biological agent administration, and anaesthesia"	MARÍA JOSÉ TORRES JAEN	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
D-04	CD22/00112 Contrato Sara Borrell_Patricia Diez Echave_Jefe de Grupo Maria Jose Torres Jaen.	MARÍA JOSÉ TORRES JAEN	National	HR	INSTITUTO DE SALUD CARLOS III	2022
D-04	FI22/00199 Contratos predoctorales de formación en investigación de salud. BN Jose Antonio Céspedes Lago IP: Maria Jose Torres Jaen	MARÍA JOSÉ TORRES JAEN	National	HR	INSTITUTO DE SALUD CARLOS III	2022
D-04	RD21/0002/0008 Red de Enfermedades Inflamatorias IP: María José Torres Jaén	MARÍA JOSÉ TORRES JAEN	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2021
D-04	C1-0006-2022 PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2022. Mecanismos moleculares y base genética de las reacciones de hipersensibilidad a anti-inflamatorios no esteroideos.	JOSE ANTONIO CORNEJO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2022
D-04	PI-0047-2022. Biomarcadores diagnósticos y de gravedad clínica para la optimización del fenotipado de pacientes con alergia a LTP	CRISTOBALINA MAYORGA MAYORGA	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2022
D-04	CNS2023-145123-RHH Contrato.Papel del sistema inmune innato en alergia a alimentos y en la inducción de tolerancia específica. (INNA-TOOLS)	CRISTOBALINA MAYORGA MAYORGA	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
D-04	FI22/00106 Contratos predoctorales de formación en investigación de salud. BN: María Del Carmen Martín Astorga IP: Cristobalina Mayorga	CRISTOBALINA MAYORGA MAYORGA	National	HR	INSTITUTO DE SALUD CARLOS III	2022
D-04	PI21/00346 Microagujas y nanopartículas como estrategia innovadora para la administración de inmunoterapia epicutánea en enfermedades alérgicas. Identificación de biomarcadores para una tolerancia duradera.	CRISTOBALINA MAYORGA MAYORGA	National	PI	INSTITUTO DE SALUD CARLOS III	2021
D-04	RC-0004-2021 Renovación II del Programa Nicolás Monardes 2013	CRISTOBALINA MAYORGA MAYORGA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2021
D-04	FI21/00274 Contratos predoctorales de formación en investigación en salud. Isabel María Jiménez Sánchez jefe de grupo Inmaculada Doña Diaz .	INMACULADA DOÑA DIAZ	National	HR	INSTITUTO DE SALUD CARLOS III	2021
D-04	ProyExcel_00971 Diseño de Nanoestructuras Multivalentes Conjugadas a Antibióticos para el Estudio de la Activación de Células Efectoras. Aplicación Diagnóstica en Reacciones Alérgicas a Antibióticos Betalactámicos	JUAN LUIS PARIS FERNÁNDEZ DE LA PUENTE	Regional	PI	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2022

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
D-04	PI20/01734 Nanoarquitecturas altamente eficientes para un entrecruzamiento eficaz de la IgE en mastocitos y basófilos. Aplicación al diagnóstico de reacciones alérgicas a amoxicilina y ácido clavulánico	MARÍA ISABEL MONTAÑEZ VEGA	National	PI	INSTITUTO DE SALUD CARLOS III	2020
D-04	PI23/01655 Reacciones de hipersensibilidad a anti-inflamatorios no esteroideos: desarrollo de un algoritmo diagnóstico basado en métodos de aprendizaje automático y caracterización de biomarcadores. IP:INMACULADA DOÑA DIAZ_ COI:JOSE ANTONIO CORNEJO GARCIA	INMACULADA DOÑA DIAZ	National	PI	INSTITUTO DE SALUD CARLOS III	2023
D-04	PI23/00620 Nuevas aproximaciones aplicadas al diagnóstico de alergia a fármacos: Desarrollo de nanoestructuras que incorporan ligando TLR y determinantes antigénicos de antibióticos betalactámicos.IP: MARIA ISABEL MONTAÑEZ VEGA_ COI:CECILIA FRECHA	MARÍA ISABEL MONTAÑEZ VEGA	National	PI	INSTITUTO DE SALUD CARLOS III	2023
D-04	C1-0007-2023 Programa Nicolas Monarde_Convocatoria 2023. Optimización del diagnóstico de las enfermedades alérgicas a fármacos: antibióticos betalactámicos y agentes quimioterapéuticos.	ADRIANA ARIZA VEGUILLAS	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
D-04	PI23/00875 Caracterización de endofenotipos en Rinosinusitis Crónica con Pólipos Nasales y Asma T2 comórbida. Análisis ómicos en el tratamiento con biológicos. IP: ALMUDENA TESTERA MONTES_ COI: CARMEN RONDON SEGOVIA	ALMUDENA TESTERA MONTES	National	PI	INSTITUTO DE SALUD CARLOS III	2023
D-04	PID2022-142781OA-I00 Nanoingeniería de tolerancia inmunitaria para alergia: interacción de nanomateriales y vía de administración (NANO-TOLERANCE)	JUAN LUIS PARIS FERNÁNDEZ DE LA PUENTE	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
D-04	PID2022-142781OA-I00 AYUDAS CONCEDIDAS PARA LA FORMACIÓN DE PERSONAL INVESTIGADOR PREDOCTORAL_PREP2022-000567	JUAN LUIS PARIS FERNÁNDEZ DE LA PUENTE	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
D-04	RYC2021-034536-I Contrato Ramon y Cajal	JUAN LUIS PARIS FERNÁNDEZ DE LA PUENTE	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
D-04	RYC2021-034536-I Proyecto Ramon y Cajal	JUAN LUIS PARIS FERNÁNDEZ DE LA PUENTE	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
D-04	PI20/01540 Hipersensibilidad a anti-inflamatorios no esteroides: Fenotipado preciso e historia natural. Papel de la atopía y de una respuesta inmute innata	INMACULADA DOÑA DIAZ	National	PI	INSTITUTO DE SALUD CARLOS III	2020
D-04	PI21/01391 Fenotipado clínico e inmunologico de pacientes con alergia a LTP	FRANCISCA GOMEZ PEREZ	National	PI	INSTITUTO DE SALUD CARLOS III	2021
D-04	PI22/01119 Biomarcadores endofenotípicos y pronósticos en las reacciones de hipersensibilidad por quimioterápicos. Gestión del riesgo de la administración controlada y desensibilización	GÁDOR BOGAS HERRERA	National	PI	INSTITUTO DE SALUD CARLOS III	2022
D-04	PI23/01516 Identificación de biomarcadores inmunológicos de linfocitos B para diferenciar fenotipos, diagnosticar la presencia de asma y predecir la respuesta a la inmunoterapia con alérgenos en pacientes con rinitis de causa alérgica. IP:IBON EGUILUZ GRACIA_COI:CARLOS JOSE ARANDA CLEMENTE.	IBON EGUILUZ GRACIA	National	PI	INSTITUTO DE SALUD CARLOS III	2023
D-04	MV24-00030 Estancia M-AES. Análisis e identificación de biomarcadores en células B y sus subpoblaciones en la alergia alimentaria de origen vegetal	Mª DEL CARMEN MARTÍN ASTORGA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
D-04	C1-0008-2024 PROGRAMA NICOLAS MONARDES_CONVOCATORIA 2024	CECILIA ARIANA FRECHA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
D-04	A1-0007-2024 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS).	MARÍA JOSÉ TORRES JAEN	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
D-04	B-0007-2023 Refuerzo con RRHH de la actividad investigadora en las UC del SAS - Acción B	IBON EGUILUZ GRACIA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
D-04	FI24/00145 Contratos Predoctorales de Formación en Investigación en Salud (PFIS)	JOSE ANTONIO CORNEJO GARCIA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
D-04	CM23/00092 Contrato Rio Hortega 2023_ Guillermo Bentabol Ramos_Jefe de Grupo: Carmen Rondon Segovia	CARMEN RONDON SEGOVIA	National	HR	INSTITUTO DE SALUD CARLOS III	2023

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
D-04	CM23/00130 Contrato Rio Hortega 2023_ Marta Libertad Andugar Moreno.Jefe de Grupo: Cristobalina Mayorga Mayorga	CRISTOBALINA MAYORGA MAYORGA	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-04	MV24/00062 Estancia M-AES. Título CytoBas implementation to the different approaches for the improvement of the in vitro diagnostic method of the BAT (Basophil Activation Test) in the evaluation of drug reactions.	JOSE ANTONIO CESPEDES LAGO	National	HR	INSTITUTO DE SALUD CARLOS III	2024
D-04	FI24/00233 Contratos Predoctorales de Formación en Investigación en Salud (PFIS)	IBON EGUILUZ GRACIA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
D-04	JR22/00048 Contratos Juan Rodes 2022	ALMUDENA TESTERA MONTES	National	HR	INSTITUTO DE SALUD CARLOS III	2022
D-04	JR23/00039 Contratos Juan Rodes 2023	MARINA LABELLA ÁLVAREZ	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-04	PR_PUBLICACIONES_02_2025 Premio a las Mejores Publicaciones del Año IBIMA Plataforma BIONAND.	CARMEN RONDON SEGOVIA	Local	AWARDS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
D-04	A1-0008-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: CARMEN RONDON SEGOVIA E INMACULADA DOÑA DIAZ.	MARÍA JOSÉ TORRES JAEN	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
D-04	RYC2023-044231-I-PI Proyecto Ramon y Cajal.	ADRIANA ARIZA VEGUILLAS	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
D-04	RBL-0002-2023_Renovación 2023 Acción B-Refuerzos de larga duración	MARÍA JOSÉ TORRES JAEN	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
D-04	B-0007-2022 SAS 2022-REFUERZO CON RRHH DE LA ACTIVIDAD INVESTIGADORA EN LAS UC DEL SAS -ACCIONES B	GÁDOR BOGAS HERRERA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2022
D-04	CM23/00151_Contrato Rio Hortega 2023_IP:Rocio Saenz de Santa Maria Garcia_Jefe de grupo: Maria Jose Torres Jaen	MARÍA JOSÉ TORRES JAEN	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-04	RYC2023-044231-I Contrato Ramon y Cajal.	ADRIANA ARIZA VEGUILLAS	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
D-04	MA-INV-0031-2022-01 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:María José Torres	MARÍA JOSÉ TORRES JAEN	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
D-04	JR21/00024 Contratos Juan Rodes 2021	NATALIA ISABEL PÉREZ SÁNCHEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2021
D-04	PI24/01913 En busca del diagnóstico correcto de la alergia a betalactámicos: desde la validación de una herramienta de estratificación del riesgo a un endotipado preciso.	MARÍA JOSÉ TORRES JAEN	National	PI	INSTITUTO DE SALUD CARLOS III	2024
D-04	FI23/00027 Contratos predoctorales de formación en investigación de salud,BN: CLARA ENCARNACION LEBRON MARTIN. IP:GADOR BOGAS HERRERA	GÁDOR BOGAS HERRERA	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-04	PI24/00132 Endofenotipado preciso para diagnóstico de alergia a alimentos de origen vegetal, firma de biomarcadores de tolerancia y evaluación de mecanismos en inmunoterapia basada en microagujas.	CRISTOBALINA MAYORGA MAYORGA	National	PI	INSTITUTO DE SALUD CARLOS III	2024
D-04	PRIBEIR25-01 Premio al mejor expediente investigador EIR de IBIMA Plataforma BIONAND	DULCENOMBRE DE MARIA SANCHEZ TORRALVO	Local	AWARDS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
D-04	PI23/00820 Análisis de la eficacia clínica y del efecto inmunomodulador de pectinas administradas en pacientes alérgicos a LTP mediante un estudio de intervención controlado con placebo y seguimiento a largo plazo. IP: NATALIA ISABEL PEREZ SANCHEZ	NATALIA ISABEL PEREZ SANCHEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2023
D-04	FI21/00116: Contrato PFIS 2021 Pablo Torres Fernández. Jefe de grupo: Maria Isabel Montañez Vega.	MARÍA ISABEL MONTAÑEZ VEGA	National	HR	INSTITUTO DE SALUD CARLOS III	2021
D-04	CM24/00135 Contrato Río Hortega	IBON EGUILUZ GRACIA	National	HR	INSTITUTO DE SALUD CARLOS III	2024
D-04	RD24/0007/0024 Red de Enfermedades Inflamatorias (REI)	MARÍA JOSÉ TORRES JAEN	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2024
D-05	Creación de una red prospectiva multinacional para evaluar nuevas terapias en toxicidad hepática	MARÍA ISABEL LUCENA GONZÁLEZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2025
D-05	Papel del sistema inmune y la permeabilidad intestinal en el daño hepático inducido por fármacos (DILI) y la esteatosis inducida por fármacos (DIS).	MARÍA ISABEL LUCENA GONZÁLEZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
D-05	Estudio de fase II prueba de concepto y análisis mecanístico para evaluar la eficacia y seguridad de los corticosteroides en el tratamiento de la hepatotoxicidad idiosincrásica (DILI-CORT)	RAÚL J. ANDRADE BELLIDO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
D-05	Generación de un modelo Multi-organ on a Chip (MIVO) para el estudio del eje hígado-intestino en enfermedades del sistema digestivo.	CARLOS LOPEZ GOMEZ	Regional	PI	JUNTA DE ANDALUCIA	2024
D-05	FPU22/03868. Ayudas para Formación de Profesorado Universitario (FPU). Gonzalo Matilla Cabello. Jefe de grupo: Raúl J. Andrade Bellido	RAÚL J. ANDRADE BELLIDO	National	HR	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
D-05	halt-RONIN - Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies	RAÚL J. ANDRADE BELLIDO	European Union	PI	COMISIÓN EUROPEA	2022
D-05	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	CARLOS LOPEZ GOMEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
D-05	PID2021-127764OB-I00_Uso de biomarcadores como medicina personalizada en la predicción de la respuesta terapéutica a fármacos biológicos en la enfermedad de Crohn (BIORESCROHN)	EDUARDO GARCIA FUENTES	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
D-05	PI-0117-2022 Multiómicas para la identificación de biomarcadores microbianos predictivos de la respuesta a Ustekinumab en pacientes con enfermedad de Crohn	EDUARDO GARCIA FUENTES	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2022
D-05	RC-0005-2020 Renovación de la Acción C (Programa Nicolás Monardes) de la Convocatoria 2016.	EDUARDO GARCIA FUENTES	Regional	HR	SERVICIO ANDALUZ DE SALUD	2020
D-05	TRANSBIOLINE - Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease	RAÚL J. ANDRADE BELLIDO	European Union	PI	COMISIÓN EUROPEA	2018
D-05	PI21-01248 Fenotipado y caracterización mecanística de la lesión hepática inducida por fármacos, la esteatosis inducida por fármacos y la enfermedad del hígado graso asociado al metabolismo	RAÚL J. ANDRADE BELLIDO	National	PI	INSTITUTO DE SALUD CARLOS III	2021
D-05	PID2022-140169OB-C21 AYUDAS CONCEDIDAS PARA LA FORMACIÓN DE PERSONAL INVESTIGADOR PREDOCTORAL-PREP2022-000511	MARÍA ISABEL LUCENA GONZÁLEZ	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
D-05	B-0006-2024 Refuerzo con RRHH de la actividad investigadora en las UC del SAS - Acción B. BN: Jose Pinazo. D: Raúl Andrade.	RAÚL J. ANDRADE BELLIDO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
D-05	CM23-00103 Contrato Rio Hortega 2023_ Irene Diaz Alberola_jefe de grupo: Maria Isabel Lucena Gonzalez.	MARÍA ISABEL LUCENA GONZÁLEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-05	MS22-00050 Contrato Miguel Servet 2022.	CARLOS LOPEZ GOMEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2022

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
D-05	MS23/00088 Contrato Miguel Servert 2023	CRISTINA RODRÍGUEZ DÍAZ	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-05	PID2022-140169OB-C21 Funcionalidad mitocondrial y estrés oxidativo en un estudio fase II para evaluar la eficacia y seguridad del tratamiento con corticoides en hepatotoxicidad	MARÍA ISABEL LUCENA GONZÁLEZ	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
D-05	IFI21-00034 Contratos I-PFIS: Doctorados IIS - Empresas de ciencias y tecnología en salud.Daniel Enrique Di Zeo Sánchez jefe de grupo Raúl J. Andrade Bellido	RAÚL J. ANDRADE BELLIDO	National	HR	INSTITUTO DE SALUD CARLOS III	2021
D-05	C-0028-2024 CONTRATO INVESTIGA C	RAÚL J. ANDRADE BELLIDO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
D-05	CM23-00126 Contrato Rio Hortega 2023_ Juan Pedro Toro Ortiz_Jefe de Grupo:Raul Jesús Andrade Bellido	RAÚL J. ANDRADE BELLIDO	National	HR	INSTITUTO DE SALUD CARLOS III	2023
D-05	JR21-00066 Contratos Juan Rodes 2021	JUDITH ADRIANA SANABRIA CABRERA	National	HR	INSTITUTO DE SALUD CARLOS III	2021
D-05	MA-INV-0031-2022-04 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Eduardo García Fuentes	EDUARDO GARCIA FUENTES	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
D-05	CD21-00198 Contratos Sara Borrell 2021 Marina Villanueva jefe de grupo Maria Isabel Lucena Gonzalez	MARÍA ISABEL LUCENA GONZÁLEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2021
D-05	PMP22-00055 Proyecto iPHARMGx: Estudio colaborativo nacional para evaluar la efectividad y eficiencia de la implementación de biomarcadores farmacogenéticos mediante una estrategia de genotipado anticipado en el SNS.	JUDITH ADRIANA SANABRIA CABRERA	National	PI	INSTITUTO DE SALUD CARLOS III	2022
D-05	PR_PUBLICACIONES_01_2025 Premio a las Mejores Publicaciones del Año IBIMA Plataforma BIONAND.	MARÍA ISABEL LUCENA GONZÁLEZ	Local	AWARDS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
D-05	RETOS245779LLOV_Neoadjuvant-adjuvant immunotherapy and cancer vaccines to improve survival in hepatocellular carcinoma. IP: Raúl Andrade	RAÚL J. ANDRADE BELLIDO	National	PI	ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER	2024
D-05	RHJ-0052-2024 Hepatotoxicidad inducida por fármacos, DILI, biomarcadores, reprogramación directa, high content screening, modelos in vitro	RAÚL J. ANDRADE BELLIDO	Regional	HR	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
D-05	PI24/01205 Análisis integrado de epigenómica, transcriptómica y exposoma en el contexto del daño hepático inducido por fármacos.	RAÚL J. ANDRADE BELLIDO	National	PI	INSTITUTO DE SALUD CARLOS III	2024
D-05	CP22-00050 Ayuda Adiccional Contrato Miguel Servet 2022	CARLOS LOPEZ GOMEZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022
D-05	PI-0244-2021. Búsqueda de biomarcadores de respuesta terapéutica a fármacos biológicos en enfermedad de Crohn. Un enfoque desde la medicina personalizada de precisión.	CARLOS LOPEZ GOMEZ	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2021
D-05	CPP2024-011262 CATIB NOVEL ANTI-CCR9 ANTIBODY FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IP: Eduardo García Fuentes	EDUARDO GARCIA FUENTES	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2025
D-05	PI-0106-2025 PROBIOCROHN: Descifrando la complejidad de los biofilms intestinales en la progresión de la enfermedad de Crohn y su respuesta al tratamiento: caracterización multiómica y estrategias terapéuticas basadas en probióticos	ANTONIO JESUS RUIZ MALAGON	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2025
DE-07	ECRAID-Base - European Clinical Research Alliance on Infectious Diseases	MANUEL ENRIQUE HERRERA GUTIERREZ	European Union	PI	COMISIÓN EUROPEA	2020

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
DE-08	MICRO GILD24_25620 MICROELIMINACIÓN DE HEPATITIS C Y DE DIAGNÓSTICO Y VINCULACIÓN DE HEPATITIS B Y D AL SISTEMA SANITARIO EN EL SERVICIO DE APARATO DIGESTIVO DEL HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA.	ROCÍO GONZALEZ GRANDE	National	PI	GILEAD SCIENCES, S.L.U	2024
DE-09	Innate immune response to SARS-CoV-2 infection and mechanisms of viral immunopathology	JOSÉ MANUEL JIMÉNEZ GUARDEÑO	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
DE-09	Estudio de la interacción entre HIV-1 y la respuesta de interferón: investigando los factores del hospedador y las estrategias de evasión.	JOSÉ MANUEL JIMÉNEZ GUARDEÑO	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
DE-09	INTAR25-04 De la virología a la terapia oncológica: proteínas del SARS-CoV-2 como nuevas armas contra tumores uroteliales.	JOSÉ MANUEL JIMÉNEZ GUARDEÑO	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
DE-09	INN25_01 Utilización de long non-coding RNAs en la terapia antiviral contra el VIH-1	ANA MARIA ORTEGA PRIETO	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
DE-09	MS24/00058 Contrato Miguel Servet	ANA MARIA ORTEGA PRIETO	National	HR	INSTITUTO DE SALUD CARLOS III	2024
DE-09	PI-0128-2024 Investigación de los determinantes inmunogenéticos humanos asociados con la resistencia y vulnerabilidad frente a la COVID-19: hacia el diseño de nuevas estrategias de prevención y tratamiento basadas en medicina de precisión	JOSÉ MANUEL JIMÉNEZ GUARDEÑO	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
DE-09	Ayudas Ramón y Cajal 2021_JIMENEZ GUARDEÑO, JOSE MANUEL	JOSÉ MANUEL JIMÉNEZ GUARDEÑO	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
DE-09	Postdoctorales Junta Andalucía 2024_LEIVA REBOLLO, ROCÍO DE LAS MERCEDES	ROCIO DE LAS MERCEDES LEIVA REBOLLO	Regional	HR	JUNTA DE ANDALUCIA	2024
DE-10	Estudio de biomarcadores en humor acuoso y sangre en LHON	IGNACIO GARCIA BASTERRA	National	PI	CHESI	2022
F-02	Detección Automática de Epilepsia Focal No Lesional mediante Modelos Neuronales Profundos de Difusión Probabilística	ESTEBAN JOSÉ PALOMO FERRER	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
F-02	Detección de trayectorias anómalas de vehículos en cámaras de tráfico	JOSE DAVID FERNANDEZ RODRIGUEZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2022
F-02	Detección automática de Enfermedad Coronaria No Obstructiva en Coronariografías	EZEQUIEL LÓPEZ RUBIO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
F-02	IFI19/00009 Contratos I-PFIS: Doctorados IIS-Empresa en ciencias y tecnologías de la salud Rosa Maria Maza Quiroga. Jefe de grupo: Ezequiel Lopez Rubio	EZEQUIEL LÓPEZ RUBIO	National	HR	INSTITUTO DE SALUD CARLOS III	2019
F-02	MA-INV-0031-2022-22 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Ezequiel López Rubio.	EZEQUIEL LÓPEZ RUBIO	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
F-02 / A-03	PUNI-003_2023 Sistema Inteligente de Ayuda al Diagnóstico Clínico de la Enfermedad Coronaria No Obstructiva en Coronariografías	ESTEBAN JOSÉ PALOMO FERRER	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2023
F-03	Contratos Predoctorales	ANA SANCHEZ RAMIREZ	Regional	HR	-	2020
F-03	Sensores de campo lejano en fotónica del silicio	ALEJANDRO ORTEGA MOÑUX/ ROBERT HALIR	National	PI	-	2022
F-03	Diseño Inverso Inteligente para Fotónica Integrada Avanzada usando Metamateriales Sublongitud de Onda	ROBERT HALIR/ IÑIGO MOLINA FERNANDEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
F-03	Antenas ópticas integradas para transceptores ópticos inalámbricos.	ALEJANDRO ORTEGA MOÑUX/ JUAN GONZALO WANGUEMERT PEREZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
F-03	SELFOCO	ALEJANDRO ORTEGA MOÑUX	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
F-04	Percepción robotica avanzada para construccion de mapas y localizacion	JAVIER GONZÁLEZ JIMÉNEZ	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
F-04	Creación de mapas topológicos de lugares para la localización de una cámara	JAVIER GONZÁLEZ JIMÉNEZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
F-04	VOXELAND: HACIA UNA REPRESENTACIÓN EFECTIVA DEL ENTORNO DE TRABAJO DE ROBOTS MÓVILES	JOSÉ RAÚL RUIZ SARMIENTO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
F-04	Tiempo de acción variable en el aprendizaje por refuerzo para robots.	JUAN ANTONIO FERNÁNDEZ MADRIGAL	National	PI	MINISTERIO DE ECONOMÍA	2023
F-04	MINDMAPS: Semantic Topometric Maps as Models of the Environment for Intelligent Robots /Mapas semánticos topométricos como modelos del entorno para robots inteligentes.	JAVIER GONZÁLEZ JIMÉNEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
F-04	FPU2024_MONCADA RAMÍREZ, JESÚS	JESUS MONCADA RAMIREZ	National	HR	MINISTERIO DE EDUCACION	2024
F-04	MA-INV-0031-2022-23 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Francisco Ángel Moreno Dueñas	FRANCISCO ÁNGEL MORENO DUEÑAS	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
F-05	FPU23_HERREA LOPEZ, JUAN MARIA	JUAN MARÍA HERRERA LOPEZ	National	HR	MINISTERIO DE EDUCACION	2023
F-05	Planificador de tareas con aprendizaje para la colaboración humano-robot en un sistema industrial ciber-físico.	VICTOR FERNANDO MUÑOZ MARTÍNEZ	National	PI	-	2022
F-05	Asistente robótico colaborativo para mejorar la cirugía laparoscópica del hígado	VICTOR FERNANDO MUÑOZ MARTÍNEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
F-05	Digital Twin for VET schools (DiTwin)	VICTOR FERNANDO MUÑOZ MARTÍNEZ	European Union	PI	COMISIÓN EUROPEA	2023
F-05	Robot quirúrgico para el aspirado autónomo de sangrado durante una intervención laparoscópica	RIVAS BLANCO, IRENE	National	PI	-	2022
F-05	Percepción y Navegación Híbrida para Exploración Planetaria	CARLOS JESÚS PÉREZ DEL PULGAR MANCEBO	National	PI	MINISTERIO DE ECONOMÍA	2024
F-05	I Doctoral workshop on Space Robotics	CARLOS JESÚS PÉREZ DEL PULGAR MANCEBO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2025
F-09	INSTRUMENTACION INTELIGENTE Y APLICACION EN SALUD	FERNANDO VIDAL VERDÚ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2021
F-09	Estímulos Táctiles para Transmitir Música a Personas con Discapacidad Auditiva	FERNANDO VIDAL VERDÚ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
F-09	CONtrol Colaborativo para Interacción física Empática entre RoboT y humanO	JESÚS MANUEL GÓMEZ DE GABRIEL	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2021
F-09	Wearables y mobiliario inteligente	FERNANDO VIDAL VERDÚ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2024
F-10	SISTEMAS MULTIVALENTES Y MARCADORES LUMINISCENTES PARA APLICACIONES BIOMEDICAS	EZEQUIEL PÉREZ-INESTROSA VILLATORO	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
F-10	Poliaminales para el encapsulamiento y liberación de fármacos antineoplásicos.	ANTONIO JESÚS RUIZ SÁNCHEZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2024
F-10	Síntesis de sistemas Dendrimericos multivalentes tipo Janus	EZEQUIEL PÉREZ-INESTROSA VILLATORO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
F-10	CNS2022-135409 ioglicósidos: epítopos de glicano no hydrolizables para el desarrollo de vacunas sintéticas basadas en carbohidratos contra el VIH. (HIVTHIOVAC)	EZEQUIEL PÉREZ-INESTROSA VILLATORO	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
F-10	MA-INV-0031-2022-19 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Ezequiel Perez-Inestrosa	EZEQUIEL PÉREZ-INESTROSA VILLATORO	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
F-14	Mejora de la fatiga en hombro inestable a través de un programa de ejercicio terapéutico en fisioterapia (MoveUS).	ANTONIO CUESTA VARGAS	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
F-14	Identificación de personas frágiles en atención primaria a través de parámetros funcionales, metabólicos, cognitivos y de composición corporal	JERÓNIMO GARCÍA ROMERO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
F-14	CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care	CRISTINA ROLDÁN JIMÉNEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
F-14	MA-INV-0031-2022-21 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP:Antonio Cuesta	ANTONIO CUESTA VARGAS	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
F-14/A-06	PI22-00315 Efectividad de un programa de rehabilitación cardiaca en biomarcadores cinemáticos, estructurales y fisiológicos en pacientes de edad avanzada con insuficiencia cardíaca. FUNNEL+	ANTONIO CUESTA VARGAS	National	PI	INSTITUTO DE SALUD CARLOS III	2022
F-15	5G+TACTILE_3. Gestión “zero touch” de los servicios con IA aplicada a datos masivos en redes B5G/6G	JOSÉ FRANCISCO ALDANA MONTES/ PEDRO MERINO GÓMEZ	National	PI	MINISTERIO DE ECONOMÍA	2021
F-15	Hacia la creación del Espacio de Datos Federado del Sector Agroalimentario de Andalucía (EDAA)	JOSÉ FRANCISCO ALDANA MONTES/ MARIA DEL MAR ROLDAN GARCIA	National	PI	MINISTERIO DE ECONOMÍA	2024
F-15	Potenciando los Ecosistemas de Compartición de Datos Federados con un Enfoque Multidimensional -Gestión de Metadatos en Entornos Federados	JOSÉ FRANCISCO ALDANA MONTES/ JOSÉ MANUEL GARCÍA NIETO	National	PI	MINISTERIO DE ECONOMÍA	2024
F-15	BIOREFOREST: Reforestation of forests and orchards after disturbances A transformative action plan balancing socioeconomic and biodiversity needs	JOSÉ FRANCISCO ALDANA MONTES/ JOSÉ MANUEL GARCÍA NIETO	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2025
F-15	Ágora Data Spaces Sandbox: Validación, Integración y Experimentación en Espacios de Datos. Productos y servicios tecnológicos para espacios de datos	MARIA DEL MAR ROLDAN GARCIA	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2025
F-15	PID2020-112540RB-C41 Una aproximación holística de smart data para el análisis de datos guiado por el contexto: explotación de semántica y contexto.	JOSÉ FRANCISCO ALDANA MONTES	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
F-16	SECOT_02.Estudio del transcriptoma con identificación de nuevos biomarcadores no invasivos para el diagnóstico de la escoliosis idiopática del adolescente.	ENRIQUE GUERADO PARRA	National	PI	SOCIEDAD ESPAÑOLA DE CIRUGÍA ORTOPÉDICA Y TRAUMATOLOGÍA	2022
F-16	SECOTPI2025-02 Dispositivo bioeléctrico para el tratamiento de biopelículas bacterianas cultivadas en implantes de Cromo-Cobalto-Molibdeno: estudio de biocompatibilidad en conejos.	ISKANDAR TAMIMI MARIÑO	National	PI	SOCIEDAD ESPAÑOLA DE CIRUGÍA ORTOPÉDICA Y TRAUMATOLOGÍA	2025
F-19	La emoción racional a través de las redes de sociabilidad presenciales y los ecosistemas digitales	JOSÉ IGNACIO PELÁEZ SÁNCHEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2021
F-19	Familia Digital: El impacto de las TIC sobre las nuevas estructuras y dinámicas familiares en España	JOSÉ MANUEL GARCÍA MORENO	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
F-19	Prevención de la conducta suicida a través de los Procesos de Comunicación Efectiva y Risk Analytics	JOSÉ IGNACIO PELÁEZ SÁNCHEZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2023
F-19	Sostenibilidad social de la moda en el metaverso.	EDUARDO VILLENA ALARCÓN	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
F-19	El nuevo pacto intergeneracional: emancipación, vivienda y cuidados en el contexto del familiarismo digital	FÉLIX SANTOS REQUENA	National	PI	Fundacvión BBVA	2024
FA-07	SECOT-001 ESTABILIDAD EN LA CARGA AXIAL DEL FIJADOR EXTERNO Francisco Javier Duran Garrido.	FRNCISCO JAVIER DURAN GARRIDO	National	PI	SOCIEDAD ESPAÑOLA DE CIRUGÍA ORTOPÉDICA Y TRAUMATOLOGÍA	2019
FE-17	FPU2023_CALVIÑO LOPEZ, ANA	ANA CALVIÑO LOPEZ	National	HR	MINISTERIO DE EDUCACION	2023
FE-17	Mecanismos cerebrales y cognitivos de los errores del habla en la afasia	JAVIER GARCÍA ORZA	Regional	PI	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2022
FE-17	CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research	RAQUEL CANTERO TELLEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
FE-18	Efectividad de la adición del entrenamiento de la musculatura inspiratoria a un programa de rehabilitación cardiaca de personas con cardiopatía isquémica revascularizadas mediante angioplastia coronaria transluminal percutánea	ADELA MARÍA GÓMEZ GONZÁLEZ	National	PI	Sociedad Española de Rehabilitación Cardiorrespiratoria SORECAR	2024
FE-20	Diseño de un entorno de multimodal de evaluación del habla: aplicación al caso de pacientes con disfunción velofaríngea	ENRIQUE NAVA BARO	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
FE-22	FPU23_SANCHEZ ABSELAM, OMAR	OMAR SANCHEZ ABSELAM	National	HR	MINISTERIO DE EDUCACION	2023
G-01	Targeting strategies of multifunctional magnetic nanosystems for therapy and in vivo imaging of high-grade gliomas: validation in PDOX models	Mª LUISA GARCÍA MARTÍN	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2021
H-02	Cellular Stress And Senescence As a Crosstalk Mechanism Of Disease In Bone Fragility	IVAN DURAN JIMENEZ	Regional	PI	CONSEJERÍA DE TRANSFORMACIÓN ECONÓMICA, INDUSTRIA, CONOCIMIENTO Y UNIVERSIDADES	2020
H-02	Desarrollo de terapias avanzadas para enfermedades musculoesqueléticas	IVAN DURAN JIMENEZ	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
H-02	Evaluación in vitro e in vivo del uso de postbióticos y polisacáridos de algas frente a patógenos de importancia en acuicultura	MANUEL MARI BEFFA	Regional	PI	Consejería de Universidad, Investigación e Innovación	2023
H-02	Mechanisms of bone pathologies caused by alteration of skeletal differentiation towards adipogenesis and its link with metabolism	FABIANA CSUKASI	Regional	PI	JUNTA DE ANDALUCIA	2022
H-02	CA22170 (TENET) - TEndon Regeneration NETwork	IVAN DURAN JIMENEZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2022
H-02	MORBIUS - Cure for Miniature Brittle Bones: Treatment of Osteogenesis ImpeRfecta patient-derived Bone organoids with Innovative AAV-mediated Ultimate Gene-editing System	IVAN DURAN JIMENEZ	European Union	HR	COMISIÓN EUROPEA	2023
H-02	MA-INV-0031-2022-11 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Iván Durán	IVAN DURAN JIMENEZ	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
H-03	Beatriz Galindo_PASCUAL ANAYA, JUAN	JUAN PASCUAL ANAYA	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2020
H-03	Ayudas Ramón y Cajal 2021_RUIZ VILLALBA, ADRIAN	ADRIÁN RUIZ VILLALBA	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2021

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
H-03	Estratificación de fibroblastos cardíacos: origen y segregación espacial de fibroblastos activados en la fisiopatología cardiovascular	JOSE MARIA PEREZ POMARES	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
H-03	Análisis histopatológico y transcriptómico de constructos de bioingeniería cardíaca para el estudio de la fibrosis	JOSE MARIA PEREZ POMARES	Regional	PI	UNIVERSIDAD DE MÁLAGA	2023
H-03	Estudio evolutivo del sistema sanguíneo en peces cartilaginosos: implicaciones sobre el origen de la hematopoyesis en vertebrados	Juan Pascual Anaya	Regional	PI	CONSEJERÍA DE UNIVERSIDAD, INVESTIGACIÓN E INNOVACIÓN	2022
H-03	Estudio evolutivo del sistema sanguíneo de la lamprea: implicaciones sobre el origen de la hematopoyesis en vertebrados	Juan Pascual Anaya	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
H-03	Estudio evolutivo del sistema cardiovascular y sanguíneo de anélidos: implicaciones sobre el origen de la sangre en metazoos	Juan Pascual Anaya	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2023
H-03	Descifrando el endotelio hemogénico en la aorta dorsal de la lamprea: Perspectivas sobre los mecanismos ancestrales de la hematopoyesis en vertebrados	Juan Pascual Anaya	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
H-03	Estudio de la transición de los fibroblastos activados en la patología cardíaca: desde la caracterización molecular y funcional hasta la modulación de la fibrosis cardíaca	ADRIÁN RUIZ VILLALBA	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2024
H-03	Desenmarañando el interactoma celular en el infarto de miocardio	ADRIÁN RUIZ VILLALBA	National	PI	AGENCIA ESTATAL DE INVESTIGACIÓN	2022
H-03	SECFEC-INV-BAS 22016 Nueva perspectiva en los mecanismos fisiopatológícos de la Enfermedad de Kawasaki	ADRIÁN RUIZ VILLALBA	National	PI	SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA	2022
H-03	PI-0185-2024 RUTAS DE SEÑALIZACIÓN CLAVE EN LA PATOGÉNESIS DE LA ENFERMEDAD DE KAWASAKI: HACIA LA VALIDACIÓN DE CTHRC1 COMO MARCADOR DIAGNÓSTICO Y PRONÓSTICO	ADRIÁN RUIZ VILLALBA	Regional	PI	CONSEJERÍA DE SANIDAD, PRESIDENCIA Y EMERGENCIAS	2024
HE-01	Pluripotencia adquirida: Análisis de la reprogramación celular usando factores del ovocito para estudiar los estados de pluripotencia humana para aplicaciones biomédicas	MARIA ELENA GONZALEZ MUÑOZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2022
HE-01	Estados de pluripotencia humana usando la reprogramación a iPSC basada en factores del ovocito para estudiar el desarrollo embrionario temprano para aplicaciones biomédicas.	MARIA ELENA GONZALEZ MUÑOZ	National	PI	MINISTERIO DE CIENCIA E INNOVACIÓN	2024
HE-01	CA21151 (HAPLO-iPS) - GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELLS FROM HAPLO-SELECTED CORD BLOOD SAMPLES	MARIA ELENA GONZALEZ MUÑOZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
HE-01	CA20140 (CorEuStem) - The European Network for Stem Cell Core Facilities	MARIA ELENA GONZALEZ MUÑOZ	European Union	NETWORKS AND STRUCTURES	COMISIÓN EUROPEA	2021
HE-01	Reprogramación Celular y modelos de enfermedad	MARIA ELENA GONZALEZ MUÑOZ	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
HE-01	MA-INV-0031-2022-13 Contratos de jóvenes investigadores y técnicos de apoyo de I+D+i. Programa Ivestigo. IP: Elena González Muñoz	MARIA ELENA GONZALEZ MUÑOZ	Regional	HR	CONSEJERÍA DE EMPLEO, EMPRESA Y TRABAJO AUTÓNOMO	2022
HE-01	Molecular Characterization of Secondary Progressive Multiple Sclerosis Using FTIR Synchrotron Radiation. ALBA CELLS (Consortium for the Construction, Equipping and Exploitation of the Synchrotron Light Source (CELLS)	MARIA ELENA GONZALEZ MUÑOZ	International non-EU	INFRAESTRUC-TURA	ALBA CELLS (Consortium for the Construction, Equipping and Exploitation of the Synchrotron Light Source (CELLS)	2024
IBIMA	UICM24-00019 Mejora Unidad Investigación Clínica Hospital Regional de Málaga (UIC HRUM)	PEDRO JESÚS SERRANO CASTRO	National	INFRAESTRUC-TURA	INSTITUTO DE SALUD CARLOS III	2024

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Call Year
IBIMA	INBIO25 Ayuda para la asistencia a BIOSPAIN	ISABEL MARÍA GUERRERO MOLINA	Local	COMPLEMENTARY ACTIONS	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
IBIMA	CERT22/00034. Consorcio Estatal en Red para el desarrollo de Medicamentos de Terapias Avanzadas (CERTERA)	FRANCISCO JOSÉ TINAHONES MADUEÑO	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2023
IBIMA	PT23/00082 Unidad de Innovación de IBIMA Plataforma BIONAND. Impulso a la valorización tecnológica, transferencia de conocimiento y consolidación del tejido industrial.	FERNANDO RODRÍGUEZ FONSECA	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2023
IBIMA	GIS22-00015 Contratos de Gestión en Investigación en Salud en IIS acreditados 2022	ROSA MARIA GOMEZ GALVEZ	National	HR	INSTITUTO DE SALUD CARLOS III	2022
ECAI BIOBANCO	RF2-0003-2023 SOLICITUD PARA LA VINCULACIÓN DE TÉCNICOS A LAS ESTRUCTURAS COMUNES DE APOYO A LA INVESTIGACIÓN (ECAI) DE LOS CENTROS SANITARIOS DEL SERVICIO ANDALUZ DE SALUD (SAS)	TATIANA DIAZ CORDOBA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
ECAI BIOBANCO	PT23/00049 Plataforma Biobanco y Biomodelos piedra angular de la Medicina de Precisión: ampliación, virtualización e internacionalización del servicio. Generación de organoides	FRANCISCO JOSÉ TINAHONES MADUEÑO	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2023
ECAI BIOINFORMATICA	F2-0026-2022 MEMORIA DESCRIPTIVA DE LA ECAI: ORGANIZACIÓN, RECURSOS Y ACTIVIDAD DE LA ECAI.	ANDRES GONZÁLEZ JIMENEZ	Regional	HR	SERVICIO ANDALUZ DE SALUD	2022
ECAI GENOMICA	RF2-0005-2024 RENOVACIÓN TÉCNICOS VINCULADOS A ECAIS 2024	DANIEL ALAMEDA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
ECAI INVESTIGACIÓN CLÍNICA Y EECC	PT23/00137 Unidad de Investigación Clínica y Ensayos Clínicos, UICEC IBIMA_Plataforma BIONAND. Plataforma de Investigación Clínica ISCiii: Consolidación de su proyección internacional, gestión integral, colaboración y transferencia.	MARÍA ISABEL LUCENA GONZÁLEZ	National	NETWORKS AND STRUCTURES	INSTITUTO DE SALUD CARLOS III	2023
ECAI INVESTIGACIÓN CLÍNICA Y EECC	RF2-0002-2023 SOLICITUD PARA LA VINCULACIÓN DE TÉCNICOS A LAS ESTRUCTURAS COMUNES DE APOYO A LA INVESTIGACIÓN (ECAI) DE LOS CENTROS SANITARIOS DEL SERVICIO ANDALUZ DE SALUD (SAS), Gloria Luque	GLORIA LUQUE FERNÁNDEZ	Regional	HR	SERVICIO ANDALUZ DE SALUD	2023
ECAI NANOIMAGEN	PTA2020-019744 AYUDAS PERSONAL TÉCNICO DE APOYO . ECAI NANOIMAGEN. IBIMA PLATAFORMA BIONAND. CANDIDATA:MÓNICA FEIJÓO CUARESMA	MARIA LUISA GARCIA MARTIN	National	HR	AGENCIA ESTATAL DE INVESTIGACIÓN	2021
ECAI PRODUCCIÓN CELULAR Y SALAS GMP	RF2-0004-2022 Vinculación de Técnicos a las Estructuras Comunes de Apoyo a la Investigación. Renovación de los refuerzos de la actividad investigadora cuyas ayudas vencen en 2022	RAFAEL MALDONADO	Regional	HR	SERVICIO ANDALUZ DE SALUD	2022
ECAI PRODUCCIÓN CELULAR Y SALAS GMP	PI22-01627 Evaluación preclínica de implantes personalizados, fabricados por bioimpresión, para la corrección quirúrgica de defectos críticos cráneo-maxilofaciales en pacientes pediátricos	LEONOR SANTOS RUIZ	National	PI	INSTITUTO DE SALUD CARLOS III	2022
ECAI PRODUCCIÓN CELULAR Y SALAS GMP	RF2-0004-2024 RENOVACIÓN TÉCNICOS VINCULADOS A ECAIS 2024	ANTONIO RODRIGUEZ ACOSTA	Regional	HR	SERVICIO ANDALUZ DE SALUD	2024
ECRIN	LIVERaTION - Unravelling the impact of Radiofrequency in liver surgery: the key to decrease local recurrence?	MIRIAM ROL GARCÍA	European Union	PI	COMISIÓN EUROPEA	2022
ECRIN	ORTHOALLOUNION - ORTHOpaedic treatment with Allogeneic combined ATMP in long bone fracture delayed UNION and non-union	MIRIAM ROL GARCÍA	European Union	PI	COMISIÓN EUROPEA	2023
ECRIN	ERA4Health - Fostering a European Research Area for Health Research	MIRIAM ROL GARCÍA	European Union	PI	COMISIÓN EUROPEA	2022

ACTIVE COMPETITVE GRANTS FROM EXTERNAL ASSOCIATED GROUPS

Group	Title	PI Name	Scope	Subtype	Name of Funding Entity	Year of Call
AA-24	AP-0333-2022-C3-F2 Valoración del estrés psicosocial como un factor determinante en las enfermedades cardiovasculares agudas y análisis de implantación de un programa de intervención estructurado grupal psicoeducativo.	MIGUEL ÁNGEL GARCIA ORDOÑEZ	REGIONAL	PI	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.	2022
AA-24	AP-0553-2024-C5-F2 Efecto de la monitorización intersticial de glucosa en pacientes con diabetes mellitus tipo 2 en tratamiento con una dosis de insulina basal.	MARIA JOSE PERAL PRADOS	REGIONAL	PI	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.	2024
AA-24	CA20104 (PhysAgeNet) - Network on evidence-based physical activity in old age	MIGUEL ÁNGEL GARCIA ORDOÑEZ	European Union	OTHERS	COMISIÓN EUROPEA	2021
AA-24	CA22169 (EU-METAHEART) - EUropean network to tackle METAbolic alterations in HEART failure	MIGUEL ÁNGEL GARCIA ORDOÑEZ	European Union	OTHERS	COMISIÓN EUROPEA	2022
CA-15	INN25_03 Prototipo APP para un Plan de Cuidados de pacientes en situación en últimos días: APP-Cui-DAR-CUDECA	PILAR BARNESTEIN FONSECA	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025
CA-19	PI25_CUIDADOS_03 Optimización de la Monitorización Flash de Glucosa en Atención Primaria para Mejorar el Control y la Adherencia en Personas con Diabetes Mellitus tipo 2 (OPTIMA-Diab2). Estudio cualitativo y ensayo aleatorizado crossover. IP: Carmen Aránzazu Bermúdez.	CARMEN ARANZAZU BERMUDEZ MARTIN	Local	PI	FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD	2025

ACTIVE CLINICAL STUDIES IN 2025

Group	Title	Subtype	PI Name	Phase
A-01	Registro español informatizado de pacientes con Bronquiectasias.	NON-POST-APPROVAL STUDY	CASILDA OLVEIRA FUSTER	Not applicable
A-01	Estudio fase III, multicéntrico, aleatorizado, doble ciego, de 48 semanas, con un periodo inicial de 12 semanas controlado con placebo, para evaluar la seguridad y la eficacia de osilodrostat en pacientes con enfermedad de Cushing	COMMERCIAL CLINICAL TRIAL	INMACULADA GONZALEZ MOLERO	III
A-01	Eficacia del tratamiento con metformina en diabetes gestacional no controlada con dieta frente al uso de insulinoterapia. Estudio MeDiGes	INDEPENDENT CLINICAL TRIAL	STELLA GONZALEZ ROMERO	IV
A-01	Impacto sobre el estrés oxidativo de los distintos análogos de insulina en personas con diabetes tipo 1. Ensayo clínico de bajo nivel de intervención. Estudio Ineox	INDEPENDENT CLINICAL TRIAL	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	IV
A-01	Pemafibrato para reducir los episodios cardiovasculares mediante la reducción de los triglicéridos en pacientes con diabetes (PROMINENT)	COMMERCIAL CLINICAL TRIAL	INMACULADA GONZALEZ MOLERO	III
A-01	Estudio europeo, observacional, de pasireotida LAR en acromegalia. Estudio ACRONIS. CSOM230CIC05	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZALEZ MOLERO	Not applicable
A-01	Estudio Fase IIb, 2-brazos, aleatorizado, Doble-ciego, Placebo-Controlado, Multicéntrico para Optimizar la terapia de Diamyd® Administrada dentro de los ganglios linfáticos combinados con la vitamina D oral para investigar el impacto en la progresión de la diabetes tipo 1.	COMMERCIAL CLINICAL TRIAL	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	II
A-01	Estudio observacional restrospectivo del uso de evolucumab en unidades españolas de endocrinología (Retrospective Observational Study of Evalocumab Use in Spain Endocrinology Units [RETOSS-Endo]). Código Promotor: 20160140	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZALEZ MOLERO	Not applicable
A-01	Estudio observacional, trasversal y multicéntrico, para valorar el grado de actividad de la enfermedad de los pacientes acromegálicos en España según la escala ACRODAT (ACROmegaly Disease Activity Tool). Estudio ACROVAL	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZALEZ MOLERO	Not applicable
A-01	Cumplimiento de un Suplemento Nutricional Oral (SNO) de alto contenido energético y bajo volumen	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Suplementos nutricionales específicos con probióticos para el tratamiento dietético de enfermedades crónicas	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Ensayo en fase III, aleatorizado, con enmascaramiento doble, comparativo con placebo y multicéntrico para evaluar la eficacia y la seguridad de Diamyd® en la conservación del funcionamiento de las células ß endógenas en adolescentes y adultos con un diagnóstico reciente de diabetes de tipo 1 que presentan el haplotipo genético HLA DR3-DQ2. DIAGNODE-3	COMMERCIAL CLINICAL TRIAL	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	III
A-01	Registro observacional sobre la enfermedad y los resultados clínicos de pacientes con deficiencia de lipasa ácida lisosomal (LAL)	NON-POST-APPROVAL STUDY	INMACULADA GONZALEZ MOLERO	Not applicable
A-01	Accu-Chek Solo Country Implementation Observational Network SCION	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	Not applicable
A-01	Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, multicéntrico y en 2 partes para evaluar la eficacia, la seguridad y la tolerabilidad de RGH-706 en el síndrome de Prader-Willi	DRUG CLINICAL TRIALS	JOSÉ CARLOS FERNANDEZ GARCIA	II
A-01	Real-world patient experience with weekly injectable dulaglutide versusdaily oral semaglutide in SpainTRU-Experience Study	OBSERVATIONAL STUDY WTIH MEDICINES	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly	DRUG CLINICAL TRIALS	INMACULADA GONZALEZ MOLERO	III
A-01	Estudio multicéntrico, prospectivo, no intervencionista y de un solo grupo, para investigar los parámetros clínicos asociados al uiso de semaglutida por vía oral una vez al día en una ploblación adulta no restringida con diabetes detipo 2 en España.	OBSERVATIONAL STUDY WTIH MEDICINES	GABRIEL OLVEIRA FUSTER	Not applicable

Group	Title	Subtype	PI Name	Phase
A-01	Efecto de un suplemento dietético con propiedades antioxidantes y antiinflamatorias sobre la microbiota intestinal en pacientes con cáncer de colon. Ensayo clínico aleatorizado y controlado con placebo. Estudio TERATROFO.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Valoración de la calidad de vida, el estado nutricional y la capacidad funcional en personas con enfermedad renal crónica avanzada (ERCA) tras la implantación de un plan de educación nutricional e intervención dietética individualizada.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Protocolo maestro para investigar la eficacia y la seguridad de LY3437943 administrado una vez a la semana en participantes con diabetes mellitus de tipo 2 y obesidad o sobrepeso: un estudio aleatorizado, doble ciego y controlado con placebo (TRIUMPH-2).	DRUG CLINICAL TRIALS	GABRIEL OLVEIRA FUSTER	III
A-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, de olezarsen (ISIS 678354) administrado por vía subcutánea a pacientes con hipertrigliceridemia grave	DRUG CLINICAL TRIALS	INMACULADA GONZALEZ MOLERO	III
A-01	Estudio observacional, prospectivo y multicéntrico de práctica clínica real (RWE) para evaluar el grado de adherencia a un programa de soporte nutricional y su relación con el estado nutricional evaluado mediante valoración morfofuncional en pacientes oncológicos desnutridos	OBSERVATIONAL STUDY WTIH MEDICINES	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Estudio de fase 2b, aleatorizado, doble ciego, controlado con placebo y multicéntrico de 52 semanas de duración con una extensión ciega de 52 semanas que evalúa la seguridad y la eficacia de frexalimab, un anticuerpo monoclonal antagonista de CD40L, para la preservación de la función de las células ß pancreáticas en adultos y adolescentes con diagnóstico reciente de diabetes tipo 1 en tratamiento con insulina	DRUG CLINICAL TRIALS	MARÍA SOLEDAD RUIZ DE ADANA NAVAS	II
A-01	Estudio de extensión abierto de Olezarsen (ISIS 678354) administrado por vía subcutánea a pacientes con hipertrigliceridemia grave	DRUG CLINICAL TRIALS	INMACULADA GONZALEZ MOLERO	III
A-01	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome	DRUG CLINICAL TRIALS	GABRIEL OLVEIRA FUSTER	III
A-01	A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome.	DRUG CLINICAL TRIALS	GABRIEL OLVEIRA FUSTER	III
A-01	Ensayo sobre el efecto del apoyo nutrirional coninuado tras el alta hospitalaria sobre la mortalidad, la debilidad, los resultados funcionales y la recuperación	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	GABRIEL OLVEIRA FUSTER	Not applicable
A-01	Ensayo clínico multicéntrico, aleatorizado, controlado, simple ciego, de doble brazo para evaluar el impacto del tratamiento guiado por farmacogenética en pacientes con diabetes tipo 2 insuficientemente controlada.	DRUG CLINICAL TRIALS	FRANCISCO JAVIER BERMÚDEZ SILVA	IV
A-01	Un comparador activo aleatorizado, doble ciego, con placebo y de etiqueta abierta, controlado, Estudio de Fase II multicéntrico, de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de ro7795081 una vez al día administrado durante 30 SEMANAS a participantes con DIABETES MELLITUS TIPO 2	DRUG CLINICAL TRIALS	GABRIEL OLVEIRA FUSTER	II
A-02	Eficacia del tratamiento con metformina en diabetes gestacional no controlada con dieta frente al uso de insulinoterapia. Estudio MeDiGes.	INDEPENDENT CLINICAL TRIAL	MARÍA JOSÉ PICON CESAR	IV
A-02	Estudio observacional restrospectivo del uso de evolucumab en unidades españolas de endocrinología (Retrospective Observational Study of Evalocumab Use in Spain Endocrinology Units [RETOSS-Endo]). Código Promotor: 20160140	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ ANTONIO LOPEZ MEDINA	Not applicable
A-02	Registro Nacional de pacientes con Diabetes tipo 1	INDEPENDENT POSTAUTHORIZATION STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	Estudio observacional multinacional para evaluar la seguridad de Repatha en el embarazo. (20150162, 200150162)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	Antagonismo del receptor de glucocorticoides en el tratamiento del síndrome de Cushing estudio (GRACE): ensayo en fase III, con dobleenmascaramiento, controlado con placebo y con retirada aleatorizada sobre la eficacia y la seguridad del relacorilant.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III

Group	Title	Subtype	PI Name	Phase
A-02	Eficacia de dos fórmulas de suplementación nutricional oral sobre parámetros metabólicos y de monitorización glucémica en pacientes en riesgo nutricional con diabetes mellitus tipo 2. PS19089 Estudio JGA-DIACARE-2018-01 Bi1	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JOSÉ MANUEL GARCIA ALMEIDA	Not applicable
A-02	Estudio de resultados cardiovasculares con semaglutida en pacientes con diabetes tipo 2 Estudio ALMA	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar el impacto de evolocumab sobre los acontecimientos cardiovasculares mayores en pacientes con riesgo cardiovascular elevado sin infarto de miocardio o ictus previo	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio Metabolómico de Potenciales Factores Involucrados en la Cardioprotección. Inhibición de SGLT-2 y Enfermedad Cardiovascular	INDEPENDENT CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	IV
A-02	Estudio de extensión sin enmascaramiento de la seguridad de relacorilant (CORT125134) en el tratamiento de los signos y síntomas del síndrome de Cushing endógeno	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (SURPASS-CVOT)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2, aleatorizado, sin enmascaramiento, con un tratamiento comparativo y grupos paralelos, para evaluar la seguridad y la eficacia de LY3209590 en pacientes con diabetes mellitus de tipo 1 que anteriormente han recibido tratamiento con varias inyecciones diarias.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Antagonismo del receptor de glucocorticoides en el tratamiento del hipercortisolismo en pacientes con adenomas suprarrenales que secretan cortisol o hiperplasia (GRADIENT): Estudio de fase III, aleatorizado, doble ciego y comparado con placebo sobre la eficacia y la seguridad de relacorilant	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo clínico para valorar el Impacto de un suplemento nutricional en la Recuperación del Estadio Nutricional de pacientes ancianos con fractura Espontánea de cadera	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	JOSÉ MANUEL GARCIA ALMEIDA	Not applicable
A-02	Estudio aleatorizado, doble ciego (investigador y sujeto) y controlado con placebo para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia de CFZ533 en niños y adultos jóvenes con diabetes mellitus de tipo 1 (DMT1) de nueva aparición	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Cambios en la capacidad de digestión y secreción pancreática exocrina en pacientes tras una cirugía gástrica	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCIA ALMEIDA	Not applicable
A-02	Eficacia y seguridad de insulina icodec una vez a la semana en comparación con 100 unidades/ml una vez al día de insulina degludec, ambas en combinación con insulina aspart, en adultos con diabetes de tipo 1. Ensayo de tratamiento hasta conseguir el objetivo, de 26 semanas de duración, aleatorizado, multicéntrico, abierto, con control activo, de grupos paralelos y con dos brazos para investigar el efecto sobre el control de la glucemia y la seguridad del tratamiento con insulina icodec una vez a la semana en comparación con insulina degludec una vez al día, ambas en combinación con insulina aspart en adultos con diabetes de tipo 1, con una extensión de 26 semanas para investigar la seguridad a largo plazo. (ONWARDS 6)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2a, abierto, aleatorizado y controlado con un producto comparativo activo, para evaluar la eficacia y la seguridad de efinopegdutida (MK-6024) en participantes con esteatosis hepática no alcohólica	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio aleatorizado, doble ciego, controlado con placebo sobre la relación dosis-respuesta para evaluar la eficacia y la seguridad de MEDI7352 en pacientes con neuropatía diabética dolorosa	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Red global de ensayos de pacientes renales.	NON-POST-APPROVAL STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	A Phase 2b Multicentre, Randomised, Double-Blind, PlaceboControlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozinin Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2 (Zenith-CKD)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Correlación en el mundo real del tiempo dentro del rango con los resultados notificados por los pacientes y el uso de recursos sanitarios en pacientes con diabetes en España: estudio CorrelaTIR	RESTO DE ESTUDIOS OBSERVACIONALES CON MEDICAMENTOS	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable

Group	Title	Subtype	PI Name	Phase
A-02	Estrategias de control y estudio farmacogenético para el tratamiento personalizado del hígado graso asociado a disfunción metabólica en pacientes con prediabetes.	INDEPENDENT CLINICAL TRIAL	LOURDES GARRIDO SÁNCHEZ	III
A-02	Estudio de fase 3, multicéntrico, aleatorizado, sin enmascaramiento, con grupos paralelos, para evaluar la eficacia y la seguridad de LY3209590 en comparación con la insulina degludec en participantes con diabetes de tipo 2 actualmente tratados con insulina basal (QWINT-3)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la seguridad y eficacia a largo plazo de lanifibranor en pacientes adultos con esteatohepatitis no alcohólica (EHNA) sin cirrosis y estadio de fibrosis hepática grado 2 (F2)/grado 3 (F3)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio en fase II, doble ciego y controlado con placebo de setmelanotide en pacientes con defectos genéticos específicos en la vía del receptor de la melanocortina 4, en dos etapas (preinclusión abierta seguida de retirada aleatorizada)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase 3, aleatorizado, comparativo, sin enmascaramiento, con grupos paralelos, para comparar la eficacia y la seguridad de LY3209590 como insulina basal semanal con la de la insulina glargina en adultos con diabetes de tipo 2 que reciben múltiples inyecciones diarias	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo fase IIb/III, aleatorizado, doble ciego, comparado con placebo para evaluar la seguridad y eficacia de la cotadutida en pacientes con esteatohepatitis no alcohólica no cirrótica con fibrosis. (Estudio PROXYMO-ADVANCE)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio fase IIa, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y farmacodinámica de AZD4831 en pacientes con esteatohepatitis no alcohólica (EHNA) no cirrótica con fibrosis (COSMOS)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, multicéntrico y en 2 partes para evaluar la eficacia, la seguridad y la tolerabilidad de RGH-706 en el síndrome de Prader-Willi	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase 3, aleatorizado, doble ciego, comparativo con un placebo, para investigar el efecto de tirzepatida sobre la reducción de la morbimortalidad en adultos con obesidad	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2, aleatorizado, controlado con placebo, doble ciego y de búsqueda de dosis para evaluar la eficacia, seguridad y tolerabilidad de AMG 133 en sujetos adultos con sobrepeso u obesidad, con o sin diabetes mellitus tipo 2	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio multicéntrico y transversal para caracterizar la distribución delos niveles de lipoproteína(a) entre pacientes con antecedentes documentados de enfermedad cardiovascular aterosclerótica (ECVA).	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ TINAHONES MADUEÑO	Not applicable
A-02	Ensayo fase IIb, aleatorizado, doble ciego, multicéntrico, comparado con placebo para evaluar eficacia, seguridad y tolerabilidad de AZD2693 en pacientes con esteatohepatitis no alcohólica no cirrótica con fibrosis portadores del alelo de riesgo PNPLA3 rs738409 148M (FORTUNA)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio en fase III, aleatorizado a doble ciego y controlado con placebo: 5 subestudios independientes de setmelanotide en pacientes con defectos en los genes POMC, PCSK1, LEPR, SRC1, SH2B1 o PCSK1 N221D en la vía del receptor 4 de melanocortina	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessingthe Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	I
A-02	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisirán en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1 Prevent).	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2b, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de la efinopegdutida (MK-6024) en adultos con esteatohepatitis no alcohólica precirrótica.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III

Group	Title	Subtype	PI Name	Phase
A-02	Estudio de fase 3, aleatorizado, doble ciego, para investigar la eficacia y seguridad de LY3502970 administrado una vez al día por vía oral en comparación con placebo en participantes adultos con obesidad o sobrepeso con comorbilidades relacionadas con el peso (ATTAIN-1).	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 3, aleatorizado, doble ciego para investigar la eficacia y la seguridad de LY3437943 administrado una vez a la semana en comparación con placebo en participantes con obesidad severa y con enfermedad cardiovascular establecida (TRIUMPH-3).	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio observacional, prospectivo y multicéntrico de práctica clínica real (RWE) para evaluar el grado de adherencia a un programa de soporte nutricional y su relación con el estado nutricional evaluado mediante valoración morfofuncional en pacientes oncológicos desnutridos	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ MANUEL GARCIA ALMEIDA	Not applicable
A-02	Protocolo maestro para investigar la eficacia y la seguirdd del LY3437943 administrado una vez a la semana en participantes con diabetes mellitus de tipo 2 y obesidad o sobrepeso: un estudio aleatorizado, doble ciego y controlado con placebo (TRIUMPH-2)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de MK-0616 para reducir las complicaciones cardiovasculares graves en participantes con riesgo cardiovascular elevado	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo global de fase 3, de grupos paralelos, aleatorizado, prospectivo, intervencionista, doble ciego y multicéntrico para investigar la eficacia y seguridad de finerenona frente a placebo, en adición al tratamiento estándar, en participantes con enfermedad renal crónica asociada a diabetes tipo 1	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de seguridad cardiovascular de fase 3, aleatorizado, doble ciego, de grupos paralelos, basado en eventos con BI 456906 administrado por vía subcutánea en comparación con placebo en participantes con sobrepeso u obesidad con enfermedad cardiovascular (ECV) establecida o enfermedad renal crónica, y/o al menos dos complicaciones relacionadas con el peso o factores de riesgo de ECV	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio en fase II, de grupos paralelos, doble ciego y con tres grupos de tratamiento, para evaluar la eficacia y la seguridad de finerenona más empagliflozina en comparación con finerenona o empagliflozina en participantes con enfermedad renal crónica y diabetes tipo 2 CONFIDENCE	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio para evaluar la eficacia y seguridad de la insulina Icodec de administración semanal al cambiar de insulinas basales diarias en comparación con 100 UI de insulina glargina una vez al día en adultos con diabetes tipo 2	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo Fase III, aleatorizado, doble-ciego, de grupos paralelos y controlado con principio activo para evaluar la eficacia, seguridad y tolerabilidad de Baxdrostat combinado con Dapagliflozina, comparado con Dapagliflozina sola en la progresión de Enfermedad Renal Crónica (ERC) en pacientes con ERC e hipertensión arterial. BaxDUO ARCTIC	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index =27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Eficacia en el control glucémico, la percepción de hipoglucemia, el miedo a la hipoglucemia, la calidad de vida relacionada con la diabetes y la satisfacción de los pacientes con el uso del sistema Dexcom one + como método de monitorización continua de glucosa en pacientes con DM2 y tratamiento con insulina basal o con múltiples dosis de insulina. Estudio Life-One	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	MARÍA JOSÉ PICON CESAR	Not applicable
A-02	Estudio de extensión de fase 3 abierto para evaluar la seguridad y la eficacia de MK-0616 en adultos con hipercolesterolemia.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III

Group	Title	Subtype	PI Name	Phase
A-02	Estudio de fase 3, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de MK-0616 en comparación con ezetimiba o ácido bempedoico o ezetimiba más ácido bempedoico en adultos con hipercolesterolemia	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Label Extension in Patients with Prader-Willi Syndrome.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de búsqueda de dosis de fase 2, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de maridebart cafraglutida en sujetos adultos con diabetes mellitus tipo 2.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio fase IIB, aleatorizado, doble ciego, controlado con placebo y con comparador activo abierto para evaluar la eficacia, seguridad y tolerabilidad de AZD5004 en adultos con diabetes mellitus tipo 2.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase II, aleatorizado, doble ciego y comparativo con placebo para investigar la eficacia y la seguridad de la volenrelaxina en adultos con insuficiencia renal crónica.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Effect of levothyroxine as adjuvant therapy to a hypocaloric diet in the treatment of obesity: a randomized placebo-controlled trial	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo Fase III, aleatorizado, doble-ciego, controlado con placebo, dirigido por eventos para evaluar la eficacia, seguridad y tolerabilidad de Baxdrostat combinado con Dapagliflozina, comparado con Dapagliflozina en monoterapia, en resultados renales y mortalidad cardiovascular en pacientes con Enfermedad Renal Crónica (ERC) e Hipertensión Arterial. (BaxDuo-PACIFIC)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A randomized, double-blind, placebo-controlled phase 2 trial to assess efficacy, safety, and tolerability of ro7204239 in combination with tirzepatide in participants with obesity or overweight with at least one weight-related comorbidity.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Un comparador activo aleatorizado, doble ciego, con placebo y de etiqueta abierta, controlado, Estudio de Fase II multicéntrico, de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de ro7795081 una vez al día administrado durante 30 SEMANAS a participantes con DIABETES MELLITUS TIPO 2	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase III, aleatorizado, doble ciego y comparativo con placebo para investi-gar el efecto de la muvalaplina en la disminución de los episodios cardiovasculares ad-versos graves en adultos con lipoproteína (a) elevada que han tenido un episodio car-diovascular ateroesclerótico previo o que están en riesgo de presentar un primer episo-dio cardiovascular ateroesclerótico – MOVE-Lp(a)	DRUG CLINICAL TRIALS	BALDOMERA MARTINEZ ALFARO	III
A-03	Registro prospectivo, multicéntrico e internacional de pacientes de ambos sexos con diagnóstico recientes de fibrilación auricular (GARFIELD)	INDEPENDENT POSTAUTHORIZATION STUDY	MANUEL FRANCISCO JIMENEZ NAVARRO	Not applicable
A-03	Efectividad de la titulación de fármacos por la enfermera especializada en pacientes de Insuficiencia Cardiaca (IC). Proyecto ETIFIC (Enfermera Titular Fármacos en IC).	INDEPENDENT POSTAUTHORIZATION STUDY	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Evaluación de la eficacia de la Atorvastatina en la progresión de la dilatación aórtica y la degeneración valvular en pacientes con válvula aórtica bicúspide (BICATOR)	INDEPENDENT CLINICAL TRIAL	JUAN MANUEL ROBLEDO CARMONA	III
A-03	Ensayo prospectivo de INRA frente a inhibidor de la ECA para determinar la superioridad en reducir los acontecimientos de insuficiencia cardíaca tras infarto de miocardio. Estudio multicéntrico, aleatorizado, doble ciego, controlado con tratamiento activo, de grupos paralelos, de fase 3 para evaluar la eficacia y seguridad de LCZ696 comparado con ramipril en la morbimortalidad en pacientes de alto riesgo tras un infarto agudo de miocardio. PARADISE-MI:	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Non-vitamin K antagonist Oral anticoagulants in patients with Atrial high rate episodes	INDEPENDENT CLINICAL TRIAL	JUAN JOSÉ GOMEZ DOBLAS	III
A-03	Registro Español de pacientes portadores de dispositivos cardiacos implantables que requieran una prueba de imagen diagnóstica con Resonancia Magnética Nuclear	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	ALBERTO BARRERA CORDERO	Not applicable
A-03	Estudio no intervencionista sobre el tratamiento con edoxabán en la práctica clínica habitual para pacientes con fibrilación auricular no valvular (ETNA-AF-Europe)	COMMERCIAL POST-AUTHORIZATION STUDY	JUAN JOSÉ GOMEZ DOBLAS	Not applicable
A-03	Eficacia de la transposición de un pedículo adiposo pericárdico sobre el infarto de miocardio en pacientes (AGTP II trial).)	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	MANUEL FRANCISCO JIMENEZ NAVARRO	Not applicable

Group	Title	Subtype	PI Name	Phase
A-03	LCZ696 en pacientes con insuficiencia cardiaca con fracción de eyección deprimida y elevada comorbilidad: efecto en el remodelado y fibrosis de ventrículo izquierdo valorado por nuevos biomarcadores de insuficiencia cardiaca y resonancia magnética cardíaca.	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	IV
A-03	Tratamiento de la fibrilación auricular en pacientes con hipertensión arterial que son tratados por ablación venosa pulmonar en combinación y con la denervación arterial renal o solo ablación venosa pulmonar. Estudio ASAF	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	ALBERTO BARRERA CORDERO	Not applicable
A-03	Estudio observacional retrospectivo del uso de evolocumab en unidades españolas de cardiología - RETrospective Observational Study of Evolocumab Use in Spanish Cardiology Units RETOSS-Cardio. 20160139	COMMERCIAL POST-AUTHORIZATION STUDY	ELOY CARLOS RUEDA CALLE	Not applicable
A-03	Crioablación de venas pulmonares vs fármacos antiarrítmicos en fibrilación auricular persistente (CRAFT)	INDEPENDENT CLINICAL TRIAL	ALBERTO BARRERA CORDERO	IV
A-03	Registro prospectivo, de brazo único, multicéntrico, observacional, de utilización de stent liberador de zotarolimus RESOLUTE-ONYX™ en el intervencionismo coronario percutáneo en vasos pequeños	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	Estudio de seguridad post autorización PASS: estudio observacional de cohorte con pacientes HAP tratados por primera vez con Uptravi selexipag u otra terapia específica contra la hipertensión arterial pulmonar HAP en la práctica clínica. EXPOSURE, AC-065A401	COMMERCIAL POST-AUTHORIZATION STUDY	VÍCTOR MANUEL BECERRA MUÑOZ	Not applicable
A-03	Registro Observacional prospectivo de pacientes con implante de stent bioabsorbible de magnesio MAGMARIS ES en la práctica clínica habitual	NON-POST-APPROVAL STUDY	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	Observación de la Asistencia Clínica Habitual en los pacientes con insuficiencia cardiaca y dispositivos de TRC BIOTRONIK implantados	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	ALBERTO BARRERA CORDERO	Not applicable
A-03	Beneficio del bloqueo del sistema renina-angiotensina sobre la evolución clínica y el remodelado ventricular tras la colocación de una prótesis percutánea aórtica	INDEPENDENT CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	IV
A-03	Evaluación de seguridad y comportamiento eléctrico de las sondas INVICTA equipadas con conector DF4. FRIENDS	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	ALBERTO BARRERA CORDERO	Not applicable
A-03	Insuficiencia cardíaca Reducción de eventos con Monitorización Remota y Soporte de Salud Iniciada por el investigador. (Heart failure Events reduction with Remote Moni toring and eHealth Support Investigator Initiated Trial)	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Estudio sobre la PRevalencia de Amiloidosis Cardiaca por Transtiretina en pacientes con Insuficiencia CArdiaca con fracción de eyección preservada. Estudio PRACTICA	NON-POST-APPROVAL STUDY	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Registo Prospectivo observacional de pacientes con enfermedad de Fabry. Código Promotor: AT1001-030 Estudio Amicus FollowMe	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Estudio multicntrico, aleatorizado, doble ciego (paciente e investigador) y controlado con placebo para estudiar la eficacia de sacubitrilo/valsartán por vía oral en pacientes adultos con miocardiopatía hipertrófica no obstructiva (MCH no obstructiva).	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	II
A-03	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de vutrisirán en pacientes con amiloidosis cardiaca por transtiretina (amiloidosis por ATTR con miocardiopatía). HELIOS-B.	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Estudio observacional de terapias inapropiadas tras recambio de DAI. Estudio OSIRIS	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	AMALIO RUIZ SALAS	Not applicable
A-03	COVID-19 en pacientes con insuficicnecia cardiaca y cardiopatías familiares. CDC	INDEPENDENT POSTAUTHORIZATION STUDY	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Un registro multicéntrico para evaluar la calidad del tratamiento antitrombótico en pacientes con fibrilación auricular y cáncer activo. Registro CANAC-FA (CÁNcer ACtivo y Fibrilación Auricular):	INDEPENDENT POSTAUTHORIZATION STUDY	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Seguridad y rendimiento de las Sondas DF4 ventriculares invicta con fijación activa. Estudio APOLLO	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	ALBERTO BARRERA CORDERO	Not applicable

Group	Title	Subtype	PI Name	Phase
A-03	Ensayo clínico multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para evaluar la eficacia y la seguridad de finerenona sobre la morbilidad y la mortalidad en participantes con insuficiencia cardíaca (NYHA II-IV) y fracción de eyección del ventrículo izquierdo =40 % (FEVI =40 %).	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Estudio observacional para evaluar el beneficio clínico neto del edoxabán en pacientes con fibrilación auricular no valvular, según la práctica clínica habitual en España Registro BENEFIT.Observational study to evaluate the Net Clinical Benefit of edoxaban in non-valvular Atrial Fibrillation patients, according to the routine clinical practice in Spain BENEFIT Registry	COMMERCIAL POST-AUTHORIZATION STUDY	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Registro Observacional Prospectivo de Pacientes con Insuficiencia Cardíaca	INDEPENDENT POSTAUTHORIZATION STUDY	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Dapagliflozina después del implante de prótesis valvular aórtica percutánea. DAPATAVI	INDEPENDENT CLINICAL TRIAL	ANTONIO JESÚS MUÑOZ GARCIA	III
A-03	Eficacia y Seguridad de la Furosemida Intravenosa administrada con Suero Salino Hipertónico en el Hospital de día de Insuficiencia Cardiaca. Estudio SSH-IC	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	IV
A-03	Impacto de DAPAGLIFOZINA en el remodelado auricular de pacientes con insuficiencia cardiaca: MODA study.	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Registo prospectivo, de brazo único, multicéntrico, observacional para la evaluación de la seguridad y eficacia del Stent Ultimaster Tnasei en pacientes con lesiones coronarias complejas. Estudio TANSEI	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	Estudio de resultados clínicos del NVT ALLEGRA TAVI System TF en pacientes tratados con válvulas aórticas calcificadas en la vida real en una población de pacientes con riesgo quirúrgico elevado (FOLLOW)	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	OpSens dPR para la evaluación fisiológica de lesiones coronarias iintermedias en estenosis aórtica.	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	Estudio de fase 2b, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento por vía oral con AZD9977 y dapagliflozina en pacientes con insuficiencia cardíaca (con fracción de eyección del ventrículo izquierdo por debajo del 55%) y nefropatía crónica (MIRACLE)	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	II
A-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de la eficacia y seguridad del espray nasal de etripamil para la resolución de episodios espontáneos de taquicardia supraventricular paroxística. El estudio RAPID (NODE-301 Parte 2)	COMMERCIAL CLINICAL TRIAL	MARÍA DEL CARMEN MEDINA PALOMO	III
A-03	Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria	INDEPENDENT CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	IV
A-03	Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo queevalúa el impacto de inclisirán en los acontecimientos cardiovascularesadversos mayores (MACE) en participantes con enfermedad cardiovascularestablecida (ECV) (VICTORION-2 PREVENT)	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo de FDY-5301 intravenoso en pacientes con infarto de miocardio con elevación del segmento ST anterior. IOCYTE AMI-3	COMMERCIAL CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	III
A-03	Tratamiento cardiovascular y renal en pacientes con insuficiencia cardíaca con hiperpotasemia o con alto riesgo de hiperpotasemia (CARE-HK en el registro de IC)	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Estudio en fase III, prospectivo, aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos y flexible con ampliación abierta para evaluar la eficacia y la seguridad de macitentán 75 mg en la hipertensión pulmonar tromboembólica crónica inoperable o persistente/recurrente.Macitentán en la hipertensión pulmonar tromboembólica crónica inoperable o persistente/recurrente (MACiTEPH)	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL BECERRA MUÑOZ	III
A-03	Retirada de tratamiento farmacologico en pacientes respondedores a terapia de resincronización cardiaca: Estudio abierto y aleatorizado	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	IV
A-03	Registro prospectivo del stent ihtDESTiny en práctica clínica habitual(Estudio VELAZQUEZ)	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JUAN HORACIO ALONSO BRIALES	Not applicable

Group	Title	Subtype	PI Name	Phase
A-03	Inicio temprano de tratamiento con Candesartan vs Placebo en portadores genéticos de mutaciones causales de MCD sin evidencia de enfermedad (EARLY-GENE trial).	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCIA PINILLA	III
A-03	SEC-FA-2022-1 Registro SEC - EXCELENTE FA: una herramienta para la mejora de la calidad de la atención médica a pacientes con fibrilación auricular en España.	OBSERVATIONAL STUDY WTIH MEDICINES	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Estudio de fase 2, doble ciego, aleatorizado, controlado con placebo, de 4 grupos para estudiar los síntomas, la funcionalidad, la calidad de vida relacionada con la salud y la seguridad de la administración subcutánea repetida de ponsegromab comparado con placebo en participantes adultos con insuficiencia cardíaca.	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	II
A-03	Estudio de fase 2, aleatorizado, con enmascaramiento doble, comparativo con un placebo, para investigar la eficacia y la seguridad de LY3540378 en adultos con empeoramiento de la insuficiencia cardíaca crónica con fracción de eyección preservada (ICFEp)	DRUG CLINICAL TRIALS	JUAN JOSÉ GOMEZ DOBLAS	II
A-03	Plan de investigación de seguimiento clínico de poscomercialización (PMCF) para evaluar la seguridad y efectividad clínica de los dispositivos iVascular para el tratamiento de las enfermedades coronarias	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	SAvvyWire™ Eficacia y seguridad en los procedimientos de implantación transcatéter de válvulas aórticas.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ANTONIO JESÚS MUÑOZ GARCIA	Not applicable
A-03	Ensayo fase III multicéntrico, internacional, aleatorizado, controlado con un comparador activo, doble ciego, con doble simulación y 2 grupos paralelos, para comparar la eficacia y la seguridad del inhibidor oral de FXIa asundexian (BAY 2433334) con apixaban para la prevención del ictus o embolia sistémica en participantes masculinos y femeninos de 18 años o más con fibrilación auricular y riesgo de ictus.	DRUG CLINICAL TRIALS	ALEJANDRO ISIDORO PEREZ CABEZA	III
A-03	Estudio preliminar en fase IIa, abierto para evaluar la eficacia, la farmacocinética, la farmacodinámica, la seguridad y la tolerabilidad de MYK-224 en participantes con miocardiopatía hipertrófica sintomática y obstrucción del conducto de salida del ventrículo izquierdo	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	II
A-03	Tratamiento antiplaquetario único con ticagrelor frente a aspirina después del implante percutáneo de válvula aórtica: ensayo clínico aleatorizado multicéntrico. REAC TAVI 2	DRUG CLINICAL TRIALS	ANTONIO JESÚS MUÑOZ GARCIA	IV
A-03	Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies.	DRUG CLINICAL TRIALS	JUAN JOSÉ GOMEZ DOBLAS	III
A-03	Seguimiento clínico retrospectivo, prospectivo y multicéntrico de pacientes con regurgitación tricúspidea severa tras tratamiento con el sistema de válvulas bicavales transcatéter TricValveTRICUS REGISTRY	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	Estudio clínico aleatorizado, doble ciego y controlado con placebo para evaluar mavacamten en adultos con cardiomiopatía hipertrófica sintomática no obstructiva	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	New pathophysiological pathways involved in iron metabolism disorder in hear failure: The IRON PATH II investigator initiated Study.	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Diferencias de género en el manejo temprano y posterior al alta después de un infarto agudo de miocardio - genami prevention.	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN JOSÉ GOMEZ DOBLAS	Not applicable
A-03	Estudio en fase IV, de doble ciego, controlado con placebo, de retirada aleatorizada, para evaluar el uso de ciclosilicato de sodio y zirconio (CSZ) para el tratamiento de la hiperpotasemia en pacioentes con insuficiencia cardíaca sintomática con fracción de eyección reducida y que reciben espironolactona (REALIZE-K).	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	IV
A-03	Prevalencia en España de mal control de la anticoagulación en pacientes con fibrilación auricular 'no valvular' tratados con antagonistas de la Vitamina K. (20230228)	OBSERVATIONAL STUDY WTIH MEDICINES	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y motivado por los acontecimientos para demostrar la eficacia y seguridad de milvexian, un inhibidor oral del factor XIa, después de padecer un síndrome coronario agudo reciente	DRUG CLINICAL TRIALS	MANUEL FRANCISCO JIMENEZ NAVARRO	III
A-03	Estudio prospectivo, aleatorizado, multicéntrico, abierto, guiado por eventos, para evaluar la no inferioridad de una estrategia personalizada de precisión para la prevención de la muerte súbita en pacientes con miocardiopatía dilatada no isquémica. ESTUDIO CIBER-SPANISH I.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JOSÉ MANUEL GARCIA PINILLA	Not applicable

Group	Title	Subtype	PI Name	Phase
A-03	Estudio aleatorizado, simple ciego, para demostrar la seguridad y la eficacia de la terapia corticosteroidea a altas dosis para tratar pacientes con miocarditis aguda complicada/fulminante. (Single blind randomized controlled trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant acute myocarditis)	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Estudio de seguridad posterior a la autorización (PASS): Revisiónretrospectiva de las historias clínicas de los pacientes con HAP tratados recientemente con Uptravi®(selexipag) o cualquier otro tratamiento específico para la HAP	OBSERVATIONAL STUDY WTIH MEDICINES	VÍCTOR MANUEL BECERRA MUÑOZ	Not applicable
A-03	VIVA Estudio pivotal/de viabilidad de primera aplicación en seres humanos (PASH) en dos fases del sistema autoexpandible de válvula aórtica Vienna	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation	DRUG CLINICAL TRIALS	JUAN JOSÉ GOMEZ DOBLAS	III
A-03	Registro PERSEO: Prevención de eventos Embólicos tras una hemoRragia SEvera en pacientes anticoagulados con fibrilaciOn auricular.	OBSERVATIONAL STUDY WTIH MEDICINES	ALEJANDRO ISIDORO PEREZ CABEZA	Not applicable
A-03	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaLuar la efIcacia y la seguridad de abeLacimab en pacientes de alto riesgo con fibrilación Auricular que no se consideren adecuados para la antiCoagulación oral (LILAC)	DRUG CLINICAL TRIALS	JUAN JOSÉ GOMEZ DOBLAS	III
A-03	Estudio en fase 2ª, multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo y de grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de JTT-861 administrado durante 12 semanas en pacientes con insuficiencia cardíaca con fracción de eyección reducida (POWER-HF)	DRUG CLINICAL TRIALS	JUAN JOSÉ GOMEZ DOBLAS	II
A-03	Estudio de prueba de concepto y búsqueda de dosis, multicéntrico, aleatorizado, con control activo y placebo, de grupos paralelos y de 24 semanas de duración en el que se evalúan la eficacia, la seguridad y la tolerabilidad de XXB750 en pacientes con insuficiencia cardíaca	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	II
A-03	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Estudio de fase 2, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la seguridad y la eficacia de tovinontrina en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	II
A-03	Título del Estudio: Predicción de riesgo de cardiotoxicidad en las unidades de cardiooncología. Valor de la genética y diferentes biomarcadores. El registro CARDIOTOX	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN JOSÉ GOMEZ DOBLAS	Not applicable
A-03	Estudio de fase 3, multinacional, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de NTLA-2001 en participantes con amiloidosis por transtiretina con miocardiopatía (ATTR-CM)	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Plan de investigación de seguimiento poscomercialización (PMCF) para evaluar la seguridad y efectividad del dispositivo liberador de paclitaxel SEQUENT PLEASE NEO en pacientes con enfermedad arterial coronaria	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	Uso clínico y seguridad de Vericiguat (agonista oral de la guanilato ciclasa) en la práctica clínica real. Estudio observacional con medicamentos prospectivo.	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Resultados isquémicos y hemorrágicos tras la implantación del stent angiolite y una terapia antiplaquetaria dual abreviada. Un ensayo controlado aleatorizado, multicéntrico, factorial 2x2, de todos los participantes elegibles (allcomers) Angiodapt.”	DRUG CLINICAL TRIALS	JUAN HORACIO ALONSO BRIALES	III
A-03	A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF).	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	II

Group	Title	Subtype	PI Name	Phase
A-03	Encuesta Europea sobre prevención de enfermedades cardiovasculares, diabetes y enfermedad renal crónica	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN JOSÉ GOMEZ DOBLAS	Not applicable
A-03	Seguimiento clínico post-comercialización de los sistemas con dispositivo cardíaco electrónico implantable de MicroPort CRM (PIANO)	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	MARÍA DEL CARMEN MEDINA PALOMO	Not applicable
A-03	Riesgo cardiovascular de la población atendida por cardiólogos en España.	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN JOSÉ GOMEZ DOBLAS	Not applicable
A-03	Estudio clínico de fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ovinontrina en pacientes con insuficiencia cardíaca crónica con fracción de eyección conservada.	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	II
A-03	EASi-HF - Ensayo de fase III de superioridad, doble ciego, aleatorizado y con grupos paralelos para evaluar la eficacia y la seguridad del uso combinado de BI 690517 por vía oral y empagliflozina en comparación con placebo y empagliflozina en participantes con insuficiencia cardíaca sintomática (IC: clases II-IV de la NYHA) y fracción de eyección ventricular izquierda (FEVI) =40 %	DRUG CLINICAL TRIALS	MANUEL FRANCISCO JIMENEZ NAVARRO	III
A-03	Estudio no intervencionista sobre el tratamiento con ácido bempedoico y/o su combinación de dosis fija con ezetimiba en la práctica clínica habitual en pacientes con hipercolesterolemia primaria o dislipidemia mixta (MILOS)	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN JOSÉ GOMEZ DOBLAS	Not applicable
A-03	A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (ACACIA)	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Estudio de extensión abierto para evaluar la seguridad y la eficacia de vutrisirán en pacientes con amiloidosis cardiaca por transtiretina (amiloidosis por ATTR con miocardiopatía).	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Reparación temprana de la válvula mitral transcatéter después de un infarto de miocardio	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JUAN HORACIO ALONSO BRIALES	Not applicable
A-03	Estudio multicéntrico prospectivo no aleatorizado, de una cohorte no seleccionada de pacientes con diagnóstico de amiloidosis cardiaca por transtiretina que inicien tratamiento diario con tafamidis 61 mg.	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtagliflozin in symptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Estudio de correlación del grado de congestión en insuficiencia cardiaca con el dispositivoEstudio de correlación del grado de congestión en insuficiencia cardiaca con el dispositivoSENSOCOR.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y basado en eventos para evaluar el efecto de Baxdrostat combinado con dapagliflozina en comparación con dapagliflozina sola sobre el riesgo de insuficiencia cardíaca incidente y muerte cardiovascular en pacientes con alto riesgo de desarrollar insuficiencia cardíaca.	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Eficacia y seguridad combinadas de una estrategia de tratamiento intensiva con finerenona y un inhibidor de SGLT2 en pacientes hospitalizados con insuficiencia cardíaca (CONFIRMATION-HF).	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	Aislamiento ampliado de venas pulmonares en pacientes sometidos a ablación de fibrilación auricular con técnica single-shot: el estudio wider-pvi.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	AMALIO RUIZ SALAS	Not applicable
A-03	Registro Cardiasept España. Resultados a corto y medio plazo del dispositivo de cierre de Foramen Oval permeable Cardia Ultrasept	OBSERVATIONAL STUDY WTIH MEDICINES	ANTONIO JESÚS DOMINGUEZ FRANCO	Not applicable
A-03	Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Re-duced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	II
A-03	Providing information on hypertrophic cardiomyopathy and observational outcomes in the real world (DISCOVER-HCM): European Prospective Registry Regional Study.	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ MANUEL GARCIA PINILLA	Not applicable
A-03	Estrategia de descongestión guiada por ReDS en pacientes hospitalizados por insuficiencia cardíaca: el estudio ReDS-SAFE HF II	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	AINHOA ROBLES MEZCUA	Not applicable

Group	Title	Subtype	PI Name	Phase
A-03	EASi-HF reduced – Ensayo de superioridad de fase III, doble ciego, aleatorizado y con grupos paralelos para evaluar la eficacia y la seguridad del uso combinado del vicadrostat (BI 690517) y la empagliflozina por vía oral en comparación con un placebo y la empagliflozina en participantes con insuficiencia cardíaca crónica sintomática (IC: grado II-IV de la clasificación de la NYHA) y una fracción de eyección ventricular izquierda (FEVI) <40	DRUG CLINICAL TRIALS	MANUEL FRANCISCO JIMENEZ NAVARRO	III
A-03	A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF).	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event.	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN JOSÉ GOMEZ DOBLAS	Not applicable
A-03	Evaluación de la investigación de seguimiento y sin enmascaramiento del tratamiento continuado con aficamten (CK3773274) en pacientes con miocardiopatía hipertrófica (MH)	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	PulseSelect™ PFA Global Registry (Registro PulseSelect) Producto Sanitario: PulseSelect™ PFA System	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ALBERTO BARRERA CORDERO	Not applicable
A-03	Efecto de la suplementación con vitamina D sobre la fibrosis miocárdica en pacientes con miocarditis aguda(EDITAM): un ensayo controlado aleatorio, multicéntrico y abierto.	DRUG CLINICAL TRIALS	AINHOA ROBLES MEZCUA	III
A-03	Encuesta de Recogida de Datos Clínicos Agregados sobre el sistema de ablación mediante campos electromagnéticos pulsados (PFA) PulseSelect™ de Medtronic (SELECT-PF Clinical Survey)	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ALBERTO BARRERA CORDERO	Not applicable
A-03	(Ensayo EASThigh-AFNET 11) Un ensayo temprano de ablación por fibrilación para la prevención de accidentes cerebrovasculares en pacientes con una alta carga de comorbilidad: un ensayo de estrategia terapéutica, multicéntrico, no comercial, de grupos paralelos, prospectivo, aleatorizado, abierto y ciego, con evaluación de criterios de valoración (PROBE)	OBSERVATIONAL STUDY WTIH MEDICINES	ALBERTO BARRERA CORDERO	Not applicable
A-03	CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-03	MAVERICS™ coronary revascularization study. Prospective single-arm feasibility study for bypassing severely diseased coronary arteries with the MAVERICS graft in subjects who cannot undergo conventional CABG due to lack of suitable conduits. MAVERICS	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	GEMMA SANCHEZ ESPIN	Not applicable
A-03	Prospective Observacional Trial for a Cardiac Rehabilitation eHealth application in post-ACS patientes (Rehab+)	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN JOSÉ GOMEZ DOBLAS	Not applicable
A-03	Estudio pragmático, aleatorizado, doble ciego y controlado con placebopara evaluar la seguridad y la eficacia clínica de la finerenona enpacientes con insuficiencia cardíaca y fracción de eyección reducida queson intolerantes o no son aptos para el tratamiento con antagonistasesteroideos del receptor de mineralocorticoides (FINALITY-HF)	DRUG CLINICAL TRIALS	JOSÉ MANUEL GARCIA PINILLA	III
A-06	Prevención temprana de complicaciones por diabetes en personas con hiperglucemia en Europa (e-PREDICE)	INDEPENDENT CLINICAL TRIAL	RICARDO GOMEZ HUELGAS	III
A-06	Registro de pacientes con enfermedad del Hígado graso no alcohólico	NON-POST-APPROVAL STUDY	SERGIO JANSEN CHAPARRO	Not applicable
A-06	Cribado de la enfermedad de Pompe de inicio tardío mediante muestra de sangre seca de pacientes provenientes de Unidades de Medicina Interna. Estudio POMPE	NON-POST-APPROVAL STUDY	IVÁN PEREZ DE PEDRO	Not applicable
A-06	Estudio de seguridad post autorización PASS: estudio observacional de cohorte con pacientes HAP tratados por primera vez con Uptravi selexipag u otra terapia específica contra la hipertensión arterial pulmonar HAP en la práctica clínica. EXPOSURE, AC-065A401	COMMERCIAL POST-AUTHORIZATION STUDY	MARÍA DEL MAR AYALA GUTIERREZ	Not applicable
A-06	Registro de la Sociedad española de Medicina Interna (SEMI) de pacientes hospitalizados por COVID-19	NON-POST-APPROVAL STUDY	RICARDO GOMEZ HUELGAS	Not applicable

Group	Title	Subtype	PI Name	Phase
A-06	Prevención de infección por COVID19 mediante administración de hidroxicloroquina en mayores institucionalizados y personal asistencial de residencias. Ensayo clínico controlado, abierto y aleatorizado escalonado (stepped-wedge) por clusters. CDC	INDEPENDENT CLINICAL TRIAL	RICARDO GOMEZ HUELGAS	III
A-06	Efectos de semaglutida sobre la capacidad funcional en pacientes con diabetes tipo 2 y arteriopatía periférica	COMMERCIAL CLINICAL TRIAL	MARÍA DOLORES LOPEZ CARMONA	III
A-06	Seguridad de edoxabán en pacientes con fibrilación auricular no valvular (FANV) y diabetes mellitus tipo 2 (DM2). SEMI-FADIA-2020	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA GUIL GARCIA	Not applicable
A-06	Valoración del manejo y adecuación del tratamiento antitrombótico de los pacientes con Fibrilación Auricular No Valvular que ingresan en los Servicios de Medicina Interna de España.	COMMERCIAL POST-AUTHORIZATION STUDY	MARÍA GUIL GARCIA	Not applicable
A-06	Estudio de fase IV, multicéntrico, aleatorizado, doble ciego y controlado con placebo de la eficacia, seguridad, tolerabilidad y calidad de vida de un tratamiento en curso hipolipemiante, optimizado individualmente, con o sin inclisirán (KJX839), en participantes con hipercolesterolemia.	COMMERCIAL CLINICAL TRIAL	SERGIO JANSEN CHAPARRO	IV
A-06	Estrategias de control y estudio farmacogenético para el tratamiento personalizado del hígado graso asociado a disfunción metabólica en pacientes con prediabetes.	INDEPENDENT CLINICAL TRIAL	RICARDO GOMEZ HUELGAS	III
A-06	Estudio de fase II, prospectivo, en doble ciego, aleatorizado, de grupos paralelos, controlado con placebo y multicéntrico, para investigar la eficacia, el efecto neutralizador de los autoanticuerpos frente a los receptores acoplados a la proteína G (GPCR), la seguridad y la tolerabilidad del BC 007 en participantes con COVID-19 persistente	DRUG CLINICAL TRIALS	RICARDO GOMEZ HUELGAS	II
A-06	Evaluación de la seguridad de Edoxabán en pacientes ancianos con criterios de fragilidad	OBSERVATIONAL STUDY WTIH MEDICINES	RICARDO GOMEZ HUELGAS	Not applicable
A-06	Estudio muilticéntrico, aleatoriazdo, doble ciegoy controlado con placebo ene l que se evalúa el efecto de inclisirán en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-PREVENT)	DRUG CLINICAL TRIALS	SERGIO JANSEN CHAPARRO	III
A-06	Estudio observacional retrospectivo para describir las características y resultados clínicos de pacientes con Lupus Eritematoso Sistémico que iniciaron Saphnelo (anifrolumab) en un entorno en vida real. D3461R00080 AZAHAR	OBSERVATIONAL STUDY WTIH MEDICINES	CARLOS ROMERO GOMEZ	Not applicable
A-06	Estudio no intervencionista sobre el tratamiento con ácido bempedoico y/o su combinación de dosis fija con ezetimiba en la práctica clínica habitual en pacientes con hipercolesterolemia primaria o dislipidemia mixta (MILOS)	OBSERVATIONAL STUDY WTIH MEDICINES	SERGIO JANSEN CHAPARRO	Not applicable
A-06	Estudio de fase III, aleatorizado, doble ciego y comparativo con placebo para investigar el efecto de la muvalaplina en la disminución de los episodios cardiovasculares adver-sos graves en adultos con lipoproteína (a) elevada que han tenido un episodio cardio-vascular ateroesclerótico previo o que están en riesgo de presentar un primer episodio cardiovascular ateroesclerótico – MOVE-Lp(a)	DRUG CLINICAL TRIALS	RICARDO GOMEZ HUELGAS	III
A-09	Revisión observacional en serie de historias clínicas del uso de Repath® en sujetos europeos con hiperlipidemia (20130296)	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL SANCHEZ CHAPARRO	Not applicable
A-09	Manejo del paciente dislipémico pre-diabético en las unidades de lípidos. Estudio PRELIPID	INDEPENDENT POSTAUTHORIZATION STUDY	MIGUEL ÁNGEL SANCHEZ CHAPARRO	Not applicable
A-09	Registro informatizado de la enfermedad tromboembólica (RIETE)	NON-POST-APPROVAL STUDY	RADKA IVANOVA GEORGIEVA	Not applicable
A-09	Estudio multicéntrico sobre comorbilidad no infecciosa e inmunodeficiencia común variable	INDEPENDENT POSTAUTHORIZATION STUDY	JUAN LUIS CARRILLO LINARES	Not applicable
A-09	Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar el efecto de la disminución de la lipoproteína (a) con TQJ230 sobre los acontecimientos cardiovasculares mayores en pacientes con enfermedad cardiovascular (ECV) establecida.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL SANCHEZ CHAPARRO	III
A-09	Estudio multicéntrico, aleatorizado y de dos partes (inclisirán doble ciego frente a placebo [año 1] y a continuación inclisirán abierto [año 2]) para evaluar la seguridad, tolerabilidad y eficacia de inclisirán en adolescentes (de 12 a menos de 18 años de edad) con hipercolesterolemia familiar heterocigótica y colesterol LDL elevado (ORION-16).	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL SANCHEZ CHAPARRO	III

Group	Title	Subtype	PI Name	Phase
A-09	Estudio de seguridad posterior a la autorización y registro de producto de WAYLIVRA. (WAY4001)	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA COCA PRIETO	Not applicable
A-09	Seguridad de edoxabán en pacientes con fibrilación auricular no valvular (FANV) y diabetes mellitus tipo 2 (DM2). SEMI-FADIA-2020	INDEPENDENT POSTAUTHORIZATION STUDY	M.ª JOSÉ BENITEZ TOLEDO	Not applicable
A-09	Valoración del manejo y adecuación del tratamiento antitrombótico de los pacientes con Fibrilación Auricular No Valvular que ingresan en los Servicios de Medicina Interna de España.	COMMERCIAL POST-AUTHORIZATION STUDY	M.ª JOSÉ BENITEZ TOLEDO	Not applicable
A-09	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	CARLOS CRUZ COSME	Not applicable
A-09	Estudio de fase 3, aaleatorizado, doble ciego, controlado con placebo, de olezarsen (ISIS678354) asministrado por vía subcutánea a pacientes con hipertrigliceridemia grave.	DRUG CLINICAL TRIALS	INMACULADA COCA PRIETO	III
A-09	Estudio de fase III, aleatorizado, doble ciego, comparativo con placebo, de olezarsén (ISIS 679354) en pacientes con hipertrigliceridemia y enfermedad cardiovascular ateroesclerótica (establecida o con mayor riesgo de ella), o con hipertrigliceridemia grave	DRUG CLINICAL TRIALS	INMACULADA COCA PRIETO	III
A-09	Estudio de fase 2b, multinacional, aleatorizado y doble ciego para investigar la eficacia y la seguridad de redasemtide (S-005151) comparado con placebo en pacientes mayores de edad con ictus isquémico agudo que no son candidatos a tratamiento con activador tisular del plasminógeno o trombectomía.	DRUG CLINICAL TRIALS	ALEJANDRO GALLARDO TUR	II
A-09	Estudio de extensión abierto de Olezarsen (ISIS 678354) administrado por vía subcutánea a pacientes con hipertrigliceridemia grave	DRUG CLINICAL TRIALS	INMACULADA COCA PRIETO	III
A-09	Estudio aleatorizado, doble ciego con doble enmascaramiento y grupos paralelos en el que secompara la eficacia y seguridad de remibrutinib frente a teriflunomida en participantes con esclerosismúltiple recurrente, seguido de una extensión abierta del tratamiento con remibrutinib.	DRUG CLINICAL TRIALS	CARLOS CRUZ COSME	III
A-09	Un ensayo clínico fase IV adaptativo, multicéntrico, controlado, aleatorizado y simple ciego para evaluar la efecacia, seguridad y coste eficacia de una estrategia de fenotipado anticipado en una población en riesgo de enfermedad cardiovascular y susceptible de recibir de estatinas de alta o moderada intensidad.	DRUG CLINICAL TRIALS	INMACULADA COCA PRIETO	IV
A-09	Estudio no intervencionista sobre el tratamiento con ácido bempedoico y/o su combinación de dosis fija con ezetimiba en la práctica clínica habitual en pacientes con hipercolesterolemia primaria o dislipidemia mixta (MILOS)	OBSERVATIONAL STUDY WTIH MEDICINES	MIGUEL ÁNGEL SANCHEZ CHAPARRO	Not applicable
A-09	Ensayo de extensión multicéntrico, abierto y de un único grupo para evaluar la seguridad y la tolerabilidad a largo plazo de pelacarsén (TQJ230) en participantes que hayan completado el ensayo principal Lp(a) HORIZON.	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL SANCHEZ CHAPARRO	III
A-09	Estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y eficacia de KarXT + KarX-EC para el tratamiento de la agitación asociada a la enfermedad de Alzheimer (ADAGIO-1)	DRUG CLINICAL TRIALS	CARLOS CRUZ COSME	III
A-09	A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer's Disease (ADAGIO-3)	DRUG CLINICAL TRIALS	CARLOS CRUZ COSME	III
A-11	Estudio posautorización de seguridad multicéntrico y no intervencionista de 6 años de duración realizado en pacientes a los que se ha recetado JINARC debido a poliquistosis renal autosómica dominante. Estudio 156-12-299	COMMERCIAL POST-AUTHORIZATION STUDY	MARÍA DOLORES MARTINEZ ESTEBAN	Not applicable
A-11	Impacto de los niveles de tacrólimus en la prevención del rechazo en pacientes de edad avanzada receptores de trasplante renal de novo: estudio observacional prospectivo en las condiciones de la práctica clínica habitual. Estudio BITÁCORA	COMMERCIAL POST-AUTHORIZATION STUDY	VERÓNICA LOPEZ JIMENEZ	Not applicable
A-11	Estudio de fase II, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de ravulizumab en participantes adultos con nefritis lúpica (NL) proliferativa o nefropatía por inmunoglobulina A (NIgA)	COMMERCIAL CLINICAL TRIAL	REMEDIOS TOLEDO ROJAS	II
A-11	Desarrollo y validación de la escala Neuro-Score for Transplanted Patients para la detección del deterioro cognitivo en pacientes con trasplante renal o hepático tratados con inmunosupresores	NON-POST-APPROVAL STUDY	VERÓNICA LOPEZ JIMENEZ	Not applicable

Group	Title	Subtype	PI Name	Phase
A-11	Prevalencia de fragilidad en pacientes con enfermedad renal crónica en lista de espera de trasplante renal en España: un estudio multicéntrico	COMMERCIAL POST-AUTHORIZATION STUDY	VERÓNICA LOPEZ JIMENEZ	Not applicable
A-11	Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico: estudio prospectivo, controlado y aleatorizado de grupos paralelos (TRAINING)	INDEPENDENT CLINICAL TRIAL	VERÓNICA LOPEZ JIMENEZ	IV
A-11	Estudio prospectivo observacional para evaluar el cambio en la calidad de vida relacionada con la salud y la productividad laboral en pacientes con síndrome hemolítico urémico atípico primario tratados con eculizumab y cambian a ravulizumab en España. Estudio PROMET-SHUa.	OBSERVATIONAL STUDY WTIH MEDICINES	VERÓNICA LOPEZ JIMENEZ	Not applicable
A-11	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de LNP023 en pacientes con nefropatía por IgA primaria. APPLAUSE	DRUG CLINICAL TRIALS	REMEDIOS TOLEDO ROJAS	III
A-11	Estudio de fase II, aleatorizado, doble ciego y controlado con placebo de búsqueda de dosis para evaluar la eficacia y la seguridad de ALXN2050 en participantes adultos con nefritis lúpica (NL) proliferativa o nefropatía por inmunoglobulina A (NIgA).	DRUG CLINICAL TRIALS	REMEDIOS TOLEDO ROJAS	II
A-11	Estudio aleatorizado, doble ciego, controlado con placebo de ALE.F02 administrado por vía intravenosa para evaluar la seguridad, la tolerabilidad, la farmacocinética y la preservación renal en la vasculitis asociada con anticuerpos citoplasmáticos antineutrófilos con glomerulonefritis rápidamente progresiva	DRUG CLINICAL TRIALS	CANDELA MOLIZ CORDON	II
A-11	Ensayo Fase III, aleatorizado, doble-ciego, de grupos paralelos y controlado con principio activo para evaluar la eficacia, seguridad y tolerabilidad de Baxdrostat combinado con Dapagliflozina, comparado con Dapagliflozina sola en la progresión de Enfermedad Renal Crónica (ERC) en pacientes con ERC e hipertensión arterial. BaxDUO ARCTIC	DRUG CLINICAL TRIALS	BEATRIZ AVILES BUENO	III
A-11	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de Ravulizumab en participantes adultos con nefropatía por inmunoglobulina A (IgAN)	DRUG CLINICAL TRIALS	REMEDIOS TOLEDO ROJAS	III
A-11	Estudio observacional posterior a la autorización de seguridad (PASS) en Europa para caracterizar y cuantificar mejor el perfil de seguridad a largo plazo en relación con la neurotoxicidad, la nefrotoxicidad crónica y las neoplasias malignas con el uso de voclosporina	OBSERVATIONAL STUDY WTIH MEDICINES	PILAR HIDALGO GUZMAN	Not applicable
A-11	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Eval-uate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Par-ticipants at High Risk of Delayed Graft Function after Kidney Transplantation	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	VERÓNICA LOPEZ JIMENEZ	Not applicable
A-11	Estudio multicéntrico, abierto y de un único grupo en el que se evalúan la eficacia y la seguridad del cam-bio de un tratamiento con un anticuerpo anti-C5 a un tratamiento con iptacopán en participantes con sín-drome hemolítico urémico atípico.	DRUG CLINICAL TRIALS	REMEDIOS TOLEDO ROJAS	III
A-11	Ensayo Clínico Fase IV, multicéntrico, controlado, aleatorizado y simple ciego, adaptativo, para evaluar la eficacia y coste-efectividad de la estrategia de genotipado pretrasplante para optimizar la dosis de tacrolimus en una cohorte de población con enfermedad renal crónica.	DRUG CLINICAL TRIALS	VERÓNICA LOPEZ JIMENEZ	IV
A-11	A multicenter, open, prospective, randomized, parallel-group, 12-month trial of REduced immunosuppression for oLdEr AdultS kidnEy transplant recipients: the RELEASE study	DRUG CLINICAL TRIALS	VERÓNICA LOPEZ JIMENEZ	IV
A-11	Retrospective chart review of safety outcomes associated with use of maribavir in patients with post-transplant refractory cytomegalovirus (CMV) infection and comorbid severe chronic kidney disease (CKD) or comorbid end-stage renal disease (ESRD), including patients on peritoneal dialysis or hemodialysis.	OBSERVATIONAL STUDY WTIH MEDICINES	VERÓNICA LOPEZ JIMENEZ	Not applicable
A-11	A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients	DRUG CLINICAL TRIALS	VERÓNICA LOPEZ JIMENEZ	II/III
A-19	Kuvan Adult Maternal Pediatric European Registry (KAMPER)	NON-POST-APPROVAL STUDY	JAVIER BLASCO ALONSO	Not applicable
A-19	Estudio postautorización de seguridad (EPAS) no intervencional para evaluar la seguridad a largo plazo del tratamiento con Orfadin en la Tirosinemia hereditaria tipo 1 (TH-1) en la práctica clínica estándar	COMMERCIAL POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable

Group	Title	Subtype	PI Name	Phase
A-19	Estudio clínico multicéntrico, aleatorizado, doble ciego, controlado para evaluar los efectos en el crecimiento, la seguridad y la tolerancia de una leche infantil a base de proteína hidrolizada de arroz comparada con una leche infantil de proteína de leche de vaca extensamente hidrolizada en el manejo de la alergia a la proteína de la leche de vaca (APLV) en lactantes	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable
A-19	Estudio de seguimiento para evaluar la seguridad y los resultados a largo plazo en lactantes nacidos de madres que participaron en los estudios de tratamiento con retosibán	COMMERCIAL CLINICAL TRIAL	TOMÁS SANCHEZ TAMAYO	III
A-19	Ensayo internacional, aleatorizado y controlado para el tratamiento del sarcoma de Ewing de diagnóstico reciente (EE2012)	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	III
A-19	Registro español informatizado de pacientes con Bronquiectasias	NON-POST-APPROVAL STUDY	ESTELA PEREZ RUIZ	Not applicable
A-19	Ensayo internacional, aleatorizado y controlado de quimioterapia para el tratamiento del sarcoma de Ewing recurrente o refractario	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	II
A-19	Validación de la dosis única diaria de isoniazida a 10 mg/kg de peso en el lactante menor de 3 meses de vida.	INDEPENDENT POSTAUTHORIZATION STUDY	DAVID MORENO PEREZ	Not applicable
A-19	Un registro no intervencionista a largo plazo para evaluar la seguridad y efectividad de HUMIRA (adalimumab) en pacientes pediátricos con enfermedad de Crohn (EdC) activa entre moderada y grave (CAPE). P11-292	COMMERCIAL POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable
A-19	Efectos de la suplementación con probióticos durante el periodo neonatal sobre el recién nacido prematuro.	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	TOMÁS SANCHEZ TAMAYO	Not applicable
A-19	European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	II
A-19	LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	II
A-19	Factores farmacogenómicos y monitorización terapéutica como predictores de respuesta a anti-TNFs en enfermedad inflamatoria intestinal en niños	INDEPENDENT POSTAUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable
A-19	Ensayo aleatorizado y doble ciego de fase IIIb para evaluar la seguridad y la eficacia de 2 regímenes de tratamiento con Aztreonam 75 mg polvo y disolvente para solución para inhalación por nebulizador / Aztreonam solución para inhalación (AZLI) en pacientes pediátricos con fibrosis quística (FQ) e infección/ colonización de las vías respiratorias por Pseudomonas aeruginosa (PA) de nueva aparición	COMMERCIAL CLINICAL TRIAL	ESTELA PEREZ RUIZ	III
A-19	Estudio prospectivo internacional de Meduloblastoma riesgo estándar clínico en niños de 3 a 5 años con perfil bajo de riesgo biológico (PNET 5 MB-LR) o perfil-medio de riesgo biologico (PNET 5 MB-SR)	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	II
A-19	Estudio abierto, aleatorizado, controlado en grupos paralelos para evaluar la seguridad, la farmacocinética y el control de amonio de RAVICTI® (fenilbutirato de glicerol [GPB]) líquido oral y del fenilbutirato de sodio (NaPBA) en pacientes que padecen trastornos del ciclo de la urea (TCU) y que no han recibido previamente tratamiento con fenilbutirato	COMMERCIAL CLINICAL TRIAL	JAVIER BLASCO ALONSO	III
A-19	Estudio Fase IIb, 2-brazos, aleatorizado, Doble-ciego, Placebo-Controlado, Multicéntrico para Optimizar la terapia de Diamyd® Administrada dentro de los ganglios linfáticos combinados con la vitamina D oral para investigar el impacto en la progresión de la diabetes tipo 1.	COMMERCIAL CLINICAL TRIAL	ISABEL LEIVA GEA	II
A-19	Estudio de Fase I, abierto y aleatorizado para evaluar la farmacocinética, la farmacodinamia y la seguridad de ETROLIZUMAB seguido de una extensión abierta y una vigilancia de la seguridad en pacientes pediátricos de entre 4 y menos de 18 años de edad con colitis ulcerosa o enfermedad de CROHN moderada o grave.	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LOPEZ	I
A-19	Ensayo internacional pediátrico en tumor hepático	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	III
A-19	Ensayo de fase III, para evaluación de la eficacia y la seguridad de los comprimidos sublinguales de inmunoterapia frente a ácaros del polvo doméstico, en niños y adolescentes (de 5 a 17 años) con asma alérgica inducida por ácaros del polvo doméstico	COMMERCIAL CLINICAL TRIAL	CANDELARIA MUÑOZ ROMAN	III

Group	Title	Subtype	PI Name	Phase
A-19	Estudio Nacional de vigilancia de infección nosocomial en UCI. (ENVIN-HELICS)	INDEPENDENT POSTAUTHORIZATION STUDY	PATRICIA GARCIA SOLER	Not applicable
A-19	Estudio fase 3 aleatorizado, abierto, para evaluar la Eficacia, Seguridad y Farmacocinética del tratamiento de Golimumab, un anticuerpo humano monoclonal anti-TNFa, administrado por vía subcutánea en pacientes pediátricos con Colitis Ulcerosa activa de moderada a severa.	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LOPEZ	III
A-19	A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated with Distributive Shock	COMMERCIAL CLINICAL TRIAL	ANTONIO MORALES MARTINEZ	II
A-19	Investigación integrada y guías para diagnóstico y terapia estandarizados de tumores de riñón en niños, adolescentes y adultos jóvenes. UMBRELLA SIOP-RTSG 2016	NON-POST-APPROVAL STUDY	GUIOMAR GUTIERREZ SCHIAFFINO	Not applicable
A-19	Estudio observacional multicéntrico de pacientes con parálisis cerebral: aspectos neurológicos y nutricionales	NON-POST-APPROVAL STUDY	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable
A-19	Estudio en fase II/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en niños de alto riesgo (MEDLEY)	COMMERCIAL CLINICAL TRIAL	PILAR CARO AGUILERA	III
A-19	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. GIS-DUMBO-2018	INDEPENDENT POSTAUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable
A-19	Estudio en fase 3, aleatorizado, enmascarado para el evaluador y multicéntrico para evaluar la eficiacia y seguridad de ALXN1840 administrado durante 48 semanas en comparación con el tratamiento de referencuia en pacientes con enfermedad de Wilson de 12 años de edad o más con un período de extensión de hasta 60 mesesmeses	COMMERCIAL CLINICAL TRIAL	JUALIANA SERRANO NIETO	III
A-19	Marcadores genéticos,transcriptómicos y celulares de respuesta a terapia biológica en enfermedad inflamatoria intestinal pediátrica	INDEPENDENT POSTAUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable
A-19	Ensayo Clínico Fase I para establecer la seguridad del uso de células mesenquimales troncales fetales alogénicas de cordón umbilical expandidas en pacientes prematuros con displasia broncopulmonar..	INDEPENDENT CLINICAL TRIAL	TOMÁS SANCHEZ TAMAYO	I
A-19	Diseño y validación psicométrica de un conjunto de cuestionarios “Toolbox” para evaluar los resultados de salud en atrofia muscular espinal desde el punto de vista del paciente. Estudio SMA TOOL. Código protocolo Promotor: ML41962	NON-POST-APPROVAL STUDY	ROCÍO CALVO MEDINA	Not applicable
A-19	Estudio aleatorizado con control activo para comparar la eficacia y la seguridad de isoflurano inhalado administrado mediante el dispositivo AnaConDa-S (dispositivo de conservación de anestésico) con midazolam intravenoso para la sedación en pacientes pediátricos con ventilación mecánica de entre 3 y 17 años (menos de 18 años). IsoCOMFORT Study	COMMERCIAL CLINICAL TRIAL	PILAR SANCHEZ YAÑEZ	III
A-19	Estudio de Fase III, Abierto y Multicéntrico para Evaluar la Eficacia y Seguridad de Darvadstrocel en el Tratamiento de la Fístula Perianal Compleja en Población Pediátrica con Enfermedad de Crohn Durante 24 Semanas y un período de seguimiento extendido de hasta 52 semanas	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LOPEZ	III
A-19	Estudio multicéntrico, sin enmascaramiento, con un grupo de referencia con adalimumab, para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de ixekizumab por vía subcutánea en niños con los subtipos de artritis idiopática juvenil: artritis relacionada con entesitis (incluida la espondilitis anquilosante de aparición durante la infancia) y artritis psoriásica juvenil	COMMERCIAL CLINICAL TRIAL	ESMERALDA NUÑEZ CUADROS	III
A-19	Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al Virus Respiratorio Sincitial (VRS), administrada por vía IM a gestantes de 18 a 49 años de edad, para la prevención de la Enfermedad vías respiratorias Bajas (EVRB) asociada al VRS en sus hijos hasta los 6 meses de edad. RSV-MAT-009	COMMERCIAL CLINICAL TRIAL	BEGOÑA CARAZO GALLEGO	III
A-19	Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de 2 partes, para evaluar pautas de tratamiento de EDP-938 en pacientes de 28 días a 24 meses de edad con infección por el virus respiratorio sincitial (VRS) RSVPEDs	COMMERCIAL CLINICAL TRIAL	PILAR CARO AGUILERA	II

Group	Title	Subtype	PI Name	Phase
A-19	Un estudio global para niños y adultos con Rabdomiosarcoma recién diagnosticado y recidivante. FaR-RMS	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	I
A-19	Registro ALERGODATA	INDEPENDENT POSTAUTHORIZATION STUDY	CANDELARIA MUÑOZ ROMAN	Not applicable
A-19	Ensayo clínico para evaluar la eficacia y seguridadd de la adición de la granulocitoféresis al tratamiento con Infliximab en pacientes pediátricos con colitis ulcerosa corticorresistente	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable
A-19	Estudio de inducción abierto y de mantenimiento de CP-690,550 (Tofacitinib) oral en niños con colitis ulcerosa de moderada a gravemente activa	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LOPEZ	III
A-19	Registro Español de Artritis Idiopática Juvenil Sistémica (AIJS) y Enfermedad de Still del Adulto	NON-POST-APPROVAL STUDY	ESMERALDA NUÑEZ CUADROS	Not applicable
A-19	Estudio observacional y abierto en niños y adolescentes con asma grave con fenotipo eosinofílico tratados con mepolizumab. Estudio CASAM	RESTO DE ESTUDIOS OBSERVACIONALES CON MEDICAMENTOS	PILAR CARO AGUILERA	Not applicable
A-19	Beneficio de los programas de transición de pediatría a gastroenterólogos de adultos en pacientes con enfermedad inflamatoria intestinal. Estudio BUTTERFLY	INDEPENDENT POSTAUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable
A-19	Ensayo clínico aleatorizado doble ciego comparando noradrenalina más placebo versus noradrenalina más terlipresina en shock séptico	INDEPENDENT CLINICAL TRIAL	PILAR CARO AGUILERA	III
A-19	Ensayo de 6 meses multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad, farmacocinética y farmacodinámica de un régimen de finerenona oral, ajustado por edad y peso corporal, añadido a un IECA o ARA II para el tratamiento de pacientes pediátricos de 6 meses a <18 años con enfermedad renal crónica y proteinuria	COMMERCIAL CLINICAL TRIAL	VERÓNICA MARTINEZ RIVERA	III
A-19	Estudio con enmascaramiento doble, controlado con placebo, de aumento progresivo de la dosis ara evaluar la eficacia, la seguridad y la farmacocinética de la voclosporina en adolescentes con nefritis lúpica	COMMERCIAL CLINICAL TRIAL	FRANCISCO ANTONIO NIETO VEGA	III
A-19	Estudio multicéntrico, abierto, de búsqueda de dosis, de dosis única y múltiples, con una extensión abierta opcional para evaluar la seguridad, tolerabilidad y farmacocinética del ácido obeticólico en sujetos pediátricos con atresia biliar	COMMERCIAL CLINICAL TRIAL	JAVIER BLASCO ALONSO	II
A-19	Estudio en fase III para evaluar la seguridad y farmacocinética de la profilaxis con berotralstat en niños de 2 a <12 años con angioedema hereditario	DRUG CLINICAL TRIALS	CANDELARIA MUÑOZ ROMAN	III
A-19	Estudio integral, en canasta, abierto, sobre la seguridad y la farmacocinética de Daprodustat para tratar la anemia asociada a la enfermedad renal crónica en niños y adolescentes de ambos sexos de entre 3 meses y menos de 18 años, necesiten o no diálisis.	DRUG CLINICAL TRIALS	FRANCISCO ANTONIO NIETO VEGA	III
A-19	Estudio aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de taldefgrobep alfa en participantes ambulatorios y no ambulatorios con atrofia muscular espinal con extensión abierta (RESILIENT)	DRUG CLINICAL TRIALS	ROCÍO CALVO MEDINA	III
A-19	Estudio de cohortes prospectivo, observacional, de canasta e integral de niños y adolescentes menores de 18 años con anemia asociada a la enfermedad renal crónica que requieren o no diálisis.	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO ANTONIO NIETO VEGA	Not applicable
A-19	Estudio aleatorizado. doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y seguridad de la terapia adyuvante de Cenobamato en pacientes con crisis tónico-clónicas generalizadas primarias.	DRUG CLINICAL TRIALS	ROCÍO CALVO MEDINA	III
A-19	Estudio del Neuroblastoma de alto riesgo 2.0 de SIOPEuropa-Neuroblastoma/SIOPENEstudio internacional, multicéntrico y aleatorizado de fase III,que evalúa y compara dos estrategias de tratamiento en tresfases terapéuticas (inducción, quimioterapia de altas dosis yradioterapia) para pacientes con neuroblastoma de altoriesgo.	DRUG CLINICAL TRIALS	LAURA GARCIA HIDALGO	III
A-19	Estudio aleatorizado de fase III, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de la inmunoterapia epicutánea con DBV712 250 µg en niños de entre 4 y 7 años con alergia al cacahuete.	DRUG CLINICAL TRIALS	CANDELARIA MUÑOZ ROMAN	III
A-19	Estudio observacional retrospectivo para evaluar el manejo diagnóstico y terapéutico del SÍndrome de Noonan en España/ retrospective observational study to assess the diagnostic and therapeutic management of noonan syndrome in Spain.	OBSERVATIONAL STUDY WTIH MEDICINES	SILVIA GALLEGO GUTIERREZ	Not applicable

Group	Title	Subtype	PI Name	Phase
A-19	Ensayo de extensión de seguridad de 18 meses, abierto y de un solo brazo, de un régimen de finerenona oral, ajustado por edad y peso corporal, añadido a un IECA o ARA II para el tratamiento de pacientes pediátricos y adultos jóvenes de 1 a 18 años con enfermedad renal crónica y proteinuria.	DRUG CLINICAL TRIALS	VERÓNICA MARTINEZ RIVERA	III
A-19	Manejo terapéutico y situación actual de uso de recursos y costes de la Atrofia Muscular Espinal (AME) en España: análisis retrospectivo, multicéntrico de revisión de historias clínicas. Estudio TREaSURE	OBSERVATIONAL STUDY WTIH MEDICINES	ROCÍO CALVO MEDINA	Not applicable
A-19	Estudio de fase 3 multicéntrico para evaluar la eficacia, seguridad y farmacocinética de la inducciónde upadacitinib en régimen abierto, aleatorizado, mantenimiento doble ciego y extensión abierta a largoplazo en sujetos pediátricos con colitis ulcerosa activa de moderada a severa y con respuesta insuficiente,intolerancia o contraindicaciones médicas al tratamiento con corticosteroides, inmunosupresores o terapiasbiológicas.	DRUG CLINICAL TRIALS	RAFAEL MARTIN MASOT	III
A-19	Estudio de fase III, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para evaluar la farmacocinética, farmacodinamia, eficacia y seguridad de anifrolumab intravenoso en participantes pediátricos de entre 5 y <18 años de edad con lupus eritematoso sistémico activo de moderado a severo que reciben tratamiento estándar de base	DRUG CLINICAL TRIALS	ROCÍO GALINDO ZAVALA	III
A-19	Ensayo Clínico Fase II para establecer la seguridad del uso de células mesenquimales troncales fetales alogénicas de cordón umbilical expandidas en pacientes prematuros con displasia broncopulmonar	DRUG CLINICAL TRIALS	NATALIA SALDAÑA GARCIA	II
A-19	A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluatethe safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants withglycogen storage disease type 1a (GSD1a), followed by an open-label extension	DRUG CLINICAL TRIALS	JAVIER BLASCO ALONSO	I/II
A-19	Estudio multicéntrico de fase 3 para evaluar la farmacocinética, la eficacia y laseguridad de risankizumab en periodo inducción abierto, mantenimiento aleatorizado dobleciego y períodos de extensión a largo plazo en pacientes pediátricos (de 2 a < 18 años deedad) con enfermedad de Crohn activa de moderada a grave	DRUG CLINICAL TRIALS	PILAR ORTIZ PEREZ	III
A-19	Observational multicentre RWE study to characterize neurofibromatosis type1 (NF1) diagnosed patients with plexiform neurofibromas (PN) in Spain. “MULtyMAtin Study	OBSERVATIONAL STUDY WTIH MEDICINES	LAURA GARCIA HIDALGO	Not applicable
A-19	Alergopediátrica. Estudio epidemiológico de las enfermedades alérgicas pediátricas en España	OBSERVATIONAL STUDY WTIH MEDICINES	CANDELARIA MUÑOZ ROMAN	Not applicable
A-19	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños (registro DUMBO)	DRUG CLINICAL TRIALS	VÍCTOR MANUEL NAVAS LOPEZ	II
A-19	Estudio multicéntrico de fase III para evaluar la eficacia, seguridad y farmacocinética de upadacitinib en una inducción abierta, un mantenimiento aleatorizado doble ciego y una extensión abierta a largo plazo en pacientes pediátricos con enfermedad de Crohn activa de moderada a grave y respuesta inadecuada,intolerancia o contraindicaciones médicas a los corticoesteroides, inmunodepresores y/o tratamientosbiológicos.	DRUG CLINICAL TRIALS	VÍCTOR MANUEL NAVAS LOPEZ	III
A-19	Understanding the long-term Management of Organic Acidemia Patients with CARBAGLU®: A Mixed Methods Approach	OBSERVATIONAL STUDY WTIH MEDICINES	JAVIER BLASCO ALONSO	Not applicable
A-19	Uso del Isavuconazole en pediatría. Una alternativa atractiva para las infecciones fúngicas invasivas.	OBSERVATIONAL STUDY WTIH MEDICINES	BEGOÑA CARAZO GALLEGO	Not applicable
A-19	Eficacia y seguridad de la tirzepatida administrada una vez a la semana en comparación con un placebo en el tratamiento de la obesidad y enfermedades asociadas con el peso en adolescentes: estudio aleatorizado, con enmascaramiento doble y comparativo con un placebo (SURMOUNT-ADOLESCENTS-2).	DRUG CLINICAL TRIALS	ISABEL LEIVA GEA	III
A-19	Un estudio abierto, multicántrico, de un solo grupo para evaluar la seguridad, tolerabilidad y farmacociéntica de Vaborem (meropenem-vaborbactam) en problación pediátrica con infecciones urinarias complicadas incuida pielonefritis aguda	DRUG CLINICAL TRIALS	FRANCISCO ANTONIO NIETO VEGA	II
A-19	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. Registro DUMBO 2	OBSERVATIONAL STUDY WTIH MEDICINES	VÍCTOR MANUEL NAVAS LOPEZ	Not applicable

Group	Title	Subtype	PI Name	Phase
A-19	Estudio multicéntrico, aleatorizado y de dos partes (inclisirán doble ciego frente a placebo [año 1] y, a continuación, inclisirán abierto [año 2]) para evaluar la seguridad, tolerabilidad y eficacia de inclisirán en niños (de 6 a menos de 12 años de edad) con hipercolesterolemia familiar heterocigótica y colesterol LDL elevado (ORION-20).	DRUG CLINICAL TRIALS	VÍCTOR MANUEL NAVAS LOPEZ	III
A-19	Registro de pacientes tratados con Fintepla	OBSERVATIONAL STUDY WTIH MEDICINES	ROCÍO CALVO MEDINA	Not applicable
A-19	Estudio abierto, secuencial, de búsqueda de dosis ascendentes y repetidas de sarilumab administrado con inyección subcutánea (s. c.) a niños y adolescentes con edades comprendidas entre 1 y 17 años con artritis idiopática juvenil sistémica (AIJS), seguido de una fase de extensión.	DRUG CLINICAL TRIALS	ESMERALDA NUÑEZ CUADROS	II
A-19	Estudio en fase III, aleatorizado y doble ciego para investigar la eficacia y la seguridad de te-plizumab en comparación con placebo en participantes de 1 a 25 años con diabetes tipo 1 (DT1) en estadio 3 recién diagnosticada.	DRUG CLINICAL TRIALS	ISABEL LEIVA GEA	III
A-19	Análisis del perfil biológico, farmacogenético y metabolómico prospectivo de muestras de pacientes diagnosticados con neuroblastoma e incorporación y actualización de sus datos clínicos en registros nacionales en colaboración con el RETI SEHOP.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	LAURA GARCIA HIDALGO	Not applicable
A-19	Estudio de fase III, aleatorizado, con doble enmascaramiento y controlado con placebo para evaluar la seguridad de la inmunoterapia epicutánea con DBV712 250 µg en niños de entre 1 y 3 años con alergia a los cacahuetes (COMFORT Toddlers)	DRUG CLINICAL TRIALS	ANA MARÍA PRIETO DEL PRADO	III
A-19	Ensayo aleatorizado, doble ciego y controlado con placebo, con una fase de extensión abierta, para evaluar la farmacocinética, la seguridad y la eficacia de los comprimidos de empagliflozina en pacientes pediátricos con enfermedad renal crónica (EMPA-KIDNEY® Kids).	DRUG CLINICAL TRIALS	FRANCISCO ANTONIO NIETO VEGA	III
A-19	Caracterización y manejo de los pacientes con fenilcetoanuria por deficiencia de fenilalanina hidroxilasa en España.	OBSERVATIONAL STUDY WTIH MEDICINES	JAVIER BLASCO ALONSO	Not applicable
A-19	Estudio de Fase III multicéntrico, doble ciego, aleatorizado, de tratamiento continuo, para evaluar la farmacocinética, farmacodinámica, inmunogenicidad, seguridad y eficacia del tratamiento de inducción y mantenimiento con AFIMKIBART (RO7790121) en niños y niñas de 2 a 17 años con colitis ulcerosa activa de moderada a grave.	DRUG CLINICAL TRIALS	VÍCTOR MANUEL NAVAS LOPEZ	III
A-19	A Phase 3, multicentre, randomised (1:1), parallel-group, active-controlled, central reader colon-oscopist-blind study to evaluate the bowel cleansing efficacy, safety, tolerability, palatability, and acceptability of PLENVU® as compared to sodium picosulfate in paediatric participants from 1 to < 18 years of age in preparation for colonoscopy (CLARITY)	DRUG CLINICAL TRIALS	VÍCTOR MANUEL NAVAS LOPEZ	III
A-19	Estudio de fase III multicéntrico, doble ciego, aleatorizado, de tratamiento continuo, para evaluar la farmacocinética, seguridad y eficacia del tratamiento de inducción y mantenimiento con afimkibart (ro7790121) en niños y niñas de 2 a 17 años con colitis ulcerosa activa de moderada a grave	DRUG CLINICAL TRIALS	VÍCTOR MANUEL NAVAS LOPEZ	III
A-19	Estudio de fase III, aleatorizado, con doble enmascaramiento y controlado con placebo de Mevrometostat (PF-06821497) con enzalutamida en cáncer de próstata metastásico resistente a la castración (MEVPRO-3).	DRUG CLINICAL TRIALS	SILVIA OLIVA RODRIGUEZ PASTOR	III
A-21	Evaluación de la nefroprotección en cirugía cardiaca de sustitución valvular aórtica del desflurano en comparación con el propofol	INDEPENDENT POSTAUTHORIZATION STUDY	JOSÉ LUIS GUERRERO ORRIACH	Not applicable
A-21	Análisis de la expresión de microRNAs en pacientes sometidos a cirugía cardíaca tratados con anestésicos halogenados. Identificación de microRNAs relacionados con el efecto cardioprotector	INDEPENDENT CLINICAL TRIAL	JOSÉ LUIS GUERRERO ORRIACH	IV
A-21	Mecanismos de cardio y nefroprotección en pacientes que van a ser intervenidos de cirugía cardiaca con disfunción ventricular derecha, con tratamiento preoperatorio de levosimendán en comparación con placebo. (PRELEVD-Estudio piloto)	INDEPENDENT CLINICAL TRIAL	JOSÉ LUIS GUERRERO ORRIACH	III
A-23	A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19	DRUG CLINICAL TRIALS	MARÍA JESÚS LOPEZ FERNANDEZ	II

Group	Title	Subtype	PI Name	Phase
A-23	A prospective study to evaluate the immune status in the elderly afterreceiving a booster dose under the Covid-19 vaccination program in Spain. N Covid Senior II, a substudy ofCovidvac@spain.	OBSERVATIONAL STUDY WTIH MEDICINES	BLANCA O'DONNELL CORTES	Not applicable
A-23	A Phase IIb/III, open label, single arm, multi-centre, clinical trial to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.	DRUG CLINICAL TRIALS	MARÍA JESÚS LOPEZ FERNANDEZ	III
A-23	Epidemiology and Burden of Invasive Pneumococcal Disease in the Adult Population in Spain: the EBINDAS study.	OBSERVATIONAL STUDY WTIH MEDICINES	BLANCA O'DONNELL CORTES	Not applicable
AA-04	STrategic Reperfusion in elderly patients Early After Myocardial Infarction. STREAM-2	INDEPENDENT CLINICAL TRIAL	MARÍA NIETO GONZALEZ	IV
AA-15	Un estudio prospectivo, aleatorizado, multicéntrico para evaluar la seguridad y la eficacia del sistema de stent coronario liberador de sirolimus en el tratamiento de pacientes con hasta tres lesiones arteriales coronarias de novo o reestenóticas". Estudio BIOFLOW-V	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Factores de riesgo asociados con la progresión de la Insuficiencia Cardíaca (IC) en pacientes con fibrilación auricular tratados con un anticoagulante oral directo (rivaroxaban). Estudio FARAONIC	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MARÍA PEREZ RUIZ	Not applicable
AA-15	Registro Observacional Prospectivo de Pacientes con Insuficiencia Cardíaca	INDEPENDENT POSTAUTHORIZATION STUDY	JOSÉ MARÍA PEREZ RUIZ	Not applicable
AA-15	Estudio observacional para evaluar el beneficio clínico neto del edoxabán en pacientes con fibrilación auricular no valvular, según la práctica clínica habitual en España Registro BENEFIT.Observational study to evaluate the Net Clinical Benefit of edoxaban in non-valvular Atrial Fibrillation patients, according to the routine clinical practice in Spain BENEFIT Registry	COMMERCIAL POST-AUTHORIZATION STUDY	ANA MARÍA GARCIA BELLON	Not applicable
AA-15	AF en la práctica real sobre el manejo de la anticoagulación oral - AFIRMA 4.0 (B0661131)	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS DELGADO PRIETO	Not applicable
AA-15	Estudio observacional para evaluar la evolución clínica de pacientes de alto riesgo sometidos a intervención coronaria percutánea (ICP), con implante de stents liberadores de everolimus, utilizando técnicas intracoronarias para guiar y optimizar la ICP	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Estudio aleatorizado paralelo para evaluar la utilidad de la revisión angiográfica rutinaria 6 meses después del intervencionismo percutáneo en el tronco coronario izquierdo. Estudio ANGELINE	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Establecimiento de una referencia para la utilización de recursos y la calidad de asistencia en pacientes sometidos a la implantación transcatéter de una válvula aórtica en Europa	RESTO DE ESTUDIOS OBSERVACIONALES CON MEDICAMENTOS	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Registro prospectivo del stent ihtDEStiny en práctica clínica habitual(Estudio VELAZQUEZ)	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria	INDEPENDENT CLINICAL TRIAL	CRISTÓBAL ANTONIO URBANO CARRILLO	IV
AA-15	Ensayo VERifyNow para Optimizar la iNhibición plaquetarla en el síndrome Coronario Agudo (VERONICA)	DRUG CLINICAL TRIALS	CRISTÓBAL ANTONIO URBANO CARRILLO	IV
AA-15	EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriersof Dilated Cardiomyopathy (EARLY-GENE trial).	DRUG CLINICAL TRIALS	ANA MARÍA GONZALEZ GONZALEZ	III
AA-15	Registro de seguimiento clínico postcomercialización en cirugía cardiaca de Medtronic - Cardiac Surgery Post Market (CSPM) Clinical Follow up Registry	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ENRIQUE RUIZ ALONSO	Not applicable
AA-15	Registro PERSEO: Prevención de eventos Embólicos tras una hemoRragia SEvera en pacientes anticoagulados con fibrilaciOn auricular.	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ LUIS DELGADO PRIETO	Not applicable
AA-15	Plan de investigación de seguimiento poscomercialización (PMCF) para evaluar la seguridad y efectividad del dispositivo liberador de paclitaxel SEQUENT PLEASE NEO en pacientes con enfermedad arterial coronaria	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Estudio multicéntrico prospectivo no aleatorizado, de una cohorte no seleccionada de pacientes con diagnóstico de amiloidosis cardiaca por transtiretina que inicien tratamiento diario con tafamidis 61 mg.	OBSERVATIONAL STUDY WTIH MEDICINES	ANA MARÍA GONZALEZ GONZALEZ	Not applicable

Group	Title	Subtype	PI Name	Phase
AA-15	Crioablación de Fibrilación Auricular guiada por Ondas de Presión: Registro POLAR-WAVE	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	GABRIEL BALLESTEROS DERBENTI	Not applicable
AA-15	Riesgo cardiovascular de la población atendida por Cardiólogos en España.	OBSERVATIONAL STUDY WTIH MEDICINES	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with ST-segment elevation myocardial infarction. COPERNICAN TRIAL	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Resultados isquémicos y hemorrágicos tras la implantación del stent angiolite y una terapia antiplaquetaria dual abreviada. Un ensayo controlado aleatorizado, multicéntrico, factorial 2x2, de todos los participantes elegibles (allcomers) Angiodapt."	DRUG CLINICAL TRIALS	CRISTÓBAL ANTONIO URBANO CARRILLO	III
AA-15	Evaluación de la viabilidad y seguridad de un protocolo de alta muy precoz tras implante de TAVI.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Registro Cardiasept España. Resultados a corto y medio plazo del dispositivo de cierre de foramen oval permeable Cardia Ultrasept.	OBSERVATIONAL STUDY WTIH MEDICINES	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy after left atrial appendage closure with the LAmbre device in patients with nonvalvular atrial fibrillation: A multinational real-world Registry. (S-SAPT SECURE-LAMBRE REGISTRY).	OBSERVATIONAL STUDY WTIH MEDICINES	CRISTÓBAL ANTONIO URBANO CARRILLO	Not applicable
AA-15	A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)	DRUG CLINICAL TRIALS	JAVIER MORA ROBLES	III
AA-15	Monotherapy with a P2Y12 inhibitor followed by a direct-acting oral anticoagulant in patients with ATRial fIbrillation undergoing suprafleX cruz coronary stent implantation.	DRUG CLINICAL TRIALS	CRISTÓBAL ANTONIO URBANO CARRILLO	III
AA-15	Estudio observacional prospectivo para evaluar la efectividad de inclisiran (leqvio®) en pacientes con enfermedad vascular aterosclerótica y/o hipercolesterolemia familiar heterocigota tratados en práctica clínica en españa. Estudio INSPIRE	OBSERVATIONAL STUDY WTIH MEDICINES	JAVIER MORA ROBLES	Not applicable
B-01	Estudio multicéntrico, doble ciego, randomizado, controlado con placebo, para comparar quimioterapia más trastuzumab y placebo con quimioterapia más trastuzumab y pertuzumab, como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positivo operable	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye quimioterapia estándar vs histotipo-dirigida neoadyuvante	INDEPENDENT CLINICAL TRIAL	ISABEL SEVILLA GARCIA	III
B-01	Ensayo aleatorizado, fase III, de terapia endocrina adyuvante estándar +/-quimioterapia en pacientes con cáncer de mama positivo para receptores hormonales y negativo para HER2 con afectación de 1 a 3 ganglios y con un recurrence score (RS) de 25 o inferior	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo clínico multicéntrico fase III, randomizado para la comparación de la combinación de Epirubicina y Ciclofosfamida (EC) seguido de Docetaxel (T) con Epirubicina y Docetaxel (ET) seguido de Capecitabina (X) en el tratamiento adyuvante de pacientes con cáncer de mama operable y ganglios linfáticos axilares positivos	INDEPENDENT CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
B-01	Registro de sarcomas raros: Herramienta de ayuda para evaluar el número de casos de cada subtipo y su orientación terapéutica por el Grupo Español de Investigación en Sarcomas (GEIS)	INDEPENDENT POSTAUTHORIZATION STUDY	ISABEL SEVILLA GARCIA	Not applicable
B-01	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, de ARN-509 controlado con placebo en hombres con cáncer de próstata no metastásico (M0) y resistente a la castración.	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Estudio de fase III, aleatorizado, para evaluar cabazitaxel y radioterapia pelviana en pacientes con cáncer de próstata localizado con alto riesgo de recaída, según un diseño factorial. PEACE 2	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2, que han finalizado el tratamiento local y la quimioterapia neoadyuvante o adyuvante". Estudio OLYMPIA.	COMMERCIAL CLINICAL TRIAL	ANTONIA MARQUEZ ARAGONES	III

Group	Title	Subtype	PI Name	Phase
B-01	Estudio de fase IIIb, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de continuar el tratamiento con enzalutamida en pacientes con cáncer de próstata resistente a la castración metastásico, que no han recibido quimioterapia previa, que han experimentado progresión al tratamiento con enzalutamida sola, tratados con docetaxel más prednisolona. Estudio PRESIDE	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de Próstata resistente a la castración tratados con doceTAxel o Cabazitaxel. Estudio PROSTAC	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA ISABEL SAEZ MEDINA	Not applicable
B-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de Próstata resistente a la castración tratados con doceTAxel o Cabazitaxel. Estudio PROSABI	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA ISABEL SAEZ MEDINA	Not applicable
B-01	Estudio observacional para evaluar la estrategia de uso de las terapias dirigidas, en cáncer de colon metastásico. Estudio GEMCAD 1401	INDEPENDENT POSTAUTHORIZATION STUDY	ISABEL SEVILLA GARCIA	Not applicable
B-01	Ensayo internacional, aleatorizado y controlado para el tratamiento del sarcoma de Ewing de diagnóstico reciente (EE2012)	INDEPENDENT CLINICAL TRIAL	ISABEL SEVILLA GARCIA	III
B-01	Ensayo internacional, aleatorizado y controlado de quimioterapia para el tratamiento del sarcoma de Ewing recurrente o refractario	INDEPENDENT CLINICAL TRIAL	ISABEL SEVILLA GARCIA	II
B-01	Estudio observacional, retrospectivo y multicéntrico para identificar los perfiles de pacientes que más se benefician del tratamiento con Trabectedina en segunda línea en pacientes con sarcoma de tejidos blandos, localmente avanzados o metastáticos, que han progresado a un tratamiento de primera línea. GEIS 38	INDEPENDENT POSTAUTHORIZATION STUDY	ISABEL SEVILLA GARCIA	Not applicable
B-01	Estudio retrospectivo de casos y controles para la caracterización clínica y molecular del cáncer de próstata en pacientes con y sin defecto germinal en la reparación del DNA (BRCA1, BRCA2, Síndrome de Lynch)	NON-POST-APPROVAL STUDY	ANTONIA MARQUEZ ARAGONES	Not applicable
B-01	Ensayo de fase III de quimioterapia postoperatoria frente a ningún tratamiento posterior en pacientes con cáncer de endometrio de riesgo intermedio o alto, en estadios I o II, con ganglios negativos	INDEPENDENT CLINICAL TRIAL	ALFONSO SANCHEZ MUÑOZ	III
B-01	Cáncer de vejiga invasivo hacia una medicina de precisión. SOG-CVI-2014-05	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA ISABEL SAEZ MEDINA	Not applicable
B-01	Estudio fase III randomizado en el que se compara el tratamiento con imatinib adyuvante durante 3 años frente a 5 años para pacientes con GIST operable con alto riesgo de recurrencia	INDEPENDENT CLINICAL TRIAL	ISABEL SEVILLA GARCIA	III
B-01	Estudio prospectivo de registro de pacientes con cáncer de mama localmente avanzado, no resecable o mestastásico (CMM). RegistEM	NON-POST-APPROVAL STUDY	ANA GODOY ORTIZ	Not applicable
B-01	Estudio piloto para la evaluación de la utilidad clínica del SWITCH (o cambio) de predniona por dexametasona tras progresión bioquímica inicial en pacientes con cáncer de próstata resistentes a la castración (CPRC) tratados con abiraterona. Estudio SWITCH	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA ISABEL SAEZ MEDINA	Not applicable
B-01	Estudio observacional, retrospectivo y multicéntrico para identificar el papel pronóstico y posibles implicaciones terapéuticas del receptor de la somatostatina (SSTR) en el tumor de estroma gastrointestinal (GIST) localizado (SOMAGIST). SOMAGIST	INDEPENDENT POSTAUTHORIZATION STUDY	ISABEL SEVILLA GARCIA	Not applicable
B-01	Multicenter, open-label, phase II trial to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2 negative breast cancer.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	II
B-01	Ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados con sobreexpresión CDK4.	INDEPENDENT CLINICAL TRIAL	ISABEL SEVILLA GARCIA	II
B-01	Trastuzumab y pertuzumab sin quimioterapia en cáncer de mama HER2 positivo: estrategia adaptada en función de la respuesta evaluada por FDG-PET. Estudio PHERGain	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	II
B-01	Estudio para evaluar los desenlaces del embarazo y la seguridad de la interrupción del tratamiento endocrino de mujeres jóvenes con cáncer de mama y respuesta el tratamiento endocrino que deseen quedarse embarazadas. Estudio POSITIVE	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA JOSÉ BERMEJO PEREZ	Not applicable
B-01	Ensayo de fase III aleatorizado de palbociclib con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar en cáncer de mama precoz con receptores hormonales positivos (RH+) y HER2-negativo	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	III

Group	Title	Subtype	PI Name	Phase
B-01	Estudio en fase III, multicéntrico, aleatorizado y abierto de rucaparib frente al tratamiento elegido por el médico para pacientes con cáncer de próstata metastásico resistente a la castración asociado a una deficiencia en la recombinación homóloga. TRITON3	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Estudio prospectivo de la utilidad de la biopsia líquida como factor predictor y pronóstico en pacientes con carcinoma urotelial metastásico en progresión tras quimioterapia basada en platino	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA ISABEL SAEZ MEDINA	Not applicable
B-01	EEstudio de largo seguimiento de pacientes con cáncer de mama incluidos en estudios en estadios precoces del Grupo GEICAM.	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	IV
B-01	Estudio de Fase III multicéntrico, doble ciego, randomizado, controlado con placebo para evaluar la eficacia y la seguridad de Atezolizumab más quimioterapia en pacientes con cáncer de mama triple negativo recurrente (localmente avanzado o metastásico inoperable) con recidiva precoz.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Estudio Observacional multicéntrico prospectivo en pacientes con Cáncer de Origen Desconocido a los que se les realiza el test diagnóstico CODEPICUP	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	ESPERANZA TORRES SANCHEZ	Not applicable
B-01	Estudio de Fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo para comparar la eficacia y seguridad de POLATUZUMAB VEDOTIN en combinación con RITUXIMAB Y CHP (R-CHP) en comparación con RITUXIMAB Y CHOP (R-CHOP) en pacientes con linfoma difuso de células grandes tipo b no tratado anteriormente. POLARIX	COMMERCIAL CLINICAL TRIAL	LAURA GALVEZ CARVAJAL	III
B-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de PROstata resistente a la castración tratados con RADUIM-223. PRORADIUM	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA ISABEL SAEZ MEDINA	Not applicable
B-01	Carolina conoce a HANNA - Análisis holístico de la supervivencia a largo plazo con cáncer de ovario.Código Promotor: Expression VI	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA JOSÉ BERMEJO PEREZ	Not applicable
B-01	Registro español de tumores neuroendocrinos	NON-POST-APPROVAL STUDY	ISABEL SEVILLA GARCIA	Not applicable
B-01	Estudio en fase 3 aleatorizado, abierto, de abemaciclib en combinación con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar, en pacientes con cáncer de mama en estadios iniciales, de alto riesgo, con afectación ganglionar, receptores hormonales positivos, HER2 negativo.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo fase III, aleatorizado y doble ciego de quimioterapia basada en platino con o sin atezolizumab, seguida de mantenimiento con niraparib con o sin atezolizumab, en pacientes con cáncer de ovario, de trompa de Falopio o peritoneal recidivante e intervalo libre de tratamiento con platino (ILP) >6 meses.	INDEPENDENT CLINICAL TRIAL	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	Estudio Observacional Retrospectivo de Evolución de Casos de Cáncer de Mama en el Varón y Evaluación del Riesgo de Recidiva Mediante Secuenciación Genética. GEICAM/2016-04	INDEPENDENT POSTAUTHORIZATION STUDY	ALFONSO SANCHEZ MUÑOZ	Not applicable
B-01	Estudio aleatorizado fase III de quimioterapia con platino y paclitaxel mas bevacizumab y atezolizumab frente a quimioterapia con platino y paclitaxel mas bevacizumab en carcinoma de cérvix metastásico (estadio IVB), persistente o recurrente. Estudio BEATcc	INDEPENDENT CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Estudio de fase III, aleatorizado, secuencial y abierto, para evaluar la eficacia de FOLFOX + panitumumab seguido por FOLFIRI + bevacizumab (Secuencia 1) frente a FOLFOX + bevacizumab seguido por FOLFIRI + panitumumab (Secuencia 2) en pacientes con cáncer colorrectal metastásico no resecable, RAS nativo, tumor primario en lado izquierdo, no tratado previamente: CR-SEQUENCE	INDEPENDENT CLINICAL TRIAL	ESPERANZA TORRES SANCHEZ	III
B-01	Ensayo abierto, multicéntrico, de un solo brazo, de fase II con avelumab en combinación con doxorrubicina liposomal pegilada en pacientes con cáncer endometrial recurrente o metastásico	INDEPENDENT CLINICAL TRIAL	ANTONIA MARQUEZ ARAGONES	II
B-01	Estudio de fase II de durvalumab (MEDI4736) más tremelimumab para el tratamiento de pacientes con carcinoma tiroideo avanzado, resistente al tratamiento y progresivo (ensayo DUTHY)	INDEPENDENT CLINICAL TRIAL	SOFÍA RUIZ MEDINA	II
B-01	Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo, de cabozantinib (XL184) en pacientes con cáncer diferenciado de tiroides resistente a radioyodo que han progresado después de tratamiento dirigido previo con VEGFR	COMMERCIAL CLINICAL TRIAL	SOFÍA RUIZ MEDINA	III

Group	Title	Subtype	PI Name	Phase
B-01	Estudio fase III, doble ciego, aleatorizado y controlado con placebo de niraparib en combinación con acetato de abiraterona y prednisona en comparación con acetato de abiraterona y prednisona para el tratamiento de sujetos con Cáncer de Próstata Metastásico	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Estudio en fase III, multicéntrico, aleatorizado, abierto y controlado con principio activo de DS-8201a, un conjugado de fármaco y anticuerpo anti-HER2, frente al tratamiento de elección del investigador para sujetos con cáncer de mama irresecable y/o metastásico que expresa HER-2 tratados previamente con tratamientos estándares para HER2, incluido T-DM1	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	Estudio de Fase 1b-2 para evaluar la seguridad, eficacia, farmacocinética y farmacodinamia de erdafitinib más JNJ-63723283, un anticuerpo monoclonal anti-PD-1, en sujetos con cáncer urotelial metastásico o no resecable con determinadas alteraciones del gen del FGFR	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	II
B-01	Ensayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (nuevo ensayo clínico en adyuvancia con ribociclib - [LEE011]: NATALEE)	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo aleatorizado, fase II, abierto, con el anti-PD1 TSR-042 como terapia de mantenimiento en pacientes con cáncer de cérvix localmente avanzado de alto riesgo después de quimioradioterapia	INDEPENDENT CLINICAL TRIAL	MARÍA JOSÉ BERMEJO PEREZ	II
B-01	Ensayo Clínico de fase III, doble ciego y aleatorizado, para evaluar la eficacia y seguridad de capivasertib + paclitaxel en comparación con un placebo + paclitaxel como tratamiento de primera línea en pacientes con cáncer de mama triple negativo (CMTN) localmente avanzado (inoperable) o metastásico, confirmado histológicamente	COMMERCIAL CLINICAL TRIAL	BELLA ISABEL PAJARES HACHERO	III
B-01	Estudio en fase III, multicéntrico, aleatorizado, abierto y controlado con principio activo de DS-8201a, un conjugado de fármaco y anticuerpo (CAF) anti-HER2, en comparación con el tratamiento elegido por el médico en sujetos con cáncer de mama irresecable o metastásico (o ambos) con expresión baja de HER-2	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	Estudio fase 3, aleatorizado, de quimioterapia neoadyuvante sola frente a quimioterapia neoadyuvante más Nivolumab o Nivolumab y BMS-986205, seguido por tratamiento continuado post-cirugía con Nivolumab o Nivolumab y BMS-986205 en pacientes con cáncer de vejiga músculo-invasivo.	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Incidencia de mutaciones BRCA somáticas y germinales en una cohorte amplia de pacientes procedentes de hospitales españoles con cáncer de ovario epitelial no mucinoso con validación de técnica somática entre laboratorios (BoRNEO).	NON-POST-APPROVAL STUDY	ANTONIA MARQUEZ ARAGONES	Not applicable
B-01	Ensayo clínico en fase III abierto y aleatorizado de REGN2810 en comparación con el tratamiento de quimioterapia a elección del investigador para el carcinoma cervicouterino resistente a platino recurrente o metastásico	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	Estudio de fase III, abierto, multicéntrico y aleatorizado de palbociclib como tratamiento adyuvante combinado con hormonoterapia en comparación con hormonoterapia sola en pacientes con recidiva locorregional aislada de cáncer de mama extirpado con receptor hormonal positivo y HER2 negativo. POLAR	INDEPENDENT CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
B-01	Proyecto de colaboración global en CIC-DUX4, BCOR-CCN3, células redondas no diferenciadas de alto grado (URCS)GEIS-2l	NON-POST-APPROVAL STUDY	ISABEL SEVILLA GARCIA	Not applicable
B-01	Estudio Fase IIIB multicéntrico, abierto, de un solo brazo, para evaluar la seguridad de ATEZOLIZUMAB (TECENTRIQ) en combinación con NAB-PACLITAXEL O PACLITAXEL para el tratamiento del cáncer de mama triple negativo inoperable, localmente avanzado o metastásico.	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Ensayo clínico de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de niraparib más inhibidores de aromatasa en el cáncer de mama metastásico con receptor hormonal (RH) positivo/receptor del factor de crecimiento epidérmico humano 2 (HER2) negativo con o sin mutación de BRCA en línea germinal y con deficiencia en la recombinación homóloga (HRD) - La estrategia LUZERN.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	II
B-01	Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302. HER2-PREDICT	INDEPENDENT CLINICAL TRIAL	MARÍA JOSÉ BERMEJO PEREZ	II

Group	Title	Subtype	PI Name	Phase
B-01	Estudio en fase III aleatorizado y doble ciego para evaluar la eficacia y la seguridad de capivasertib + fulvestrant frente a placebo + fulvestrant como tratamiento para el cáncer de mama localmente avanzado (inoperable) o metastásico con receptor hormonal positivo, receptor del factor de crecimiento epidérmico humano 2 negativo (HR+/HER2?) después de la recurrencia o la progresión durante o después del tratamiento con un inhibidor de la aromatasa (CAPItello-291)	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
B-01	Un ensayo multicéntrico, aleatorizado y abierto de fase 3 que compara selpercatinib con los medicamentos cabozantinib o vandetanib, preferidos por los médicos, en pacientes con cáncer medular de tiroides progresivo y avanzado con RET mutante y sin tratamiento anterior con inhibidores de quinasa (LIBRETTO-531)	COMMERCIAL CLINICAL TRIAL	SOFÍA RUIZ MEDINA	III
B-01	Estudio fase 3, aleatorizado, multicéntrico, doble ciego, controlado con placebo, de nivolumab frente a placebo en combinación con quimioterapia neoadyuvante y tratamiento hormonal adyuvante en pacientes con cáncer de mama primario de alto riesgo, receptores estrogénicos positivos (RE+) y receptor del factor de crecimiento epidérmico humano 2 negativo (HER2-). (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
B-01	Ensayo de Fase IIa, multicéntrico, abierto, no comparativo y de tres brazos de IPATASERTIB (GDC-0068) en combinación con quimioterapia sin TAXANOS para pacientes con cáncer de mama triple-negativo localmente avanzado irresecable o metastásico previamente tratadas con TAXANOS (PATHFINDER)	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	II
B-01	Primer estudio en seres humanos, fase 1/2 de BMS-986249 en monoterapia y en combinación con nivolumab en tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	JAVIER GARCIA CORBACHO	I
B-01	Ensayo de fase II randomizado para evaluar la actividad antitumoral del tratamiento con Enzalutamida y Talazoparib (PF-06944076) en pacientes con cáncer de próstata metastásico sin terapia hormonal previa. (ZZFIRST)	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	II
B-01	Estudio observacional en pacientes con cáncer de mama metastásico HR+ y Her2- tratados con abemaciclib en el programa NPU (Programa de Uso Compasivo) en España- Estudio AbemusS	COMMERCIAL POST-AUTHORIZATION STUDY	ANTONIA MARQUEZ ARAGONES	Not applicable
B-01	Estudio de fase 2a de ZW25 en combinación con palbociclib más fulvestrant	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	II
B-01	Estudio abierto, de un solo brazo, de continuación de tratamiento con darolutamida a pacientes incluidos previamente en estudios promovidos por Bayer.	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Estudio de fase III, multicéntrico, aleatorizado (1:1), doble ciego, controlado con placebo, de dos partes para evaluar la eficacia y seguridad de alpelisib (BYL719) en combinación con trastuzumab y pertuzumab como terapia de mantenimiento en pacientes con cáncer de mama avanzado HER2 positivo con una mutación de PIK3CA. EPIK-B2	COMMERCIAL CLINICAL TRIAL	MARÍA EMILIA DOMINGUEZ RECIO	III
B-01	Ensayo clínico exploratorio “basket” de cabozantinib más atezolizumab en neoplasias avanzadas y en progresión del sistema endocrino.	INDEPENDENT CLINICAL TRIAL	ISABEL SEVILLA GARCIA	II
B-01	Estudio de fase II, aleatorizado, abierto, internacional y multicéntrico, para comparar la eficacia de la quimioterapia estándar frente a letrozol más abemaciclib como terapia neoadyuvante en pacientes con cáncer de mama con RH-positivo/HER2-negativo de riesgo alto/intermedio. “Estudio CARABELA”	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	II
B-01	Estudio de fase 2, aleatorizado y doble ciego para evaluar la eficacia de Dostarlimab más quimioterapia en comparación con Pembrolizumab más quimioterapia en el cáncer de pulmón no microcítico metastásico	COMMERCIAL CLINICAL TRIAL	ANDRES MESAS RUIZ	II
B-01	Ensayo Clínico de Fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento adyuvante con Atezolizumab o placebo y Trastuzumab Emtansina en el cáncer de mama con HER2+ y alta riesgo de recidiva después del tratamiento preoperatorio.	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Estudio clínico de determinación de tiempos y desplazamientos de la combinación de una dosis fija subcutánea de PERTUZUMAB y TRASTUZUMAB para el tratamiento de pacientes con cáncer de mama precoz HER2 POSITIVO.	COMMERCIAL CLINICAL TRIAL	JAVIER PASCUAL LOPEZ	IV

Group	Title	Subtype	PI Name	Phase
B-01	Estudio de Fase III, multicéntrico, aleatorizado, abierto y controlado de Trastuzumab Deruxtecán (T-DXd) frente a Trastuzumab Emtansina (T-DM1) en pacientes con cáncer de mama primario HER2 positivo de alto riesgo que presentan enfermedad invasiva residual en mama o en ganglios linfáticos axilares trás el tratamiento neoadyuvante. Estudio DESTINY	COMMERCIAL CLINICAL TRIAL	MARÍA EMILIA DOMINGUEZ RECIO	III
B-01	Ensayo aleatorizado de fase III de trastuzumab + ALpelisib +/- fulvestrant frente a trastuzumab + quimioterapia en pacientes con cáncer de mama avanzado HER2+ con mutación de PIK3CA previamente tratadas. “Estudio ALPHABET”	INDEPENDENT CLINICAL TRIAL	ANA GODOY ORTIZ	III
B-01	Estudio plataforma, de fase II, abierto y multicéntrico para evaluar la eficacia y la seguridad de tratamientos basados en biomarcadores en pacientes con tumores epiteliales de ovario raros persistentes o recurrente	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ BERMEJO PEREZ	II
B-01	Estudio en fase III, aleatorizado, doble ciego y multicéntrico de dostarlimab (TSR-042) más carboplatino-paclitaxel frente a placebo más carboplatino-paclitaxel en pacientes con cáncer de endometrio avanzado recidivante o primario (RUBY)	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	Estudio de Fase 3, aleatorizado, doble ciego, para comparar la eficacia y seguridad de niraparib frente a placebo en participantes con cáncer de mama HER2 negativo con mutación en BRCA o cáncer de mama triple negativo, con enfermedad molecular basada en la presencia de ADN tumoral circulante después de una terapia definitiva (ZEST).	COMMERCIAL CLINICAL TRIAL	JAVIER PASCUAL LOPEZ	III
B-01	Registro clinico de pacientes diagnosticadas con cáncer ginecológico del Grupo Español de Investigación en Cáncer de Ovario (GEICO)	NON-POST-APPROVAL STUDY	MARÍA JOSÉ BERMEJO PEREZ	Not applicable
B-01	Ensayo en fase III, doble ciego, aleatorizado para evaluar el cambio a AZD9833 (SERD oral de nueva generación) + inhibidor de CDK4/6 (palbociclib o abemaciclib) frente a continuar con un inhibidor de la aromatasa (letrozol o anastrozol) + inhibidor de CDK4/6 en pacientes con cáncer de mama mestastásico HR+/HER2-con mutación detectable del ESR1 sin progresión de la enfermedad durante el tratamiento de 1L con inhibidor de la aromatasa + inhibidor de CDK4/6: estudio de cambio temprano guiado por ADNtc. SERENA-6	COMMERCIAL CLINICAL TRIAL	JAVIER PASCUAL LOPEZ	III
B-01	Ensayo en fase 3 aleatorizado, multicéntrico, abierto, comparativo con tratamiento activo para evaluar la eficacia y seguridad de octreotida (CAM2029) subcutánea de liberación prolongada frente a octreotida LP o lanreotida ATG en pacientes con tumores neuroendocrinos gastroenteropancreáticos	COMMERCIAL CLINICAL TRIAL	ISABEL SEVILLA GARCIA	III
B-01	Ensayo clínico, fase III, abierto, aleatorizado de Dato-DXd en comparación con la quimioterapia a elección del investigador en pacientes con cáncer de mama inoperable o metastásico con receptores hormonales positivos, HER2 negativo, que han recibido una o dos líneas previas de quimioterapia sistémica (TROPION-Breast01)	COMMERCIAL CLINICAL TRIAL	MARÍA EMILIA DOMINGUEZ RECIO	III
B-01	Estudio de fase III, multicéntrico y abierto de ribociclib en comparación con palbociclib en pacientes con cáncer de mama avanzado con receptores hormonales positivos/HER2-negativo/HER2-Enriquecido - ensayo HARMONIA	COMMERCIAL CLINICAL TRIAL	MARÍA EMILIA DOMINGUEZ RECIO	III
B-01	Estudio fase 1b/2, abierto, aleatorizado, no comparativo de nadunolimab en combinación con gemcitabina y carboplatino en pacientes con cáncer de mama avanzado triple negativo. “Estudio TRIFOUR”.	COMMERCIAL CLINICAL TRIAL	JAVIER GARCIA CORBACHO	I
B-01	Estudio de fase 3, multicéntrico y abierto para evaluar la seguridad y la eficacia a largo plazo en participantes que actualmente están en tratamiento o en seguimiento en estudios que incluyen Pembrolizumab.	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Estudio de fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de Giredestrant adyuvante en comparación con la monoterapia endocrina adyuvante elegida por el médico en pacientes con cáncer de mama incipiente con receptores estrogénicos positivos y HER2 negativo. LIDERA	COMMERCIAL CLINICAL TRIAL	JAVIER PASCUAL LOPEZ	III
B-01	Estudio tipo cesta de fase 1b/2, multicéntrico y abierto que evalúa la seguridad y eficacia de bemarituzumab en monoterapia en tumores sólidos con sobreexpresión de FGFR2b (FORTITUDE-301)	COMMERCIAL CLINICAL TRIAL	JAVIER GARCIA CORBACHO	I
B-01	Estudio fase III de post-neoadyuvancia que evalúa Sacituzumab Govitecan, un anticuerpo conjugado, en pacientes con cáncer primario de mama HER2 negativo con alto riesgo de recaída tras el tratamiento neoadyuvante estándar - SASCIA	INDEPENDENT CLINICAL TRIAL	JAVIER PASCUAL LOPEZ	III

Group	Title	Subtype	PI Name	Phase
B-01	Brightline-1: Ensayo de fase II/III, aleatorizado, abierto, multicéntrico de BI 907828 comparado con doxorrubicina como tratamiento de primera línea de pacientes con liposarcoma desdiferenciado avanzado	COMMERCIAL CLINICAL TRIAL	ISABEL SEVILLA GARCIA	III
B-01	Estudio en fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo de fuzuloparib combinado con acetato de abiraterona y prednisona (AA-P) frente a placebo combinado con AA-P como tratamiento de primera línea en pacientes con cáncer de próstata resistente a la castración metastásico	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SAEZ MEDINA	III
B-01	Estudio de fase I/IIa, abierto y multicéntrico, para evaluar la seguridad, tolerabilidad, farmacocinética y, de manera preliminar, la eficacia de ART0380, un inhibidor de la quinasa ATR, administrado por vía oral en monoterapia y en combinación a pacientes con tumores sólidos avanzados o metastásicos	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	II
B-01	Estudio de fase III, aleatorizado, abierto de sacituzumab govitecán frente al tratamiento elegido por el médico en pacientes con cáncer de mama triple negativo localmente avanzado, inoperable o metastásico, no tratado anteriormente cuyos tumores no presenten expresión de PD-L1 o en pacientes tratados previamente con agentes anti PD(L)1 en fase inicial cuyos tumores presenten expresión de PD-L1	INDEPENDENT CLINICAL TRIAL	JAVIER PASCUAL LOPEZ	III
B-01	Estudio observacional retrospectivo de los linfomas hodgkin (hdk) y no hodgkin (no-hdk) diagnosticados por el grupo cooperativo gotel para evaluar la supervivencia global y sus características.	INDEPENDENT POSTAUTHORIZATION STUDY	LAURA GALVEZ CARVAJAL	Not applicable
B-01	Estudio aleatorizado de paclitaxel – carboplatino seguido de mantenimiento con niraparib en comparación con paclitaxel – carboplatino – bevacizumab seguido de mantenimiento con niraparib + bevacizumab en pacientes con cáncer de ovario avanzado después de una cirugía citorreductora completa de primera línea	DRUG CLINICAL TRIALS	MARÍA JOSÉ BERMEJO PEREZ	II
B-01	Estudio multicéntrico en fase I, abierto, de INCA00186 en monoterapia o en combinación con inmunoterapia en participantes con tumores sólidos avanzados	INDEPENDENT CLINICAL TRIAL	JAVIER GARCIA CORBACHO	I
B-01	Estudio de fase 3, aleatorizado, abierto, controlado, de cabozantinib (XL184) en combinación con atezolizumab frente a una segunda terapia hormonal novedosa (THN) en pacientes con cáncer de próstata metastásico y resistente a la castración	DRUG CLINICAL TRIALS	MARÍA ISABEL SAEZ MEDINA	III
B-01	Un estudio de Fase Ia/Ib, etiqueta abierta, multicéntrico, de escalado de dosis para evaluar la seguridad, farmacocinética y actividad de RO7502175 como agente único y en combinación con ATEZOLIZUMAB en pacientes con tumores sólidos localmente avanzados o metastásicos.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio en fase II, multicéntrico y sin enmascaramiento para evaluar la eficacia y la seguridad de la monoterapia con Olaparib y la combinación de Olaparib junto con Durvalumab como tratamiento neoadyuvante en pacientes con mutaciones BRCA y cáncer de mama HER2 negativo en fase temprana (OlympiaN)	DRUG CLINICAL TRIALS	ANTONIA MARQUEZ ARAGONES	II
B-01	Estudio con aumento escalonado y ampliación de la dosis para evaluar la seguridad y la farmacocinética del XB002 en monoterapia y politerapia en pacientes con tumores sólidos localmente avanzados o metastásicos inoperables	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Ensayo fase 3, abierto, aleatorizado, de Datopotamab Deruxtecan (Dato-DXd) en comparación con la quimioterapia de elección del investigador en pacientes con cáncer de mama triple negativo, localmente recurrente inoperable o metastásico, que no son candidatos a terapia con inhibidores de PD-1/PD-L1 en primera línea (TROPION-Breast02)	DRUG CLINICAL TRIALS	EMILIO ALBA CONEJO	III
B-01	Estudio de fase III, aleatorizado, abierto de sacituzumab govitecán y pembrolizumab frente al tratamiento elegido por el médico y pembrolizumab en pacientes con cáncer de mama triple negativo localmente avanzado inoperable o metastásico, no tratado anteriormente cuyos tumores presenten expresión de PD-L1	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Estudio abierto, de fase I de escalado de dosis, con confirmación y expansión de la dosis, de BI 1810631 en monoterapia en pacientes con tumores sólidos avanzados o metastásicos con aberraciones en HER2	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Observación de cáncer residual mediante evaluación por biopsia líquida (Observation of ResiduAl Cancer with Liquid biopsy Evaluation) ORACLE	OBSERVATIONAL STUDY WTIH MEDICINES	EMILIO ALBA CONEJO	Not applicable
B-01	Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158)	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	II

Group	Title	Subtype	PI Name	Phase
B-01	Ensayo clínico aleatorizado, abierto, fase 3 de datopotamab deruxtecán (Dato-DXd) con o sin durvalumab frente al tratamiento de elección del investigador en pacientes con cáncer de mama triple negativo en estadio I-III que tienen enfermedad residual invasiva en la mama y/o en los ganglios linfáticos axilares en la resección quirúrgica después de tratamiento sistémico neoadyuvante (TROPION-Breast03)	DRUG CLINICAL TRIALS	EMILIO ALBA CONEJO	III
B-01	Evaluación de la Mitigación de las Reacciones Relacionadas con la Infusión de Amivantamab.	DRUG CLINICAL TRIALS	ANDRES MESAS RUIZ	II
B-01	Estudio de fase II, aleatorizado, abierto, de optimización de la dosis/pauta de NUC-3373/leucovorina/ irinotecán más bevacizumab (NUFIRI-bev) frente a 5-FU/leucovorina/irinotecán más bevacizumab (FOLFIRI-bev) para el tratamiento de pacientes con cáncer colorrectal metastásico irresecable previamente tratado	DRUG CLINICAL TRIALS	ESPERANZA TORRES SANCHEZ	II
B-01	Estudio abierto de fase 1, primera vez en humanos, con GSK4381562 administrado en monoterapia y en combinación con agentes antineoplásicos en participantes con tumores sólidos avanzados seleccionados.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio de fase III aleatorizado, abierto para evaluar la eficacia y seguridad de GIREDESTRANT en combinación con PHESGO comparado con PHESGO tras tratamiento de inducción con PHESGO + TAXANO en pacientes con cáncer de mama localmente avanzado o metastásico HER2 Positivo y receptor de estrógenos positivo, no tratados previamente.	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Estudio en fase I del inhibidor de SHP2 BBP-398 (anteriormente conocido comoIACS-15509) en combinación con el inhibidor de KRAS-G12C sotorasib en pacientes con tumores sólidos avanzados y una mutación de KRAS-G12C	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio de fase 3, aleatorizado, abierto, multicéntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con cáncer de mama avanzado con receptores estrogénicos, sin mutación del gen HER2 cuya enfermedad haya progresado después de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2)	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Estudio fase 1/2 de BMS-986340 en monoterapia y en combinación con Nivolumab o Docetaxel en pacientes con tumores sólidos avanzados.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Ensayo en fase I/IIa, primero en el ser humano, de aumento de la dosis, multicéntrico y sin enmascaramiento, con cohortes de prolongación, para evaluar la seguridad y la eficacia preliminar de BNT142 en pacientes con tumores sólidos avanzados con presencia de CLDN6	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio observacional de cohortes retrospectivo que utiliza datos secundarios obtenidos de la práctica clínica para evaluar los patrones de tratamiento y el índice de abandono entre líneas de tratamiento en pacientes con cáncer de mama metastásico HER2+	OBSERVATIONAL STUDY WTIH MEDICINES	NURIA RIBELLES ENTRENA	Not applicable
B-01	Estudio fase 1, primero en humanos, multicéntrico y abierto con ABBV-CLS579 solo y en combinación, en pacientes con tumores localmente avanzados o metastásicos	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio de Fase II multicéntrico, aleatorizado, doble ciego de RO7247669 en combinación con NAB-PACLITAXEL comparado con Pembrolizumab en combinación con NAB-PACLITAXEL en participantes con cáncer de mama TRIPLE NEGATIVO PD-L1 POSITIVO localmente avanzado no resecable o metastásico, no tratados previamente.	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	II
B-01	Ensayo en Fase I/IIa Multicéntrico, Abierto, para evaluar la Seguridad, Tolerabilidad, Farmacocinética, Farmacodinámica y actividad antitumoral preliminar del AZD8205 en pacientes con tumores sólidos avanzados o metastásicos.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	III
B-01	Estudio de Fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de INAVOLISIB en combinación con PHESGO® comparado con placebo en combinación con PHESGO® como tratamiento de mantenimiento tras tratamiento de inducción de primera línea en participantes con cáncer de mama localmente avanzado o metastásico HER2 POSITIVO con mutación PIK3CA.	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Estudio aleatorizado, doble ciego y en fase III de tucatinib o placebo en combinación con trastuzumab y pertuzumab como tratamiento de mantenimiento para el cáncer de mama HER2+metastásico (HER2CLIMB-05)	DRUG CLINICAL TRIALS	EMILIO ALBA CONEJO	III

Group	Title	Subtype	PI Name	Phase
B-01	Estudio de Fase 3, aleatorizado, abierto, multicéntrico de ARV-471 (PF07850327) más PALBOCICLIB en comparación con LETROZOL más PALBOCICLIB para el tratamiento de participantes con cáncer de mama con receptor estrogénico positivo y HER2 Negativo que no han recibido ningún tratamiento antineoplásico sistémico previo para la enfermedad avanzada (VERITAC-3).	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Estudio aleatorizado para investigar la eficacia y seguridad de la proteína de fusión humana L19TNF anticuerpo-citoquina dirigida a tumores en pacientes con sarcoma de tejidos blandos en estado avanzado o metastásico previamente tratados	DRUG CLINICAL TRIALS	ISABEL SEVILLA GARCIA	II
B-01	Un estudio por módulos, abierto, de fase I/II para evaluar la seguridad, la tolerabilidad, lafarmacocinética y la eficacia de EP0031 en pacientes con neoplasias malignas avanzadas con alteracionesen el gen RET	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio fase 1/2 de BMS-986449 en monoterapia y en combinación con Nivolumab en pacientes con tumores sólidos avanzados.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento estándar en pacientes con cáncer de colon resecable con pérdida del mecanismo de reparación de apareamiento de bases (dMMR)/inestabilidad de microsatélites alta (MSI-H), T4N0 o estadio III, no tratado. AZUR 2	DRUG CLINICAL TRIALS	ESPERANZA TORRES SANCHEZ	III
B-01	Estudio ambispectivo de pacientes con cáncer de mama triple negativo tratados con sacituzumab govitecan en el sur de España.	OBSERVATIONAL STUDY WTIH MEDICINES	ANA GODOY ORTIZ	Not applicable
B-01	Estudio marco abierto de fase Ib/II para evaluar la seguridad y eficacia de elacestrant en varias combinaciones en pacientes con cáncer de mama metastásico (ELEVATE)	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II
B-01	Estudio observacional, internacional, retrospectivo de revisión de historias clínicas, para describir las características, patrones de tratamiento y resultados clínicos en los pacientes tratados con selpercatinib dentro de un Programa de Acceso Temprano en España y Portugal (Estudio SELPIBER).	OBSERVATIONAL STUDY WTIH MEDICINES	ANDRES MESAS RUIZ	Not applicable
B-01	A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio de fase Ib/II, multicéntrico, abierto y de escalada de dosis de JDQ443 en pacientes con tumores sólidos avanzados con mutación KRAS G12C	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio de fase III, aleatorizado, multicéntrico y en abierto para evaluar DB-1303 frente a la quimioterapia elegida por el investigador en pacientes con cáncer de mama metastásico con receptor 2 del factor de crecimiento epidérmico humano (HER2) bajo y positivo para el receptor hormonal (HR+) cuyo cáncer ha progresado con el tratamiento endocrino (DYNASTY-Breast02)	DRUG CLINICAL TRIALS	MARÍA EMILIA DOMINGUEZ RECIO	III
B-01	Ensayo de fase III, multicéntrico, aleatorizado, controlado con placebo y con doble enmascaramiento sobre el tratamiento de mantenimiento con selinexor tras un tratamiento sistémico en pacientes con carcinoma endometrial avanzado o recurrente sin mutaciones en la proteína p53	DRUG CLINICAL TRIALS	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	A retrospective, observational, multicenter study of treatment with sacituzumab govitecan in patients with locally advanced and/or metastatic triple-negative breast cancer within routine clinical practice in Spain (TROPSPAIN)	OBSERVATIONAL STUDY WTIH MEDICINES	JAVIER PASCUAL LOPEZ	Not applicable
B-01	Un estudio observacional prospectivo multicéntrico y en varios países de pacientes que inician T-DXd en la primera o segunda línea de tratamiento para el cáncer de mama irresecable y/o metastásico HER2+ y HER2-bajo. DESTINY BREAST – RESPOND	OBSERVATIONAL STUDY WTIH MEDICINES	JAVIER PASCUAL LOPEZ	Not applicable
B-01	Primer ensayo clínico en humanos, abierto de BAY 2927088 en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con mutación EGFR y/o HER2	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio preliminar de eficacia para evaluar la eficacia de los tratamientos mediante el control de la enfermedad residual mínima con ADNtc en población con cáncer de mama precoz RH positivo/HER2 negativo. MIRADOR	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	II
B-01	A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I

Group	Title	Subtype	PI Name	Phase
B-01	Ensayo modular fase I/IIa, abierto, multicéntrico, para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia preliminar del escalado de dosis de AZD5335 en monoterapia y en combinación con otros agentes antineoplásicos en pacientes con tumores sólidos (FONTANA)	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II
B-01	Estudio en fase III aleatorizado, abierto y multicéntrico de mirvetuximab soravtansina en combinación con bevacizumab frente a bevacizumab en monoterapia como tratamiento de mantenimiento para pacientes con cáncer de trompas de falopio, peritoneal primario o epitelial de ovario con expresión FRa alta recurrente y sensible al platino que no han progresado después de la quimioterapia de segunda línea con platino más bevacizumab (GLORIOSA).	DRUG CLINICAL TRIALS	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	Estudio en fase III, abierto y aleatorizado para evaluar la eficacia y la seguridad de camizestrant (AZD9833, un degradador selectivo del receptor de estrógenos por vía oral de última generación) frente a la hormonoterapia estándar (inhibidor de la aromatasa o tamoxifeno), como tratamiento adyuvante en pacientes con cáncer de mama en fase temprana RE+/HER2-y un riesgo intermedio-alto o alto de recidiva que han completado tratamiento locorregional definitivo y no presentan indicios de enfermedad.	DRUG CLINICAL TRIALS	ANA GODOY ORTIZ	III
B-01	Estudio de fase 1/2, multicéntrico, abierto, para evaluar la seguridad, tolerabilidad y actividad antitumoral preliminar del TNG462 en pacientes con tumores sólidos avanzados ometastásicos con deleción del gen MTAP	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Ensayo de fase 1, primero en humanos, abierto, de escalada y expansión de dosis para evaluar la seguridad, la tolerabilidad, la dosis máxima tolerada o administrada, la farmacocinética, la farmacodinamia y la respuesta tumoral del inhibidor del diacilglicerol quinasa alfa (DGKai) BAY 2862789 en pacientes con tumores sólidos avanzados.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	Estudio de fase I/IIa, abierto y multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia preliminar del inhibidor de la ADN-polimerasa Theta, ART6043, administrado por vía oral en monoterapia y en combinación a pacientes con tumores sólidos avanzados o metastásicos	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	I
B-01	Estudio en fase I, doble ciego, aleatorizado, con tres grupos paralelos y controlado con principio activo para evaluar la similitud farmacocinética de tres formulaciones de pembrolizumab (CT-P51, Keytruda aprobado por la UE y Keytruda autorizado por EE. UU.) como tratamiento adyuvante en pacientes con melanoma en estadio IIB, IIC y III completamente resecado.	DRUG CLINICAL TRIALS	MANUEL ZALABARDO AGUILAR	I
B-01	Estudio de intervención, abierto, aleatorizado, multicéntrico, de Fase 2 de PF-07220060 más Letrozol comparado con Letrozol solo en mujeres posmenopáusicas de 18 años o más con cáncer de mama con receptores hormonales Positivos y HER2 Negativo en el contexto neoadyuvante.	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	II
B-01	Estudio en fase III aleatorizado y abierto de saruparib (AZD5305) más camizestrant en comparación con el inhibidor de CDK4/6 seleccionado por el médico más hormonoterapia o más camizestrant para el tratamiento de primera línea de pacientes con cáncer de mama avanzado positivo para receptores hormonales y HER2 negativo (0, 1+, 2+ según IHQ/sin amplificación por ISH) con mutaciones en BRCA1, BRCA2 o PALB2.	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Exploración de los reordenamientos del GEN NTRK 1/2/3 en sarcomas GIST Y ÓSEOS. GIBOTREK.	OBSERVATIONAL STUDY WTIH MEDICINES	ISABEL SEVILLA GARCIA	Not applicable
B-01	A Phase IIIB study to evaluate the useof durvalumab in combination with platinun-bas chemotherpy followed by urvalumab with olaparib as first-line tratment in Patientsw Newly Diagnosed pMMR Advanced or Recurret Endometrial Cancer in Spain.	DRUG CLINICAL TRIALS	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy	DRUG CLINICAL TRIALS	MARÍA JOSÉ BERMEJO PEREZ	III
B-01	Estudio de fase Ib/II para evaluar la seguridad y eficacia preliminar del inhibidor de wee1 debio 0123 en combinación con sacituzumab govitecan en cáncer de mama triple negativo o hr+/her2-avanza-do/ metastásico (<win-b>)	DRUG CLINICAL TRIALS	NURIA RIBELLES ENTRENA	II

Group	Title	Subtype	PI Name	Phase
B-01	A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Elacestrant frente a la hormonoterapia de referencia en personas de ambos sexos con cáncer de mama incipiente con afectación ganglionar, con receptores estrogénicos y sin sobreexpresión del receptor HER2 con alto riesgo de recurrencia: estudio en fase III, aleatorizado, sin enmascaramiento, global y multicéntrico (ELEGANT) // Elacestrant versus Standard ndocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence — A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT).	DRUG CLINICAL TRIALS	EMILIO ALBA CONEJO	III
B-01	A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292-D361DC00001)	DRUG CLINICAL TRIALS	MARÍA EMILIA DOMINGUEZ RECIO	III
B-01	Observational study on the efficacy of aDjuvant chemotheApY in high-graDe uteRinE sArcoMas	OBSERVATIONAL STUDY WTIH MEDICINES	MARCOS IGLESIAS CAMPOS	Not applicable
B-01	A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II
B-01	Estudio de fase 3, multicéntrico, abierto y aleatorizado de zilovertamab vedotina (MK-2140) en combinación con R-CHP en comparación con R-CHOP en participantes con linfoma difuso de células B grandes (LDCBG) no tratado previamente (waveLINE-010)	DRUG CLINICAL TRIALS	LAURA GALVEZ CARVAJAL	III
B-01	Estudio intervencional, abierto, aleatorizado, multicéntrico, de fase III de PF-07220060 en combinación con letrozol comparado con un inhibidor CDK4/6 en combinación con letrozol en participantes mayores de 18 años con cáncer de mama. avanzado/metastásico receptor hormonal (RH) positivo, HER2 negativo que no han recibido ningún tratamiento antineoplásico sistémico previo para la enfermedad avanzada/metastásica (FourLight-3).	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Estudio fase III. aleatorizado, multicéntrico y controlado con placebo para evaluar la eficacia y la seguiridad del péptico HER2/neu GLSI-100 (GP2+GM-CSF) en sujetos con enefermedad residual o RCp de alto riesgo HER2/neu positivo tras tratamiento neoadjuvate bbasada en trastuzumab (FLAMINGO-01)	DRUG CLINICAL TRIALS	ANA GODOY ORTIZ	III
B-01	A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtecan as Induction Treatment for HER2-positive Unresectable Locally Recurrent or Metastatic Breast Cancer Patients (The DEMETHER study)	DRUG CLINICAL TRIALS	ANA GODOY ORTIZ	II
B-01	Un estudio de fase 1/2 de ASP1570 como monoterapia y en combinación con pembrolizumab o terapias estándar que incluyen quimioterapia y/o inmunoterapia en participantes con tumores sólidos localmente avanzados o metastásicos	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	II
B-01	A Natural History Study of Patients with Previously Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer-Europe.	OBSERVATIONAL STUDY WTIH MEDICINES	ESPERANZA TORRES SANCHEZ	Not applicable
B-01	Estudio de fase 2 de tipo paraguas para evaluar la seguridad, la tolerabilidad y la actividad clínica de diferentes fármacos en investigación para el cáncer de mama triple negativo en estadio temprano, de alto riesgo, recién diagnosticado.	DRUG CLINICAL TRIALS	MARÍA EMILIA DOMINGUEZ RECIO	II
B-01	Ensayo de fase II, multicéntrico, en abierto y pantumoral para evaluar la eficacia y la seguridad del raludotatug deruxtecán (R-DXd) en participantes con tumores sólidos avanzados o metastásicos	DRUG CLINICAL TRIALS	MARÍA JOSÉ BERMEJO PEREZ	II
B-01	Estudio de fase 1/2 abierto para evaluar la seguridad y la eficacia de MK-3120 en participantes con tumores sólidos avanzados.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II
B-01	Estudio de fase I/II, abierto y multicéntrico de ALE.P02 (conjugado de anticuerpo y fármaco dirigido a la claudina 1) en monoterapia en pacientes adultos con determinados tumores sólidos epidermoides CLDN1+ avanzados o metastásicos.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II

Group	Title	Subtype	PI Name	Phase
B-01	Estudio de fase I/II, aleatorizado, multicohorte para evaluar la seguridad, tolerabilidad, farmacoci-nética y actividad clínica de GSK5733584 en combinación con otros tratamientos contra el cáncer en participantes con tumores sólidos avanzados.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II
B-01	Estudio de Fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de inavolisib más un inhibidor de CDK4/6 y LETROZOL comparado con placebo más un inhibidor de CDK4/6 y LETROZOL en pacientes con cáncer de mama avanzado hormonodependiente con mutación de PIK3CA, positivo para receptores hormonales y HER2 Negativo	DRUG CLINICAL TRIALS	ANA GODOY ORTIZ	III
B-01	Estudio en fase II/III aleatorizado, doble ciego, controlado con comparador activo, adaptativo y multicéntrico para evaluar la seguridad y la eficacia de EIK1001 en combinación con pembrolizumab, frente a placebo y pembrolizumab, como tratamiento de primera línea en pacientes con melanoma avanzado	DRUG CLINICAL TRIALS	MANUEL ZALABARDO AGUILAR	II/III
B-01	Phase II Study to assess the efficacy of Niraparib rechallenge after surgery in ovarian cancer patient with oligometastatic progression (The ANALLISA study)	DRUG CLINICAL TRIALS	MARÍA JOSÉ BERMEJO PEREZ	II
B-01	Estudio de fase II aleatorizado para evaluar la seguridad y la eficacia del trastuzumab derux-teca´n frente a la hormonoterapia con inhibidores de CDK4/6, como terapia de primera li´nea, en pacientes con ca´ncer avanzado de mama HR-positivo y HER2-bajo/ultrabajo, clasificados como subtipo no luminal segu´n el perfil de expresio´n gene´tica (Estudio PONTIAC).	DRUG CLINICAL TRIALS	MARÍA EMILIA DOMINGUEZ RECIO	II
B-01	Un estudio de fase 1/2, por primera vez en humanos, de etiqueta abierta, multicéntrico, de escalada y expansión de dosis del inhibidor oral de ADN helicasa Werner (WRNi) GSK4418959 solo o en combinación con otros agentes anticancerígenos en participantes adultos con tumores sólidos deficientes en reparación de desajustes (dMMR) o inestabilidad de microsatélites altos (MSI-H) (SYLVER).	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II
B-01	A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors	DRUG CLINICAL TRIALS	ISABEL SEVILLA GARCIA	III
B-01	Estudio de fase I para evaluar la seguridad, tolerabilidad, farmacocinética y actividad clínica de GSK5764227 en Monoterapia y en Combinación en participantes con tumores sólidos avanzados.	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I
B-01	A Study to Learn About the Study Medicine Called PF-07248144 inCombination with Fulvestrant in People with HR-positive, HER2-negative Advanced orMetastatic Breast Cancer who Progressed After a Prior Line of Treatmen	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	III
B-01	Phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/ MSI-H stage II-III endometrial cancer.	DRUG CLINICAL TRIALS	MARÍA JOSÉ BERMEJO PEREZ	II
B-01	Estudio de fase 2, abierto, multicéntrico, independiente del tipo tumoral, de MK-1084 en monote-rapia y en combinación con cetuximab en participantes con tumores sólidos avanzados con mu-tación de KRAS G12C (KANDLELIT-014).	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	II
B-01	IZABRIGHT-Breast01: Estudio aleatorizado, abierto, inferencial continuo de Fase 2/3 de Izalontamab Brengitecan (BMS-986507) versus el tratamiento de elección del médico en pacientes con cáncer de mama triple negativo (CMTN) o cáncer de mama con baja expresión de receptores de estrógeno y HER2 negativo, localmente avanzado, recurrente irresecable o metastásico, que no han sido tratados previamente y que no son elegibles para el tratamiento con Anti-PD1/PD-L1.	DRUG CLINICAL TRIALS	MARÍA EMILIA DOMINGUEZ RECIO	II/III
B-01	Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants with Advanced Malignancies	DRUG CLINICAL TRIALS	MARCOS IGLESIAS CAMPOS	I
B-01	AndroMETa-CRC-064: Estudio global fase 3, abierto, aleatorizado, controlado para comparar telisotuzumab adizutecan (ABBV-400) en monoterapia con LONSURF (trifluridina y tipiracilo) más bevacizumab en pacientes con cáncer colorrectal metastásico, resistente, con un nivel de expre-sión de proteína c-Met superior a un valor de corte definido	DRUG CLINICAL TRIALS	ESPERANZA TORRES SANCHEZ	III
B-01	An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triplenegative breast cancer (DIAMOND)	DRUG CLINICAL TRIALS	JAVIER PASCUAL LOPEZ	II

Group	Title	Subtype	PI Name	Phase
B-01	Estudio de fase I/IIa, modular, abierto y multicéntrico, para evaluar la seguridad, tolerabilidad, farmacocinética, farmacodinamia y, de manera preliminar, la eficacia de dosis crecientes de AZD9574, en monoterapia y en combinación con agentes antineoplásicos, en pacientes con tumores sólidos avanzados (CERTIS1).	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II
B-01	A Phase 1b/2 Clinical Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in combination with Standard of Care (SoC) or other agents in Participants with Advanced Solid Tumors	DRUG CLINICAL TRIALS	JAVIER GARCIA CORBACHO	I/II
B-01	Natural History, Treatment Patterns, and Real-World Clinical Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Europe and China	OBSERVATIONAL STUDY WTIH MEDICINES	NURIA RIBELLES ENTRENA	Not applicable
B-05	Estudio fase I/2a, de escalada de dosis y de expansión de cohortes de la seguridad, tolerabilidad, y eficacia del anticuerpo monoclonal anti-LAG-3(BMS-986016) administrado solo y en combinación con el anticuerpo monoclonal anti-PD-1 (Nivolumab, BMS-936558) en tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Ensayo fase III, internacional, multicéntrico, doble ciego, aleatorizado y controlado con placebo de Durvalumab tras el tratamiento con radioterapia estereotáctica corporal (SBRT), para el tratamiento de pacientes con cáncer de pulmón no microcítico, estadio I/II no resecado, con ganglios linfáticos negativos (PACIFIC-4/RTOG-3515)	COMMERCIAL CLINICAL TRIAL	JOSE CARLOS BENITEZ MONTAÑEZ	III
B-05	Estudio de fase I-II para evaluar la seguridad, tolerabilidad y eficacia de PM01183 y atezolizumab en pacientes con cáncer de pulmón de células pequeñas avanzado que hayan progresado tras una quimioterapia previa de platino	INDEPENDENT CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	II
B-05	Estudio en fase IIa, sin enmascaramiento y multicéntrico para analizar la seguridady eficacia de la combinación de BL-8040 y pembrolizumab en pacientes con cáncer pancreático metastásico, el estudio COMBAT.	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	II
B-05	Estudio en fase I, sin enmascaramiento, de aumento gradual y ampliación de la dosis para evaluar la seguridad, la tolerabilidad, la farmacocinética, la inmunogenia y la actividad antineoplásica de MEDI5752 en pacientes con tumores sólidos avanzados.	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio Fase 1, multicentrico, abierto, de busqueda de dosis para evaluar la seguridad, tolerabilidady eficacia preliminar de CC-90011 administrado en combinacioncon con Cisplatino y Etoposido, de primera linea para sujetos con cancer de pulmon de celulas pequeñas en estadio extenso	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio de Fase IB multicéntrico, abierto de RO7082859 y Atezolizumab o Polatuzumab Vedoitna (más una dosis única de Obinutuzumab como pretratamiento) en pacientes adultos con linfoma no Hodgkin de células B recurrente/Refractario.	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMINGUEZ	I
B-05	Estudio de Fase II/III, aleatorizado, doble ciego, de diseño adaptativo, de GSK3359609 o placebo en combinación con pembrolizumab para el tratamiento en primera línea del carcinoma de células escamosas de cabeza y cuello recurrente o metástico con expresiónde PD-L1	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMINGUEZ	III
B-05	Ensayo aleatorizado fase III de nivolumab en adyuvancia y quimioterapia concomitante en pacientes de alto riesgo con carcinoma de células escamosas de cabeza y cuello resecado (NIVO POST-OP)	INDEPENDENT CLINICAL TRIAL	ELISABETH PEREZ RUIZ	III
B-05	Primer ensayo en humanos, abierto, de aumento escalonado de la dosis con cohortes de ampliación para evaluar la seguridad de GEN1046 en sujetos con tumores sólidos malignos	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	II
B-05	Estudio de fase IB, sin enmascaramiento, multicéntrico, no aleatorizado, para evaluar la seguridad, la farmacocinética y la eficacia de mosunetuzumab en combinación con lenalidomida, o RO7082859 en combinación con lenalidomida, o RO7082859 en combinación con obinutuzumab más lenalidomida en pacientes con linfoma folicular resistente o recidivante	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMINGUEZ	I
B-05	Primer Estudio en seres humanos fase 1/2a, del anticuerpo monoclonal BMS-986218 en monoterapia y en combinación con nivolumab en tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I

Group	Title	Subtype	PI Name	Phase
B-05	Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de Debio 1143 en combinación con quimioterapia con un derivado del platino y radioterapia de intensidad modulada con fraccionamiento convencional en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado apto para quimiorradioterapia definitiva (TrilynX).	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	III
B-05	Estudio de fase I/II, multicéntrico, en dos partes, abierto, orientado a evaluar la seguridad y tolerabilidad de la administración de dosis crecientes de AGI-134 en los tumores sólidos no operables/metastásicos.	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	II
B-05	Estudio fase Ib/IIa para Evaluar la Seguridad y Eficacia del Tratamiento con el Inhibidor de la Ruta de Hedhegog NLM-001 Antes de Quimioterapia (Gemcitabina y Nab-Paclitaxel) más Zalifrelimab como Tratamiento de Primera Línea en Pacientes con Cáncer de Páncreas Avanzado.	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio de Fase IA/IB de aumento y ampliación de la dosis para evaluar la seguridad, la farmacocinética y la actividad de GDC-6036 en monoterapia y en combinación con otros tratamientos antineoplásicos en pacientes con tumores sólidos avanzados o metastásicos con la mutación KRAS G12C	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y seguridad de tafasitamab más lenalidomida además de rituximab frente a lenalidomida además de rituximab en pacientes con linfoma folicular recidivante/resistente (R/R) de grado 1 a 3a o linfoma de la zona marginal R/R	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMINGUEZ	III
B-05	Estudio de fase Ib, abierto, global, multicéntrico, aleatorizado, de determinación y ampliación de la dosis, para determinar la dosis máxima tolerada y evaluar la seguridad, tolerabilidad, la farmacocinética y la eficacia preliminar de iberdomida (CC-220) en combinación con R-CHOP-21 y de CC-99282 en combinación con R-CHOP-21 en sujetos con linfoma de células B agresivo de bajo riesgo (IPI de 3 a 5) sin tratamiento previo.	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMINGUEZ	I
B-05	Ensayo en Fase 1B, abierto, con escalado de dosis, para determinar la seguridad y las respuestas inmunitarias dirigidas contra antígenos específicos provocadas por VB.01 NEO en combinación con ATEZOLIZUMAB en sujetos con tumores localmente avanzados y metastásicos	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Ensayo clínico de fase II de un solo brazo para evaluar la eficacia y seguridad de Bintrafusp alfa (M7824) en el mesotelioma pleural maligno avanzado previamente tratado (BIMES).	INDEPENDENT CLINICAL TRIAL	JOSE CARLOS BENITEZ MONTAÑEZ	II
B-05	Estudio de fase I/II de NM21-1480 (anticuerpo triespecífico anti-PDL-1/anti-4-1BB/anti-HSA) en pacientes adultos con tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio en Fase II de ALX148 en combinación con PEMBROLIZUMAB en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (ASPEN-03).	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	II
B-05	Estudio Fase 1, multicéntrico, abierto para determinar la seguridad, farmacocinética y eficacia preliminar de una molécula pequeña, CC-99282, disponible para administración oral en monoterapia y en combinación con rituximab en sujetos con linfoma no Hodgkin en recaída o refractario (LNH R/R)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMINGUEZ	I
B-05	Nivolumab e Ipilimumab más dos ciclos de quimioterapia basada en platino como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico (CPNM) estadio IV o recurrente con metástasis cerebrales sincrónicas. (NIVIPI-Brain)	INDEPENDENT CLINICAL TRIAL	ALEXANDRA CANTERO GONZALEZ	II
B-05	Estudio de fase 1 de JNJ-78278343, un agente de redireccionamiento de células T dirigido a la Calicreína Humana 2 (KLK2), para cáncer de próstata avanzado	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio clínico de fase 1 para evaluar la biodisponibilidad de pembrolizumab administrado en inyección subcutánea de MK-3475A, una formulación de pembrolizumab con MK-5180, en participantes con tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor	COMMERCIAL CLINICAL TRIAL	JOSE CARLOS BENITEZ MONTAÑEZ	II
B-05	Estudio en fase II de ALX148 en combinación con pembrolizumab y quimioterapia en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (ASPEN-04)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMINGUEZ	II

Group	Title	Subtype	PI Name	Phase
B-05	Estudio en Fase III, aleatorizado, doble ciego sobre los efectos de Encorafenib y Binimetinib más Pembrolizumab frente a placebo más Pembrolizumab en pacientes con diagnóstico de melanoma metastásico o melanoma localmente avanzado irresecable con mutación V600E/K en Braf positiva.	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	III
B-05	Ensayo de Fase 3, Abierto, Aleatorizado y Multicéntrico para Evaluar la Eficacia y Seguridad de Trastuzumab Deruxtecan como Tratamiento de Primera Línea en Cáncer de Pulmón No Microcítico, no Resecable y localmente Avanzado o Metastásico que presenta mutación del Exon 19 o 20 de HER2 (Destiny-Lung04)	COMMERCIAL CLINICAL TRIAL	ALEXANDRA CANTERO GONZALEZ	III
B-05	Ensayo en fase II con varios grupos (en canasta) para investigar la seguridad y eficacia de IO102-IO103 en combinación con pembrolizumab, como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico (CPNM) metastásico, carcinoma de células escamosas de cabeza y cuello (CCECC) o carcinoma urotelial de vejiga metastásico (CUVm)	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	II
B-05	Estudio de Fase I, abierto, de búsqueda de dosis de CC-95251, un anticuerpo monoclonal dirigido contra SIRPa, solo y en combinación con cetuximab o rituximab en sujetos con tumores sólidos y hematológicos avanzados	DRUG CLINICAL TRIALS	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio en fase III, abierto y aleatorizado, de LOXO-305 en comparación con un inhibidor de tirosina cinasa de Bruton (BTK, por sus siglas en inglés) a elegir por el investigador, en pacientes con linfoma de células del manto tratados previamente y sin tratamiento previo con inhibidoresde BTK (BRUIN MCL-321).	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMINGUEZ	III
B-05	Estudio de fase 2 de tratamiento combinado con magrolimab en pacientes con carcinoma de células escamosas de cabeza y cuello	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	II
B-05	Primer ensayo clínico en el ser humano, en fase I, de BMS-986406 como tratamiento en monoterapia y en combinación en participantes con tumores malignos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio de fase III multicéntrico, aleatorizado y doble ciego de HBI-8000 combinado con nivolumab frente a placebo con nivolumab en pacientes con melanoma irresecable o metastásico no tratados previamente con inhibidores de PD-1 o PD-L1	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	III
B-05	Estudio en fase II, aleatorizado, doble ciego y multicéntrico de retifanlimab en combinación con INCAGN02385 (anti-LAG-3) e INCAGN02390 (anti-TIM-3) como tratamiento de primera línea en participantes con carcinoma escamoso de cabeza y cuello metastásico/recidivante positivo para PD-L1 (CPS =1).	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	II
B-05	Estudio de fase 2 de multiples brazos de Magrolimab en pacientes con tumores solidos	INDEPENDENT CLINICAL TRIAL	ALEXANDRA CANTERO GONZALEZ	II
B-05	Estudio multicéntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirugía y una terapia adyuvante frente a cirugía y una terapia adyuvante en pacientes con melanoma en estadio IIIB/C	DRUG CLINICAL TRIALS	ELISABETH PEREZ RUIZ	III
B-05	Primer ensayo en humanos, abierto, de aumento escalonado de la dosis con cohortes de ampliación para evaluar la seguridad y actividad antitumoral de GEN1042 en sujetos con tumores sólidos malignos	COMMERCIAL CLINICAL TRIAL	LAURA MARÍA MEDINA RODRIGUEZ	II
B-05	Estudio aleatorizado, prospectivo y multicéntrico para evaluar el impacto de la detección temprana de metástasis cerebrales asintomáticas (metástasis cerebrales) frente al seguimiento estándar en la supervivencia libre de metástasis cerebrales sintomáticas (SBMFS) en pacientes con melanoma no tratado previamente, no resecable o metastásico.	OBSERVATIONAL STUDY WTIH MEDICINES	ELISABETH PEREZ RUIZ	Not applicable
B-05	Protocolo maestro de fase II, multicéntrico, abierto, para evaluar la eficacia y seguridad de datopotamab deruxtecán (Dato-DXd) en monoterapia y en combinación con antineoplásicos, en pacientes con tumores sólidos en estadio avanzado o metastásico (TROPION-PanTumor03)	DRUG CLINICAL TRIALS	LAURA MARÍA MEDINA RODRIGUEZ	II
B-05	Estudio en fase II abierto y aleatorizado de MORAb-202 (farletuzumab ecteribulina), un conjugado de anticuerpo y fármaco dirigido al receptor a de folato, en participantes con adenocarcinoma (AC) de pulmón no microcítico (ACPNM) metastásico después de haber progresado con tratamientos anteriores	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	II

Group	Title	Subtype	PI Name	Phase
B-05	Estudio de fase 1b que evalúa la seguridad, tolerabilidad, farmacocinética y eficacia de bemarituzumab en monoterapia y en combinación con otra terapia contra el cancer en sujetos con cáncer de pulmón no microcítico escamoso (FORTITUDE-201)	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	I
B-05	Estudio de fase III de fianlimab (REGN3767, anti-LAG-3) + cemiplimab en comparación con pembrolizumab en pacientes con melanoma metastásico o localmente avanzado inoperable no tratado previamente	DRUG CLINICAL TRIALS	ELISABETH PEREZ RUIZ	III
B-05	Estudio de fase 1/1b para evaluar la seguridad y la tolerabilidad de AB308 en combinación con AB122 en participantes con neoplasias malignas avanzadas	DRUG CLINICAL TRIALS	LAURA MARÍA MEDINA RODRIGUEZ	I
B-05	Estudio fase 1b/2 de BMS-986442 en combinación con nivolumab o nivolumab y quimioterapias en participantes con tumores sólidos avanzados y cáncer de pulmón no microcítico.	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	II
B-05	Estudio de Fase III, aleatorizado, abierto y multicéntrico de lurbinectedina en combinación con atezolizumab, en comparación con atezolizumab, como tratamiento de mantenimiento en pacientes con cáncer de pulmón microcítico en enfermedad extensa (CPM-EE) después de tratamiento de inducción de primera línea con carboplatino, etopósido y atezolizumab.	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	III
B-05	Estudio multicéntrico, abierto, de fase I/II de EOS884448 en combinación con el tratamiento estándar y/o terapias experimentales en participantes con tumores sólidos avanzados	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	II
B-05	Estudio abierto, multicéntrica fase II de selección de dosis intravenosa de BI 764532, un T cell engager dirigido a DLL3, en pacientes con cáncer extensivo de pulmón microcítico refractario o en recaída y en pacientes con otras carcinomas neuroendocrinos refractarios o en recaída. DAREON™-5.	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	II
B-05	Estudio en Fase III, abierto y aleatorizado para comparar la eficacia y la seguridad de Odronextamab (REGN1979), un anticuerpo biespecífico ANTI-CD20 y ANTI-CD3, frente al tratamiento elegido por el investigador en participantes con Linfoma Folicular sin tratamiento previo (OLYMPIA-1).	DRUG CLINICAL TRIALS	ANTONIO RUEDA DOMINGUEZ	III
B-05	Estudio fase 1, multicéntrico, abierto, de búsqueda de dosis, para evaluar la seguridad, tolerabilidad, farmacocinética, farmacodinamia y eficacia preliminar de BMS-986458, en monoterapia y en combinación con agentes antilinfoma, en participantes con linfomas no Hodgkin en recaída/refractarios (LNH R/R).	DRUG CLINICAL TRIALS	ANTONIO RUEDA DOMINGUEZ	I
B-05	Ensayo fase 3, aleatorizado, abierto, multicéntrico de repotrectinib frente a crizotinib en participantes con cáncer de pulmón no microcítico (CPNM), localmente avanzado o metastásico, ROS1-positivo, que no han sido previamente tratados con inhibidores de la tirosina quinasa (TKI) (TRIDENT-3)	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	III
B-05	A Randomized Study of Two Dosing Regimens of Adagrasib in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	II
B-05	BelieveIT-201: A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 ß/?, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC).	DRUG CLINICAL TRIALS	ANTONIO RUEDA DOMINGUEZ	II
B-05	Estudio de fase I/II, primero en seres humanos, abierto y de aumento escalonado de la dosis de TAK-280 en pacientes con cáncer no resecable localmente avanzado o metastásico.	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	I
B-05	Estudio clínico aleatorizado, de fase III, de MK 4280A (coformulación de favezelimab [MK 4280] y pembrolizumab [MK 3475]) en comparación con la quimioterapia de elección del médico en el Linfoma de Hodgkin clásico en recaída o refractario, con resistencia a PD-(L)1 (KEYFORM-008)	DRUG CLINICAL TRIALS	ANTONIO RUEDA DOMINGUEZ	III
B-05	Estudio de plataforma base 1b/2, multicéntrico, abierto para selección de combinaciones de inmunoterapia en participantes adultos con cáncer de pulmón de células no pequeñas (CPCNP) avanzado no tratados previamente con elevada expresión de PD-L1	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	I
B-05	Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para comparar la eficacia y la seguridad de golcadomida más quimioterapia R-CHOP frente a placebo más quimioterapia R-CHOP en participantes con linfoma de células B grandes de alto riesgo no tratado previamente.	DRUG CLINICAL TRIALS	ANTONIO RUEDA DOMINGUEZ	III
B-05	A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	I

Group	Title	Subtype	PI Name	Phase
B-05	Estudio en fase II, multicéntrico, de varios grupos, abierto y de prueba de concepto de patritumab deruxtecán (HER3-DXd; U3-1402) en sujetos con tumores sólidos localmente avanzados o metastásicos (HERTHENA-PanTumor01).	DRUG CLINICAL TRIALS	ELISABETH PEREZ RUIZ	II
B-05	Un estudio de fase I/II de avutometinib (VS-6766) en combinación con sotorasib en pacientes con cáncer de pulmón de células no pequeñas (CPCNP) con mutación KRAS G12C (RAMP 203).	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	I/II
B-05	A randomised, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after secondary resistance to anti-PD(L)1 inhibitors.	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	III
B-05	The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Afficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)	DRUG CLINICAL TRIALS	ELISABETH PEREZ RUIZ	II
B-05	Estudio Fase I/II abierto para evaluar la seguridad, farmacocinética y actividad antitumoral preliminar de RO7227166 (ligando 4-1BB dirigido contra CD19) en combinación con Obinutuzumab y con Glofitamab después de una dosis de pretratamiento con Obinutuzumab, en pacientes con Linfoma no Hodgkin de Linfocitos B recidivante/refractario.	DRUG CLINICAL TRIALS	ANTONIO RUEDA DOMINGUEZ	I
B-05	A phase 3 randomized, controlled study of IMC-F106C plus Nivolumab versus Nivolumab regimens in HLA-A202:01-positive participants with previously untreated advanced melanoma (PRISM-MEL-301)	DRUG CLINICAL TRIALS	ELISABETH PEREZ RUIZ	III
B-05	Estudio de fase III, abierto, multicéntrico y aleatorizado de una combinación de CBP501, cisplatino y nivolumab o la terapia elegida por el médico para pacientes con adenocarcinoma pancreático avanzado, en =3ª línea de tratamiento [FUJI-PanC01] /// A Phase 3, Open-Label, Multicenter, Randomized Study of a Combination of CBP501, Cisplatin and Nivolumab or Physician's Choice of Therapy for =3rd Line Treatment of Patients with Advanced Pancreatic Adenocarcinoma [FUJI-PanC01]	DRUG CLINICAL TRIALS	LAURA MARÍA MEDINA RODRIGUEZ	III
B-05	An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice settings in Europe (CEMI-LUNG).	OBSERVATIONAL STUDY WTIH MEDICINES	JOSE CARLOS BENITEZ MONTAÑEZ	Not applicable
B-05	Registro para recoger datos de las características y resultados de pacientes con Tumores Sólidos a los que se realizó una prueba de secuenciación de nueva generación (WAYFIND-R).	OBSERVATIONAL STUDY WTIH MEDICINES	JOSE CARLOS BENITEZ MONTAÑEZ	Not applicable
B-05	Estudio ambispectivo, no intervencionista, de cohortes múltiples para evaluar el manejo del tratamiento con osimertinib en pacientes con cáncer de pulmón no microcítico con mutaciones EGFR en condiciones reales en España	OBSERVATIONAL STUDY WTIH MEDICINES	JOSE CARLOS BENITEZ MONTAÑEZ	Not applicable
B-05	A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with hylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	II
B-05	Estudio en fase Ib/II, abierto y de múltiples cohortes para evaluar la seguridad, la eficacia y la dosis óptima de ABBV-400 en combinación con budigalimab en el CPNM no epidermoide avanzado o metastásico sin tratamiento previo en caso de enfermedad avanzada y sin variaciones genómicas accionables (AndroMETa-Lung-536).	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	I/II
B-05	Un Estudio de escalada y expansión de dosis de Fase I/II que evalua la seguridad, farmacocinética y actividad de GDC-7035 como agente único y en combinación con otras terapias anticáncer en pacientes con tumores sólidos avanzados con una mutación KRAS G12D	DRUG CLINICAL TRIALS	LAURA MARÍA MEDINA RODRIGUEZ	I/II
B-05	Estudio clínico de fase 1/2 abierto para evaluar la seguridad y la eficacia de MK-6070 e ifinatamab deruxtecán (I-DXd) en participantes con cáncer de pulmón no microcítico en estadio avanzado recidivante o resistente.	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	I/II
B-05	Ensayo aleatorizado de fase I/II en pacientes con carcinoma de células escamosas de la ca-beza y el cuello (SCCHN) locorregionalmente avanzado, negativo para el VPH, de diagnóstico reciente, en el que se evalúa una inmunoterapia dirigida al mutanoma iniciada al finalizar el tratamiento primario o en el momento de la recidiva.	DRUG CLINICAL TRIALS	ANTONIO RUEDA DOMINGUEZ	I/II

Group	Title	Subtype	PI Name	Phase
B-05	Estudio de Fase III aleatorizado, abierto, para evaluar la eficacia y seguridad de DIVARASIB y PEMBROLIZUMAB comparado con PEMBROLIZUMAB y PEMETREXED más CARBOPLATINO o CISPLATINO en pacientes con cáncer de pulmón no microcítico no escamoso con mutación KRAS G12C, avanzado o metastásico, no tratados previamente.	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	III
B-05	Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study. PULSE	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	III
B-05	A Phase I Dose-Finding Study to Evaluate Safety and Tolerability of CVHNLC plus Pembrolizumab in Patients with Squamous Non Small-Cell Lung Cancer (sqNSCLC).	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	I
B-05	Ensayo clínico de fase Ib, abierto y aleatorizado para evaluar la seguridad y la eficacia de BI 770371 en combinación con pembrolizumab con o sin cetuximab en comparación con pembro-lizumab en monoterapia para el tratamiento de primera línea de pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) metastásico o recidivante.	DRUG CLINICAL TRIALS	ANTONIO RUEDA DOMINGUEZ	I
B-05	Ensayo clínico multicéntrico de fase II, de un solo brazo, para evaluar la actividad de encorafenib más binimetinib seguido de cemiplimab y fianlimab en pacientes con melanoma con BRAF mutado y metástasis cerebrales sintomáticas.	DRUG CLINICAL TRIALS	ELISABETH PEREZ RUIZ	II
B-05	A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046)in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	III
B-05	Ensayo abierto, multicéntrico, aleatorizado, de fase III de trastuzumab deruxtecán en combinación con pembrolizumab frente a quimioterapia basada en platino en combinación con pembrolizumab como tratamiento de primera línea en participantes con cáncer de pulmón no microcítico, no escamoso, localmente avanzado irresecable o metastático, con sobreexpresión de HER2 y TPS de PD-L1 <50 % (DESTINY-Lung06).	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	III
B-05	Ensayo abierto, multicéntrico, aleatorizado, de fase III de trastuzumab deruxtecán en combinación con pembrolizumab frente a quimioterapia basada en platino en combinación con pembrolizumab como tratamiento de primera línea en participantes con cáncer de pulmón no microcítico, no escamoso, localmente avanzado irresecable o metastático, con sobreexpresión de HER2 y TPS de PD-L1.<50 % (DESTINY-Lung06)	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	III
B-05	Ensayo multicéntrico, aleatorizado, abierto, de Fase 1B/2 de Tosilato de Valemetostat más Pembrolizumab frente a Pembrolizumab solo en participantes con cáncer de pulmón no microcítico avanzado o metastásico cuyos tumores expresan PD-L1 con una puntuación de proporción tumoral =50 % sin alteraciones genomicas procesables. (Tosilato de Valemetostat más Pembrolizumab frente a Pembrolizumab solo en el CPNM de primera línea sin alteraciones genomicas procesables)	DRUG CLINICAL TRIALS	JOSE CARLOS BENITEZ MONTAÑEZ	I/II
B-05	Estudio de fase 2/3, aleatorizado, de BMS-986504 en combinación con pembrolizumab y quimio-terapia frente a placebo más pembrolizumab y quimioterapia en participantes con cáncer de pul-món no microcítico metastásico en primera línea con deleción homocigótica de MTAP	DRUG CLINICAL TRIALS	ALEXANDRA CANTERO GONZALEZ	II/III
B-05	Estudio en fase II/III aleatorizado, doble ciego, controlado con comparador activo, adaptativo y multicén-trico para evaluar la seguridad y la eficacia de EIK1001 en combinación con pembrolizumab, frente a placebo y pembrolizumab, como tratamiento de primera línea en pacientes con melanoma avanzado	DRUG CLINICAL TRIALS	ELISABETH PEREZ RUIZ	III
B-05	Ensayo en fase III, aleatorizado, controlado con placebo y doble ciego para evaluar la seguridad, tolerabilidad e inmunogenicidad de una vacuna multivalente contra el estreptococo del grupo B en mujeres embarazadas sanas y sus bebés	DRUG CLINICAL TRIALS	JOSÉ CLAUDIO MAAÑÓN DI LEO	III
B-10	Estudio de extensión abierto y multicéntrico para caracterizar la seguridad y la eficacia a largo plazo de BMS-986165 en pacientes con psoriasis en placas de moderada a grave	COMMERCIAL CLINICAL TRIAL	ENRIQUE HERRERA ACOSTA	III
B-10	Ensayo Clínico fase II para evaluar la seguridad y eficacia de dos modelos de piel autóloga creada mediante ingeniería de tejidos en la cirugía reconstructiva del carcinoma basocelular.	INDEPENDENT CLINICAL TRIAL	RICARDO BOSCH GARCIA	II

Group	Title	Subtype	PI Name	Phase
B-10	Estudio observacional transversal para la caracterización del Paciente Adulto con Dermatitis Atópica (DA) moderada a grave y la estimación de la prevalencia de la DA en Unidades de Dermatología del ámbito hospitalario en España. (NIS-AD-2193). Estudio DACAR	NON-POST-APPROVAL STUDY	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio observacional prospectivo con pacientes adultos en tratamiento con Dupixent para la dermatitis atópica	COMMERCIAL POST-AUTHORIZATION STUDY	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Uso en vida real de upadacitinib en pacientes adultos y adolescentes que padecen dermatitis atópica de moderada a grave (AD-VISE) P20-441. Estudio ADVISE	OBSERVATIONAL STUDY WTIH MEDICINES	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio observacional retrospectivo en pacientes con Dermatitis Atópica tratados con baricitinib en España (Estudio DAMA-S)	OBSERVATIONAL STUDY WTIH MEDICINES	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	A multicenter, Prospective, observational study measuring tildrakizumab benefit in Achieving Therapeutic goals in patients with moderate-to-severe plaque psoriasis and inadequate response to previous biologic treatments in clinical practice in Spain.	OBSERVATIONAL STUDY WTIH MEDICINES	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	BIOBADATOP Registro Español de Dermatitis atópica	OBSERVATIONAL STUDY WTIH MEDICINES	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	An international, prospective, observational cohort study to assess patient treatment satisfaction, patient-reported outcomes, effectiveness, and safety of a fixed-dose combination of Calcipotriene/Betamethasone Dipropionate PAD cream in the treatment of mild-to-moderate plaque psoriasis of the scalp in adults (PRO-SCALP)	OBSERVATIONAL STUDY WTIH MEDICINES	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio en fase IIIb sin enmascaramiento para evaluar la eficacia y la seguridad del tratamiento con lebrikizumab en adultos y adolescentes con dermatitis atópica de moderada a grave.	DRUG CLINICAL TRIALS	ENRIQUE HERRERA ACOSTA	III
B-10	Registro Español de Hidradenitis Supurativa	OBSERVATIONAL STUDY WTIH MEDICINES	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio observacional retrospectivo del mundo real para describir el uso de recursos sanitarios y los costes asociados a las vías de tratamiento de la psoriasis en fuentes de datos hospitalarios	OBSERVATIONAL STUDY WTIH MEDICINES	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	Estudio en fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la seguridad y eficacia de lutikizumab en pacientes adolescentes y adultos con hidradenitis supurativa de moderada a grave.	DRUG CLINICAL TRIALS	ENRIQUE HERRERA ACOSTA	III
B-10	A long-term safety and efficacy study of N-Acetyl-GED-0507-34-LEVO gel 5%, in subjects with acne vulgaris (GEDACNE-LT)	DRUG CLINICAL TRIALS	ENRIQUE HERRERA ACOSTA	III
B-10	Ensayo multicéntrico, aleatorizado, comparativo con placebo, doble ciego, con grupos paralelos para evaluar la seguridad y la eficacia del espesolimab (BI?655130) en pacientes adultos con piodermia gangrenosa (PG) ulcerativa que necesitan tratamiento sistémico	DRUG CLINICAL TRIALS	ENRIQUE HERRERA ACOSTA	II
B-10	Estudio en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de sonelokimab subcutáneo en participantes adultos con hidradenitis supurativa de moderada a grave	DRUG CLINICAL TRIALS	ENRIQUE HERRERA ACOSTA	III
B-10	Ensayo de fase III para evaluar la eficacia y seguridad de N-acetil-GED-0507-34-LEVO gel al 5%, aplicado una vez al día durante 12 semanas en pacientes con acné vulgar (GEDACNE-1).	DRUG CLINICAL TRIALS	ENRIQUE HERRERA ACOSTA	III
B-10	Hidradenitis suppurativa patients treated with bimekizumab: a real-life long-term prospective observation of health outcomes (Hi-LiGHT)	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa	DRUG CLINICAL TRIALS	ENRIQUE HERRERA ACOSTA	III
B-10	The Utility and Applicability of artificial intelligence in a skin cancer screening campaign in Málaga, Spain	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ENRIQUE HERRERA ACOSTA	Not applicable
B-10	A European, multicenter, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust)	OBSERVATIONAL STUDY WTIH MEDICINES	ENRIQUE HERRERA ACOSTA	Not applicable

Group	Title	Subtype	PI Name	Phase
B-10	A Phase 2b Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Patients with Moderate to Severe Atopic Dermatitis	DRUG CLINICAL TRIALS	ENRIQUE HERRERA ACOSTA	II
B-11	Estudio fase 3 aleatorizado, doble ciego y controlado con placebo de JNJ-56021927 en sujetos con cáncer de próstata localizado o localmente avanzado y de alto riesgo que estén recibiendo tratamiento con radioterapia primaria.	COMMERCIAL CLINICAL TRIAL	RAQUEL CORREA GENEROSO	III
B-11	Un Estudio prospectivo aleatorizado de Fase III de terapia de privación de andrógenos con o sin Radioterapia local con o sin Acetato de Abiraterona y Prednisona en pacientes con cáncer de próstata metastásico sin genera de hormonas.	INDEPENDENT CLINICAL TRIAL	RAQUEL CORREA GENEROSO	III
B-11	Estudio en fase II, aleatorizado y abierto de ODM-201 oral frente al tratamiento de deprivación androgénica (TDA) con agonistas oantagonistas de LHRH en varones con cáncer de próstata sin tratamiento hormonal previo	INDEPENDENT CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	II
B-11	Ensayo mundial fase III, aleatorizado, abierto, multicéntrico de Durvalumab y el Bacilo de Calmette-Guerin (BCG) administrados como terapia combinada en comparación con BCG en monoterapia, en pacientes con cáncer de vejiga no músculo invasivo de alto riesgo sin tratamiento previo con BCG (POTOMAC)	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	RECAP (Registro Español de Cáncer de Próstata). Tratamiento radioterápico en pacientes con cáncer de próstata conforme a la práctica clínica habitual en los servicios de oncología radioterápica españoles	INDEPENDENT POSTAUTHORIZATION STUDY	ANA MARÍA OTERO ROMERO	Not applicable
B-11	Estudio fase III, aleatorizado, doble ciego y controlado con placebo sobre el uso de apalutamida en pacientes con cáncer de próstata de alto riesgo, localizado o localmente avanzado candidatos a una prostatectomía radical.PROTEUS	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	Ensayo aleatorizado en fase IIIb para comparar la irradiación más la supresión adyuvante de andrógenos a largo plazo con antagonista de la GnRH frente al agonista de la GnRH más prevención de los brotes en pacientes con riesgo muy alto de cáncer de próstata localizado o localmente avanzado. Estudio conjunto ROG y GUCG de la EORTC. Pegasus	INDEPENDENT CLINICAL TRIAL	ANA MARÍA OTERO ROMERO	III
B-11	Estudio piloto de los efectos biológicos de la vitamina D en pacientes con carcinoma urotelial del tracto urinario resecable	INDEPENDENT CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	IV
B-11	Estudio multicéntrico de radioterapia postoperatoria hipofraccionada en pacientes diagnosticados de cáncer de próstata	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	ANA MARÍA OTERO ROMERO	Not applicable
B-11	Estudio en fase III, aleatorizado, controlado con placebo y doble ciego de darolutamida además de tratamiento de privación de andrógenos (TPA) frente a placebo más TPA en hombres con cáncer de próstata metastásico sensible a las hormonas (CPMSH) (ARANOTE)	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	Estudio clínico de fase 2b para evaluar la eficacia y seguridad de TAR-200 en combinación con cetrelimab, TAR-200 solo o cetrelimab solo en participantes con cáncer de vejiga no músculo-invasivo (CVNMI) de alto riesgo que no responde a la terapia del bacilo de Calmette-Guerin (BCG) intravesical y que no son candidatos o han elegido no someterse a cistectomía radical (SunRISe 1)	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio observacional de darolutamida en pacientes con cáncer de próstata resistente a la castración no metastásico. DAROL	COMMERCIAL POST-AUTHORIZATION STUDY	BERNARDO HERRERA IMBRODA	Not applicable
B-11	Estudio de fase III con un solo grupo para evaluar la eficacia y la seguridad de ONCOFID-P-B (conjugado paclitaxel-ácido hialurónico) administrado por vía intravesical a pacientes con carcinoma in situ de vejiga sin respuesta a BCG, con o sin enfermedad papilar Ta-T1	DRUG CLINICAL TRIALS	FELIPE SAEZ BARRANQUERO	III
B-11	Estudio de fase 2, multicéntrico, aleatorizado y abierto, de TAR-200 en combinación con cetrelimab y monoterapia con cetrelimab en participantes con carcinoma urotelial de vejiga músculo-invasivo que se vayan a tratar con cistectomía radical y no sean elegibles o rechacen recibir tratamiento con quimioterapia neoadyuvante basada en platino Sunrise 4	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio en fase III abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de TAR200 en combinación con cetrelimab frente al bacilo de Calmette-Guérin (BCG) intravesical en pacientes con cáncer de vejiga no músculo-invasivo de alto riesgo (HR-NMIBC) sin tratamiento previo con el BCG. Sunrise 3	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	III

Group	Title	Subtype	PI Name	Phase
B-11	Estudio en fase III, aleatorizado, controlado con placebo y doble ciego de darolutamida más tratamiento de privación de andrógenos (TPA) en comparación con placebo más TPA en pacientes con cáncer de próstata con recurrencia bioquímica (RB) de alto riesgo	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	III
B-11	Patrones de tratamiento y seguimiento prolongado de los pacientes con cáncer de próstata que recibieron darolutamida en el ensayo ARAMIS – PARASEC.	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN ANDRÉS CANTERO MELLADO	Not applicable
B-11	studio en fase 3, abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de TAR-200 frente a la quimioterapia intravesical elegida por el investigador en pacientes que recibieron el bacilo de Calmette-Guérin (BCG) y presentan recurrencia con cáncer de vejiga no músculo-invasivo de alto riesgo (HR-NMIBC) y no son elegibles o eligen no someterse a una cistectomía radical	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	III
B-11	Estudio aleatorizado en fase III para evaluar la eficacia y la seguridad del sistema de administración intravesical de erdafitinib TAR-210 en comparación con quimioterapia intravesical en monoterapia en pacientes con cáncer de vejiga no musculo-invasivo de riesgo intermedio (CVSIM-RI) y alteraciones sensibles del FGFR	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	III
B-11	Estudio de fase 3, multicéntrico, con un único grupo, para evaluar la eficacia y la seguridad de UGN-103, una nueva formulación de UGN-102, en el tratamiento de pacientes con cáncer de vejiga sin invasión muscular (CVSIM) de evolución lenta (EL) y riesgo intermedio (RI) de recurrencia (UTOPIA	DRUG CLINICAL TRIALS	FELIPE SAEZ BARRANQUERO	III
B-11	Ensayo de fase II, multicéntrico, abiertyo y aleatorizado para evaluar la eficacia de Talazoparib junto con Enzalutamida como tratamiento de primera línea para pacientes con Cáncer de Próstata Metastásico resistente a la castración tras progresión con Abiraterona.	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio clínico abierto de fase 1/2 para evaluar la seguridad y la eficacia de sacituzumab tirumotecán (sac-TMT, MK-2870) intravesical en participantes con cáncer de vejiga sin invasión muscular (CVSIM) de riesgo intermedio.	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	I/II
B-11	Estudio de Fase I/II abierto, de escalada de dosis y extensión, de eciskafusp alfa intravesical en combinación con bacilo de CALMETTE-GUÈRIN (BCG) en participantes con cáncer de vejiga no músculo invasivo (CVNMI) de alto riesgo que no responde a BCG	DRUG CLINICAL TRIALS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio en fase III, abierto, aleatorizado y multicéntrico para evaluar la seguridad y la eficacia de nadofaragén firadenovec intravesical administrado en monoterapia o en combinación con quimioterapia (gemcitabina y docetaxel) o inmunoterapia (pembrolizumab) en sujetos con cáncer de vejiga sin invasión muscular (CVSIM) de alto grado y sin respuesta al tratamiento con bacilo de Calmette-Guérin (BCG)	DRUG CLINICAL TRIALS	FELIPE SAEZ BARRANQUERO	III
B-11	Registro de cáncer de próstata hornono sensible en la zona norte. Proyecto PROHNOS	OBSERVATIONAL STUDY WTIH MEDICINES	BERNARDO HERRERA IMBRODA	Not applicable
B-14	Estudio Fase II, aleatorizado, para evaluar la incidencia de discontinuación debida a Diarrea en los 3 primeros ciclos de tratamiento en pacientes con Cáncer de Mama Precoz HER2 positivo (HER2+), Receptor Hormonal positivo (RH+), tratados con Neratinib más Loperamida versus Neratinib con escalada inicial de dosis más Loperamida (según necesidad) versus Neratinib más Loperamida más Colesevelam. “Estudio DIANER”	DRUG CLINICAL TRIALS	IRENE ZARCOS PEDRINACI	II
B-14	Estudio fase II de un solo brazo la eficacia y la seguirdad de la combinación de trastuzumab, TUCAtinib y viNorelbina en pacientes con cáncer de mama localmente avanzado no resecable o metastásico HER2-psoitivo. Estudio TrasTUCAN	DRUG CLINICAL TRIALS	IRENE ZARCOS PEDRINACI	II
B-14	Estudio ambispectivo de pacientes con cáncer de mama triple negativo tratados con sacituzumab govitecan en el sur de España.	OBSERVATIONAL STUDY WTIH MEDICINES	IRENE ZARCOS PEDRINACI	Not applicable
B-22	Estudio fase III aleatorizado, multicéntrico, abierto de lapatinib, tratuzumab, la administración secuencial de ambos y la administración combinada de ambos como tratamiento adyuvante en pacientes on cáncer de mama HER/ErbB2 positivo	COMMERCIAL CLINICAL TRIAL	FRANCISCO CARABANTES OCON	III
B-22	LUX–Head & Neck 2. Un estudio aleatorizado, doble ciego, controlado con placebo, en fase III para evaluar la eficacia y la seguridad de afatinib (BIBW 2992) como terapia adyuvante tras quimio-radioterapia en pacientes no sometidos a resección primaria con carcinoma de células escamosas de cabeza y cuello estadio III, IVa o IVb locorregionalmente avanzado	COMMERCIAL CLINICAL TRIAL	ESTER VILLAR CHAMORRO	III

Group	Title	Subtype	PI Name	Phase
B-22	Estudio fase II, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, para comparar la eficacia y tolerabilidad de Fulvestrant (FaslodexTM) 500mg con placebo y Fulvestrant (FaslodexTM) 500mg en combinación con el PD-0332991 (Palbociclib) como primera línea de tratamiento para pacientes postmenopáusicas con cáncer de mama metastásico y receptores hormonales positivos, que han completado al menos 5 años de tratamiento adyuvante endocrino y que permanecen libres de enfermedad por más de 12 meses tras la finalización del mismo o que tienen enfermedad metastásica de novo “Estudio FLIPPER	INDEPENDENT CLINICAL TRIAL	FRANCISCO CARABANTES OCON	II
B-22	Estudio de Fase III, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de AZD9291 frente a placebo en pacientes con carcinoma de pulmón no microcítico con mutación del receptor del factor de crecimiento epidérmico, en Estadio IB-IIIA, tras la resección completa del tumor, con o sin quimioterapia adyuvante (ADAURA).	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Ensayo clínico fase II, exploratorio y multicéntrico, de quimioinmunoterapia neo-adyuvante para el tratamiento del cáncer de pulmón no microcítico estadío III operable	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio fundamental, randomizado y abierto de campos eléctricos para el tratamiento de tumores (TTFields) de forma simultánea con tratamientos de referencia para el tratamiento del cáncer de pulmón no microcítico (NSCLC) en estadio 4 después del fracaso con tratamiento que contenga platino. LUNAR	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	MANUEL COBO DOLS	Not applicable
B-22	Ensayo de nivolumab más ipilimumab en combinación con quimioterapia frente a quimioterapia sola como tratamiento de primera línea en el cáncer de pulmón no microcítico (CPNM) en estadio IV	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio observacional, retrospectivo, para analizar el manejo de pacientes con adenocarcinoma ductal de páncreas en la práctica clínica habitual. Estudio PDAC2017	INDEPENDENT POSTAUTHORIZATION STUDY	INMACULADA ALES DIAZ	Not applicable
B-22	Estudio de Fase II/III, multicéntrico, para evaluar la eficacia y la seguridad de múltiples terapias dirigidas como tratamiento para pacientes con cáncer de pulmón no microcítico (CPNM) avanzado o metastásico portadores de mutaciones somáticas accionables detectadas en sangre (B-FAST: PRIMER ANÁLISIS DE SCREENING EN SANGRE).	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio fundamental, randomizado y en abierto del tratamiento simultáneo con TTFields (campos eléctricos para el tratamiento de tumores, 150 kHz) y gemcitabina y nab-paclitaxel (paclitaxel unido a albúmina en formulación de nanopartículas), como tratamiento de primera línea del adenocarcinoma pancreático en estadio localmente avanzado. PANOVA-3	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	INMACULADA ALES DIAZ	Not applicable
B-22	Estudio de Fase III, doble ciego, aleatorizado y multicéntrico para evaluar la eficacia y la seguridad del tratamiento neoadyuvante con ATEZOLIZUMAB o placebo en combinación con quimioterapia con derivados del platino, en pacientes con Cáncer de Pulmón no Microcítico Resecable en Estadio II, IIIA O IIIB de determinado tipo.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de Fase III, abierto y aleatorizado para evaluar la eficacia y seguridad de ALECTINIB adyuvante frente a la quimioterapia adyuvante con un derivado del platino en pacientes con carcinoma de pulmón no microcítico positivo para la cinasa del linfoma anaplásico en Estadio IB (tumores = 4 cm) a IIIA completamente extirpado.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio Fase II, aleatorizado, ciego y controlado con placebo de MTIG7192A, un anticuerpo ANTI-TIGIT, en combinación con ATEZOLIZUMAB en pacientes con Cáncer de Pulmón no Microcítico localmente avanzado o metastásico que no han recibido quimioterapia previa.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de extensión y observacional a largo plazo multicéntrico, abierto en pacientes incluidos previamente en un estudio clínico de atezolizumab promocionado por GENENTECH y/o f. HOFFMANN-la roche ltd.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de largo seguimiento de pacientes con cáncer de mama incluidos en estudios en estadios precoces del grupo GEICAM.	INDEPENDENT CLINICAL TRIAL	FRANCISCO CARABANTES OCON	IV
B-22	Ensayo Fase III, randomizado, doble ciego, controlado con placebo, multicéntrico, internacional con Osimertinib como tratamiento de mantenimiento en pacientes con cáncer de pulmón no microcítico (estadio III) localmente avanzado e irresecable, con mutación de EGFR positiva, cuya enfermedad no ha progresado después de tratamiento definitivo con quimioradioterapia basada en platino (LAURA)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III

Group	Title	Subtype	PI Name	Phase
B-22	Ensayo clínico fase Ib, abierto, multicéntrico, de escalada de dosis intrapaciente para evaluar el perfil de seguridad de la combinación de Tilray FS Solución oral T10: C10 (THC + CBD) con temozolomida y radioterapia en pacientes con glioblastoma recién diagnosticado	INDEPENDENT CLINICAL TRIAL	CRISTINA GARCIA GONZALEZ	I
B-22	Ensayo en fase III adaptativo, abierto, controlado, aleatorizado para evaluar la seguridad y eficacia del EndoTAG-1 más Gemcitabina frente a Gemcitabina como monoterapia en pacientes con adenocarcinoma mensurable de páncreas metastásico y /o localmente avanzado que no respondieron al tratamiento con FOLFIRINOX	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	XENERA-1: Ensayo de Fase II multicéntrico, doble-ciego, controlado con placebo y aleatorizado para comparar la eficacia de xentuzumab en combinación con everolimus y exemestano frente a everolimus y exemestano en mujeres posmenopáusicas con cáncer de mama mestastásico HR+/HER2-y enfermedad no visceral. (XENERA)	COMMERCIAL CLINICAL TRIAL	TAMARA DIAZ REDONDO	II
B-22	Estudio de fase I, con aumento escalonado de la dosis y ampliación de cohortes, de TSR-022, un anticuerpo monoclonal anti-TIM-3, en pacientes con tumores sólidos avanzados (AMBER)	COMMERCIAL CLINICAL TRIAL	BEGOÑA JIMENEZ RODRIGUEZ	I
B-22	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de pemetrexed + quimioterapia a base de platino + pembrolizumab (MK-3475) con o sin lenvatinib (E7080/MK-7902) como intervención de primera línea en participantes con cáncer de pulmón no microcítico, no epidermoide, metastásico (LEAP-006)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio fase III, aleatorizado, doble ciego, controlado con placebo que evalúa la eficacia y seguridad de pembrolizumab más quimioterapia basada en doblete de platino con o sin canakinumab, como terapia de primera línea para pacientes con cáncer de pulmón de células no pequeñas escamoso o no escamoso, localmente avanzado o metastásico (CANOPY-1)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Atezolizumab, pertuzumab y trastuzumab con quimioterapia como tratamiento neoadyuvante en pacientes con cáncer de mama precoz y localmente avanzado HER2 positivo de alto riesgo. GEICAM/2017-05 (APTneo)	INDEPENDENT CLINICAL TRIAL	TAMARA DIAZ REDONDO	III
B-22	Ensayo clínico Fase II abierto de Atezolizumab en combinación con bevacizumab como primera línea de tratamiento para pacientes con carcinoma de pulmón no microcítico no escamoso localmente avanzado o metastásico seleccionados según carga mutacional tumoral (TMB) alta-intermedia. TELMA	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Ensayo clínico Fase II randomizado de quimioinmunoterapia neo-adyuvante versus quimioterapia sola para el tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) localmente avanzado y potencialmente resecable. NADIM II	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio en fase III, abierto, aleatorizado, multicéntrico y controlado con tratamiento activo para evaluar la eficacia y la seguridad de pemigatinib comparado con quimioterapia con gemcitabina y cisplatino en el tratamiento de primera línea de participantes con colangiocarcinoma no resecable o metastásico con reordenación del FGFR2 (FIGHT-302)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Estudio clínico en fase III aleatorizado, doble ciego, controlado con placebo, para comparar la eficacia y la seguridad de tislelizumab (BGB-A317) más platino y fluoropirimidina frente a placebo más platino y fluoropirimidina como tratamiento de primera línea en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Estudio fase 3 internacional, multicéntrico, doble ciego y aleatorizado, de la eficacia de zolbetuximab (IMAB362) más CAPOX, en comparación con placebo más CAPOX, como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico, claudin (CLDN)18.2 positivo y HER2 negativo	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Estudio de fase 2, abierto, de encorafenib + binimetinib en pacientes con cáncer de pulmón no microcítico con mutación BRAFV600E (C4221008)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Registro de Tumores Torácicos.	NON-POST-APPROVAL STUDY	MANUEL COBO DOLS	Not applicable
B-22	Estudio de fase 3 de pembrolizumab en combinación con carboplatino/taxano (paclitaxel o nab-paclitaxel), seguido de pembrolizumab con o sin mantenimiento con olaparib, en el tratamiento de primera línea del cáncer de pulmón no microcítico (CPNM) epidermoide metastásico	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III

Group	Title	Subtype	PI Name	Phase
B-22	Estudio de fase 3, aleatorizado, controlado con placebo y en doble ciego, para evaluar la eficacia y la seguridad de tislelizumab (BGB-A317) en combinación con quimioterapia como tratamiento de primera línea en pacientes con carcinoma de esófago, recurrente, localmente avanzado o metastásico, no resecable.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Estudio de fase 3, aleatorizado y abierto de pembrolizumab (MK-3475) más lenvatinib (E7080/MK-7902) frente a quimioterapia para el tratamiento de primera línea del carcinoma endometrial avanzado o recurrente (LEAP-001)	COMMERCIAL CLINICAL TRIAL	TAMARA DIAZ REDONDO	III
B-22	Estudio multicéntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparación con quimiorradioterapia concurrente más placebo seguida de durvalumab en participantes con cáncer de pulmón no microcítico irresecable en estadio III	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab más gemcitabina/cisplatino en comparación con placebo más gemcitabina/cisplatino como tratamiento de primera línea en participantes con carcinoma de vías biliares avanzado o irresecable	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Atezolizumab en combinación con Bevacizumab y Quimioterapia versus Bevacizumab y Quimioterapia en el cáncer de ovario recurrente: un ensayo aleatorizado de Fase III	COMMERCIAL CLINICAL TRIAL	ESTER VILLAR CHAMORRO	III
B-22	Ensayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (nuevo ensayo clínico en adyuvancia con ribociclib - [LEE011]: NATALEE)	COMMERCIAL CLINICAL TRIAL	FRANCISCO CARABANTES OCON	III
B-22	Estudio de fase II abierto para evaluar la seguridad y la eficacia de telisotuzumab vedotina (ABBV-399) en pacientes con cáncer de pulmón no microcítico c-Met+ tratado previamente	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Ensayo clínico fase II multicéntrico aleatorizado para evaluar la eficacia y seguridad de la combinación de nivolumab y paclitaxel en primera línea de tratamiento en pacientes con carcinoma escamoso de cabeza y cuello recurrente o metastásico no candidatos a recibir quimioterapia basada en platino (NIVOTAX).	INDEPENDENT CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Ensayo de fase 3 abierto, aleatorizado de SAR408701 versus Docetaxel en pacientes con cáncer de pulmón no microcítico no escamoso metastásico previamente tratados, con tumores positivos a CEACAM5 (CARMEN-LC03)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase III, abierto, aleatorizado y multicéntrico de irinotecán liposómico inyectable, oxaliplatino, 5-fluorouracilo/leucovorina frente a nab-paclitaxel más gemcitabina en pacientes que no han recibido previamente quimioterapia para el adenocarcinoma de páncreas metastásico	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Ensayo fase III, doble ciego, controlado con placebo, Internacional y multicéntrico de tratamiento neoadyuvante/adyuvante de Durvalumab para el tratamiento de pacientes con cáncer de pulmón no microcítico resecable en estadios II y III (AEGEAN)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio fase III, aleatrorizado, doble ciego y controlado con placebo de Tiragolumab, un anticuerpo anti-Tigit, en combinación con Atezolizumab en pacientes con cáncer de pulmón no microcítico localmente avanzado irresecable o metastásico no tratado previamente seleccionados por PD-L1.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio pantumoral para el seguimiento a largo plazo de supervivientes de cáncer que han participado en ensayos de investigación de nivolumab	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Estudio en fase III, aleatorizado y abierto de brigatinib (ALUNBRIG®) en comparación con alectinib (ALECENSA®) en pacientes con cáncer de pulmón no microcítico avanzado positivo para cinasa de linfoma anaplásico que han progresado con crizotinib (XALKORI®)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase II, multicéntrico, aleatorizado y abierto que evalúa la eficacia y seguridad de capmatinib (INC280) más pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para cáncer de pulmón de células no pequeñas localmente avanzado o metastásico con PD-L1 >/=50 %	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Utilidad clínica de la biopsia líquida como herramienta para evaluar la evolución de pacientes tratados con brigatinib con cáncer de pulmón de células no pequeñas con translocación EML4-ALK: un estudio exploratorio	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II

Group	Title	Subtype	PI Name	Phase
B-22	Estudio de un solo grupo de lorlatinib en participantes con cáncer de pulmón no microcítico (CPNM) positivo para cinasa del linfoma anaplásico (ALK) cuya enfermedad ha progresado después de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generación	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	IV
B-22	Estudio Fase 3 aleatorizado de la combinación de Amivantamab y Lazertinib frente a Osimertinib como tratamiento de Primera Línea en Pacientes con Cáncer de Pulmón No Microcítico Localmente Avanzado o Metastásico con mutación del EGFR. MARIPOSA	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de Fase III, aleatorizado, doble ciego y controlado con placebo de Atezolizumab con o sin Tiragolumab (Anticuerpo Anti-TIGIT) en pacinetes con cardinoma epidermoide de esófago localmente avanzado irresecable.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors	COMMERCIAL CLINICAL TRIAL	BEGOÑA JIMENEZ RODRIGUEZ	I
B-22	Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparación con durvalumab en pacientes con cáncer de pulmón no microcítico localmente avanzado en estadio III irresecable que no han presentado progresión después de quimiorradioterapia con platino concomitante (skyscraper-03)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo de pembrolizumab (MK-3475) en combinación con quimiorradioterapia concomitante seguido de pembrolizumab con o sin olaparib (MK-7339) en comparación con la quimiorradioterapia concomitante sola en participantes con cáncer de pulmón microcítico en estadio limitado (CPM-EL) de diagnóstico reciente y sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	IV
B-22	Estudio epidemiológico observacional multicéntrico descriptivo sobre tumores digestivos. RETUD (Registro Español TUmores Digestivos)	NON-POST-APPROVAL STUDY	INMACULADA ALES DIAZ	Not applicable
B-22	Ensayo clínico Fase II de tratamiento neoadyuvante con Carboplatino-Pemetrexed-Bevacizumab más Atezolizumab para el tratamiento de pacientes con cáncer de pulmón localmente avanzado y potencialmente resecable y mutaciones de EGFR	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Ensayo fase III, aleatorizado, controlado, multicéntrico de 3 brazos para evaluar osimertinib neoadyuvante en monoterapia o en combinación con quimioterapia, frente a la quimioterapia de referencia, para el tratamiento de pacientes con CPNM resecable con mutación del EGFR positiva (NeoADAURA)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Ensayo Fase III, Randomizado, Doble ciego y controlado con Placebo de Durvalumab y Quimioterapia FLOT Neoadyuvante-Adyuvante seguido de Durvalumab Adyuvante en pacientes con cáncer gástrico y de la unión gastroesofágica resecable (GC/GEJC) (MATTERHORN)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Estudio de paraguas de fase Ib/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamiento basados en múltiples inmunoterapias en pacientes con carcinoma de pulmón no microcítico metastásico (Morpheus Pulmonar)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de fase III aleatorizado de DS-1062a frente a docetaxel en cáncer de pulmón no microcítico avanzado o metastásico sin alteraciones genómicas accionales que ha recibido tratamiento previo. Estudio TROPION-LUNG01	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase 2 de MRTX849 en monoterapia y en combinación con pembrolizumab en pacientes con cáncer de pulmón no microcítico avanzado con mutación KRAS G12C	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Estudio observacional para identificar pacientes con CPNM avanzado/metastásico y translocación de ALK y ROS1 y conocer su manejo terapéutico (IDEALK&ROS).	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	Not applicable
B-22	Estudio BURAN sobre buparlisib (AN2025) en combinación con paclitaxel frente a paclitaxel en monoterapia, para pacientes con carcinoma de células escamosas de cabeza y cuello recurrente o metastásico Estudio BURAN	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	III

Group	Title	Subtype	PI Name	Phase
B-22	Estudio fase 1/2 de relatlimab (anticuerpo monoclonal anti-LAG-3) administrado en combinación con nivolumab (anticuerpo monoclonal anti-PD-1) y BMS-986205 (inhibidor de IDO1) o en combinación con nivolumab e ipilimumab (anticuerpo monoclonal anti-CTLA-4) en tumores malignos avanzados	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio en fase II, aleatorizado, doble ciego de relatlimab más nivolumab en combinación con quimioterapia frente a nivolumab en combinación con quimioterapia como tratamiento de primera línea para los participantes con cáncer de pulmón de células no pequeñas (CPCNP) en estadio IV o recurrente.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio Fase III multicéntrico, abierto, aleatorizado de Entrectinib comparado con Crizotinib en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico on reordenamientos del Gen ROS1, con o sin metástasis en el sistema nervioso central.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Ensayo de fase II abierto, aleatorizado, de BNT113 en combinación con pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) irresecable, recurrente o metastásico, que es positivo para el genotipo 16 del virus del papiloma humano (VPH16+) y expresa PD-L1	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Ensayo clínico de fase I para evaluar la seguridad y eficacia de repotrectinib combinado con osimertinib en pacientes con Cáncer de pulmón no microcítico (CPCNP) avanzado o metastásico con mutación del EGFR (TOTEM).	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	I
B-22	Estudio en fase II multicéntrico, abierto en pacientes con cáncer de pulmón no microcítico (CPNM) irresecable o metastásico no tratado anteriormente, CPNM resistente a PD-X recurrente o cáncer epidermoide de cabeza y cuello (CECC) recurrente o metastásico que reciben la proteína de fusión LAG-3 soluble eftilagimod alfa (IMP321) en combinación con pembrolizumab (antagonista de PD-1). TACTI-002 (Dos inmunoterapias activas):	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se evalúa la administración adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusión en el gen RET (LIBRETTO-432)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio en fase III aleatorizado de MRTX849 en comparación con docetaxel en pacientes con y mutación G12C de KRAS previamente tratado	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3 de pembrolizumab (MK-3475) en combinación con quimiorradioterapia concurrente, seguidos de pembrolizumab con o sin olaparib, frente a quimiorradioterapia concurrente seguida de durvalumab en participantes con cáncer de pulmón no microcítico (CPNM) en estadio III, localmente avanzado e irresecable.	COMMERCIAL CLINICAL TRIAL	JOSÉ MIGUEL JURADO GARCIA	III
B-22	Estudio en fase III abierto y aleatorizado del tratamiento combinado de amivantamab y lazertinib con quimioterapia basada en platino en comparación con quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico con mutación del EGFR localmente avanzado o metastásico tras el fracaso de osimertinib. MARIPOSA 2	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Proyecto basado en encuestas para evaluar la facilidad de uso y el nivel de satisfacción de los pacientes y sus profesionales sanitarios después de utilizar una herramienta de monitorización médica digital para pacientes con cáncer de pulmón	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	MANUEL COBO DOLS	Not applicable
B-22	Estudio de fase III, aleatorizado y abierto para comparar ociperlimab (BGB-A1217) más tislelizumab (BGB-A317) combinados con quimiorradioterapia simultánea (QRTs) seguida de ociperlimab más tislelizumab o tislelizumab más QRTs seguida de tislelizumab frente a QRTs seguida de durvalumab en pacientes con cáncer de pulmón no microcítico irresecable, localmente avanzado y sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	JOSÉ MIGUEL JURADO GARCIA	III
B-22	Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera línea del cáncer de pulmón metastático no microcítico metastático positivo para el gen de fusión RET (BO42864)	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3, aleatorizado y doble ciego de MK-7684A en combinación con etopósido y platino seguido de MK-7684A en comparación con atezolizumab en combinación con etopósido y platino seguido de atezolizumab para el tratamiento de primera línea de participantes con cáncer de pulmón microcítico en estadio extenso	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	III

Group	Title	Subtype	PI Name	Phase
B-22	Estudio fase III, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia y seguridad del osimertinib en adyuvancia frente al placebo en pacientes con cáncer de pulmón de células macrociticas en estadio IA2-IA3 con mutación EGFR positiva, después de una resección tumoral completa. (ADAURA2)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Evaluación fase 1/2a/3 de la seguridad y eficacia de añadir AL3828 (Anlotinib, INN: Catequentinib), un inhibidor del receptor dual tirosina quinasa, a la quimioterapia estándar basada en platino en sujetos con carcinoma endometrial, ovárico, de trompas de Falopio, peritoneal primario o cervical recurrente o metastásico.	COMMERCIAL CLINICAL TRIAL	ESTER VILLAR CHAMORRO	III
B-22	Estudio de Fase 1b/2, multicéntrico, de un solo grupo de RBN 2397 en combinación con pembrolizumab en pacientes con carcinoma epidermoide pulmonar (CEP)	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Estudio observacional para describir las características genotípicas y las mutaciones de resistencia en el NSCLC ALK	INDEPENDENT POSTAUTHORIZATION STUDY	MANUEL COBO DOLS	Not applicable
B-22	Estudio de fase II abierto para evaluar la eficacia y la seguridad de tusamitamab ravtansina en participantes con carcinoma pulmonar no microcítico no escamoso (CPNM NE), con tumores con expresión negativa o moderada de CEACAM5 y niveles de ACE circulante elevados (CARMEN-LC06)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Un estudio de fase III, aleatorizado, doble ciego y controlado con placebo de alpelisib en combinación con fulvestrant para hombres y mujeres posmenopáusicas con cáncer de mama avanzado HR positivo, HER2 negativo con mutación en PIK3CA, que ha progresado durante o después del tratamiento con un inhibidor de la aromatasa y un inhibidor de CDK4/6. EPIK-B5	COMMERCIAL CLINICAL TRIAL	TAMARA DIAZ REDONDO	III
B-22	Estudio de fase III, abierto, aleatorizado, global y multicéntrico de sacituzumab govitecán frente a docetaxel en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado o metastásico con progresión durante o después de la quimioterapia a base de platino e inmunoterapia anti-PD-1/PD-L1	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio en paraguas de múltiples cohortes en fase IB/II para evaluar la seguridad y la eficacia de nuevos tratamientos y/o combinaciones de tratamientos en participantes con cáncer de ovario (OPAL).Cohorte C: Estudio de fase II, abierto, aleatorizado, controlado y multicéntrico para comparar niraparib frente a quimioterapia doble con platino-taxano como tratamiento neoadyuvante en participantes con cáncer de ovario en estadio III/IV con deficiencia de recombinación homóloga.	COMMERCIAL CLINICAL TRIAL	ESTER VILLAR CHAMORRO	II
B-22	Estudio de fase III, multicéntrico y aleatorizado de zanidatamab en combinación con quimioterapia, con o sin tislelizumab, en sujetos con adenocarcinoma gastroesofágico (AGE) irresecable, localmente avanzado o metastásico, con HER-2 positivo (HERIZON-GEA-01)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Estudio de fase 3 aleatorizado, multicéntrico, doble ciego y controlado con placebo de bemarituzumab más quimioterapia frente a placebo más quimioterapia en sujetos con cáncer gástrico o de la unión gastroesofágica avanzado no tratado previamente con sobreexpresión de FGFR2b (FORTITUDE-101)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Estudio en fase II, multicéntrico, abierto, de combinaciones de sacituzumab govitecán como primera línea de tratamiento en pacientes con cáncer de pulmón no microcítico (CPNM) metastásico o avanzado sin alteraciones genómicas de utilidad clínica	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio de fase 2 para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de AMG 757 en sujetos con cáncer de pulmón microcítico en recaída/refractario después de dos o más líneas de tratamiento previas	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Estudio de Fase III multicéntrico para evaluar la eficacia y seguridad de múltiples tratamientos en cohortes de pacientes seleccionados basándose en el estado de los biomarcadores, con cáncer de pulmón no microcítico en estadio III localmente avanzado, no resecable.	DRUG CLINICAL TRIALS	JOSÉ MIGUEL JURADO GARCIA	III
B-22	Estudio de fase Ib de búsqueda de dosis que evalúa la seguridad y la actividad de [177Lu]Lu-DOTATATE en el cáncer de pulmón avanzado de células pequeñas de nuevo diagnóstico, en combinación con carboplatino, etopósido y tislelizumab en la fase de inducción y en combinación con tislelizumab en la fase de mantenimiento del tratamiento.	COMMERCIAL CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	I

Group	Title	Subtype	PI Name	Phase
B-22	Ensayo en fase III, aleatorizado, abierto de Dato-DXd más pembrolizumab frente a pembrolizumab en monoterapia en pacientes sin tratamiento previo con cáncer de pulmón no microcítico avanzado o metastásico con PD-L1 alto (PPT =50 %) sin alteraciones genómicas susceptibles de ser dianas terapéuticas (Tropion-Lung08)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio aleatorizado, doble ciego, y controlado con placebo de nab-paclitaxel y gemcitabina con o sin SBP-101 en pacientes con adenocarcinoma ductal de páncreas metastásico no tratados previamente.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALES DIAZ	III
B-22	Estudio en fase II abierto, de un solo grupo y multicéntrico para evaluar la eficacia y la seguridad de taletrectinib en pacientes con CPNM ROS1 positivo avanzado o metastásico y otros tumores sólidos	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio en fase I/II, abierto, multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia antitumoral de DZD9008 en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con mutación de EGFR o HER2	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
B-22	Estudio fase III, randomizado, abierto con savolitinib en combinación con osimertinib versus quimioterapia basada en doblete de platino en participantes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo y que la enfermedad ha progresado tras haber recibido tratamiento con osimertinib (SAFFRON)	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio en fase III, aleatorizado, abierto de patritumab deruxtecán frente a quimioterapia basada en platino en el cáncer de pulmón no microcítico (CPNM) metastásico o localmente avanzado con mutación del receptor del factor de crecimiento epidérmico (EGFRm) tras el fracaso del tratamiento con inhibidores de la tirosina cinasa (ITC) del factor de crecimiento epidérmico (EGFR). HERTHENA–Lung02:	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	III
B-22	Estudio de fase II abierto, multicéntrico y aleatorizado de DS-7300a, un conjugado de anticuerpo y fármaco (CAF) B7-H3, en participantes con cáncer de pulmón microcítico en estadio avanzado (CPM-EA) pretratado	INDEPENDENT CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Ensayo clínico Fase II de combinación de pembrolizumab, lenvatinib y quimioterapia en primera línea para pacientes con cáncer de pulmón de células pequeñas con enfermedad avanzada (EA-CPNM)	INDEPENDENT CLINICAL TRIAL	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Olaparib y durvalumab (MEDI4736) en pacientes con cáncer de páncreas metastásico y alteraciones en los genes de reparación de daño en el ADN	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	II
B-22	Estudio de fase III aleatorizado, multicéntrico y abierto de Lurbinectedina como agente único o Lurbinectedina en combinación con Irinotecán frente a la elección del investigador (Topotecán o Irinotecán) en Pacientes con cáncer de pulmón de células pequeñas en recaída (CPCP) (Ensayo LAGOON)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase III, abierto, aleatorizado y multicéntrico, de ceralasertib más durvalumab frente a docetaxel en pacientes con cáncer de pulmón no microcítico avanzado o metastásico sin alteraciones genómicas aprovechables terapéuticamente y cuya enfermedad haya progresado durante o después del tratamiento previo con anti-PD-(L)1 y quimioterapia basada en el platino: LATIFY	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio de plataforma de fase 2, aleatorizado, abierto que utiliza el protocolo maestro para evaluar nuevas combinaciones con inmunoterapia en participantes con cáncer de pulmón no microcítico localmente avanzado/metastásico, seleccionados según la expresión del ligando de muerte programada 1, que no han recibido tratamiento previo	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Estudio Fase 3, Abierto, Aleatorizado de Lazertinib con Amivantamab Subcutáneo Administrado por Inyección Manual, en Comparación con Amivantamab Intravenoso o Amivantamab Subcutáneo en un Sistema de Administración Corporal, en Pacientes con Cáncer de Pulmón No Microcítico Avanzado o Metastásico con mutación del EGFR tras la Progresión a Osimertinib y Quimioterapia. PALOMA-3.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio en fase II abierto y de cohortes paralelas de amivantamab subcutáneo con diversas pautas posológicas en pacientes con tumores sólidos avanzados o metastásicos, incluido el cáncer de pulmón no microcítico con mutaciones en el gen EGFR. PALOMA-2	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Estudio aleatorizado, abierto, de fase 2/3 para comparar cobolimab + dostarlimab + docetaxel, dostarlimab + docetaxel y docetaxel en monoterapia en participantes con cáncer de pulmón no microcítico avanzado que hayan progresado al tratamiento previo con anti-PD (L)1 y quimioterapia (COSTAR Lung).	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III

Group	Title	Subtype	PI Name	Phase
B-22	Ensayo multicéntrico, de fase II, abierto y aleatorizado para evaluar la eficacia de Tedopi y docetaxel o Tedopi y nivolumab como tratamiento de segunda línea en el cáncer de pulmón de células no pequeñas metastásico y en progresión tras el tratamiento de primera línea con quimioinmunoterapia (Combi-TED)	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	EMBER-4: Estudio de fase 3, aleatorizado, abierto, en el que se compara la administración adyuvante de imlunestrant versus terapia endocrina adyuvante estándar en pacientes que recibieron previamente de 2 a 5 años de terapia endocrina adyuvante para el cáncer de mama temprano ER+, HER2-con un mayor riesgo de recurrencia	DRUG CLINICAL TRIALS	ESTER VILLAR CHAMORRO	III
B-22	Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de dos grupos, para evaluar la eficacia y la seguridad de xevinapant y radioterapia en comparación con placebo y radioterapia para demostrar la mejora de la supervivencia sin enfermedad en participantes con carcinoma de células escamosas de cabeza y cuello resecado, que presentan un riesgo alto de recidiva y no son aptos para la administración de dosis altas de cisplatino.	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio en fase III, aleatorizado y abierto para evaluar Zimberelimab y Domvanalimab en combinación con quimioterapia frente a pembrolizumab con quimioterapia, como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico metastásico sin aberraciones tumorales genómicas del receptor del factor de crecimiento epidérmico ni de la quinasa del linfoma anaplásico	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Registro de enfermedades en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con alteraciones por omisión de METex14 MOMENT (Met nOn sMall cEll caNcer registry)	OBSERVATIONAL STUDY WTIH MEDICINES	MANUEL COBO DOLS	Not applicable
B-22	Estudio de Fase II, de un único brazo y abierto para evaluar la seguridad y la farmacocinética de una combinación a dosis fija por vía intravenosa (CDF IV) de Tiragolumab y Atezolizumab en pacientes con tumores sólidos localmente avanzados, recurrentes o metastásicos.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) / Estudio en fase III aleatorizado de datopotamab deruxtecán (Dato-DXd) y pembrolizumab, con o sin quimioterapia con platino, en sujetos sin tratamiento previo para cáncer de pulmón avanzado o metastásico con TPS PD-L1 <50 % no microcítico no epidermoide sin alteraciones genómicas susceptibles de ser dianas terapéuticas (TROPION-Lung07).	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio de fase III, aleatorizado, en doble ciego y controlado con placebo, de platino y pemetrexed como quimioterapia más osimertinib frente a platino y pemetrexed como quimioterapia más placebo en pacientes con cáncer de pulmón no microcítico con mutación del EGFR, localmente avanzado o metastásico, que ha progresado extracranealmente tras el tratamiento de primera línea con osimertinib (COMPEL)	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio de fase III, abierto, aleatorizado, multicéntrico y global para investigar la eficacia y la seguridad de furmonertinib en comparación con quimioterapia basada en platino como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio en fase I/II, abierto, de escalada de dosis y ampliación de la dosis del agonista de TLR7/8 TransCon, en monoterapia o en combinación con pembrolizumab, en participantes con tumores sólidos malignos localmente avanzados o metastásicos	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	I/II
B-22	Estudio de fase II, abierto, multicéntrico y aleatorizado, del tratamiento neoadyuvante y adyuvante de pacientes con cáncer de pulmón no microcítico resecable, en estadio inicial (II a IIIA) (NeoCOAST-2)	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Estudio observacional ambispectivo que describe los patrones de diagnóstico y de tratamiento en adultos con carcinomas pulmonares no microcíticos metastásicos con mutación del gen BRAF V600E en la práctica clínica, para evaluar la efectividad del tratamiento y la calidad de vida OCTOPUS	OBSERVATIONAL STUDY WTIH MEDICINES	MANUEL COBO DOLS	Not applicable
B-22	Ensayo clínico fase II de quimio-inmunoterapia neoadyuvante seguida de tratamiento adyuvante según el estado de resección para el tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) con diagnóstico de tumor de pancoast. Un estudio exploratorio multicéntrico. DUMAS	DRUG CLINICAL TRIALS	JOSÉ MIGUEL JURADO GARCIA	III

Group	Title	Subtype	PI Name	Phase
B-22	Estudio multicéntrico, sin enmascaramiento, con un grupo de referencia aleatorizado para evaluar la eficacia, la seguridad y la farmacocinética de berubicina mediante infusión intravenosa en pacientes adultos con glioblastoma multiforme (grado IV de la OMS) recidivante tras el fracaso del tratamiento de referencia de primera línea	DRUG CLINICAL TRIALS	CAROLINA MURIEL LOPEZ	II
B-22	Profilaxis de la enfermedad tromboembólica venosa con HBPM (TINzaparina) en pacientes con cáncer colorrectal metastásico que inician la primera línea de tratamiento.	DRUG CLINICAL TRIALS	DAVID FERNANDEZ GARAY	II
B-22	Estudio de fase 1, primero en el ser humano, de búsqueda de dosis/Estudio de fase 2, aleatorizado, de IMM60 y pembrolizumab en el melanoma avanzado y en el cáncer de pulmón no microcítico metastásico	DRUG CLINICAL TRIALS	JOSÉ MIGUEL JURADO GARCIA	I
B-22	Estudio en Fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de Inavolisib más Fulvestrantfrente a alpelisib más Fulvestrant en pacientes con cáncer de mama con receptor hormonal positivo, HER2 NEGATIVO y PIK3CA Mutado, localmente avanzado o metastásico que experimentaron progresión durante o después del tratamiento combinado con inhibidor de CDK4/6 y tratamiento endocrino.	DRUG CLINICAL TRIALS	TAMARA DIAZ REDONDO	III
B-22	Estudio de fase Ib/II, multicéntrico, abierto, para evaluar la seguridad/tolerabilidad, la farmacocinética y la eficacia de GFH925 en combinación con cetuximab en pacientes con CPNM con mutación KRAS G12C en estadio avanzado no tratado previamente	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Estudio en fase II, aleatorizado y abierto para evaluar la eficacia y la seguridad de zolbetuximab (IMAB362) en combinación con nab paclitaxel y gemcitabina (Nab-P + GEM) como tratamiento de primera línea en pacientes con adenocarcinoma de páncreas metastásico con presencia de claudina-18.2 (CLDN18.2)	OBSERVATIONAL STUDY WTIH MEDICINES	INMACULADA ALES DIAZ	Not applicable
B-22	Estudio en fase I/II de cemiplimab (anticuerpo anti-pd-1) en combinación con bnt116 (fixvac de pulmón) comparado con cemiplimab en monoterapia como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico (cpnm) avanzado con tumores con expresión de pd-l1 =50 %	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Estudio aleatorizado y abierto de fase 3 en el que se compara tarlatamab con el tratamientoestándar en sujetos con cáncer de pulmón microcítico en recaída después de recibir quimioterapia deprimera línea basada en platino (DeLLphi-304)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio en fase I/II, abierto, multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética, la farmacodinámica y la eficacia de CLN-081 en pacientes con carcinoma pulmonar no microcítico localmente avanzado o metastásico con mutaciones por inserción en el exón 20 del EGFR que han recibido anteriormente quimioterapia sistémica con un derivado del platino	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Estudio preliminar, de un solo grupo, del uso concomitante de campos eléctricos para el tratamiento de tumores (TTFields, 150 kHz) y atezolizumab, gemcitabina y nab-paclitaxel como tratamiento de primera línea del adenocarcinoma ductal pancreático etastásico (ADPm)	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	I
B-22	An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies (DDRiver NSCLC 322)	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio intervencional tipo plataforma para investigar el impacto de las soluciones de salud digital en los resultados en la salud y la utilización de recursos sanitarios en participantes que reciben tratamiento sistémico en la práctica clínica (ORIGAMA).	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	IV
B-22	Estudio de Fase II multicéntrico, aleatorizado, doble ciego, controlado, de RO7247669 más quimioterapia basada en platino frente a Pembrolizumab más quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico no tratados previamente	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II

Group	Title	Subtype	PI Name	Phase
B-22	Ensayo abierto, de fase 2b, global multicéntrico de cohortes para evaluar la seguridad y la eficacia de Zipalertinib en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico coninserciones del Exón 20 y mutaciones poco frecuentes/simples o compuestas del receptor del factor de crecimiento epidérmico.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer (HARMONi-3)	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Ensayo Fase III, randomizado, en dos brazos paralelos, abierto, multicéntrico, internacional para comparar la eficacia de volrustomig (MEDI5752) en combinación con quimioterapia en primera línea de tratamiento vs pembrolizumab en combinación con quimioterapia en pacientes con cáncer de pulmón no microcítico avanzado (eVOLVE-Lung02).	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio en fase II abierto y aleatorizado que evalúa el impacto del tratamiento dermatológico mejorando frente al de referencia en acontecimientos adversos dermatológicos seleccionados en pacientes con CPNM localmente avanzado o metastásico con mutación del EGFR tratados en primera línea con amivantamab + lazertinib (COCOON)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Estudio pivotal internacional en participantes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación en KRAS G12C para comparar el tratamiento de primera línea con LY3537982 y pembrolizumab frente a placebo y pembrolizumab en pacientes con expresión de PD-L1 =50% o con LY3537982 y pembrolizumab, pemetrexed, platino frente a placebo y pembrolizumab, pemetrexed, platino con independencia de la expresión de PD-L1 (SUNRAY-01)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase III, abierto, aleatorizado, multicéntrico, de DZD9008 frente a quimioterapia basada en doblete con platino como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación de inserción del exón 20 del receptor del factor de crecimiento epidérmico	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation	DRUG CLINICAL TRIALS	BEGOÑA JIMENEZ RODRIGUEZ	III
B-22	Retrospective, observational, multicentric and non-interventional study in Spain. Real-world trends in clinical management of metastatic non-small cell lung cancer patients (REVEAL Study)	OBSERVATIONAL STUDY WTIH MEDICINES	MANUEL COBO DOLS	Not applicable
B-22	Estudio de fase 3 multicéntrico, aleatorizado y abierto que evalúa la eficacia de la combinación de doblete de platino con sotorasib frente a la combinación de doblete de platino con pembrolizumab como tratamiento de primera línea en sujetos con cáncer de pulmón no microcítico y no escamoso en estadio IV o en estadio IIIB/C avanzado, negativo para PD-L1 y positivo para p.G12C en el KRAS (CodeBreaK 202)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3, aleatorizado, doble ciego y multicéntrico de MK-1084 en combinación con pembrolizumab en comparación con pembrolizumab más un placebo como tratamiento de primera línea de participantes con CPNM metastásico con mutación KRAS G12C y TPS de PD-L1 =50%	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3, abierto y aleatorizado de MK-2870 en comparación con quimioterapia (docetaxel o pemetrexed) en pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide, avanzado o metastásico, tratado previamente, con mutaciones de EGFR u otras alteraciones genómicas.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	An open-label randomized trial of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (BTC)	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	III
B-22	Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Randomized, Controlled, Open-label, Phase 3, Global MultiCenter Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III

Group	Title	Subtype	PI Name	Phase
B-22	Ensayo internacional Fase III, Randomizado, Doble ciego, controlado con Placebo, multicéntrico, de Rilvegostomig en combinación con quimioterapia como tratamiento adyuvante tras Resección del cáncer de las vías biliares con intención curativa (ARTEMIDE-Biliary01)	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	III
B-22	Un estudio de fase 3, abierto, multicéntrico, aleatorizado de tarlatamab en combinación con durvalumab versus solo durvalumab en sujetos con cáncer de pulmón de células pequeñas en estadio extenso después de platino, etopósido y durvalumab (DeLLphi-305)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	1479-0008BEAMION Lung-2: estudio de fase III, abierto, aleatorizado, con control activo y multicéntrico para evaluar BI 1810631 por vía oral en comparación con el tratamiento de referencia como tratamiento de primera línea en pacientes con carcinoma pulmonar no microcítico no escamoso irresecable, localmente avanzado o metastásico con mutaciones del dominio tirosina-quinasa de HER2	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours.	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	I
B-22	Estudio en fase II/III, aleatorizado y doble ciego de fianlimab (anticuerpo anti-LAG-3) en combinación con cemiplimabanticuerpo anti-PD-1) en comparación con cemiplimab en monoterapia como tratamiento de primera línea en cientes con cáncer de pulmón no microcítico (CPNM) avanzado con tumores que expresen PD-L1 =50 %	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II/III
B-22	Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer .	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	AIRAM AYOZE PADILLA ALVAREZ	Not applicable
B-22	Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	MANUEL COBO DOLS	Not applicable
B-22	Estudio en fase III, multicéntrico, aleatorizado y sin enmascaramiento de ifinatamab deruxtecán (I-DXd), un conjugado anticuerpo-fármaco (CAF) B7-H3 frente al tratamiento elegido por el médico (TPC) en participantes con carcinoma pulmonar de células pequeñas (CPCP) recidivante (IDeate-Lung02).	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de plataforma sobre combinaciones de inhibidores de RAS(ON) en pacientes con cáncer de pulmón no microcítico (CPNM) con mutación de RAS”/ “Estudio de fase 1b/2, abierto y multicéntrico de RMC-6291 en combinación con pembrolizumab, con o sin quimioterapia, en pacientes con tumores sólidos con mutación KRASG12C: subprotocolo A.	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	I
B-22	Ensayo aleatorizado de fase I/II en pacientes con carcinoma de células escamosas de la cabeza y el cuello (SCCHN) locorregionalmente avanzado, negativo para el VPH, de diagnóstico reciente, en el que se evalúa una inmunoterapia dirigida al mutanoma iniciada al finalizar el tratamiento primario o en el momento de la recidiva.	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	I
B-22	Estudio Fase II, abierto, multicéntrico y aleatorio sobre la eficacia y seguridad de Adjuvant Autogene Cevumeran más Atezolizumab y mFOLFIRINOX frente a mFOLFIRINOX solo en pacientes con adenocarcinoma ductal pancreático resecado.	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	II
B-22	A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive stage Small Cell Lung Cancer (ES SCLC) (IDeate-Lung03).	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	I/II
B-22	A randomized, controlled, open-label, phase III trial on Adjuvant Dynamic marker – Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+/HER2-early breast cancer (ADAPTlate)	DRUG CLINICAL TRIALS	TAMARA DIAZ REDONDO	III
B-22	Primer estudio en seres humanos de STX-721 en participantes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del gen EGFR.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II

Group	Title	Subtype	PI Name	Phase
B-22	Estudio de fase 3, abierto y aleatorizado de MK-2870 combinado con pembrolizumab en comparación con pembrolizumab en monoterapia en el tratamiento de primera línea de participantes con cáncer de pulmón no microcítico metastásico con una TPS de PD-L1 superior o igual al 50%	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio de plataforma sobre combinaciones de inhibidores de RAS(ON) en pacientes con cáncer de pulmón no microcítico (CPNM) con mutación de RAS"/ "Estudio de fase 1b/2, abierto y multicéntrico de RMC-6236 en combinación con pembrolizumab, con o sin quimioterapia, en pacientes con cáncer de pulmón no microcítico (CPNM) con mutación de RAS: subprotocolo B	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	I/II
B-22	Estudio en Fase III multicéntrico, abierto, randomizado para evaluar la eficacia y la seguiridad de divarasib comparado con sotorasib o adbrasib en pacientes con cáncer de pulmón no cicrcítico KRAS G12C ppositivo avanzado o metastásico, tratados previamente.	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico sobre el tratamiento con tarlatamab en sujetos con cáncer de pulmón microcítico en estadio limitado (CPM-EL) que no han progresado tras la quimiorradioterapia concurrente (DeLLphi-306).	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio de fase 1b para evaluar la seguridad, tolerabilidad, farmacocinética y actividad antitumoral preliminar de tarlatamab subcutáneo en sujetos con cáncer de pulmón microcítico en estadio extenso (DeLLphi-308)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	I
B-22	Estudio de fase 3, aleatorizado, abierto, de nivolumab + relatlimab en combinación a dosis fijas con quimioterapia frente a Pembrolizumab con quimioterapia como tratamiento de primera línea en participantes con cáncer de pulmón no microcítico no escamoso (NESC), en estadio IV o recurrente y con expresión de PD-L1 en las células tumorales del 1% al 49%.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio de fase I-III multicéntrico para evaluar la eficacia y seguridad de múltiples tratamientos en cohortes de pacientes con cáncer de pulmón no microcítico en estadio I-III resecable, seleccionados de acuerdo con el estado de los Biomarcadores.	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	I
B-22	A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Ribo-Age: Análisis descriptivo estratificado por edad de las reacciones adversas farmacológicas enpacientes con cáncer de mama avanzado tratado con Kisqali (ribociclib) e inhibidores no esteroideos de laaromatasa: estudio retrospectivo de cohortes	OBSERVATIONAL STUDY WTIH MEDICINES	TAMARA DIAZ REDONDO	Not applicable
B-22	A Post-Hoc Exploratory Outcomes Analysis of the Phase II PANOVA (EF-20) Trial	OBSERVATIONAL STUDY WTIH MEDICINES	INMACULADA ALES DIAZ	Not applicable
B-22	Ensayo en fase III, aleatorizado, con enmascaramiento doble, en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado/metastásico que reciben eftilagimod alfa (agonista del CPH de clase II) en combinación con pembrolizumab (antagonista de PD-1) y quimioterapia.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination de?ciency (HRD) positive epithelial ovarian cancer that progressed on prior PARP inhibitor therapy // Estudio en fase II, aleatorizado, abierto y multicéntrico del inhibidor de la ATR tuvusertib, en combinación con el inhibidor de la PARP niraparib o el inhibidor de la ATM lartesertib, en participantes con cáncer ovárico epitelial con mutación de BRCA o con deficiencia de recombinación homóloga (HRD) que progresó durante el tratamiento previo con inhibidores de la PARP	DRUG CLINICAL TRIALS	DAVID FERNANDEZ GARAY	II
B-22	Un estudio de fase 1/2 de ASP1570 como monoterapia y en combinación con pembroli-zumab o terapias estándar que incluyen quimioterapia y/o inmunoterapia en participantes con tumores sólidos localmente avanzados o metastásicos	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Ensayo clínico fase II con diseño adaptativo basado en la respuesta a cemiplimab en monoterapia mediante CTDNA y tratamiento posterior con quimioterapia (QT) y cemiplimab o cemiplimab en mo-noterapia en primera línea en pacientes con cáncer de pulmón no microcítico avanzado.	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma with KRAS p.G12C mutation.	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	II

Group	Title	Subtype	PI Name	Phase
B-22	A phase 2, randomized, blinded, placebo-controlled trial investigating the efficacy and safety of visugromab versus placebo, in combination with pembrolizumab, pemetrexed, and car-boplatin, in first-line treatment of participants with metastatic non-squamous non-small cell lung cancer (GDFATHER-NSCLC-01).	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Estudio fase III Trastuzumab Deruxtecan (T-DXd) y Rilvegostomig versus tratamiento estándar: Gemcitabina, cisplatino y durvalumab para el tratamiento de primea línea de cáncer tractor biliar localmente avanzado o metastásico que ex-presa HER2. DESTINY-BTC01.	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	III
B-22	Estudio fase III, aleatorizado, doble ciego, de adagrasib más pembrolizumab más quimioterapia frente a placebo más pembrolizumab más quimioterapia en participantes con cáncer de pulmón no microcítico no escamoso localmente avanzado o metastásico, no tratado previamente, con muta-ción KRAS G12C (KRYSTAL-4).	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Estudio de fase 3, multicéntrico, doble ciego y controlado con placebo para evaluar la efecacia y la seguirdad d olomorasib en combinación con inmunoterapia estándar en participantes con cáncer de pulmón no microcítico o irresecable, con muitación en KRAS G12C - SUNRAY.02.	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pem-brolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (TPS = 50%) (HARMONi-7)	DRUG CLINICAL TRIALS	AIRAM AYOZE PADILLA ALVAREZ	III
B-22	Estudio abierto y multicéntrico para evaluar la seguridad, la tolerabilidad y la farmacocinética de ZL-1310 en pacientes con cáncer de pulmón de células pequeñas	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	I
B-22	A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR).	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	Elacestrant frente a la hormonoterapia de referencia en personas de ambos sexos con cáncer de mama incipiente con afectación ganglionar, con receptores estrogénicos y sin sobreexpresión del receptor HER2 con alto riesgo de recurrencia: estudio en fase III, aleatorizado, sin enmascaramiento, global y multicéntrico (ELEGANT)	DRUG CLINICAL TRIALS	BEGOÑA JIMENEZ RODRIGUEZ	III
B-22	Un estudio multicéntrico de fase 1/2 para determinar la dosis de OSE-279, un anticuerpo monoclonal que bloquea PD-1, en sujetos con tumores sólidos avanzados o linfomas	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	I/II
B-22	Estudio de fase 2, multicéntrico, de linfocitos infiltrantes de tumores autólogos (LN-145) en pacientes con cáncer de pulmón no microcítico metastásico	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Estudio en fase I/Ib de IAM1363 en participantes con cánceres avanzados que albergan altera-ciones de HER2.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	I/II
B-22	Estudio de fase II, multicéntrico, aleatorizado, abierto, para evaluar la seguridad y la eficacia de BMS-986504 en monoterapia en participantes con cáncer de pulmón no microcítico (CPNM) avanzado o metastásico con deleción homocigótica de MTAP después de la progresión a trata-mientos previos.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Ensayo de fase III, multicéntrico, aleatorizado y en abierto de trastuzumab deruxtecán (Enhertu®) más quimioterapia con o sin pembrolizumab en comparación con quimioterapia más trastuzumab con o sin pembrolizumab como tratamiento de primera línea en participantes con cáncer gástrico o de la unión gastroesofágica (UGE) positivo para HER2 irresecable, localmente avanzado o metastásico (DESTINY-GASTRIC05).	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	III
B-22	A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-02)	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II
B-22	Protocolo maestro para un estudio de plataforma de fase II, abierto, con varios fárma-cos, multicéntrico, para evaluar la seguridad, tolerabilidad, farmacocinética y actividad antitumoral preliminar de fármacos novedosos o combinaciones como tratamiento pe-rioperatorio en participantes con adenocarcinoma gastroesofágico resecable localmente avanzado (GEMINI PeriOp GC)	DRUG CLINICAL TRIALS	INMACULADA ALES DIAZ	II

Group	Title	Subtype	PI Name	Phase
B-22	Estudio de fase III global de la monoterapia con rilvegostomig o pembrolizumab para el tratamiento de primera línea del cáncer de pulmón no microcítico metastásico con niveles altos de PD-L1. (ARTEMIDE)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	Estudio fase I/IIa, abierto, de búsqueda de dosis, para evaluar laseguridad, la tolerabilidad, la farmacocinética y la eficacia preliminar de combinacione	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	I/II
B-22	Estudio fase IIIb de durvalumab como tratamiento de consolidación para pacientes diagnosti-cados de cáncer de pulmón de célula pequeña en estadio limitado que no han progresado tras quimiorradioterapia definitiva concurrente o secuencial basada en platino en España (ALBO-RAN)."	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III/IV
B-22	Estudio de fase 2, abierto y multicéntrico del zoldonrasib (RMC-9805) en pacientes con cáncer de pulmón no microcítico (CPNM) con mutación RAS G12D tratados previamente: subprotocolo D	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Estudio en fase III, aleatorizado, en abierto y multicéntrico del RMC-6236 en comparación con docetaxel en pacientes con CBPNM con mutaciones de RAS localmente avanzado o metastásico tratado previamente. RASolve 301	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.	DRUG CLINICAL TRIALS	BEGOÑA JIMENEZ RODRIGUEZ	III
B-22	A Phase 3, Open Label, Multicenter, Randomized Study of FirstLine Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versusDurvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-CellLung Cancer (DeLLphi-312).	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	III
B-22	A Phase II clinical trial of Tarlatamab as maintenance treatment after sequential chemo-radiotherapy for limited stage SCLC patients not eligible for concurrent chemo-radiotherapy.	DRUG CLINICAL TRIALS	AIRAM AYOZE PADILLA ALVAREZ	II
B-22	Estudio en fase II de zelenectida pevedotina en participantes con cáncer de pulmón no microcítico avanzado o metastásico amplificado con NECTIN4 que han recibido tratamiento previamente (Duravelo-4)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	Estudio de fase III, aleatorizado, abierto, multicéntrico y global sobre el puxitatug samrotecán (AZD8205) en monoterapia frente a la quimioterapia de elección del médico en participantes con cán-cer de endometrio avanzado/metastásico con expresión de B7-H4 que presentaron progresión durante o después de la quimioterapia basada en platino y la terapia anti-PD-1/anti-PD-L1 (BLUESTAR-Endometrial01).	DRUG CLINICAL TRIALS	DAVID FERNANDEZ GARAY	III
B-22	Estudio de fase 1b/2, abierto y multicéntrico de RMC-9805, con o sin RMC-6236, en combi-nación con otros fármacos antineoplásicos, en pacientes con cáncer de pulmón no microcíti-co (CPNM) con mutación RAS G12D: subprotocolo C	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	I/II
B-22	A Randomized, Double-Blind, Multicenter, Pharmacokinetic Equivalence Clinical Trial of QL2107 (Keytruda® Biosimilar Candidate) in Comparison with Keytruda® (Pembrolizumab) for Adjuvant Therapy to Demonstrate Pharmacokinetic Similarity in Subjects with Resected Non Small Cell Lung Cancer.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	III
B-22	An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer (DIAMOND).	DRUG CLINICAL TRIALS	BEGOÑA JIMENEZ RODRIGUEZ	II
B-22	Estudio preliminar de eficacia para evaluar la eficacia de los tratamientos mediante el control de la enfermedad residual mínima con ADNtc en población con cáncer de mama precoz RH positivo/HER2 negativoMIRADOR	DRUG CLINICAL TRIALS	ESTER VILLAR CHAMORRO	II
B-22	Primer estudio en seres humanos de fase I/II, en abierto y multicéntrico del DS-3939a en participantes con tumores sólidos avanzados	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	I/II
B-22	Un estudio de Fase 1b de GILTERITINIB en participantes con localmente Carcinoma de pulmón de células no pequeñas avanzado o metastásico con reordenamiento de Linfoma quinasa anaplásico después tratamiento previo con un inhibidor de alk	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	I
B-22	Estudio de Fase 2b/3, aleatorizado, doble ciego para investigar la eficacia, la seguridad y la tolerabilidad del PONSEGROMAB (PF-06946860) en comparación con el placebo tanto con quimioterapia de base de primera línea en participantes adultos con caquexia como con adenocarcinoma ductal pancreático metastásico.	OBSERVATIONAL STUDY WTIH MEDICINES	INMACULADA ALES DIAZ	Not applicable

Group	Title	Subtype	PI Name	Phase
B-22	Trasplante de microbiota fecal en pacientes con cáncer de pulmón en estadios II-III	DRUG CLINICAL TRIALS	AIRAM AYOZE PADILLA ALVAREZ	II
B-22	IZABRIGHT-Lung01: Estudio fase 2/3 aleatorizado y abierto de izalontamab brengitecán (BMS-986507) frente a quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico con mutación de EGFR y progresión de la enfermedad durante el tratamiento con un inhibidor de la tirosina quinasa de EGFR.	DRUG CLINICAL TRIALS	MANUEL COBO DOLS	II/III
B-22	Estudio centrado en el paciente de trastuzumab deruxtecán (T-DXd) en el cáncer de mama metastásico HER2+ en primera línea con tratamiento proactivo de la toxicidad basado en la práctica clínica real“ TOP-REAL	DRUG CLINICAL TRIALS	BEGOÑA JIMENEZ RODRIGUEZ	III
B-22	Estudio descriptivo de la evolución en el diagnóstico y tratamiento de pacientes con cáncer microcítico de pulmón en España	OBSERVATIONAL STUDY WTIH MEDICINES	MARÍA VANESA GUTIERREZ CALDERON	Not applicable
B-22	A Phase II, Multicenter, Randomized Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)	DRUG CLINICAL TRIALS	MARÍA VANESA GUTIERREZ CALDERON	II
B-22	A First-In-Human (FIH) phase I/II open-label, multicentre, dose escalation and expansion trial of VERT-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) harboring MET alterations	DRUG CLINICAL TRIALS	AIRAM AYOZE PADILLA ALVAREZ	I/II
BA-20	Estudio postautorización, multicéntrico, observacional, retrospectivo, de evaluación de seguridad, tolerabilidad y efectividad en el tratamiento con fármacos antiepilépticos en pacientes con crisis epilépticas secundarias a tumor cerebral tratados con radioterapia. NERAD	INDEPENDENT POSTAUTHORIZATION STUDY	ASUNCIÓN VILLANUEVA ALVAREZ	Not applicable
BA-20	RECAP (Registro Español de Cáncer de Próstata). Tratamiento radioterápico en pacientes con cáncer de próstata conforme a la práctica clínica habitual en los servicios de oncología radioterápica españoles	INDEPENDENT POSTAUTHORIZATION STUDY	ASUNCIÓN VILLANUEVA ALVAREZ	Not applicable
BA-20	Estudio pivotal, multinacional, aleatorizado, doble ciego y controlado con placebo, de SGX942 (Dusquetide) para el tratamiento de la mucositis oral en pacientes con carcinoma de células escamosas de cabeza y cuello tratado con quimiorradiación concomitante	COMMERCIAL CLINICAL TRIAL	JORGE CONTRERAS MARTINEZ	III
BA-20	Estudio de fase I de aumento escalonado de la dosis de NBTXR activado mediante radioterapia de intensidad modulada en pacientes con carcinoma de células escamosas localmente avanzado en la cavidad bucal o la orofaringe	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	JORGE CONTRERAS MARTINEZ	Not applicable
BA-20	Irradiación parcial acelerada de la mama: nuevo fraccionamiento alterado.	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JOSE Mª AZCOAGA BLASCO	Not applicable
BA-20	Estudio de fase III (etapa pivotal) de NBTXR3 activado por radioterapia, en monoterapia o en combinación con cetuximab a elección del investigador, en pacientes ancianos con carcinoma de células escamosas de cabeza y cuello localmente avanzado, que no cumplen los requisitos para recibir quimioterapia basada en platino	OBSERVATIONAL STUDY WTIH MEDICINES	JORGE CONTRERAS MARTINEZ	Not applicable
BA-20	Estudio de fase III (etapa pivotal) de NBTXR3 activado por radioterapia, en monoterapia o en combinación con cetuximab a elección del investigador, en pacientes ancianos con carcinoma de células escamosas de cabeza y cuello localmente avanzado, que no cumplen los requisitos para recibir quimioterapia basada en platino.	DRUG CLINICAL TRIALS	JORGE CONTRERAS MARTINEZ	III
BE-03	Ensayo adaptativo de fase 3 aleatorizado, abierto y controlado para investigar la eficacia, seguridad y tolerabilidad del anticuerpo BiTE® blinatumomab como tratamiento de consolidación frente a la quimioterapia de consolidación convencional en sujetos pediátricos con leucemia linfoblástica aguda (LLA) de precursores B en primera recaída de alto riesgo	COMMERCIAL CLINICAL TRIAL	ANTONIA PASCUAL MARTINEZ	III
BE-03	Infusión de células Natural Killer como tratamiento de consolidación en niños y adolescentes con leucemia mieloblástica aguda.	INDEPENDENT CLINICAL TRIAL	ANTONIA PASCUAL MARTINEZ	II
BE-03	Estudio observacional prospectivo para evaluar la precocidad, estabilidad y profundidad de la respuesta molecular en pacientes recién diagnosticados de leucemia mieloide crónica en fase crónica (LMC-FC) tratados con inhibidores de la actividad tirosina-quinasa (ITK) como tratamiento de primera línea en la práctica clínica	INDEPENDENT POSTAUTHORIZATION STUDY	CONCEPCIÓN RUIZ NUÑO	Not applicable

Group	Title	Subtype	PI Name	Phase
BE-03	Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico del inhibidor PI3K intravenoso Copanlisib en combinación con inmunoquimioterapia estándar versus inmunoquimioterapia estándar en pacientes con linfoma no Hodgkin indolente tras recaída	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	III
BE-03	Estudio de fase IV multinacional para evaluar el patrón de tratamiento en la vida real en pacientes con hemofilia A tratados previamente que reciben KOVALTRY (octocog alfa) para la profilaxis habitual. TAURUS	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Estudio prospectivo de 24 meses, multicéntrico, no intervencional para evaluar la efectividad de Elocta en comparación con productos del factor convencional en el tratamiento profiláctico de pacientes con hemofilia A. (Sobi.Elocta-002)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Estudio de fase I/II internacional, abierto y multicéntrico de la seguridad y del aumento de dosis de BAX 888, un vector de virus adenoasociado de serotipo 8 (VAA8) que expresa un factor VIII con el dominio B eliminado (B-Domain Deleted Factor VIII, BDD-FVIII) en sujetos con hemofilia A grave administrado como infusión única por vía intravenosa.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ LOPEZ JAIME	I
BE-03	Trasplante alogénico de células madre en niños y adolescentes con leucemia linfoblástica aguda - FORUM (Para omitir radioterapia por debajo de la mayoría de edad)	INDEPENDENT CLINICAL TRIAL	ANTONIA PASCUAL MARTINEZ	III
BE-03	Estudio observacional prospectivo sobre la supervivencia global y la calidad de vida en pacientes mayores de 60 años diagnosticados de leucemia mieloide aguda en España, tratados según la práctica clínica habitual. (Estudio SvLMA).	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL BARRIOS GARCIA	Not applicable
BE-03	Estudio internacional para el tratamiento de la LLA infantil de alto riesgo 2010. IntReALL HR 2010	INDEPENDENT CLINICAL TRIAL	ANA ISABEL RODRIGUEZ JIMENEZ	II
BE-03	Estudio prospectivo, multinacional y observacional en pacientes con hemofilia A y B, con o sin inhibidores, tratados según la práctica clínica habitual (explorer™6)Código Promotor: NN7415-4322	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Estudio posautorización de seguridad, no intervencionista, en pacientes con linfoma recurrente o resistente de células del manto, para seguir investigando y caracterizando la asociación de lenalidomida con la reacción de exacerbación tumoral y carga tumoral elevada. Cód. Protocolo del Promotor: CC-5013-MCL-005	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL ESPESO DE HARO	Not applicable
BE-03	Estudio fase II con aleatorización 2:1 para comparar la eficacia y seguridad del tratamiento con quimioterapia estándar más quizartinib frente a quimioterapia estándar más placebo en pacientes adultos con LMA de nuevo diagnóstico con el gen FLT3 no mutado	INDEPENDENT CLINICAL TRIAL	MANUEL BARRIOS GARCIA	II
BE-03	Estudio prospectivo español de pacientes hematológicos pre y postrasplante hematopoyético que ingresan en unidades de cuidados intensivos: análisis de la práctica clínica, resultados en salud, factores pronósticos y utilización de recursos sanitarios.	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA ÁNGELES CUESTA CASAS	Not applicable
BE-03	Guía de recomendaciones de la SEHOP para el tratamiento de la Leucemia Linfobástica Aguda o Bifenotípica del lactante menor de 1 año	NON-POST-APPROVAL STUDY	ANA ISABEL RODRIGUEZ JIMENEZ	Not applicable
BE-03	Estudio fase III aleatorizado abierto para comparar el tratamiento con azacitidina más pevonedistat frente a azacitidina en adultos con LMA de nuevo diagnóstico ancianos y/o no candidatos a quimioterapia estándar de inducción	INDEPENDENT CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
BE-03	Estudio internacional del tratamiento y resultados de la leucemia mieloide crónica (LMC) en niños y adolescentesCódigo Promotor: I-CML-Ped Study	INDEPENDENT POSTAUTHORIZATION STUDY	ANTONIA PASCUAL MARTINEZ	Not applicable
BE-03	Estudio de fase II, multicéntrico, abierto, de un solo brazo , de ruxolitinib añadido a corticosteroides en sujetos pediátricos con enfermedad de injerto contra huésped crónica moderada y grave tras trasplante alogénico de células madre.	COMMERCIAL CLINICAL TRIAL	ANTONIA PASCUAL MARTINEZ	II
BE-03	Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B sin inhibidores.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ LOPEZ JAIME	III
BE-03	Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B con inhibidores	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ LOPEZ JAIME	III
BE-03	Estudio de fase III, aleatorizado, abierto y multicéntrico, para comparar zanubrutinib (BGB-3111) más rituximab frente a bendamustina más rituximab en pacientes con linfoma de células del manto no tratados previamente que no son aptos para recibir un trasplante de células madre.	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	III

Group	Title	Subtype	PI Name	Phase
BE-03	Estudio de fase Ib, abierto, aleatorizado, para evaluar la seguridad y la eficacia preliminar de Tafasitamab en combinación con R-CHOP o Tafasitamab más Lenalidomida en combinación con R-CHOP en pacientes con linfoma difuso de células B grandes (LDCBG) de nuevo diagnóstico - First-MIND	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	I
BE-03	Estudio observacional, multicéntrico de 48 meses de seguimiento para evaluar la eficacia a largo plazo de Elocta en la salud articular. Estudio A-MORE-ES	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Seguridad, tolerabilidad, farmacocinética y farmacodinámica de dosis subcutáneas únicas y múltiples de NNC0365-3769 (Mim8) en pacientes sanos y en pacientes con hemofilia A con o sin inhibidores del factor VIII. (FRONTIER 1)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ LOPEZ JAIME	II
BE-03	Estudio de fase III, abierto, aleatorizado y multicéntrico de ravulizumab en pacientes adultos y adolescentes que presentan microangiopatía trombótica (MAT) después de un trasplante de células madre hematopoyéticas (TCMH)	COMMERCIAL CLINICAL TRIAL	MARÍA JESÚS PASCUAL CASCON	III
BE-03	Evaluación de la seguridad a largo plazo de ADYNOVI/ADYNOVATE (factor antihemofílico [recombinante] pegilado, rurioctocog alfa pegol) en pacientes con hemofilia A: un estudio de seguridad posterior a la autorización (PASS) de ADYNOVI/ADYNOVATE. (TAK-660-403)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Estudio observacional prospectivo para investigar la relación entre la duración del tratamiento (DoT) y la respuesta en pacientes con mieloma múltiple (MM) o amiloidosis sistémica (AL) tratados en condiciones de práctica clínica real. Estudio DOrianTCódigo Promotor: C16054	COMMERCIAL POST-AUTHORIZATION STUDY	MAGDALENA ALCALA PEÑA	Not applicable
BE-03	Impacto del disbalance del metaboloma y microbioma intestinales de receptores de trasplante hematopoyético en el desarrollo de enfermedad injerto contra huésped	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA JESÚS PASCUAL CASCON	Not applicable
BE-03	Estudio de fase IV, multicéntrico y abierto para evaluar la Salud general, la actividad física y los resultados articulares en participantes de 13 años o más y menos de 70 años con Hemofilia a grave o moderada sin inhibidores del FVIII que reciben profilaxis con emicizumab	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ LOPEZ JAIME	IV
BE-03	Un ensayo aleatorizado multicéntrico de fosfomicina frente a ciprofloxacino para la neutropenia febril en pacientes hematológicos: eficacia y seguridad microbiológica.	INDEPENDENT CLINICAL TRIAL	MARÍA ÁNGELES CUESTA CASAS	III
BE-03	Estudio postautorización internacional, prospectivo, abierto, no controlado y no intervencionista de turoctocog alfa pegol (N8-GP) durante la profilaxis habitual y tratamiento a largo plazo de los episodios de sangrados en pacientes con hemofilia A	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Estudio en fase III, aleatorizado, abierto, con control activo, multicéntrico, para evaluar la eficacia y la seguridad de Crovalimab frente a Eculizumab en pacientes adultos y adolescentes con hemoglobinuria paroxística nocturna (HPN) actualmente tratada con inhibidores del complemento. Estudio COMMODORE	COMMERCIAL CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
BE-03	Estudio abierto para investigar la eficacia, la seguridad y la farmacocinética de la profilaxis con concizumab en niños menores de 12 años con hemofilia A o B con o sin inhibidores NN7415-4616	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ LOPEZ JAIME	III
BE-03	Estudio de fase 1/2, abierto, de aumento escalonado de la dosis para evaluar la seguridad, la tolerabilidad, la eficacia preliminar y la farmacocinética de TAK-981 en pacientes adultos con tumores sólidos avanzados o metastásicos o con neoplasias malignas hematológicas recidivantes/resistentes	INDEPENDENT CLINICAL TRIAL	MANUEL ESPESO DE HARO	II
BE-03	Estudio en fase III, aleatorizado, abierto, para evaluar la seguridad y la eficacia de magrolimab en combinación con azacitidina frente a la elección del médico de venetoclax más azacitidina o quimioterapia intensiva, en pacientes con leucemia mieloide aguda y TP53 mutado no tratados previamente	INDEPENDENT CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
BE-03	Protocolo de registro y análisis de macroglobulinemia de waldenström en España	COMMERCIAL POST-AUTHORIZATION STUDY	MAGDALENA ALCALA PEÑA	Not applicable
BE-03	Estudio de los parámetros clínicos y biológicos determinantes de respuesta en pacientes con LLC tratados en primera línea con Ibrutinib (IBROMICS)	OBSERVATIONAL STUDY WTIH MEDICINES	MACARENA ORTIZ PAREJA	Not applicable
BE-03	Estudio de fase III, abierto, de un solo grupo y con dosis repetidas, para evaluar la seguridad y tolerabilidad, la farmacocinética y la actividad antiviral de maribavir para el tratamiento de la infección por el citomegalovirus (CMV) en niños y adolescentes que han recibido un trasplante de células madre hematopoyéticas (HSCT) o un trasplante de órgano sólido (TOS)	COMMERCIAL CLINICAL TRIAL	ANTONIA PASCUAL MARTINEZ	III

Group	Title	Subtype	PI Name	Phase
BE-03	A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease ESTUDIO MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DECITABINA-TETRAHIDROURIDINA ORAL (NDec) EN PACIENTES CON ANEMIA FALCIFORME	DRUG CLINICAL TRIALS	ALEJANDRO CONTENTO GONZALO	II
BE-03	Estudio de fase 3, de dos etapas, aleatorizado, multicéntrico, abierto, para comparar CC 92480 (BMS-986348), carfilzomib y dexametasona (480Kd) frente a carfilzomib y dexametasona (Kd) en participantes con mieloma múltiple en recidiva o refractario (MMRR).	DRUG CLINICAL TRIALS	MAGDALENA ALCALA PEÑA	III
BE-03	Ensayo de fase III en pacientes con MMND candidatos a TASPE para comparar VRD extendido hasta 18 ciclos más intervención temprana de rescate vs. Isatuximab-VRD vs. Isatuximab-V-iberdomida-D	DRUG CLINICAL TRIALS	MAGDALENA ALCALA PEÑA	III
BE-03	HA-SAFE: Estudio observacional para evaluar la seguridad a largo plazo del tratamiento con damoctocog alfa pegol en práctica habitual en pacientes con hemofilia A tratados previamente	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Estudio de investigación observacional sobre la salud de las articulaciones en personas con hemofilia que toman el medicamento Esperoct®	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Real-World Evidence, Non-interventional Study on Clinical Characteristics, Epidemiology, Treatment Patterns and Patient Journey of Chronic Lymphocytic Leukemia Patients in Spain (SPARCLL)	OBSERVATIONAL STUDY WTIH MEDICINES	MACARENA ORTIZ PAREJA	Not applicable
BE-03	Estudio retrospectivo observacional del tratamiento de la Macroglobulinemia DE Waldenström con Ibrutinib en la práctica clínica habitual en españa. Estudio MACRO.	OBSERVATIONAL STUDY WTIH MEDICINES	MAGDALENA ALCALA PEÑA	Not applicable
BE-03	Estudio abierto de la seguridad y la eficacia a largo plazo de Mim8 en participantes con hemofilia A con o sin inhibidores	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ LOPEZ JAIME	III
BE-03	Ambispective Non-Interventional Study to Assess the Effectiveness of Recombinant Fusion Protein linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) in Hemophilia B in a Real-World Setting	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Ensayo de fase III, aleatorizado, sin enmascaramiento y multicéntrico del tratamiento de primera línea con células mesenquimales estromales MC0518 en comparación con el mejor tratamiento disponible en sujetos adultos y adolescentes con enfermedad de injerto contra huésped aguda refractaria a esteroides después del trasplante alogénico de células madre hematopoyéticas (ensayo IDUNN)	DRUG CLINICAL TRIALS	MARÍA JESÚS PASCUAL CASCON	III
BE-03	A Global, Non-interventional Study to Prospectively Evaluate Bleeding Episodes and Treatment Use inPatients with Hemophilia. 7037209	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Epidemiology of idiopathic multicentric Castleman disease in Spain.	OBSERVATIONAL STUDY WTIH MEDICINES	MANUEL ESPESO DE HARO	Not applicable
BE-03	Estudio observacional, multinacional y no intervencionista con isatuximab enpacientes con mieloma múltiple recidivante o resistente al tratamiento (MMRR)	OBSERVATIONAL STUDY WTIH MEDICINES	MAGDALENA ALCALA PEÑA	Not applicable
BE-03	Estudio abierto de seguridad en adultos y adolescentes con hemofilia A con y sin inhibidores del FVIII que cambian directamente de la profilaxis con emicizumab a la profilaxis con NNC0365 3769 (Mim8)	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ LOPEZ JAIME	III
BE-03	Estudio en Fase III, abierto, de 2 grupos, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de Elranatamab (PF-06863135) + DARATUMUMAB + LENALIDOMIDA en comparación con DARATUMUMAB + LENALIDOMIDA + DEXAMETASONA en participantes con mieloma múltiple de diagnóstico reciente no aptos para trasplante.	DRUG CLINICAL TRIALS	MAGDALENA ALCALA PEÑA	III
BE-03	Estudio de bajo nivel de intervención, prospectivo, multicéntrico, de 18 meses de duración para evaluar los resultados en salud articular de pacientes con Hemofilia A o B en tratamiento profiláctico con Efmoroctocog alfa o Eftrenonacog alfa.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ LOPEZ JAIME	IV
BE-03	Estudio de la prevalencia de la Enfermedad déficit de esfingomielinasa ácida(ASMD) y Enfermedad de Gaucher en pacientes con Gammapatías Monoclonales y/o Mieloma	OBSERVATIONAL STUDY WTIH MEDICINES	ALEJANDRO CONTENTO GONZALO	Not applicable
BE-03	Estudio observacional, multicéntrico, de un solo brazo, para evaluar la efectividad de pegcetacoplán en condiciones reales en pacientes con hemoglobinuria paroxística nocturna (HPN).	OBSERVATIONAL STUDY WTIH MEDICINES	ALEJANDRO CONTENTO GONZALO	Not applicable
BE-03	Estudio observacional para describir el impacto clínico de los patrones de tratamiento en personas con hemofilia a leve-moderada en España (ESTUDIO LEMON).	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable

Group	Title	Subtype	PI Name	Phase
BE-03	Estudio global, abierto y de diseño adaptativo para investigar la eficacia y la seguridad de SerpinPC en pacientes con hemofilia A grave o con hemofilia B de moderadamente grave a grave	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ LOPEZ JAIME	III
BE-03	Ensayo de fase II, aleatorizado, sin enmascaramiento, controlado y multicéntrico del tratamiento de primera línea con células mesenquimales estromales MC0518 en comparación con el mejor tratamiento disponible en participantes pediátricos con enfermedad de injerto contra huésped aguda refractaria a esteroides después del trasplante alogénico de células madre (ensayo BALDER)	DRUG CLINICAL TRIALS	ANTONIA PASCUAL MARTINEZ	II
BE-03	Efectividad comparada en la vida real del belumosudil frente al mejor tratamiento disponible elegido por el médico para la enfermedad crónica de injerto contra huésped: Estudio retrospectivo basado en las historias clínicas de los pacientes	OBSERVATIONAL STUDY WTIH MEDICINES	MARÍA JESÚS PASCUAL CASCON	Not applicable
BE-03	Estudio de Fase I/II para evaluar la seguridad, Tolerabilidad, farmacocinética, farmacodinámica y eficacia de NXT007 en pacientes con hemofilia a grave o moderada.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ LOPEZ JAIME	II
BE-03	Fundación de la Sociedad Española de Hematología y Oncología Pediátricas, actuando en nombre y representación del Promotor International BFM Study Group	OBSERVATIONAL STUDY WTIH MEDICINES	ANA ISABEL RODRIGUEZ JIMENEZ	Not applicable
BE-03	Estudio aleatorizado, doble ciego, multicéntrico, fase 3, para evaluar la eficacia y la seguridad de belumosudil en combinación con corticoesteroides frente a placebo en combinación con corticoesteroides en participantes de al menos 12 años con diagnóstico reciente de enfermedad de injerto contra huésped crónica (EICHc).	DRUG CLINICAL TRIALS	MARÍA JESÚS PASCUAL CASCON	III
BE-03	Estudio europeo, multicéntrico, retrospectivo y no intervencionista para describir los resultados clínicos, los patrones de tratamiento y el uso de recursos sanitarios en la práctica real en pacientes tratados con avatrombopag para la trombocitopenia inmunitaria primaria (TPI) (AVA-EU)	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Ensayo clínico abierto, multicéntrico y de búsqueda de dosis para evaluar la seguridad, farmacocinética, farmacodinámica y eficacia clínica de RVU120 en combinación con venetoclax en participantes con leucemia mieloide aguda en los que fracasó el tratamiento previo con venetoclax y un agente hipometilante	DRUG CLINICAL TRIALS	ALEJANDRO CONTENTO GONZALO	II
BE-03	Estudio multicéntrico en fase III, aleatorizado, con enmascaramiento doble, controlado con placebo, de itolizumab en combinación con corticoesteroides para el tratamiento inicial de la enfermedad aguda del injerto contra el anfitrión	DRUG CLINICAL TRIALS	MARÍA JESÚS PASCUAL CASCON	III
BE-03	A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)	DRUG CLINICAL TRIALS	ALEJANDRO CONTENTO GONZALO	II
BE-03	Estudio transversal para evaluar la percepción de la actividad física en pacientes con Hemofilia a tratados con Emicizumab. Estudio HEMO-ACT.	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable
BE-03	Estudio multicéntrico, de fase 2, randomizado y abierto para evaluar la eficacia y seguridad de zanubrutinib en combinación con obinutuzumab en pacientes con Leucemia Linfocítica Crónica (LLC) o Linfoma Linfoblástico de Células Pequeñas (LLP) no tratados previamente.	DRUG CLINICAL TRIALS	MACARENA ORTIZ PAREJA	II
BE-03	A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ LOPEZ JAIME	I
BE-03	Estudio en fase II, abierto, aleatorizado y multicéntrico para evaluar la seguridad y la eficacia de axatilimab en combinación con ruxolitinib en participantes con enfermedad de injerto contra huésped crónica recién diagnosticada	DRUG CLINICAL TRIALS	MARÍA JESÚS PASCUAL CASCON	II
BE-03	A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB198 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies	DRUG CLINICAL TRIALS	CONCEPCIÓN RUIZ NUÑO	I/II
BE-03	Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors: an exploratory study from Spanish GETH/TC Centers	DRUG CLINICAL TRIALS	MARÍA JESÚS PASCUAL CASCON	II
BE-03	Análisis de los pacientes con Leucemia Linfática Crónica (LLC) que discontinúan la monoterapia con un inhibidor de BTK sin progresión de la enfermedad.	OBSERVATIONAL STUDY WTIH MEDICINES	MACARENA ORTIZ PAREJA	Not applicable
BE-03	Registro Español de la Trombocitopenia Inmune Primaria y otras trombocitopenias inmunes	OBSERVATIONAL STUDY WTIH MEDICINES	FRANCISCO JOSÉ LOPEZ JAIME	Not applicable

Group	Title	Subtype	PI Name	Phase
BE-03	Estudio de seguridad posterior a la autorización (PASS), internacional, multicéntrico y no intervencionista, para evaluar la efectividad y la seguridad de elranatamab en pacientes con mieloma múltiple recidivante/ resistente (MMRR) tratados en situaciones de la vida real (VR). MAGNETISMM-16.	OBSERVATIONAL STUDY WTIH MEDICINES	MAGDALENA ALCALA PEÑA	Not applicable
BE-03	Estudio abierto, en Fase III, que evalúa ELRANATAMAB en monoterapia frente a Elotuzumabm, Pomalidomida y Dexametasona (EPd) o Pomalidomida, Btortezomib y Dexametasona (PVd) o Arfilzomib y Dexametasona (Kd) en participantes con Mieloma Múltiple Recidivante/Resistente al tratamiento que han recibido, tratamiento dirigido contra CD38.	DRUG CLINICAL TRIALS	MAGDALENA ALCALA PEÑA	III
BE-03	Ensayo de fase III, doble ciego, aleatorizado y comparativo con placebo de Quizartinib administrado en combinación con quimioterapia de inducción y consolidación, y como tratamiento de mantenimiento, en pacientes adultos con diagnóstico reciente de Leucemia Mieloide Aguda negativa para ITD-FLT3 (QuANTUM-Wild) (QUIZARTINIB o placebo más quimioterapia en pacientes con diagnóstico reciente de LMA negativa para ITD-FLT3).	DRUG CLINICAL TRIALS	ALEJANDRO CONTENTO GONZALO	III
BE-03	Impacto de la reconstitución inmune de CMV-específica al final de la profilaxis con Letermovir en el desarrollo de infección tardía por citomegalovirus en pacientes con trasplante de progenitores hematopoyéticos (Estudio INMUNOEND)	OBSERVATIONAL STUDY WTIH MEDICINES	MARÍA ÁNGELES CUESTA CASAS	Not applicable
BE-03	A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE).	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ LOPEZ JAIME	IV
BE-03	Estudio observacional retrospectivo para caracterizar a los pacientes con leucemia linfocítica crónica tratados con zanubrutinib en la práctica clínica habitual en España. ReaLLCZa	OBSERVATIONAL STUDY WTIH MEDICINES	MACARENA ORTIZ PAREJA	Not applicable
BE-03	A non-interventional study of melphalan flufenamide (melflufen, Pepaxti®) in combination with dexa-methasone in patients with relapsed and/or refractory multiple myeloma (RRMM) in Spain, according to the approved label. Protocol code and Spanish Agency of Medicines and Medical Devices code.	OBSERVATIONAL STUDY WTIH MEDICINES	MAGDALENA ALCALA PEÑA	Not applicable
BE-03	International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020. A Random-ized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group	DRUG CLINICAL TRIALS	ANA ISABEL RODRIGUEZ JIMENEZ	III
BE-03	Estudio fase II, multicéntrico, abierto y de un brazo de acalabrutinib, en combinación con el estándar de tratamiento R-CHOP, para el linfoma de células del manto no tratado previamente en España (SOUND-MCL)	DRUG CLINICAL TRIALS	MANUEL ESPESO DE HARO	II
BE-03	A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic TherapyA Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy.A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy	DRUG CLINICAL TRIALS	MARÍA JESÚS PASCUAL CASCON	III
BE-03	Eficacia real de Belumosudil en el tratamiento de la enfermedad crónica de injerto contra huésped: Un estudio de cohortes retrospectivo no intervencionista que utiliza los historiales médicos de los pacientes (ROCKreal 2).	OBSERVATIONAL STUDY WTIH MEDICINES	MARÍA JESÚS PASCUAL CASCON	Not applicable
BE-03	A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2).	DRUG CLINICAL TRIALS	CONCEPCIÓN RUIZ NUÑO	III
BE-03	Protocolo piloto de estudio de tratamiento del consorcio ALLTogether para niños y adultos jóvenes (0-18 años) con diagnóstico reciente de leucemia linfoblástica (LLA).	OBSERVATIONAL STUDY WTIH MEDICINES	ANA ISABEL RODRIGUEZ JIMENEZ	Not applicable
BE-03	Seguridad, tolerabilidad, farmacocinética y farmacodinámica de dosis orales múltiples ascendentes de Inno8 en personas con hemofilia A.	DRUG CLINICAL TRIALS	FRANCISCO JOSÉ LOPEZ JAIME	I
BE-03	A phase 3 multicenter, randomized, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adaption of treatment duration to improve outcomes.	DRUG CLINICAL TRIALS	MACARENA ORTIZ PAREJA	III

Group	Title	Subtype	PI Name	Phase
BE-03	Un estudio de fase 2, aleatorizado y abierto de axatilimab versus La mejor terapia disponible en participantes pediátricos con Enfermedad crónica de injerto contra huésped después de al menos 2 líneas previas de Terapia Sistémica (AGAVE-256).	DRUG CLINICAL TRIALS	ANTONIA PASCUAL MARTINEZ	II
BE-17	Optimización de la radiación a través de la Evaluación Molecular de ganglios linfáticos después del tratamiento sistémico primario (OPTIMAL IIa).	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	ISABEL GARCIA RIOS	Not applicable
BE-17	Linfadenectomía axilar versus Radioterapia axilar en pacientes con cáncer de mama y ganglio centinela positivo tras terapia neoadyuvante. Estudio multicéntrico aleatorizado. (ADARNAT)	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ÁNGEL CALVO TUDELA	Not applicable
BE-17	START-MET HS Prostate Cancer: SbrT & Androgen Receptor Therapy METastatic HSPC.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ANTONIO LAZO PRADOS	Not applicable
BE-17	Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía: un ensayo fase III aleatorizado, controlado, multicéntrico.	DRUG CLINICAL TRIALS	ÁNGEL CALVO TUDELA	III
BE-21	Estudio observacional prospectivo para identificar los aspectos clínicos que conducen a la toma de decisiones terapéuticas en pacientes con mielofibrosis. Estudio TRATABILIDAD	INDEPENDENT POSTAUTHORIZATION STUDY	REGINA GARCIA DELGADO	Not applicable
BE-21	Estudio de Fase 2, multicéntrico, aleatorizado y abierto, que evalúa la seguridad y eficacia de tres regímenes diferentes de panobinostat en combinación con bortezomib subcutáneo y dexametasona oral en pacientes con mieloma múltiple recidivante o recidivante/refractario que hayan sido previamente expuestos a agentes inmunomoduladores.	COMMERCIAL CLINICAL TRIAL	RICARDA GARCIA SANCHEZ	II
BE-21	Lenalidomida y dexametasona (Ld) versus Claritomicina/Lenalidomida (Revlimid) /Dexametasona (BiRd) como tratamiento del miloma multiple	INDEPENDENT CLINICAL TRIAL	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio aleatorizado, doble ciego fase 3 de vadastuximab talirine (SGN-CD33A) frente a placebo en combinación con azacitidina o decitabina en el tratamiento de pacientes mayores con leucemia mieloide aguda de nuevo diagnóstico.	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	III
BE-21	Estudio aleatorizado, múlticéntrico, abierto, de fase II para evaluar la eficacia y la seguridad de azacitidina subcutánea en combinación con durvalumab (MEDI4736) en pacientes con síndromes mielodisplásicos (SMD) de alto riesgo no tratados previamente o en pacientes de edad avanzada (= 65 años) con leucemia mieloide aguda (LMA) que no son aptos para un trasplante de células madre hematopoyéticas (TCMH). Estudio de fusión SMD de alto riesgo/LMA de edad avanzada 001.	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	II
BE-21	Estudio clínico de fase II, aleatorizado, controlado y abierto para comparar la eficacia y la seguridad de pevonedistat más azacitidina frente a azacitidina en monoterapia en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica y leucemia mielógena aguda pobre en blastos	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	II
BE-21	Estudio aleatorizado, doble ciego, controlado con placebo, Fase 3, de Venetoclax en combinación con Azacitidina en comparación con Azacitidina, en pacientes con leucemia mieloide aguda no tratados anteriormente y no elegibles para terapias de inducción estándar.	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	III
BE-21	Estudio multicéntrico, de extensión abierto y de seguridad, para describir la experiencia clínica a largo plazo con mepolizumab en pacientes con síndrome hipereosinofílico (HES) procedentes del estudio 200622	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	III
BE-21	Estudio de discontinuación de inhibidores de la tirosina quinasa en LMC-FC	INDEPENDENT POSTAUTHORIZATION STUDY	ANA ISABEL ROSELL MAS	Not applicable
BE-21	Estudio observacional para valorar la carga de la enfermedad, en términos de Calidad de Vida Relacionada con la Salud y costes sanitarios directos, en pacientes con Mieloma Múltiple de nuevo diagnóstico no candidatos a trasplante autólogo de progenitores hematopoyéticos en España. QoLMMBuS	COMMERCIAL POST-AUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio observacional ambispectivo para evaluar la incidencia y el manejo de la aplasia medular en el Estado Español (IMAS)	INDEPENDENT POSTAUTHORIZATION STUDY	ANA ISABEL ROSELL MAS	Not applicable

Group	Title	Subtype	PI Name	Phase
BE-21	Estudio observacional, internacional, multicéntrico, sobre el uso de ruxolitinib en el tratamiento de pacientes con policitemia vera que presentan resistencia o intolerancia a la hidroxiurea. Código Promotor: CINC424BIC04	COMMERCIAL POST-AUTHORIZATION STUDY	REGINA GARCIA DELGADO	Not applicable
BE-21	Tratamiento de inducción con bortezomib, melfalán y prednisona (VMP) seguido de lenalidomida y dexametasona (Rd) frente a carfilzomib, lenalidomida y dexametasona (KRd) más/menos daratumumab, 18 ciclos, seguido de tratamiento de consolidación y mantenimiento con lenalidomida y daratumumab: un ensayo clínico de fase III, multicéntrico, aleatorizado para pacientes adultos mayores, de entre 65 y 80 años, con buen estado general y mieloma múltiple de nuevo diagnóstico	DRUG CLINICAL TRIALS	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio de fase II, multicéntrico, aleatorizado, controlado con placebo y doble ciego de MBG453 intravenoso en combinación con fármacos hipometilantes en pacientes adultos con síndrome mielodisplásico (SMD) de riesgo intermedio, alto o muy alto según los criterios del IPSS-R.	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	II
BE-21	Estudio retrospectivo de viabilidad de la guía clínica de PETHEMA-POMCIDEX para el tratamiento de pacientes con mieloma múltiple en recaída y refractario (RRMM)	INDEPENDENT POSTAUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio fase III aleatorizado abierto para comparar el tratamiento con azacitidina más pevonedistat frente a azacitidina en adultos con LMA de nuevo diagnóstico ancianos y/o no candidatos a quimioterapia estándar de inducción	INDEPENDENT CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	III
BE-21	Estudio en fase III, multicéntrico, abierto y aleatorizado para evaluar la eficacia y la seguridad del fedratinib comparado con la mejor terapia disponible en pacientes con mielofibrosis primaria de riesgo intermedio o alto riesgo según el Sistema dinámico internacional de puntuación pronóstica (DIPSS), mielofibrosis post-policitemia vera o mielofibrosis post-trombocitemia esencial tratados previamente con ruxolitinib	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	III
BE-21	Estudio fase II con aleatorización 2:1 para comparar la eficacia y seguridad del tratamiento con quimioterapia estándar más quizartinib frente a quimioterapia estándar más placebo en pacientes adultos con LMA de nuevo diagnóstico con el gen FLT3 no mutado	INDEPENDENT CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	II
BE-21	Ensayo multicéntrico en fase III, no enmascarado, aleatorizado, para evaluar la eficacia y la seguridad de CPI-613 en combinación con dosis altas de citarabina y mitoxantrona (CHAM) comparado con dosis altas de citarabina y mitoxantrona (HAM) en pacientes de edad avanzada (=60 años) con leucemia mieloide aguda (LMA) en recaída o refractaria	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	III
BE-21	Eficacia y seguridad de M281 en adultos con anemia hemolítica autoinmunitaria por anticuerpos calientes: estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo. Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled, Study with a Long-term Open label Extension	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	III
BE-21	Impacto de la monitorización de enfermedad mínima residual mediante citometría de flujo en el manejo del mieloma múltiple. Estudio EMR CLINICAL	INDEPENDENT POSTAUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio de fase 3, abierto y aleatorizado para comparar la eficacia y la seguridad de luspatercept (ACE-536) frente a epoetina alfa para el tratamiento de la anemia debida a síndromes mielodisplásicos (SMD) de riesgo muy bajo, bajo o intermedio según la clasificación IPSS-R en pacientes sin tratamiento previo con estimulantes de la eritropoyesis que necesitan transfusiones de glóbulos rojos.	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	III
BE-21	Estudio fase II, exploratorio, multicéntrico, abierto, no controlado, para evaluar la reinducción y la segunda parada a un TKI como ponatinib en pacientes con LMC en respuesta molecular (ResToP).	INDEPENDENT CLINICAL TRIAL	ANA ISABEL ROSELL MAS	II
BE-21	Estudio abierto, multicéntrico, de fase Ib/II de la seguridad y eficacia de KRT-232 en combinación con citarabina en dosis bajas (CDB) o decitabina en pacientes con leucemia mieloide aguda (LMA).	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	II
BE-21	Estudio retrospectivo, observacional y no intervencionista, para registrar el uso, seguridad y efectividad de la utilización de inotuzumab en pacientes con leucemia linfoblástica aguda refractaria o resistente a tratamientos previos	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA GARCIA FORTES	Not applicable
BE-21	Estudio multicéntrico, prospectivo, no aleatorizado, fase I-II para evaluar la eficacia y la seguridad de la combinación de quizartinib oral con el esquema de quimioterapia FLAG-IDA en pacientes con leucemia mieloide aguda en primera recidiva o refractarios (LMA R/R)	INDEPENDENT CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	II

Group	Title	Subtype	PI Name	Phase
BE-21	Ensayo doble ciego, aleatorizado y de fase III, para evaluar la eficacia de Uproleselan administrado con quimioterapia en comparación con quimioterapia sola en pacientes con leucemia mieloide aguda recidivante/refractaria	COMMERCIAL CLINICAL TRIAL	MARÍA GARCIA FORTES	III
BE-21	Estudio abierto en fase 2 para evaluar la tolerabilidad y la eficacia de navitoclax solo o en combinación con ruxolitinib en pacientes con mielofibrosis	COMMERCIAL CLINICAL TRIAL	MARÍA GARCIA FORTES	II
BE-21	Estudio de fase 3, multicéntrico, abierto, aleatorizado de dos grupos de tratamiento, venetoclax y azacitidina en comparación con el mejor tratamiento de soporte, como tratamiento de mantenimiento en pacientes con leucemia mieloide aguda en primera remisión después de recibir quimioterapia convencional (VIALE M)	COMMERCIAL CLINICAL TRIAL	MARÍA GARCIA FORTES	III
BE-21	Estudio de fase I/II, aleatorizado, abierto y de plataforma abierta en el que se evalúa la seguridad y eficacia de nuevas combinaciones de ruxolitinib en pacientes con mielofibrosis. (ADORE)	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	II
BE-21	Estudio de fase 1/2 de dos partes para determinar la seguridad, tolerabilidad, farmacocinética y actividad de K0706, un nuevo inhibidor de la tirosina cinasa (ITC), en pacientes sanos y pacientes con leucemia mieloide crónica (LMC) o leucemia linfoblástica aguda (LLA) positiva para el cromosoma Filadelfia	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	II
BE-21	Estudio observacional para describir la repercusión de los anticuerpos monoclonales como tratamiento de primera línea frente a otros regímenes estándar en pacientes con mieloma múltiple de nuevo diagnóstico que no sean candidatos a trasplante. Datos de práctica clínica habitual en España. Estudio CARINAE (54767414MMY4024)	COMMERCIAL POST-AUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio de fase 3, controlado con placebo, aleatorizado y doble ciego de Navitoclax en combinación con Ruxolitinib comparado con Ruxolitinib en pacientes con Mielofibrosis	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	III
BE-21	Transformando la mielofibrosis y la policitemia vera incontrolada en enfermedades cuantificables y de diagnóstico precoz. Estudio de casos y controles	NON-POST-APPROVAL STUDY	REGINA GARCIA DELGADO	Not applicable
BE-21	Estudio de fase Ib/II abierto y multicéntrico de la seguridad y eficacia de KRT-232 combinado con ruxolitinib en pacientes con mielofibrosis primaria (MFP), mielofibrosis post-policitemia vera (MF-post-PV) o mielofibrosis post-trombocitemia esencial (MF-post-TE) que tienen una respuesta subóptima a ruxolitinib	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	II
BE-21	Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia analgésica y la seguridad de una combinación en dosis fijas por vía oral de dexketoprofeno trometamol y tramadol hidrocloruro en el dolor agudo de moderado a intenso en pacientes con lumbalgia aguda: estudio DANTE	COMMERCIAL CLINICAL TRIAL	ANDRÉS FONTALBA NAVAS	IV
BE-21	Estudio de fase I, aleatorizado, de evaluación de dosis y esquema de tratamiento, para investigar la seguridad, farmacocinética, farmacodinámica y actividad clínica de Belantamab Mafodotín administrado en combinación con tratamiento estándar en pacientes con mieloma múltiple recién diagnosticado. DREAMM	COMMERCIAL CLINICAL TRIAL	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio de fase 3, aleatorizado y abierto, para evaluar imetelstat (GRN163L) frente al mejor tratamiento disponible en pacientes con mielofibrosis de riesgo intermedio 2 o alto resistente a inhibidores de las cinasas Jano	DRUG CLINICAL TRIALS	REGINA GARCIA DELGADO	III
BE-21	Estudio de fase 2, abierto y multicéntrico de TL-895 en pacientes con mielofibrosis recidivante/resistente, mielofibrosis intolerante para el inhibidor de la cinasa de Janus y mielofibrosis no apta para el tratamiento con inhibidor de la cinasa de Janus	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	II
BE-21	Estudio Fase 1b de escalado de dosis de Lemzoparlimab (TJ011133) en combinación con Azacitidina y/o Venetoclax en pacientes con Leucemia Mieloide Aguda (LMA) o Síndrome Mielodisplásico (SMD)	COMMERCIAL CLINICAL TRIAL	ALFONSO FERNÁNDEZ FERNÁNDEZ	I
BE-21	Estudio de fase 3 abierto, aleatorizado y multicéntrico para comparar Iberdomida, Daratumumab y Dexametasona (IberDd) con Daratumumab, Bortezomib y Dexametasona (DVd) en pacientes con mieloma múltiple recidivante o resistente (MMRR)	DRUG CLINICAL TRIALS	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio de fase III aleatorizado, doble ciego y controlado con principio activo de CPI-0610 y ruxolitinib frente a placebo y ruxolitinib en pacientes con MF sin tratamiento previo con iJAK (NZA68438)	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	III

Group	Title	Subtype	PI Name	Phase
BE-21	Estudio de fase I/II, abierto y multicéntrico para determinar la dosis y la pauta recomendadas y evaluar la seguridad y la eficacia preliminar del CC-92480 en combinación con tratamientos estándar en sujetos con mieloma múltiple en recaída o refractario (MMRR) y mieloma múltiple de nuevo diagnóstico (MMND)".	COMMERCIAL CLINICAL TRIAL	RICARDA GARCIA SANCHEZ	II
BE-21	Protocolo de registro y análisis de macroglobulinemia de waldenström en España PRAME HVV	COMMERCIAL POST-AUTHORIZATION STUDY	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio de fase 1b/2, abierto y multicéntrico para evaluar la seguridad y la eficacia de TL-895 combinado con ruxolitinib en sujetos con mielofibrosis (MF) sin tratamiento previo con inhibidores de la cinasa Janus (iJAK) y sujetos con mielofibrosis y respuesta subóptima a ruxolitinib.	COMMERCIAL CLINICAL TRIAL	REGINA GARCIA DELGADO	II
BE-21	Estudio aleatorizado de fase III para comparar Talquetamab SC combinado con Daratumumab SC y Pomalidomida (Tal-DP) o Talquetamab SC combinado con Daratumumab SC (Tal-D) frente a Daratumumab SC combinado con Pomalidomida y Dexametasona (DPd) en pacientes con mieloma múltiple refractario o recidivante que han recibido al menos 1 línea de tratamiento	DRUG CLINICAL TRIALS	RICARDA GARCIA SANCHEZ	III
BE-21	Ensayo de fase III en pacientes con MMND candidatos a TASPE para comparar VRD extendido hasta 18 ciclos más intervención temprana de rescate vs. Isatuximab-VRD vs. Isatuximab-V-iberdomida-D	DRUG CLINICAL TRIALS	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio en fase Ib abierto para evaluar la seguridad y la tolerabilidad de modakafusp alfa intravenoso como parte de un tratamiento combinado en pacientes adultos con mieloma múltiple	DRUG CLINICAL TRIALS	RICARDA GARCIA SANCHEZ	II
BE-21	Estudio observacional, naturalístico, transversal para describir el uso de Esketamina en pulverizador nasal en la depresión resistente al tratamiento en práctica clínica real. Estudio INtegrate.	OBSERVATIONAL STUDY WTIH MEDICINES	ANDRÉS FONTALBA NAVAS	Not applicable
BE-21	A First-In-Human Phase 1/2 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Hematological Tumors	DRUG CLINICAL TRIALS	REGINA GARCIA DELGADO	II
BE-21	Estudio de cohortes no intervencionista en pacientes con leucemia linfocítica crónica no tratados previamente o intolerantes a inhibidores BTK de primera generación para describir el uso de acalabrutinib en primera línea y sus resultados en vida real en España: estudio PICAROS.	OBSERVATIONAL STUDY WTIH MEDICINES	BORJA CIDONCHA MORCILLO	Not applicable
BE-21	Estudio en fase II/III, aleatorizado, doble ciego, con grupos paralelos, comparativo con placebo, con dosis flexible y multicéntrico para evaluar la eficacia y la seguridad de SEP-363856 en el tratamiento de adultos con trastorno de ansiedad generalizada.	DRUG CLINICAL TRIALS	ANDRÉS FONTALBA NAVAS	III
BE-21	A Phase 1b/2 Dose Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB 11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/ Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)	DRUG CLINICAL TRIALS	RICARDA GARCIA SANCHEZ	I
BE-21	Un estudio de Fase 3, aleatorizado, de etiqueta abierta de Linvoseltamab (REGN5458; Anticuerpo Bispecífico ANTI-BCMA X ANTI-CD3) versus la combinación de Elotuzumab, Pomalidomida y Dexametasona (EPd), en pacientes con Mieloma Múltiple en recidiva/refractario (LINKER-MM3).	DRUG CLINICAL TRIALS	RICARDA GARCIA SANCHEZ	III
BE-21	Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL.	DRUG CLINICAL TRIALS	REGINA GARCIA DELGADO	III
BE-21	Estudio en fase I/III para evaluar la eficacia y la seguridad del selinexor, un inhibidor selectivo de la exportación nuclear, en combinación con ruxolitinib en pacientes con mielofibrosis que no han recibido tratamiento previo"	DRUG CLINICAL TRIALS	REGINA GARCIA DELGADO	III
BE-21	A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy ofNavtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with MyelofibrosisWho Have a Suboptimal Response to Ruxolitinib	DRUG CLINICAL TRIALS	REGINA GARCIA DELGADO	III
BE-21	Estudio clínico de fase 3, abierto, aleatorizado y controlado con comparador activo para evaluar la seguridad y la eficacia de bomedemstat (MK 3543/IMG-7289) en comparación con el mejor tratamiento disponible (MTD) en participantes con trombocitemia esencial que presentan respuesta insuficiente o intolerancia a hidroxiurea.	DRUG CLINICAL TRIALS	REGINA GARCIA DELGADO	III

Group	Title	Subtype	PI Name	Phase
BE-21	Estudio observacional retrospectivo para describir las características clínicas, el manejo y los resultados del anticuerpo Blespecífico antiGPRC5D (TALquetamab) en pacientes con mieloma múltiple en recaída refractario tratados fuera de ensayo clínico (SPR	OBSERVATIONAL STUDY WTIH MEDICINES	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Estudio en fase II sin enmascaramiento para evaluar momelotinib en combinación con luspatercept en participantes con mielofibrosis primaria o secundaria dependiente de transfusiones.	DRUG CLINICAL TRIALS	REGINA GARCIA DELGADO	II
BE-21	A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2).	DRUG CLINICAL TRIALS	ANA ISABEL ROSELL MAS	III
BE-21	Estudio observacional retrospectivo para caracterizar a los pacientes con leucemia linfocítica crónica tratados con zanubrutinib en la práctica clínica habitual en España, Estudio ReaLLCZa.	OBSERVATIONAL STUDY WTIH MEDICINES	BORJA CIDONCHA MORCILLO	Not applicable
BE-21	Study of Vysis IntelliFISH CCND1/IGH XT FISH Probe Kit in a Phase 1b/2 Dose Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB 11417 as Monotherapy, in Combination With Dexamethasone, methasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/ Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	A Phase 3, randomized, open-label study of belantamab mafodotin administered in combina-tion with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineli-gible for autologous stem cell transplantation (TI-NDMM)-DREAMM-10.	DRUG CLINICAL TRIALS	RICARDA GARCIA SANCHEZ	III
BE-21	Estudio de confirmación de fase III, multicéntrico, internacional, abierto, aleatorio de lisaftoclax (APG-2575) en combinación con acalabrutinib versus inmunoquimioterapia en pacientes con diagnóstico reciente de leucemia linfocítica crónica/linfoma linfocítico de células pequeñas (estu-dio GLORA-2).	DRUG CLINICAL TRIALS	BORJA CIDONCHA MORCILLO	III
BE-21	Estudio no intervencionista de melfalán flufenamida (melflufen, Pepaxti®) en combinación con dexametasona en pacientes con mieloma múltiple recidivante y/o refractario (MMRR) en España, de acuerdo con la indicación aprobada	OBSERVATIONAL STUDY WTIH MEDICINES	RICARDA GARCIA SANCHEZ	Not applicable
BE-21	Un estudio global multicéntrico, doble ciego, aleatorizado y de registro de fase 3 de Li-saftoclax (APG-2575) en combinación con azacitidina (AZA) en pacientes con síndrome mielodisplásico de mayor riesgo recién diagnosticado (HR-MDS) (GLORA-4).	DRUG CLINICAL TRIALS	MARÍA GARCIA FORTES	III
BE-21	A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic Syndrome	DRUG CLINICAL TRIALS	REGINA GARCIA DELGADO	II
BE-23	Estudio en Fase III, multicéntrico, Randomizado, doble ciego, controlado con placebo para investigar ipatasertib en combinación con abiraterona más Prednisona/Prednisolona, comparado con placebo en combinación con Abiraterona más Prednisona/Prednisolona, en pacientes adultos con cáncer de próstata resistente a castración metastásico, asintomáticos o levemente sintomáticos que no han sido tratados previamente.	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	III
BE-23	Describe III Revisión retrospectiva de las historias clínicas de la monoterapia con dabrafenib y/o la terapia de combinación con dabrafenib y trametinib en pacientes con melanoma metastásico con el objeto de caracterizar a los pacientes que han obtenido un beneficio a largo plazo en el programa individualizado de pacientes (PIP)	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
BE-23	Ensayo fase III, aleatorizado, abierto, controlado, multicéntrico, internacional de durvalumab en combinación con el tratamiento estándar con quimioterapia y durvalumab en combinación con tremelimumab y el tratamiento estándar con quimioterapia frente al tratamiento estándar con quimioterapia solo, en primera línea en pacientes con cáncer urotelial localmente avanzado irresecable o metastásico.	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	III
BE-23	Estudio Observacional descriptivo sobre las características del melanoma avanzado y metastásico en España. GEM -1801	INDEPENDENT POSTAUTHORIZATION STUDY	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
BE-23	Ensayo de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de pembrolizumab (MK-3475) y lenvatinib (E7080/MK-7902) en comparación con pembrolizumab en monoterapia como intervención de primera línea en participantes con melanoma avanzado (LEAP-003).	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III

Group	Title	Subtype	PI Name	Phase
BE-23	Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar pembrolizumab frente a un placebo como tratamiento adyuvante después de cirugía y radioterapia del carcinoma epidermoide cutáneo localmente avanzado (CEC LA) de alto riesgo, MK3475-630.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase 3, aleatorizado y abierto de pembrolizumab (MK-3475) más olaparib frente a acetato de abiraterona o enzalutamida en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) que no son seleccionados por defectos en la reparación por recombinación homóloga y que han mostrado fracaso con el tratamiento previo con un fármaco hormonal de última generación (FHUG) y quimioterapia (KEYLYNK-010)	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	III
BE-23	Ensayo de fase 3, aleatorizado y doble ciego de pembrolizumab (MK-3475) más enzalutamida frente a un placebo más enzalutamida en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) (KEYNOTE-641)	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	III
BE-23	Un estudio en fase IV de seguimiento a largo plazo para definir el perfil de seguridad del dicloruro de radio 223	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	IV
BE-23	Ensayo fase 2 de nivolumab más ipilimumab, ipilimumab en monoterapia o cabazitaxel en varones con cáncer de próstata metastásico resistente a la castración	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	II
BE-23	Ensayo clínico fase 3b, aleatorizado, de nivolumab en monoterapia, nivolumab en combinación con ipilimumab o quimioterapia a elección del investigador en pacientes con cáncer colorrectal metastásico (CRCm) con alta inestabilidad de microsatélites (MSI-H) o déficit de reparación de discordancias (dMMR)	COMMERCIAL CLINICAL TRIAL	SILVIA GIL CALLE	III
BE-23	Estudio fase 3, aleatorizado, a doble ciego, de inmunoterapia adyuvante con nivolumab frente a placebo después de resección completa de melanoma en estadio IIB/C (CheckMate 76K: Evaluación en ensayo clínico de la vía de punto de control y nivolumab 76K)	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención de eventos cardiovasculares en Europa - Estudio Multinacional Observacional. Estudio SANTORINI (DSE-HCL-01-19)	COMMERCIAL POST-AUTHORIZATION STUDY	BEATRIZ PEREZ VILLARDON	Not applicable
BE-23	Estudio de fase III multicéntrico, aleatorizado, abierto para evaluar la eficacia y seguridad de Atezolizumab administrado en combinación con Cabozantinib frente a Cabozantinib en monoterapia en pacientes con carcinoma de células renales localmente avanzado o metastásico inoperable que han presentado progresión tumoral radiológica durante o después del tratamiento con un inhibidor de puntos de control inmunitario.	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	III
BE-23	Estudio de fase IV, aleatorizado, abierto, multicéntrico de la eficacia y la seguridad de la dosis habitual de dicloruro de radio-223 en comparación con las dosis habituales de un tratamiento antihormonal nuevo (AHN) en pacientes con cáncer de próstata resistente a la castración metastásico predominante en huesos y en progresión durante/después de una línea de AHN.	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	IV
BE-23	Estudio de fase III, multicéntrico, aleatorizado y abierto en el que se compara 177Lu-PSMA-617 frente a un cambio de terapia dirigida al receptor de andrógenos en el tratamiento de hombres con cáncer de próstata metastásico progresivo resistente a la castración que no hayan recibido taxanos. (PSMAfore) PSMAddition	COMMERCIAL CLINICAL TRIAL	ÁLVARO MONTESA PINO	III
BE-23	A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio de fase 2, aleatorizado y abierto, de ceralasertib en monoterapia y ceralasertib más durvalumab en pacientes con melanoma irresecable o avanzado y con resistencia primaria o secundaria a la inhibición de PD (L)1. MONETTE	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio AGAMENON. Registro Español de Cáncer Esofagogástrico	INDEPENDENT POSTAUTHORIZATION STUDY	CARMEN REYNA FORTES	Not applicable
BE-23	Estudio aleatorizado, abierto de Fase III, para comparar PRALSETINIB con el tratamiento estándar del cáncer medular de tiroides con mutación en RET.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio abierto, multicéntrico, de fase 1b/2 con E7386 en combinación con Pembrolizumab en pacientes previamente tratados con tumores sólidos específicos	INDEPENDENT CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II

Group	Title	Subtype	PI Name	Phase
BE-23	Estudio farmacocinético en fase III, abierto, aleatorizado y de no inferioridad de nivolumab administrado por vía subcutánea (Nivo s.c.) en comparación con la administración intravenosa de nivolumab en participantes con melanoma en estadio IIIA/B/C/D o estadio IV tras la resección completa en un entorno adyuvante	INDEPENDENT CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase III, aleatorizado y triple ciego en colaboración con el Grupo de Melanoma de la Organización Europea para la Investigación y el Tratamiento del Cáncer (EORTC) de encorafenib y binimetinib como tratamiento complementario comparado con placebo en el melanoma en estadio IIB/C completamente resecado con mutación V600E/K de BRAF	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio fase II, abierto de la eficacia preliminar de Sitravatinib en combinación con Tislelizumab en pacientes con melanoma metastásico uveal con hepáticas metástasis.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio de fase 2, multicéntrico y de varios grupos para evaluar MK-1308A (coformulación de quavonlimab (MK-1308)/ pembrolizumab) frente a otros tratamientos en participantes con cáncer colorrectal en estadio IV con inestabilidad de microsatélites alta (MSI-H) o con defectos en la reparación de los errores de emparejamiento (dMMR): (MK-1308A-008)	INDEPENDENT CLINICAL TRIAL	JULIA ALCAIDE GARCIA	II
BE-23	Ensayo clínico de fase III, abierto y aleatorizado de IO102-IO103 en combinación con pembrolizumab en comparación con pembrolizumab en monoterapia en pacientes con melanoma irresecable o metastásico (avanzado) no tratados anteriormente	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio en fase II, multicéntrico, sin enmascaramiento, aleatorizado y controlado para comparar la eficacia de RO7198457 con la estrategia de actitud expectante en pacientes con cáncer colorrectal resecado en estadio II (riesgo elevado) y estadio III que presenten positividad de ADN tumoral circulante (ADNct) tras la resección tumoral.	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	II
BE-23	Estudio en fase III, abierto y aleatorizado de tucatinib en combinación con trastuzumab y mFOLFOX6 frente a mFOLFOX6 administrado con o sin cetuximab o bevacizumab como tratamiento de primera línea para pacientes con cáncer colorrectal metastásico HER2+.	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	III
BE-23	Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con un comparador activo de MK-7684A (vibostolimab con pembrolizumab) adyuvante frente a pembrolizumab adyuvante en participantes con melanoma en estadio II-IV de alto riesgo (KEYVIBE-010)	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Protocolo maestro de encorafenib/binimetinib: Estudio abierto de continuación para participantes que continúen desde ensayos clínicos de encorafenib/binimetinib.	DRUG CLINICAL TRIALS	ÁLVARO MONTESA PINO	IV
BE-23	Ensayo de extensión de fase III, abierto y multicéntrico para estudiar la seguridad y la eficacia a largo plazo en participantes con tumores avanzados que actualmente están en tratamiento o en seguimiento en un ensayo de pembrolizumab	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	III
BE-23	Comparison of different techniques for testing BRAF V600 mutation in blood in melanoma patients. BRAFI	OBSERVATIONAL STUDY WTIH MEDICINES	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
BE-23	Estudio abierto en fase I/II de la seguridad, la farmacocinética y la actividad preliminar de ASTX295 en pacientes con tumores sólidos avanzados con TP53 de tipo natural	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio fase II, multicéntrico, aleatorizado, abierto, de 2 brazos, para evaluar la eficacia y seguridad del retratamiento con cetuximab e irinotecán en tercera línea frente a la terapia de elección del investigador en pacientes con cáncer colorrectal metastásico seleccionados mediante análisis genómico de ADN tumoral circulante (ADNtc) (Estudio CITRIC)	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	II
BE-23	Estudio de fase II para evaluar INCB099280 en participantes con carcinoma epidermoide avanzado	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Estudio aleatorizado y doble ciego para evaluar la eficacia, seguridad e inmunogenicidad de ABP 206 en comparación con OPDIVO® (nivolumab) en pacientes con melanoma irresecable o metastásico no tratado anteriormente	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase III, aleatorizado, doble ciego, comparativo con placebo y con tratamiento activo de V940 (ARNm-4157) adyuvante más pembrolizumab frente a un placebo adyuvante más pembrolizumab en participantes con melanoma en estadio II-IV de alto riesgo.	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	III

Group	Title	Subtype	PI Name	Phase
BE-23	Estudio de fase III aleatorizado y abierto de XL092 + nivolumab en comparación con sunitinib en participantes con carcinoma de células renales no claras metastásico o avanzado	DRUG CLINICAL TRIALS	ÁLVARO MONTESA PINO	III
BE-23	Estudio de fase 2 multicéntrico para evaluar la eficacia y la seguridad de Cetuximab en combinación con Encorafenib y Binimetinib como tratamiento de inducción en el cáncer colorrectal avanzado inicialmente resecable o potencialmente resecable con mutación BRAF V600E y MSS.	DRUG CLINICAL TRIALS	CARMEN REYNA FORTES	II
BE-23	Estudio aleatorizado de fase 2/3 de tebentafusp como monoterapia y en combinación con pembrolizumab frente a la elección del investigador en pacientes positivos para HLA-A*02:01 con melanoma avanzado tratado previamente (TEBE-AM).	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacyand safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combinationwith pembrolizumab compared with pembrolizumab monotherapy in participants with untreated,unresectable or metastatic melanoma	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio aleatorizado, con doble enmascaramiento y de grupos paralelos para comparar la farmacocinética, la eficacia, la seguridad y la inmunogenia de JPB898 (biosimilar de nivolumab propuesto) y Opdivo® con licencia de EE. UU. y autorizado por la UE en combinación con Yervoy® en participantes con melanoma avanzado (irresecable/metastásico) sin tratar	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	IL Believe: Estudio de fase I/II, abierto, de escalada de dosis y expansión de dosis para investigar la seguridad y tolerabilidad de TransCon IL-2 ß/? solo o en combinación con pembrolizumab, quimioterapia estándar o agonista de TransCon TLR7/8, o en combinación con pembrolizumab y quimioterapia estándar,en participantes adultos con tumores sólidos malignos localmente avanzados o metastásicos	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
BE-23	Estudio de fase 3 aleatorizado, abierto, con control activo y multicéntrico de sotorasib, panitumumab y FOLFIRI frente a FOLFIRI con o sin bevacizumab-awwb en sujetos con cáncer colorrectal metastásico con la mutación p.G12C en el KRAS no tratados previamente (CodeBreaK 301)	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	III
BE-23	Un ensayo perioperatorio de Fase 2 y Fase 3 de Fianlimab y Cemiplimab comparados con Pembrolizumab en pacientes con Melanoma Resecable en Estadios III y IV.	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
BE-23	Outcome research of a European registry platform on real-world treatment data of patients withadvanced non-melanoma skin cancer (NMSC)	OBSERVATIONAL STUDY WTIH MEDICINES	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
BE-23	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy	DRUG CLINICAL TRIALS	ÁLVARO MONTESA PINO	III
BE-23	Estudio en fase Ia/Ib del inhibidor pan-KRAS LY4066434 en participantes que padezcan tumores sólidos con mutación en KRAS	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	I/II
BE-23	Estudio de fase 1/1b, abierto y multicéntrico, para investigar la seguridad, tolerabilidad, farmacocinética y actividad antitumoral de KIN-2787 en participantes con tumores sólidos y positividad de mutación del gen BRAF y/o el gen NRAS.	DRUG CLINICAL TRIALS	MIGUEL ÁNGEL BERCIANO GUERRERO	I
BE-23	A Phase 3, Multicenter, Randomized, Open-label Study of IfinatamabDeruxtecan (I-DXd) in Subjects with Pretreated Unresectable/Metastatic Esophageal SquamousCell Carcinoma (ESCC) (IDeate-4)	DRUG CLINICAL TRIALS	CARMEN REYNA FORTES	III
BE-23	A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer (CANTOR) .	DRUG CLINICAL TRIALS	SILVIA GIL CALLE	II
BE-23	Bevacizumab plus encoRAfenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	II
BE-23	Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600-mutated melanoma treated in real life in Spain: a multi-centric, retrospective and non-interventional study.	OBSERVATIONAL STUDY WTIH MEDICINES	MIGUEL ÁNGEL BERCIANO GUERRERO	Not applicable
BE-23	Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progres-sion in molecular selected metastatic colorectal cancer patients.	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	III

Group	Title	Subtype	PI Name	Phase
BE-23	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.	DRUG CLINICAL TRIALS	ÁLVARO MONTESA PINO	III
BE-23	Observational retrospective study to evaluate real-world effectiveness, safety and tolerability of Fruquintinib for treatment of advanced colorectal cancer in Spain – FrESP Study	OBSERVATIONAL STUDY WTIH MEDICINES	CARMEN REYNA FORTES	Not applicable
BE-23	CA266-0003	DRUG CLINICAL TRIALS	JULIA ALCAIDE GARCIA	II/III
BE-23	Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (De-Escalate)	DRUG CLINICAL TRIALS	ÁLVARO MONTESA PINO	III
C-01	Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex como fármaco comtrol, para evaluara la eficacia, determinadas por las lesiones cerebrales que aparecen en la RMN y la seguridad de dos pautas terapéuticas de ocrelizumab en pacientes con EMRR	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNANDEZ SANCHEZ	II
C-01	Estudio de extensión del estudio AC 058B201, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, para evauar la seguridad, tolerabilidad, y eficacia a largo plazo de 10, 20, y 40 mg/día de ACT-128800, un agonista oral de los receptores S1P1, en pacientes con esclerosis múltiple recurrente-remitente.	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNANDEZ SANCHEZ	II
C-01	Estudio multicéntrico, aleatorizado, doble ciego, con control activo, de dos años de duración para evaluar la seguridad y la eficacia de fingolimod administrado por vía oral una vez al día frente a interferon ?-1a i.m. administrado una vez a la semana en pacientes pediátricos con esclerosis múltiple	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNANDEZ SANCHEZ	III
C-01	Ensayo Clínico Fase II, Multicéntrico, Abierto, Controlado y Aleatorizado, para valorar la eficacia de la Infusión Intra arterial de células Mononucleadas de Médula Ósea Autóloga en Pacientes Con Ictus Isquémico	INDEPENDENT CLINICAL TRIAL	JOSÉ ANTONIO TAMAYO TOLEDO	II
C-01	Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con LEMTRADA® (Alemtuzumab) en pacientes con formas recidivantes de esclerosis múltiple. (Estudio OBS13434)	COMMERCIAL POST-AUTHORIZATION STUDY	ANA ALONSO TORRES	Not applicable
C-01	Estudio de extensión del ensayo AC-058B301, multicéntrico, no comparativo, para valorar la seguridad, tolerabilidad y control de la enfermedad a largo plazo de ponesimod 20 mg en sujetos con esclerosis múltiple recidivante	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNANDEZ SANCHEZ	III
C-01	Estudio de extensión abierto, de brazo único y multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de ofatumumab, en pacientes con esclerosis múltiple que cursa con brotes	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico, para evaluar la seguridad, la tolerabilidad y la eficacia del XEN1101 como tratamiento adyuvante en la epilepsia de inicio focal	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio multicéntrico no intervencional para evaluar la efectividad de ocrelizumab en pacientes con esclerosis múltiple recurrente o primaria progresiva en práctica clínica habitual. ESTUDIO MuSicalE (MN39889)	COMMERCIAL POST-AUTHORIZATION STUDY	ANA ALONSO TORRES	Not applicable
C-01	Estudio de evidencia en práctica clínica real: Estudio de cohorte prospectivo no intervencional post-autorización para evaluar la efectividad, la seguridad y los resultados de salud a largo plazo del tratamiento de la esclerosis múltiple recurrente en la práctica clínica de rutina en España con cladribina comprimidos. Código Promotor: MS700568_0073. MAVEN 4 -	COMMERCIAL POST-AUTHORIZATION STUDY	ANA ALONSO TORRES	Not applicable
C-01	Monitorización de la Movilidad de enfermos de Parkinson con fines terapéuticos - Ensayo Clínico. Estudio (oMoPa-EC.	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	TERESA MUÑOZ RUIZ	Not applicable
C-01	Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultoscon trastorno del espectro de neuromielitis óptica (NMOSD)	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	III
C-01	Estudio de Fase IIIb, multicéntrico, aleatorizado, doble ciego y controlado para evaluar la eficacia, la seguridad y la farmacocinética de una dosis más alta de Ocrelizumab en adultos con formas recurrentes de esclerosis múltiple.	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III

Group	Title	Subtype	PI Name	Phase
C-01	Estudio de eficacia y seguridad de fase 3, aleatorizado y doble ciego que compara SAR442168 con placebo en participantes con esclerosis múltiple secundaria progresiva no recidivante (HERCULES)	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio multicéntrico aleatorizado, doble ciego, controlado con placebo y de grupos paralelos acerca de CVL-865 como tratamiento complementario en adultos con crisis convulsivas de inicio focal resistentes a los fármacos (estudio REALIZE)	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio de eficacia y seguridad de fase 3, aleatorizado y doble ciego que compara SAR442168 con teriflunomida (Aubagio®) en participantes con formas recidivantes de esclerosis múltiple (GEMINI 1)	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio en fase 3, aleatorizado, doble ciego para evaluar la eficacia y seguridad del tratamiento con SAR442168 frente a placebo en pacientes con esclerosis múltiple primaria progresiva (PERSEUS)	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio prospectivo, no intervencionista, observacional y multicéntrico para investigar la dosis, la eficacia y la seguridad de perampanel cuando se utiliza como primer tratamiento complementario en la asistencia clínica habitual de pacientes mayores de 12 años con crisis de inicio parcial con o sin generalización secundaria o con crisis tonicoclónicas generalizadas primarias asociadas a epilepsia generalizada idiopática (sponsor's code E2007-M044-512)	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO JESÚS SERRANO CASTRO	Not applicable
C-01	Estudio fase III multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento y grupos paralelos para evaluar la eficacia y seguridad de Fenebrutinib comparado con Ocrelizumab en pacientes adultos con Esclerosis Múltiple Primaria Progresiva	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio de extensión abierto, multicéntrico y con tratamiento activo de 57 semanas de CVL-865 como tratamiento complementario en adultos con crisis convulsivas de inicio focal resistentes a los fármacos	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio de fase 2, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar la eficacia, seguridad y farmacocinética de rozanolixizumab en adultos con encefalitis autoinmune asociada a anticuerpos dirigidos frente a la proteína 1 inactivada del glioma rica en leucina	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio en fase IIb, aleatorizado, con doble enmascaramiento, comparativo con placebo y multicéntrico, para evaluar la eficacia y la seguridad de prasinezumab intravenoso en participantes con enfermedad de parkinson incipiente	COMMERCIAL CLINICAL TRIAL	LUCÍA DE FLORES GARCIA TRUJILLO	II
C-01	Estudio multinacional, observacional y no intervencionista de 12 meses para evaluar la efectividad, tolerabilidad y calidad de vida de la terapia añadida con brivaracetam en líneas de tratamiento precoz en pacientes adultos con antecedentes de crisis de inicio focales en la práctica clínica diaria. EP0103 UCB BRITOBA	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO JESÚS SERRANO CASTRO	Not applicable
C-01	Estudio de Fase III, multicéntrico, aleatorizado, doble ciego y con doble simulación para evaluar la seguridad y la eficacia de OCRELIZUMAB en comparación con FINGOLIMOD en niños y adolescentes con esclerosis múltiple esclerosis múltiple remitente-recurrente.	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio controlado aleatorizado y multicéntrico para evaluar la seguridad y eficacia de HEMOPATCH en comparación con la práctica habitual para el sellado de duramadre como refuerzo de la sutura dural para la prevención de fugas de líquido cefalorraquídeo (LCR) postoperatorias en pacientes sometidos a cirugía de fosa posterior.	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	MIGUEL ÁNGEL ARRAEZ SANCHEZ	Not applicable
C-01	Estudio abierto, aleatorizado, con evaluador ciego, multicéntrico, de brazos paralelos, con comparador activo para evaluar la eficacia y tolerabilidad de Ofatumumab 20 mg s.c. administrado mensualmente vs. TME de primera línea a elección del médico en el tratamiento de pacientes con Esclerosis Múltiple Recurrente (EMR) de reciente diagnóstico (STHENOS)	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio aleatorizado, doble ciego con doble enmascaramiento y grupos paralelos en el que se compara la eficacia y seguridad de remibrutinib 100 mg b.i.d. frente a teriflunomida 14 mg q.d. en participantes con esclerosis múltiple recurrente, seguido de una extensión abierta del tratamiento con remibrutinib.	COMMERCIAL CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio de fase 2, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de ALXN2050 en participantes adultos con miastenia grave generalizada	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	II
C-01	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JOSÉ ANTONIO TAMAYO TOLEDO	Not applicable

Group	Title	Subtype	PI Name	Phase
C-01	Estudio de fase 3, aleatorizado, doble ciego para evaluar la eficacia y seguridad del tratamiento con SAR442168 frente a teriflunomida(Aubagio®) en pacientes con esclerosis múltiple recidivante (GEMINI 2)	INDEPENDENT CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio de prolongación multicéntrico, de un solo grupo, abierto y de extensión para evaluar la seguridad y la eficacia a largo plazo de ocrelizumab en pacientes con esclerosis múltiple	INDEPENDENT CLINICAL TRIAL	ANA ALONSO TORRES	III
C-01	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y seguridad de FAB122 en pacientes con esclerosis lateral amiotrófica	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	III
C-01	Ensayo en fase III, doble ciego, aleatorizado y controlado con placebo del tratamiento adyuvante con ganaxolona (GNX) en niños y adultos con epilepsia relacionada con el complejo de esclerosis tuberosa (CET) (TrustTSC)	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	III
C-01	Registro en España del uso de los inhibidores de la COMT en el manejo de pacientes con enfermedad de Parkinson que presentan fluctuaciones motoras tempranas. Estudio REONPARK	OBSERVATIONAL STUDY WTIH MEDICINES	LUCÍA DE FLORES GARCIA TRUJILLO	Not applicable
C-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, paralelo y multicéntrico para evaluar la seguridad y eficacia de ALXN1720 en adultos con miastenia gravis generalizada.	DRUG CLINICAL TRIALS	VIRGINIA REYES GARRIDO	III
C-01	Estudio de fase 2B, de 30 semanas, prospectivo, multicéntrico, cruzado, doble ciego, aleatorizado y controlado con placebo, seguido de un estudio de extensión abierto de 52 semanas, para evaluar la eficacia y seguridad de basimglurant como adyuvante de la terapia anticonvulsiva en curso en niños, adolescentes y adultos jóvenes con epilepsia asociada al complejo de esclerosis tuberosa	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio multicéntrico, aleatorizado, con enmascaramiento doble, controlado con placebo y de fase 2 en el que se evalúan la seguridad y la eficacia de CORT113176 (Dazucorilant) en pacientes con esclerosis lateral amiotrófica (DAZALS)	DRUG CLINICAL TRIALS	VIRGINIA REYES GARRIDO	II
C-01	Estudio fase 3 prospectivo, abierto, multicéntrico y de extensión de los estudios Fase 3, para evaluar la seguridad y tolerabilidad a largo plazo de Soticlestat como tratamiento adyuvante en pacientes con Síndrome Dravet o Síndrome de Lennox-Gastaut (ENDYMION 2).	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad y la eficacia de XEN1101 como tratamiento complementario de las crisis convulsivas de inicio focal_	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase III, sin enmascaramiento, de un único grupo, multicéntrico para evaluar la farmacocinética, la farmacodinámica, la eficacia, la seguridad y la inmunogenicidad del ravulizumab administrado por vía intravenosa en participantes pediátricos (de 6 a <18 años de edad) con miastenia grave generalizada (MGg)	DRUG CLINICAL TRIALS	VIRGINIA REYES GARRIDO	III
C-01	Estudio abierto de fase III del tratamiento adyuvante con ganaxolona (GNX) en niños y adultos con epilepsia relacionada con el complejo de esclerosis tuberosa (CET) (TrustTSC OLE)	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	A 12-month, prospective, observational study in adult patients with focal onset seizures who are treated with adjunctive ASM in real world setting	OBSERVATIONAL STUDY WTIH MEDICINES	PEDRO JESÚS SERRANO CASTRO	Not applicable
C-01	Estudio de fase 3, de carácter pivotal, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, con un período de extensión abierta, para evaluar la eficacia y la seguridad de rozanolixizumab en participantes adultos con enfermedad asociada a anticuerpos contra la glucoproteína de la mielina del oligodendrocito (MOG)	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	III
C-01	Observational, multicenter study to describe the persistence in relapsing remitting multiple sclerosis naive patients with low-moderate activity treated with Ozanimod (Zeposia ®) in clinical practice in Spain (AppreZiate Study).	OBSERVATIONAL STUDY WTIH MEDICINES	ANA ALONSO TORRES	Not applicable
C-01	Estudio de fase II, de 2 partes, multicéntrico, aleatorizado, ciego y controlado con principio activo para evaluar de forma secuencial la seguridad y la eficacia de BIIB091 en monoterapia y del tratamiento combinado de BIIB091 con fumarato de diroximel en participantes con formas recidivantes de esclerosis múltiple	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	II
C-01	Medidas de seguridad y terapéuticas de la estimulación con corriente continua catódica transcraneal (TDCS) en pacientes con epilepsia focal resistente al tratamiento.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	PEDRO JESÚS SERRANO CASTRO	Not applicable

Group	Title	Subtype	PI Name	Phase
C-01	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos y con fase de extensión para evaluar la eficacia y la seguridad de Dysport® en relación con la prevención de la migraña crónica en participantes adultos	DRUG CLINICAL TRIALS	LUCÍA DE FLORES GARCIA TRUJILLO	III
C-01	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos y con fase de extensión para evaluar la eficacia y la seguridad de Dysport® en relación con la prevención de la migraña crónica en participantes adultos	DRUG CLINICAL TRIALS	LUCÍA DE FLORES GARCIA TRUJILLO	III
C-01	Un estudio de extensión multicéntrico y abierto para investigar a largo plazo seguridad de FAB122 en pacientes con esclerosis lateral amiotrófica. Adorexto	DRUG CLINICAL TRIALS	VIRGINIA REYES GARRIDO	III
C-01	Estudio intervencionista de extensión en fase III para investigar la seguridad y la tolerabilidad a largo plazo de tolebrutinib en participantes con esclerosis múltiple recidivante, esclerosis múltiple primaria progresiva o esclerosis múltiple secundaria progresiva no recidivante.	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	III
C-01	Early detection of Multiple Sclerosis progression with MSCopilot® Detect	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	ANA ALONSO TORRES	Not applicable
C-01	Estudio transversal para evaluar la eficacia y seguridad de Ofatumumab (Kesimpta®) en pacientes con esclerosis múltiple recurrente en la práctica clínica española: estudio CRONOS-MS	OBSERVATIONAL STUDY WTIH MEDICINES	ANA ALONSO TORRES	Not applicable
C-01	Estudio de Fase III, aleatorizado, multicéntrico, doble ciego, controlado con placebo para evaluar la seguridad, la tolerabilidad y la eficacia de XEN1101 como terapia complementaria en las crisis convulsivas tónico-clónicas primarias generalizadas.	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase 3, doble ciego, aleatorizado, comparando la eficacia y seguridad de frexalimab (SAR441344) con placebo en participantes adultos con Esclerosis Múltiple Secundaria Progresiva sin recaídas.	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	III
C-01	Estudio en fase III, aleatorizado y doble ciego que compara la eficacia y la seguridad de frexalimab (SAR441344)aleatorizado y doble ciego que compara la eficacia y la seguridad de frexalimab (SAR441344) con teriflunomida en participantes adultos con formas recidivantes de esclerosis múltiple	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	III
C-01	Protocolo maestro para tres estudios independientes, de reclutamiento continuo, con doble ciego, controlados con placebo, sobre la eficacia y la seguridad del ACP 204 en adultos con psicosis por enfermedad de Alzheimer	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de extensión en abierto de 52 semanas para evaluar el ACP-204 en adultos con psicosis por enfermedad de Alzheimer	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase 3, randomizado, doble ciego, multicéntrico para evaluar la eficacia y seguridad de Riliprubart (SAR445088) en comparación con inmunoglobulina intravenosa (IVIg) en participantes con polineuropatía desmielinizante inflamatoria crónica (CIDP)	DRUG CLINICAL TRIALS	VIRGINIA REYES GARRIDO	III
C-01	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy.	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Real-life effectiveness of eptinezumab in migraine patients. Observational prospective study assessing the effectiveness in patients treated with eptinezumab as a preventive treatment for migraine in a real-world setting in Spain.	OBSERVATIONAL STUDY WTIH MEDICINES	LUCÍA DE FLORES GARCIA TRUJILLO	Not applicable
C-01	Estudio abierto, multicéntrico y a largo plazo para evaluar la seguridad, la tolerabilidad y la eficacia de XEN1101 en sujetos con diagnóstico de epilepsia	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension"	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de cohortes, observacional, prospectivo y con enfoque en la lesión hepática inducida por fármacos (LHIF), para evaluar la seguridad a largo plazo en los pacientes a quienes se les recetó Epidyolex®.	OBSERVATIONAL STUDY WTIH MEDICINES	PEDRO JESÚS SERRANO CASTRO	Not applicable
C-01	Estudio multicéntrico restrospectivo sobre la neurotoxicidad asociada a la terapia con células CART	OBSERVATIONAL STUDY WTIH MEDICINES	PABLO CABEZUDO GARCIA	Not applicable

Group	Title	Subtype	PI Name	Phase
C-01	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab, in Patients with Relapsing Multiple Sclerosis	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	II
C-01	Estudio de seguridad a largo plazo, de fase 2, global y multicéntrico diseñado para evaluar la seguridad y la tolerabilidad de BHV-7000 en sujetos con epilepsia de inicio focal refractaria	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	II
C-01	A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	II
C-01	A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	DRUG CLINICAL TRIALS	GUILLERMINA GARCIA MARTIN	II
C-01	Estudio de fase II, aleatorizado, doble ciego, comparativo con placebo y con grupos paralelos del VHB937 de la esclerosis lateral amiotrófica (ELA) de 40 semanas de duración seguidas de una prolongación en abierto (ASTRALS)	DRUG CLINICAL TRIALS	VIRGINIA REYES GARRIDO	II
C-01	A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics,Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus!(Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	III
C-01	Un ensayo multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de PRAX-628 en adultos con convulsiones focales (POWER 1)	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	II/III
C-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia, la seguridad y la tolerabilidad de LP352 en el tratamiento de las crisis convulsivas en niños y adultos con ncefalopatías epilépticas y del desarrollo	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia, la seguridad y la tolerabilidad de LP352 en el tratamiento de las crisis convulsivas en niños y adultos con síndrome de Dravet Syndrome.	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad del remibrutinib en pacientes con miastenia grave generalizada, seguido de una fase de extensión abierta /// A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis, followed by an open-label extension phase	DRUG CLINICAL TRIALS	VIRGINIA REYES GARRIDO	III
C-01	An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients withFocal Onset or Primary Generalized Tonic-Clonic Seizu	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	II
C-01	A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of mRNA-1195 Intramuscular Injection in Participants 18 to =55 Years of Age with Early Multiple Sclerosis	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	II
C-01	Estudio de fase I/II, multicéntrico y abierto para evaluar la seguridad, la progresión de la en-fermedad y la cinética celular después de administrar YTB323 a los participantes con esclero-sis múltiple progresiva no activa	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	I/II
C-01	Estudio observacional prospetivo para evaluar la eFectividad y el perfil de seguiridad de los comprimidos de cladribina en una cohorte de pacientes con esclerosis múltiple recurrente mayores y menores de 50 años MAVENAGE	OBSERVATIONAL STUDY WTIH MEDICINES	ANA ALONSO TORRES	Not applicable
C-01	Estudio Europeo observacional, prospectivo y multicéntrico para valorar la satisfacción con el tratamiento, la preferencia de trata-miento, la calidad de vida y la tolerabilidad al tratamiento con Briumvi® para diferentes formas de esclerosis múltiple recurrente (EMR) con enfermedad activa en la práctica clínica habitual (estudio BRILL-EU)	OBSERVATIONAL STUDY WTIH MEDICINES	ANA ALONSO TORRES	Not applicable
C-01	Estudio abierto de fase 3 para investigar la seguridad y la eficacia a largo plazo de LP352 en el tratamiento de las crisis convulsivas en niños y adultos con encefalopatía epiléptica y del desarro-llo	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III

Group	Title	Subtype	PI Name	Phase
C-01	Ensayo clínico de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico y con un periodo de extensión para evaluar la eficiacia y la seguridad de inyecciones de Xeomin para la prevención de la migraña episódica.	DRUG CLINICAL TRIALS	LUCÍA DE FLORES GARCIA TRUJILLO	III
C-01	Ensayo clínico de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico y con un período de extensión para evaluar la eficacia y la seguridad de inyecciones de Xeomin para la prevención de migraña crónica.	DRUG CLINICAL TRIALS	LUCÍA DE FLORES GARCIA TRUJILLO	III
C-01	Estudio de no inferioridad, aleatorizado, abierto y de grupos paralelos en el que se comparan la efecacia, la seguirdad y la tolerabilidad de remibrutinib después del cambio desde ocrelizumab en participantes con esclerosis múltiple recurrene, seguido de tratamiento abierto con remibrutinib.	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	III
C-01	A Phase IIb Randomized, Double-blind, Pacebo-controlled, Multi-Dose Study to Evaluiate tehe Effects of PHENOGENE-1a (Cromolyn) as Adjuvant Treatment in Subjects with Moderate Amoyotrophic Lateral Sclerosis (ALS).	DRUG CLINICAL TRIALS	JOSÉ CARLOS ARRABAL GÓMEZ	II/III
C-01	Estudio tipo “BASKET” Fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de SATRALIZUMAB en pacientes con encefalitis por anticuerpos anti-nmdar (Receptor del Ácido N-METIL-D-Aspártico) o ANTI-LGI1 (proteína 1 inactivada del glioma rica en leucina).	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolera-bility of iptacopan in patients with generalized Myasthenia Gravis, followed by an open-label extension phase.	DRUG CLINICAL TRIALS	GUILLERMINA GARCIA MARTIN	III
C-01	Estudio de fase II/III, doble ciego y controlado con placebo sobre el uso del BHV-8000 en participantes con enfermedad de Parkinson en etapa inicial	DRUG CLINICAL TRIALS	LUCÍA DE FLORES GARCIA TRUJILLO	II/III
C-01	Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy	DRUG CLINICAL TRIALS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Long-term extension study to evaluate the safety and efficacy of riliprubart (SAR445088) in partic-ipants with chronic inflammatory demyelinating polyneuropathy (CIDP).	DRUG CLINICAL TRIALS	VIRGINIA REYES GARRIDO	III
C-01	Estudio de fase III aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de remibrutinib en pacientes con esclerosis múltiple secundaria progresiva.	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	III
C-01	Estudio de Fase III, multicéntrico, aleatorizado, con doble enmascaramiento y comparativo con placebo para evaluar la eficacia y la seguridad de PRASINEZUMAB intravenoso en participantes con enfermedad de Parkinson incipiente.	DRUG CLINICAL TRIALS	LUCÍA DE FLORES GARCIA TRUJILLO	III
C-01	Estudio Fase II multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad, farmacocinética, farmacodinámica y eficacia de RO7268489, un inhibidor de la monoacilglicerol lipasa, como terapia añadida a OCRELIZUMAB en pacientes con formas progresivas de esclerosis múltiple.	DRUG CLINICAL TRIALS	ANA ALONSO TORRES	II
C-01	Protocolo maestro para un estudio de fase IIa de viabilidad, exploratorio y de plataforma para evaluar la seguridad, tolerabilidad y eficacia de varios tratamientos en participantes con miastenia grave	DRUG CLINICAL TRIALS	GUILLERMINA GARCIA MARTIN	II
C-02	Prevención universal de la depresión y ansiedad en población general mediante una intervención personalizada basada en algoritmos de riesgo, TICs y sistemas de ayudas a las decisiones: Ensayo Aleatorio Controlado (Estudio PredictPlusPrevent)	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JUAN ÁNGEL BELLON SAAMEÑO	Not applicable
C-02	Prevención de la depresión a través de una intervención personalizada basada en TICs, algoritmos predictivos de riesgo, y DSS para pacientes y médicos de familia: estudio e-predictD	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JUAN ÁNGEL BELLON SAAMEÑO	Not applicable
C-02	Prevención de la depresión en el medio laboral mediante una intervención personalizada basada en algoritmos de riesgo, TICs y sistemas de ayuda a las decisiones: ensayo controlado aleatorio	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	JUAN ÁNGEL BELLON SAAMEÑO	Not applicable
C-03	Características clínicas de los pacientes tratados con lurasidona en España: análisis restrospectivo de la información recogida en las historias clínicas electrónicas mediante el Procesamiento del Lenguaje Natural	COMMERCIAL POST-AUTHORIZATION STUDY	CARLOS GOMEZ SANCHEZ-LAFUENTE	Not applicable

Group	Title	Subtype	PI Name	Phase
C-03	Estudio de las características de la enfermedad y la eficacia del tratamiento habitual en la vida real en pacientes con trastorno depresivo mayor (TDM) con anhedonia y respuesta inadecuada al tratamiento antidepresivo actual, incluido un ISRS o un IRSN (VENTURA)	OBSERVATIONAL STUDY WTIH MEDICINES	JESÚS HERRERA IMBRODA	Not applicable
C-03	Estudio de cohortes no intervencionista sobre el aerosol nasal de esketamina en la depresión resistente al tratamiento - ECHO.	OBSERVATIONAL STUDY WTIH MEDICINES	JESÚS HERRERA IMBRODA	Not applicable
C-03	Estudio de cohorte, no Intervencionista, Prospectivo, de práctica real para evaluar la remisión funcional en pacientes con TRD tratados con ES Ketamina intranasal." (Estudio HIPOCRAT-ESK).	OBSERVATIONAL STUDY WTIH MEDICINES	JESÚS HERRERA IMBRODA	Not applicable
C-08	Estudio observacional de cohortes de la seguridad posterior a la autorización (PAS) para cuantificar la incidencia y la seguridad comparativa de eventos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación UMEC /VI por inhalación o UMEC por inhalación en comparación con tiotropio. (Estudio 201038)	COMMERCIAL POST-AUTHORIZATION STUDY	LEOVIGILDO GINEL MENDOZA	Not applicable
C-08	Registro de pacientes con psoriasis y riesgo cardiovascular en Atención Primaria	NON-POST-APPROVAL STUDY	LEOVIGILDO GINEL MENDOZA	Not applicable
C-08	Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia analgésica y la seguridad de una combinación en dosis fijas por vía oral de dexketoprofeno trometamol y tramadol hidrocloruro en el dolor agudo de moderado a intenso en pacientes con lumbalgia aguda: estudio DANTE	COMMERCIAL CLINICAL TRIAL	LEOVIGILDO GINEL MENDOZA	IV
C-08	Estudio Observacional con Medicamento, para evaluar y documentar con monitorización continua de glucosa (MCG) la aparición de hipoglucemia en pacientes con diabetes mellitus tipo 2 (DM2) tratados con Glargina-100 en el ámbito de la Atención Primaria. Estudio GPDetect.	OBSERVATIONAL STUDY WTIH MEDICINES	JUAN PABLO GARCIA PAINE	Not applicable
C-08	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de bemnifosbuvir en pacientes ambulatorios de alto riesgo con COVID-19	DRUG CLINICAL TRIALS	LEOVIGILDO GINEL MENDOZA	III
C-08	A prospective study to evaluate the immune status in the elderly after receiving a booster dose under the Covid-19 vaccination program in Spain	OBSERVATIONAL STUDY WTIH MEDICINES	LEOVIGILDO GINEL MENDOZA	Not applicable
C-08	Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®	DRUG CLINICAL TRIALS	LEOVIGILDO GINEL MENDOZA	IV
C-08	Estudio observacional para evaluar el grado de control de la EPOC en la Atención Primaria de la Sanidad Española. Estudio AGORA	OBSERVATIONAL STUDY WTIH MEDICINES	LEOVIGILDO GINEL MENDOZA	Not applicable
C-08	Estudio observacional para evaluar el grado de control de la EPOC en la Atención Primaria de la Sanidad Española. Estudio AGORA.	OBSERVATIONAL STUDY WTIH MEDICINES	MIGUEL DOMINGUEZ SANTAELLA	Not applicable
C-08	Eficacia de un Test Rápido Dual de Gripe y Covid-19 en la reducción de la prescripción antibiótica en Atención Primaria: Estudio RAPRIM	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	LEOVIGILDO GINEL MENDOZA	Not applicable
C-11	Estudio nacional retrospectivo para evaluar la efectividad, tolerancia y seguridad del citrato de fentanilo sublingual en pacientes ancianos con dolor irruptivo oncológico. Estudio PODIO.Código Promotor: FKAP-NIS-2001	COMMERCIAL POST-AUTHORIZATION STUDY	MARIANO FERNANDEZ BAENA	Not applicable
C-14	Sustitución de Dolutegravir por Raltegravir 1200 mg QD en pacientes infectados con VIH que desarrollan síntomas neuropsiquiátricos tras iniciar triple terapia. Estudio clínico piloto.	INDEPENDENT CLINICAL TRIAL	XAVIER PEREZ STACHOWSKI	IV
C-14	Ensayo clínico piloto, multicéntrico, para comparar la eficacia de RAL 1200 QD vs DRV-cb (800-150) QD ambos en combinación con TAF/FTC en pacientes con infección VIH y CD4<200 cel/microL	INDEPENDENT CLINICAL TRIAL	XAVIER PEREZ STACHOWSKI	IV
C-14	Ensayo abierto multicéntrico aleatorizado y pragmático de Fase III para evaluar la eficacia y seguridad de diferentes duraciones de tratamiento antimicrobiano de infecciones asociadas al material de osteosíntesis tras fractura de hueso largo (DURATIOM).	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	III
C-14	Ensayo clínico aleatorizado de no inferioridad para evaluar la eficacia y seguridad del tratamiento corto de la bacteriemia enterocócica no complicada. INTENSE	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	IV

Group	Title	Subtype	PI Name	Phase
C-14	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR.	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	IV
C-14	Estudio Fase I/II observador ciego, aleatorizado, internacional y controlado con placebo para evaluar la reactogenicidad, seguridad, respuesta inmune y eficacia de la vacuna frente al virus Herpes simplex (VHS) en sujetos sanos de 18 a 40 años o en pacientes de 18 a 60 años con herpes genital recurrente por VHS tipo 2.	INDEPENDENT CLINICAL TRIAL	JULIÁN OLALLA SIERRA	II
C-14	Ensayo clínico fase IV, aleatorizado, multicéntrico y doble ciego diseñado para evaluar la seguridad y la conveniencia del cambio de Dolutegravir/Lamivudina por Bictegravir/Emtricitabina/Tenofovir alafenamida en personas con VIH, buen control virológico y vulnerabilidades neuropsiquiátricas: Estudio MIND	INDEPENDENT CLINICAL TRIAL	JULIÁN OLALLA SIERRA	IV
C-14	Estudio FaseIIb, aleatorizado, con grupo control activo, parcialmente cegado, de búsqueda de dosis de GSK3640254 en comparación con un brazo control de dolutegravir, cada uno en combinación con inhibidores de la transcriptasa inversa análogos de nucleósidos, en adultos infectados con VIH-1 que no han recibido tratamiento antirretroviral previo.	DRUG CLINICAL TRIALS	JULIÁN OLALLA SIERRA	II
C-14	Estudio descriptivo, prospectivo, multinacional y multicéntrico para evaluar las variables relacionadas con la enfermedad genital causada por el virus herpes simple tipo 2 (VHS-2) según los resultados obtenidos a partir de cuestionarios de salud y muestras anogenitales realizados por pacientes = 18 años de edad en Estados Unidos y Europa mediante un proceso descentralizado	OBSERVATIONAL STUDY WTIH MEDICINES	JULIÁN OLALLA SIERRA	Not applicable
C-14	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de bemnifosbuvir en pacientes ambulatorios de alto riesgo con COVID-19	DRUG CLINICAL TRIALS	JULIÁN OLALLA SIERRA	III
C-14	DTG / 3TC frente a BIC / FTC / TAF como terapia de mantenimiento en personas que viven con VIH: ensayo clínico abierto y aleatorizado	DRUG CLINICAL TRIALS	XAVIER PEREZ STACHOWSKI	IV
C-14	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisirán en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1 PREVENT).	DRUG CLINICAL TRIALS	JULIÁN OLALLA SIERRA	III
C-14	Estudio en vida real sobre el uso de Cabotegravir/Rilpivirina de acción prolongada (CAB/RPV AP) en pacientes pretratados que viven con el VIH (PVVIH).	OBSERVATIONAL STUDY WTIH MEDICINES	JULIÁN OLALLA SIERRA	Not applicable
C-14	Implementation of Out-of-HOspital administration of the Long-Acting combination cabotegravir+rilpivirine as an optional therapy in HIV-Infected patients from Spain. Acceptability, appropriateness, feasibility and satisfaction .. The HOLA Study	DRUG CLINICAL TRIALS	JULIÁN OLALLA SIERRA	IV
C-14	Estudio de fase IIIb, abierto, multicéntrico, aleatorizado, de grupos paralelos y de no inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad de la combinación de dolutegravir/lamivudina administrada por vía oral una vez al día como tratamiento de primera línea, en comparación con la combinación de bictegravir/emtricitabina/tenofovir alafenamida administrada por vía oral una vez al día, para la inhibición y el mantenimiento virológico en adultos con VIH sin tratamiento antirretroviral previo.	DRUG CLINICAL TRIALS	JULIÁN OLALLA SIERRA	III
C-14	Estudio de fase 2b sobre regímenes orales e inyectables de acción prolongada con VH4524184 en personas con VIH-1 sin tratamiento previo. (Estudio INNOVATE)	DRUG CLINICAL TRIALS	JULIÁN OLALLA SIERRA	II
C-16	Estudio de observación multicéntrico, prospectivo y multinacional para evaluar la seguridad a largo plazo de Esmya, especialmente la seguridad endometrial, y los patrones de prescripción y gestión actuales de Esmya en el contexto de un tratamiento a largo plazo. Estudio PGL14-001.	COMMERCIAL POST-AUTHORIZATION STUDY	EMILIA VILLEGAS MUÑOZ	Not applicable
C-16	Estudio observacional, prospectivo y multicéntrico para evaluar el uso clínico de la prueba molecular GynEC-Dx para el descarte de cáncer de endometrio y posterior seguimiento en mujeres asintomáticas con formaciones polipoideas endometriales	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	JESÚS SALVADOR JIMENEZ LOPEZ	Not applicable
C-16	Estudio de extensión, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de linzagolix a largo plazo en pacientes con dolor asociado a endometriosis (Extensión del Edelweiss 3)	COMMERCIAL CLINICAL TRIAL	EMILIA VILLEGAS MUÑOZ	III

Group	Title	Subtype	PI Name	Phase
C-16	Ensayo clínico de fase 2, multicéntrico, abierto, aleatorizado, para evaluar la inhibición de la ovulación de tres dosificaciones de levonorgestrel (LNG) en un sistema de liberación vaginal (SLV), que se libera durante 28 días de manera continua, frente a desogestrel (Cerazet®).	COMMERCIAL CLINICAL TRIAL	JESÚS SALVADOR JIMENEZ LOPEZ	II
C-16	Ensayo clínico aleatorizado, abierto, multicéntrico de grupos paralelos y con grupo control, para explorar la eficacia del gel vaginal papilocare® en la reparación de la mucosa cervical con lesiones causadas por virus papiloma humano de alto riesgo	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	JESÚS SALVADOR JIMENEZ LOPEZ	Not applicable
C-16	Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al Virus Respiratorio Sincitial (VRS), administrada por vía IM a gestantes de 18 a 49 años de edad, para la prevención de la Enfermedad vías respiratorias Bajas (EVRB) asociada al VRS en sus hijos hasta los 6 meses de edad. RSV-MAT-009	COMMERCIAL CLINICAL TRIAL	JESÚS SALVADOR JIMENEZ LOPEZ	III
C-16	Evaluación de la seguridad y la capacidad predictiva de parto prematuro del dispositivo de investigación clínica 'Cervisense TPTL': un estudio clínico internacional	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JESÚS SALVADOR JIMENEZ LOPEZ	Not applicable
CE-17	Un Ensayo de Fase III, Aleatorizado, Doble ciego y Controlado con placebo de?una solución para inhalación de acetato de flecainida?para la cardioversión de la fibrilación auricular sintomática de inicio reciente a ritmo sinusal (RESTORE-1)	DRUG CLINICAL TRIALS	FRANCISCO TEMBOURY RUIZ	III
CE-20	Evaluación de la eficacia y la seguridad de Vismed® Gel Multi 0,3% frente a Vismed® Multi 0,18% en el tratamiento de la sequedad ocular de moderada a grave	CLINICAL RESEARCH COMM. HEALTHCARE PRODUCT	MARINA RODRIGUEZ CALVO DE MORA	Not applicable
CE-20	Estudio de extensión para evaluar los resultados a largo plazo de los pacientes que recibieron tratamiento para la retinopatía del prematuro en el ensayo 20090	COMMERCIAL CLINICAL TRIAL	JULIA ESCUDERO GOMEZ	III
CE-20	Recopilación de datos a largo plazo del mundo real para obtener información clínica sobre Roche Productos de Oftalmología (Estudio Voyager).	OBSERVATIONAL STUDY WTIH MEDICINES	ANA SOFIA DELGADO FERNANDEZ	Not applicable
D-01	Estudio de fase III, aleatorizado, multicéntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a dolutegravir más lamivudina en adultos infectados por el VIH 1 con supresión virológica	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZALEZ	III
D-01	Estudio observacional para evaluar la tasa de reinfección en personas que se inyectan drogas (PID) infectadas con el virus de la hepatitis C (VHC) que se han sometido con éxito a un tratamiento para el VHC en España. Estudio LIVERate.Código Promtor: ID VEAP: 6375	COMMERCIAL POST-AUTHORIZATION STUDY	ROSARIO PALACIOS MUÑOZ	Not applicable
D-01	Estudio en fase III para evaluar el efecto de la pitavastatina para prevenir los acontecimientos vasculares en personas con infección por VIH-1. Estudio REPRIEVE	INDEPENDENT CLINICAL TRIAL	CRISTINA GOMEZ AYERBE	III
D-01	Ensayo clínico piloto, multicéntrico, para comparar la eficacia de RAL 1200 QD vs DRV-cb (800-150) QD ambos en combinación con TAF/FTC en pacientes con infección VIH y CD4<200 cel/microL	INDEPENDENT CLINICAL TRIAL	ROSARIO PALACIOS MUÑOZ	IV
D-01	Estudio de intervención quasi-experimental para la optimización del uso de nuevos antibióticos (Poyecto NEW_SAFE).	INDEPENDENT POSTAUTHORIZATION STUDY	GUILLERMO OJEDA BURGOS	Not applicable
D-01	Estudio de fase IV, multicéntrico, abierto y aleatorizado, para evaluar el impacto del cambio de tratamiento antirretroviral de terapia dual a terapia triple sobre la inflamación en pacientes con infección por VIH tipo 1	INDEPENDENT CLINICAL TRIAL	JESÚS SANTOS GONZALEZ	IV
D-01	Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar el cambio a doravirina/islatravir (DOR/ISL) una vez al día en participantes con supresión virológica del VIH-1 con bictegravir/emtricitabina/tenofovir alafenamida(BIC/FTC/TAF)	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZALEZ	III
D-01	Estudio clínico de fase 3, aleatorizado, doble ciego y comparativo con tratamiento activo para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de doravirina/islatravir una vez al día en participantes infectados por el VIH-1 sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZALEZ	III
D-01	Eficacia virológica de dolutegravir/lamivudina en personas virológicamente suprimidas con resistencia confirmada o sospechada a lamivudina. Estudio VOLVER	INDEPENDENT CLINICAL TRIAL	JESÚS SANTOS GONZALEZ	II
D-01	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR	INDEPENDENT CLINICAL TRIAL	ROSARIO PALACIOS MUÑOZ	IV

Group	Title	Subtype	PI Name	Phase
D-01	Estudio abierto, multicéntrico y aleatorizado para investigar el tratamiento antirretroviral con inhibidor de la integrasa frente al inhibidor de la proteasa potenciado para pacientes con enfermedad por el VIH avanzada. Estudio Late Presenter Treatment Optimisation (Optimización del tratamiento para pacientes con infección avanzada, LAPTOP).	INDEPENDENT CLINICAL TRIAL	CRISTINA GOMEZ AYERBE	III
D-01	Estudio prospectivo de las infecciones del torrente sanguíneo por Pseudomonas aeruginosa en pacientes adultos: eficacia y seguridad de diferentes estrategias terapéuticas, en el contexto actual de resistencia a múltiples fármacos	COMMERCIAL POST-AUTHORIZATION STUDY	ANDREA PROLO ACOSTA	Not applicable
D-01	Estudio clínico de fase 3, aleatorizado, doble ciego y comparativo con tratamiento activo para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de doravirina/islatravir (DOR/ISL 100 mg/0,25 mg) una vez al día en participantes infectados por el VIH-1 sin tratamiento previo.	DRUG CLINICAL TRIALS	ROSARIO PALACIOS MUÑOZ	III
D-01	Estudio de fase IIIb, multicéntrico, no aleatorizado, de grupos paralelos, abierto, híbrido de tipo I que evalúa la eficacia, la seguridad, la efectividad de la implementación y los resultados comunicados por el paciente de dolutegravir/lamivudina por vía oral una vez al día como tratamiento de primera línea, seguido de un cambio opcional elegido por el participante a cabotegravir intramuscular de acción prolongada más rilpivirina cada dos meses para el mantenimiento de la supresión virológica en adultos con VIH-1 sin tratamiento antirretrovíricos	DRUG CLINICAL TRIALS	ROSARIO PALACIOS MUÑOZ	III
D-01	Eficacia y seguridad de la perfusión continua vs. perfusión intermitente de ampicilina y ceftriaxona para el tratamiento de endocarditis infecciosa por Enterococcus faecalis (Estudio DOßLEI).	DRUG CLINICAL TRIALS	GUILLERMO OJEDA BURGOS	IV
D-01	Prevalencia del VHD en pacientes coinfectados VIH/VHB en España.	OBSERVATIONAL STUDY WTIH MEDICINES	ROSARIO PALACIOS MUÑOZ	Not applicable
D-01	Estudio de fases 2/3 operativamente sin interrupciones, aleatorizado y con control activo para evaluar la seguridad y la eficacia de una pauta semanal por vía oral de GS-1720 en combinación con GS-4182 en comparación con Biktarvy en personas con VIH-1 sin tratamiento previo	DRUG CLINICAL TRIALS	ROSARIO PALACIOS MUÑOZ	II
D-01	Optimising TREATment for Gram-Negative Bacterial infections (TREAT-GNB): phase 4 multicen-tre, open trial with individualized randomization for the treatment of bacteraemia caused by car-bapenem-resistant gram negative microorganisms.	DRUG CLINICAL TRIALS	ISABEL ASCENSIÓN PEREZ HERNANDEZ	IV
D-01	Estudio de fase 3b, abierto, aleatorizado, controlado con tratamiento estándar, multicéntrico, de superioridad para evaluar la eficacia, la seguridad y la tolerabilidad de CAB AP + RPV AP inyec-table en participantes virémicos que viven con VIH-1. (CROWN)	DRUG CLINICAL TRIALS	MARIA LOPEZ JODAR	III/IV
D-01	A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of Oral VH4524184 Coadministered withEmtricitabine and Tenofovir Alafenamide in Treatment Naïve Viremic Persons with HIV-1 (INNOVATE Study).	DRUG CLINICAL TRIALS	ROSARIO PALACIOS MUÑOZ	II
D-03	Evolución del Lupus Eritematoso Sistémico en España	NON-POST-APPROVAL STUDY	ANTONIO FERNANDEZ NEBRO	Not applicable
D-03	Registro español de acontecimientos adversos de terapias dirigidas en enfermedades reumáticas (Fase III)	INDEPENDENT POSTAUTHORIZATION STUDY	SARA MANRIQUE ARIJA	Not applicable
D-03	Estudio de extensión a largo plazo con dosis múltiples para demostrar la seguridad y la eficacia del tildrakizumab en sujetos con artritis psoriásica y espondilitis anquilosante o espondiloartritis axial no radiográfica que hayan completado previamente estudios con tildrakizumab	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio multicéntrico para caracterizar la seguridad y la eficacia a largo plazo de BMS-986165 en pacientes con lupus eritematoso sistémico	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNANDEZ NEBRO	II
D-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de dapirolizumab pegol en participantes del estudio con lupus eritematoso sistémico de moderado a grave	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio observacional de la persistencia del tratamiento en la artritis psoriásica (Estudio PRO-SPIRIT, I1F-MC-B009)	COMMERCIAL POST-AUTHORIZATION STUDY	ANTONIO FERNANDEZ NEBRO	Not applicable

Group	Title	Subtype	PI Name	Phase
D-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia y la seguridad de tildrakizumab en sujetos con artritis psoriásica activa I que habían recibido tratamiento previo con anti-TNF (INSPIRE 1)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio de fase IV, multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y la seguridad de guselkumab administrado por vía subcutánea en pacientes que no han recibido tratamiento biológico previo con artritis psoriásica axial activa.	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNANDEZ NEBRO	IV
D-03	Estudio de extensión, abierto y multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de BIMEKIZUMAB en el tratamiento de sujetos con artritis psoriásica activa (BE VITAL).	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio de fase 3b, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de guselkumab administrado por vía subcutánea en la mejoría de los signos y síntomas clínicos y en la inhibición de la progresión radiográfica en participantes con artritis psoriásica activa.(APEX)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de PRA023 en sujetos con esclerosis sistémica asociada a enfermedad pulmonar intersticial (ES-EPI).	INDEPENDENT CLINICAL TRIAL	ANTONIO FERNANDEZ NEBRO	II
D-03	Estudio de fase 3B, multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y seguridad de Guselkumab administrado por vía subcutánea en participantes con artritis psoriásica activa que tuvieron una respuesta inadecuada y/o intolerancia a un tratamiento anterior de inhibición del factor de necrosis tumoral a	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	Un estudio multinacional, no intervencionista de tofacitinib en pacientes tratados para la artritis psoriásica. Estudio TOPSATI .Código Protocolo Promotor: A3921332	OBSERVATIONAL STUDY WTIH MEDICINES	ANTONIO FERNANDEZ NEBRO	Not applicable
D-03	Estudio de fase II, doble ciego, de rango de dosis, con grupos paralelos y de extensión a largo plazo para evaluar la seguridad y la eficacia de Enpatoran en participantes con lupus eritematoso cutáneo subagudo, lupus eritematoso discoide y/o lupus eritematoso sistémico que han completado el tratamiento del estudio WILLOW (MS200569_0003)	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	II
D-03	Estudio de extensión, abierta y multicéntrico, para evaluar la seguridad y tolerabilidad a largo plazo del tratamiento con dapirolizumab pegol en participantes del estudio con lupus eritematoso sistémico	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio en fase II, aleatorizado, doble ciego, de búsqueda de dosis, controlado con placebo, de grupos paralelos y adaptativo para evaluar la eficacia y la seguridad de enpatoran en participantes con lupus eritematoso sistémico y con lupus eritematoso cutáneo (lupus eritematoso cutáneo subagudo o lupus eritematoso discoide) que toman el tratamiento de referencia.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	II
D-03	Registro Multicéntrico de Vasculitis Asociadas a ANCA (granulomatosis con poliangeítis, granulomatosis eosinofílica con poliangeítis y poliangeítis microscópica)	OBSERVATIONAL STUDY WTIH MEDICINES	ANTONIO FERNANDEZ NEBRO	Not applicable
D-03	Estudio observacional ambispectivo para describir la persistencia de la secuenciación de guselkumab oTNFi como terapia de segunda línea para el tratamiento de la artritis psoriásica activaMANHATTAN	OBSERVATIONAL STUDY WTIH MEDICINES	ANTONIO FERNANDEZ NEBRO	Not applicable
D-03	Estudio de extensión abierto para evaluar la seguridad y la eficacia a largo plazo de tildrakizumab en pacientes con artritis psoriásica.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	I
D-03	Estudio multicéntrico, aleatorizado, con doble enmascaramiento y de comparación con placebo para evaluar la eficacia, la seguridad, la tolerabilidad, la farmacocinética y la farmacodinámica de GLPG3667 administrado por vía oral en pacientes adultos con lupus eritematoso sistémico activo	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	II
D-03	Ensayo fase III, multicéntrico, aleatorizado, en grupos paralelos, doble ciego, de dos brazos, para evaluar la seguridad y eficacia de anifrolumab frente a placebo en pacientes entre 18 y 70 años con esclerosis sistémica (Estudio DAISY)	DRUG CLINICAL TRIALS	NATALIA MENA VAZQUEZ	III
D-03	Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de SAR441566 más metotrexato en adultos con artritis reumatoide de moderada a grave	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	II

Group	Title	Subtype	PI Name	Phase
D-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de Dapirolizumab Pegol en participantes del estudio con lupus eritematoso sistémico de moderado a grave.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio fase 1, multicéntrico, abierto, de CC-97540 (BMS-986353), linfocitos T con receptor de antígeno quimérico (CAR) NEX-T dirigidos a CD19, en participantes con lupus eritematoso sistémico (LES) severo y refractario.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	I
D-03	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de belimumab administrado por vía subcutánea en adultos con enfermedad pulmonar intersticial (EPI) asociada a enfermedad del tejido conectivo (ETC)	DRUG CLINICAL TRIALS	NATALIA MENA VAZQUEZ	III
D-03	Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de ianalumab.	DRUG CLINICAL TRIALS	NATALIA MENA VAZQUEZ	II
D-03	A multicenter, randomized, double-blind, risankizumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult study participants with active psoriatic arthritis	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio de fase II, multicéntrico, aleatorizado, abierto, ciego para el evaluador, con control activo, de varias partes y de 3 años de duración para evaluar la eficacia y la seguridad del tratamiento con rapcabtagene autoleucel frente a rituximab en participantes con esclerosis sistémica cutánea difusa refractaria grave.	DRUG CLINICAL TRIALS	NATALIA MENA VAZQUEZ	II
D-03	Estudio de fase 2, aleatorizado, abierto y controlado para evaluar la eficacia y la seguridad de rapcabtagene autoleucel frente a un comparador en participantes con miopatías inflamatorias idiopáticas refractarias graves.	DRUG CLINICAL TRIALS	NATALIA MENA VAZQUEZ	II
D-03	A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease ActivityA	DRUG CLINICAL TRIALS	SARA MANRIQUE ARIJA	III
D-03	Estudio fase 3 multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y la seguridad de JNJ-77242113 para el tratamiento de pacientes con artritis psoriásica activa sin tratamiento biológico previo.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio fase 3 multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y la seguridad de JNJ-77242113 para el tratamiento de pacientes con artritis psoriásica activa con tratamiento biológico previo.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	Un estudio multicéntrico de fase 3, de grupos paralelos, aleatorizado, doble ciego, de 3 brazos, controlado con placebo para investigar la eficacia y seguridad del sonelokimab subcutáneo en Participantes masculinos y femeninos de 18 años o más con artritis psoriásica activa que no han recibido FARME biológicos.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	A Phase 3, parallel-group, randomized, double-blind, 4-arm, placebo-controlled, multicenter study withrisankizumab as active reference arm, to investigate the efficacy and safety of subcutaneous sonelokimab inmale and female participants aged 18 years and over with active psoriatic arthritis and previous inadequateresponse or intolerance to tumor necrosis factor-a inhibitors,	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio de fase 3 multicéntrico, aleatorizado, doble ciego, controlado con placebo y con tratamiento activo, para evaluar la eficacia y la seguridad del zasocitinib (TAK-279) en sujetos con artritis psoriásica activa que no han recibido tratamiento previo con fármacos antirreumáticos modificadores de la enfermedad biológicos (LATITUDE-PsA-3001)	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	III
D-03	Estudio de extensión, multicéntrico, a largo plazo y aleatorizado para evaluar la seguridad y la tolerabilidad de dazodalibep en participantes con síndrome de Sjögren (SS).	DRUG CLINICAL TRIALS	SARA MANRIQUE ARIJA	III
D-03	Eficacia, seguridad y coste-efectividad de un modelo predictivo de remisión persistente basado en biomarcadores en pacientes con artritis reumatoide sometidos a optimización de terapia biológica	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	NATALIA MENA VAZQUEZ	Not applicable
D-03	Estudio de fase IIb, multicéntrico, doble ciego, controlado con placebo, de retirada aleatorizada para evaluar la eficacia, la seguridad y la tolerabilidad de IMVT-1402 en participantes adultos con artritis reumatoide activa, difícil de tratar positiva para ACPA.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	II/III

Group	Title	Subtype	PI Name	Phase
D-03	Protocolo para el seguimiento a largo plazo de pacientes tratados con linfocitos T modificados genéticamente.	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	II/III
D-03	Estudio fase II, multicéntrico, abierto, de CC-97540 (BMS-986353), células NEXT CAR T dirigidas a CD19, en participantes con LES activo (incluida nefritis lúpica) con respuesta insuficiente a los glucocorticoides y a, al menos, 2 inmunodepresores (Breakfree-SLE)	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	II
D-03	Un Estudio de Fase II, multicéntrico, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de RO7790121 en pacientes con artritis reumatoide de moderada a grave que tienen una respuesta inadecuada o intolerancia al TNF y/o INHIBIDORES DE JAK	DRUG CLINICAL TRIALS	ANTONIO FERNANDEZ NEBRO	II
D-04	Estudio multicéntrico, aleatorizado, doble ciego, con control activo y placebo para investigar la eficacia y seguridad de ligelizumab (QGE031) en el tratamiento de la urticaria crónica espontánea (UCE) en adolescentes y adultos inadecuadamente controlados con antihistamínicos H1	COMMERCIAL CLINICAL TRIAL	FRANCISCA GOMEZ PEREZ	III
D-04	Estudio aleatorizado doble ciego controlado por placebo para evaluar la eficacia y mecanismos implicados en la inmunoterapia sublingual especifica con Pru p 3 (Pru p 3-ITSL) en pacientes con alergia a nsLTP con síntomas graves en su respuesta frente a melocotón, cacahuete artemisia y olivo.	INDEPENDENT CLINICAL TRIAL	FRANCISCA GOMEZ PEREZ	III
D-04	Estudio de extensión multicéntrico, doble ciego y abierto para evaluar la eficacia y seguridad de ligelizumab como retratamiento, terapia autoadministrada y monoterapia en pacientes con urticaria crónica espontánea que han completado los estudios CQGE031C2302, CQGE031C2303, CQGE031C2202 o CQGE031C1301.	COMMERCIAL CLINICAL TRIAL	FRANCISCA GOMEZ PEREZ	III
D-04	Estudio de fase II para evaluar la tolerabilidad, seguridad y eficacia de la inmunoterapia sublingual en pacientes con alergia a los ácaros del polvo doméstico. (SULGEN Study)	COMMERCIAL CLINICAL TRIAL	CARMEN RONDON SEGOVIA	II
D-04	Reacciones de hipersensibilidad cruzada a Ibuprofeno y otros derivados Arilpropiónicos: entidades clínicas y mecanismos implícitos. Papel de la atopia e interacción fenotipo-genotipo SEAIC2018	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAEN	Not applicable
D-04	Ensayo prospectivo multicéntrico aleatorizado, controlado con placebo y comparativo de la eficacia y la seguridad de la inmunoterapia subcutánea con mezcla de gramíneas y ácaros a dosis adecuadas frente a monoterapia, para el tratamiento de la alergia	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAEN	III
D-04	BIOBADALER. Understanding similarities and differences of biological therapies for severe asthma	INDEPENDENT POSTAUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAEN	Not applicable
D-04	Estudio de 52 semanas de duración, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad, para evaluar la tasa de exacerbación, las mediciones adicionales de control del asma y la seguridad en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico tratados con GSK3511294 en comparación con mepolizumab o benralizumab	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAEN	III
D-04	Estudio de 52 semanas, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y multicéntrico de la eficacia y la seguridad del tratamientocomplementario con GSK3511294 en participantes adultos y adolescentes con asma grave no controlada con fenotipo eosinofílico	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAEN	III
D-04	Protocolo maestro de dos estudios aleatorizados, controlados con placebo, doble ciegos, multicéntricos, de grupos paralelos de dupilumab en pacientes con urticaria crónica espontánea (UCE) que siguen siendo sintomáticosa pesar del uso de tratamiento antihistamínico H1 en pacientes sin tratamiento previo con omalizumab y en pacientes intolerantes o con respuesta incompleta a omalizumab. (CUPID)	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III
D-04	Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea (Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del polvo en pacientes con rinitis/rinoconjuntivitis alérgica	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAEN	III
D-04	Ensayo de fase 3 de 3 partes, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para demostrar la eficacia y seguridad de Benralizumab en pacientes con Gastritis y/o Gastroenteritis eosinofílica (ensayo HUDSON GI)	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III
D-04	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de ligelizumab (QGE031) en el tratamiento de la urticaria crónica inducible (CINDU) en adolescentes y adultos inadecuadamente controlados con antihistamínicos H1.	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAEN	III

Group	Title	Subtype	PI Name	Phase
D-04	Estudio observacional prospectivo para evaluar la seguridad y la efectividad de la inmunoterapia con un alergoide de polen de olivo y gramíneas en pacientes con asma alérgica estacional. Estudio GOL.	COMMERCIAL POST-AUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAEN	Not applicable
D-04	Similarities and differences of biological therapies for allergic diseases	RESTO DE ESTUDIOS OBSERVACIONALES CON MEDICAMENTOS	MARÍA JOSÉ TORRES JAEN	Not applicable
D-04	Estudio de extensión, abierto, multicéntrico y de un solo grupo para evaluar la seguridad a largo plazo de GSK3511294 (depemokimab) en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico de los estudios 206713 o 213744	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAEN	III
D-04	Ensayo clínico fase III multicéntrico, doble ciego, aleatorizado y controlado con placebo, en grupos paralelos, que evalúa la eficacia clínica y seguridad de la inmunoterapia con el alérgeno mayor purificado Cup a 1, en pacientes con rinoconjuntivitis alérgica moderada/ grave con o sin asma controlado, sensibilizados a Cupresáceas	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III
D-04	Ensayo clínico de eficacia y seguridad, prospectivo, aleatorizado, doble ciego, de doble simulación, controlado con placebo, multicéntrico, con inmunoterapia en pacientes con asma de leve a moderada controlada y rinitis/rinoconjuntivitis, alérgicos a Dermatophagoides pteronyssinus y/o Dermatophagoides farinae	INDEPENDENT CLINICAL TRIAL	CARMEN RONDON SEGOVIA	III
D-04	Efectos de la combinación fija de dipropionato de beclometasona/fumarato de formoterol administrada con NEXT(haler) en un estudio en condiciones reales sobre la probabilidad de mejora del estado de control del asma después de 6 meses de tratamiento. Estudio NEWTON	OBSERVATIONAL STUDY WTIH MEDICINES	IBON EGUILUZ GRACIA	Not applicable
D-04	Estudio de fase III, multicéntrico y abierto: monitorización ambulatoria de la presión arterial en pacientes adultos con urticaria crónica espontánea inadecuadamente controlada con antihistamínicos H1 y tratados con remibrutinib hasta 12 semanas	DRUG CLINICAL TRIALS	ALMUDENA TESTERA MONTES	III
D-04	Estudio doble ciego para participante e investigador de un mes de duración en el que se evalúan la eficacia y la seguridad de remibrutinib (LOU064) en varios niveles de dosis en participantes adultos con alergia al cacahuete.	DRUG CLINICAL TRIALS	MARÍA JOSÉ TORRES JAEN	II
D-04	Estudio de fase II de búsqueda de dosis, aleatorizado, doble ciego y controlado con un placebo, para evaluar la eficacia y la seguridad del CDX-0159 en pacientes con urticaria crónica espontánea	DRUG CLINICAL TRIALS	MARÍA JOSÉ TORRES JAEN	II
D-04	Estudio observacional prospectivo para evaluar la seguridad del tratamiento con “ALLERGOVAC® HIMENÓPTEROS” en pacientes sensibilizados a este veneno HIPNOS.	OBSERVATIONAL STUDY WTIH MEDICINES	MARINA LABELLA ALVAREZ	Not applicable
D-04	Ensayo multicéntrico, prospectivo y no intervencionista que supervisa las vías terapéuticas de los pacientes con asma tratados con una triple terapia extrafina de un único inhalador con ICS/LABA/LAMA en condiciones reales y que caracteriza los efectos sobre los resultados relacionados con la salud	OBSERVATIONAL STUDY WTIH MEDICINES	IBON EGUILUZ GRACIA	Not applicable
D-04	Estudio de extensión multicéntrico, abierto y doble ciego, controlado con placebo con retirada aleatorizada, seguido de ciclos de tratamiento abierto de larga duración para evaluar la eficacia, seguridad y tolerabilidad de remibrutinib (LOU064) en pacientes adultos con urticaria crónica espontánea que hayan completado los estudios anteriores de fase III de remibrutinib	DRUG CLINICAL TRIALS	ALMUDENA TESTERA MONTES	III
D-04	Estudio de fase II de búsqueda de dosis, aleatorizado, doble ciego y controlado con unplacebo, para evaluar la eficacia y la seguridad del CDX-0159 en pacientes con urticariacrónica inducible	DRUG CLINICAL TRIALS	MARÍA JOSÉ TORRES JAEN	II
D-04	Estudio de fase IIb, multicentrico, aleatorizado, doble ciego y controlado con placebo sobre la eficacia y la seguridad de brensocatib en participantes con rinosinusitis cronica sin polipos nasales - Estudio BiRCh	DRUG CLINICAL TRIALS	MARÍA JOSÉ TORRES JAEN	II
D-04	Estudio observacional, multicéntrico, prospectivo, para evaluar la efectividad y seguridad en vida real de Depigoid® DUO Gato- Dermatophagoides pteronyssinus (DPT) (100/100 DPP/ml) en pacientes con rinitis/ rinoconjuntivitis persistente moderada-grave con o sin asma alérgica controlada en España”	OBSERVATIONAL STUDY WTIH MEDICINES	CARMEN RONDON SEGOVIA	Not applicable
D-04	A 12-WEEK double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 PMDI 200/6/12.5 µg hfa-152a, compared to CHF5993 PMDI 200/6/12.5 µg hfa-134a, in subjects with asthma.	DRUG CLINICAL TRIALS	ALMUDENA TESTERA MONTES	III

Group	Title	Subtype	PI Name	Phase
D-04	Estudio pRagmático multinacional no intervEncioniSta y prospectivo para evaluar el mePOlizumab en pacientes con rinosinusitis crónica con poliposis Nasal y asma o aSma eosinofílico gravE y pólipos nasales. RESPONSE	OBSERVATIONAL STUDY WTIH MEDICINES	ALMUDENA TESTERA MONTES	Not applicable
D-04	Evaluación de la tolerabilidad y la eficacia de la administración de inmunoterapia subcutánea en pauta clúster, en pacientes con rinoconjuntivitis y/o asma con sensibilización a olivo con o sin sensibilización a gramíneas: Pauta de inicio y primer año de tratamiento	OBSERVATIONAL STUDY WTIH MEDICINES	ALMUDENA TESTERA MONTES	Not applicable
D-04	Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, con dos brazos para investigar la eficacia, seguridad y tolerabilidad de lunsekimig subcutáneo (SAR443765) en participantes adultos con asma de alto riesgo que no son actualmente elegibles para tratamiento biológico.	DRUG CLINICAL TRIALS	CARMEN RONDON SEGOVIA	II
D-04	Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial of efficacy and safety with Dermatophagoides pteronyssinus and Dermatophagoides farinae mannan-conjugated allergoids in patients with rhinitis/rhinoconjunctivitis, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae	DRUG CLINICAL TRIALS	CARMEN RONDON SEGOVIA	III
D-04	A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria.	DRUG CLINICAL TRIALS	MARÍA JOSÉ TORRES JAEN	II
D-04	Dermatophagoides mezcla (D. pteronyssinus + D. farinae) estandarizado en TBU/ml en formu-lación líquida para inmunoterapia sublingual: Ensayo clínico Fase II aleatorizado de determi-nación de dosis. Estudio: DEDO-D.	DRUG CLINICAL TRIALS	MARÍA JOSÉ TORRES JAEN	II
D-04	Estudio observacional retrospectivo para caracterizar y evaluar los resultados clínicos de los pacientes tratados con tezepelumab tras la aprobación de comercialización en España.	OBSERVATIONAL STUDY WTIH MEDICINES	IBON EGUILUZ GRACIA	Not applicable
D-05	Registro no intervencionista de larga duración para evaluar la seguridad y la efectividad de HUMIRA® (adalimumab) en pacientes con colitis ulcerosa (CU) de actividad moderada a grave. P11-282, LEGACY	COMMERCIAL POST-AUTHORIZATION STUDY	RAQUEL CAMARGO CAMERO	Not applicable
D-05	Estudio de fase 3, multicéntrico, aleatorizado, con doble enmascaramiento, a largo plazo y controlado con placebo para evaluar la seguridad y la eficacia del ácido obeticólico en sujetos con esteatohepatitis no alcohólica.	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio Epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España.	NON-POST-APPROVAL STUDY	RAQUEL CAMARGO CAMERO	Not applicable
D-05	Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio multicéntrico de Fase III aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del Etrolizumab como tratamiento de inducción y mantenimiento en pacientes con Enfermedad de Crohn activa de moderada a grave.	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio abierto de extensión y supervisión de la seguridad de pacientes con Enfermedad de Crohn con actividad de moderada a grave previamente inscritos en el protocolo de Fase III con Etrolizumab, GA29144.	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase III, multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo, para evaluar la eficacia y seguridad de cenicriviroc para el tratamiento de la fibrosis hepática en pacientes adultos con esteatohepatitis no alcohólica	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Suspensión del tratamiento anti-tnf en pacientes con enfermedad inflamatoria intestinal: ensayo clínico multicéntrico, prospectivo y aleatorizado.	INDEPENDENT CLINICAL TRIAL	RAQUEL CAMARGO CAMERO	IV
D-05	Estudio observacional de regorafenib en carcinoma hepatocelular. REFINE	COMMERCIAL POST-AUTHORIZATION STUDY	RAÚL J. ANDRADE BELLIDO	Not applicable
D-05	Fluid Day HTF-FLU-2018-01	INDEPENDENT POSTAUTHORIZATION STUDY	JOSÉ AURELIO GOMEZ LUQUE	Not applicable

Group	Title	Subtype	PI Name	Phase
D-05	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. GIS-DUMBO-2018	INDEPENDENT POSTAUTHORIZATION STUDY	RAQUEL CAMARGO CAMERO	Not applicable
D-05	Evaluación integrada mecanística, diagnóstica y pronóstica en hepatotoxicidad	INDEPENDENT POSTAUTHORIZATION STUDY	RAÚL J. ANDRADE BELLIDO	Not applicable
D-05	Estudio abierto para evaluar la seguridad, actividad antiviral y farmacocinética de IMC-I109V en pacientes positivos para HLA-A*02:01 con infección crónica por VHB, no cirróticos, negativos para el antígeno e de hepatitis B y con carga viral suprimida	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio fase 2, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de múltiples dosis, para evaluar la eficacia y la seguridad de BMS-986263 en adultos con cirrosis compensada por esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de Seladelpar en pacientes con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al ácido ursodesoxicólico (UDCA).RESPONSE	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio doble ciego, aleatorizado, controlado con placebo y en fase II de búsqueda de dosis en el que se comparan distintas dosis de RhuDex gránulos con placebo en el tratamiento de la colangitis biliar primaria	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio abierto a largo plazo para evaluar la seguridad y la tolerabilidad de seladelpar en sujetos con colangitis biliar primaria (CBP). ASSURE	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	IV
D-05	Estudio prospectivo, multicéntrico (B-Sure) para evaluar la durabilidad a largo plazo de la respuesta virológica sostenida en participantes con hepatitis B crónica tratados y no tratados con nucleósidos/ nucleótidos, que recibieron GSK3228836 en un estudio de tratamiento previo y respondieron a dicho tratamiento	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio de fase IIB, aleatorizado, multicéntrico, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de CRV431 en sujetos adultos con esteatohepatitis no alcohólica y fibrosis hepática avanzada.	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Ensayo doble ciego, aleatorizado, controlado con placebo, fase IIb sobre la eficacia y seguridad de comprimidos de ácido norursodesoxicólico en pacientes con esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Ensayo clínico de fase IIb/III, adaptativo, doble ciego, aleatorizado, controlado con placebo y de 52 semanas de duración de setanaxib con una fase de extensión de 52 semanas en pacientes con colangitis biliar primaria (CBP) y rigidez hepática elevada.	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	III
D-05	A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	II
D-05	Minimización de la 17b-hidroxiesteroide deshidrogenasa tipo 13 para el tratamiento de EHNA (HORIZON): Estudio Fase 2b, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de GSK4532990 en adultos con esteatohepatitis no alcohólica precirrótica.	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio de fase III aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de fazirsiran en el tratamiento de la enfermedad hepática asociada a la deficiencia de alfa-1 antitripsina con fibrosis en estadio F2 a F4 de METAVIR.	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio Fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de la administración de bepirovirsen en pacientes con Hepatitis B crónica HBeAg negativos y en tratamiento con análogos de nucleós(t)idos (B-Well 1)	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase II, aleatorizado, doble ciego, comparativo con placebo y de búsqueda de dosis para evaluar la eficacia y la seguridad de TAK-062 para el tratamiento de la celiaquía activa en participantes que siguen una dieta sin gluten	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	II

Group	Title	Subtype	PI Name	Phase
D-05	Estudio Multicéntrico, Aleatorizado, Doble Ciego y Controlado con Placebo para evaluar la eficacia y la seguridad de la rifaximina en comprimidos de Dispersión Sólida Soluble (SSD) para el retraso de la Descompensación de la Encefalopatía en la Cirrosis (Red-C)	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	III
D-05	A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants with Primary Biliary Cholangitis (PBC)	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	III
D-05	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños (registro DUMBO)	OBSERVATIONAL STUDY WTIH MEDICINES	RAQUEL CAMARGO CAMERO	Not applicable
D-05	Estudio en Fase II abierto para evaluar la seguridad y la eficacia de Bemnifosbuvir (BEM) y Ruzasvir (RZR) en sujetos con infección crónica por el virus de la Hepatitis c (VHC).	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	II
D-05	Proof-of-concept Phase II study to evaluate the efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity and its mechanistic pathways through an integrative analysis: the DILICORT clinical trial.	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio en fase IIIb, aleatorizado, de grupos paralelos, con doble enmascaramiento, comparado con placebo y de dos grupos para evaluar la eficacia de elafibranor 80 mg en la normalización de la fosfatasa alcalina en participantes adultos con colangitis biliar primaria (CBP) y una respuesta inadecuada o intolerancia al ácido ursodesoxicólico	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio en fase IIa/b, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para investigar la eficacia y la seguridad de amlitelimab subcutáneo en pacientes adultos con enfermedad celíaca sin respuesta de forma conjunta a una dieta sin	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	II
D-05	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. Registro DUMBO 2.	OBSERVATIONAL STUDY WTIH MEDICINES	RAQUEL CAMARGO CAMERO	Not applicable
D-05	Ensayo de fase 3, global, aleatorizado, abierto y multicéntrico, de evaluación de BJT-778 frente a bulevirtida en el tratamiento de la hepatitis delta cónica (AZURE-2)	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	III
D-05	An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study.	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase II, aleatorizado, abierto, nacional y multicéntrico que evalúa la eficacia y seguridad de la combinación de atezolizumab y bevacizumab como tratamiento neoadyuvante y adyuvante en pacientes con carcinoma hepatocelular.	DRUG CLINICAL TRIALS	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio aleatorizado, doble ciego, controlado con placebo y de dos partes, para evaluar la farmacocinética, la seguridad, la tolerabilidad y la eficacia preliminar de dos niveles de dosis de golexanolona, en sujetos con colangitis biliar primaria, fatiga y disfunción cognitiva	DRUG CLINICAL TRIALS	MIREN GARCIA CORTES	I/II
D-05	Clinical Benefit of Bulevirtide Therapy in AdultPatients With Chronic Hepatitis Delta Compared to aHistorical Control Group Receiving Standard of Care	OBSERVATIONAL STUDY WTIH MEDICINES	AIDA ORTEGA ALONSO	Not applicable
DA-06	Estudio de prevalencia y adecuación del uso hospitalario de antimicrobianos en España.	INDEPENDENT POSTAUTHORIZATION STUDY	ELENA SANCHEZ YAÑEZ	Not applicable
DA-06	Factores asociados al descenso de densidad mineral ósea y a la incidencia de fracturas durante el periodo de descanso terapéutico con BifosfonatosCódigo Promotor: Vacaciones Terapéuticas	INDEPENDENT POSTAUTHORIZATION STUDY	BLANCA PANERO LAMOTHE	Not applicable
DA-06	Pautas de tratamiento con upadacitinib, consecución de los objetivos terapéuticos y mantenimiento de la respuesta en pacientes con artritis reumatoide de moderada a grave en la práctica real (Estudio UPHOLD, P20-095)	COMMERCIAL POST-AUTHORIZATION STUDY	ROSA GARCIA PORTALES	Not applicable
DA-06	Estudio observacional para evaluar la adherencia a TREMFYA (Guselkumab) en la práctica clínica en pacientes con psoriasis moderada a grave. ADHERENCE	OBSERVATIONAL STUDY WTIH MEDICINES	ELENA SANCHEZ YAÑEZ	Not applicable
DA-06	Estudio multicéntrico, ambispectivo y observacional, en pacientes con psoriasis en placas de moderada a grave, para evaluar su satisfacción con el tratamiento con tildrakizumab.	OBSERVATIONAL STUDY WTIH MEDICINES	ISABEL MOYA CARMONA	Not applicable

Group	Title	Subtype	PI Name	Phase
DA-06	Estudio observacional ambispectivo para describir la persistencia de la secuenciación de guselkumab o TNFi como terapia de segunda línea para el tratamiento de la artritis psoriásica activa. MANHATTAN	OBSERVATIONAL STUDY WTIH MEDICINES	ROSA GARCIA PORTALES	Not applicable
DA-06	A multinational, prospective, non-interventional study, to assess real world use of a tocilizumab biosimilar in rheumatoid arthritis patients.	OBSERVATIONAL STUDY WTIH MEDICINES	ROSA GARCIA PORTALES	Not applicable
DA-06	Evaluación de los resultados reportados por el paciente con psoriasis tratado con un fármaco anti IL-17AF a través de un modelo de atención farmacéutica telemática.	OBSERVATIONAL STUDY WTIH MEDICINES	ELENA SANCHEZ YAÑEZ	Not applicable
DA-06	Estudio prospectivo de varios países, de la vida real, de varios grupos sobre la persistencia del tratamiento con risankizumab en la artritis psoriásica (PERIS).	OBSERVATIONAL STUDY WTIH MEDICINES	ALBA MARÍA RODRIGUEZ VERDU	Not applicable
DE-02	Estudio Fase III aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapiaantirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intramuscular de acción prolongada con cabotegravir y rilpivirina en pacientes adultos infectados por el VIH-1 con supresión virológica.	COMMERCIAL CLINICAL TRIAL	MANUEL CASTAÑO CARRACEDO	III
DE-02	Estudio Fase IIIb, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia, seguridad y tolerabilidad de cabotegravir de acción prolongada más rilpivirina de acción prolongada administrados cada 8 semanas o cada 4 semanas en adultos infectados por VIH-1 que presentan supresión virológica	COMMERCIAL CLINICAL TRIAL	MANUEL CASTAÑO CARRACEDO	III
DE-02	Estudio Clínico, Farmacológico y Microbiológico del Tratamiento Optimizado con beta-lactámicos en combinación con colistina de la infección osteoarticular con y sin material ortopédico por bacilos gram-negativos resistentes a fluoroquinolonas. Estudio COLBETA-17	INDEPENDENT POSTAUTHORIZATION STUDY	BEATRIZ SOBRINO DIAZ	Not applicable
DE-02	Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el tratamiento de pacientes con bacteriemia por Enterobacteriaceae	INDEPENDENT CLINICAL TRIAL	ANTONIO PLATA CIEZAR	III
DE-02	Estudio comparativo en fase III, prospectivo, aleatorizado, multicéntrico, abierto pero enmascarado para el evaluador principal y de grupos paralelos para determinar la eficacia, seguridad y tolerabilidad de Aztreonam-Avibactam (ATM-AVI) ± Metronidazol (MTZ) en comparación con Meropenem ± Colistina (MER ± COL) en el tratamiento de infecciones graves por Bacterias Gramnegativas, incluidos los patógenos multirresistentes que producen Metalo-?-Lactamasa (MBL), para las que hay pocas o ninguna opción de tratamiento (REVISIT)	COMMERCIAL CLINICAL TRIAL	JOSÉ MARÍA REGUERA IGLESIAS	III
DE-02	Estudio de cohortes, no intervencionista, en múltiples países, de la efectividad, seguridad, adherencia y calidad de vida relacionada con la salud en pacientes adultos infectados con el VIH-1 que reciben bictegravir/emtricitabina/tenofovir alafenamida (B/F/TAF). GS-EU-380-4472	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL CASTAÑO CARRACEDO	Not applicable
DE-02	Eficacia de fosfomicina intravenosa en la infección urinaria complicada con condiciones de vida real. Impacto de la CMI y de las mutaciones basales. Proyecto FOSFO-MIC	INDEPENDENT POSTAUTHORIZATION STUDY	JOSÉ MARÍA REGUERA IGLESIAS	Not applicable
DE-02	Temocilina vs Meropenem para el Tratamiento de la Bacteriemia por Enterobacteriales Resistentes a Cefalosporinas de Tercera Generación: Ensayo Aleatorizado y Pragmático.	INDEPENDENT CLINICAL TRIAL	CARMEN PEREZ LOPEZ	III
DE-02	Estudio Salutem: uso de hidroxicloroquina en profilaxis pre-exposición a la COVID-19 en trabajadores sanitarios	INDEPENDENT CLINICAL TRIAL	JUAN DIEGO RUIZ MESA	III
DE-02	Multicentre EuRopean study of MAjor Infectious Disease Syndromes (MERMAIDS). Acute RespiratoryInfections (MERMAIDS ARI) 2.0. Estudio RECoVER.	NON-POST-APPROVAL STUDY	JOSÉ MARÍA REGUERA IGLESIAS	Not applicable
DE-02	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR	INDEPENDENT CLINICAL TRIAL	BEATRIZ SOBRINO DIAZ	IV
DE-02	Ensayo abierto multicéntrico aleatorizado y pragmático de Fase IV para evaluar la eficacia y seguridad de diferentes duraciones de tratamiento antimicrobiano de infecciones asociadas al material de osteosíntesis tras fractura de hueso largo.	INDEPENDENT CLINICAL TRIAL	BEATRIZ SOBRINO DIAZ	III

Group	Title	Subtype	PI Name	Phase
DE-02	Ensayo clínico aleatorizado, de superioridad, doble ciego, controlado con placebo, en fase ii, para demostrar la eficacia del trasplante de microbiota fecal en la descolonización intestinal selectiva de los pacientes colonizados por Enterobacterias productoras de carbapenemasa tipo KPC u OXA-48	INDEPENDENT CLINICAL TRIAL	JUAN DIEGO RUIZ MESA	II
DE-02	Ensayo clínico aleatorizado de no inferioridad para evaluar la eficacia y seguridad del tratamiento corto de la bacteriemia enterocócica no complicada. INTENSE	INDEPENDENT CLINICAL TRIAL	ANTONIO PLATA CIEZAR	IV
DE-02	Clínica y Epidemiología del brote de infección por Monkeypox en España en el año 2022. ESTUDIO CEME 22	OBSERVATIONAL STUDY WTIH MEDICINES	INÉS PEREZ CAMACHO	Not applicable
DE-02	Estudio de la función tubular renal y marcadores de remodelado óseo durante el tratamiento prolongado con entecavir y tenofovir en pacientes con infección crónica por el virus de la hepatitis B. Estudio MENTE	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ MARÍA REGUERA IGLESIAS	Not applicable
DE-02	CABO-CHANCE: Estudio en vida real sobre el uso de Cabotegravir/Rilpivirinade acción prolongada (CAB/ RPV AP) en pacientes pretratados que viven con el VIH (PVVIH).	OBSERVATIONAL STUDY WTIH MEDICINES	INÉS PEREZ CAMACHO	Not applicable
DE-02	Estudio en Fase IV con diseño de prueba negativa para evaluar la eficacia de una vacuna conjugada antineumocócica 20-valente contra la neumonía adquirida en la comunidad causada por serotipos vacunales confirmada radiológicamente en adultos =65 años.	DRUG CLINICAL TRIALS	ANTONIO PLATA CIEZAR	IV
DE-02	Eficacia y seguridad de la perfusión continua vs. perfusión intermitente de ampicilina y ceftriaxona para el tratamiento de endocarditis infecciosa por Enterococcus faecalis (Estudio DOßLEI).	DRUG CLINICAL TRIALS	ANTONIO PLATA CIEZAR	IV
DE-02	Estudio de fase 3, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar el cambio a una pauta semanal de islatravir/lenacapavir por vía oral en personas con VIH 1 con supresión virológica bajo tratamiento con bictegravir/emtricitabina/tenofovir (B/F/TAF)	DRUG CLINICAL TRIALS	MANUEL CASTAÑO CARRACEDO	III
DE-02	Estudio de fase 3b, abierto, aleatorizado, controlado con tratamiento estándar, multicéntrico, de superioridad para evaluar la eficacia, la seguridad y la tolerabilidad de CAB AP + RPV AP inyectable en participantes virémicos que viven con VIH-1 (CROWN).	DRUG CLINICAL TRIALS	MANUEL CASTAÑO CARRACEDO	III
DE-02	Optimising TREATment for Gram-Negative Bacterial infections (TREAT-GNB): phase 4 multicen-tre, open trial with individualized randomization for the treatment of bacteraemia caused by car-bapenem-resistant gram negative microorganisms	DRUG CLINICAL TRIALS	ANTONIO PLATA CIEZAR	IV
DE-02	Asociación entre la eficacia clínica y microbiológica y los parámetros farmacocinéticos/farmacodinámicos de dalbavancina para el tratamiento de infecciones causadas por microorganismos Gram positivos (Proyecto DAPHNE).	OBSERVATIONAL STUDY WTIH MEDICINES	ANTONIO PLATA CIEZAR	Not applicable
DE-02	Enfermedad tuberculosa en receptores de trasplante de órgano sólido	OBSERVATIONAL STUDY WTIH MEDICINES	INÉS PEREZ CAMACHO	Not applicable
DE-07	Estudio exploratorio para evaluar la eficacia y seguridad de la administración en la nutrición de 1,5 g de proteína/kg/día frente a 1,0 g de proteína/kg/día en la fase catabólica del paciente crítico bajo ventilación mecánica.	INDEPENDENT CLINICAL TRIAL	JUAN FRANCISCO MARTINEZ CARMONA	IV
DE-07	Retrospective Analysis of Real-World Use of Cefiderocol in the Management of Gram-Negative Infections as part of the Early Access Program (PERSEUS Study)." // "Análisis retrospectivo del uso en la práctica real de cefiderocol para el tratamiento de infecciones por gramnegativos como parte del programa de acceso precoz (estudio PERSEUS).	OBSERVATIONAL STUDY WTIH MEDICINES	CÉSAR ARAGON GONZALEZ	Not applicable
DE-07	Estudio retrospectivo de revisión de historias clínicas en el que se evalúa la práctica clínica, los patrones de tratamiento y los resultados relacionados con los concentrados de complejo de protrombina de 4 factores (4F-PCC) en pacientes tratados con inhibidores del factor Xa (FXa) antes de una cirugía o un procedimiento invasivo y en aquellos que precisan una neutralización a demanda por una hemorragia grave	OBSERVATIONAL STUDY WTIH MEDICINES	MARÍA DOLORES ARIAS VERDU	Not applicable
DE-07	Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)	DRUG CLINICAL TRIALS	MANUEL ENRIQUE HERRERA GUTIERREZ	IV
DE-08	Duodenopancreatectomía cefálica en tumores de páncreas y periampulares: abordaje inicial de la arteria mesentérica superior versus abordaje clásico. Estudio prospectivo, aleatorizado y multicéntrico.	NON-POST-APPROVAL STUDY	JULIO SANTOYO SANTOYO	Not applicable
DE-08	Estudio Epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España.	NON-POST-APPROVAL STUDY	RAÚL VICENTE OLMEDO MARTIN	Not applicable

Group	Title	Subtype	PI Name	Phase
DE-08	Registro informatizado de pacientes con Patologías Pancreáticas	NON-POST-APPROVAL STUDY	LETICIA LUCIA MONGIL POCE	Not applicable
DE-08	Eficacia del cambio de diana terapéutica en práctica clínica tras el fracaso del tratamiento con un primer fármaco antiTNF en la enfermedad de Crohn	INDEPENDENT POSTAUTHORIZATION STUDY	RAÚL VICENTE OLMEDO MARTIN	Not applicable
DE-08	Dice Incidence Capture: Determinantes, Incidencia y Consecuencias del Exceso de corticoesteroides en EII	COMMERCIAL POST-AUTHORIZATION STUDY	PATRICIA ROMERO CARA	Not applicable
DE-08	Efectividad y seguridad de Ustekinumab en pacientes Bionaive con enfermedad de Chron moderada-grave refractaria a tratamiento convencional: un estudio retrospectivo observacional multicéntrico	INDEPENDENT POSTAUTHORIZATION STUDY	RAÚL VICENTE OLMEDO MARTIN	Not applicable
DE-08	Estudio de fase 4, multicéntrico y observacional para evaluar la seguridad y la tolerabilidad de lenvatinib en pacientes con carcinoma hepatocelular avanzado o irresecable (STELLAR)E7080-M000-508	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL JIMENEZ PEREZ	Not applicable
DE-08	Ensayo ABC-HCC: Ensayo en fase IIIb, aleatorizado, multicéntrico y abierto de atezolizumab más bevacizumab frente a quimioembolización transarterial (QETA) en carcinoma hepatocelular en estadio intermedio	DRUG CLINICAL TRIALS	MIGUEL JIMENEZ PEREZ	III
DE-08	A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitits (MASH) and Fibrosis.	DRUG CLINICAL TRIALS	MIGUEL JIMENEZ PEREZ	III
DE-08	Proof-of-concept Phase II study to evaluate the efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity and its mechanistic pathways through an integrative analysis: the DILICORT clinical trial.	DRUG CLINICAL TRIALS	ROCÍO GONZALEZ GRANDE	II
DE-08	A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)	DRUG CLINICAL TRIALS	MIGUEL JIMENEZ PEREZ	III
DE-08	Registro AIRIS Crohn. Assessing the Impact of RISankizumab on clinical outcomes and biomarkers in Crohns Disease	OBSERVATIONAL STUDY WTIH MEDICINES	RAÚL VICENTE OLMEDO MARTIN	Not applicable
DE-08	An Open-Label, Multicenter, Prospective, Interventional Study to Assess the Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon® 35,000) in Patients with Pancreatic Exocrine Insufficiency (PEI) after Pancreatic Surgery	DRUG CLINICAL TRIALS	MIGUEL JIMENEZ PEREZ	III
DE-08	A double-blind, randomized, placebo-controlled, multicenter trial evaluating the efficacy and safety of Saccharomyces boulardii CNCM I-745 in adult patients with non-constipated Irritable Bowel Syndrome	DRUG CLINICAL TRIALS	MIGUEL JIMENEZ PEREZ	III
DE-10	Evaluación de una pauta de tratamiento extendida y proactiva en pacientes con degeneración macular asociada a la edad húmeda (DMAEh) sin tratamiento previo [Evaluation of an eXtended and proacTive dosing regimEn in treatment-Naïve patients with wet age-related macular Degeneration (wAMD)]	COMMERCIAL POST-AUTHORIZATION STUDY	ISABEL MARIA BAQUERO ARANDA	Not applicable
DE-10	Evaluación prospectiva de la eficacia y la seguridad del tratamiento tópico con hidrocortisona en los signos y síntomas clínicos de la xeroftalmia asociada a una disfunción moderada de las glándulas de Meibomio.	COMMERCIAL CLINICAL TRIAL	YOLANDA FERNANDEZ BARRIENTOS	IV
DE-11	Estudio fase IV, observacional, multinacional sobre el control de la enfermedad y los resultados notificados por los pacientes en tratamiento con inhaladores de combinación a dosis fija para asma persistente y EPOC en la práctica clínica habitual (SPRINT). BFS-AS-40087	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Ensayo de extensión de seguridad, multicéntrico, abierto, con benralizumab (MEDI-563) en adultos asmáticos con un corticosteroide inhalado más un agonista β2 de acción larga (MELTEMI)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio observacional de cohortes de la seguridad posterior a la autorización (PAS) para cuantificar la incidencia y la seguridad comparativa de eventos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación UMEC/VI por inhalación o UMEC por inhalación en comparación con tiotropio. (Estudio 201038)	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Carga de la enfermedad en pacientes con EPOC eosinofílica en España: Estudio observacional multicéntrico. HO-16-16447	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable

Group	Title	Subtype	PI Name	Phase
DE-11	Nuevo estudio observacional, longitudinal en pacientes con un diagnóstico o sospecha de diagnóstico de asma y/o EPOC para describir las características de los pacientes, patrones de tratamiento y carga de la enfermedad con el paso del tiempo para identificar fenotipos y endotipos asociados a resultados diferenciales que pueden respaldar el desarrollo futuro de estrategias de tratamiento personalizadas. D2287R00103	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Estudio observacional transversal para caracterizar la EPOC grave en España. Estudio CLAVE	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Ensayo multicéntrico de fase II, doble ciego, aleatorizado, de grupos paralelos y controlado por placebo, para investigar el efecto del antagonista PBF-680 de receptor A1 de adenosina sobre el volumen espiratorio forzado en 1 segundo (FEV1) en sujetos con asma atópica persistente leve a moderada (PIVOTAL)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio en fase 2a, multicéntrico, con grupos paralelos, controlado con placebo, doble ciego y aleatorizado para investigar la eficacia y la seguridad de tezepelumab en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) de moderada a muy grave (COURSE)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Ensayo de fase III, multicéntrico, aleatorizado, doble ciego, de administración crónica, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de benralizumab 100 mg en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) de moderada a muy grave y con antecedentes de exacerbaciones frecuentes de la EPOC y eosinófilos elevados en sangre periférica (RESOLUTE)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio en fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de MEDI3506 en pacientes con enfermedad pulmonar obstructiva crónica de moderada a grave y bronquitis crónica (FRONTIER 4)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de la ensifentrina a lo largo de 24 semanas en pacientes con enfermedad pulmonar obstructiva crónica de moderada a grave. (VERONA)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Non-Interventional, descriptive, cross-sectional and unicentric study to describe the clinical management in asthmatic patients attended in the influential area of Hospital Universitario Virgen de la Victoria, Málaga. Código: 2020	INDEPENDENT POSTAUTHORIZATION STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Estudio observacional retrospectivo para caracterizar y evaluar los resultados clínicos de los pacientes tratados con benralizumab tras su autorización de comercialización en España. Estudio ORBE II	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Ensayo aleatorizado, doble ciego, con doble simulación, de grupos paralelos y multicéntrico de 24 a 52 semanas de duración variable para evaluar la eficacia y seguridad de budesonida, glucopirronio y fumarato de formoterol en inhalador de dosis medida en comparación con budesonida y fumarato de formoterol en inhalador de dosis medida y Symbicort® en inhalador de dosis medida presurizada en pacientes adultos y adolescentes con asma mal controlada (KALOS)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio de fase 3, aleatorizado, controlado con placebo, con doble ciego y de grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de SAR440340/REGN3500/itepekimab (AcMo anti-IL-33) en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) de moderada a grave - AERIFY-2	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio observacional transversal para evaluar la calidad de vida relacionada con la salud (CVRS) y la medida de utilidad en pacientes con asma grave no controlado en España. Estudio UTILITY	NON-POST-APPROVAL STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Estudio de 52 semanas de duración, aleatorizado, doble ciego, controlado con placebo en grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de dupilumab en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) de moderada a grave con inflamación tipo 2 (NOTUS)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio observacional prospectivo para evaluar el efecto de la triple terapia fija extrafina en un solo inhalador sobre el control de los síntomas y la adherencia al tratamiento en pacientes con EPOC moderada o grave en condiciones de práctica clínica habitual. Estudio TRIATHLON (CHI-EPO-2020-01)	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS VELASCO GARRIDO	Not applicable

Group	Title	Subtype	PI Name	Phase
DE-11	Estudio de prueba de concepto (PoC) de 12 semanas, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para evaluar la eficacia, seguridad y tolerabilidad de rilzabrutinib en pacientes con asma moderada a grave que no están bien controlados con corticoesteroides inhalados (CEI) más terapia con agonistas beta2 adrenérgicos de acción prolongada (ABAP)	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio de 52 semanas de duración, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad, para evaluar la tasa de exacerbación, las mediciones adicionales de control del asma y la seguridad en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico tratados con GSK3511294 en comparación con mepolizumab o benralizumab	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Frecuencia y características diferenciales del asma en el tabaquismo ASMATAB.	INDEPENDENT POSTAUTHORIZATION STUDY	EVA CABRERA CESAR	Not applicable
DE-11	Estudio de 52 semanas, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y multicéntrico de la eficacia y la seguridad del tratamientocomplementario con GSK3511294 en participantes adultos y adolescentes con asma grave no controlada con fenotipo eosinofílico	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Ensayo Fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, dosis crónica y controlado con placebo, para evaluar la eficacia y seguridad de dos dosis de MEDI3506 en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) sintomática y con historial de exacerbaciones de la EPOC (Oberon)	INDEPENDENT CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio de extensión, abierto, multicéntrico y de un solo grupo para evaluar la seguridad a largo plazo de GSK3511294 (depemokimab) en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico de los estudios 206713 o 213744	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio de fase 2, aleatorizado, doble ciego, controlado con placebo y comparador activo para evaluar la eficacia y la seguridad de distintos niveles de dosis de AZD5718, en administración oral una vez al día durante 12 semanas, en adultos con asma no controlada de grado moderado o severo	COMMERCIAL CLINICAL TRIAL	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio de fase 3, multinacional, aleatorizado, doble ciego y controlado con placebo de la eficacia y la seguridad de treprostinil inhalado en sujetos con fibrosis pulmonar idiopática (TETON-2)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Ensayo multicéntrico Fase III, aleatorizado, doble-ciego, de grupos paralelos y controlado frente a placebo, para evaluar la eficacia y seguridad de tozorakimab (MEDI3506) en pacientes hospitalizados por infección pulmonar vírica que requieren oxigenoterapia (TILIA)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Ensayo doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y seguridad del BI 1015550 durante al menos 52 semanas en pacientes con Fibrosis Pulmonar Idiopática (FPI)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Ensayo de fase IIa aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico para evaluar la eficacia y seguridad de AZD4831, durante 12-24 semanas, en la enfermedad pulmonar obstructiva crónica (EPOC) de moderada a grave. (CRESCENDO)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Ensayo de extensión fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, dosis crónica y controlado con placebo, para evaluar la eficacia y la seguridad a largo plazo de Tozorakimab en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y con historial de exacerbaciones - PROSPERO	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio doble ciego, aleatorizado y controlado con placebo que evalúa la eficacia y seguridad de BI 1015550 durante al menos 52 semanas en pacientes con enfermedades pulmonares intersticiales fibrosantes progresivas (EPI-FP)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio de 52 semanas aleatorizado, con doble ciego y con doble simulación, controlado con placebo y tratamiento activo (Roflumilast, Daliresp® 500 µg) y de grupos paralelos para evaluar la eficacia y la seguridad de dos dosis de CHF6001 administradas con inhalador de polvo seco (DPI) como complemento a un tratamiento triple de mantenimiento en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y bronquitis crónica.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio en fase III, de 52 semanas, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos con unaextensión abierta sobre la eficacia y seguridad de BLU-5937 en participantes adultos con tos crónica refractaria, incluida tos crónica inexplicada (CALM-1).	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III

Group	Title	Subtype	PI Name	Phase
DE-11	Ensayo multicéntrico, prospectivo y no intervencionista que supervisa las vías terapéuticas de los pacientes con asma tratados con una triple terapia extrafina de un único inhalador con ICS/LABA/LAMA en condiciones reales y que caracteriza los efectos sobre los resultados relacionados con la salud	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Estudio de extensión abierto de Fase III para evaluar la seguridad a largo plazo de ASTEGOLIMAB en pacientes con enfermedad pulmonar obstructiva crónica.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Dos cohortes, Fase II, multicéntrico, aleatorizado, doble ciego, grupo paralelo, estudio controlado con placebo que evalúa la eficacia y seguridad de VIXARELIMAB.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio de extensión abierto de treprostinilo inhalado en sujetos con fibrosis pulmonar idiopática.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Ensayo de 52 semanas, aleatorizado, con enmascaramiento doble, multicéntrico y con dos grupos paralelos para evaluar la eficacia y la seguridad del inhalador de polvo seco (IPS) CHF6001 (dosis diaria total de 3200 µg) como tratamiento complementario de corticoesteroides inhalados en dosis media o alta de mantenimiento en combinación con agonistas ß2 de acción prolongada en pacientes con asma no controlada	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio Fase III, multicéntrico, aleatorizado, doble ciego, dosis crónica, de grupos paralelos y controlado con placebo para evaluar la eficacia y seguridad de Tozorakimab en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) sintomática y con historial de exacerbaciones de la EPOC (MIRANDA)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio aleatorizado, doble ciego, de búsqueda de la dosis, controlado con placebo para evaluar la eficacia y la seguridad de PLN-74809 (bexotegrast) en el tratamiento de la fibrosis pulmonar idiopática (BEACON-IPF	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Ensayo de extensión abierto sobre la eficacia y la seguridad a largo plazo de BI 1015550 administrado por vía oral en pacientes con fibrosis pulmonar idiopática (FPI) y fibrosis pulmonar progresiva (FPP) (FIBRONEER™-ON)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Observational retrospective study To characterize and assess clinical outcomes of patients Receiving tezepelumab in the framework Of use in Special Situations prior to commercialisation in Spain / Estudio observacional retrospectivo para caracterizar y evaluar los resultados clínicos de pacientes que recibieron tezepelumab en el marco de uso en situaciones especiales antes de la comercialización en España (T-ROSS)	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacyof Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio de fase IIa/IIb de determinación de dosis, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para examinar la eficacia y la seguridad de BI 1839100 administrado por vía oral durante un período de tratamiento de 12 semanas en pacientes con fibrosis pulmonar idiopática o fibrosis pulmonar progresiva con tos clínicamente importante”	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Ensayo aleatorizado, doble ciego, de grupos paralelos, multicéntrico , fase III para evaluar la eficacia de budesonida, glicopirronio y fumarato de formoterol en inhalador de dosis medida en comparación con glicopirronio y fumarato de formoterol en inhalador de dosis medida en acontecimientos cardiopulmonares en Enfermedad Pulmonar Obstructiva Crónica (THARROS)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio de búsqueda de dosis, aleatorizado, con enmascaramiento doble y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de diferentes dosis orales de BI 1819479 durante al menos 24 semanas en pacientes con fibrosis pulmonar idiopática (FPI)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Observational REtrospective Study To Describe Characteristics And Evaluate Real-World Outcomes in Patients Initiating TrixEo Aerosphere (budesonide/glycopyrronium bromide/formoterol fumarate) in Spain	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Estudio de fase 3, multinacional, aleatorizado, doble ciego y controlado con placebo sobre la eficacia y la seguridad del treprostinilo inhalado en sujetos con fibrosis pulmonar progresiva (TETON-PPF).	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio de extensión doble-ciego para evaluar la seguridad y tolerabilidad a largo plazo de itepekimab en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) que participaron en los estudios clínicos EFC16750 o EFC16819.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III

Group	Title	Subtype	PI Name	Phase
DE-11	Ensayo en fase 2b, aleatorizado, doble ciego y controlado con placebo de búsqueda de rango de dosis para evaluar la eficacia y seguridad de múltiples dosis de AZD8630 inhalado administrado una vez al día durante 12 semanas en adultos con asma no controlada con riesgo de exacerbaciones (LEVANTE)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de BMS-986278 en participantes con fibrosis pulmonar progresiva	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio de fase IIIb, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con tratamiento activo para evaluar la eficacia y la seguridad de benralizumab 30 s.c. en pacientes con asma eosinofílico no controlado con orticosteroides inhalados a dosis medias más agonistas ß2 de acción prolongada. BRISOTE	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, con dos brazos para investigar la eficacia, seguridad y tolerabilidad de lunsekimig subcutáneo (SAR443765) en participantes adultos con asma de alto riesgo que no son actualmente elegibles para tratamiento biológico.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	A Multinational, Uncontrolled, Usability Evaluation Study of the TD-300/A Tyvaso Inhalation Device in RIN-PF-305.	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Ensayo clínico de fase IV, aleatorizado, abierto, controlado, paralelo y multicéntrico en pacientes candidatos a la cesación tabáquica para evaluar la seguridad y la eficacia de la terapia mantenida con citisiniclina.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	IV
DE-11	Ensayo aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, de fase III para evaluar la eficacia y seguridad de Tezepelumab en pacientes adultos con enfermedad pulmonar obstructiva crónica de moderada a muy severa (EMBARK).	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Ensayo fase IIb, multicéntrico, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de Tozorakimab en pacientes adultos con asma no controlada en tratamiento con corticosteroides inhalados en dosis medias a altas. (UMBRIEL)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio de fase II, multicéntrico, aleatorizado, doble ciego, comparativo con placebo, de determinación de la dosis y con grupos paralelos para evaluar un anticuerpo anti-TSLP (GSK5784283) en adultos de 18 a 75 años con asma no controlada.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad del depemokimab en participantes adultos con EPOC e inflamación de tipo 2	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
DE-11	Estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico de 26 semanas de duración para evaluar la eficacia, seguridad y tolerabilidad de axatilimab en pacientes con fibrosis pulmoonar idiopática (FPI) / A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pul-monary Fibrosis (IPF)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	Sin dato
DE-11	Estudio en fase IIb, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de verekitug (UPB-101) en participantes con enfermedad pulmonar obstructiva crónica (EPOC) de moderada a grave.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Un estudio de Fase 2, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, de rango de dosis para investigar la eficacia y seguridad de PF-07275315 en participantes adultos con asma de moderado a severo controlado inadecuadamente	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	Estudio observacional retrospectivo para caracterizar y evaluar los resultados clínicos de los pacientes tratados con tezepelumab tras la aprobación de comercialización en España.	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ LUIS VELASCO GARRIDO	Not applicable
DE-11	Ensayo Fase IIb, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, de cuatro brazos, con duración de 24 semanas para evaluar la eficacia y seguridad de comprimidos de AZD6793 en pacientes adultos con enfermedad pulmonar obstructiva crónica (EPOC) moderada a muy grave.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II
DE-11	A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Efficacy of WIN378 in Adult Partici-pants with Moderate or Severe Asthma.	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	II

Group	Title	Subtype	PI Name	Phase
DE-11	Estudio de fase III, de 24 semanas, aleatorizado, doble ciego, comparativo con placebo y con grupos paralelos sobre la eficacia y la seguridad del BLU-5937 con una prolongación en abierto en participantes adultos con tos crónica refractaria, incluida tos crónica inexplicada (CALM-2)	DRUG CLINICAL TRIALS	JOSÉ LUIS VELASCO GARRIDO	III
F-02	Registro clínico de pacientes diagnosticadas con cáncer ginecológico del Grupo Español de Investigación en Cáncer de Ovario (GEICO)	OBSERVATIONAL STUDY WTIH MEDICINES	JOSÉ DAVID FERNÁNDEZ RODRÍGUEZ	Not applicable
F-05	MAVERICS™ coronary revascularization study. Prospective single-arm feasibility study for bypassing severely diseased coronary arteries with the MAVERICS graft in subjects who cannot undergo conventional CABG due to lack of suitable conduits. MAVERICS	CLINICAL RESEARCH WITH HEALTHCARE PRODUCTS	IGNACIO DIAZ DE TUESTA REVILLA	Not applicable
FA-07	Estudio de extensión de fase III, abierto, para evaluar la seguridad y la eficacia a largo plazo de BMN 111 en pacientes pediátricos con acondroplasia	COMMERCIAL CLINICAL TRIAL	ANTONIO LEIVA GEA	III
FA-07	Ensayo clínico fase III, multicéntrico, aleatorizado, abierto, de comparación del tratamiento con células mesenquimales alogénicas frente a células mesenquimales autólogas y frente a control activo con ácido hialurónico en pacientes con artrosis de rodilla.	INDEPENDENT CLINICAL TRIAL	JUAN MIGUEL GOMEZ PALOMO	III
FA-07	Estudio de fase IIb, multicéntrico, aleatorizado, con doble enmascaramiento y comparativo con placebo, para evaluar la eficacia y la seguridad de un único implante de osteoblastos alogénicos (ALLOB®) en la fractura de tibia	COMMERCIAL CLINICAL TRIAL	ANTONIO LEIVA GEA	II
FA-07	Estudio de fase II, abierto, de escalada y expansión de dosis de Infigratinib, un inhibidor selectivo de la tirosina quinasa de los receptores del factor de crecimiento fibroblástico 1-3 (fgfr 1-3), en niños con acondroplasia: Propel 2.	COMMERCIAL CLINICAL TRIAL	FRANCISCO DE BORJA DELGADO RUFINO	II
FA-07	Estudio de extensión de fase II, abierto, a largo plazo de infigratinib, un inhibidor selectivo de la tirosina quinasa de los receptores del factor de crecimiento fibroblástico 1-3 (FGFR 1-3), en niños con acondroplasia: PROPEL OLE	COMMERCIAL CLINICAL TRIAL	FRANCISCO DE BORJA DELGADO RUFINO	II
FA-07	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3	DRUG CLINICAL TRIALS	ANTONIO LEIVA GEA	III
FE-18	Eficacia de un programa de rehabilitación cardiaca domiciliario de supervisión mixta mediante chaleco de monitorización modelo NUUBO en pacientes con cardiopatía isquémica de riesgo moderado	CLINICAL RESEARCH WITH INDEP. HEALTHCARE PRODUCT	RAQUEL BRAVO ESCOBAR	Not applicable
FE-18	Evaluación prospectiva del rendimiento clínico en pacientes con amputación transfemoral protetizados en carga distal a partir de un implante Keep Walking	OBSERVATIONAL STUDY WITH MEDICINES	FRANCISCO MANUEL RODRIGUEZ JIMENEZ	Not applicable

ACTIVE CLINICAL STUDIES IN 2025 FROM EXTERNAL ASSOCIATED GROUPS

Group	Title	Subtype	PI Name	Phase
AA-24	Influencia en práctica clínica real de dabigatrán y acenocumorol en la función renal de pacientes diabéticos de edad avanzada con fibrilación auricular no valvular y enfermedad renal crónica leve-moderada. Estudio Dadifarec.	INDEPENDENT POSTAUTHORIZATION STUDY	MIGUEL ÁNGEL GARCIA ORDOÑEZ	Not applicable
AA-24	Estudio de resultados cardiovasculares con semaglutida en pacientes con diabetes tipo 2	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL GARCIA ORDOÑEZ	III
AA-24	Estudio ALCALOTIC: La ALCALOsis MeTabólica en la Insuficiencia Cardiaca descompensada: prevalencia e influencia en el pronóstico	NON-POST-APPROVAL STUDY	JESÚS OLMEDO LLANES	Not applicable
AA-24	Estudio de fase 3, aleatorizado, enmascarado para el observador y comparado con producto activo, para evaluar la seguridad y la eficacia de mRNA-1010, una vacuna experimental frente a la gripe estacional en adultos de 50 o más años.	DRUG CLINICAL TRIAL	MIGUEL ÁNGEL GARCIA ORDOÑEZ	III
AA-24	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisirán en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1)	DRUG CLINICAL TRIAL	MIGUEL ÁNGEL GARCIA ORDOÑEZ	III
AA-24	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	OBSERVATIONAL STUDY WITH DRUGS	MIGUEL ÁNGEL GARCIA ORDOÑEZ	Not applicable
AA-24	Seguridad cardiovascular de 2,4 mg de cagrilintida s.c. en combinación con 2,4 mg de semaglutida s.c. (CagriSema 2,4 mg/2,4 mg s.c.) una vez a la semana en participantes con obesidad y enfermedad cardiovascular establecida	DRUG CLINICAL TRIAL	MIGUEL ÁNGEL GARCIA ORDOÑEZ	III
CA-19	Registro informatizado de la enfermedad tromboembólica (RIETE)	NON-POST-APPROVAL STUDY	MÓNICA LORING CAFFARENA	Not applicable

PATENTS FROM EXTERNAL ASSOCIATED GROUPS:

REQUEST FOR INTERNATIONAL PATENT EXTENSIONS			
DEVICE, SYSTEM, AND ACTIVATION PROCEDURE FOR INTRAOPERATIVE DISINFECTION OF BONE PROSTHESES USING THE BIOELECTRIC EFFECT	EP23815357.1	12/27/2024	FA-16

REQUESTS FOR PATENTS AWARDED 2020-2024		
TITLE	**REQUEST No.**	**IBIMA GROUP**
DEVICE, SYSTEM, AND ACTIVATION PROCEDURE FOR INTRAOPERATIVE DISINFECTION OF BONE PROSTHESES USING THE BIOELECTRIC EFFECT	P202230480	FA-16


ibima
Plataforma BIONAND